0001558370-24-01251710-K PHIBRO ANIMAL HEALTH CORP 20240828202408281642361642361642360 0001558370-24-012517 10-K 171 20240630 20240828 20240828 PHIBRO ANIMAL HEALTH CORP 0001069899 2834 131840497 DE 0630 10-K 34 001-36410 241256090 GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300 GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 PHILIPP BROTHERS CHEMICALS INC 19980908 10-K 1 pahc-20240630x10k.htm 10-K http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#PensionPlansDefinedBenefitMemberhttp://fasb.org/us-gaap/2024#PensionPlansDefinedBenefitMemberhttp://fasb.org/us-gaap/2024#PensionPlansDefinedBenefitMemberhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://xbrl.sec.gov/country/2024#UShttp://xbrl.sec.gov/country/2024#UShttp://xbrl.sec.gov/country/2024#US0001069899FYfalsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://www.pahc.com/20240630#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://xbrl.sec.gov/country/2024#UShttp://xbrl.sec.gov/country/2024#UShttp://xbrl.sec.gov/country/2024#UShttp://fasb.org/us-gaap/2024#FundedPlanMemberhttp://fasb.org/us-gaap/2024#FundedPlanMemberhttp://fasb.org/us-gaap/2024#FundedPlanMemberhttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://www.pahc.com/20240630#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://www.pahc.com/20240630#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://www.pahc.com/20240630#AccruedLiabilitiesAndOtherLiabilitiesCurrent0.00010.0001http://fasb.org/us-gaap/2024#StraightLineDepreciationMethodMemberhttp://fasb.org/us-gaap/2024#StraightLineDepreciationMethodMemberP2YP3Yhttp://fasb.org/us-gaap/2024#StraightLineDepreciationMethodMemberP3Yhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://www.pahc.com/20240630#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrentP1Yhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://www.pahc.com/20240630#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrentP5YP4YP5Yhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense0001069899us-gaap:RetainedEarningsMember2024-06-30000106989 9us-gaap:AdditionalPaidInCapitalMember2024-06-30000106989 9us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30000106989 9us-gaap:RetainedEarningsMember2023-06-30000106989 9us-gaap:AdditionalPaidInCapitalMember2023-06-30000106989 9us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30000106989 9us-gaap:RetainedEarningsMember2022-06-30000106989 9us-gaap:AdditionalPaidInCapitalMember2022-06-30000106989 9us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-30000106989 9us-gaap:RetainedEarningsMember2021-06-30000106989 9us-gaap:AdditionalPaidInCapitalMember2021-06-30000106989 9us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-30000106989 8992008-03-31000106989 9pahc:July2023Memberus-gaap:RestrictedStockUnitsRSUMember2023-07-052023-07-050001069899pahc:July2023Memberpahc:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-02-012024-02-290001069899pahc:July2023Memberpahc:TimeBasedRestrictedStockUnitsMember2024-02-012024-02-290001069899pahc:July2023Memberpahc:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-07-012023-07-310001069899us-gaap:EMEAMember2023-07-012024-06-300001069899srt:AsiaPacificMember2023-07-012024-06-300001069899pahc:VaccinesMember2023-07-012024-06-300001069899pahc:PerformanceProductsMember2023-07-012024-06-300001069899pahc:PerformanceProductsMember2023-07-012024-06-300001069899pahc:NutritionalSpecialtiesMember2023-07-012024-06-300001069899pahc:MineralNutritionMember2023-07-012024-06-300001069899pahc:MineralNutritionMember2023-07-012024-06-300001069899pahc:MedicatedFeedAdditivesAndOthersMember2023-07-012024-06-300001069899pahc:LatinAmericaAndCanadaMember2023-07-012024-06-300001069899pahc:AnimalHealthMember2023-07-012024-06-300001069899pahc:AnimalHealthMember2023-07-012024-06-300001069899country:US2023-07-012024-06-300001069899us-gaap:EMEAMember2022-07-012023-06-300001069899srt:AsiaPacificMember2022-07-012023-06-300001069899pahc:VaccinesMember2022-07-012023-06-300001069899pahc:PerformanceProductsMember2022-07-012023-06-300001069899pahc:PerformanceProductsMember2022-07-012023-06-300001069899pahc:NutritionalSpecialtiesMember2022-07-012023-06-300001069899pahc:MineralNutritionMember2022-07-012023-06-300001069899pahc:MineralNutritionMember2022-07-012023-06-300001069899pahc:MedicatedFeedAdditivesAndOthersMember2022-07-012023-06-300001069899pahc:LatinAmericaAndCanadaMember2022-07-012023-06-300001069899pahc:AnimalHealthMember2022-07-012023-06-300001069899pahc:AnimalHealthMember2022-07-012023-06-300001069899country:US2022-07-012023-06-300001069899us-gaap:EMEAMember2021-07-012022-06-300001069899srt:AsiaPacificMember2021-07-012022-06-300001069899pahc:VaccinesMember2021-07-012022-06-300001069899pahc:PerformanceProductsMember2021-07-012022-06-300001069899pahc:PerformanceProductsMember2021-07-012022-06-300001069899pahc:NutritionalSpecialtiesMember2021-07-012022-06-300001069899pahc:MineralNutritionMember2021-07-012022-06-300001069899pahc:MineralNutritionMember2021-07-012022-06-300001069899pahc:MedicatedFeedAdditivesAndOthersMember2021-07-012022-06-300001069899pahc:LatinAmericaAndCanadaMember2021-07-012022-06-300001069899pahc:AnimalHealthMember2021-07-012022-06-300001069899pahc:AnimalHealthMember2021-07-012022-06-300001069899country:US2021-07-012022-06-300001069899pahc:CompensationAndBenefitForServicesMemberus-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember2023-07-012024-06-300001069899pahc:CompensationAndBenefitForServicesMemberus-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember2022-07-012023-06-300001069899pahc:CompensationAndBenefitForServicesMemberus-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember2021-07-012022-06-300001069899srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-300001069899srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-06-300001069899srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-06-300001069899srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-300001069899srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-06-300001069899srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-06-300001069899pahc:OtherCountriesMember2024-06-300001069899country:US2024-06-300001069899country:IL2024-06-300001069899country:IE2024-06-300001069899country:BR2024-06-300001069899pahc:OtherCountriesMember2023-06-300001069899country:US2023-06-300001069899country:IL2023-06-300001069899country:IE2023-06-300001069899country:BR2023-06-300001069899us-gaap:LandMember2024-06-300001069899us-gaap:ConstructionInProgressMember2024-06-300001069899us-gaap:MachineryAndEquipmentMember2023-06-300001069899us-gaap:LandMember2023-06-300001069899us-gaap:ConstructionInProgressMember2023-06-300001069899us-gaap:BuildingAndBuildingImprovementsMember2023-06-300001069899us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-300001069899us-gaap:MachineryAndEquipmentMember2024-06-300001069899us-gaap:BuildingAndBuildingImprovementsMember2024-06-300001069899 2023-02-012024-06-300001069899us-gaap:InterestRateSwapMember2023-07-012024-06-300001069899us-gaap:ForeignExchangeOptionMember2023-07-012024-06-300001069899us-gaap:InterestRateSwapMember2022-07-012023-06-300001069899us-gaap:ForeignExchangeOptionMember2022-07-012023-06-300001069899us-gaap:ForeignCountryMember2024-06-300001069899pahc:TermALoanMemberus-gaap:LoansPayableMember2023-07-012024-06-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2023-07-012024-06-300001069899pahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMember2023-07-012024-06-300001069899pahc:TermALoanMemberus-gaap:LoansPayableMember2022-07-012023-06-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2022-07-012023-06-300001069899pahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMember2022-07-012023-06-300001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMember2022-07-012023-06-300001069899pahc:TermALoanMemberus-gaap:LoansPayableMember2021-07-012022-06-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2021-07-012022-06-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2022-11-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2021-04-300001069899us-gaap:LetterOfCreditMember2024-06-300001069899srt:MinimumMember2024-06-300001069899srt:MaximumMember2024-06-300001069899pahc:CreditFacilitiesMember2023-07-012024-06-300001069899pahc:CreditAgreement2022TermLoanMember2023-07-012024-06-300001069899pahc:CreditFacilitiesMember2022-07-012023-06-300001069899pahc:CreditAgreement2022TermLoanMember2022-07-012023-06-300001069899pahc:CreditFacilitiesMember2021-07-012022-06-300001069899srt:ScenarioForecastMember2024-07-012025-06-300001069899srt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-06-300001069899srt:WeightedAverageMemberus-gaap:CustomerRelationshipsMember2024-06-300001069899srt:WeightedAverageMemberpahc:TrademarksAndTradeNamesAndOtherMember2024-06-300001069899srt:WeightedAverageMemberpahc:ProductRegistrationsMarketingAndDistributionRightsMember2024-06-300001069899us-gaap:TechnologyBasedIntangibleAssetsMember2024-06-300001069899us-gaap:CustomerRelationshipsMember2024-06-300001069899pahc:TrademarksAndTradeNamesAndOtherMember2024-06-300001069899pahc:ProductRegistrationsMarketingAndDistributionRightsMember2024-06-300001069899us-gaap:TechnologyBasedIntangibleAssetsMember2023-06-300001069899us-gaap:CustomerRelationshipsMember2023-06-300001069899pahc:TrademarksAndTradeNamesAndOtherMember2023-06-300001069899pahc:ProductRegistrationsMarketingAndDistributionRightsMember2023-06-300001069899us-gaap:RestrictedStockUnitsRSUMember2024-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMemberus-gaap:ShortMember2024-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMemberus-gaap:LongMember2024-06-300001069899us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-07-012024-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember2023-07-012024-06-300001069899us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-07-012023-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember2022-07-012023-06-300001069899pahc:InterestRateSwapJuly2022Memberus-gaap:CashFlowHedgingMember2022-07-310001069899us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-06-300001069899us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember2023-06-300001069899us-gaap:OtherCurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-06-300001069899us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember2024-06-300001069899us-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-06-300001069899us-gaap:OtherCurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-06-300001069899us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember2023-06-300001069899us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2024-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Member2024-06-300001069899us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2023-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Member2023-06-300001069899us-gaap:CorporateNonSegmentMember2023-07-012024-06-300001069899us-gaap:CorporateNonSegmentMember2022-07-012023-06-300001069899us-gaap:CorporateNonSegmentMember2021-07-012022-06-300001069899us-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-06-300001069899us-gaap:DefinedBenefitPlanDebtSecurityMember2024-06-300001069899pahc:DefinedBenefitPlanPlanAssetsOtherMember2024-06-300001069899pahc:DefinedBenefitPlanGlobalAssetAllocationsAndRiskParityMember2024-06-300001069899us-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-06-300001069899us-gaap:DefinedBenefitPlanDebtSecurityMember2023-06-300001069899pahc:DefinedBenefitPlanGlobalAssetAllocationsAndRiskParityMember2023-06-300001069899srt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-06-300001069899srt:MinimumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-06-300001069899srt:MinimumMemberpahc:DefinedBenefitPlanPlanAssetsOtherMember2024-06-300001069899srt:MinimumMemberpahc:DefinedBenefitPlanGlobalAssetAllocationsAndRiskParityMember2024-06-300001069899srt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-06-300001069899srt:MaximumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-06-300001069899srt:MaximumMemberpahc:DefinedBenefitPlanPlanAssetsOtherMember2024-06-300001069899srt:MaximumMemberpahc:DefinedBenefitPlanGlobalAssetAllocationsAndRiskParityMember2024-06-300001069899us-gaap:FairValueInputsLevel3Member2023-07-012024-06-300001069899us-gaap:FairValueInputsLevel3Member2022-07-012023-06-300001069899us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member2024-06-300001069899us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2024-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMemberus-gaap:FairValueInputsLevel3Member2024-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001069899us-gaap:MutualFundMember2024-06-300001069899us-gaap:FairValueInputsLevel3Member2024-06-300001069899us-gaap:FairValueInputsLevel2Member2024-06-300001069899us-gaap:FairValueInputsLevel1Member2024-06-300001069899us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMember2024-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustFixedIncomeSecuritiesMember2024-06-300001069899us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member2023-06-300001069899us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2023-06-300001069899pahc:DefinedBenefitPlanPlanAssetsOtherMemberus-gaap:FairValueInputsLevel3Member2023-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001069899us-gaap:MutualFundMember2023-06-300001069899us-gaap:FairValueInputsLevel3Member2023-06-300001069899us-gaap:FairValueInputsLevel2Member2023-06-300001069899us-gaap:FairValueInputsLevel1Member2023-06-300001069899us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-06-300001069899pahc:DefinedBenefitPlanPlanAssetsOtherMember2023-06-300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMember2023-06-

300001069899pahc:DefinedBenefitPlanCommonCollectiveTrustFixedIncomeSecuritiesMember2023-06-300001069899us-gaap:FairValueInputsLevel3Member2022-06-300001069899srt:MaximumMemberus-gaap:LetterOfCreditMember2023-07-012024-06-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2024-06-300001069899pahc:RevolverMemberus-gaap:RevolvingCreditFacilityMember2023-06-300001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMember2023-07-012024-06-300001069899pahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2024-07-310001069899pahc:CreditAgreement20242024CreditFacilitiesInitialTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2024-07-310001069899pahc:CreditAgreement20242024CreditFacilitiesInitialTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2024-07-310001069899pahc:CreditAgreement20242024CreditFacilitiesDelayedDrawTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2024-07-310001069899pahc:CreditAgreement20242024CreditFacilitiesDelayedDrawTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2024-07-310001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMember2022-09-300001069899pahc:TermALoanMemberus-gaap:LoansPayableMember2021-04-300001069899pahc:TermALoanMemberus-gaap:LoansPayableMember2024-06-300001069899pahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMember2024-06-300001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMember2024-06-300001069899pahc:TermALoanMemberus-gaap:LoansPayableMember2023-06-300001069899pahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMember2023-06-300001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMember2023-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:CreditAgreement20242024CreditFacilitiesTerm2LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2024-07-012024-07-310001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioOneMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:IncrementalTermLoan2023DueApril2026Memberus-gaap:LoansPayableMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:DebtInstrumentBasisSpreadOnVariableRateScenarioFourMemberpahc:CreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-07-012024-06-300001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-07-012024-06-300001069899pahc:CreditAgreement2022TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:FederalFundsEffectiveSwapRateMember2023-07-012024-06-300001069899pahc:TenLargestCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-07-012024-06-300001069899pahc:TenLargestCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-06-300001069899us-gaap:RetainedEarningsMember2023-07-012024-06-300001069899us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012024-06-300001069899us-gaap:RetainedEarningsMember2022-07-012023-06-300001069899us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012023-06-300001069899us-gaap:RetainedEarningsMember2021-07-012022-06-300001069899us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012022-06-300001069899us-gaap:CommonStockMember2024-06-300001069899us-gaap:CommonStockMember2023-06-300001069899us-gaap:CommonStockMember2022-06-300001069899us-gaap:CommonStockMember2021-06-300001069899us-gaap:CommonClassBMember2023-06-300001069899us-gaap:CommonClassAMember2023-06-300001069899us-gaap:AccountingStandardsUpdate202309Member2024-06-300001069899us-gaap:AccountingStandardsUpdate202307Member2024-06-300001069899us-gaap:OperatingSegmentsMember2024-06-300001069899us-gaap:CorporateNonSegmentMember2024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:PerformanceProductsMember2024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:MineralNutritionMember2024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:AnimalHealthMember2024-06-300001069899us-gaap:OperatingSegmentsMember2024-06-300001069899us-gaap:CorporateNonSegmentMember2024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:PerformanceProductsMember2023-06-300001069899us-gaap:OperatingSegmentsMemberpahc:MineralNutritionMember2023-06-300001069899us-gaap:OperatingSegmentsMemberpahc:AnimalHealthMember2023-06-300001069899us-gaap:OperatingSegmentsMember2023-06-300001069899us-gaap:CorporateNonSegmentMember2023-06-300001069899pahc:ZoetisIncMedicatedFeedAdditiveProductPortfolioMember2024-04-012024-04-300001069899pahc:AccumulatedOtherComprehensiveIncomeLongTermIntercompanyInvestmentsMember2024-06-300001069899pahc:AccumulatedOtherComprehensiveIncomeLongTermIntercompanyInvestmentsMember2023-06-300001069899us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300001069899us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300001069899us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300001069899us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001069899us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300001069899us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300001069899us-gaap:RestrictedStockUnitsRSUMember2023-07-012024-06-300001069899us-gaap:EmployeeStockOptionMember2023-07-012024-06-300001069899us-gaap:RestrictedStockUnitsRSUMember2022-07-012023-06-300001069899us-gaap:EmployeeStockOptionMember2022-07-012023-06-300001069899us-gaap:RestrictedStockUnitsRSUMember2021-07-012022-06-300001069899us-gaap:EmployeeStockOptionMember2021-07-012022-06-300001069899us-gaap:AdditionalPaidInCapitalMember2023-07-012024-06-300001069899pahc:July2023Memberpahc:PerformanceBasedRestrictedStockUnitsMember2023-07-012024-06-300001069899pahc:July2023Memberus-gaap:RestrictedStockUnitsRSUMember2024-06-300001069899pahc:July2023Memberus-gaap:RestrictedStockUnitsRSUMember2023-07-012024-06-300001069899us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember2024-06-300001069899us-gaap:StateAndLocalJurisdictionMember2024-06-300001069899920232023-07-012023-07-310001069899pahc:CreditAgreement2024Memberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2024-07-310001069899pahc:CreditFacilitiesMemberus-gaap:LineOfCreditMember2024-06-300001069899us-gaap:CommonClassBMember2024-06-300001069899us-gaap:CommonClassAMember2024-06-300001069899920222022-07-012023-06-300001069899us-gaap:OperatingSegmentsMemberpahc:PerformanceProductsMember2023-07-012024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:MineralNutritionMember2023-07-012024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:AnimalHealthMember2023-07-012024-06-300001069899us-gaap:OperatingSegmentsMember2023-07-012024-06-300001069899us-gaap:OperatingSegmentsMemberpahc:PerformanceProductsMember2022-07-012023-06-300001069899us-gaap:OperatingSegmentsMemberpahc:MineralNutritionMember2022-07-012023-06-300001069899us-gaap:OperatingSegmentsMemberpahc:AnimalHealthMember2022-07-012023-06-300001069899us-gaap:OperatingSegmentsMember2022-07-012023-06-300001069899us-gaap:OperatingSegmentsMemberpahc:PerformanceProductsMember2021-07-012022-06-300001069899us-gaap:OperatingSegmentsMemberpahc:MineralNutritionMember2021-07-012022-06-300001069899us-gaap:OperatingSegmentsMemberpahc:AnimalHealthMember2021-07-012022-06-300001069899us-gaap:OperatingSegmentsMember2021-07-012022-06-300001069899920232024-06-300001069899920232023-06-300001069899920242024-06-300001069899920232023-12-310001069899us-gaap:CommonClassBMember2023-07-012024-06-300001069899us-gaap:CommonClassAMember2023-07-012024-06-300001069899us-gaap:CommonClassBMember2024-08-230001069899us-gaap:CommonClassAMember2024-08-230001069899920232023-07-012024-06-30xbrli:sharesiso4217:USDxbrli:sharesiso4217:USDpahc:Votexbrli:pureiso4217:BRLpahc:segmentTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-K (Mark One)â˜Â Â Â ANNUAL REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscalÂ year endedÂ JuneÂ 30,Â 2024ORâ˜Â Â Â TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromÂ Â Â Â Â Â Â Â Â Â Â to Â Â Â Â Â Â Â Â Â Â Â Â Commission File Number: 001-36410Phibro Animal Health Corporation(Exact name of registrant as specified in its charter)â€‹â€‹Delaware13-1840497(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)â€‹â€‹Glenpointe Centre East, 3rd Floorâ€‹300 Frank W. Burr Boulevard, Suite 21, Teaneck, New Jersey07666-6712(Address of Principal Executive Offices)(Zip Code)â€‹(Registrantâ€™s telephone number, including area code) (201) 329-7300Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹â€‹â€‹â€‹â€‹Title of each classâ€‹Trading Symbol(s)â€‹Name of each exchange on which registeredClass A Common Stock, $0.0001 par value per shareâ€‹PAHCâ€‹Nasdaq Stock Marketâ€‹Securities registered pursuant to SectionÂ 12(g)Â of the Act: NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in RuleÂ 405 of the Securities Act. Yes â˜ No â˜’Indicate by check mark if the registrant is not required to file reports pursuant to SectionÂ 13 or SectionÂ 15(d)Â of the Act. Yes â˜ No â˜’Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Yes â˜’ No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files.) Yes â˜’ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹Large accelerated filerâ˜Accelerated filerâ˜’Non-accelerated filerâ˜Smaller reporting companyâ˜Emerging growth companyâ˜â€‹â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â—»Indicate by check mark whether the registrant has filed a report on and attestation to its managementâ€™s assessment of the effectiveness of its internal control over financing reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit reportâ€‡Yesâ€‰â˜’ Noâ€‰â˜ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. â˜Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrantâ€™s executive officers during the relevant recovery period pursuant to Â§ 240.10D-1(b). â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Act). Yes â˜ No â˜’The aggregate market value of the registrantâ€™s ClassÂ A common stock and ClassÂ B common stock held by non-affiliates of the registrant was $234,820,329 as of DecemberÂ 31, 2023, the last business day of the registrantâ€™s most recently completed second fiscal quarter based on the closing price of the common stock on the Nasdaq Stock Market. The registrant has no non-voting common stock.As of AugustÂ 23, 2024, there were 20,337,574 shares of the registrantâ€™s ClassÂ A common stock, par value $0.0001 per share, and 20,166,034 shares of the registrantâ€™s ClassÂ B common stock, par value $0.0001 per share, outstanding.DOCUMENTS INCORPORATED BY REFERENCE:Portions of the registrantâ€™s Proxy Statement for the 2024 Annual Meeting of Shareholders (hereinafter referred to as the â€œ2024 Proxy Statementâ€) are incorporated herein by reference in PartÂ III of this Annual Report on FormÂ 10-K. Such proxy statement will be filed with the Securities and Exchange Commission within 120Â days of the registrantâ€™s fiscalÂ year ended JuneÂ 30,Â 2024.â€‹â€‹â€‹â€‹ Table of ContentsPHIBRO ANIMAL HEALTH CORPORATIONTABLE OF CONTENTSâ€‹â€‹â€‹â€‹PageForward-Looking Statements and Risk Factors Summary3Market Ranking and Other Industry Data5Trademarks, Service Marks and Trade Names5â€‹â€‹PART Iâ€‹â€‹Item 1.Business6Item 1A.Risk Factors27Item 1B.Unresolved Staff Comments52Item 1C.Cybersecurity52Item 2.Properties54Item 3.Legal Proceedings54Item 4.Mine Safety Disclosures54PART IIâ€‹â€‹Item 5.Market for Registrantâ€™s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities55Item 6.(Reserved)56Item 7.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations56Item 7A.Quantitative and Qualitative Disclosures About Market Risk76Item 8.Financial Statements and Supplementary Data77Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure116Item 9A.Controls and Procedures116Item 9B.Other Information116Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections116PART IIIâ€‹â€‹Item 10.Directors, Executive Officers and Corporate Governance117Item 11.Executive Compensation117Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters117Item 13.Certain Relationships and Related Transactions, and Director Independence117Item 14.Principal Accountant Fees and Services117PART IVâ€‹â€‹Item 15.Exhibits and Financial Statement Schedules118Item 16.Form 10-K Summary122SIGNATURESâ€‹123â€‹â€‹â€‹2 Table of ContentsForward-Looking Statements and Risk Factors SummaryThis Annual Report on Form 10-K contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as â€œaim,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œexpect,â€ â€œforecast,â€ â€œoutlook,â€ â€œpotential,â€ â€œproject,â€ â€œprojection,â€ â€œplan,â€ â€œintend,â€ â€œseek,â€ â€œmay,â€ â€œcould,â€ â€œwould,â€ â€œwill,â€ â€œshould,â€ â€œcan,â€ â€œcan have,â€ â€œlikely,â€ the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:â—outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials;â—perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;â—restrictions on the use of antibacterials in food-producing animals may become more prevalent;â—the potential Food and Drug Administration (â€œFDAâ€) withdrawal of approval of our MecadoxÂ® (carbadox) product;â—a material portion of our sales and gross profits are generated by antibacterials and other related products;â—competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (â€œR&Dâ€), production and other resources than we have;â—our business may be negatively affected by weather conditions and the availability of natural resources;â—the negative effects of a pandemic, epidemic, or outbreak of an infectious disease in humans, such as COVID-19, on our business, financial results, manufacturing facilities and supply chain, as well as our customers, protein processors and markets;â—climate change could have a material adverse impact on our operations and our customersâ€™ businesses;â—actions of regulatory bodies, including obtaining approvals related to the testing, manufacturing and marketing of certain of our products;â—the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;â—our ability to control costs and expenses;â—any unforeseen material loss or casualty;â—misuse or extra-label use of our products;â—exposure relating to rising costs and reduced customer income;â—heightened competition, including those from generics and those deriving from advances in veterinary medical practices and animal health technologies;â—unanticipated safety or efficacy concerns;â—our dependence on suppliers having current regulatory approvals;â—our raw materials are subject to price fluctuations and their availability can be limited;3 Table of Contentsâ—natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;â—business interruption from political and social instability, including crime, civil disturbance, terrorist activities, outbreaks of disease and pandemics and armed conflicts, such as the ongoing armed conflicts between Israel and Hamas (and potential broader military conflict in the region) and between Russia and Ukraine;â—terrorist attacks, particularly attacks on or within markets in which we operate, including the terrorist attack on Israel by Hamas militants and the ongoing related conflict;â—risks related to changes in tax rates and exposure;â—our ability to successfully implement our strategic initiatives;â—our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;â—adverse U.S. and international economic market conditions, including currency fluctuations;â—failure of our product approval, R&D, acquisition and licensing efforts to generate new products;â—the risks of product liability claims, legal proceedings and general litigation expenses;â—the impact of current and future laws and regulatory changes, including risks related to the protection of our customersâ€™ privacy and risks related to environmental, health and safety laws and regulations;â—modification of foreign trade policy may harm our food animal product customers;â—our ability to successfully integrate acquired businesses, including the medicated feed additive product portfolio, certain water-soluble products and related assets, which we have agreed to acquire from Zoetis Inc.;â—our dependence on our Israeli and Brazilian operations;â—impact of increased or decreased inventory levels at our direct customers or channel distributors;â—our substantial level of indebtedness and related debt-service obligations;â—restrictions imposed by covenants in our debt agreements;â—the risk of breaches of data security and cybersecurity attacks;â—the risk of work stoppages; andâ—other factors as described in â€œRisk Factorsâ€ in ItemÂ 1A. of this Annual Report on Form 10-K.While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.4 Table of Contentsâ€‹Market, Ranking and Other Industry DataUnless otherwise indicated, information contained in this report concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market share, is based on management estimates. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. We believe these estimates are reasonable as of the date of this report, or if an earlier date is specified, as of such earlier date. However, this information may prove to be inaccurate because of the method by which we obtained some of the data for our estimates or because this information is subject to change and cannot always be verified due to limits on the availability and reliability of independent sources, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market shares. In addition, purchasing patterns and consumer preferences can and do change. As a result, you should be aware that market share, ranking and other similar data set forth in this report, and estimates and beliefs based on such data, may not be reliable.â€‹Trademarks, Service Marks and Trade NamesThe following trademarks and service marks used throughout this report belong to, are licensed to, or are otherwise used by us in our business: AB20Â®; AnimateÂ®; AviaxÂ®; Aviax PlusÂ®; Avi-CarbÂ®; BanminthÂ®; Bloat GuardÂ®; Cellerate Yeast SolutionsÂ®; CarbigenÂ®; CerdimixÂ®; CoxistacÂ®; EASEÂ®; EmulsigenÂ®; EskalinÂ®; GemstoneÂ®; LactrolÂ®; Magni-PhiÂ®; MB-1Â®; MecadoxÂ®; MicroLifeÂ® Prime; MJPRRSÂ®; MVP adjuvantsÂ®; Neo-TerramycinÂ®; NicarbÂ®; NicarmixÂ®; OmniGenÂ®; Phi-ShieldÂ®; pHi-TechÂ®; PhivaxÂ®; PolygenÂ®; PosistacÂ®; RejensaÂ®; RumatelÂ®; Salmin PlusÂ®; StafacÂ®; TAbicÂ®; Tailor-MadeÂ®; TerramycinÂ®; V.H.â„¢; V-MaxÂ®; and VistoreÂ®. In subsequent uses of the marks in this report, the symbols may be omitted.â€‹5 Table of ContentsPART IItemÂ 1.Â Â Â BusinessOverviewPhibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 750 product lines in over 80 countries to approximately 4,200 customers. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. Our products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through animal feed manufacturers, wholesalers, distributors and veterinarians.Our products include:â—Animal health products such as antibacterials, anticoccidials, nutritional specialty products, and vaccines and vaccine adjuvants that help improve the animalâ€™s health and therefore improve performance, food safety and animal welfare. Our Animal Health segment also includes antibacterials and other processing aids used in the ethanol fermentation industry.â—Mineral nutrition products that fortify the animalâ€™s diet and help maintain optimal health.We have focused our efforts in regions where the majority of livestock production is consolidated in large commercial farms. We believe we are well positioned to grow our sales with our established network of sales, marketing and distribution professionals in markets in North America, Latin America, Asia Pacific, Europe, Africa and the Middle East.We are investing resources to further develop products for the companion animal sector. Our business is currently concentrated in the livestock sector.In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries. We sell performance products directly to customers in the aforementioned industries.Our ClassÂ A common stock trades on the Nasdaq Stock Market (â€œNasdaqâ€) under the trading symbol â€œPAHC.â€ Our ClassÂ B common stock is not listed or traded on any stock exchange. We are a Delaware corporation.Unless otherwise indicated or the context requires otherwise, references in this report to â€œwe,â€ â€œour,â€ â€œus,â€ the â€œCompany,â€ â€œPhibro,â€ â€œPAHCâ€ and similar expressions refer to Phibro Animal Health Corporation and its subsidiaries.For discussion regarding the impact of the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine on our financial results, see PartÂ II, ItemÂ 7, Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.Business SegmentsWe manage our business in three segmentsâ€‰â€”â€‰Animal Health, Mineral Nutrition, and Performance Productsâ€‰â€”â€‰each with its own dedicated management and sales team, for enhanced focus and accountability. Net sales by segments, species and regions were:â€‹â€‹â€‹â€‹

—antibacterials, which inhibit the growth of pathogenic bacteria that cause infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and related products (MFAs and other);â—nutritional specialty products, which support nutrition to help improve health and performance (nutritional specialties); andâ—vaccines, which induce an increase in antibody levels against a specific virus or bacteria, thus preventing disease due to infection with wild strains of that virus or bacteria (vaccines).Our animal health products help our customers prevent, control and treat diseases and support nutrition to help improve health and well-being, enabling our customers to more efficiently produce high-quality, wholesome and affordable animal protein products for human consumption. We develop, manufacture and market a broad range of animal health products for food animals including poultry, swine, beef and dairy cattle and aquaculture. We provide technical and product support directly to our customers to ensure the optimal use of our products. The animal health industry and demand for many of our animal health products in a particular region are affected by changing disease pressures and by weather conditions, as usage of our products follows varying weather patterns and seasons. As a result, we may experience regional and seasonal fluctuations in our animal health segment.We continue to build our companion animal business and pipeline. Our RejensaÂ® joint supplement for dogs continues to gain customer acceptance. Our companion animal development pipeline includes an early-stage atopic dermatitis compound, a potential treatment for mitral heart valve disease in dogs, a pain product and two oral care products. Animal Health net sales by product group and regions were:â€‹Product Groupsâ€‹Changeâ€‹PercentageÂ ofÂ totalÂ For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Â Â Â 2024Â /Â 2023Â Â Â Â 2023Â /Â 2022Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€‹â€‹Â â€‹â€‹â€‹($ in millions)â€‹â€‹â€‹â€‹â€‹â€‹â€‹MFAs and otherÂ Â Â Â $ 421Â Â Â Â $ 387Â Â Â Â $ 362Â Â Â Â $ 34Â Â Â Â 9%Â Â $ 26Â Â Â Â 7%Â Â 60%Â Â 59%Â Â 60%Nutritional specialtiesâ€‹Â 165â€‹Â 173â€‹Â 157â€‹Â (8)Â (5)%Â Â Â 15Â 10%Â Â 23%Â Â 26%Â Â 26%Vaccinesâ€‹Â 121â€‹Â 100â€‹Â 88â€‹Â 21Â 21%Â Â Â 12Â 13%Â Â 17%Â Â 15%Â Â 15%Animal Healthâ€‹$ 706â€‹$ 660â€‹$ 607â€‹$ 47Â 7%Â Â $ 53Â 9%Â Â Â Â Â Â Â Â Â Â â€‹Regions(1)â€‹Changeâ€‹PercentageÂ ofÂ totalÂ For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Â Â Â 2024Â /Â 2023Â Â Â Â 2023Â /Â 2022Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€‹â€‹Â â€‹â€‹â€‹($ in millions)â€‹â€‹â€‹â€‹â€‹â€‹â€‹United StatesÂ Â Â Â $ 287Â Â Â Â $ 277Â Â Â Â $ 248Â Â Â Â $ 10Â Â Â Â 4%Â Â $ 29Â Â Â Â 12%Â Â 41%Â Â 42%Â Â 41%Latin America and Canadaâ€‹â€‹ 238â€‹â€‹ 207â€‹â€‹ 175â€‹â€‹ 31â€‹ 15%â€‹ 32â€‹ 18%Â Â 34%Â Â 31%Â Â 29%Europe, Middle East and Africaâ€‹â€‹ 119â€‹â€‹ 116â€‹â€‹ 120â€‹â€‹ 3â€‹ 3%â€‹ (4)â€‹ (3)%Â Â 17%Â Â 18%Â Â 20%Asia Pacificâ€‹Â 62â€‹Â 60â€‹Â 64â€‹Â 2Â 3%Â Â Â (4)Â (6)%Â Â 9%Â Â 9%Â Â 11%Totalâ€‹$ 706â€‹$ 660â€‹$ 607â€‹$ 46Â 7%Â Â $ 53Â 9%Â Â Â Â Â Â Â Â Â Â â€‹(1)Net sales by region are based on country of destination.Certain amounts andÂ percentages may reflect rounding adjustments.8 Table of ContentsMFAs and OtherOur MFAs and other products primarily consist of concentrated medicated products administered through animal feeds, commonly referred to as Medicated Feed Additives (â€œMFAsâ€). Our MFAs and other products primarily consist of the production and sale of antibacterials (including StafacÂ®, TerramycinÂ®, Neo-TerramycinÂ® and MecadoxÂ®) and anticoccidials (including NicarbÂ®, AviaxÂ®, Aviax PlusÂ®, CoxistacÂ® and amprolium). Antibacterials inhibit the growth of pathogenic bacteria that cause infections in animals, while anticoccidials inhibit growth of coccidia (parasites) that damage the intestinal tract of animals. The â€œMFAs and other productsâ€ product group also includes antibacterial products and other processing aids used in the ethanol fermentation industry.Approximately 43% of our MFAs and other sales in fiscal year 2024 were to the poultry industry, with sales to swine, beef and dairy cattle and other customers accounting for the remainder. We market our MFAs and other products in all regions where we do business.Nutritional SpecialtiesNutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. Many of our proprietary nutritional specialty products have been developed through applied research in cooperation with private research companies or by leading universities with whom we collaborate and then further develop through commercial trials with customers. Our nutritional specialty products include the OmniGenÂ® family of products, patented nutritional specialty products that have been shown in several studies to help maintain a cowâ€™s healthy immune system; AnimateÂ®, an anionic nutritional specialty product that helps optimize the health and performance of the transition dairy cow; Magni-PhiÂ®, a proprietary nutritional specialty product that has been shown to help improve intestinal health and immune response in poultry; MicroLifeÂ® Prime, a four-strain direct-fed microbial product for optimization of gut health, which leads to better pathogen control and improved performance in poultry; and, Cellerate Yeast SolutionsÂ®, a line of proprietary yeast culture products that are used to help improve digestive health, which may lead to improved animal health and performance.We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers. We market our nutritional specialty products in all regions in which we operate.VaccinesOur vaccine products are primarily focused on preventing diseases in poultry, swine, beef and dairy cattle and aquaculture. We market our vaccine products to protect animals from either viral or bacterial disease challenges in all regions in which we operate.We have developed and market approximately 50 product lines for the prevention of diseases in poultry, including vaccines to protect against Infectious Bursal Disease, Infectious Bronchitis, Newcastle Disease, Reovirus, Salmonella and Coryza.We develop, manufacture and market autogenous vaccines against animal diseases for swine, poultry and beef and dairy cattle in the United States and Brazil. Our autogenous bacterial and viral vaccines enable us to produce custom vaccines for veterinarians that contain antigens specific to each farm, allowing Phibro to provide comprehensive and customized health management solutions to our customers. Our autogenous vaccine products include the Tailor-MadeÂ® and Phi-ShieldÂ® lines of vaccines and the MJPRRSÂ® vaccine. We also develop, manufacture and market adjuvants to animal vaccine manufacturers globally.We have developed TAbicÂ®, an innovative and proprietary delivery platform for vaccines. TAbic is a patented technology for formulation and delivery of vaccine antigens in effervescent tablets, packaged in sealed aluminum blister packages. The technology replaces the glass bottles that are in common use today, and offers significant sustainability advantages including reduced storage requirements, customer handling and disposal. Several of our vaccine products are available in the patented TAbic format.9 Table of ContentsWe also focus on innovation to produce new antigens or new presentations of antigens, and have developed new vaccines and related technologies, such as:â—MB-1Â®, a live attenuated vaccine for Infectious Bursal disease, developed from the M.B. strain, adapted for in-ovo or subcutaneous injection at the hatchery;â—TAbicÂ® IBVAR206, a live attenuated virus vaccine for Infectious Bronchitis developed from a unique genotype 2 variant strain;â—The inactivated subunit Infectious Bursal Disease Virus;â—Salmin PlusÂ®, the first multi-variant inactivated vaccine containing Salmonella Enteritis, Salmonella Typhimurium and Salmonella Infantis;â—EASEÂ® (Enhanced Antigen Surface Expression), a new bacterial growth procedure to improve the performance of our autogenous vaccines; andâ—pHi-TechÂ®, a portable electronic vaccination device and software that ensures proper delivery of vaccines and provides health management information.We continue to invest in a vaccine production facility in Sligo, Ireland to manufacture poultry vaccines, with our first commercial sale of product from this facility having occurred in fiscal year 2022, and longer-term expectations to add swine and cattle vaccines production at this facility. Installation of additional machinery and equipment is planned while we continue to submit necessary registrations on a country-by-country basis in order to obtain regulatory approvals needed to sell these products to a broader geographic market.We completed construction of a new vaccine production facility in Guarulhos, Brazil in fiscal year 2023 and are now marketing autogenous vaccines that combat disease in swine, poultry and aquaculture for the Brazilian market.â€‹Mineral NutritionOur Mineral Nutrition business manufactures and markets approximately 380 formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their animalsâ€™ diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine and beef and dairy cattle. Volume growth in the mineral nutrition sector is primarily driven by livestock production and customer inventory levels, while pricing is largely based on costs of the underlying commodity metals. Demand for our mineral nutrition products can vary due to changes in customer buying patterns, seasonal variability and weather conditions in a particular region, which may cause animal feed consumption to fluctuate. Performance ProductsOur Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.Our ProductsAnimal HealthMFAs and OtherOur MFAs and other products primarily consist of the production and sale of antibacterials (StafacÂ®, TerramycinÂ®, Neo-TerramycinÂ® and MecadoxÂ®) and anticoccidials (NicarbÂ®, AviaxÂ®, Aviax PlusÂ®, CoxistacÂ® and amprolium). We sell our MFAs and other products in all regions where we do business.10 Table of ContentsAntibacterials and AnticoccidialsWe manufacture and market a broad range of antibacterials and other medicated products to the global livestock industry. These products provide therapeutic benefits for the animals while helping to control pathogens that have a negative impact on animal health and productivity. The table below presents our core MFA products:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â MarketÂ EntryÂ ofÂ Â Â Â Â â€‹Product â€‹ActiveÂ IngredientÂ Â ActiveÂ IngredientÂ â€‹DescriptionÂ TerramycinÂ® Â oxytetracyclineÂ 1951Â Antibacterial with multiple applications for a wide number of speciesNicarbÂ® Â nicarbazinÂ 1954Â Anticoccidial for poultryAmprolium Â ampróliumÂ 1960Â Anticoccidial for poultry and cattleBloat GuardÂ® Â poloxaleneÂ 1967Â Anti-bloat treatment for cattleBanminthÂ® Â pyrantel tartrateÂ 1972Â Anthelmintic for livestockMecadoxÂ® Â carbadoxÂ 1972Â Antibacterial for enteric pathogens in swine including salmonellosis and swine dysenteryStafacÂ®/EskalinÂ®/V-MaxÂ® Â virginiamycinÂ 1975Â Antibacterial used to prevent and control diseases in poultry, swine and cattleCoxistacÂ® /PosistacÂ® Â salinomycinÂ 1979Â Anticoccidial for poultry, cattle and swineRumatelÂ® Â morantel tartrateÂ 1981Â Anthelmintic for livestockCerdimixÂ® Â oxibendazoleÂ 1982Â Anthelmintic for livestockAviaxÂ® Â semduramicinÂ 1995Â Anticoccidial for poultryNeo-TerramycinÂ®Â oxytetracycline + neomycinÂ 1999Â Combination of two antibacterials with multiple applications for a wide number of speciesAviax PlusÂ®/Avi-CarbÂ® Â semduramicin + nicarbazinÂ 2010Â Anticoccidial for poultryâ€‹Antibacterials are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases, thereby promoting animal health, resulting in more efficient livestock production. Several factors contribute to limit the efficiency, weight gain and feed conversions of livestock production, including stress, poor nutrition, environmental and management challenges and disease. Antibacterials help prevent, control and treat disease in livestock, which can also lead to improved overall health of the animals, improved rate of weight gain and more efficient feed conversion. Our antibacterial products include:â—Virginiamycin.Â Â Â Virginiamycin is an antibacterial marketed under the brand names StafacÂ® to poultry, swine and cattle producers, EskalinÂ® to dairy cows and beef cattle producers and V-MaxÂ® for beef cattle producers. Virginiamycin is used primarily to prevent necrotic enteritis in chickens, treat and control swine dysentery and aid in the prevention or reduce the incidence of rumen acidosis and liver abscesses in cattle. Our experience in the development and production of virginiamycin has enabled us to develop significant intellectual property through trade secret know-how, which has helped protect against competition from generics. We are the sole worldwide manufacturer and marketer of virginiamycin.â—Carbadox.Â Â Â We market carbadox under the brand name MecadoxÂ® for use in swine feeds to control swine salmonellosis and swine dysentery and, as a result, improve animal health and production efficiencies. MecadoxÂ® is sold primarily in the United States to feed companies and large integrated swine producers.â—Oxytetracycline and Neomycin.Â Â Â TerramycinÂ® utilizes the active ingredient oxytetracycline and Neo-TerramycinÂ® combines the active ingredients neomycin and oxytetracycline to prevent, control and treat a wide range of diseases in chickens, turkeys, cattle, swine and aquaculture. We sell Terramycin and Neo-Terramycin products primarily to livestock and aquaculture producers, feed companies and distributors.â€‹Anticoccidials are produced through fermentation or chemical synthesis and are primarily used to prevent and control the disease coccidiosis in poultry and cattle, thereby promoting intestinal health, resulting in healthier animals. Coccidiosis is a disease of the digestive tract that has considerable health consequences to livestock and, as a result, is of 11 Table of Contentsgreat concern to livestock producers. We sell our anticoccidials primarily to integrated poultry producers and feed companies and to international animal health companies. Our anticoccidial products include:â—Nicarbazin.Â Â Â We produce and market nicarbazin, a broad-spectrum anticoccidial used for coccidiosis prevention in poultry. We market nicarbazin under the trademarks NicarbÂ® and NicarmixÂ® and as an active pharmaceutical ingredient.â—Amprolium.Â Â Â We produce and market amprolium primarily as an active pharmaceutical ingredient.â—Salinomycin and Semduramicin.Â Â Â We produce and market CoxistacÂ®, AviaxÂ®/Aviax PlusÂ®/Avi-CarbÂ® and PosistacÂ®, which are in a class of compounds known as ionophores, to combat coccidiosis in poultry and increase feed efficiency in swine.Anthelmintics are used to treat infestations of parasitic intestinal worms. Our anthelmintic products, RumatelÂ®, BanminthÂ® and CerdimixÂ® are marketed to control major intestinal parasites. Rumatel is indicated for cattle while Banminth and Cerdimix are used in swine.Bloat GuardÂ® is an anti-bloat treatment used in cattle to control bloat in animals grazing on legume or wheat-pasture.Other includes products used in the ethanol fermentation industry, including antimicrobials, yeasts, process cleaning, corn oil recovery and other processing aids.Nutritional SpecialtiesOur primary nutritional specialty products have been identified, developed and commercialized by our staff of nutritionists and veterinarians working with private research companies, leading universities and customers with whom we collaborate. For those of our nutritional specialty products that are not proprietary or exclusive to us, we typically maintain unique supply agreements or exclusive distributor status with the product developers giving us preferential access to trademarks, territories and research data.Our nutritional specialty products include:â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â MarketÂ Â Â Â Â â€‹Product Â EntryÂ â€‹DescriptionÂ AB20Â® Â 1989Â Natural flow agent that improves overall feed qualityAnimateÂ® Â 1999Â Helps maintain proper blood calcium levels in dairy cows during critical transition periodOmniGenÂ® Â 2004Â Optimize immune function in dairy cows and improve productivityMagni-PhiÂ® & Magni-PhiÂ® UltraÂ 2015Â Proprietary blend that helps to improve intestinal health and immune response which may lead to improved absorption and utilization of nutrients for poultryCellerate Yeast SolutionsÂ® Â 2017Â Proprietary yeast culture products for all classes of livestock to help improve digestive healthMicroLifeÂ® PrimeÂ 2019Â 4-way combination direct-fed microbial for optimization of gut health, which can lead to better pathogen control in poultryâ€‹AB20Â® is a natural flow agent that, when added to feed, binds moisture to improve the overall feed quality. The product is one of the most thoroughly researched in the flow agent product category.AnimateÂ® is a patented anionic mineral supplement that helps optimize the health and performance of the transition dairy cow and improves profitability for dairy producers.OmniGenÂ® is a proprietary nutritional specialty product line designed to help maintain a cowâ€™s healthy immune system, improve their natural response to potential environmental stressors and health challenges, and improve productivity.Magni-PhiÂ® and Magni-PhiÂ® Ultra are a proprietary blend of saponins, triterpenoids and polyphenols (classes of phytogenic feed additives or natural botanicals) that help improve intestinal health and immune response which may lead to improved absorption and utilization of nutrients for poultry.12 Table of ContentsCellerate Yeast SolutionsÂ® is a line of proprietary yeast culture and yeast culture blends with yeast fractions and/or live cell yeast used in all classes of livestock and companion animals for improved digestive health. Improved digestive health may lead to improved animal health and performance.MicroLifeÂ® Prime represents a proprietary combination of four strains of bacillus-based direct-fed microbials that have been shown to promote beneficial gut bacteria, which can help promote health, immunity and productivity in poultry, which leads to lower pathogen challenges in commercial poultry production. Phibro continues to work in the development of new bacillus-based products, which are being developed for multiple animal species.We market nutritional specialty products to livestock producers with the support of key influencers, such as animal nutritionists and veterinarians.VaccinesWe develop, manufacture and market fully licensed and autogenous vaccines for poultry, swine, beef and dairy cattle and aquaculture globally. We also develop, manufacture and market vaccination devices. We produce vaccines that protect animals from either viral or bacterial disease challenges. Our vaccine products include:â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â MarketÂ Â Â Â Â â€‹Product Â EntryÂ â€‹DescriptionÂ V.H.TM Â 1974Â Live vaccine for the prevention of Newcastle Disease in poultryTailor-MadeÂ® Vaccines Â 1982Â Autogenous vaccines against either bacterial or viral diseases in poultry, swine and beef and dairy cattle in the U.S.MVP adjuvantsÂ® Â 1982Â Components of veterinary vaccines that enhance the immune response to a vaccineTAbicÂ® M.B. Â 2004Â Live vaccine for the prevention of Infectious Bursal Disease in poultryMJPRRSÂ® Â 2007Â Autogenous vaccine for the prevention of porcine reproductive and respiratory syndrome (â€œPRRSâ€) in swineTAbicÂ® IB VAR Â 2009Â Live vaccine for the prevention of Infectious Bronchitis variant 1 strain 233A in poultryTAbicÂ® IBVAR206 Â 2010Â Live vaccine for the prevention of Infectious Bronchitis variant 206 in poultryMB-1Â® Â 2017Â Live vaccine for the prevention of Infections Bursal Disease in the hatchery in poultrypHi-TechÂ® Â 2019Â Portable electronic vaccination device and software that ensures proper delivery of vaccines and provides health management informationPhivaxÂ® SLEâ€‹2019â€‹A live attenuated Salmonella Enteritidis vaccine for the control of Salmonella infection in poultryPhi-ShieldÂ® Vaccinesâ€‹2023â€‹Autogenous vaccines against either bacterial or viral diseases in poultry, swine and aquaculture in Brazilâ€‹The V.H. strain of Newcastle Disease vaccine is a pathogenic strain and is effective when applied by aerosol, coarse spray, drinking water or eye-drops. It has been used successfully under various management and climate conditions in many breeds of poultry.Tailor-MadeÂ® vaccines are autogenous vaccines against either bacterial or viral diseases which contain antigens specific to each farm. We manufacture and sell these vaccines to U.S. veterinarians for use primarily in swine, poultry and beef and dairy cattle.MVP adjuvantsÂ® are integral components used in veterinary vaccines which enhance the immune response to a vaccine. Our adjuvants include

EmulsigenÂ®, EmulsigenÂ® D, EmulsigenÂ® P, CarbigenÂ® and PolygenÂ®.The M.B. strain of Gumboro vaccine is an intermediate virulence live vaccine strain used for the prevention of Infectious Bursal Disease in poultry. The intermediate strain was developed to provide protection against the new field epidemic virus, which is more virulent than those previously encountered.13 Table of ContentsMJPRRSÂ®, an autogenous vaccine for swine, is administered to pregnant sows to protect their offspring from PRRS. This vaccine includes multiple PRRS isolates representing different virus strains of PRRS.TAbicÂ® IB VAR and TAbicÂ® IBVAR206 vaccines are intermediate virulence live vaccine strains used for the prevention of infectious bronchitis in poultry. Both vaccines have become significant tools in the increasing fight against infectious bronchitis in regions throughout the world.MB-1Â® is a live attenuated vaccine for Infectious Bursal disease in poultry, developed from the M.B. strain, adapted for in-ovo or subcutaneous injection in the hatchery.pHi-TechÂ® is a portable electronic vaccination device and software that ensures proper delivery of vaccines and provides health management information.PhivaxÂ® SLE is a vaccine used as an aid in the reduction of Salmonella Enteritidis colonization in layers and breeder broiler chickens.Phi-ShieldÂ® vaccines are autogenous vaccines against either bacterial or viral diseases which contain antigens specific to each farm. We manufacture and sell these vaccines to Brazilian producers for use primarily in swine, poultry and aquaculture. We focus on innovation to produce new antigens or new presentations of antigens, and have developed new vaccines, such as the inactivated subunit Infectious Bursal Disease Virus and Egg Drop Syndrome vaccines, being sold as monovalent vaccines or in combinations with other antigens.Mineral NutritionOur mineral nutrition products principally include inorganic and organic compounds of copper, zinc, cobalt, iron, selenium, manganese, magnesium and iodine.Our mineral nutrition products also include GemStoneÂ®, our exclusive line of chelated organic trace minerals, including zinc, manganese, copper and iron glycine chelates. Our formulas feature high metal content to ensure greater mineral presence and preserve critical ration space. Each product is also highly chelated for superior bioavailability to maximize mineral absorption and minimize environmental impact. These organic trace minerals are available in a highly concentrated, easy-flowing granule.Our mineral nutrition products also include the VistoreÂ® portfolio of products, our chloride mineral option of value-driven trace mineral offerings. Our formulas feature high metal content to ensure optimal mineral presence and preserve critical ration space. High bioavailability also promotes maximized absorption for enhanced results and minimized waste.Our major mineral nutrition customers are U.S. regional and national feed companies, distributors, co-ops, pre-mixers, integrated swine, beef and poultry producers and pet food manufacturers. The majority of our customers have nutrition staffs who determine their specific formulas for custom trace mineral premixes. Trace mineral costs and our selling prices fluctuate with commodity markets, and therefore, these products are price sensitive. Their sale requires a focused effort on cost and inventory management, quality control, customer service, pricing and logistics execution to be profitable.Performance ProductsOur Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. We operate the business through our PhibroChem (a division of PAHC), Ferro Metal and Chemical Corporation Limited and Phibro-Tech, Inc. (â€œPhibro-Techâ€) businessÂ units.Sales and MarketingOur sales organization includes sales, marketing and technical support employees. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products. Together, our Animal Health and Mineral Nutrition businesses have a sales, marketing and technical support organization of more than 400 employees and approximately 200 distributors who market our portfolio 14 Table of Contentsof approximately 670 product lines to livestock producers, veterinarians, nutritionists, animal feed companies and distributors in over 80 countries.In markets where we have a direct commercial presence, we sell our animal health and mineral nutrition products through our local sales offices, either directly to integrated poultry, swine and beef and dairy cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Our sales representatives visit our customers, including livestock producers, veterinarians, nutritionists, animal feed companies and distributors, to inform, promote and sell our products and services. In direct service markets, our technical operations specialists provide scientific consulting focused on disease management and herd management, and training and education on diverse topics, including responsible product use.We sell our Performance Products through our local sales offices to the personal care, industrial chemical and chemical catalyst industries. We market these products predominately in the United States.CustomersWe have approximately 4,200 customers, of which approximately 3,900 customers are served by our Animal Health and Mineral Nutrition businesses. We consider a diverse set of livestock producers, including poultry and swine operations and beef and dairy cattle farmers, to be the primary customers of our livestock products. We sell our animal health and mineral nutrition products directly to livestock and aquaculture producers and to distributors that typically re-sell the products to livestock producers. We sell our companion animal product using a distributor calling on veterinary clinics. We do not consider the business to be dependent on a single customer or a few customers, and we believe the loss of any one customer would not have a material adverse effect on our results.We typically sell pursuant to purchase orders from customers and generally do not enter into long-term delivery contracts.Product Registrations, Patents and TrademarksWe own certain product registrations, patents, trade names and trademarks, and use know-how, trade secrets, formulae and manufacturing techniques, which assist in maintaining the competitive positions of certain of our products. We believe that technology is an important component of our competitive position, and it provides us with low-cost positions enabling us to produce high quality products. Patents protect some of our technology, but a significant portion of our competitive advantage is based on know-how built up over manyÂ years of commercial operation, which is protected as trade secrets. We own, or have exclusive rights to use under license, approximately 300 patents or pending applications in more than 40 countries but we believe that no single patent is of material importance to our business and, accordingly, that the expiration or termination thereof would not materially affect our business.We market our animal health products under hundreds of governmental product registrations approving many of our products with respect to animal drug safety and efficacy. The use of many of our medicated products is regulated by authorities that are specific to each country, e.g., the FDA in the United States, Health Canada in Canada and European Food Safety Authority (â€œEFSAâ€) and the European Medicines Agency (â€œEMAâ€) in Europe. Medicated product registrations and requirements are country- and product-specific for each country in which they are sold. We continuously monitor, maintain and update the appropriate registration files pertaining to such regulations and approvals. In certain countries where we work with a third-party distributor, local regulatory requirements may require registration in the name of such distributor. As of JuneÂ 30,Â 2024, we had approximately 1,050 Animal Health product registrations globally, including approximately 390 MFA registrations, 320 vaccine registrations (including autogenous vaccines) and 340 registrations for nutritional specialty products. Our MFA global registrations included approximately 90 registrations for virginiamycin.Additionally, many of our vaccine products are based on proprietary master seeds, proprietary adjuvant formulations or patented virus grouping technology. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by seeking to require our employees, consultants, advisors and partners to enter into confidentiality agreements and other arrangements upon the commencement of their employment or engagement.We seek to file and maintain trademark registrations around the world based on commercial activities in most regions where we have, or desire to have, a business presence for a particular product or service. We currently maintain, 15 Table of Contentsor have rights to use under license, approximately 3,400 trademark registrations or pending applications globally, identifying goods and services related to our business.Our technology, brands and other intellectual property are important elements of our business. We rely on patent, trademark, copyright and trade secret laws, as well as non-disclosure agreements, to protect our intellectual property rights. Our policy is to vigorously protect, enforce and defend our rights to our intellectual property, as appropriate.Compliance with Government RegulationMany of our animal health and mineral nutrition products require licensing by a governmental agency before marketing. To maintain compliance with these regulatory requirements, we have established processes, systems and dedicated resources with end-to-end involvement from product concept to launch and maintenance in the market. Our regulatory function seeks to engage in dialogue with various global agencies regarding their policies that relate to animal health products. For products that are currently subject to formal licensing by government agencies, our business relies on the ongoing approval and/or periodic re-approval of those licenses. Failure to maintain and, where applicable, renew those licenses for any reason including, but not limited to, changing regulations, more stringent technical, legal or regulatory requirements, or failure of the company or its agents to make timely, complete or accurate submissions, could result in suspension or loss of the companyâ€™s rights to market its products in one or more countries.United StatesIn the United States, governmental oversight of animal nutrition and health products is conducted primarily by the FDA and/or the United States Department of Agriculture (â€œUSDAâ€). The United States Environmental Protection Agency (the â€œEPAâ€) has jurisdiction over certain products applied topically to animals or to premises to control external parasites and shares regulatory jurisdiction of ethanol manufactured in biofuel manufacturing facilities with the FDA.The FDA regulates foods intended for human consumption and, through the Center for Veterinary Medicine (â€œCVMâ€), regulates the manufacture and distribution of animal drugs marketed in the U.S. including those administered to animals from which human foods are derived. All manufacturers of animal health pharmaceuticals marketed in the United States, must show their products to be safe, effective and produced by a consistent method of manufacture as defined under the Federal Food, Drug, and Cosmetic Act. To protect the food and drug supply, the FDA develops technical standards for human and animal drug safety, effectiveness, labeling and Good Manufacturing Practice. The CVM evaluates data necessary to support approvals of veterinary drugs. Drug sponsors are required to file reports of certain product quality defects and adverse events in accordance with agency requirements.FDA approval of Type A Medicated Feed Articles and drugs is based on satisfactory demonstration of safety, efficacy, manufacturing quality standards and appropriate labeling. Efficacy requirements are based on the desired label claim and encompass all species for which label indication is desired. Safety requirements include target animal safety and, in the case of food animals, human food safety (â€œHFSâ€). HFS reviews include drug residue levels and the safety of those residue levels. In addition to the safety and efficacy requirements for animal drugs used in food-producing animals, environmental safety must be demonstrated. Depending on the compound, the environmental studies may be quite extensive and expensive. In many instances, the regulatory hurdles for a drug that will be used in food-producing animals are at least as stringent as, if not more so than, those required for a drug used in humans. In addition, certain safety requirements relating to antimicrobial resistance must be met for antimicrobial products.The CVM Office of New Animal Drug Evaluation is responsible for reviewing information submitted by drug sponsors who wish to obtain approval to manufacture and sell animal drugs. A new animal drug is deemed unsafe unless there is an approved New Animal Drug Application (â€œNADAâ€). Virtually all animal drugs are â€œnew animal drugsâ€ within the meaning of the Federal Food, Drug, and Cosmetic Act. An approved Abbreviated New Animal Drug Application (â€œANADAâ€) is a generic equivalent of an NADA previously approved by the FDA. Both are regulated by the FDA. The drug development process for human therapeutics is generally more involved than that for animal drugs. However, because human food safety and environmental safety are issues for food-producing animals, the animal drug approval process for food-producing animals typically takes longer than for companion animals.The FDA may deny an NADA or ANADA if applicable regulatory criteria are not satisfied, require additional testing or information, or require post-marketing testing and surveillance to monitor the safety or efficacy of a product. There can be no assurances that FDA approval of any NADA or ANADA will be granted on a timely basis, or at all. Moreover, if regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for 16 Table of Contentswhich it may be marketed. Finally, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur following initial marketing. Among the conditions for NADA or ANADA approval is the requirement that the prospective manufacturerâ€™s quality control and manufacturing procedures conform to FDAâ€™s current Good Manufacturing Practice (â€œcGMPâ€) regulations. A manufacturing facility is periodically inspected by the FDA for determination of compliance with cGMP after an initial pre-approval inspection. Certain subsequent manufacturing changes must be approved by the FDA prior to implementation. In complying with standards set forth in these regulations, manufacturers must continue to expend time, monies and effort in the area of production and quality control to ensure compliance. The process of seeking FDA approvals can be costly, time consuming and subject to unanticipated and significant delays. There can be no assurance that such approvals will be granted on a timely basis, or at all. Any delay in obtaining or any failure to obtain FDA or foreign government approvals, or the suspension or revocation of such approvals, would adversely affect our ability to introduce and market our products and to generate revenue.The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on the use of antibiotics in these food-producing animals. The sale of antibiotics is a material portion of our business. Legislative bills are introduced in the United States Congress from time to time that, if adopted, could have an adverse effect on our business. One of these initiatives is a proposed bill called the Preservation of Antibiotics for Medical Treatment Act, which has been introduced in almost every Congress since the mid 2000â€™s. To date, such bills have not had sufficient support to become law. Should statutory, regulatory or other developments result in restrictions on the sale of our products, it could have a material adverse impact on our financial position, results of operations and cash flows.The USDA regulates the U.S. veterinary vaccines through the Center for Veterinary Biologics (â€œCVBâ€), which implements the Virus-Serum-Toxin Act to assure that pure, safe, potent and effective veterinary biologics are available for diagnosis, prevention and treatment of animal diseases. The CVB monitors and inspects vaccine products and the manufacturing facilities.The EPA has established and monitors the Renewable Fuel Standard program, for which some of our biofuel manufacturing facilities must comply. Compliance includes generating and tracking renewable identification numbers documentation over transfer, blending and exporting, and quarterly reporting.Virginiamycin. In NovemberÂ 2004, the CVM released a draft for comment of its risk assessment of streptogramin resistance for treatment of certain infections in humans attributable to the use of streptogramins in animals (the â€œrisk assessmentâ€). The risk assessment was initiated after approval of a human drug called SynercidÂ® (quinupristin/dalfopristin) for treating vancomycin-resistant Enterococcus faecium (â€œVREfâ€), which led to increased attention regarding the use of streptogramins in animals. Synercid and virginiamycin (the active ingredient in our Stafac product) are both members of the streptogramin class of antimicrobial drugs. The risk assessment was unable to produce any firm conclusions as to whether, and, if so, how much, the use of virginiamycin in food animals contributes to the occurrence of streptogramin-resistant infections in humans via a foodborne pathway.In classifying streptogramins in 2003 as a â€œmedically important antimicrobialâ€ (â€œMIAâ€) on the CVMâ€™s Guidance for Industry (â€œGFIâ€) 152 list, a guidance document for evaluating the microbial safety of antimicrobial new animal drugs on food for human consumption, the FDAâ€™s stated concern was the potential impact on use of Synercid for treating VREf in humans. In 2010, the U.S. label for Synercid was changed and the VREf indication was removed. The FDA determined that data submitted by the sponsor of Synercid failed to verify clinical benefit of the product for the treatment of VREf infections in humans. We requested that the FDA remove the streptogramin class of antimicrobials from GFI 152 to reflect that they are not â€œmedically importantâ€ for human therapy, however, the FDA declined our request. The FDA has issued a draft of GFI 152 and the streptogram class of antimicrobials was still included as medically important. Phibro submitted comments again to the open docket recommending that streptogramins be listed as not medically important, particularly in light of the withdrawal of Synercid from the U.S. market by the sponsor. There is no certainty surrounding the outcome of the current review of the GFI 152 list and actions that may be taken by the FDA.MIAs. Effective JanuaryÂ 2017, the CVMâ€™s revised Veterinary Feed Directive (â€œVFDâ€) regulations, which included changes to the control and use of antimicrobial products for use in animal feed, require that affected antimicrobial products may only be used if authorized by a veterinarian in accordance with the regulations. Prior to implementation of the revised VFD regulations, many approved antimicrobial products could be obtained and used without formal veterinary authorization.17 Table of ContentsIn JanuaryÂ 2017, the FDA and industry, including us, completed the process of label changes for MIA products to remove production claims and to limit the use of MIAs to those uses that are considered necessary for assuring animal health, namely for the prevention, control and/or treatment of disease, and that MIA use in food-producing animals should include veterinary oversight or consultation. The label changes were the result of recommendations from the CVM, as described in GFI 213 (â€œNew Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI 209â€) and GFI 209 (â€œThe Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animalsâ€).Carbadox. In April 2016, the FDA began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a Notice of Opportunity for Hearing (â€œNOOHâ€), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDAâ€™s Center for Veterinary Medicine (â€œCVMâ€) inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method. In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues. The

FDA also provided notice in the Federal Register proposing to withdraw approval of all NADAs providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVMâ€™s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is continuing to defend swine producersâ€™ ability to use Mecadox. We have requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the year ended JuneÂ 30,Â 2024 were approximately $22 million. As of the date of this Annual Report on Form 10-K, Mecadox continues to be available for use by swine producers.Manufacturing. The FDA routinely carries out audits related to cGMP standards for manufacturing facilities that make veterinary drug products and active pharmaceutical ingredients approved for sale in the U.S. The FDA inspectors may make observations during these inspections, which may require corrective action in order for the manufacturing facility to remain in compliance with cGMP standards. Failure to take such corrective actions could result in the manufacturing facility being ineligible to receive future FDA approvals. In very serious cases of noncompliance with cGMP standards, the FDA may issue a warning letter which could result in products produced in such manufacturing facilities to be ineligible for sale in the U.S. Although it is our objective to remain in full conformance with U.S. cGMP standards, we have in the past received adverse observations and may in the future receive adverse observations or warning letters. Failure to comply with cGMP standards could have a material impact on our business and financial results.European UnionEuropean Union (â€œE.U.â€) legislation requires that veterinary medicinal products must have a marketing authorization before they are placed on the market in the European Union. A veterinary medicinal product must meet certain quality, safety, efficacy and environmental criteria to receive a marketing authorization. The European Medicines Agency (and its main veterinary scientific committee, the Committee for Medicinal Products for Veterinary Use) and the national authorities in the various E.U. Member States, are responsible for administering this regime.A separate E.U. regime applies to feed additives. It provides for a re-registration process for existing additives and this process is ongoing. For certain types of additives, the authorizations are not generic in nature (so that they can be relied upon by any operator) but are limited to the company that obtained the marketing authorization. They are known 18 Table of Contentsas Brand Specific Approvals (â€œBSAâ€). The system is similar to the U.S. system, where, for certain types of additives, regulatory approval is for the formulated product or â€œbrand.â€The EFSA is responsible for the E.U. risk assessment regarding food and feed safety. Operating under the European Commission, in close collaboration with national authorities and in open consultation with its stakeholders, the EFSA provides independent scientific advice and communication on existing and emerging risks. The EFSA may issue advice regarding the process of adopting or revising European legislation on food or feed safety, deciding whether to approve regulated substances such as pesticides and food additives, or developing new regulatory frameworks and policies, for instance, in the field of nutrition. The EFSA aims to provide appropriate, consistent, accurate and timely communications on food safety issues to all stakeholders and the public at large, based on the Authorityâ€™s risk assessments and scientific expertise. The containment of antimicrobial resistance is one of the key areas of concern for the EFSA, EMA, the European Commission and its Directorates, the European Parliament and European Member State Governments.A number of manufacturers, including us, submitted dossiers in order to re-register various anticoccidials for the purpose of obtaining regulatory approval from the European Commission. The BSA for our nicarbazin product was published in October 2010. Our reauthorization submission was made on time and is pending. We sell nicarbazin under our own BSA and as an active ingredient for another marketerâ€™s product that has obtained a BSA and is sold in the European Union. Similarly, a BSA for our semduramicin product, AviaxÂ®, was published in 2006 and our reauthorization submission was made on time and is pending. We have submitted a dossier for reauthorization in accordance with the requirements of the EFSA and responded to requests for additional information from the EFSA by submitting additional data for each product. The current BSAs remain valid while the EFSA reviews the additional data we have submitted. There can be no guarantee that these submissions will be reviewed favorably or in a timely manner. Failure to gain reauthorization in a timely manner could have an adverse financial impact on our business.The Delegating and Implementing Acts under E.U. RegulationÂ 2019/6 includes provisions that could require animals or animal origin products imported into the E.U. from other countries to be produced under the same conditions as are required in the E.U. This may preclude the use of veterinary products not approved in the E.U. or require animal health products to be used in the manner approved in the E.U. If such restrictions are implemented, they could result in a reduction or elimination of the use of our products, especially our antibacterial products, in countries that export animals or animal origin products to the E.U. and other countries that align their regulations with E.U. regulations.BrazilThe Ministry of Agriculture, Livestock Production and Supply (â€œMAPAâ€) is the regulatory body in Brazil responsible for the regulation and control of pharmaceuticals, biologicals and medicinal feed additives for animal use. MAPAâ€™s regulatory activities are conducted through the Secretary of Agricultural Defense and its Livestock Products Inspection Department. These activities include the inspection and licensing of both manufacturing and commercial establishments for veterinary products, as well as the submission, review and approval of pharmaceuticals, biologicals and medicinal feed additives.Other CountriesWe are subject to regulatory requirements governing investigation, clinical trials and marketing approval for animal drugs in many other countries in which our products are sold. The regulatory approval process includes similar risks to those associated with the FDA and European Commission approvals set forth above.Global Policy and GuidanceCountry-specific regulatory laws have provisions that include requirements for certain labeling, safety, efficacy and manufacturersâ€™ quality procedures (to assure the consistency of the products), as well as company records and reports. With the exception of Australia, Canada, Japan and New Zealand, most other countriesâ€™ regulatory agencies will generally refer to the FDA, USDA, European Union and other international animal health entities, including the World Organization for Animal Health, Codex Alimentarius Commission, the recognized international standard-setting body for food (â€œCodexâ€), before establishing their own standards and regulations for veterinary pharmaceuticals and vaccines.19 Table of ContentsThe Joint FAO/WHO Expert Committee on Food Additives is an international expert scientific committee that is administered jointly by the Food and Agriculture Organization of the United Nations and the World Health Organization. It provides risk assessments and safety evaluations of residues of veterinary drugs in animal products as well as exposure and residue definition and maximum residue limit proposals for veterinary drugs in traded food commodities. These internationally published references may also be used by national authorities when setting domestic standards. We work with the national authorities to establish acceptable safe levels of residual product in food-producing animals after treatment. This in turn enables the calculation of appropriate withdrawal times for our products prior to an animal entering the food chain.In JulyÂ 2014, the Codex adopted risk management advice language for a number of compounds including carbadox. The advice language states â€œauthorities should prevent residues of carbadox in food. This can be accomplished by not using carbadox in food producing animals.â€ The advice language is to provide advice only and is not binding on individual national authorities, and almost all national authorities already have long-established regulatory standards for carbadox, including prohibiting the use of carbadox in swine production within their territory, prohibiting the importation of pork from swine that are fed carbadox, or permitting the importation of pork from swine that are fed carbadox provided there is no detection of carbadox residues in the meat. The advice language may be considered by national authorities in making future risk management determinations. To the extent additional national authorities elect to follow the advice and prohibit the use of carbadox in food-producing animals and/or the importation of pork from swine that are fed carbadox, such decisions could have an adverse effect on our sales of carbadox in those countries or in countries that produce meat for export to those countries.Advertising and Promotion ReviewPromotion of animal health products is controlled by regulations in many countries. These rules generally restrict advertising and promotion to those approved claims and uses that have been reviewed and endorsed by the applicable agency. We conduct a review of promotion material for compliance with the local and regional requirements in the markets where we sell animal health products.Food Safety Inspection Service/Generally Recognized As SafeThe FDA is authorized to determine the safety of substances (including â€œgenerally recognized as safeâ€ or â€œGRASâ€ substances, and food and feed additives), as well as prescribing safe conditions of use. The FDA, which has the responsibility for determining the safety of substances, together with the Food Safety and Inspection Service, the food safety branch within the USDA, maintain the authority in the United States to determine that new substances and new uses of previously approved substances are suitable for use in meat, milk and poultry products.CompetitionWe are engaged in highly competitive industries and, with respect to all our major products, face competition from a substantial and continually evolving number of global and regional competitors. Some competitors have greater financial, R&D, manufacturing and other resources than we have. Our competitive position is based principally on our product registrations, customer service and support, breadth of product line, product quality, manufacturing technology, facility locations and product prices. We face competition in every market in which we participate. Many of our products face competition from products that may be used as an alternative or substitute.There has been, and there may continue to be, consolidation in the animal health market, which could strengthen our competitors. Our competitors can be expected to continue to improve the design and performance of their products and to introduce new products with competitive price and performance characteristics. There can be no assurance that we will have sufficient resources to maintain our current competitive position, however, we believe the following strengths create sustainable competitive advantages that will enable us to continue our growth as a leader in our industry.Products Aligned with Need for Increased Protein ProductionIncreased scarcity of natural resources is increasing the need for efficient production of food animals such as poultry, swine and cattle. Our animal health products, including our MFAs, vaccines and nutritional specialty products, help prevent and manage disease outbreaks and enhance nutrition to help support natural defenses against diseases. These products are often critical to our customersâ€™ efficient production of healthy animals. Our leading MFAs product 20 Table of Contentsfranchise, StafacÂ®/V-MaxÂ®/EskalinÂ®, is approved in over 30 countries for use in poultry, swine and beef and dairy cattle and is regarded as one of the leading MFA products for production animals. Our nicarbazin and amprolium MFAs are globally recognized anticoccidials. Our nutritional specialty product offerings such as OmniGen-AF and Animate are used increasingly in the global dairy industry, and Magni-PhiÂ® and MicroLifeÂ® Prime are rapidly becoming important products for poultry producers. Our vaccine products are effective against critical diseases in poultry, swine and beef and dairy cattle.Global Presence with Existing Infrastructure in Key High-Growth MarketsWe have an established direct presence in many important emerging markets, and we believe we are a leader in many of the emerging markets in which we operate. Our existing operations and established sales, marketing and distribution network in over 80 countries provide us with opportunities to take advantage of global growth opportunities. Outside of the United States, our global footprint reaches to key high growth regions (countries where the livestock production growth rate is expected to be higher than the average growth rate) including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries and South Africa and other countries in Africa. Our operations in countries outside of the United States contributed approximately 59% of our Animal Health segment revenues for the year ended JuneÂ 30,Â 2024.Leading Positions in High Growth Sub-sectors of the Animal Health MarketWe are a global leader in the development, manufacture and commercialization of MFAs and nutritional specialty products for the animal health market. We believe we are well positioned in the fastest growing food animal species segments of the animal health market with significant presence in poultry and swine. We believe our sales of MFA products were third largest in the animal health market.Diversified and Complementary Product Portfolio with Strong Brand Name RecognitionWe market products across the three largest livestock species (poultry, swine, and beef and dairy cattle) and aquaculture and in the major product categories (MFAs, vaccines and nutritional specialty products). We believe our diversity of species and product categories enhances our sales mix and lowers our sales concentration risk. The complementary nature of our Animal Health and Mineral Nutrition portfolio provides us with unique cross-selling opportunities that can be used to gain access to new customers or deepen our relationships with existing customers. We believe we have strong brand name recognition for the Phibro name and for many of our animal health and mineral nutrition products, and we believe Phibro vaccines are recognized as an industry standard in efficacy against highly virulent disease challenges. Our diverse portfolio of products also allows us to address the distinct growing conditions of livestock in different regions.Experienced Sales Force and Technical Support Staff with Strong, Consultative Customer RelationshipsWithin our Animal Health and Mineral Nutrition segments, utilizing both our sales, marketing and technical support organization of approximately 400 employees and a broad distribution network, we market our portfolio of more than 670 product lines to livestock producers and veterinarians in over 80 countries. We interact with customers at both their corporate and operating level, which we believe allows us to develop an in-depth understanding of their needs. Our technical support and research personnel are also important contributors to our overall sales effort. We have a total of approximately 180 technical, field service and quality control/quality assurance personnel throughout the world. These professionals interface directly with our key customers to provide practical solutions to derive optimum benefits from our products.21 Table of ContentsExperienced, Committed Employees and Management TeamWe have a diverse and highly skilled team of animal health professionals, including technical and field service personnel located in key countries throughout the world. These individuals have extensive field experience and are vital to helping us maintain and grow our business. Many of our field team have more than 20Â years of experience in the animal health industry and many have been with us for more than 10Â years.We have a strong management team with a proven track record of success at both the corporate and operating levels. The executive management team has diverse backgrounds and on average more than 30 years of experience in the animal health or related industry.Human CapitalAs of JuneÂ 30,Â 2024, we had approximately 1,940 employees in 53 locations spanning 32 countries. Certain of our Brazilian employees are covered by multi-employer regional industry-specific unions. Certain of our Israeli employees are covered by site-specific collective bargaining agreements. Certain employees globally are covered by individual employment agreements. We strive to nurture a strong culture that empowers team members and provides opportunities for growth and development. The Denison Organization Culture survey was administered to all employees globally in 2017 and 2021, with an abbreviated survey on key points conducted in 2023, and will continue to be used as a key metric to measure our ongoing organizational health initiative focused on building employee capability, leadership development, employee onboarding and sales force effectiveness.At Phibro we view the strength of our team as a critical component of our success. The following principles, which guide our decisions and actions, provide an overview of how we approach management of human capital resources.Our Most Valuable Asset â€“ The Company and its EmployeesWe recognize that our employees provide the competitive edge needed to compete successfully in world markets. We adhere to human resources policies and practices that meet the needs of the business and the individual, so that we can attract and retain the highest caliber employees. Talent development is a strategic priority at Phibro, and we offer opportunities for growth at all levels of the company. Our goal is to ensure we have the right colleagues with the right skills in the right roles and with the appropriate support to build leadership capabilities and drive organizational results. As business priorities evolve and we seek to innovate, we work to nurture and develop current talent to best serve future needs. We take a programmatic and focused approach to developing our people. Achievement of business objectives and the fulfillment of individual career aspirations are reinforced by our competitive compensation and benefit programs, comprehensive training and development programs, health and safety programs that promote and safeguard employeesâ€™ well-being, and work environments that are conducive to the successful application of skills and knowledge. In addition to traditional professional development, we offer a robust, cloud-based online training curriculum from one of the leading providers of development material for learning-focused organizations. Employee safety is paramount. We have implemented our Road to Zero initiative, which utilizes teaming concepts to elevate employee involvement in project-based improvement activities. Participation drives a strong culture of safety and quality. Road to Zero provides a formal system for engagement, shared responsibility, leadership opportunities, meaningful contributions and accountability. We have and will continue to take the necessary daily precautions as recommended by local government authorities to keep our employees safe.Strength Through Diversity & InclusionWe create a positive and supportive work environment for our employees. Our approach enables opportunity for inclusion and encourages diverse perspectives and thinking to maximize the achievement of innovative and successful outcomes. We aim to protect employees from being discriminated against because of gender, sexual orientation, age, marital status, race, religion, political beliefs, ethnic background, country of origin, language or non-job-related disabilities, and we follow these same principles when recruiting new talent to our organization. 22 Table of ContentsRespecting Employees Phibro employees are our greatest strength and most valuable asset. When we equip team members to apply their skills, talent and passions to contribute and make a positive impact, everyone succeeds. When we thrive as individuals and teams, the Company thrives. We promote from within wherever possible, safeguard the confidentiality of employee records and keep employees informed of issues affecting them.Cultivating One Leader at a Time Our proprietary Leadership Model is a framework that guides how our people plan and act to advance company priorities. We strive for each executive/manager/employee to be consistently challenged to:â——See what needs to be done (strategy, vision, growth);â——Get it done (execution); andâ——Get it done the right way (how you do it).Recognizing that leadership may be exhibited differently by an individual contributor versus a first-line manager versus an upper-level manager, all Phibro employees are consistently expected to demonstrate leadership behaviors.ManufacturingThe Animal Health business segment manufactures many products internally and supplements that production with contract manufacturing organizations (â€œCMOsâ€) as necessary.We manufacture active pharmaceutical

ingredients for certain of our antibacterial and anticoccidial products in Guarulhos, Brazil and Braganca Paulista, Brazil. We manufacture active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products in Neot Hovav, Israel. We produce vaccines in Beit Shemesh, Israel, Sligo, Ireland, Omaha, Nebraska, and Guarulhos, Brazil. We produce adjuvants in Omaha, Nebraska. We produce pharmaceuticals, disinfectants and other animal health products in Petach Tikva, Israel. We produce certain of our nutritional specialty products in Quincy and Chillicothe, Illinois and Sarasota, Florida. We produce certain of our mineral nutrition products in Quincy, Illinois and Omaha, Nebraska.We supplement internal manufacturing and production capabilities with CMOs. We purchase certain active pharmaceutical ingredients for other medicated products from CMOs in China, India and other locations. We then formulate the final dosage form in our facilities and in contract facilities located in Argentina, Australia, Brazil, Canada, China, Israel, Malaysia, Mexico, South Africa and the United States.We purchase certain raw materials necessary for the commercial production of our products from a variety of third-party suppliers. Such raw materials are generally available from multiple sources, are purchased worldwide and are normally available in quantities adequate to meet the needs of the Companyâ€™s business.We believe that our existing facilities, as supplemented by CMOs, are adequate for our current requirements and for our operations in the foreseeable future.Research and DevelopmentMost of our manufacturing facilities have chemists and technicians on staff involved in product development, quality assurance, quality control and providing technical services to customers. Research, development and technical service efforts are conducted by our veterinarians (DVMs) and nutritionists at various facilities.We operate Animal Health R&D and product testing at several of our domestic and international facilities. We also engage various independent contract research organizations to undertake research and development activities.These facilities provide R&D services relating to: fermentation development and micro-biological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional specialty product development; and ethanol-related products.23 Table of ContentsEnvironmental, Health and SafetyOur operations and properties are subject to Environmental Laws (as defined below) and regulations. We have incurred, and will continue to incur, expenses to attain and maintain compliance with Environmental Laws. While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring to address contamination associated with historical operations. We maintain accruals for costs and liabilities associated with Environmental Laws, which we currently believe are adequate. In many instances, it is difficult to predict the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred.Governmental authorities have the power to enforce compliance with their regulations. Violators of Environmental Laws may be subject to civil, criminal and administrative penalties, injunctions or both. Failure to comply with Environmental Laws may result in the temporary or permanent suspension of operations and/or permits, limitations on production, or increased operating costs. In addition, private plaintiffs may initiate lawsuits for personal injury, property damage, diminution in property value or other relief as a result of our operations. Environmental Laws, and the interpretation or enforcement thereof, are subject to change and may become more stringent in the future, potentially resulting in substantial future costs or capital or operating expenses. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under and maintain compliance with Environmental Laws; however, we cannot predict with certainty the impact of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.Environmental, Health and Safety RegulationsThe following summarizes the principal Environmental Laws affecting our business.Waste Management.Â Â Â Our operations are subject to statutes and regulations addressing the contamination by, and management of, hazardous substances and solid and hazardous wastes. In the United States, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (â€œCERCLAâ€), also known as the â€œSuperfundâ€ law, and comparable state laws, generally impose strict joint and several liability for costs of investigation and remediation and related liabilities, on defined classes ofâ€‰â€œpotentially responsible partiesâ€ (â€œPRPsâ€). PRPs can be required to bear all of such costs regardless of fault, the legality of the original disposal or ownership of the disposal site. We have been, and may become, subject to liability under CERCLA for cleanup costs or investigation or clean up obligations or related third-party claims in connection with releases of hazardous substances at or from our current or former sites or offsite waste disposal facilities used by us, including those caused by predecessors or relating to divested properties or operations.We must also comply with the Resource Conservation and Recovery Act of 1976, as amended (â€œRCRAâ€), and comparable state laws regulating the treatment, storage, disposal, remediation and transportation of solid and hazardous wastes. These laws impose management requirements on generators and transporters of such wastes and on the owners and operators of treatment, storage and disposal facilities. As current or historic recyclers of chemical waste, certain of our subsidiaries have been, and are likely to be, the focus of extensive compliance reviews by environmental regulatory authorities under RCRA. Our subsidiary Phibro-Tech currently has a RCRA operating permit for its Santa Fe Springs, California facility, for which a renewal application is under review and a draft permit has been issued for public review and comment. Phibro-Tech initially submitted an application for renewal of its permit for the Santa Fe Springs facility in 1996. We are unable to predict when the State of California will make a final permitting decision. Until the State of California issues its final decision on the renewal application, the facility is continuing to operate under the exiting permit. Phibro-Tech has updated its permit application on several occasions, and Department of Toxic Substances Control has approved a number of permit modifications to the existing permit. In addition, because we or our subsidiaries have closed several facilities that had been the subject of RCRA permits, we or our subsidiaries have been and will be required to investigate and remediate certain environmental contamination conditions at these closed plant sites within the requirements of RCRA corrective action programs.24 Table of ContentsFederal Water Pollution Control Act, as amended.Â Â Â We must comply with regulations related to the discharge of pollutants to the waters of the United States without governmental authorization, including those pursuant to the Federal Water Pollution Control Act.Chemical Product Registration Requirements.Â Â Â We must comply with regulations related to the testing, manufacturing, labeling, registration and safety analysis of our products in order to distribute many of our products, including, for example, in the United States, the federal Toxic Substances Control Act and Federal Insecticide, Fungicide and Rodenticide Act, and in the European Union, the Regulation on Registration, Evaluation, Authorization and Restriction of Chemical Substances (â€œREACHâ€).Air Emissions.Â Â Â Our operations are subject to the U.S. Clean Air Act (the â€œCAAâ€) and comparable U.S. state and foreign statutes and regulations, which regulate emissions of various air pollutants and contaminants. Certain of the CAAâ€™s regulatory programs are the subject of ongoing review and/or are subject to ongoing litigation, such as the rules establishing new Maximum Achievable Control Technology for industrial boilers; significant expenditures may be required to meet current and emerging air quality standards. Regulatory agencies can also impose administrative, civil and criminal penalties for non-compliance with air permits or other air quality regulations. States may choose to set more stringent air emissions rules than those in the CAA. State, national and international authorities have also issued requirements focusing on greenhouse gas reductions. In the United States, the EPA has promulgated federal greenhouse gas regulations under the CAA affecting certain sources. In addition, a number of state, local and regional greenhouse gas initiatives are also being developed or are already in place. In Israel and Brazil, implementation of the Kyoto Protocol requirements regarding greenhouse gas emission reductions consists of energy efficiency regulations, carbon dioxide emissions allowances trading and renewable energy requirements.Capital ExpendituresWe have incurred and expect to continue to incur costs to maintain compliance with environmental, health and safety laws and regulations. Our capital expenditures relating to environmental, health and safety regulations were $2.6 million for the fiscal year ended JuneÂ 30,Â 2024. See â€œBusinessâ€‰â€”â€‰Environmental, Health and Safety Regulationsâ€ for further descriptions. Our environmental capital expenditure plans cover, among other things, the currently expected costs associated with known permit requirements relating to facility improvements.Contamination and Hazardous Substance RisksInvestigation, Remediation and Monitoring Activities.Â Â Â Certain of PAHCâ€™s subsidiaries that are currently or were historically engaged in recycling and other activities involving hazardous materials have been required to perform site investigations at their active, closed and former facilities and neighboring properties. Contamination of soil, groundwater and other environmental media has been identified or is suspected at several of these locations, including Santa Fe Springs, California; Powder Springs, Georgia; Union, Illinois; Sewaren, New Jersey; Sumter, South Carolina; and Joliet, Illinois, and regulatory authorities have required, and will continue to require, further investigation, corrective action and monitoring over futureÂ years. These subsidiaries also have been, and in the future may be, required to undertake additional capital improvements as part of these actions. In addition, RCRA and other applicable statutes and regulations require these subsidiaries to develop closure and post-closure plans for their facilities and in the event of a facility closure, obtain a permit that sets forth a closure plan for investigation, remediation and monitoring and requires post-closure monitoring and maintenance for up to 30Â years. We believe we are in material compliance with these requirements and maintain adequate reserves to complete remediation and monitoring obligations at these locations.In connection with past acquisitions and divestitures, we have undertaken certain indemnification obligations that require us, or may in the future require us, to conduct or finance environmental cleanups at sites we no longer own or operate. Under the terms of the sale of the former facility in Joliet, Illinois, Phibro-Tech remains responsible for any required investigation and remediation of the site attributable to conditions at the site at the time of the FebruaryÂ 2011 sale date, and we believe we have sufficient reserves to cover the cost of the remediation.Participating Responsible Parties (â€œPRPsâ€) at Omega Chemical Superfund Site.Â The EPA oversees remediation of contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (â€œOmega Chemical Siteâ€), which is upgradient of Phibro-Techâ€™s Santa Fe Springs, California facility. The EPA entered into a settlement agreement and court-approved consent decree (the â€œConsent Decreeâ€) with a group of companies, including Phibro-Tech 25 Table of Contentsand certain other subsidiaries of PAHC due to groundwater contamination from Phibro-Techâ€™s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In February 2023, Phibro-Tech signed a definitive settlement agreement that provided for a â€œcash-outâ€ settlement, with contribution protection, for Phibro-Tech and its affiliates releasing Phibro-Tech and its affiliates from liability for contamination of the groundwater plume affected by the Omega Chemical Site (with certain exceptions). The settlement agreement does not constitute an admission of liability on the part of Phibro-Tech or its affiliates. As part of the settlement, Phibro-Tech also resolved all claims for indemnification and contribution between Phibro-Tech and the successor to the prior owner of the Phibro-Tech site. The EPA, the Department of Justice and the district court have approved the definitive settlement agreement and the Consent Decree. The district courtâ€™s order can be appealed within 60 days, which period will expire on September 10, 2024. As of June 30, 2024, Phibro-Tech and one of its affiliates have made settlement payments totaling $5 million, which represents all cash payments required by the definitive settlement agreement.Potential Claims.Â Â Â In addition to cleanup obligations, we could also be held liable for all consequences arising out of human exposure to hazardous substances or other environmental damage, which liability may not be covered by insurance.Environmental Accruals and Financial Assurance.Â Â Â We have established environmental accruals to cover known remediation and monitoring costs at certain of our current and former facilities. Our accruals for environmental liabilities are recorded by calculating our best estimate of probable and reasonably estimable future costs using current information that is available at the time of the accrual. Our accruals for environmental liabilities totaled $4.3 million and $8.5 million as of JuneÂ 30,Â 2024 and 2023, respectively.In certain instances, regulatory authorities have required us to provide financial assurance for estimated costs of remediation, corrective action, monitoring and closure and post-closure plans. Our subsidiaries, in most instances, have chosen to provide the required financial assurance by means of surety bonds or letters of credit issued pursuant to our revolving credit facility. As of JuneÂ 30,Â 2024, surety bonds and letters of credit provided $15.5Â million of financial assurance.Workplace Health and SafetyWe are committed to manufacturing safe products and achieving a safe workplace. Our Environmental Health and Safety (â€œEHSâ€) Global Director, along with regional and site-based EHS professionals, manage environmental, health and safety matters throughout the Company. The site managers are responsible for implementing the established EHS controls. To protect employees, we have established health and safety policies, programs and processes at all our manufacturing sites. An external EHS audit is performed at each of our sites as needed based on the conditions at the respective sites.Proposed AcquisitionIn April 2024, we entered into a Purchase and Sale Agreement (the â€œPurchase Agreementâ€) with Zoetis Inc. (â€œZoetisâ€) to acquire Zoetisâ€™s medicated feed additive (MFA) product portfolio, certain water- soluble products and related assets (the â€œProposed Acquisitionâ€). The purchase price is $350 million, subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. The product portfolio to be acquired, which generated approximately $400 million in revenue in 2023, is comprised of more than 37 product lines that are sold in approximately 80 countries. Also included in the Proposed Acquisition are six manufacturing sites, comprised of four in the U.S., one in Italy and one in China. We anticipate that the Proposed Acquisition will be completed between October and December 2024. Completion of the Proposed Acquisition is subject to satisfaction of customary closing conditions, including clearances by applicable regulatory authorities.Where You Can Find More InformationWe are subject to the information and periodic and current reporting requirements of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) and, in accordance therewith, will file periodic and current reports, proxy statements and other information with the Securities and Exchange Commission (â€œSECâ€). Such periodic and current reports, proxy statements and other information will be available to the public on the SECâ€™s website at www.sec.gov and 26 Table of Contentsthrough our website at www.pahc.com. None of the information accessible on or through our website is incorporated into this Annual Report on Form 10-K.Item 1A.Â Â Â Risk Factors Risk Factors SummaryFor a summary of risk factors, see our â€œForward-Looking Statements and Risk Factors Summaryâ€ on page 3.Risk FactorsYou should carefully consider all of the information set forth in this Annual Report on Form 10-K, including the following risk factors, before deciding to invest in our ClassÂ A common stock. If any of the following risks occurs, our business, financial condition, results of operation or cash flows could be materially adversely affected. In any such case, the trading price of our ClassÂ A common stock could decline, and you could lose all or part of your investment. The risks below are not the only ones the Company faces. Additional risks not currently known to the Company or that the Company presently deems immaterial may also impair its business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. The Companyâ€™s results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks it faces described below and elsewhere. See also â€œForward-Looking Statements and Risk Factors Summary.â€Risk Factors Relating to Our BusinessOutbreaks of animal diseases could significantly reduce demand for our products.Sales of our food animal products could be materially adversely affected by the outbreak of disease carried by food animals, which could lead to the widespread death or precautionary destruction of food animals as well as the reduced consumption and demand for animal protein. The demand for our products could be significantly affected by outbreaks of animal diseases, and such occurrences may have a material adverse impact on the sale of our products and our financial condition and results of operations. The outbreaks of disease are beyond our control and could significantly affect demand for our products and consumer perceptions of certain meat products. An outbreak of disease could result in governmental restrictions on the import and export of chicken, pork, beef or other products to or from our customers. This could also create adverse publicity that may have a material adverse effect on our ability to sell our products successfully and on our financial condition and results of operations. In addition, outbreaks of disease carried by animals may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products due to reduced herd or flock sizes.In recent years, outbreaks of African Swine Fever, primarily in China, have reduced animal populations and have reduced consumer demand for pork in the affected markets. In the past decade, there has been substantial publicity regarding H1N1, known as North American (or Swine) Influenza and, H5N1, known as Highly Pathogenic Avian Influenza, in the human population, birds and, most recently, dairy cattle. According to the WHO, in 2022, 67 countries in five continents reported H5N1 high pathogenicity avian influenza outbreaks in poultry and wild birds to the World Organization for Animal Health, with more than 131 million domestic poultry lost due to death or culling in affected farms and villages. In 2023, another 14 countries reported outbreaks, mainly in the Americas, as the disease continued to spread. There have also been concerns relating to E. coli in beef and Salmonella in poultry and other food poisoning micro-organisms in meats and other foods. Consumers may associate human health fears with animal diseases, food, food production or food animals whether or not it is scientifically valid, which may have an adverse impact on the demand for animal protein. Occurrences of this type could significantly affect demand for animal protein, which in turn could affect the demand for our products in a manner that has a significant adverse effect on our financial condition and results of operations. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Outbreaks of an exotic or highly contagious disease in a country where we produce our products may result in other countries halting importation of our products for fear that our product may be contaminated with the exotic organism.27 Table of ContentsPerceived adverse effects on human health linked to the consumption of food derived from

animals that utilize our products could cause a decline in the sales of those products.Our business depends heavily on a healthy and growing livestock industry. Some in the public perceive risks to human health related to the consumption of food derived from animals that utilize certain of our products, including certain of our MFA products. In particular, there is increased focus in the United States, the E.U., China and other countries on the use of antimicrobials in the livestock industry. In the United States, this focus is primarily on the use of medically important antimicrobials, which include classes that are prescribed in animal and human health and are listed in the Appendix of the FDA-CVM Guidance for Industry (GFI) 152. As defined by the FDA, medically important antimicrobials (â€œMIAsâ€) include classes that are prescribed in animal and human health and are listed in the Appendix of GFI 152. Our products that contain virginiamycin, oxytetracycline or neomycin are classified by the FDA as medically important antimicrobials and are included in the GFI 152 list. The FDA announced its intention to further review the GFI 152 list and to review labeling directions of products on the GFI 152 list, which may lead to increased restrictions on the use of these products. In addition to the United States, the World Health Organization (WHO), the E.U., Australia and Canada have promulgated rating lists for antimicrobials that are used in veterinary medicine and that include certain of our products. The classification of our products as MIAs or similar listings may lead to a decline in the demand for and production of food products derived from animals that utilize our products and, in turn, demand for our products. Rules or regulations adopted by any territory that restrict the use of our products, especially our antibacterial products, which require animals or animal origin products imported into that territory to be produced under the same conditions as are required within the territory could result in a reduction or elimination of the use of our products in countries that export animals or animal origin products to such territories. Livestock producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of nutrition and health-related concerns, animal rights and other concerns. Any reputational harm to the livestock industry may also extend to companies in related industries, including us. In addition, campaigns by interest groups, activists and others with respect to perceived risks associated with the use of our products in animals, including position statements by livestock producers and their customers based on non-use of certain medicated products in livestock production, whether or not scientifically supported, could affect public perceptions and reduce the use of our products. Those adverse consumer views related to the use of one or more of our products in animals could have a material adverse effect on our financial condition and results of operations.Restrictions on the use of antibacterials in food-producing animals may become more prevalent.The issue of the potential transfer of antibacterial resistance from bacteria from food-producing animals to human bacterial pathogens, and the causality and impact of that transfer, are the subject of global scientific and regulatory discussion. Antibacterials refer to molecules that can be used to treat or prevent bacterial infections and are a sub-categorization of the products that make up our medicated feed additives portfolios. In some countries, this issue has led to government restrictions on the use of specific antibacterials in some food-producing animals, regardless of the route of administration (in feed, water, intra-mammary, topical, injectable or other route of administration). These restrictions include prohibitions on use of antibacterials for non-therapeutic uses, preventative use, duration of use and requiring veterinary oversight to use products. These restrictions are more prevalent in countries where animal protein is plentiful and governments are willing to take action even when there is scientific uncertainty.Effective JanuaryÂ 1, 2017, we voluntarily removed non-therapeutic claims from several of our antibacterial products sold in the United States, in order to align with the FDAâ€™s GFI 209 and GFI 213. The FDA objective, as described in GFI 209 and GFI 213, was to eliminate the production (non-therapeutic) uses of medically important antimicrobials administered in feed or water to food producing animals while providing for the continued use of medically important antimicrobials in food-producing animals for treatment, control and prevention of disease (â€œtherapeuticâ€ use) under the supervision of a veterinarian. The FDA indicated that it took this action to help preserve the efficacy of medically important antimicrobials to treat infections in humans.Our global sales of antibacterials, anticoccidials and other products, including our Mecadox product, were $421 million, $387 million and $362 million for the years ended JuneÂ 30,Â 2024, 2023 and 2022, respectively. We cannot predict whether concerns regarding the use of antibacterials will result in additional restrictions, expanded regulations or consumer preferences to discontinue or reduce use of antibacterials in food-producing animals, which could materially adversely affect our operating results and financial condition. 28 Table of ContentsIf the FDA withdraws approval of our Mecadox (carbadox) product, the loss of sales of such product could have a material adverse effect on our business, financial condition and results of operations.Our Mecadox (carbadox) product has been approved for use in food animals in the United States for over 50 years. Certain regulatory bodies have raised concerns about the possible presence of certain residues of our carbadox product in meat from animals that consume the product. The product was banned for use in the European Union in 1998 and has been banned in several other countries outside the United States. In April 2016, the FDA began initial steps to withdraw approval of carbadox via a regulatory process known as a Notice of Opportunity for Hearing (â€œNOOHâ€), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDAâ€™s Center for Veterinary Medicine (â€œCVMâ€) inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method. In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues. The FDA also provided notice in the Federal Register proposing to withdraw approval of all NADAs providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVMâ€™s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is continuing to defend swine producersâ€™ ability to use Mecadox. We have requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the year ended JuneÂ 30,Â 2024 were approximately $22 million.See also â€œâ€‰â€”â€‰We are subject to product registration and authorization regulations in many of the jurisdictions in which we operate and/or distribute our products, including the United States and member states of the European Unionâ€; â€œBusinessâ€‰â€”â€‰Compliance with Government Regulationâ€‰â€”â€‰United States â€” Carbadoxâ€; and â€œBusiness â€” Compliance with Government Regulation â€” Global Policy and Guidance.â€A material portion of our sales are generated by antibacterials and other related products.Our medicated products business is comprised of a relatively small number of compounds and accounted for approximately 40% of net sales for each of the years ended JuneÂ 30,Â 2024 and 2023. The significant loss of antibacterial or other related product sales for any reason, including product bans or restrictions, public perception, competition or any of the other risks related to such products as described in this Annual Report on Form 10-K, could have a material adverse effect on our business.Our business may be negatively affected by weather conditions and the availability of natural resources.The animal health industry and demand for many of our animal health products in a particular region are affected by changing disease pressures and by weather conditions, as usage of our products follows varying weather patterns and weather-related pressures from pests and diseases. As a result, we may experience regional and seasonal fluctuations in our results of operations.In addition, livestock producers depend on the availability of natural resources, including abundant rainfall to sustain large supplies of drinking water, grasslands and grain production. Their animalsâ€™ health and their ability to operate could be adversely affected if they experience a shortage of fresh water due to human population growth or floods, droughts or other weather conditions. In the event of adverse weather conditions or a shortage of fresh water, livestock producers may purchase less of our products.29 Table of ContentsAdverse weather conditions, including excessive cold or heat, natural disasters, floods, droughts and other events, could negatively impact our livestock customers by impairing the health or growth of their animals or the production or availability of feed. Such events can also interfere with our customersâ€™ operations due to power outages, fuel shortages, damage to their farms or facilities or disruption of transportation channels. In addition, droughts can lead to reduced availability of grazing pastures, forcing cattle producers to cull their herds. Fewer heads of cattle could result in reduced demand for our products. Further heat waves may cause stress in animals and lead to increased vulnerability to disease, reduced fertility rates and reduced milk production. Adverse weather conditions and natural disasters may also have a material impact on the aquaculture business. Changes in water temperatures could affect the timing of reproduction and growth of various fish species, as well as trigger the outbreak of certain water borne diseases. Adverse weather events and natural disasters may also interfere with and negatively impact operations at our manufacturing sites, research and development facilities and offices, which could have a material adverse effect on our financial condition and results of operations, especially if the impact of an event or disaster is frequent or prolonged. A pandemic, epidemic, or outbreak of an infectious disease in humans, such as COVID-19, may materially and adversely affect our business and our financial results.Our business is exposed to risks associated with public health crises, including epidemics and pandemics such as the novel coronavirus and its variants (COVID-19). The COVID-19 pandemic adversely affected workforces, customers, suppliers, consumer sentiment, economies and financial markets and led to an economic downturn in many countries in which we operate. Disruptions due to a resurgence of COVID-19 or other similar health epidemics could negatively impact our manufacturing facilities, and our logistics and supply chain operations, as well as those of our customers, third-party manufacturers, suppliers and end users of our products who raise animals or who process meat, milk, eggs and seafood for human consumption and may result in a period of economic and business disruption and could have a material adverse impact on our business and financial results.The COVID-19 pandemic and similar outbreaks could lead to decreased demand for protein, which may lead to end users of our products reducing their herd or flock sizes. In addition, demand for protein could be reduced because consumers may associate human health fears related to COVID-19 or other outbreaks with animal diseases, food, food production or food animals, whether or not it is scientifically valid. Reductions in demand for animal protein resulting from these factors could in turn affect the demand for our products in a manner that has a significant adverse effect on our financial condition and results of operations.The impact of a pandemic or similar public health crises is uncertain and subject to change and could also exacerbate the other risks discussed in this â€œRisk Factorsâ€ section. We cannot predict with certainty the full scope and severity of any potential disruptions to our business, operating results, cash flows and/or financial condition, but we expect that the resulting adverse impact on our business and financial results could be material.Climate change could have a material adverse impact on our operations and our customersâ€™ businesses.Our operations, and the activities of our customers, could be disrupted by climate change. The physical impact of climate change may prompt shifts in regulations or consumer preferences which in turn could have negative consequences for our and our customersâ€™ businesses. Climate change may negatively impact our customersâ€™ operations, particularly those in the livestock industry, through climate-related impacts such as increased air and water temperatures, rising water levels and increased incidence of disease in livestock. Potential physical risks from climate change may include altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and other natural disasters, rising sea levels and a rising heat index, any of which could cause negative impacts to our and our customersâ€™ businesses. If such events affect our customersâ€™ businesses, they may purchase fewer of our products, and our revenues may be negatively impacted. Climate driven changes could have a material adverse effect on our financial condition and results of operations. There has been a broad range of proposed and promulgated state, national and international regulations aimed at reducing the effects of climate change. Such regulations could result in additional costs to maintain compliance and additional income or other taxes. Climate change regulations continue to evolve, and it is not possible to accurately estimate potential future compliance costs.30 Table of ContentsThe testing, manufacturing and marketing of certain of our products are subject to extensive regulation by numerous government authorities in the United States and other countries, including, but not limited to, the FDA.Among other requirements, FDA approval of antibacterials and other medicated products, including the manufacturing processes and facilities used to produce such products, is required before such products may be marketed in the United States. Further, cross-clearance approvals are generally required for such products to be used in combination in animal feed. Similarly, marketing approval by a foreign governmental authority is typically required before such products may be marketed in a particular foreign country. In addition to approval of the product and its labeling, regulatory authorities typically require approval and periodic inspection of the manufacturing facilities. In order to obtain FDA approval of a new animal health product, we must, among other things, demonstrate to the satisfaction of the FDA that the product is safe and effective for its intended uses and that we are capable of manufacturing the product with procedures that conform to FDAâ€™s current cGMP regulations, which must be followed at all times.Audits related to cGMP standards are typically carried out by the FDA on a two-year cycle. We are routinely subject to these inspections and respond to the FDA to address any concerns they may make in their inspectional observations (Form 483). Although it is our objective to remain in full conformance with U.S. cGMP standards, there can be no assurance that future inspections will not raise adverse inspectional observations. Failure to comply with cGMP standards could have a material impact on our business and financial results.The process of seeking FDA approvals can be costly, time-consuming, and subject to unanticipated and significant delays. There can be no assurance that such approvals will be granted to us on a timely basis, or at all. Any delay in obtaining or any failure to obtain FDA or foreign government approvals or the suspension or revocation of such approvals would adversely affect our ability to introduce and market medicated feed additive products and to generate product revenue. For more information on FDA and foreign government approvals and cGMP issues, see â€œBusinessâ€‰â€”â€‰Compliance with Government Regulation.â€We may experience declines in the sales volume and prices of our products as the result of the continuing trend toward consolidation of certain customer and distributor groups as well as the emergence of large buying groups.We make a majority of our sales to integrated poultry, swine and beef and dairy cattle operations and to a number of regional and national feed companies, distributors, co-ops and blenders. Food animal producers, particularly, swine and poultry producers, and our distributors have seen recent consolidation in their industries. Significant consolidation of our customers and distributors may result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our business. Additionally, the emergence of large buying groups potentially could enable such groups to attempt to extract price discounts on our products. Moreover, if, as a result of increased leverage, customers require us to reduce our pricing such that our gross margins are diminished, we could decide not to sell our products to a particular customer, which could result in a decrease in our revenues. Consolidation among our customer base may also lead to reduced demand for our products and replacement of our products by the combined entity with those of our competitors. The result of these developments could have a material adverse effect on our business, financial condition and results of operations.Our business is subject to risk based on customer exposure to rising costs and reduced customer income.Livestock producers may experience increased feed, fuel, transportation and other key costs or may experience decreased animal protein prices or sales, inflationary pressures as a result of interest rate increases or otherwise and including as a result of the uncertainties and potential economic downturn relating to a resurgence of the COVID-19 pandemic or similar public health crises, or relating to armed conflicts, including the ongoing conflicts between Israel and Hamas and between Russia and Ukraine. International sanctions, trade disputes and tariffs could reduce demand for our customersâ€™ products. These trends could cause deterioration in the financial condition of our livestock producer customers, potentially inhibiting their ability to purchase our products or pay us for products delivered. Our livestock producer customers may offset rising costs by reducing spending on our products, including by switching to lower-cost alternatives to our products.Generic products may be viewed as more cost-effective than certain of our products.We face competition from products produced by other companies, including generic alternatives to certain of our products. We depend primarily on trade secrets to provide us with competitive advantages for many of our products. The 31 Table of Contentsprotection afforded is limited by the availability of new competitive products or generic versions of existing products that can successfully compete with our products. As a result, we may face competition from new competitive products or lower-priced generic alternatives to many of our products. Generic competitors are becoming more aggressive in terms of pricing, and generic products are an increasingÂ percentage of overall animal health sales in certain regions. If animal health customers increase their use of new or existing generic products, our financial condition and results of operations could be materially adversely affected.Advances in veterinary medical practices and animal health technologies could negatively affect the market for our products.The market for our products could be impacted negatively by the introduction and/or broad market acceptance of newly developed or alternative products that address the diseases and conditions for which we sell products, including â€œgreenâ€ or â€œholisticâ€ health products or specially bred disease-resistant animals. In addition, technological breakthroughs by others may obviate our technology and reduce or eliminate the market for our products. Introduction or acceptance of such products or technologies could materially adversely affect our business, financial condition and results of operations.The misuse or extra-label use of our products may harm our reputation or result in financial or other damages.Our products have been approved for use under specific circumstances

for, among other things, the prevention, control and/or treatment of certain diseases and conditions in specific species, in some cases subject to certain dosage levels or minimum withdrawal periods prior to the slaughter date. There may be increased risk of product liability if livestock producers or others attempt any extra-label use of our products, including the use of our products in species for which they have not been approved, or at dosage levels or periods prior to withdrawal that have not been approved. If we are deemed by a governmental or regulatory agency to have engaged in the promotion of any of our products for extra-label use, such agency could request that we modify our training or promotional materials and practices and we could be subject to significant fines and penalties. The imposition of such fines and penalties could also affect our reputation and position within the industry. Even if we were not responsible for having promoted the extra-label use, concerns could arise about the safety of the resulting meat in the human food supply. Any of these events could materially adversely affect our financial condition and results of operations.The public perception of the safety, quality and efficacy of certain of our animal health products may harm our reputation.The public perception of the safety, quality and efficacy of certain of our animal health products, whether or not these concerns are scientifically or clinically supported, may lead to product recalls, withdrawals, suspensions or declining sales as well as product liability and other claims.Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion of a productâ€™s sales and could, depending on the circumstances, materially adversely affect our results of operations.In addition, we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products generally, by our customers, veterinarians and end-users, and such concerns may harm our reputation. In some countries, these perceptions may be exacerbated by the existence of counterfeit versions of our products, which, depending on the legal and law enforcement recourse available in the jurisdiction where the counterfeiting occurs, may be difficult to police or stop. These concerns and the related harm to our reputation could materially adversely affect our financial condition and results of operations, regardless of whether such reports are accurate.We are dependent on suppliers having current regulatory approvals, and the failure of those suppliers to maintain these approvals or other challenges in replacing any of those suppliers could affect our supply of materials or affect the distribution or sale of our products.Suppliers and third-party contract manufacturers for our animal health and mineral nutrition products or the active pharmaceutical ingredients or other materials we use in our products, like us, are subject to extensive regulatory compliance. If any one of these third parties discontinues its supply to us because of changes in the regulatory environment to which such third parties are subject, significant regulatory violations or for any other reason, or an 32 Table of Contentsadverse event occurs at one of their facilities, the interruption in the supply of these materials could decrease sales of our affected products. In this event, we may seek to enter into agreements with third parties to purchase active ingredients, raw materials or products or to lease or purchase new manufacturing facilities. We may be unable to find a third party willing or able to provide the necessary products or facilities suitable for manufacturing pharmaceuticals on terms acceptable to us or the cost of those pharmaceuticals may be prohibitive. If we have to obtain substitute materials or products, additional regulatory approvals will likely be required, as approvals are typically specific to a single product produced by a specified manufacturer in a specified facility and there can be no assurances that such regulatory approvals will be obtained. As such, the use of new facilities also requires regulatory approvals. While we take measures where economically feasible and available to secure back-up suppliers, the continued receipt of active ingredients or products from a sole source supplier could create challenges if a sole source was interrupted. We may not be able to provide adequate and timely product to eliminate any threat of interruption of supply of our products to customers and these problems may materially adversely impact our business.The raw materials used by us and our third-party contract manufacturers in the manufacture of our products can be subject to price fluctuations and their availability can be limited.While the selling prices of our products tend to increase or decrease over time with the cost of raw materials, such changes may not occur simultaneously or to the same degree. The costs of certain of our significant raw materials are subject to considerable volatility, and we generally do not engage in activities to hedge the costs of our raw materials and our third-party contract manufacturers may demand price increases related to increases in the costs of raw materials. In addition, we may be subject to new or increased tariffs on imported raw materials with limited ability to pass those increased costs through to our customers. Although no single raw material accounted for more than 5% of our cost of goods sold for the year ended JuneÂ 30,Â 2024, volatility in raw material costs can result in significant fluctuations in our cost of goods sold of the affected products. The costs of raw materials used by our Mineral Nutrition business are particularly subject to fluctuations in global commodities markets and cost changes in the underlying commodities markets typically lead directly to a corresponding change in our revenues. Although we attempt to adjust the prices of our products to reflect significant changes in raw material costs, we may not be able to pass any increases in raw material costs through to our customers in the form of price increases. Significant increases in the costs of raw materials, if not offset by product price increases, could have a material adverse effect on our financial condition and results of operations. The supply of certain of our raw materials is dependent on third party suppliers. There is no guarantee that supply shortages or disruptions of such raw materials will not occur and the likelihood of such supply shortages and disruptions has been, and may continue to be, increased due to global supply chain disruptions, including those caused by the COVID-19 pandemic or similar health crises and the ongoing conflicts between Israel and Hamas and between Russia and Ukraine. In addition, if any one of these third parties discontinues its supply to us, or an adverse event occurs at one of their facilities, the interruption in the supply of these materials could decrease sales of our affected products. In the event that we cannot procure necessary major raw materials from other suppliers, the occurrence of any of these may have an adverse impact on our business.Our revenues are dependent on the continued operation of our various manufacturing facilities.Although presently all our manufacturing facilities are considered to be in good condition, the operation of our manufacturing facilities involves many risks which could cause product interruptions, including the breakdown, failure or substandard performance of equipment, construction delays, mislabeling, shortages of materials, labor problems, power outages, political and social instability, the improper installation or operation of equipment, natural disasters, terrorist activities, armed conflicts, the outbreak of any highly contagious diseases, such as COVID-19 in humans or African Swine Fever in swine, near our production sites and the need to comply with environmental and other directives of governmental agencies. In addition, regulatory authorities such as the FDA typically require approval and periodic inspection of the manufacturing facilities to confirm compliance with applicable regulatory requirements, and those requirements may be enforced by various means, including seizures and injunctions. Certain of our product lines are manufactured at a single facility, and certain of our product lines are manufactured at a single facility with limited capacity at a second facility, and production would not be easily transferable to another site. The occurrence of material operational problems, including but not limited to the above events, may adversely affect our financial condition and results of operations.Our manufacturing network may be unable to meet the demand for our products or we may have excess capacity if demand for our products changes. The unpredictability of a productâ€™s regulatory or commercial success or failure, the 33 Table of Contentslead time necessary to construct highly technical and complex manufacturing sites and shifting customer demand (including as a result of market conditions or entry of branded or generic competition) increase the potential for capacity imbalances. In addition, construction of manufacturing sites is expensive, and our ability to recover costs will depend on the market acceptance and success of the products produced at the new sites, which is uncertain.We could be subject to changes in our tax rates, the adoption of new U.S. or foreign tax legislation or exposure to additional tax liabilities.We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Changes in the relevant tax laws, regulations and interpretations could adversely affect our future effective tax rates. Modifications to key elements of the U.S. or international tax framework could have a material adverse effect on our consolidated financial statements.Our consolidated effective tax rate is subject to potential risks that various taxing authorities may challenge the pricing of our cross-border arrangements and subject us to additional tax, adversely affecting our expected consolidated effective tax rate and our tax liability. If our effective tax rates were to increase, particularly in the U.S. or other material foreign jurisdictions, our business, financial condition and results of operations could be materially adversely affected. In addition, our tax returns and other tax filings and positions are subject to review by the Internal Revenue Service (the â€œIRSâ€) and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes. There can be no assurance as to the outcome of these examinations or the effects on our consolidated financial statements.A significant portion of our operations are conducted in foreign jurisdictions and are subject to the economic, political, legal and business environments of the countries in which we do business.Our international operations could be limited or disrupted by any of the following:â—volatility in the international financial markets;â—compliance with governmental controls;â—difficulties enforcing contractual and intellectual property rights;â—compliance with a wide variety of laws and regulations, such as the U.S. Foreign Corrupt Practices Act (â€œFCPAâ€) and similar non-U.S. laws and regulations;â—compliance with foreign labor laws;â—compliance with Environmental Laws;â—burdens to comply with multiple and potentially conflicting foreign laws and regulations, including those relating to EHS requirements;â—changes in laws, regulations, government controls or enforcement practices with respect to our business and the businesses of our customers;â—political and social instability, including crime, civil disturbance, terrorist activities, outbreaks of disease and pandemics and armed conflicts, such as the ongoing conflicts between Israel and Hamas (and potential broader military conflict in the region) and between Russia and Ukraine;â—trade restrictions, export controls and sanctions laws and restrictions on direct investments by foreign entities, including restrictions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury;â—government limitations on foreign ownership;â—government takeover or nationalization of businesses;â—changes in tax laws and tariffs;â—changes in the economic, business, competitive and regulatory environment, including changes in the value of foreign currencies relative to the U.S. dollar or high inflation;34 Table of Contentsâ—imposition of anti-dumping and countervailing duties or other trade-related sanctions;â—costs and difficulties and compliance risks in staffing, managing and monitoring international operations;â—corruption risk inherent in business arrangements and regulatory contacts with foreign government entities;â—longer payment cycles and increased exposure to counterparty risk; andâ—additional limitations on transferring personal information between countries or other restrictions on the processing of personal information.The multinational nature of our business subjects us to potential risks that various taxing authorities may challenge the pricing of our cross-border arrangements and subject us to additional tax, adversely impacting our effective tax rate and our tax liability.In addition, international transactions may involve increased financial and legal risks due to differing legal systems and customs, as well as restrictions and sanctions that may be imposed on one or more persons and/or jurisdictions in which we operate, including those arising from the ongoing armed conflicts between Israel and Hamas (and potential broader military conflict in the region) and between Russia and Ukraine. Compliance with these requirements may prohibit the import or export of certain products and technologies or may require us to obtain a license before importing or exporting certain products or technology. A failure to comply with any of these laws, regulations or requirements could result in civil or criminal legal proceedings, monetary or non-monetary penalties, or both, disruptions to our business, limitations on our ability to import and export products and services, and damage to our reputation. In addition, variations in the pricing of our products in different jurisdictions may result in the unauthorized importation of our products between jurisdictions. While the impact of these factors is difficult to predict, any of them could materially adversely affect our financial condition and results of operations. Changes in any of these laws, regulations or requirements, or the political environment in a particular country, may affect our ability to engage in business transactions in certain markets, including investment, procurement and repatriation of earnings.We are subject to product registration and authorization regulations in many of the jurisdictions in which we operate and/or distribute our products, including the United States and member states of the European Union.We are subject to regulations related to testing, manufacturing, labeling, registration and safety analysis in order to lawfully distribute many of our products, including for example, in the United States, the Federal Toxic Substances Control Act and the Federal Insecticide, Fungicide, and Rodenticide Act, and in the European Union, the Regulation on REACH. We are also subject to similar requirements in many of the other jurisdictions in which we operate and/or distribute our products. In some cases, such registrations are subject to periodic review by relevant authorities. Such regulations may lead to governmental restrictions or cancellations of, or refusal to issue, certain registrations or authorizations, or cause us or our customers to make product substitutions in the future. Such regulations may also lead to increased third party scrutiny and personal injury or product liability claims. Compliance with these regulations can be difficult, costly and time consuming and liabilities or costs relating to such regulations could have a material adverse effect on our business, financial condition and results of operations.We have significant assets located outside the United States and a significant portion of our sales and earnings is attributable to operations conducted abroad that may be adversely affected by foreign currency exchange rate fluctuations and other inherent risks.As of JuneÂ 30,Â 2024, we had manufacturing and direct sales operations in 24 countries and sold our products in over 80 countries. Our operations outside the United States accounted for 59% and 58% of our consolidated assets as of JuneÂ 30,Â 2024 and 2023, respectively, and 43% and 41% of our consolidated net sales for theÂ years ended JuneÂ 30,Â 2024 and 2023, respectively. Our foreign operations are subject to currency exchange fluctuations and restrictions, political instability in some countries, and uncertainty of, and governmental control over, commercial rights.Changes in the relative values of currencies take place from time to time and could in the future adversely affect our results of operations as well as our ability to meet interest and principal obligations on our indebtedness. To the extent that the U.S. dollar fluctuates relative to the applicable foreign currency, our results are favorably or unfavorably affected. We may from time to time manage this exposure by entering into foreign currency contracts. Such contracts generally are entered into with respect to anticipated costs denominated in foreign currencies for which timing of the 35 Table of Contentspayment can be reasonably estimated. No assurances can be given that such hedging activities will not result in, or will be successful in preventing, losses that could have an adverse effect on our financial condition or results of operations. There are times when we do not hedge against foreign currency fluctuations and therefore are subject to the risks associated with fluctuations in currency exchange rates.In addition, international manufacturing, sales and raw materials sourcing are subject to other inherent risks, including possible nationalization or expropriation, labor unrest, political instability, price and exchange controls, limitation on foreign participation in local enterprises, health-care regulation, export duties and quotas, domestic and international customs and tariffs, compliance with export controls and sanctions laws, the Foreign Corrupt Practices Act and other laws and regulations governing international trade, unexpected changes in regulatory environments, difficulty in obtaining distribution and support, and potentially adverse tax consequences. Although such risks have not had a material adverse effect on us in the past, these factors could have a material adverse impact on our ability to increase or maintain our international sales or on our results of operations in the future.We have manufacturing facilities located in Israel and a portion of our net sales and earnings is attributable to products produced and operations conducted in Israel.Our Israeli manufacturing facilities and local operations accounted for 28% and 27% of our consolidated assets, as of JuneÂ 30,Â 2024 and 2023, and 21% and 19% of our consolidated net sales for theÂ years ended JuneÂ 30,Â 2024 and 2023, respectively. We maintain manufacturing facilities in Israel, which manufacture:â—anticoccidials and antimicrobials, most of which are exported;â—vaccines, a substantial portion of which are exported; andâ—animal health pharmaceuticals, nutritional specialty products and trace minerals for the domestic animal industry.A substantial portion of this production is exported from Israel to major world markets. Accordingly, our Israeli operations are dependent on foreign markets and the ability to reach those markets. Hostilities between Israel and its neighbors, including the ongoing conflict between Israel and Hamas (and potential broader military conflict in the region), may hinder Israelâ€™s international trade. This, in turn, could have a material adverse effect on our business, financial condition and results of operations. See â€œPart II. Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations â€“ Factors affecting our performance â€“ Armed conflicts â€“ Israel and Hamas.â€Certain countries, companies and organizations continue to participate in a boycott of Israeli firms and other companies doing business in Israel or with Israeli companies. We do not believe that the boycott has had a material adverse effect on us, but we cannot provide assurance that restrictive laws, policies or practices directed toward Israel or Israeli businesses will not have an adverse impact on our operations or expansion of our business. Our business, financial condition and results of operations in Israel may be adversely affected by factors outside of our control, such as currency fluctuations, energy shortages and other political, social and economic developments in or affecting Israel, including as a result of the impact of any resurgence of the COVID-19 pandemic or the ongoing conflict between Israel and Hamas.We have manufacturing facilities located in Brazil and a portion of our sales and earnings is attributable to products produced and operations conducted in Brazil.Our Brazilian manufacturing facilities and local operations accounted for 14% of our consolidated assets, as of JuneÂ 30,Â 2024 and 2023, and 16% of our consolidated net sales for theÂ years ended JuneÂ 30,Â 2024 and 2023. We maintain manufacturing facilities in Brazil, which manufacture virginiamycin, semduramicin, salinomycin and nicarbazin. Our Brazilian facilities also produce Stafac, Aviax, Aviax Plus, Coxistac, Nicarb, KamoranÂ®, and Terramycin granular formulations. A substantial portion of the production is exported from Brazil to major world markets. Accordingly, our Brazilian operations are dependent on foreign markets and the ability to reach those markets.Our business, financial condition and results of operations in Brazil may be adversely affected by factors outside of our control, such as currency fluctuations, energy shortages and other political, social and economic developments in or affecting Brazil, including as a result of the impact of a resurgence of the COVID-19 pandemic or similar public health crises in Brazil.36 Table of ContentsCertain of our employees are covered by collective bargaining or other labor agreements.As of JuneÂ 30,Â 2024, approximately 300 of our Israeli employees and 600 of our Brazilian employees were covered

by collective bargaining agreements. We believe we have satisfactory relations with our employees. There can be no assurance that we will not experience a work stoppage or strike at our manufacturing facilities. A prolonged work stoppage or strike at any of our manufacturing facilities could have a material adverse effect on our business, financial condition and results of operations.The loss of key personnel may disrupt our business and adversely affect our financial results.Our operations and future success are dependent on the continued efforts of our senior executive officers and other key personnel. Although we have entered into employment agreements with certain executives, we may not be able to retain all of our senior executive officers and key employees. These senior executive officers and other key employees may be hired by our competitors, some of which have considerably more financial resources than we do. The loss of the services of any of our senior executive officers or other key personnel, or the inability to hire and retain qualified employees, could have a material adverse effect on our business, financial condition and results of operations.Our R&D relies on evaluations in animals, which may become subject to bans or additional regulations.As a company that produces animal health medicines and vaccines, evaluation of our existing and new products in animals is required in order to be able to register our products. Animal testing in certain industries has been the subject of controversy and adverse publicity. Some organizations and individuals have attempted to ban animal testing or encourage the adoption of additional regulations applicable to animal testing. To the extent that the activities of such organizations and individuals are successful, our R&D, and by extension our financial condition and results of operations, could be materially adversely affected. In addition, negative publicity about us or our industry could harm our reputation.Our operations, properties and subsidiaries are subject to a wide variety of complex and stringent federal, state, local and foreign environmental laws and regulations.We are subject to environmental, health and safety laws and regulations, including those governing pollution; protection of the environment; the use, management and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees and the public (collectively, â€œEnvironmental Lawsâ€). See â€œBusinessâ€‰â€”â€‰Environmental, Health and Safety.â€Pursuant to Environmental Laws, certain of our subsidiaries are required to obtain and maintain numerous governmental permits, licenses, registrations, authorizations and approvals, including â€œRCRA PartÂ Bâ€ hazardous waste permits, to conduct various aspects of their operations (collectively â€œEnvironmental Permitsâ€), any of which may be subject to suspension, revocation, modification, termination or denial under certain circumstances or which may not be renewed upon their expiration for various reasons, including noncompliance. See â€œBusinessâ€‰â€”â€‰Environmental, Health and Safety.â€ These Environmental Permits can be difficult, costly and time consuming to obtain and may contain conditions that limit our operations. Additionally, any failure to obtain and maintain such Environmental Permits could restrict or otherwise prohibit certain aspects of our operations, which could have a material adverse effect on our business, financial condition and results of operations.We have expended, and may be required to expend in the future, substantial funds for compliance with Environmental Laws. As recyclers of hazardous metal-containing chemical wastes, certain of our subsidiaries have been, and are likely to be, the focus of extensive compliance reviews by environmental regulatory authorities under Environmental Laws, including those relating to the generation, transportation, treatment, storage and disposal of solid and hazardous wastes under the RCRA. In the past, some of our subsidiaries have paid fines and entered into consent orders to address alleged environmental violations. See â€œBusinessâ€‰â€”â€‰Environmental, Health and Safety.â€ We cannot assure you that our operations or activities or those of certain of our subsidiaries, including with respect to compliance with Environmental Laws, will not result in civil or criminal enforcement actions or private actions, regulatory or judicial orders enjoining or curtailing operations or requiring corrective measures, installation of pollution control equipment or remedial measures or costs, revocation of required Environmental Permits, or fines, penalties or damages, 37 Table of Contentswhich could have a material adverse effect on our business, financial condition and results of operations. In addition, we cannot predict the extent to which Environmental Laws, and the interpretation or enforcement thereof, may change or become more stringent in the future, each of which may affect the market for our products or give rise to additional capital expenditures, compliance costs or liabilities that could be material.Our operations or products may impact the environment or cause or contribute to contamination or exposure to hazardous substances.Given the nature of our current and former operations, particularly at our chemical manufacturing sites, we have incurred, are currently incurring and may in the future incur liabilities under CERCLA, or under other federal, state, local and foreign Environmental Laws related to releases of or contamination by hazardous substances, with respect to our current or former sites, adjacent or nearby third-party sites, or offsite disposal locations. See â€œBusinessâ€‰â€”â€‰Environmental, Health and Safety.â€ Certain Environmental Laws, including CERCLA, can impose strict, joint, several and retroactive liability for the cost of investigation and cleanup of contaminated sites on owners and operators of such sites, as well as on persons who dispose of or arrange for disposal of hazardous substances at such sites. Accordingly, we could incur liability, whether as a result of government enforcement or private claims, for known or unknown liabilities at, or caused by migration from or hazardous waste transported from, any of our current or former facilities or properties, including those owned or operated by predecessors or third parties. See â€œBusinessÂ â€” Environmental, Health and Safety.â€ Such liability could have a material adverse effect on our business, financial condition and results of operations.The nature of our current and former operations also exposes us to the risk of claims under Environmental Laws. We could be subject to claims by environmental regulatory authorities, individuals and other third parties seeking damages for alleged personal injury, property damage and damages to natural resources resulting from hazardous substance contamination or human exposure caused by our operations, facilities or products, and there can be no assurance that material costs and liabilities will not be incurred in connection with any such claims. Our insurance may not be sufficient to cover any of these exposures, product, injury or damage claims.Furthermore, regulatory agencies are showing increasing concern over the impact of animal health products and livestock operations on the environment. This increased regulatory scrutiny may necessitate that additional time and resources be spent to address these concerns for both new and existing products and could affect product sales and materially adversely affect our business, financial condition or results of operations.We cannot assure you that our liabilities arising from past or future releases of, or exposure to, hazardous substances will not materially adversely affect our business, financial condition or results of operations.We have been and may continue to be subject to claims of injury from direct exposure to certain of our products that constitute or contain hazardous substances and from indirect exposure when such substances are incorporated into other companiesâ€™ products.Because certain of our products constitute or contain hazardous substances, and because the production of certain chemicals involves the use, handling, processing, storage and transportation of hazardous substances, from time to time we are subject to claims of injury from direct exposure to such substances and from indirect exposure when such substances are incorporated into other companiesâ€™ products. There can be no assurance that as a result of past or future operations, there will not be additional claims of injury by employees or members of the public due to exposure, or alleged exposure, to such substances. We are also party to a number of claims and lawsuits arising out of the normal course of business, including product liability claims and allegations of violations of governmental regulations, and face present and future claims with respect to workplace exposure, workersâ€™ compensation and other matters. In most cases, such claims are covered by insurance and, where applicable, workersâ€™ compensation insurance, subject to policy limits and exclusions; however, our insurance coverage, to the extent available, may not be adequate to protect us from all liabilities that we might incur in connection with the manufacture, sale and use of our products. Insurance is expensive and, in the future, may not be available on acceptable terms, if at all. A successful claim or series of claims brought against us in excess of our insurance coverage could have a materially adverse effect on our business, financial condition and results of operations. In addition, any claims, even if not ultimately successful, could adversely affect the marketplaceâ€™s acceptance of our products.38 Table of ContentsWe are subject to risks from litigation that may materially impact our operations.We face an inherent business risk of exposure to various types of claims and lawsuits. We are involved in various legal proceedings that arise in the ordinary course of our business. Although it is not possible to predict with certainty the outcome of every pending claim or lawsuit or the range of probable loss, we believe these pending lawsuits and claims will not individually or in the aggregate have a material adverse impact on our results of operations. However, we could, in the future, be subject to various lawsuits, including intellectual property, product liability, personal injury, product warranty, environmental or antitrust claims, among others, and incur judgments or enter into settlements of lawsuits and claims that could have a material adverse effect on our results of operations in any particular period.We are subject to risks that may not be covered by our insurance policies.In addition to pollution and other environmental risks, we are subject to risks inherent in the animal health, mineral nutrition and performance products industries, such as explosions, fires, spills or releases. Any significant interruption of operations at our principal facilities could have a material adverse effect on us. We maintain general liability insurance, pollution legal liability insurance and property and business interruption insurance with coverage limits that we believe are adequate. Because of the nature of industry hazards, it is possible that liabilities for pollution and other damages arising from a major occurrence may not be covered by our insurance policies or could exceed insurance coverages or policy limits or that such insurance may not be available at reasonable rates in the future. Any such liabilities, which could arise due to injury or loss of life, severe damage to and destruction of property and equipment, pollution or other environmental damage or suspension of operations, could have a material adverse effect on our business.We may fail to consummate the proposed acquisition of certain Zoetis products and assets, may not consummate the proposed acquisition on expected terms, or may not achieve the anticipated benefits.In April 2024, we entered into a definitive agreement with Zoetis to acquire Zoetisâ€™s MFA product portfolio, certain water-soluble products and related assets. It is currently anticipated that the Proposed Acquisition will be completed between October and December 2024. Completion of the Proposed Acquisition is subject to customary closing conditions, including clearances by applicable regulatory authorities. Until all such closing conditions are satisfied or waived, the possible timing and likelihood of completion of the Proposed Acquisition are uncertain, and, accordingly, there can be no assurance that the Proposed Acquisition will be completed on the expected terms, on the anticipated schedule or at all. Any delay in consummation of the Proposed Acquisition may result in greater transaction costs and professional fees. Our efforts to complete the Proposed Acquisition could cause substantial disruptions in our business. A substantial amount of our managementâ€™s attention is being directed towards the completion of the Proposed Acquisition and such distraction could affect our managementâ€™s ability to service our existing business, pursue other business opportunities or could otherwise adversely affect our business. If consummated, the success of the Proposed Acquisition will depend, in significant part, on our ability to successfully integrate the acquired business, establish and maintain good relationships with new and existing customers, suppliers, and other business partners, grow the revenue of the consolidated company and realize the anticipated strategic benefits and synergies. The combination of businesses is a complex, costly and time-consuming process. As a result, we expect to devote significant management attention and resources prior to closing to prepare for integration, and we expect to devote significant management attention and resources post-closing to integrate the business practices and operations. The integration process may disrupt the businesses and, if implemented ineffectively, would impair the realization of the full expected benefits. The growth and the anticipated benefits of the Proposed Acquisition may not be realized fully or at all, or may take longer to realize than we expect. Actual operating, strategic and revenue opportunities, if achieved at all, may be less significant than we expect or may take longer to achieve than anticipated. If we are not able to achieve these objectives and realize the anticipated benefits and synergies expected from the Proposed Acquisition within a reasonable time, our business, financial condition and operating results may be adversely affected.Adverse U.S. and international economic and market conditions may adversely affect our product sales and business.Current U.S. and international economic and market conditions are uncertain. The COVID-19 pandemic adversely affected international economic conditions and financial markets and led to economic downturns in many countries in which we operate. Our revenues and operating results may be affected by uncertain or changing economic and market 39 Table of Contentsconditions, including as a result of a resurgence of the COVID-19 pandemic or other similar public health crises, and other challenges faced in the credit markets and financial services industry. Economic, business, political and financial disruptions from the ongoing armed conflicts between Israel and Hamas (and potential broader military conflict in the region) and between Russia and Ukraine and the imposition of sanctions and business disruptions as well as inflation, could also have a material adverse effect on our operating results, financial condition, and liquidity. Certain of our customers and suppliers could be affected directly by an economic downturn and could face credit issues or cash flow problems that could give rise to payment delays, increased credit risk, bankruptcies and other financial hardships that could decrease the demand for our products or hinder our ability to collect amounts due from customers. Customers may seek lower price alternatives to our products if they are negatively impacted by poor economic conditions. Furthermore, our exposure to credit and collectability risk and cybersecurity risk is higher in certain international markets and as a result of the crisis resulting from the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine, our ability to mitigate such risks may be limited. While we have procedures to monitor and limit exposure to credit and collectability risk and we have defensive measures in place to prevent and mitigate cyberattacks, there can be no assurance that such procedures and measures will effectively limit such risks and avoid losses. If domestic and global economic and market conditions remain uncertain or persist or deteriorate further, we may experience material impacts on our business, financial condition and results of operations. Adverse economic conditions impacting our customers, including, among others, increased taxation, higher unemployment, lower customer confidence in the economy, higher customer debt levels, lower availability of customer credit, higher interest rates and hardships relating to declines in the stock markets, could cause purchases of meat products to decline, resulting in a decrease in purchases of our products, which could adversely affect our financial condition and results of operation. Adverse economic and market conditions could also negatively impact our business by negatively affecting the parties with whom we do business, including among others, our customers, our manufacturers and our suppliers.We may not be able to realize the expected benefits of our investments in emerging markets.We have been taking steps to take advantage of the rise in global demand for animal protein in emerging markets, including by expanding our manufacturing presence, sales, marketing and distribution in these markets. Failure to continue to maintain and expand our business in emerging markets could also materially adversely affect our operating results and financial condition.Some countries within emerging markets may be especially vulnerable to periods of local, regional or global economic, political or social instability or crisis. For example, our sales in certain emerging markets have suffered from extended periods of disruption due to natural disasters. Furthermore, we have also experienced lower than expected sales in certain emerging markets due to local, regional and global restrictions on banking and commercial activities in those countries. For all these and other reasons, sales within emerging markets carry significant risks.Modification of foreign trade policy may harm our food animal product customers.Changes in laws, agreements and policies governing foreign trade in the territories and countries where our customers do business could negatively impact such customersâ€™ businesses and adversely affect our results of operations. A number of our customers, particularly U.S.-based food animal producers have benefited from free trade agreements, including, in the past, the North American Free Trade Agreement (â€œNAFTAâ€). The U.S., Canada and Mexico reached an agreement to replace NAFTA with the United States-Mexico-Canada Agreement. Any other changes to international trade agreements or policies could harm our customers, and as a result, negatively impact our financial condition and results of operations. Additionally, in response to new U.S. tariffs affecting foreign imports, some foreign governments, including China, have instituted or are considering instituting tariffs on certain U.S. goods. While the scope and duration of these and any future tariffs remain uncertain, tariffs imposed by the U.S. or foreign governments on our customersâ€™ products, or on our products or the active pharmaceutical ingredients or other components thereof, could negatively impact our financial condition and results of operations.40 Table of ContentsOur product approval, R&D, acquisition and licensing efforts may fail to generate new products and product lifecycle developments.Our future success depends on both our existing product portfolio, including our ability to obtain cross-clearances enabling the use of our medicated products in conjunction with other products, approval for use of our products with new species, approval for new claims for our products, approval of our products in new markets and our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition. The majority of our R&D programs focus on product lifecycle development, which is defined as R&D programs that leverage existing animal health products by adding new species or claims, achieving approvals in new markets or creating new combinations and reformulations. We commit substantial effort, funds and other resources to expanding our product approvals and R&D, both through our own dedicated resources and through collaborations with third parties.We may be unable to determine with accuracy when or whether any of our expanded product approvals for our existing product portfolio or any of our products now under development will be approved or launched, or we may be unable to obtain expanded product approvals or develop, license or otherwise acquire product candidates or products. In addition, we cannot predict whether any products, once launched, will be commercially successful or will achieve sales and revenues that are consistent with our expectations. The animal health industry is subject to regional and local trends and regulations and, as a result, products that are successful in some of our markets may not achieve similar success when introduced into new markets. Furthermore, the timing and cost of our R&D may increase, and our R&D may become less predictable. For example, changes in regulations applicable to our industry may make it more time-consuming and/or costly to research, test and develop products.Products in the animal health industry are sometimes derived from molecules and compounds discovered or developed as part of human

health research. We may enter into collaboration or licensing arrangements with third parties to provide us with access to compounds and other technology for purposes of our business. Such agreements are typically complex and require time to negotiate and implement. If we enter into these arrangements, we may not be able to maintain these relationships or establish new ones in the future on acceptable terms or at all. In addition, any collaboration that we enter into may not be successful, and the success may depend on the efforts and actions of our collaborators, which we may not be able to control. If we are unable to access human health-generated molecules and compounds to conduct R&D on cost-effective terms, our ability to develop new products could be limited.The actual or purported intellectual property rights of third parties may negatively affect our business.A third party may sue us, our distributors or licensors, or otherwise make a claim, alleging infringement or other violation of the third-partyâ€™s patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights. If we do not prevail in this type of litigation, we may be required to:â—pay monetary damages;â—obtain a license in order to continue manufacturing or marketing the affected products, which may not be available on commercially reasonable terms, or at all; orâ—stop activities, including any commercial activities, relating to the affected products, which could include a recall of the affected products and/or a cessation of sales in the future.The costs of defending an intellectual property claim could be substantial and could materially adversely affect our operating results and financial condition, even if we successfully defend such claims. We may also incur costs in connection with an obligation to indemnify a distributor, licensor or other third party. Moreover, even if we believe that we do not infringe a validly existing third-party patent, we may choose to license such patent, which would result in associated costs and obligations. The intellectual property positions of animal health medicines and vaccines businesses frequently involve complex legal and factual questions, and an issued patent does not guarantee us the right to practice the patented technology or develop, manufacture or commercialize the patented product. We cannot be certain that a competitor or other third party does not have or will not obtain rights to intellectual property that may prevent us from manufacturing, developing or marketing certain of our products, regardless of whether we believe such intellectual property rights are valid and 41 Table of Contentsenforceable or we believe we would be otherwise able to develop a more commercially successful product, which may harm our financial condition and results of operations.If our intellectual property rights are challenged or circumvented, competitors may be able to take advantage of our R&D efforts. We are also dependent upon trade secrets, which in some cases may be difficult to protect.Our long-term success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements with our employees and others, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents, or be approved on a timely basis, or at all. Similarly, any term extensions that we seek may not be approved on a timely basis, if at all. In addition, our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area. The scope of our patent claims also may vary between countries, as individual countries have their own patent laws. For example, some countries only permit the issuance of patents covering a novel chemical compound itself, and its first use, and thus further methods of use for the same compound, may not be patentable. We may be subject to challenges by third parties regarding our intellectual property, including claims regarding validity, enforceability, scope and effective term. The validity, enforceability, scope and effective term of patents can be highly uncertain and often involve complex legal and factual questions and proceedings. Our ability to enforce our patents also depends on the laws of individual countries and each countryâ€™s practice with respect to enforcement of intellectual property rights. In addition, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, including because such agreements expire or are terminated, our financial condition and results of operations could be materially adversely affected.Patent law changes in the United States and other countries may also weaken our ability to enforce our patent rights or make such enforcement financially unattractive. Any such changes could result in increased costs to protect our intellectual property or limit our ability to obtain and maintain patent protection for our products in these jurisdictions. Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies, which could diminish or eliminate sales and profits from those regions and materially adversely affect our operating results and financial condition.Likewise, in the United States and other countries, we currently hold issued trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the same and thus create the potential need to rebrand or relabel a product. As our products mature, our reliance on our trademarks to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, our business could be materially adversely affected.Our competitive position is also dependent upon unpatented trade secrets, which in some cases may be difficult to protect. Others may independently develop substantially equivalent proprietary information and techniques or may otherwise gain access to our trade secrets and trade secrets may be disclosed or we may not be able to protect our rights to unpatented trade secrets.Many of our vaccine products and other products are based on or incorporate proprietary information, including proprietary master seeds and proprietary or patented adjuvant formulations. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute confidentiality agreements upon the commencement of their employment, engagement or other relationship. Despite these efforts and precautions, we may be unable to prevent a third party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.42 Table of ContentsThe misappropriation and infringement of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States, may occur even when we take steps to prevent it. In the future, we may be party to patent lawsuits and other intellectual property rights claims that are expensive and time consuming, and if resolved adversely, could have a significant impact on our business and financial condition. In the future, we may not be able to enforce intellectual property that relates to our products for various reasons, including licensor restrictions and other restrictions imposed by third parties, and the costs of doing so may outweigh the value of doing so, and this could have a material adverse impact on our business and financial condition.We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws or trade control laws, as well as other laws governing our international operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, financial condition and results of operations.Our operations are subject to anti-corruption laws, including the FCPA and other anti-corruption laws that apply in countries where we do business. The FCPA, UK Bribery Act and other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and we participate in relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.We are also subject to other laws and regulations governing our international operations, including regulations administered by the U.S. Department of Commerceâ€™s Bureau of Industry and Security, the U.S. Department of Treasuryâ€™s Office of Foreign Asset Control and various non-U.S. government entities, including applicable export control regulations, economic sanctions on countries and persons, customs requirements, currency exchange regulations and transfer pricing regulations (collectively, the â€œTrade Control lawsâ€).There is no assurance that we will be completely effective in ensuring our compliance with all applicable anticorruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA other anti-corruption laws or Trade Control laws by U.S. or foreign authorities could also have an adverse impact on our reputation, business, financial condition and results of operations.Increased regulation or decreased governmental financial support for the raising, processing or consumption of food animals could reduce demand for our animal health products.Companies in the animal health industry are subject to extensive and increasingly stringent regulations. If livestock producers are adversely affected by new regulations or changes to existing regulations, they may reduce herd sizes or become less profitable and, as a result, they may reduce their use of our products, which may materially adversely affect our operating results and financial condition. Furthermore, adverse regulations related, directly or indirectly, to the use of one or more of our products may injure livestock producersâ€™ market position. More stringent regulation of the livestock industry or our products could have a material adverse effect on our operating results and financial condition. Also, many industrial producers, including livestock producers, benefit from governmental subsidies, and if such subsidies were to be reduced or eliminated, these companies may become less profitable and, as a result, may reduce their use of our products.Increased or decreased inventory levels at our channel distributors can lead to fluctuations in our revenues and variations in payment terms extended to our distributors can impact our cash flows.In addition to selling our products directly to customers, we also sell to distributors who, in turn, sell our products to third parties. Inventory levels at our distributors may increase or decrease as a result of various factors, including end customer demand, new customer contracts, the influence of competition, political and socio-economic climate, contractual obligations related to minimum inventory levels, changing perceptions, including those of alternative products, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, 43 Table of Contentsregulatory restrictions, armed conflicts, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics and procedures and environmental factors beyond our control, including weather conditions or an outbreak of infectious disease such as COVID-19 or diseases carried by farm animals such as African Swine fever. These increases and decreases can lead to variations in our quarterly and annual revenues.In addition, we have policies that govern the payment terms that we extend to our customers. From time to time, our distributors have requested exceptions to the payment term policies that we extend to them for various reasons, including consolidation amongst our distributors, changes in the buying patterns of end customers, as well as the perception of our distributors regarding the need to maintain certain inventory levels to avoid supply disruptions. Extensions of anticipated customer payment terms can impact our cash flows, liquidity and results of operations.We have substantial debt and interest payment requirements that may restrict our future operations and impair our ability to meet our obligations under our indebtedness. Restrictions imposed by our outstanding indebtedness, including the restrictions contained in our 2024 Credit Facilities, may limit our ability to operate our business and to finance our future operations or capital needs or to engage in other business activities.As of JuneÂ 30,Â 2024, we had outstanding indebtedness (reflecting the principal amounts) of $256.9 million under our 2021 Term A loan (as defined below), $45.0 million under our 2023 Incremental Term loan (as defined below), $176.0Â million of outstanding borrowings under our revolving credit facility, $11.3 million under our 2022 Term Loan (as defined below) and $2.3Â million of outstanding letters of credit. In July 2024, to refinance our existing indebtedness and to fund the pending Proposed Acquisition, we entered into the 2024 Credit Facilities (as defined below). Subject to restrictions in our 2024 Credit Facilities, we may incur significant additional indebtedness. If we and our subsidiaries incur significant additional indebtedness, the related risks that we face could intensify.Our substantial debt may have important consequences. For instance, it could:â—make it more difficult for us to satisfy our financial obligations, including those relating to the 2024 Credit Facilities;â—require us to dedicate a substantial portion of any cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes, including capital expenditures and acquisitions;â—increase our vulnerability to general adverse economic and industry conditions;â—limit our flexibility in planning for or reacting to changes in our business and the industry in which we operate;â—place us at a competitive disadvantage compared with some of our competitors that may have less debt and better access to capital resources; andâ—limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.Our ability to satisfy our obligations and to reduce our total debt depends on our future operating performance and on economic, financial, competitive and other factors, many of which are beyond our control. Our business may not generate sufficient cash flow, and future financings may not be available to provide sufficient net proceeds, to meet these obligations or to successfully execute our business strategy.The terms of the 2024 Credit Facilities contain certain covenants that limit our ability and that of our subsidiaries to create liens, merge or consolidate, dispose of assets, incur indebtedness and guarantees, repurchase or redeem capital stock and indebtedness, make certain investments or acquisitions, enter into certain transactions with affiliates or change the nature of our business. As a result of these covenants and restrictions, we will be limited in how we conduct our business, and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We may not be able to maintain compliance with the covenants in any of our debt instruments in the future and, if we fail to do so, we may not be able to obtain waivers from the lenders and/or amend the covenants.44 Table of ContentsWe may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors beyond our control, including the impact of any public health crises, such as the COVID-19 pandemic, the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine, and the related economic downturn in the debt markets. In connection with the pending Proposed Acquisition and corresponding refinancing of our existing indebtedness through the 2024 Credit Facilities, we expect our debt interest payments to increase substantially. We may be unable to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal and interest on our indebtedness.If our cash flows and capital resources are insufficient to fund our debt service obligations, we could face substantial liquidity problems and could be forced to reduce or delay investments and capital expenditures, or to dispose of material assets or operations, alter our dividend policy, seek additional debt or equity capital or restructure or refinance our indebtedness. We may not be able to effect any such alternative measures on commercially reasonable terms or at all and, even if successful, those alternative actions may not allow us to meet our scheduled debt service obligations. The instruments that govern our indebtedness may restrict our ability to dispose of assets and may restrict the use of proceeds from those dispositions and may also restrict our ability to raise debt or equity capital to be used to repay other indebtedness when it becomes due. We may not be able to consummate those dispositions or to obtain proceeds in an amount sufficient to meet any debt service obligations when due.In addition, we conduct our operations through our subsidiaries. Accordingly, repayment of our indebtedness will depend on the generation of cash flow by our subsidiaries, including our international subsidiaries, and their ability to make such cash available to us, by dividend, debt repayment or otherwise. Our subsidiaries may not have any obligation to pay amounts due on our indebtedness or to make funds available for that purpose. Our subsidiaries may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each subsidiary is a distinct legal entity, and under certain circumstances, legal, tax and contractual restrictions may limit our ability to obtain cash from our subsidiaries or may subject any transfer of cash from our subsidiaries to substantial tax liabilities. In the event that we do not receive distributions from our subsidiaries, we may be unable to make required principal and interest payments on our indebtedness.Our inability to generate sufficient cash flows to satisfy our debt obligations, or to refinance our indebtedness on commercially reasonable terms or at all, may materially adversely affect our operating results, financial condition and liquidity and our ability to satisfy our obligations under our indebtedness or pay dividends on our common stock.We are subject to change of control provisions.We are a party to certain contractual arrangements that are subject to change of control provisions. In this context, â€œchange of controlâ€ is generally defined as including (a)Â any person or group, other than Mr.Â JackÂ C. Bendheim and his family and affiliates (the current holders of approximately 90.9% of the combined voting power of all classes of our outstanding common stock), becoming the beneficial owner of more than 50% of the total voting power of our stock, and (b)Â a change in any twelve month period in the majority of the members of the Board that is not approved by Mr.Â Bendheim and/or his family and affiliates or by the majority of directors in office at the start of such period.Mr.Â Bendheim and his family and affiliates may choose to dispose of part or all of their stakes in us and/or may cease to exercise the current level of control they have over the appointment and removal of members of our Board. Any such changes may trigger a â€œchange of controlâ€ event that could result in us being forced to repay the 2024 Credit Facilities or lead to the termination of a significant contract to which we are a party. If any such event occurs, this may negatively affect our financial condition and operating results. In addition, we may not

have sufficient funds to finance repayment of any of such indebtedness upon any such â€œchange in control.â€We depend on sophisticated information technology and infrastructure.We rely on various information systems to manage our operations, and we increasingly depend on third parties and applications on virtualized, or â€œcloud,â€ infrastructure to operate and support our information technology systems. These third parties include large established vendors as well as small, privately owned companies. Failure by these providers to 45 Table of Contentsadequately service our operations or a change in control or insolvency of these providers could have an adverse effect on our business, which in turn may materially adversely affect our business, financial condition or results of operations.We may be required to write down goodwill or identifiable intangible assets.Under generally accepted accounting principles in the United States (â€œGAAPâ€), if we determine goodwill or identifiable intangible assets are impaired, we will be required to write down these assets and record a non-cash impairment charge. As of JuneÂ 30,Â 2024, we had goodwill ofâ€‰$54.6Â million and identifiable intangible assets, less accumulated amortization, of $45.0Â million. Identifiable intangible assets consist primarily of developed technology rights and patents and customer relationships.Determining whether an impairment exists and the amount of the potential impairment involves quantitative data and qualitative criteria that are based on estimates and assumptions requiring significant management judgment. Future events or new information may change managementâ€™s valuation of goodwill or an intangible asset in a short amount of time. The timing and amount of impairment charges recorded in our consolidated statements of operations and write-downs recorded in our consolidated balance sheets could vary if managementâ€™s conclusions change. Any impairment of goodwill or identifiable intangible assets could have a material adverse effect on our financial condition and results of operations.We may be unable to adequately protect our customersâ€™ privacy or we may fail to comply with privacy laws.The protection of customer, employee and company data is critical and the regulatory environment surrounding information security, storage, use, processing, disclosure and privacy is demanding, with the frequent imposition of new and changing requirements. In addition, our customers expect that we will adequately protect their personal information. Any actual or perceived significant breakdown, intrusion, interruption, cyber-attack or corruption of customer, employee or company data or our failure to comply with federal, state, local and foreign privacy laws could damage our reputation and result in lost sales, fines and lawsuits. Despite our considerable efforts and technology to secure our computer network, security could be compromised, confidential information could be misappropriated or system disruptions could occur. Any actual or perceived access, disclosure or other loss of information or any significant breakdown, intrusion, interruption, cyber-attack or corruption of customer, employee or company data or our failure to comply with federal, state, local and foreign privacy laws or contractual obligations with customers, vendors, payment processors and other third parties, could result in legal claims or proceedings, liability under laws or contracts that protect the privacy of personal information, regulatory penalties, disruption of our operations and damage to our reputation, all of which could materially adversely affect our business, revenue and competitive position.We may be subject to information technology system failures, network disruptions and breaches in data security.We are increasingly dependent upon information technology systems and infrastructure to conduct critical operations and generally operate our business, which includes using information technology systems to process, transmit and store electronic information in our day-to-day operations, including customer, employee and company data. The changes to â€œin-officeâ€ expectations resulting from the COVID-19 pandemic have resulted in a substantial portion of our employees working remotely and have increased our dependence on tools that facilitate employees working from home and gaining remote access to our information technology systems. As a result, any disruption to our information technology systems, our industrial machinery, software used in our manufacturing facilities, firmware or software embedded in our equipment or machinery, including from cyber incidents, could have a material adverse effect on our business. The increased use of these tools could also make our information technology systems more vulnerable to breaches of data security and cybersecurity attacks. The size and complexity of our computer systems make them potentially vulnerable to breakdown, malicious intrusion and random attack. We also store certain information with third parties. Our information systems and those of our third-party vendors are subjected to computer viruses or other malicious codes, unauthorized access attempts, and cyber, phishing or ransomware attacks and also are vulnerable to an increasing threat of continually evolving cybersecurity risks and external hazards. Disruption, degradation, or manipulation of these systems and infrastructure through intentional or accidental means could impact key business processes. Cyber-attacks against the Companyâ€™s systems and infrastructure could result in exposure of confidential information, the modification of critical data and/or the failure of critical operations. Likewise, improper or inadvertent employee behavior, including data privacy breaches by employees and others with permitted access to our systems may pose a risk that sensitive data may be exposed to unauthorized persons or to the public. Any such breach could 46 Table of Contentscompromise our networks, and the information stored therein could be accessed, publicly disclosed, lost or stolen. Such attacks could result in our intellectual property and other confidential information being lost or stolen, disruption of our operations and other negative consequences, such as increased costs for security measures or remediation costs, and diversion of management attention. Although the aggregate impact on the Companyâ€™s operations and financial condition has not been material to date, the Company has been the target of events of this nature and expects them to continue as cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. The Company monitors its data, information technology and personnel usage of Company systems to reduce these risks and continues to do so on an ongoing basis for any current or potential threats. If any of our operational technologies, software or hardware or other control systems are compromised, fail or have other significant shortcomings, it could disrupt our business, require us to incur substantial additional expenses or result in potential liability or reputational damage. While we have invested in protection of data and information technology, there can be no assurance that our efforts will prevent such breakdowns, cybersecurity attacks or breaches in our systems that could cause reputational damage, business disruption and legal and regulatory costs; could result in third-party claims; could result in compromise or misappropriation of our intellectual property, trade secrets and sensitive information; and could otherwise adversely affect our business and financial results. Implementing new business lines or offering new products and services may subject us to additional risks.From time to time, we may implement new business lines or offer new products and services within existing lines of business. There may be substantial risks and uncertainties associated with these efforts. We may invest significant time and resources in developing, marketing, or acquiring new lines of business and/or offering new products and services. Initial timetables for the introduction and development or acquisition of new lines of business and/or the offering of new products or services may not be achieved, and price and profitability targets may prove to be unachievable. Our lack of experience or knowledge, as well as external factors, such as compliance with regulations, competitive alternatives and shifting market preferences, may also impact the success of an acquisition or the implementation of a new line of business or a new product or service. New business lines or new products and services within existing lines of business could affect the sales and profitability of existing lines of business or products and services. Failure to successfully manage these risks in the implementation or acquisition of new lines of business or the offering of new products or services could have a material adverse effect on our reputation, business, results of operations, and financial condition.Risks Related to Ownership of Our ClassÂ A Common StockOur multiple class structure and the concentration of our voting power with certain of our stockholders will limit your ability to influence corporate matters, and conflicts of interest between certain of our stockholders and us or other investors could arise in the future.As of AugustÂ 23, 2024, BFI Co., LLC (â€œBFIâ€) beneficially owns 59,480 shares of our ClassÂ A common stock and 20,166,034 shares of our ClassÂ B common stock, which together represent approximately 90.9% of the combined voting power of all classes of our outstanding common stock. As of AugustÂ 23, 2024, our other stockholders collectively own interests representing approximately 9.1% of the combined voting power of all classes of our outstanding common stock. Because of our multiple class structure and the concentration of voting power with BFI, BFI will continue to be able to control all matters submitted to our stockholders for approval for so long as BFI holds common stock representing greater than 50% of the combined voting power of all classes of our outstanding common stock. BFI will therefore have significant influence over management and affairs and control the approval of all matters requiring stockholder approval, including the election of directors and significant corporate transactions, such as a merger or other sale of the Company or its assets, for the foreseeable future.We are classified as a â€œcontrolled companyâ€ and, as a result, we qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements.BFI controls a majority of the combined voting power of all classes of our outstanding common stock. As a result, we are a â€œcontrolled companyâ€ within the meaning of the Nasdaq corporate governance standards. Under Nasdaq rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a â€œcontrolled companyâ€ and may elect not to comply with certain corporate governance requirements, including:47 Table of Contentsâ—the requirement that a majority of the Board consists of independent directors;â—the requirement that we have a nominating and corporate governance committee and that it is composed entirely of independent directors; andâ—the requirement for an annual performance evaluation of the nominating and corporate governance and compensation committees.We utilize and intend to continue to utilize these exemptions. As a result, while we currently have a majority of independent directors:â—we may not have a majority of independent directors in the future;â—we will not have a nominating and corporate governance committee; andâ—we will not be required to have an annual performance evaluation of the compensation committee.Accordingly, you will not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements.Our stock price may be volatile or may decline regardless of our operating performance.The market price of our ClassÂ A common stock may fluctuate significantly in response to a number of factors, many of which we cannot control, including those described under â€œâ€ Risk Factors Relating to Our Businessâ€ and the following:â—changes in financial estimates by any securities analysts who follow our ClassÂ A common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our ClassÂ A common stock;â—downgrades by any securities analysts who follow our ClassÂ A common stock;â—future sales of our ClassÂ A common stock by our officers, directors and significant stockholders;â—market conditions or trends in our industry or the economy as a whole and, in particular, in the animal health industry;â—investorsâ€™ perceptions of our prospects;â—announcements by us or our competitors of significant contracts, acquisitions, joint ventures or capital commitments; andâ—changes in key personnel.In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. The COVID-19 pandemic and the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine have contributed to significant volatility in stock and financial markets in the United States and globally. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs, and our resources and the attention of management could be diverted from our business.Our majority stockholder has the ability to control significant corporate activities and our majority stockholderâ€™s interests may not coincide with yours.As of AugustÂ 23, 2024, approximately 90.9% of the combined voting power of all classes of our outstanding common stock is held by BFI. As a result of its ownership, so long as it holds a majority of the combined voting power of all classes of our outstanding common stock, BFI will have the ability to control the outcome of matters submitted to a vote of stockholders and, through our Board of Directors, the ability to control decision-making with respect to our business direction and policies. Matters over which BFI, directly or indirectly, exercises control include:â—the election of our Board of Directors and the appointment and removal of our officers;48 Table of Contentsâ—mergers and other business combination transactions, including proposed transactions that would result in our stockholders receiving a premium price for their shares;â—other acquisitions or dispositions of businesses or assets;â—incurrence of indebtedness and the issuance of equity securities;â—repurchase of stock and payment of dividends; andâ—the issuance of shares to management under our equity incentive plans.Even if BFIâ€™s ownership of our shares falls below a majority of the combined voting power of all classes of our outstanding common stock, it may continue to be able to influence or effectively control our decisions.Future sales of our ClassÂ A common stock, or the perception in the public markets that these sales may occur, may depress our stock price.Sales of substantial amounts of our ClassÂ A common stock in the public market, or the perception that these sales could occur, could adversely affect the price of our ClassÂ A common stock and could impair our ability to raise capital through the sale of additional shares. In addition, subject to certain restrictions on converting ClassÂ B common stock into ClassÂ A common stock, all of our outstanding shares of ClassÂ B common stock may be converted into ClassÂ A common stock and sold in the public market by existing stockholders. As of AugustÂ 23, 2024, we had 20,337,574 shares of ClassÂ A common stock and 20,166,034 shares of ClassÂ B common stock outstanding.BFI, which holds all of our outstanding ClassÂ B common stock, has the right to require us to register the sales of its shares under the Securities Act under the terms of an agreement between us and the holders of these securities. In the future, we may also issue our securities in connection with investments or acquisitions. The amount of shares of our ClassÂ A common stock issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding shares of our ClassÂ A common stock.Anti-takeover provisions in our charter documents and Delaware law might discourage or delay acquisition attempts for us that you might consider favorable.Our certificate of incorporation and bylaws contain provisions that may make the acquisition of the Company more difficult without the approval of our Board of Directors. These provisions:â—authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include super voting, special approval, dividend, or other rights or preferences superior to the rights of the holders of ClassÂ A common stock;â—prohibit, at any time after BFI and its affiliates cease to hold at least 50% of the combined voting power of all classes of our outstanding common stock, stockholder action by written consent, without the express prior consent of the Board of Directors;â—provide that the Board of Directors is expressly authorized to make, alter or repeal our amended and restated bylaws;â—establish advance notice requirements for nominations for elections to our Board of Directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; andâ—establish a classified Board of Directors, as a result of which our Board of Directors will be divided into three classes, with each class serving for staggered three-year terms, which prevents stockholders from electing an entirely new Board of Directors at an annual meeting; and require, at any time after BFI and its affiliates cease to hold at least 50% of the combined voting power of all classes of our outstanding common stock, the approval of holders of at least three quarters of the combined voting power of all classes of our outstanding common stock for stockholders to amend the amended and restated bylaws or amended and restated certificate of incorporation.These anti-takeover provisions and other provisions under Delaware law could discourage, delay or prevent a transaction involving a change in control of the Company, even if doing so would benefit our stockholders. These 49 Table of Contentsprovisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing and to cause us to take other corporate actions you desire.Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.Our certificate of incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)Â any derivative action or proceeding brought on our behalf, (ii)Â any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii)Â any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our by-laws or (iv)Â any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our certificate of incorporation described above. This choice of forum provision may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition and results of operations.Provisions of our certificate of incorporation could have the effect of preventing us from having the benefit of certain business opportunities that we would otherwise be entitled to pursue.Our certificate of incorporation provides that BFI and its affiliates are not required to offer corporate opportunities of which they become aware to us and could, therefore, offer such opportunities instead to other companies including affiliates of BFI. In the event that BFI obtains business opportunities from which we might otherwise benefit but chooses not to present such opportunities to us, these provisions of our certificate of incorporation could have the effect of preventing us from pursuing transactions or relationships that would otherwise be in the best interests of our stockholders.We may not pay cash dividends in the future and, as a result, you may not receive any return on investment unless you are able to sell your ClassÂ A common stock for a price greater than your initial investment.We have a paid a quarterly dividend since SeptemberÂ 2014 on our ClassÂ A and ClassÂ B common stock and our Board of Directors has declared a cash dividend ofâ€‰$0.12 per share on our ClassÂ A common stock and ClassÂ B common stock that is payable September 25, 2024. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend upon results of operations, financial condition, contractual restrictions and our ability to obtain funds from our subsidiaries to meet our obligations. Our 2024 Credit Facilities permit us to pay distributions to stockholders out of available

cash subject to certain annual limitations and so long as no default or event of default under the 2024 Credit Facilities shall have occurred and be continuing at the time such distribution is declared. Realization of a gain on your investment will depend on the appreciation of the price of our ClassÂ A common stock.General Risk FactorsWe face competition in each of our markets from a number of large and small companies, some of which have greater financial, R&D, production and other resources than we have. Many of our products face competition from alternative or substitute products. We are engaged in highly competitive industries and, with respect to all of our major products, face competition from a substantial number of global and regional competitors. Several new start-up companies also compete in the animal health industry. We believe many of our competitors are conducting R&D activities in areas served by our products and in areas in which we are developing products. Some competitors have greater financial, R&D, production and other resources than we have. Some of our principal competitors include Boehringer Ingelheim International GmbH, Ceva SantÃ© Animale, Elanco Animal Health Incorporated, Huvepharma Inc., Merck & Co., Inc. (Merck Animal Health and MSD Animal Health), Southeastern Minerals, Inc. and Zoetis. To the extent these companies or new entrants offer comparable animal health, 50 Table of Contentsmineral nutrition or performance products at lower prices, our business could be adversely affected. New entrants could substantially reduce our market share or render our products obsolete. Furthermore, many of our competitors have relationships with key distributors and, because of their size, have the ability to offer attractive pricing incentives, which may negatively impact or hinder our relationships with these distributors. In certain countries, because of our size and product mix, we may not be able to capitalize on changes in competition and pricing as fully as our competitors. In recent years, there have been new generic medicated products introduced to the livestock industry, particularly in the United States. There has been and likely will continue to be consolidation in the animal health market, which could strengthen our competitors. Our competitors can be expected to continue to improve the formulation and performance of their products and to introduce new products with competitive price and performance characteristics. There can be no assurance that we will have sufficient resources to maintain our current competitive position or market share. We also face competitive pressures arising from, among other things, more favorable safety and efficacy product profiles, limited demand growth or a significant number of additional competitive products being introduced into a particular market, price reductions by competitors, the ability of competitors to capitalize on their economies of scale and the ability of competitors to produce or otherwise procure animal health products at lower costs than us. To the extent that any of our competitors are more successful with respect to any key competitive factor, or we are forced to reduce, or are unable to raise, the price of any of our products in order to remain competitive, our business, financial condition and results of operations could be materially adversely affected. Failure to comply with requirements to design, implement and maintain effective internal controls could have a material adverse effect on our business and stock price. As a public company, we have significant requirements for enhanced financial reporting and internal controls. The process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company. If we are unable to establish or maintain appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations on a timely basis, result in material misstatements in our consolidated financial statements and harm our operating results. In addition, we are required, pursuant to Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting and a statement that our auditors have issued an attestation report on the effectiveness of our internal controls. Testing and maintaining internal controls may divert our managementâ€™s attention from other matters that are important to our business. We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 or our independent registered public accounting firm may not issue an unqualified opinion. We cannot provide any assurance we will not identify material weaknesses in the future. If we suffer deficiencies or material weaknesses in our internal controls, we may be unable to report financial information in a timely and accurate manner and it could result in a material misstatement of our annual or interim financial statements that would not be prevented or detected on a timely basis, which could cause investors to lose confidence in our financial reporting, negatively affect the trading price of our common stock and could cause a default under the agreements governing our indebtedness. If either we are unable to conclude that we have effective internal control over financial reporting or our independent registered public accounting firm is unable to provide us with an unqualified opinion, investors could lose confidence in our reported financial information, which could have a material adverse effect on the trading price of our stock. As a public company, we are subject to financial and other reporting and corporate governance requirements that may be difficult for us to satisfy and may divert managementâ€™s attention from our business. As a public company, we are required to file annual and quarterly reports and other information pursuant to the Exchange Act with the SEC. We are required to ensure that we have the ability to prepare consolidated financial statements that comply with SEC reporting requirements on a timely basis. We are also subject to other reporting and corporate governance requirements, including the applicable stock exchange listing standards and certain provisions of the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder, which impose significant compliance obligations upon us. 51 Table of ContentsAs a public company, we are required to commit significant resources and management time and attention to these requirements, which cause us to incur significant costs and which may place a strain on our systems and resources. As a result, our managementâ€™s attention might be diverted from other business concerns. Compliance with these requirements place significant demands on our legal, accounting and finance staff and on our accounting, financial and information systems and increase our legal and accounting compliance costs as well as our compensation expense as we have been or may be required to hire additional accounting, tax, finance and legal staff with the requisite technical knowledge. We may not be able to expand through acquisitions or successfully integrate the products, services and personnel of acquired businesses. From time to time, we may make selective acquisitions to expand our range of products and services and to expand the geographic scope of our business, such as the Proposed Acquisition. However, we may be unable to identify suitable targets in the future, and competition for acquisitions may make it difficult for us to consummate acquisitions on acceptable terms or at all. We may not be able to locate any complementary products that meet our requirements or that are available to us on acceptable terms or we may not have sufficient capital resources to consummate a proposed acquisition. In addition, assuming we identify suitable products or partners, the process of effectively entering into these arrangements involves risks that our managementâ€™s attention may be diverted from other business concerns. Further, if we succeed in identifying and consummating appropriate acquisitions on acceptable terms, we may not be able to successfully integrate the products, services and personnel of any acquired businesses, including the Proposed Acquisition, on a basis consistent with our current business practice. In particular, we may face greater than expected costs, time and effort involved in completing and integrating such acquisitions and potential disruption of our ongoing business. Furthermore, we may realize fewer, if any, synergies than envisaged. Our ability to manage acquired businesses may also be limited if we enter into joint ventures or do not acquire full ownership or a controlling stake in the acquired business. In addition, continued growth through acquisitions may significantly strain our existing management and operational resources. As a result, we may need to recruit additional personnel, particularly at the level below senior management, and we may not be able to recruit qualified management and other key personnel to manage our growth. Moreover, certain transactions could adversely impact earnings as we incur development and other expenses related to the transactions and we could incur debt to complete these transactions. Debt instruments could contain contractual commitments and covenants that could adversely affect our cash flow and our ability to operate our business, financial condition and results of operations. See also â€œâ€” Risk Factors Relating to Our Business â€” We may fail to consummate the proposed acquisition of certain Zoetis products and assets, may not consummate the proposed acquisition on expected terms, or may not achieve the anticipated benefits.â€We may not successfully implement our business strategies or achieve expected gross margin improvements. We are pursuing and may continue to pursue strategic initiatives that management considers critical to our long-term success, including, but not limited to, increasing sales in emerging markets, base revenue growth through new product development and value-added product lifecycle development; improving operational efficiency through manufacturing efficiency improvement and other programs; and expanding our complementary products and services. There are significant risks involved with the execution of these types of initiatives, including significant business, economic and competitive uncertainties, many of which are outside of our control. Accordingly, we cannot predict whether we will succeed in implementing these strategic initiatives. It could take several years to realize the anticipated benefits from these initiatives, if any benefits are achieved at all. We may be unable to achieve expected gross margin improvements on our products or technologies. Additionally, our business strategy may change from time to time, which could delay our ability to implement initiatives that we believe are important to our business.â€‹ItemÂ 1B.Â Â Â Unresolved Staff CommentsNone.â€‹Item 1C. Cybersecurityâ€‹Risk Management and StrategyAs a leading global diversified animal health and mineral nutrition company, we are increasingly reliant on information technology systems and infrastructure to conduct critical operations and generally operate our business, 52 Table of Contentswhich includes using information technology systems to process, transmit and store electronic information, including customer, employee and company data. The use of information technology systems makes us vulnerable to breaches of data security and cybersecurity attacks. For information on the potential risks related to cybersecurity, see â€œItem 1A. Risk Factors â€” Risk Factors Relating to Our Business â€” We may be subject to information technology system failures, network disruptions and breaches in data security.â€ Although the aggregate impact on our operations and financial condition has not been material to date, the Company has been the target of cybersecurity attacks and expects them to continue as such attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. Any such future incidents could have a material impact on our business.Our information security team, headed by our Director of IT Cyber Security and Compliance, who reports to our Chief Information Officer (â€œCIOâ€), monitors our technology systems to prevent, detect, mitigate and remediate any cybersecurity incidents. Our enterprise-wide cybersecurity program is aligned with the U.S. National Institute of Standards Technology Cybersecurity Framework and the Israel National Cyber Directorate, and we are members of the New Jersey Cybersecurity and Communications Integration Cell. This collaboration enables us to increase our cybersecurity knowledge, threat awareness, and awareness of cyber incidents within the industry. It also helps us take proactive measures to prevent incidents by defining attack group identifiers and implementing learning and improvement processes.We use tools and techniques to continually assess, monitor, manage, and mitigate security risks to our technology systems. Our processes extend to third-party service providers, who have access to data on our systems. We engage a third party to perform an independent assessment of our cybersecurity penetration test and risk assessment program at least once every two years.Our preventive and protected stratagem include the following:â—Security Operations Center (SOC) and Managed Detection and Response (MDR) services to ensure continuous monitoring and response to potential threats. â—A cyber training and awareness process based on an annual work plan, which includes monthly training, bi-weekly simulations, an interactive magazine sent once a month to all users and a cyber incident simulation for the infrastructure team. The contents are based on relevant market trends. In cybersecurity or privacy incidents, the probable frequency and magnitude of loss are evaluated by the triage team. The incidents are categorized as either high- or low-level severity and communicated to the CIO and Chief Executive Officer and the Senior Vice President, General Counsel and Corporate Secretary (â€œLegal Counselâ€), at which time a determination is made on any additional communication requirements. Our Board of Directors is notified of high-level severity incidents. Our approach to incidents generally includes a process of investigation, learning, and subsequent improvement. In addition, we believe cyber insurance is a key mechanism for supporting and managing critical cyber incidents. Aligning the policy involves a thorough review of our protection layers and processes.GovernanceOur information technology systems are managed by our CIO. He has over 45 years of experience in digital systems and technology in the animal health, bio-tech pharmaceutical, pharmaceutical and oil and gas industries. He has held multiple leadership roles driving business value for investments in digital solutions. He also spent six years as a leader within internal auditing, providing experience and wisdom in business-driven risk management.The CIO provides periodic reports to the Board of Directors and the executive management team, including our Legal Counsel. These reports include updates on our cybersecurity risks and threats, assessments of our information security program, and any changes in the threat landscape. Our information technology systems are regularly evaluated by internal and external consultants with the results of the review reported to the executive management team and the Board of Directors.53 Table of Contentsâ€‹ItemÂ 2.Â Â Â PropertiesThe following table lists our material properties:â€‹â€‹â€‹

projections of future stockholder returns. â€‹Item 6. (Reserved)Not applicableâ€‹ItemÂ 7.Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsIntroductionOur managementâ€™s discussion and analysis of financial condition and results of operations (â€œMD&Aâ€) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included under the section entitled â€œFinancial Statements and Supplementary Data.â€ Our future results could differ materially from our historical performance as a result of various factors such as those discussed in â€œRisk Factorsâ€ and â€œForward-Looking Statements and Risk Factors Summary.â€Overview of our businessPhibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. Our products help prevent, control and treat diseases, and support nutrition to help improve animal health and well-being. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries. We market approximately 750 product lines in over 80 countries to approximately 4,200 customers.56 Table of ContentsProposed AcquisitionIn April 2024, we entered into the Purchase Agreement with Zoetis to acquire Zoetisâ€™s medicated feed additive product portfolio, certain water-soluble products and related assets. The purchase price is $350 million, subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. The product portfolio to be acquired, which generated approximately $400 million in revenue in 2023, is comprised of more than 37 product lines that are sold in approximately 80 countries. Also included in the Proposed Acquisition are six manufacturing sites, comprised of four in the U.S., one in Italy and one in China. We anticipate that the Proposed Acquisition will be completed between October and December 2024. Completion of the Proposed Acquisition is subject to satisfaction of customary closing conditions, including clearances by applicable regulatory authorities.2024 Credit AgreementIn July 2024, we entered into a Credit Agreement (the â€œ2024 Credit Agreementâ€) with a group of lenders. Initial borrowings were used to refinance all our outstanding debt, to pay fees and expenses of the transaction, and for ongoing working capital requirements and general corporate purposes. Borrowings under the Delayed Draw Term A-1 and A-2 Loans will be used to finance the purchase price of the Proposed Acquisition upon completion of the acquisition. See â€œNotes to Consolidated Financial Statementsâ€‰â€”â€‰Subsequent Event â€” 2024 Credit Agreementâ€ for additional information.Factors affecting our performanceArmed conflictsIsrael and HamasOn October 7, 2023, Hamas militants crossed into Israel from Gaza in a large-scale, surprise terrorist attack. Hamas terrorists invaded Israel, first firing rockets into the country and then carrying out attacks inflicting mass casualties with hundreds more taken hostage. In order to provide immediate assistance to the victims of the attacks and their families, we and our employees provided monetary donations that were distributed to charities that offered relief services, welfare, equipment, food and other necessities. We have three manufacturing sites in Israel. A manufacturing plant in Neot Hovav that produces active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products, a facility in Beit Shemesh that produces vaccines and a plant in Petah Tikvah that manufactures premix products and nutritional products. In addition, we have an office location near Tel Aviv in Airport City. As of JuneÂ 30,Â 2024, we had approximately 500 employees located in Israel. While we initially had some disruption to our operations at the onset of the Israel-Hamas conflict, at the current time, we have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support. A significant escalation of the tensions in Israel occurred on April 13, 2024, when Iran launched more than 300 drones and missiles against Israel, but we had no material disruption to our business. While the situation surrounding the ongoing conflict remains fluid, our operations in Israel have navigated numerous challenging situations over the years. The prolonged continuation or escalation of this conflict may trigger bans, economic and other sanctions, as well as broader military conflict, which could include neighboring nations. The potential impact of the current conflict, or escalation thereof, on our business is unclear but may include, without limitation, the possible disruption of our operations, particularly at our facilities in Israel, supply chain and logistics disruptions, personnel and raw material shortages, and other consequences, including as a result of the actions of, or disruption of the operations of, certain regulatory and governmental authorities and of certain of our suppliers, collaborative partners, licensees, manufacturing sites, distributors and customers. Our Israeli manufacturing facilities and local operations account for 28% of our consolidated assets as of JuneÂ 30,Â 2024, and 21% of our consolidated net sales, for the year ended JuneÂ 30,Â 2024.Russia and UkraineIn response to the armed conflict between Russia and Ukraine that began in February 2022, we and our employees have provided support to Ukraine in the form of monetary donations, free products and humanitarian services. Our limited intent for the Russian market is to continue to provide medicines and vaccines, and related regulatory and 57 Table of Contentstechnical support, to help existing customers combat disease challenges in the production of food animals on their farms. We have no production or direct distribution operations and no planned investments in Russia.Since the conflict began, the United States and other North Atlantic Treaty Organization (â€œNATOâ€) member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises. The continuation or escalation of the conflict may trigger additional economic and other sanctions, as well as broader military conflict. The potential impacts of any resulting bans, sanctions, boycotts or broader military conflicts on our business are uncertain. The potential impacts could include supply chain and logistics disruptions, macroeconomic impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy as well as heightened cybersecurity threats. Our sales to Russia and Ukraine for the 12 months ended JuneÂ 30,Â 2024 represented approximately 1% of consolidated net sales.We cannot know if the conflict could escalate and result in broader economic and security concerns that could adversely affect our business, financial condition, or results of operations. Industry growthWe believe global population growth, the growth of the global middle class and the productivity improvements needed due to limitations of arable land and water supplies have supported and will continue to support growth of the animal health industry.Regulatory developmentsOur business depends heavily on a healthy and growing livestock industry. Some in the public perceive risks to human health related to the consumption of food derived from animals that utilize certain of our products, including certain of our MFA products. In particular, there is increased focus, in the United States and other countries, on the use of medically important antimicrobials. As defined by the FDA, medically important antimicrobials (â€œMIAsâ€) include classes that are prescribed in animal and human health and are listed in the Appendix of the FDA-CVM Guidance for Industry (GFI) 152. Our products that contain virginiamycin, oxytetracycline or neomycin are classified by the FDA as medically important antimicrobials. In addition to the United States, the World Health Organization (WHO), the E.U., Australia and Canada have promulgated rating lists for antimicrobials that are used in veterinary medicine and that include certain of our products.The classification of our products as MIAs or similar listings may lead to a decline in the demand for and production of food products derived from animals that utilize our products and, in turn, demand for our products. Livestock producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of nutrition and health-related concerns, animal rights and other concerns. Any reputational harm to the livestock industry may also extend to companies in related industries, including us. In addition, campaigns by interest groups, activists and others with respect to perceived risks associated with the use of our products in animals, including position statements by livestock producers and their customers based on non-use of certain medicated products in livestock production, whether or not scientifically-supported, could affect public perceptions and reduce the use of our products. Those adverse consumer views related to the use of one or more of our products in animals could have a material adverse effect on our financial condition and results of operations.In April 2016, the FDA began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a NOOH, due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the CVM inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method. In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the research and data that confirm the safety of carbadox. In 58 Table of ContentsNovember 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues. The FDA also provided notice in the Federal Register proposing to withdraw approval of all NADAs providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVMâ€™s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is continuing to defend swine producersâ€™ ability to use Mecadox. We have requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the year ended JuneÂ 30,Â 2024 were approximately $22 million. As of the date of this Annual Report on Form 10-K, Mecadox continues to be available for use by swine producers.See also â€œBusinessâ€‰â€”â€‰ Compliance with Government Regulation â€‰â€”â€‰United States â€”â€‰Carbadoxâ€; and â€œBusiness â€” Compliance with Government Regulation â€” Global Policy and Guidance.â€Our global sales of antibacterials, anticoccidials and other products were $421 million, $387 million and $362 million for the years ended JuneÂ 30,Â 2024, 2023 and 2022, respectively.CompetitionThe animal health industry is highly competitive. We believe many of our competitors are conducting R&D activities in areas served by our products and in areas in which we are developing products. Our competitors include stand-alone animal health businesses and the animal health businesses of large pharmaceutical companies. In addition to competition from established participants, there could be new entrants to the animal health medicines and vaccines industry in the future. Principal methods of competition vary depending on the region, species, product category or individual products, including reliability, reputation, quality, price, service and promotion to veterinary professionals and livestock producers. Foreign exchangeWe conduct operations in many areas of the world, involving transactions denominated in a variety of currencies. For the year ended JuneÂ 30,Â 2024, we generated approximately 40% of our revenues from operations outside the United States. Although a portion of our revenues are denominated in various currencies, the selling prices of the majority of our sales outside the United States are referenced in U.S. dollars, and as a result, our revenues have not been significantly affected by currency movements. We are subject to currency risk to the extent that our costs are denominated in currencies other than those in which we earn revenues. We manufacture some of our major products in Brazil and Israel and production costs are largely denominated in local currencies, while the selling prices of the products are largely set in U.S. dollars. As such, we are exposed to changes in cost of goods sold resulting from currency movements and may not be able to adjust our selling prices to offset such movements. In addition, we incur selling and administrative expenses in various currencies and are exposed to changes in such expenses resulting from currency movements. For the year ended JuneÂ 30,Â 2024, our expenses were not significantly affected by currency movements. Because we have transactions denominated in various currencies, changes in currency exchange rates have had, and will continue to have, an impact on our results of operations.ClimateAdverse weather events and natural disasters may interfere with and negatively impact operations at our manufacturing sites, research and development facilities and offices, which could have a material adverse effect on our financial condition and results of operations, especially if the impact of an event or disaster is frequent or prolonged.Our operations, and the activities of our customers, could be disrupted by climate change. The physical changes caused by climate change may prompt changes in regulations or consumer preferences which in turn could have negative consequences for our and our customersâ€™ businesses. Climate change may negatively impact our customersâ€™ operations, particularly those in the livestock industry, through climate-related impacts such as increased air and water temperatures, rising water levels and increased incidence of disease in livestock. Potential physical risks from climate change may include altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and other natural disasters, rising sea levels and a rising heat index, any of which could cause negative impacts to our and our 59 Table of Contentscustomersâ€™ businesses. If such events affect our customersâ€™ businesses, they may purchase fewer of our products, and our revenues may be negatively impacted. Climate driven changes could have a material adverse effect on our financial condition and results of operations. There has been a broad range of proposed and promulgated state, national and international regulations aimed at reducing the effects of climate change. Such regulations could result in additional costs to maintain compliance and additional income or other taxes. Climate change regulations continue to evolve, and it is not possible to accurately estimate potential future compliance costs.Product development initiativesOur future success depends on our existing product portfolio, including additional approvals for new claims for our products, for use of our products in new markets, for use of our products with new species and for cross-clearances enabling the use of our medicated products in conjunction with other products. Our future success also depends on our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition. The majority of our R&D programs focus on product lifecycle development, which is defined as R&D programs that leverage existing animal health products by adding new species or claims, achieving approvals in new markets or creating new combinations and reformulations. We commit substantial effort, funds and other resources to expanding our product approvals and R&D, both through our own dedicated resources and through collaborations with third parties. We also commit significant resources to development of new vaccine technologies.Our current strategic initiatives include several projects. We continue to invest in a vaccine production facility in Sligo, Ireland to manufacture poultry vaccines, with our first commercial sale of product realized in 2022, and longer-term expectations to add swine and cattle vaccines. We are developing microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers. We began operations at a new vaccine production facility in Guarulhos, Brazil in fiscal year 2023 that manufactures and markets autogenous vaccines against animal diseases for swine, poultry and aquaculture. We continue to build our companion animal business and pipeline. Our Rejensa joint supplement for dogs continues to gain customer acceptance. Our companion animal development pipeline includes an early-stage atopic dermatitis compound, a potential treatment for mitral heart valve disease in dogs, a pain product and two oral care products.60 Table of ContentsAnalysis of the consolidated statements of operationsSummary Results of
Operationsâ€‹ChangeÂ ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024Â Â Â 2023Â Â Â 2022 Â 2023Â Â Â 2023/Â 2022â€‹â€‹â€‹(in thousands, except per share amounts and percentages)Net salesâ€‹$ 1,017,679Â Â Â Â $ 977,889Â Â Â Â $ 942,261Â Â Â Â $ 39,790Â Â Â Â â€‹ 4%Â Â $ 35,628Â Â Â Â 4%Gross profitâ€‹Â 313,092â€‹Â 298,237â€‹Â 285,400â€‹Â 14,855Â â€‹ 5%Â Â Â 12,837Â 4%Selling, general and administrative expensesâ€‹Â 259,777â€‹Â 226,390â€‹Â 206,414â€‹Â 33,387Â â€‹ 15%Â Â Â 19,976Â 10%Operating incomeâ€‹Â 53,315â€‹Â 71,847â€‹Â 78,986â€‹Â (18,532)Â â€‹ (26)%Â Â Â (7,139)Â (9)%Interest expense, netâ€‹Â 18,536â€‹Â 15,321â€‹Â 11,875â€‹Â 3,215Â â€‹ 21%Â Â Â 3,446Â 29%Foreign currency (gains) losses, netâ€‹Â 23,863â€‹Â 2,455â€‹Â (5,216)â€‹Â 21,408Â â€‹â€‹*Â 7,671Â â€‹*Income before income taxesâ€‹Â 10,916â€‹Â 54,071â€‹Â 72,327â€‹Â (43,155)Â â€‹ (80)%Â Â Â (18,256)Â (25)%Provision for income taxesâ€‹Â 8,500â€‹Â 21,465â€‹Â 23,152â€‹Â (12,965)Â â€‹ (60)%Â Â Â (1,687)Â (7)%Net incomeâ€‹$ 2,416â€‹$ 32,606â€‹$ 49,175â€‹$ (30,190)Â â€‹ (93)%Â Â $ (16,569)Â
(34)%â€‹Net income per shareÂ Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Â â€‹Â Â â€‹Â Â Â Â Â Â â€‹Basicâ€‹$ 0.06â€‹$ 0.81â€‹$ 1.21â€‹$ (0.75)â€‹â€‹â€‹â€‹$ (0.40)Â Â Â â€‹Dilutedâ€‹$ 0.06â€‹$ 0.81â€‹$ 1.21â€‹$ (0.75)â€‹â€‹â€‹â€‹$
(0.41)â€‹Weighted average number of shares
outstandingÂ Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹BasicÂ Â 40,504â€‹Â 40,504â€‹Â 40,504â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Dilutedâ€‹â€‹ 40,523â€‹â€‹ 40,504â€‹â€‹ 40,504â€‹Ratio to net
salesÂ Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Gross profitÂ Â 30.8%Â Â Â 30.5%Â Â Â 30.3%Â Â Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Selling, general and administrative expensesÂ Â 25.5%Â Â Â 23.2%Â Â Â 21.9%Â Â Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Operating incomeÂ Â 5.2%Â Â Â 7.3%Â Â Â 8.4%Â Â Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Income before income taxesÂ Â 1.1%Â Â Â 5.5%Â Â Â 7.7%Â Â Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Net incomeÂ Â 0.2%Â Â Â 3.3%Â Â Â 5.2%Â Â Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Effective tax rateÂ Â 77.9%Â Â Â 39.7%Â Â Â 32.0%Â Â Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Certain amounts andÂ percentages may reflect rounding adjustments.*Calculation not meaningfulChanges in net sales from period to period primarily result from changes in volumes and average selling prices. Although a portion of our net sales is denominated in various currencies, the selling prices of the

majority of our sales outside the United States are referenced in U.S. dollars, and as a result, currency movements have not significantly affected our revenues.Our effective income tax rate has varied from period to period and from the federal statutory rate, due to the mix of taxable profits in various jurisdictions; changes in tax rates from period to period, including changes in income tax legislation in the United States and various international jurisdictions; and the effects of changes in uncertain tax positions and valuation allowances. Our future effective income tax rate will vary due to the relative amounts of taxable income in various jurisdictions, future changes in tax rates and legislation and other factors. We expect to repatriate approximately $80.0 million of international earnings, which will be subject to applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes. We intend to continue to reinvest indefinitely all other undistributed earnings of our foreign subsidiaries where we could be subject to applicable non-U.S. withholding and related taxes if amounts are repatriated to the U.S. See â€œNotes to Consolidated Financial Statementsâ€‰â€”â€‰Income Taxesâ€ for additional information.61 Table of ContentsNet sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDAWe report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See â€œâ€” General description of non-GAAP financial measuresâ€ for descriptions of EBITDA and Adjusted EBITDA.Segment net sales and Adjusted
EBITDA:â€‹ChangeÂ ForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2(
Â 2023Â Â Â Â 2023Â /Â 2022Â Net salesâ€‹(inÂ thousands, except percentages)Â MFAs and otherâ€‹$ 420,959â€‹$ 387,349â€‹$ 361,538â€‹$ 33,610Â 9%Â Â $ 25,811Â 7%Nutritional specialtiesâ€‹Â 164,671â€‹Â 172,504â€‹Â 157,196â€‹Â (7,833)Â (5)%Â Â Â 15,308Â 10%Vaccinesâ€‹Â 120,852â€‹Â 99,998â€‹Â 88,321â€‹Â 20,854Â 21%Â Â Â 11,677Â 13%Animal Healthâ€‹Â 706,482â€‹Â 659,851â€‹Â 607,055â€‹Â 46,631Â 7%Â Â Â 52,796Â 9%Mineral Nutritionâ€‹Â 243,663â€‹Â 242,656â€‹Â 259,512â€‹Â 1,007Â 0%Â Â Â (16,856)Â (6)%Performance Productsâ€‹Â 67,534â€‹Â 75,382â€‹Â 75,694â€‹Â (7,848)Â (10)%Â Â Â (312)Â (0)%Totalâ€‹$ 1,017,679â€‹$ 977,889â€‹$ 942,261â€‹$ 39,790Â 4%Â Â $ 35,628Â 4%â€‹Adjusted EBITDAâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹Animal Healthâ€‹$ 145,606â€‹$ 136,139â€‹$ 124,106â€‹$ 9,467Â 7%Â Â $ 12,033Â 10%Mineral Nutritionâ€‹Â 16,449â€‹Â 17,417â€‹Â 24,038â€‹Â (968)Â (6)%Â Â Â (6,621)Â (28)%Performance Productsâ€‹Â 7,662â€‹Â 9,346â€‹Â 8,706â€‹Â (1,684)Â (18)%Â Â Â 640Â 7%Corporateâ€‹Â (58,480)â€‹Â (50,149)â€‹Â (45,767)â€‹Â (8,331)Â 17%Â Â Â (4,382)Â 10%Totalâ€‹$ 111,237â€‹$ 112,753â€‹$ 111,083â€‹$ (1,516)Â (1)%Â Â $ 1,670Â 2%â€‹Adjusted EBITDA as a percentage of segment net salesâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹Animal Healthâ€‹Â 20.6%Â Â Â 20.6%Â Â Â 20.4%Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹Mineral Nutritionâ€‹Â 6.8%Â Â Â 7.2%Â Â Â 9.3%Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹Performance Productsâ€‹Â 11.3%Â Â Â 12.4%Â Â Â 11.5%Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹Corporate(1)â€‹Â (5.7)%Â Â Â (5.1)%Â Â Â (4.9)%Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹Total(1)â€‹Â 10.9%Â Â Â 11.5%Â Â Â 11.8%Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹(1)Reflects ratio to total net sales.Certain amounts andÂ percentages may reflect rounding adjustments.*Calculation not meaningful62 Table of ContentsA reconciliation of net income, as reported under GAAP, to Adjusted
EBITDA:â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ChangeÂ ForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 20
Â 2023Â Â Â Â 2023/Â 2022Â â€‹â€‹(inÂ thousands, except percentages)Â Net incomeâ€‹$ 2,416â€‹$ 32,606â€‹$ 49,175â€‹$ (30,190)Â (93)%$ (16,569)Â (34)%Interest expense, netâ€‹Â 18,536â€‹Â 15,321â€‹Â 11,875â€‹Â 3,215Â 21%Â Â Â 3,446Â 29%Provision for income taxesâ€‹Â 8,500â€‹Â 21,465â€‹Â 23,152â€‹Â (12,965)Â (60)%Â Â Â (1,687)Â (7)%Depreciation and amortizationâ€‹Â 36,178â€‹Â 34,012â€‹Â 32,705â€‹Â 2,166Â 6%Â Â Â 1,307Â 4%EBITDAâ€‹Â 65,630â€‹Â 103,404â€‹Â 116,907â€‹Â (37,774)Â (37)%Â Â Â (13,503)Â (12)%Acquisition-related cost of goods soldâ€‹Â 521â€‹Â â€”â€‹Â 316â€‹Â 521Â *â€‹Â (316)Â *â€‹Acquisition-related transaction costsâ€‹â€‹ 6,405â€‹â€‹ â€”â€‹â€‹ 279â€‹â€‹ 6,405Â *â€‹Â (279)Â *â€‹Pension settlement costâ€‹â€‹ 10,674â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 10,674â€‹*â€‹â€‹ â€”â€‹*â€‹Brazil employment taxesâ€‹â€‹ 4,202â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 4,202â€‹*â€‹â€‹ â€”â€‹*â€‹Stock-based compensationâ€‹Â 475â€‹Â â€”â€‹Â â€”â€‹Â 475Â *â€‹Â â€”Â *â€‹Phibro Forward income growth initiatives implementation costs (1)â€‹Â 366â€‹Â â€”â€‹Â â€”â€‹Â 366Â *â€‹Â â€”Â *â€‹Insurance proceedsâ€‹â€‹ (899)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (899)Â *â€‹Â â€”Â *â€‹Environmental remediation costsâ€‹â€‹ â€”â€‹â€‹ 6,894â€‹â€‹ â€”â€‹â€‹ (6,894)Â *â€‹â€‹ 6,894Â *â€‹Gain on sale of investmentâ€‹Â â€”â€‹Â â€”â€‹Â (1,203)â€‹Â â€”Â *â€‹Â 1,203Â *â€‹Foreign currency (gains) losses, netâ€‹Â 23,863â€‹Â 2,455â€‹Â (5,216)â€‹Â 21,408Â *â€‹Â 7,671Â *â€‹Adjusted EBITDAâ€‹$ 111,237â€‹$ 112,753â€‹$ 111,083â€‹$ (1,516)Â (1)%Â Â $ 1,670Â 2%(1)Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings.Certain amounts andÂ percentages may reflect rounding adjustments.*Calculation not meaningfulComparison of theÂ years ended JuneÂ 30,Â 2024 and 2023Net salesNet sales of $1,017.7 million for the year ended JuneÂ 30,Â 2024 increased $39.8 million, or 4%, as compared to the year ended JuneÂ 30,Â 2023. Animal Health and Mineral Nutrition sales increased $46.6 million and $1.0 million, respectively. Performance Products sales decreased $7.8 million.Animal HealthNet sales of $706.5 million for the year ended JuneÂ 30,Â 2024 increased $46.6 million, or 7%. Net sales of MFAs and other increased $33.6 million, or 9%, due to increased volumes in all regions and higher demand for processing aids used in the ethanol fermentation industry. Net sales of nutritional specialty products decreased $7.8 million, or 5%, due to decreased demand for dairy and microbial products, partially offset by increased sales of poultry products. Net sales of vaccines increased $20.9 million, or 21%, primarily due to poultry product introductions in Latin America, plus an increase in domestic demand.Mineral Nutrition Net sales of $243.7 million for the year ended JuneÂ 30,Â 2024 increased $1.0 million, or less than 1%, primarily due to increase in demand for trace minerals.Performance Products Net sales of $67.5 million for the year ended JuneÂ 30,Â 2024 decreased $7.8 million, or 10%, driven by decreased demand for personal care product ingredients and industrial chemicals. 63 Table of ContentsGross profit Gross profit ofâ€‰$313.1 million for the year ended JuneÂ 30,Â 2024 increased $14.9 million, or 5%, as compared to the year ended JuneÂ 30,Â 2023. Gross margin increased 30 basis points to 30.8% of net sales for the year ended JuneÂ 30,Â 2024 as compared to 30.5% for the year ended JuneÂ 30,Â 2023. Animal Health gross profit increased $17.5 million due to higher product demand. Mineral Nutrition gross profit decreased $0.3 million. Performance Products gross profit decreased $1.8 million, due to lower demand and unfavorable product mix. Acquisition-related cost of goods sold reduced gross profit by $0.5 million.Selling, general and administrative expenses SG&A expenses ofâ€‰$259.8 million for the year ended JuneÂ 30,Â 2024 increased $33.4 million, or 15%, as compared to the year ended JuneÂ 30,Â 2023. SG&A for the year ended June 30, 2024 included a $10.7 million pension settlement charge, $6.4 million for acquisition-related costs, $4.2 million cost related to Brazil employment taxes, $0.5 million in stock-based compensation and $0.4 million related to consultant fees associated with Phibro Forward income growth initiatives, slightly offset by a gain from insurance proceeds of $0.9 million. SG&A for the year ended June 30, 2023, included $6.9 million of environmental remediation costs mostly related to the definitive settlement agreement related to the Omega Chemical Site. Excluding these items, SG&A increased $19.1 million, or 9%. Animal Health SG&A increased $10.5 million, primarily due to an increase in employee-related costs and new product launches in Brazil. Mineral Nutrition SG&A increased $0.4 million due to an increase in employee-related costs. Performance Products SG&A decreased $0.1 million. Corporate expenses increased $8.3 million due to higher incentive-related employee costs and strategic investments. Interest expense, net Interest expense, net ofâ€‰$18.5 million for the year ended JuneÂ 30,Â 2024 increased by $3.2 million, or 21%, as compared to the year ended JuneÂ 30,Â 2023, as a result of higher variable interest rates and increased debt levels, partially offset by higher returns on short-term investments.Foreign currency (gains) losses, net Foreign currency losses, net for the year ended JuneÂ 30,Â 2024 wereâ€‰$23.9 million, as compared to net losses of $2.5 million for the year ended JuneÂ 30,Â 2023. Current period losses were driven by fluctuations in certain currencies relative to the U.S. dollar, including a major devaluation in the Argentine peso and the weakening of the Brazilian real.Provision for income taxesThe provision for income taxes was $8.5 million and $21.5 million for the years ended JuneÂ 30,Â 2024 and 2023, respectively. The effective income tax rate was 77.9% and 39.7% for the years ended JuneÂ 30,Â 2024 and 2023, respectively. The effective income tax rate for the year ended June 30, 2024 was unfavorably affected by the proportionally greater effect of certain items such as Global Intangible Low-Tax Income (â€œGILTIâ€) taxes when compared with reduced pre-tax income. The provision for income taxes for the year ended June 30, 2024 included (i) a $2.8 million expense for applicable non-U.S. withholding and related taxes, net of reductions in U.S. incomes taxes, related to an planned repatriation of approximately $80.0 million of international earnings, (ii) a $1.2 million benefit related to the determination of whether a foreign tax is eligible for a U.S. foreign tax credit related to our fiscal year 2023, based on Internal Revenue Service (â€œIRSâ€) guidance provided subsequent to June 30, 2023, (iii) a $1.2 million benefit related to the release of certain valuation allowances on non-U.S. companies and (iv) a $1.6 million expense from changes in uncertain tax positions related to prior years and certain other items. The provision for income taxes for the year ended June 30, 2023, included a net cost of $1.5 million for certain one-time items including (i) GILTI income taxes that were modified by IRS guidance issued subsequent to June 30, 2023, (ii) the net cost of withholding taxes related to dividends received from an international affiliate and (iii) the net benefit related to certain unrecognized tax benefits from adjustments to and the lapse of statute of limitations of prior years. The effective income tax rate without these items would have been 59.2% and 36.9% for the years ended June 30, 2024 and 2023, respectively.We record the GILTI-related aspects of comprehensive U.S. income tax legislation as a period expense. The provision for income taxes for the years ended June 30, 2024 and 2023, included $2.0 million and $1.8 million, 64 Table of Contentsrespectively, of federal tax expense from the effects of GILTI. Our effective income tax rate included 18.3% and 3.3% related to GILTI income tax expense for the years ended June 30, 2024 and 2023, respectively. Net incomeNet income of $2.4 million for the year ended JuneÂ 30,Â 2024 decreased $30.2 million, as compared to net income ofâ€‰$32.6 million for the year ended JuneÂ 30,Â 2023. Operating income decreased $18.5 million driven by higher SG&A, partially offset by higher gross profit. SG&A expenses increased by $33.4 million, which included pension settlement costs of $10.7 million, acquisition-related costs of $6.4 million, Brazil employment taxes of $4.2 million, stock-based compensation of $0.5 million and consultant fees related to Phibro Forward income growth initiatives of $0.4 million, slightly offset by a gain from insurance proceeds of $0.9 million. Changes in interest expense, net and foreign currency losses resulted in a $3.2 million and $21.4 million reduction in income before income taxes, respectively. This was partially offset by a $13.0 million decrease in income tax expense.Adjusted EBITDA Adjusted EBITDA ofâ€‰$111.2 million for the year ended JuneÂ 30,Â 2024 decreased $1.5 million, or 1%, as compared to the year ended JuneÂ 30,Â 2023. Animal Health Adjusted EBITDA increased $9.5 million, driven by higher sales and increased gross profit, partially offset by an increase in SG&A. Mineral Nutrition Adjusted EBITDA decreased $1.0 million, due to decreased gross profit and an increase in SGA. Performance Products Adjusted EBITDA decreased by $1.7 million due to lower sales and decreased gross profit. Corporate expenses increased $8.3 million due to higher incentive-related employee costs and strategic investments.Comparison of theÂ years ended JuneÂ 30,Â 2023 and 2022For a comparison of our results of operations for the years ended JuneÂ 30,Â 2023 and 2022, and an analysis of our financial condition, liquidity and capital resources for the year ended JuneÂ 30,Â 2023, see â€œPart II. Item 7.Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€Â of our Annual Report on Form 10-K for the fiscal year ended JuneÂ 30,Â 2023, filed with the SEC on August 30, 2023.Adjusted net income and adjusted diluted earnings per shareWe report adjusted net income to portray the results of our operations prior to considering certain income statement elements. See â€œâ€”General description of non-GAAP financial measuresâ€ for more information.A reconciliation of net income, as reported under GAAP, to adjusted net income is as
follows:â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ChangeÂ ForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€
Â 2023Â 2023/Â 2022â€‹â€‹â€‹â€‹(in thousands, except per share amounts and percentages)â€‹Reconciliation of GAAP Net Income to Adjusted Net
Incomeâ€‹Â Â Â â€‹Â Â Â â€‹â€‹â€‹â€‹Â Â Â Â Â Â Â Â Â â€‹â€‹Â Â Â Â â€‹â€‹Net incomeâ€‹$ 2,416â€‹$ 32,606â€‹$ 49,175â€‹$ (30,190)Â (93)%Â Â $ (16,569)â€‹ (34)%Adjustmentsâ€‹Acquisition-related items, net of income tax (1)â€‹Â 13,063â€‹Â 6,959â€‹Â 7,113â€‹Â 6,104Â *â€‹Â (154)â€‹*â€‹Certain items, net of income tax (1)â€‹â€‹ 11,420â€‹â€‹ 4,929â€‹â€‹ (927)â€‹â€‹ 6,491Â *â€‹â€‹ 5,856â€‹*â€‹Foreign currency (gains) losses, net of income tax (1)â€‹Â 19,429â€‹Â 2,936â€‹Â (2,979)â€‹Â 16,493Â *â€‹Â 5,915â€‹*â€‹Certain income tax items (1)â€‹Â 2,035â€‹Â 1,533â€‹Â 772â€‹Â 502Â *â€‹Â 761â€‹*â€‹Total adjustments, net of income taxâ€‹â€‹ 45,947â€‹â€‹ 16,357â€‹â€‹ 3,979â€‹â€‹ 29,590â€‹*â€‹â€‹ 12,378â€‹*â€‹Adjusted net incomeâ€‹$ 48,363â€‹$ 48,963â€‹$ 53,154â€‹$ (600)Â (1)%$ (4,191)â€‹ (8)%â€‹(1)See table titled â€œItems Excluded from Adjusted Net Incomeâ€ below for further details.65 Table of ContentsA reconciliation of reported diluted earnings per share (EPS), as reported under GAAP, to non-GAAP adjusted diluted EPS
is:â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Changeâ€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€‹20
Â 2023Â 2023/Â 2022â€‹â€‹â€‹â€‹(in thousands, except per share amounts and percentages)â€‹Reconciliation of GAAP diluted EPS to Adjusted diluted
EPSâ€‹GAAP EPS, dilutedâ€‹$ 0.06â€‹$ 0.81â€‹$ 1.21â€‹$ (0.75)Â (93)%$ (0.40)â€‹ (33)%Adjustmentsâ€‹Acquisition-related items, net of income taxâ€‹Â 0.32â€‹Â 0.17â€‹Â 0.17â€‹Â 0.15Â *â€‹Â 0.00â€‹*â€‹Certain items, net of income taxâ€‹Â 0.28â€‹Â 0.12â€‹Â (0.02)â€‹Â 0.16Â *â€‹Â 0.14â€‹*â€‹Foreign currency (gains) losses, net of income taxâ€‹Â 0.48â€‹Â 0.07â€‹Â (0.07)â€‹Â 0.41Â *â€‹Â 0.14â€‹*â€‹Certain income tax itemsâ€‹Â 0.05â€‹Â 0.04â€‹Â 0.02â€‹Â 0.01Â *â€‹Â 0.02â€‹*â€‹Adjustments EPS, dilutedâ€‹â€‹ 1.13â€‹â€‹ 0.40â€‹â€‹ 0.10â€‹â€‹ 0.73â€‹*â€‹â€‹ 0.30â€‹*â€‹Adjusted EPS, dilutedâ€‹$ 1.19â€‹$ 1.21â€‹$ 1.31â€‹$ (0.02)Â (2)%$ (0.10)â€‹ (8)%â€‹Items excluded from adjusted net income consisted of:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024Â Â Â Â 2023Â Â Â Â 2022â€‹â€‹â€‹(in thousands)Items Excluded from Adjusted Net Incomeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Acquisition-related itemsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Acquisition-related intangible amortization in cost of goods soldâ€‹$ 6,675â€‹$ 6,651â€‹$ 5,943Acquisition-related cost of goods soldâ€‹Â 521â€‹Â â€”â€‹Â 316Acquisition-related intangible amortization in SG&Aâ€‹â€‹ 2,986â€‹Â 3,045â€‹Â 2,981Acquisition-related transaction costs in SG&Aâ€‹â€‹ 6,405â€‹Â â€”â€‹Â 279Acquisition-related items - income taxesâ€‹â€‹ (3,524)â€‹â€‹ (2,737)â€‹â€‹ (2,406)Total acquisition-related items, net of income taxesâ€‹Â 13,063â€‹Â 6,959â€‹Â 7,113â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Certain items (in SG&A)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Pension settlement costâ€‹â€‹ 10,674â€‹Â â€”â€‹Â â€”Brazil employment taxesâ€‹â€‹ 4,202â€‹Â â€”â€‹Â â€”Stock-based compensationâ€‹â€‹ 475â€‹Â â€”â€‹Â â€”Phibro Forward income growth initiatives implementation costsâ€‹â€‹ 366â€‹Â â€”â€‹Â â€”Insurance proceedsâ€‹â€‹ (899)â€‹Â â€”â€‹Â â€”Environmental remediation costsâ€‹â€‹ â€”â€‹Â 6,894â€‹Â â€”Gain on sale of investmentâ€‹â€‹ â€”â€‹Â â€”â€‹Â (1,203)Certain items - income taxesâ€‹â€‹ (3,398)â€‹â€‹ (1,965)â€‹â€‹ 276Total certain items, net of income taxesâ€‹â€‹ 11,420â€‹â€‹ 4,929â€‹â€‹ (927)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Foreign currency (gains) losses, netâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Foreign currency (gains) losses, netâ€‹â€‹ 23,863â€‹Â 2,455â€‹Â (5,216)Foreign currency (gains) losses, net - income taxesâ€‹â€‹ (4,434)â€‹â€‹ 481â€‹â€‹ 2,237Total foreign currency (gains) losses, net, net of income taxesâ€‹â€‹ 19,429â€‹â€‹ 2,936â€‹â€‹ (2,979)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Certain income tax itemsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Non-U.S. withholding and related taxes, net, on planned repatriationâ€‹â€‹ 2,828â€‹â€‹ â€”â€‹â€‹ â€”Foreign tax credit regulationsâ€‹â€‹ (1,223)â€‹â€‹ 1,223â€‹â€‹ â€”Change in valuation allowanceâ€‹â€‹ (1,204)â€‹â€‹ â€”â€‹â€‹ (1,001)Changes in uncertain tax positions and certain other itemsâ€‹â€‹ 1,634â€‹â€‹ 310â€‹â€‹ 1,773Total certain income tax itemsâ€‹â€‹ 2,035â€‹â€‹ 1,533â€‹â€‹ 772â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Total adjustments, net of income taxesâ€‹$ 45,947â€‹$ 16,357â€‹$ 3,97966 Table of Contentsâ€‹Analysis of financial condition, liquidity and capital resourcesNet increase (decrease) in cash and cash equivalents
was:â€‹ChangeForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Â Â Â 2024/
Â 2023Â Â Â Â 2023/Â 2022â€‹â€‹(inÂ thousands)Cash provided (used) by:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating activitiesâ€‹$ 87,594â€‹$ 13,310â€‹$ 31,649â€‹$ 74,284â€‹$ (18,339)Investing activitiesâ€‹Â (48,194)â€‹Â (74,018)â€‹Â (22,582)â€‹Â 25,824â€‹Â (51,436)Financing activitiesâ€‹Â (6,768)â€‹Â 26,987â€‹Â 16,343â€‹Â (33,755)â€‹Â 10,644Effect of exchange-rate changes on cash and cash equivalentsâ€‹Â (3,300)â€‹Â 754â€‹Â (1,374)â€‹Â (4,054)â€‹Â 2,128Net increase (decrease) in cash and cash equivalentsâ€‹$ 29,332â€‹$ (32,967)â€‹$ 24,036â€‹$ 62,299â€‹$ (57,003)â€‹Operating activitiesOperating activities provided $87.6 million of net cash for the year ended JuneÂ 30,Â 2024. Cash provided by net income, adjusted for non-cash items, including depreciation and amortization, was $54.5 million. Cash provided in the ordinary course of business from changes in operating assets and liabilities and other items was $33.1 million. Accounts receivable used $8.7 million of cash due to sales growth, partially offset by an improvement in days sales outstanding. Inventory provided $2.6 million of cash due to a decrease in quantities on hand, offset by increased raw materials and production costs. Other current assets provided $11.0 million due to timing of tax payments in international regions. Accounts payable provided $12.0 million of cash due to timing of purchases and payments. Accrued expenses and other liabilities provided cash of $12.2 million, primarily due to increased employee-related liabilities and accrued transaction costs.Operating activities provided $13.3 million of net cash for the year ended JuneÂ 30,Â 2023. Net cash provided by

operating activities was driven by business performance, resulting in cash provided by net income and non-cash items, including depreciation and amortization, of $54.4 million, offset by cash used in the ordinary course of business for changes in operating assets and liabilities of $41.1 million. Cash provided by accounts receivable was $5.3 million as a result of a favorable reduction in days sales outstanding. Cash used for inventory was $11.2 million due to increased raw material and production costs, product mix, lower than anticipated demand in our Mineral Nutrition products and a projected increase in future demand of other products in our portfolio. Other current assets used $7.4 million due to the timing of insurance payments. Accounts payable used $22.8 million due to timing of purchases and payments. Accrued expenses and other liabilities used $5.7 million, primarily due to changes in employee-related and lease liabilities.Investing activities Investing activities used $48.2 million of net cash for the year ended JuneÂ 30,Â 2024. Capital expenditures were $41.2 million, related primarily to continued investments in expanded production capacity and productivity improvements. Net purchases and maturities of short-term investments used $4.0 million in cash. We acquired a business for $3.3 million, net of cash acquired. Other investing activities provided $0.3 million of cash.Investing activities used $74.0 million of net cash for the year ended JuneÂ 30,Â 2023. Capital expenditures were $51.8 million, related primarily to continued investments in expanded production capacity and productivity improvements, and the $15.0 million purchase of additional land and building at an operating facility. Net purchases and maturities of short-term investments used $23.0 million in cash. Other investing activities provided $0.8 million of cash. Financing activitiesFinancing activities used $6.8 million of net cash for the year ended JuneÂ 30,Â 2024. Net borrowings on our 2021 Revolver (as defined below) provided $35.0 million in cash. We paid $22.3 million in scheduled long-term debt maturities. We paid $19.4 million in dividends to holders of our Class A common stock and Class B common stock. Financing activities provided $27.0 million of net cash for the year ended JuneÂ 30,Â 2023. Proceeds from the 2023 Incremental Term Loan and 2022 Term Loan provided $62.0 million, with debt issuance costs of $1.5 million. We paid $15.3 million in scheduled debt maturities. Net payments on our revolving credit facility reduced the outstanding 67 Table of Contentsbalance by $4.0 million. Proceeds from insurance premium financing, net of cash payments, provided cash of $5.2 million. We paid $19.4 million in dividends to holders of our Class A common stock and Class B common stock.Liquidity and capital resourcesWe believe our cash on hand, our operating cash flows and our financing arrangements, including the availability of borrowings under the Revolving Credit Commitments (as defined below), will be sufficient to support our ongoing cash needs. We have considered the current and potential future effects of the macroeconomic market conditions in the financial markets. At this time, we expect adequate liquidity for at least the next twelveÂ months. Our future debt levels and liquidity are expected to be affected by the Proposed Acquisition and our intent to finance the transaction with new debt in the amount of $350.0 million. See â€œNotes to Consolidated Financial Statements â€" Proposed Acquisition.â€Aggregate maturities of long-term debt under the 2024 Credit Agreement, assuming completion of the Proposed Acquisition, are: â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Years Ending JuneÂ 30â€‹â€‹Annual Maturitiesâ€‹â€‹Interest Payments2025â€‹$ 11,875â€‹$ 46,4002026â€‹â€‹ 16,250â€‹â€‹ 65,4792027â€‹â€‹ 25,025â€‹â€‹ 63,8922028â€‹â€‹ 25,025â€‹â€‹ 61,9332029â€‹â€‹ 25,025â€‹â€‹ 59,973Totalâ€‹$ 103,200â€‹$ 297,677â€‹For purposes of estimating future interest payments until maturity, we assume (i) long-term debt decreases in accordance with the scheduled amortization, (ii) the Revolving Credit Commitments remains constant at $201,000, (iii) the March 2020 interest rate swap agreement remains in place through its June 2025 maturity, (iv) future floating interest rates are the same as the rates at JuneÂ 30,Â 2024, and (v) applicable rates are based on the 2024 Credit Facilities and the expected Net Leverage Ratio, assuming completion of the Proposed Acquisition.We can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the 2024 Credit Facilities based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise, including ongoing conflicts between Israel and Hamas and between Russia and Ukraine. There can be no assurance that a challenging economic environment or an economic downturn would not affect our liquidity or our ability to obtain future financing or fund operations or investment opportunities. In addition, our debt covenants may restrict our ability to invest. Certain relevant measures of our liquidity and capital resources are as follows:â€‹ChangeAs of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Â Â Â 2024Â /Â 2023Â Â Â Â 2023Â /Â 2022â€‹â€‹(in thousands, except ratios)Cash and cash equivalents and short-term investmentsâ€‹$ 114,613â€‹$ 81,281â€‹$ 91,248â€‹$ 33,332â€‹$ (9,967)Working capitalâ€‹Â 312,031â€‹Â 350,737â€‹Â 299,152â€‹Â (38,706)â€‹Â 51,585Ratio of current assets to current liabilitiesâ€‹Â 2.79:1â€‹Â 3.28:1â€‹Â 2.70:1â€‹Â Â Â â€‹Â Â Â â€‹We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.At JuneÂ 30,Â 2024, we had $176.0 million in outstanding borrowings under the 2021 Revolver. We had outstanding letters of credit and other commitments ofâ€‰$2.3 million, leaving $131.7 million available for borrowings and letters of credit, subject to restrictions in our 2021 Credit Facilities.We currently intend to pay quarterly dividends on our Class A and Class B common stock, subject to approval by the Board of Directors. Our Board of Directors has declared a cash dividend ofâ€‰$0.12 per share on Class A common 68 Table of Contentsstock and Class B common stock, payable on September 25, 2024. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.We do not expect to contribute to the domestic pension plan during 2025.At JuneÂ 30,Â 2024, our cash and cash equivalents and short-term investments included $111.9 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries.Contractual obligations Our contractual obligations include maturities under the 2021 Credit Facilities and the 2022 Term Loan, including future interest accruals, operating lease commitments, and certain purchase obligations. See â€œNotes to Consolidated Financial Statements â€" Debt, Leases, and Commitment and Contingencies.â€ Analysis of the consolidated balance sheetsâ€‹ChangeAs of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Â Â Â 2024 / 2023Â Â Â Â 2023 / 2022â€‹â€‹(inÂ thousands)Accounts receivableâ€‰-â€‰tradeâ€‹$ 169,452â€‹$ 163,479â€‹$ 166,537â€‹$ 5,973â€‹$ (3,058)DSOâ€‹Â 56â€‹Â 58â€‹Â 59â€‹Â Â Â â€‹Â Â Â â€‹Payment terms outside the U.S. are typically longer than in the United States. We regularly monitor our accounts receivable for collectability, particularly in countries where economic conditions remain uncertain. We believe that our reserve for credit losses is appropriate. Our assessment is based on such factors as past due history, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment. We calculate DSO based on a 360-day year and compare accounts receivable with sales for the quarter ending at the balance sheet date.â€‹ChangeAs of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Â Â Â 2024 / 2023Â Â Â Â 2023 / 2022â€‹â€‹(inÂ thousands)Inventoriesâ€‹$ 265,911â€‹$ 277,570â€‹$ 259,158â€‹$ (11,659)â€‹$ 18,412â€‹Inventory decreased by $11.7 million in 2024, primarily due to an effort to manage inventory levels and the effect of currency fluctuations, partially offset by increased raw material and production costs.Off-balance sheet arrangementsWe currently do not use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.69 Table of ContentsSelected Quarterly Financial Data (Unaudited)To facilitate quarterly comparisons, the following unaudited information presents the quarterly results of operations, including segment data, for theÂ years ended JuneÂ 30,Â 2024 and 2023. This quarterly financial data was prepared on the same basis as, and should be read in conjunction with, the audited consolidated financial statements and related notes included herein.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Quartersâ€‹Yearâ€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â Â Â Â Â MarchÂ 31,Â Â Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ 30 the Periods Endedâ€‹2023â€‹2023â€‹2024â€‹2024â€‹2024â€‹â€‹(inÂ thousands)Net salesÂ â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â MFAs and otherâ€‹$ 94,104â€‹$ 101,941â€‹$ 108,216â€‹$ 116,698â€‹$ 420,959Nutritional Specialtiesâ€‹Â 40,210â€‹Â 41,436â€‹Â 40,194â€‹Â 42,831â€‹Â 164,671Vaccinesâ€‹Â 26,216â€‹Â 29,727â€‹Â 32,923â€‹Â 31,986â€‹Â 120,852Animal Healthâ€‹$ 160,530â€‹$ 173,104â€‹$ 181,333â€‹$ 191,515â€‹$ 706,482Mineral Nutritionâ€‹Â 56,026â€‹â€‹ 61,347â€‹â€‹ 64,228â€‹Â 62,062â€‹Â 243,663Performance Productsâ€‹Â 14,793â€‹â€‹ 15,492â€‹â€‹ 17,662â€‹Â 19,587â€‹Â 67,534Total net salesâ€‹Â 231,349â€‹Â 249,943â€‹Â 263,223â€‹Â 273,164â€‹Â 1,017,679Cost of goods soldâ€‹Â 163,623â€‹â€‹ 171,327â€‹â€‹ 183,623â€‹Â 186,014â€‹Â 704,587Gross profitâ€‹Â 67,726â€‹Â 78,616â€‹Â 79,600â€‹Â 87,150â€‹Â 313,092Selling, general and administrative expensesâ€‹â€‹ 68,452â€‹â€‹ 62,915â€‹â€‹ 59,676â€‹â€‹ 68,734â€‹â€‹ 259,777Operating income (loss)â€‹â€‹ (726)â€‹â€‹ 15,701â€‹â€‹ 19,924â€‹â€‹ 18,416â€‹â€‹ 53,315Interest expense, netâ€‹Â 4,564â€‹â€‹ 4,659â€‹â€‹ 4,575â€‹Â 4,738â€‹Â 18,536Foreign currency (gains) losses, netâ€‹Â 6,689â€‹â€‹ 7,477â€‹â€‹ 2,427â€‹Â 7,270â€‹Â 23,863Income (expense) before income taxesâ€‹Â (11,979)â€‹Â 3,565â€‹Â 12,922â€‹Â 6,408â€‹Â 10,916Provision (benefit) for income taxesâ€‹Â (3,964)â€‹â€‹ 2,291â€‹â€‹ 4,517â€‹Â 5,656â€‹Â 8,500Net income (loss)â€‹$ (8,015)â€‹$ 1,274â€‹$ 8,405â€‹$ 752â€‹$ 2,416Net income (loss) per shareâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â basicâ€‹$ (0.20)â€‹$ 0.03â€‹$ 0.21â€‹$ 0.02â€‹$ 0.06dilutedâ€‹$ (0.20)â€‹$ 0.03â€‹$ 0.21â€‹$ 0.02â€‹$ 0.06Adjusted EBITDAâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Animal Healthâ€‹$ 28,494â€‹$ 39,299â€‹$ 36,524â€‹$ 41,289â€‹$ 145,606Mineral Nutritionâ€‹Â 2,881â€‹Â 3,507â€‹Â 4,665â€‹Â 5,396â€‹Â 16,449Performance Productsâ€‹Â 1,409â€‹Â 817â€‹Â 2,371â€‹Â 3,065â€‹Â 7,662Corporateâ€‹Â (14,133)â€‹Â (14,171)â€‹Â (13,856)â€‹Â (16,320)â€‹Â (58,480)Adjusted EBITDAâ€‹$ 18,651â€‹$ 29,452â€‹$ 29,704â€‹$ 33,430â€‹$ 111,237Reconciliation of net income (loss) to Adjusted EBITDAâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Net income (loss)â€‹$ (8,015)â€‹$ 1,274â€‹$ 8,405â€‹$ 752â€‹$ 2,416Interest expense, netâ€‹Â 4,564â€‹Â 4,659â€‹Â 4,575â€‹Â 4,738â€‹Â 18,536Provision (benefit) for income taxesâ€‹Â (3,964)â€‹Â 2,291â€‹Â 4,517â€‹Â 5,656â€‹Â 8,500Depreciation and amortizationâ€‹Â 8,871â€‹â€‹ 8,910â€‹â€‹ 9,196â€‹Â 9,201â€‹Â 36,178EBITDAâ€‹â€‹ 1,456â€‹Â 17,134â€‹Â 26,693â€‹Â 20,347â€‹Â 65,630Acquisition-related cost of goods soldâ€‹â€‹ â€"â€‹â€‹ 310â€‹â€‹ 211â€‹â€‹ â€"â€‹â€‹ 521Acquisition-related transaction costsâ€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 512â€‹â€‹ 5,893â€‹â€‹ 6,405Pension settlement costâ€‹â€‹ 10,425â€‹â€‹ 249â€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 10,674Brazil employment taxesâ€‹â€‹ â€"â€‹â€‹ 4,202â€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 4,202Stock-based compensationâ€‹Â 81â€‹Â 80â€‹Â 135â€‹Â 179â€‹Â 475Phibro Forward income growth initiatives implementation costsâ€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 366â€‹â€‹ 366Insurance proceedsâ€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ (274)â€‹â€‹ (625)â€‹â€‹ (899)Foreign currency (gains) losses, netâ€‹Â 6,689â€‹Â 7,477â€‹Â 2,427â€‹Â 7,270â€‹Â 23,863Adjusted EBITDAâ€‹$ 18,651â€‹$ 29,452â€‹$ 29,704â€‹$ 33,430â€‹$ 111,237â€‹70 Table of Contentsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Quartersâ€‹Yearâ€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â Â Â Â Â MarchÂ 31,Â Â Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ the Periods Endedâ€‹2022â€‹2022â€‹2023â€‹2023â€‹2023â€‹â€‹(inÂ thousands)Net salesÂ â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â MFAs and otherâ€‹$ 92,790â€‹$ 97,179â€‹$ 93,217â€‹$ 104,163â€‹$ 387,349Nutritional Specialtiesâ€‹Â 39,054â€‹Â 43,856â€‹Â 45,016â€‹Â 44,578â€‹Â 172,504Vaccinesâ€‹Â 23,015â€‹Â 22,768â€‹Â 26,201â€‹Â 28,014â€‹Â 99,998Animal Healthâ€‹$ 154,859â€‹$ 163,803â€‹$ 164,434â€‹$ 176,755â€‹$ 659,851Mineral Nutritionâ€‹Â 59,646â€‹â€‹ 61,644â€‹â€‹ 62,922â€‹Â 58,444â€‹Â 242,656Performance Productsâ€‹Â 18,016â€‹â€‹ 19,199â€‹â€‹ 18,317â€‹Â 19,850â€‹Â 75,382Total net salesâ€‹Â 232,521â€‹Â 244,646â€‹Â 245,673â€‹Â 255,049â€‹Â 977,889Cost of goods soldâ€‹Â 163,875â€‹â€‹ 167,261â€‹â€‹ 170,133â€‹Â 178,383â€‹Â 679,652Gross profitâ€‹Â 68,646â€‹Â 77,385â€‹Â 75,540â€‹Â 76,666â€‹Â 298,237Selling, general and administrative expensesâ€‹â€‹ 54,962â€‹â€‹ 61,541â€‹â€‹ 56,987â€‹â€‹ 52,900â€‹â€‹ 226,390Operating incomeâ€‹â€‹ 13,684â€‹â€‹ 15,844â€‹â€‹ 18,553â€‹â€‹ 23,766â€‹â€‹ 71,847Interest expense, netâ€‹Â 3,067â€‹â€‹ 3,884â€‹â€‹ 3,871â€‹Â 4,499â€‹Â 15,321Foreign currency (gains) losses, netâ€‹Â 5,200â€‹â€‹ (149)â€‹â€‹ (422)â€‹Â (2,174)â€‹Â 2,455Income before income taxesâ€‹Â 5,417â€‹Â 12,109â€‹Â 15,104â€‹Â 21,441â€‹Â 54,071Provision for income taxesâ€‹Â 1,561â€‹â€‹ 4,899â€‹â€‹ 5,062â€‹Â 9,943â€‹Â 21,465Net incomeâ€‹$ 3,856â€‹$ 7,210â€‹$ 10,042â€‹$ 11,498â€‹$ 32,606Net income per shareâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â basicâ€‹$ 0.10â€‹$ 0.18â€‹$ 0.25â€‹$ 0.28â€‹$ 0.81dilutedâ€‹$ 0.10â€‹$ 0.18â€‹$ 0.25â€‹$ 0.28â€‹$ 0.81Adjusted EBITDAâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Animal Healthâ€‹$ 26,964â€‹$ 37,059â€‹$ 34,217â€‹$ 37,899â€‹$ 136,139Mineral Nutritionâ€‹Â 5,297â€‹Â 4,399â€‹Â 3,859â€‹Â 3,862â€‹Â 17,417Performance Productsâ€‹Â 2,364â€‹Â 2,292â€‹Â 2,413â€‹Â 2,277â€‹Â 9,346Corporateâ€‹Â (12,491)â€‹Â (12,838)â€‹Â (13,122)â€‹Â (11,698)â€‹Â (50,149)Adjusted EBITDAâ€‹$ 22,134â€‹$ 30,912â€‹$ 27,367â€‹$ 32,340â€‹$ 112,753Reconciliation of net income to Adjusted EBITDAâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Net incomeâ€‹$ 3,856â€‹$ 7,210â€‹$ 10,042â€‹$ 11,498â€‹$ 32,606Interest expense, netâ€‹Â 3,067â€‹Â 3,884â€‹Â 3,871â€‹Â 4,499â€‹Â 15,321Provision for income taxesâ€‹Â 1,561â€‹Â 4,899â€‹Â 5,062â€‹Â 9,943â€‹Â 21,465Depreciation and amortizationâ€‹Â 8,450â€‹â€‹ 8,499â€‹â€‹ 8,489â€‹Â 8,574â€‹Â 34,012EBITDAâ€‹â€‹ 16,934â€‹Â 24,492â€‹Â 27,464â€‹Â 34,514â€‹Â 103,404Environmental remediation costsâ€‹â€‹ â€"â€‹â€‹ 6,569â€‹â€‹ 325â€‹â€‹ â€"â€‹â€‹ 6,894Foreign currency (gains) losses, netâ€‹â€‹ 5,200â€‹Â (149)â€‹Â (422)â€‹Â (2,174)â€‹â€‹ 2,455Adjusted EBITDAâ€‹$ 22,134â€‹$ 30,912â€‹$ 27,367â€‹$ 32,340â€‹$ 112,753â€‹General description of non-GAAP financial measuresAdjusted EBITDAAdjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investorsâ€™ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to reflect the results of our operations prior to considering certain income statement elements and to make financial and operating decisions. We calculate EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization. We calculate Adjusted EBITDA as EBITDA plus (a) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (b) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income and should not be considered as a measure of liquidity.71 Table of ContentsThe Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:â—senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;â—our annual budgets are prepared on an Adjusted EBITDA basis; andâ—other goal-setting and performance measurements are prepared on an Adjusted EBITDA basis.Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of acquired intangibles, and does not provide a comparable view of our performance to other companies.Adjusted net income and adjusted diluted earnings per shareAdjusted net income and adjusted diluted earnings per share represent alternative views of performance and we believe investorsâ€™ understanding of our performance is enhanced by disclosing these performance measures. We report adjusted net income and adjusted diluted earnings per share to portray the results of our operations prior to considering certain income statement elements. We calculate adjusted net income as net income plus (i) acquisition-related intangible amortization and other acquisition-related items, (ii) certain items we consider to be unusual, non-operational or non-recurring, (iii) stock-based compensation, (iv) foreign currency (gains) losses, as separately reported on our consolidated statements of operations, and (v) the income tax effect of pre-tax income adjustments and certain income tax items. Adjusted diluted earnings per share is calculated by dividing adjusted net income by the diluted weighted average number of shares. The adjusted net income and adjusted diluted earnings per share measures are not, and should not be viewed as, a substitute for GAAP reported net income. Adjusted net income and adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of its non-standardized definition, adjusted net income and adjusted diluted earnings per share, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted net income and adjusted diluted earnings per share are presented to permit investors to more fully understand how management assesses performance.Certain significant itemsAdjusted EBITDA, adjusted net income and adjusted diluted earnings per share are calculated prior to considering acquisition-related items and certain other items, as detailed in the table titled â€œItems Excluded from Adjusted Net Incomeâ€ above. We evaluate such other items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual, non-operational or non-recurring nature. Unusual, in this context, may represent items that are not part of our ongoing business; items

that, either because of their nature or size, we would not expect to occur as part of our normal business on a regular basis. We consider business restructuring costs related to productivity and cost saving initiatives to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.New accounting standardsFor discussion of new accounting standards, see â€œNotes to Consolidated Financial Statements â€" Summary of Significant Accounting Policies and New Accounting Standards.â€72 Table of ContentsCritical accounting policiesCritical accounting policies are those that require application of managementâ€™s most difficult, subjective and/or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all accounting policies require management to make difficult, subjective or complex judgments or estimates. In presenting our consolidated financial statements in accordance with GAAP, we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results that differ from our estimates and assumptions could have an unfavorable effect on our financial position and results of operations.The following is a summary of accounting policies that we consider critical to the consolidated financial statements.Revenue RecognitionWe recognize revenue from product sales when control of the products has transferred to the customer, typically when title and risk of loss transfer to the customer. Certain of our businesses have terms where control of the underlying product transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery.Revenue reflects the total consideration to which we expect to be entitled, in exchange for delivery of products or services, net of variable consideration. Variable consideration includes customer programs and incentive offerings, including pricing arrangements, rebates and other volume-based incentives. We record reductions to revenue for estimated variable consideration at the time we record the sale. Our estimates for variable consideration reflect the amount by which we expect variable consideration to affect the revenue recognized. Such estimates are based on contractual terms and historical experience and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of customer incentives. Sales returns and product recalls have been insignificant and infrequent due to the nature of the products we sell.Business CombinationsOur consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition; goodwill is recorded for any excess of the purchase price over the fair values of the net assets acquired. Significant judgment may be required to determine the fair values of certain tangible and intangible assets and in assigning their respective useful lives. Significant judgment also may be required to determine the fair values of contingent consideration, if any. We typically utilize third-party valuation specialists to assist us in determining fair values of significant tangible and intangible assets and contingent consideration. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect consideration of other marketplace participants and include the amount and timing of future cash flows, specifically the expected revenue growth rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets primarily are based on a number of factors including the competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Long-Lived Assets and GoodwillWe periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. We recognize an impairment loss when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss is the excess of the assetâ€™s carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. 73 Table of ContentsChanges to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations.Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in a business combination. We assess goodwill for impairment annually during the fourth quarter, or more frequently if impairment indicators exist. Impairment exists when the carrying amount of goodwill exceeds its implied fair value. We may elect to assess our goodwill for impairment using a qualitative or a quantitative approach, to determine whether it is more likely than not that the fair value of goodwill is greater than its carrying value. Income TaxesThe provision for income taxes includes U.S. federal, state and foreign income taxes and foreign withholding taxes. Our annual effective income tax rate is determined based on our income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate and the tax impacts of items treated differently for tax purposes than for financial reporting purposes. Tax law requires certain items be included in the tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as depreciation expense. These temporary differences give rise to deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in futureÂ years for which we have already recorded the tax benefit in our income statement. Deferred tax liabilities generally represent the tax effect of items recorded as tax expense in our income statement for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our income statement or the tax effect of assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.The recognition and measurement of a tax position is based on managementâ€™s best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual effective income tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, including research and development costs capitalized for income tax purposes and net operating loss carryforwards, is dependent upon generating sufficient future taxable income in the appropriate jurisdiction prior to the expiration of the amortization or carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.We may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority in the jurisdictions where we operate. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.We account for income tax contingencies using a benefit recognition model. If our initial assessment does not result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit if: (i)Â there are changes in tax law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to â€œmore likely than notâ€; (ii)Â the statute of limitations expires; or (iii)Â there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, and changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the â€œmore-likely-than-notâ€ standard.Our assessments concerning uncertain tax positions are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.74 Table of ContentsBecause there are a number of estimates and assumptions inherent in calculating the various components of our income tax provision, certain future events such as changes in tax legislation, geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an impact on those estimates and our effective income tax rate.We expect to repatriate approximately $80.0 million of international earnings, which will be subject to applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes. We intend to continue to reinvest indefinitely all other undistributed earnings of our foreign subsidiaries where we could be subject to applicable non-U.S. withholding and related taxes if amounts are repatriated to the U.S.For more information regarding our significant accounting policies, estimates and assumptions, see â€œNotes to Consolidated Financial Statementsâ€‰â€"â€‰Summary of Significant Accounting Policies and New Accounting Standards.â€ContingenciesLegal mattersWe are subject to numerous contingencies arising in the ordinary course of business, such as product liability and other product-related litigation, commercial litigation, environmental claims and proceedings and government investigations. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid and/or accrued.We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.EnvironmentalOur operations and properties are subject to Environmental Laws and regulations. As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are generally included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the impact of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities 75 Table of Contentsfor known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.For additional details, see â€œNotes to Consolidated Financial Statementsâ€‰â€"â€‰Commitments and Contingencies.â€For additional details, see â€œBusinessâ€‰â€"â€‰Environmental, Health and Safety.â€â€‹ItemÂ 7A.Â Â Â Quantitative and Qualitative Disclosures about Market RiskForeign exchange riskPortions of our net sales and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 80 countries and, as a result, our revenues are influenced by changes in foreign exchange rates. Because we operate in multiple foreign currencies, changes in those currencies relative to the U.S. dollar could affect our revenue and expenses, and consequently, net income. Exchange rate fluctuations may also have an effect beyond our reported financial results and directly affect operations. These fluctuations may affect the ability to buy and sell our goods and services in markets affected by significant exchange rate variances. Our primary foreign currency exposures are to the Brazilian and Israeli currencies. From time to time, we manage foreign exchange risk through the use of foreign currency derivative contracts. We use these contracts to mitigate the potential earnings effects from exposure to foreign currencies.We analyzed our foreign currency derivative contracts at JuneÂ 30,Â 2024 to determine their sensitivity to exchange rate changes. The analysis indicates that if the U.S. dollar were to appreciate or depreciate by 10%, the fair value of these contracts would decrease by $0.3 million or increase by $0.2Â million. For additional details, see â€œNotes to Consolidated Financial Statementsâ€‰â€"â€‰Derivatives.â€Interest rate riskOur 2021 Credit Facilities and 2022 Term Loan carry floating interest rates based on the Secured Overnight Financing Rate (â€œSOFRâ€) or the Prime Rate. Therefore, our profitability and cash flows are exposed to interest rate fluctuations. Our interest rates also include variable applicable rates in addition to the SOFR portion of our interest obligation. The applicable rates for SOFR borrowings vary from 1.50% to 2.75%, based on the First Lien Net Leverage Ratio. We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025.Based on our outstanding debt balances and the applicable rates in effect as of JuneÂ 30,Â 2024, and considering the interest rate swap agreement, a 100-basis point increase in SOFR would increase annual interest expense and decrease cash flows by $1.9 million. For additional details, see â€œNotes to Consolidated Financial Statementsâ€‰â€"â€‰Debtâ€ and â€œNotes to Consolidated Financial Statementsâ€‰â€"â€‰Derivatives.â€â€‹76 Table of ContentsItemÂ 8.Financial Statements and Supplementary DataPHIBRO ANIMAL HEALTH CORPORATIONINDEX TO CONSOLIDATED FINANCIAL STATEMENTSâ€‹Report of Independent Registered Public Accounting Firm (PCAOB ID 238)78Consolidated Statements of Operations for the fiscal years ended June 30, 2024, 2023 and 202280Consolidated Statements of Comprehensive Income (Loss) for the fiscal years ended June 30, 2024, 2023 and 202281Consolidated Balance Sheets as of June 30, 2024 and 202382Consolidated Statements of Cash Flows for the fiscal years ended June 30, 2024, 2023 and 202283Consolidated Statements of Changes in Stockholdersâ€™ Equity for the fiscal years ended June 30, 2024, 2023 and 202284Notes to Consolidated Financial Statements for the fiscal years ended June 30, 2024, 2023 and 202285â€‹â€‹77 Table of ContentsReport of Independent Registered Public Accounting Firmâ€‹To the Board of Directors and Stockholders of Phibro Animal Health CorporationOpinions on the Financial Statements and Internal Control over Financial ReportingWe have audited the accompanying consolidated balance sheets of Phibro Animal Health Corporation and its subsidiaries (the "Company") as of JuneÂ 30,Â 2024 and 2023, and the related consolidated statements of operations, of comprehensive income (loss), of changes in stockholdersâ€™ equity and of cash flows for each of the three years in the period ended JuneÂ 30,Â 2024, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of JuneÂ 30,Â 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of JuneÂ 30,Â 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended JuneÂ 30,Â 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of JuneÂ 30,Â 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.Basis for OpinionsThe Companyâ€™s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Managementâ€™s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Companyâ€™s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.Our audits of the consolidated financial statements included performing procedures to assess the risks of

material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.Definition and Limitations of Internal Control over Financial ReportingA companyâ€™s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A companyâ€™s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are 78 Table of Contentsrecorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the companyâ€™s assets that could have a material effect on the financial statements.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.Critical Audit MattersThe critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.Revenue Recognition â€“ Net SalesAs described in Notes 2 and 4 to the consolidated financial statements, the Companyâ€™s total net sales were $1,017.7 million for the year ended June 30, 2024. The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to the customers. Certain of the Companyâ€™s businesses have terms where control of the products transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery. Revenue reflects the total consideration to which management expects to be entitled, in exchange for delivery of products or services, net of variable consideration, if any. The principal consideration for our determination that performing procedures relating to revenue recognition is a critical audit matter is the high degree of auditor effort in performing procedures related to the Companyâ€™s revenue recognition. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process, including controls over the recording of net sales at the transaction price once control has passed to the customer. These procedures also included, among others, (i) testing revenue transactions by evaluating the settlement of invoices and credit memos, (ii) tracing transactions not settled to a detailed listing of accounts receivable, (iii) testing credit memos issued during the year, (iv) confirming a sample of outstanding customer invoice balances at year end and, for confirmations not returned, obtaining and inspecting source documents, including purchase orders, invoices, sales contracts, proof of delivery, and subsequent cash receipts, where applicable, and (v) testing the completeness and accuracy of data provided by management.â€‹/s/ PricewaterhouseCoopers LLPFlorham Park, New JerseyAugust 28, 2024â€‹We have served as the Companyâ€™s auditor since 1998.â€‹79 Table of ContentsPHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€‹â€‹(in thousands, except per share amounts)Net salesâ€‹$ 1,017,679â€‹$ 977,889â€‹$ 942,261Cost of goods sold â€‹Â 704,587â€‹Â 679,652â€‹Â 656,861Gross profitâ€‹Â 313,092â€‹Â 298,237â€‹Â 285,400Selling, general and administrative expensesâ€‹Â 259,777â€‹Â 226,390â€‹Â 206,414Operating incomeâ€‹Â 53,315â€‹Â 71,847â€‹Â 78,986Interest expense, netâ€‹Â 18,536â€‹Â 15,321â€‹Â 11,875Foreign currency (gains) losses, netâ€‹Â 23,863â€‹Â 2,455â€‹Â (5,216)Income before income taxes â€‹Â 10,916â€‹Â 54,071â€‹Â 72,327Provision for income taxes â€‹Â 8,500â€‹Â 21,465â€‹Â 23,152Net income â€‹$ 2,416â€‹$ 32,606â€‹$ 49,175â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net income per shareâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â basicâ€‹$ 0.06â€‹$ 0.81â€‹$ 1.21dilutedâ€‹$ 0.06â€‹$ 0.81â€‹$ 1.21Weighted average common shares outstandingâ€‹Â Â Â â€‹Â Â Â â€‹Â Â Â basicâ€‹Â 40,504â€‹Â 40,504â€‹Â 40,504dilutedâ€‹â€‹ 40,523â€‹â€‹ 40,504â€‹â€‹ 40,504â€‹The accompanying notes are an integral part of these consolidated financial statementsâ€‹80 Table of ContentsPHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

to affect the revenue recognized. Such estimates are generally based on contractual terms and historical experience and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of variable compensation. Sales returns and product recalls have been insignificant and infrequent due to the nature of the products we sell. Net sales include shipping and handling fees billed to customers. The associated costs are considered fulfillment activities and are included in cost of goods sold in the consolidated statements of operations when the related revenue is recognized. Net sales exclude value-added and other taxes based on sales.Cash and Cash EquivalentsCash equivalents include highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.Short-term InvestmentsShort-term investments include highly liquid investments with maturities greater than threeÂ months and less than oneÂ year at the time of purchase. We classify these investments as held to maturity and we record the related interest income as earned. We determine the appropriate balance sheet classification at the time of purchase and at each balance sheet date. Investments held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.Accounts Receivable and Reserve for Credit LossesTrade accounts receivable are recorded at the invoiced amount and do not bear interest. We grant credit terms in the normal course of business and generally do not require collateral or other security to support credit sales. Our ten largest customers represented, in aggregate, approximately 13% and 16% of accounts receivable at JuneÂ 30,Â 2024 and 2023, respectively.86 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)The reserve for credit losses is our best estimate of the credit losses in existing accounts receivable. We monitor the financial performance, historical and expected collection patterns, and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We also monitor domestic and international economic conditions for the potential future effect on our customers. Past due balances are reviewed individually for collectability. Account balances are charged against the reserve when we determine it is probable the receivable will not be recovered.InventoriesInventories are valued at the lower of cost or net realizable value. Cost is determined principally under weighted average and standard cost methods, which approximate first-in, first-out (FIFO) cost. Obsolete and unsalable inventories, if any, are reflected at estimated net realizable value. Inventory costs include materials, direct labor and manufacturing overhead.Property, Plant and EquipmentProperty, plant and equipment are stated at cost.Depreciation is charged to results of operations using the straight-line method based upon the assetsâ€™ estimated useful lives, ranging from two to thirty years for buildings and improvements, and three to ten years for machinery and equipment. We capitalize costs that extend the useful life or productive capacity of an asset. Repair and maintenance costs are expensed as incurred. In the case of disposals, the assets and related accumulated depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in the consolidated statements of operations.LeasesWe determine at the inception of an arrangement whether the arrangement contains a lease. If an arrangement contains a lease, we assess the lease term when the underlying asset is available for use (â€œlease commencementâ€). Individual lease terms reflect the non-cancellable period of the lease, reasonably certain renewal periods and consideration of termination options. We determine the lease classification as either operating or financing at lease commencement, which governs the pattern of expense recognition and presentation in our consolidated financial statements. Our current lease portfolio only includes operating leases.We recognize a right-of-use (â€œROUâ€) asset and a corresponding lease liability at lease commencement for leases with terms exceeding twelve months. Short-term leases with terms of twelve months or less are not recognized on the consolidated balance sheet and lease payments are recognized on a straight-line basis over the term.The values of the ROU assets and lease liabilities are calculated based on the present value of the fixed payment obligations over the lease term, using our incremental borrowing rate (â€œIBRâ€), determined at lease commencement. The IBR reflects the rate of interest we would expect to pay on a secured basis to borrow an amount equal to the lease payments under similar terms. The IBR incorporates the term and economic environment of the respective lease arrangements.We have elected to account for lease and non-lease components together as a single lease component and include fixed payment obligations related to such non-lease components in the measurement of ROU assets and lease liabilities. Fixed lease payments are recognized on a straight-line basis over the lease term. Variable lease payments can include index-based lease payments, real estate taxes, maintenance costs, utilization charges and other non-lease services paid to lessors and are not determinable at lease commencement. Variable lease payments are not included in the measurement of ROU assets and lease liabilities and are recognized in the period incurred.Capitalized Software CostsWe capitalize costs to obtain, develop and implement software for internal use. Amounts paid to third parties and costs of internal employees who are directly associated with the software project are also capitalized, depending on the stage of development.87 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)We expense software costs that do not meet the capitalization criteria. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets and are amortized on a straight-line basis over three to seven years.Debt Issuance CostsCosts and original issue discounts or premiums related to issuance or modification of our debt are deferred on the consolidated balance sheet and amortized over the lives of the respective debt instruments. Amortization of debt issuance costs is included in interest expense in the consolidated statements of operations.Business CombinationsOur consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition; goodwill is recorded for any excess of the purchase price over the fair values of the net assets acquired.Significant judgment may be required to determine the fair values of certain tangible and intangible assets and in assigning their respective useful lives. Significant judgment also may be required to determine the fair values of contingent consideration, if any. We typically utilize third-party valuation specialists to assist us in determining fair values of significant tangible and intangible assets and contingent consideration. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect consideration of other marketplace participants and include the amount and timing of future cash flows, specifically the expected revenue growth rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets primarily are based on a number of factors including the competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Intangible assets associated with acquired in-process research and development activities (â€œIPR&Dâ€) are not amortized until a product is available for sale and regulatory approval is obtained.Long-Lived Assets and GoodwillWe periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. We recognize an impairment loss when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss is the excess of the assetâ€™s carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations.Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in a business combination. We assess goodwill for impairment annually during our fourth quarter, or more frequently if impairment indicators exist. Impairment exists when the carrying amount of goodwill exceeds its implied fair value. We may elect to assess our goodwill for impairment using a qualitative or a quantitative approach, to determine whether it is more likely than not that the fair value of goodwill is greater than its carrying value. During the three months ended JuneÂ 30,Â 2024, we tested goodwill using the quantitative approach and determined goodwill was not impaired. We have not recorded any goodwill impairment charges in the periods included in the consolidated financial statements.88 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Foreign Currency TranslationWe generally use local currency as the functional currency to measure the financial position and results of operations of each of our international subsidiaries. We translate assets and liabilities of these operations at the exchange rates in effect at the balance sheet date. We translate income statement accounts at the average rates of exchange prevailing during the period. Translation adjustments that arise from the use of differing exchange rates from period to period are included as a component of accumulated other comprehensive income (loss) in stockholdersâ€™ equity. Certain of our Israeli operations have designated the U.S. dollar as their functional currency. Gains and losses arising from re-measurement of local currency accounts into U.S. dollars are included in determining net income.Comprehensive IncomeComprehensive income consists of net income and the changes in: (i)Â the fair value of derivative instruments that qualify for hedge accounting; (ii)Â foreign currency translation adjustments; (iii)Â pension settlement recognition and unrecognized net pension gains (losses); and (iv)Â the related (provision) benefit for income taxes.Derivative Financial InstrumentsWe record all derivative financial instruments on the consolidated balance sheets at fair value. Changes in the fair value of derivatives are recorded in results of operations or other comprehensive income (loss), depending on whether a derivative is designated and effective as part of a hedge transaction and, if so, the type of hedge transaction. Gains and losses on derivative instruments designated and effective as part of a hedge transaction are included in the results of operations in the periods in which operations are affected by the underlying hedged item.From time to time, we use certain derivative instruments to mitigate the risk associated with certain economic factors, such as exchange rates and interest rates, which may potentially affect our future cash flows. As of JuneÂ 30,Â 2024, we used (i)Â foreign currency option contracts to mitigate certain exposures related to changes in foreign currency exchange rates on forecasted inventory purchases, and (ii)Â an interest rate swap on $300,000 of notional principal to manage future cash flow exposure resulting from variable interest rates on that amount of debt. To qualify a derivative as a hedge, we document the nature and relationships between hedging instruments and hedged items, the prospective effectiveness of the hedging instrument as well as the ultimate effectiveness, the risk-management objectives, the strategies for undertaking the various hedge transactions and the methods of assessing hedge effectiveness. We do not engage in trading or other speculative uses of financial instruments.Environmental LiabilitiesExpenditures for ongoing compliance with environmental regulations are expensed or capitalized as appropriate. We capitalize expenditures made to extend the useful life or productive capacity of an asset, including expenditures that prevent future environmental contamination. Other expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. We record the expense and related liability in the period an environmental assessment indicates remedial efforts are probable and the costs can be reasonably estimated. Estimates of the liability are based upon currently available facts, existing technology and presently enacted laws and regulations taking into consideration the likely effects of inflation and other societal and economic factors. All available evidence is considered, including prior experience in remediation of contaminated sites, other companiesâ€™ experiences and data released by the U.S. Environmental Protection Agency and other organizations. The estimated liabilities are not discounted. We record anticipated recoveries under existing insurance contracts if probable.Income TaxesThe provision for income taxes includes U.S. federal, state, and foreign income taxes and foreign withholding taxes. Our annual effective income tax rate is determined based on our income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate and the tax effects of items treated differently for tax purposes than for financial reporting purposes. Tax law requires certain items be included in the tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as 89 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)depreciation expense. These temporary differences give rise to deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in futureÂ years for which we have already recorded the tax benefit in our income statement. Deferred tax liabilities generally represent the tax effect of items recorded as tax expense in our income statement for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our income statement, and the tax effect of assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.The recognition and measurement of a tax position is based on managementâ€™s best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual effective income tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, including research and development costs capitalized for income tax purposes and net operating loss carryforwards, is dependent upon generating sufficient future taxable income in the appropriate jurisdiction prior to the expiration of the amortization or carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.We may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority in the jurisdictions where we operate. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.Because there are a number of estimates and assumptions inherent in calculating the various components of our income tax provision, future events such as changes in tax legislation, the geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an effect on those estimates and our effective income tax rate.AdvertisingAdvertising and marketing costs are expensed as incurred and are reflected in selling, general and administrative expenses.Research and Development ExpendituresResearch and development expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Most of our manufacturing facilities have scientists and technicians on staff involved in product development, quality assurance and providing technical services to customers. Research, development and technical service efforts are conducted at various facilities. Our animal health research and development activities relate to: companion animal product development, fermentation development and microbiological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional specialties development; and ethanol-related products.Stock-Based CompensationWe recognize expense for stock-based compensation to employees, including grants of restricted stock units, over the requisite service period based on the grant date fair value of the awards. We determine the fair value of performance-based restricted stock units using the Monte Carlo simulation models. The models use historical and current market data to estimate the fair value. The models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards.Net Income per Share and Weighted Average SharesBasic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common shares equivalents, resulting from 90 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)the assumed vesting of restricted stock units, unless the effect would be antidilutive. Common share equivalents were included in the calculation of diluted net income per share for the periods included in the consolidated financial statements, when applicable.â€‹â€‹â€‹

disclosures.Â Â Â â€‹3.Â Â Â Â Proposed Acquisitionâ€‹In April 2024, we entered into a Purchase and Sale Agreement (the â€œPurchase Agreementâ€) with Zoetis Inc. (â€œZoetisâ€) to acquire Zoetisâ€™s medicated feed additive (MFA) product portfolio, certain water-soluble products and related assets (the â€œProposed Acquisitionâ€). The purchase price is $350,000, subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. Completion of the Proposed Acquisition is subject to satisfaction of customary closing conditions, including clearances by applicable regulatory authorities.â€‹ 4.Â Â Â Statements of Operationsâ€”Additional Informationâ€‹Disaggregated revenue and customer payment terms We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The products help prevent, control and treat diseases and enhance nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products directly to integrated poultry, cattle and swine customers and through commercial animal feed manufacturers, distributors and veterinarians The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and 91 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)seasons. Our operations are primarily focused on regions where the majority of livestock production is consolidated in large commercial farms. We have a diversified portfolio of products that are classified within our three reportable business segments â€” Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.Animal Health The Animal Health business develops, manufactures and markets products in three main categories: â—MFAs and other: MFAs and other products primarily consist of concentrated medicated products administered through animal feeds, commonly referred to as Medicated Feed Additives (â€œMFAsâ€). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products. The MFAs and other category also includes antibacterials and other processing aids used in the ethanol fermentation industry.â—Nutritional specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.â—Vaccines: Vaccine products are primarily focused on preventing diseases in poultry, swine, beef and dairy cattle and aquaculture. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.Mineral Nutrition The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestockâ€™s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine, and beef and dairy cattle. Performance Products The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The following tables present our revenues disaggregated by major product category and geographic region: Net Sales by Product Typeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024â€‹2023â€‹2022Animal Healthâ€‹â€‹Â Â Â â€‹Â Â â€‹â€‹â€‹MFAs and otherâ€‹$ 420,959â€‹$ 387,349â€‹$ 361,538Nutritional specialtiesâ€‹Â 164,671â€‹Â 172,504â€‹â€‹ 157,196Vaccinesâ€‹Â 120,852â€‹Â 99,998â€‹â€‹ 88,321Total Animal Healthâ€‹$ 706,482â€‹$ 659,851â€‹$ 607,055Mineral Nutritionâ€‹Â 243,663â€‹Â 242,656â€‹â€‹ 259,512Performance Productsâ€‹Â 67,534â€‹Â 75,382â€‹â€‹ 75,694Total â€‹$ 1,017,679â€‹$ 977,889â€‹$ 942,261â€‹92 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Net Sales by Regionâ€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024Â Â Â Â 2023Â 2022United Statesâ€‹$ 584,763â€‹$ 578,773â€‹$ 561,803Latin America and Canadaâ€‹Â 247,705â€‹Â 219,846â€‹â€‹ 191,047Europe, Middle East and Africaâ€‹Â 121,977â€‹Â 117,815â€‹â€‹ 122,480Asia Pacificâ€‹Â 63,234â€‹Â 61,455â€‹â€‹ 66,931Total â€‹$ 1,017,679â€‹$ 977,889â€‹$ 942,261Â â€‹Net sales by region are based on country of destination. Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized. Additional Informationâ€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024Â Â Â Â 2023Â Â Â Â 2022Interest expense, net â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2021 Credit Facilitiesâ€‹$ 20,646â€‹$ 17,302â€‹$ 11,9182022 Term loanâ€‹â€‹ 862â€‹â€‹ 589â€‹â€‹ â€”Amortization of debt issuance costsâ€‹Â 1,040â€‹Â 727â€‹Â 590Otherâ€‹Â 462â€‹Â 58â€‹Â 183Interest expenseâ€‹Â 23,010â€‹Â 18,676â€‹Â 12,691Interest incomeâ€‹Â (4,474)â€‹Â (3,355)â€‹Â (816)â€‹â€‹$ 18,536â€‹$ 15,321â€‹$ 11,875Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Depreciation and amortizationâ€‹Â â€‹â€‹Â â€‹â€‹Â Â Â Depreciation of property, plant and equipmentâ€‹$ 26,517â€‹$ 24,316â€‹$ 23,781Amortization of intangible assetsâ€‹Â 9,661â€‹Â 9,696â€‹Â 8,924â€‹â€‹$ 36,178â€‹$ 34,012â€‹$ 32,705Â â€‹Depreciation of property, plant and equipment includes amortization of capitalized software costs of $1,436, $1,455 and $1,047 during 2024, 2023 and 2022, respectively. Future amortization of intangible assets as of JuneÂ 30,Â 2024 is expected to be:â€‹â€‹â€‹â€‹â€‹For the Years Ending June 30Â Â Â Â â€‹Â Â Â Â 2025â€‹$ 7,9182026â€‹Â 6,9692027â€‹Â 6,5912028â€‹Â 6,3852029â€‹Â 6,385Thereafterâ€‹Â 10,785Totalâ€‹$ 45,033Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Research and development expenseâ€‹$ 29,194â€‹$ 24,395â€‹$ 20,832Â Â Â Â â€‹93 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)5.Â Â Â Balance Sheetsâ€”Additional Informationâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Accounts receivable, net â€‹â€‹â€‹â€‹â€‹â€‹Trade accounts receivableâ€‹$ 170,913â€‹$ 165,069Reserve for credit lossesâ€‹â€‹ (1,461)â€‹â€‹ (1,590)â€‹â€‹$ 169,452â€‹$ 163,479Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Reserve for credit lossesâ€‹â€‹Â Â â€‹â€‹Â Â Balance at beginning of period â€‹$ 1,590â€‹$ 3,510Provision for estimated credit lossesâ€‹Â 1,538â€‹Â 943Effect of changes in exchange rates â€‹Â (71)â€‹Â (61)Credit losses realizedâ€‹Â (1,596)â€‹Â (2,802)Balance at end of period â€‹$ 1,461â€‹$ 1,590Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Inventories, netâ€‹â€‹â€‹â€‹â€‹Â Â Raw materials â€‹$ 72,799â€‹$ 84,328Work-in-processâ€‹â€‹ 23,550â€‹â€‹ 22,350Finished goods â€‹â€‹ 169,562â€‹â€‹ 170,892â€‹â€‹$ 265,911â€‹$ 277,570Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Property, plant and equipment, netâ€‹â€‹â€‹â€‹â€‹â€‹Land â€‹$ 30,624â€‹$ 27,813Buildings and improvements â€‹Â 120,173â€‹Â 105,184Machinery and equipment â€‹â€‹ 273,965â€‹â€‹ 291,454Construction in progressâ€‹Â 23,892â€‹Â 34,743â€‹â€‹Â 448,654â€‹Â 459,194Accumulated depreciation â€‹Â (245,354)â€‹Â (263,626)â€‹â€‹$ 203,300â€‹$ 195,568Â â€‹Certain of our facilities in Israel are on leased land. These leases expire in calendar years 2039, 2045 and 2062.Property, plant and equipment, net includes internal-use software costs, net of accumulated amortization, of $3,123 and $3,426 at JuneÂ 30,Â 2024 and 2023, respectively.94 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-â€‹â€‹â€‹â€‹â€‹â€‹â€‹Averageâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Useful Lifeâ€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â (Years) Â Â Â Â 2024Â Â Â Â 2023Intangibles, netâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Costâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Technologyâ€‹12â€‹$ 94,259â€‹$ 95,576Product registrations, marketing and distribution rightsâ€‹9â€‹â€‹ 18,117â€‹â€‹ 18,557Customer relationships â€‹12â€‹â€‹ 30,418â€‹â€‹ 30,235Trade names, trademarks and other â€‹6â€‹â€‹ 5,213â€‹â€‹ 5,605â€‹â€‹â€‹â€‹â€‹ 148,007â€‹Â 149,973Accumulated amortizationâ€‹â€‹â€‹â€‹â€‹â€‹Â â€‹Technology â€‹â€‹â€‹â€‹ (62,119)â€‹â€‹ (55,396)Product registrations, marketing and distribution rightsâ€‹â€‹â€‹â€‹ (17,326)â€‹Â (18,553)Customer relationships â€‹â€‹â€‹â€‹ (19,001)â€‹Â (16,884)Trade names, trademarks and other â€‹â€‹â€‹â€‹ (4,528)â€‹Â (4,153)â€‹â€‹â€‹â€‹â€‹ (102,974)â€‹Â (94,986)â€‹â€‹â€‹â€‹$ 45,033â€‹$ 54,987Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023Goodwill Â â€‹Â Â â€‹Â Â Â Balance at beginning of periodÂ $ 53,274â€‹$ 53,226AcquisitionÂ â€‹ 1,397â€‹Â â€”Effect of changes in exchange ratesâ€‹â€‹ (114)â€‹â€‹ 48Balance at end of periodÂ $ 54,557â€‹$ 53,274Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023Other assetsâ€‹â€‹â€‹â€‹â€‹â€‹ROU operating lease assetsâ€‹$ 37,604Â $ 35,759Deferred income taxesâ€‹Â 19,371Â â€‹ 8,711Depositsâ€‹Â 1,646Â â€‹ 6,617Insurance investmentsâ€‹Â 6,305Â â€‹ 6,067Equity method investmentsâ€‹Â 5,183Â â€‹ 5,027Derivative instrumentsâ€‹â€‹ â€”â€‹â€‹ 10,225Debt issuance costsâ€‹Â 911Â â€‹ 1,408Otherâ€‹â€‹ 7,277â€‹â€‹ 8,031â€‹â€‹$ 78,297Â $ 81,845Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023Accrued expenses and other current liabilitiesÂ â€‹Â Â Â â€‹Â Â Employee relatedâ€‹$ 37,612â€‹$ 29,359Current operating lease liabilitiesâ€‹Â 7,460â€‹Â 6,053Commissions and rebatesâ€‹â€‹ 7,875â€‹â€‹ 5,833Professional feesâ€‹Â 8,918â€‹Â 5,032Income and other taxesâ€‹â€‹ 2,931â€‹â€‹ 8,663Insurance-relatedâ€‹Â 1,265â€‹Â 1,284Insurance premium financingâ€‹â€‹ 5,185â€‹â€‹ 4,769Otherâ€‹Â 17,540â€‹Â 18,859â€‹â€‹$ 88,786â€‹$ 79,852Â â€‹The insurance premium financing has a fixed interest rate of 6.95% and monthly payments of $648.â€‹95 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023Other liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Long-term operating lease liabilitiesâ€‹$ 29,915â€‹$ 29,077Long-term and deferred income taxesâ€‹Â 14,218â€‹â€‹ 12,146Supplemental retirement benefits, deferred compensation and otherâ€‹â€‹ 6,678â€‹â€‹ 6,552U.S. pension planâ€‹Â 2,237â€‹Â 2,286International retirement plansâ€‹Â 3,212â€‹Â 4,210Other long-term liabilitiesâ€‹Â 6,846â€‹Â 6,076â€‹â€‹$ 63,106â€‹$ 60,347Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023Accumulated other comprehensive lossâ€‹â€‹Â Â â€‹â€‹Â Â Derivative instrumentsâ€‹$ 13,104â€‹$ 24,589Foreign currency translation adjustmentâ€‹Â (124,004)â€‹Â (115,062)Unrecognized net pension lossesâ€‹Â (13,012)â€‹Â (23,996)Provision for income taxes on derivative instrumentsâ€‹Â (3,304)â€‹Â (6,207)Benefit for income taxes on long-term intercompany investmentsâ€‹â€‹ 8,166â€‹â€‹ 8,166Provision for income taxes on net pension lossesâ€‹â€‹ (4,477)â€‹â€‹ (1,700)â€‹â€‹$ (123,527)â€‹$ (114,210)Â Â Â â€‹6.Â Â Â Debtâ€‹Subsequent Event â€“ 2024 Credit AgreementIn July 2024, we entered into a Credit Agreement, (the â€œ2024 Credit Agreementâ€) with a group of lenders, to refinance all our outstanding debt, to pay fees and expenses of the transaction, to finance the purchase price of the Proposed Acquisition upon completion and for ongoing working capital requirements and general corporate purposes. See â€œNote 17 â€” Subsequent Event â€” 2024 Credit Agreement.â€ Term Loans and Revolving Credit FacilitiesIn April 2021, we entered into an amended and restated credit agreement (the â€œ2021 Credit Agreementâ€) under which we had a term A loan in an aggregate initial principal amount of $300,000 (the â€œ2021 Term A Loanâ€) and a revolving credit facility under which we could borrow up to $250,000, subject to the terms of the agreement (the â€œ2021 Revolverâ€). In November 2022, we amended the 2021 Credit Facilities to increase the revolving commitments under the 2021 Revolver to an aggregate amount of $310,000 and to adopt the SOFR as the reference for the fluctuating rate of interest on the 2021 Credit Facilities, replacing the LIBOR reference rate. In June 2023, we obtained an additional incremental Term loan (the â€œ2023 Incremental Term Loanâ€) in the amount of $50,000 (the 2021 Revolver, the 2021 Term A Loan, and the 2023 Incremental Term Loan are collectively referred to as the â€œ2021 Credit Facilitiesâ€).Borrowings under the 2021 Credit Facilities bear interest at rates based on the ratio of the Company and its subsidiariesâ€™ net consolidated first lien indebtedness to the Company and its subsidiariesâ€™ consolidated EBITDA (the â€œFirst Lien Net Leverage Ratioâ€). The interest rate per annum applicable to the 2021 Revolver and the 2021 Term A Loan is based on a fluctuating rate of interest plus an applicable rate equal to 1.50%, 1.75%, 2.00% or 2.25% in the case of adjusted SOFR rate loans and 0.50%, 0.75%, 1.00% or 1.25% in the case of base rate loans. The interest rate per annum applicable to the 2023 Incremental Term Loan is based on a fluctuating rate of interest plus an applicable rate equal to 2.00%, 2.25%, 2.50% or 2.75% in the case of adjusted SOFR rate loans and 1.00%, 1.25%, 1.50% or 1.75% in the case of base rate loans. The applicable rates are based on the First Lien Net Leverage Ratio (as defined in the 2021 Credit Agreement, as amended).Pursuant to the terms of the 2021 Credit Agreement, the 2021 Credit Facilities are subject to various covenants that, among other things and subject to the permitted exceptions described therein, restrict us and our subsidiaries with respect to: (i)Â incurring additional debt; (ii)Â making certain restricted payments or making optional redemptions of other indebtedness; (iii)Â making investments or acquiring assets; (iv)Â disposing of assets (other than in the ordinary course of 96 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)business); (v)Â creating any liens on our assets; (vi)Â entering into transactions with affiliates; (vii)Â entering into merger or consolidation transactions; and (viii)Â creating guarantee obligations; provided, however, that we are permitted to pay distributions to stockholders out of available cash subject to certain annual limitations and so long as no default or event of default under the 2021 Credit Facilities shall have occurred and be continuing at the time such distribution is declared. Indebtedness under the 2021 Credit Facilities is collateralized by a first priority lien on substantially all assets of Phibro and certain of our domestic subsidiaries. The 2021 Credit Facilities mature in April 2026.The 2021 Credit Agreement requires, among other things, compliance with financial covenants that permit: (i)Â a maximum First Lien Net Leverage Ratio of 4.00:1.00 (or, specifically with respect to the Test Periods ended JuneÂ 30, 2024, a maximum of 4.25:1.00); and (ii)Â a minimum interest coverage ratio of 3.00:1.00, each calculated on a trailing four-quarter basis. The 2021 Credit Agreement contains an acceleration clause should an event of default (as defined in the 2021 Credit Agreement) occur. As of JuneÂ 30,Â 2024, we were in compliance with the financial covenants.As of JuneÂ 30,Â 2024, we had $176,000 in borrowings drawn under the 2021 Revolver and had outstanding letters of credit of $2,294, leaving $131,706 available for further borrowings and letters of credit under the 2021 Revolver, subject to restrictions in our 2021 Credit Facilities. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year. Other Long-Term DebtIn September 2022, we entered into a credit agreement (the â€œ2022 Term Loanâ€) in the amount of $12,000, collateralized by certain facilities. The 2022 Term Loan matures in September 2027. The interest rate per annum applicable to the 2022 Term Loan is based on a fluctuating rate of interest, at the Companyâ€™s election from time to time, equal to either (i) one-month adjusted SOFR plus 2.00%; or (ii) a base rate determined by reference to the greater of (a) the Prime Rate and (b) the Federal Funds Effective Rate plus 0.50%. The 2022 Term Loan is repayable in monthly installments of $35, with the balance payable at maturity.Interest RatesInterest rates as of the balance sheet dates and the weighted-average rates for the years presented were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹June 30â€‹Years EndedÂ June 30â€‹â€‹20242023â€‹2024â€‹2023â€‹2022â€‹2021 RevolverÂ 6.00%6.09%Â Â 6.14%5.42%2.08%2021 Term A Loanâ€‹2.36%2.36%â€‹2.36%2.37%2.99%2023 Incremental Term Loanâ€‹7.68%7.44%â€‹7.64%7.40% â€”%2022 Term Loanâ€‹7.43%7.25%â€‹7.41%6.43% â€”%Â Â Interest rates as of the balance sheet dates are based on rates in effect as of those dates, including SOFR fluctuating rates of interest, applicable rates and the interest rate swap agreement.We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating SOFR portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025. We have designated the interest rate swap as a highly effective cash flow hedge. For additional details, see â€œNote 14 â€” Derivatives.â€97 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Debt Maturities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹As of June 30â€‹2024â€‹20232021 Term A Loan due April 2026â€‹$ 256,875â€‹$ 273,7502023 Incremental Term Loan due April 2026â€‹â€‹ 45,000â€‹â€‹ 50,0002022 Term Loan due September 2027â€‹â€‹ 11,265â€‹â€‹ 11,685â€‹â€‹Â 313,140â€‹Â 335,435Unamortized debt issuance costs â€‹Â (1,056)â€‹Â (1,599)â€‹â€‹Â 312,084â€‹Â 333,836Less: current maturities of long-term debt and otherâ€‹Â (29,795)â€‹Â (22,295)Long-term debtâ€‹$ 282,289â€‹$ 311,541Â Â Interest rates in the table are based on rates in effect as of the balance sheet dates, including fluctuating rates of interest, applicable rates and the interest rate swap agreement.Aggregate Maturities of Long-Term Debt and Revolverâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Years Ending JuneÂ 30Â Â Â Â â€‹Annual Maturitiesâ€‹â€‹Interest Payments2025â€‹$ 29,795â€‹$ 19,7852026â€‹â€‹ 272,920â€‹â€‹ 26,5982027â€‹â€‹ 420â€‹â€‹ 7552028â€‹â€‹ 10,005â€‹â€‹ 184Totalâ€‹$ 313,140â€‹$ 47,322Â â€‹For purposes of estimating future interest payments until maturity, we assume long-term debt decreases in accordance with the scheduled amortization and the 2021 Revolver continues unchanged at the JuneÂ 30,Â 2024. We assume the March 2020 interest rate swap agreement remains in place through its June 2025 maturity and future interest rates and applicable rates are the same as the rates at JuneÂ 30,Â 2024. â€‹7.Â Â Â Â LeasesOur lease portfolio consists of real estate, vehicles and equipment ROU assets, classified as operating leases. The remaining non-cancelable lease terms, inclusive of renewal options reasonably certain of exercise, range from one to 23 years.The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Balance Sheet ClassificationAssets:Â â€‹Â Â Â â€‹Â Â Â Â Â Operating lease ROU assetsâ€‹$ 37,604â€‹$ 35,759Â Other Assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Liabilities:â€‹Â Â Â â€‹Â Â Â Â Â Â Current portionâ€‹Â 7,460â€‹Â 6,053Â Accrued expenses and other current liabilitiesNon-current portionâ€‹Â 29,915â€‹Â 29,077Â Other liabilitiesTotal operating lease liabilitiesâ€‹$ 37,375â€‹$ 35,130Â Â Â â€‹98 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)The following table summarizes the composition of net lease expense:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â â€‹2024â€‹â€‹2023Â Â Â Â 2022Operating lease expenseâ€‹$ 8,888â€‹$ 8,363â€‹$ 8,461Variable lease

expenseâ€‹Â 1,150â€‹Â 1,139â€‹Â 1,376Short-term lease expenseâ€‹Â 1,397â€‹Â 1,522â€‹Â 1,214Total lease expenseâ€‹$ 11,435â€‹$ 11,024â€‹$ 11,051â€‹The following tables include other supplemental information:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023â€‹2022Operating cash flows used for ROU operating leasesâ€‹$ 8,231â€‹$ 7,798â€‹$ 8,642Non-cash changes to ROU operating assets and lease liabilitiesâ€‹$ 9,283â€‹$ 5,114â€‹$ 11,930â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30Â Â Â Â 2024Â Â Â Â 2023â€‹Weighted average remaining lease term (in years) - operating leases Â 9.6â€‹ 10.6â€‹Weighted average discount rate - operating leasesÂ 4.73% 3.89%Â â€‹At JuneÂ 30,Â 2024 maturities of future lease liabilities were:â€‹â€‹â€‹â€‹â€‹â€‹For the Years Ending JuneÂ 30Â Â Â Â â€‹â€‹2025â€‹$ 8,8002026â€‹Â 7,0852027â€‹Â 5,2122028â€‹Â 3,9202029â€‹Â 3,0482030 and thereafterâ€‹Â 17,200Total lease paymentsâ€‹Â 45,265Less: interestâ€‹Â 7,890Total operating lease liabilitiesâ€‹$ 37,375Â â€‹There were no significant future payment obligations related to executed lease agreements for which the related lease had not yet commenced as of JuneÂ 30,Â 2024. Our lease agreements do not contain any material restrictive covenants or residual value guarantee provisions.â€‹â€‹8.Â Â Â Common Stock, Preferred Stock and DividendsPreferred stock and common stock at JuneÂ 30,Â 2024 and 2023 were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹AuthorizedÂ Sharesâ€‹ParÂ valueâ€‹IssuedÂ andÂ outstandingÂ sharesPreferred stockÂ 16,000,000Â 16,000,000â€‹$ 0.0001Â â€”Â â€”Common stock â€“ Class AÂ 300,000,000Â 300,000,000â€‹$ 0.0001Â 20,337,574Â 20,337,574Common stock â€“ Class BÂ 30,000,000Â 30,000,000â€‹$ 0.0001Â 20,166,034Â 20,166,034Â â€‹Holders of our Class B common stock converted zero shares of Class B common stock to Class A common stock in 2024 and 2023.99 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Common StockGeneralExcept as otherwise provided by our amended and restated certificate of incorporation or applicable law, the holders of our ClassÂ A common stock and ClassÂ B common stock shall vote together as a single class. There are no cumulative voting rights.Holders of our ClassÂ A common stock and ClassÂ B common stock are entitled to receive dividends when and if declared by our Board of Directors out of funds legally available therefore, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock.Upon our dissolution or liquidation or the sale of all or substantially all of our assets, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of our ClassÂ A common stock and ClassÂ B common stock will be entitled to receive our remaining assets available for distribution.ClassÂ A Common StockHolders of our ClassÂ A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders.Holders of our ClassÂ A common stock do not have preemptive, subscription or conversion rights. Our ClassÂ A common stock is not convertible and there are no redemption or sinking fund provisions applicable to our ClassÂ A common stock. Unless our Board of Directors determines otherwise, we will issue all of our capital stock in uncertificated form.ClassÂ B Common StockHolders of our ClassÂ B common stock are entitled to 10 votes for each share held of record on all matters submitted to a vote of stockholders. BFI holds all of our outstanding ClassÂ B common stock.Holders of our ClassÂ B common stock do not have preemptive or subscription rights. There are no redemption or sinking fund provisions applicable to our ClassÂ B common stock.Each share of ClassÂ B common stock is convertible at any time at the option of the holder into one share of ClassÂ A common stock. In addition, each share of ClassÂ B common stock will convert automatically into one share of ClassÂ A common stock upon any transfer, whether or not for value, except for certain transfers by and among BFI, its affiliates and certain Bendheim family members, as described in the amended and restated certificate of incorporation. Once transferred and converted into ClassÂ A common stock, the ClassÂ B common stock will not be reissued. In addition, all shares of ClassÂ B common stock will automatically convert to shares of ClassÂ A common stock when the outstanding shares of ClassÂ B common stock and ClassÂ A common stock held by BFI, its affiliates and certain Bendheim family members, together, is less than 15% of the total outstanding shares of ClassÂ A common stock and ClassÂ B common stock, taken as a single class.Holders of our ClassÂ B common stock have the right to require us to register the sales of their shares under the Securities Act, under the terms of an agreement between us and the holders.Preferred StockWe do not have any preferred stock outstanding. Our Board of Directors has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the General Corporation Law of the State of Delaware.100 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)DividendsWe declared and paid quarterly cash dividends totaling $19,442 for theÂ years ended JuneÂ 30,Â 2024, 2023 and 2022, to holders of our ClassÂ A common stock and ClassÂ B common stock.â€‹â€‹9.Â Â Â Stock Incentive PlanIn MarchÂ 2008, our Board of Directors and stockholders adopted the 2008 Incentive Plan (the â€œIncentive Planâ€). The Incentive Plan provides directors, officers, employees and consultants to the Company with opportunities to purchase common stock pursuant to options that may be granted and receive grants of restricted stock and other stock-based awards granted, from time to time by the Board of Directors or a committee approved by the Board. The Incentive Plan provides for grants of stock options, stock awards and other incentives for up to 6,630,000 shares. There were 4,481,620 ClassÂ A shares available for grant pursuant to the Incentive Plan as of JuneÂ 30,Â 2024. Restricted Stock UnitsOur Board of Directors has approved grants of 600,000 restricted stock units (â€œRSUsâ€) to certain officers of the Company, pursuant to the Company's Incentive Plan and the RSU award agreements. Each RSU represents the right to receive a share of our common stock upon vesting. Certain RSUs are subject to time-based vesting, and certain RSUs are subject to performance-based vesting. The time-based RSUs vest in five equal annual amounts on each anniversary of the February 2024 grant date. The performance-based RSUs vest on the fourth anniversary of the July 2023 grant date and on the fifth anniversary of the February 2024 grant date, subject to continuation of employment on such dates, in increments of 10% (but no less than 20%) (with linear interpolation between increments) based upon the arithmetic average of the Companyâ€™s closing stock price per share for each trading day in the 90-calendar day period ending on the vesting date (the â€œ90-Day Averageâ€). None of the RSUs will vest if the 90-Day Average is below $20, and 100% of the RSUs will vest if the 90-Day Average is $60 or above. In the event of a change in control of the Company, following which either (i) 100% of the shares of stock cease to be traded on a nationally recognized stock exchange and the Company is no longer listed on any such exchange or (ii) a Qualifying Termination occurs within 12 months, all unvested RSUs will immediately vest in full. All RSUs were unvested as of JuneÂ 30,Â 2024.We used Monte Carlo simulation models to determine the grant date fair values of the performance-based RSUs. Assumptions used by the models were based on information as of the grant date and included a risk-free rate of return, expected volatility and an expected dividend yield. The risk-free rate of return is based on U.S. treasury yields for bonds with similar maturities. Expected volatility is based on the historical volatility of the Companyâ€™s common stock. The expected dividend yield considers estimated annual dividends and the grant date share price of the underlying common stock. The fair value of the time-based RSUs is equal to the closing market price of the underlying common stock on the grant date, less the present value of expected dividends over the vesting period. The weighted-average grant date fair value of the RSUs granted in 2024 was $5.44 per share. We recognize stock-based compensation expense for the RSUs on a straight-line basis over the vesting periods. Stock-based compensation expense related to RSUs was $475, $0 and $0 for the years ended JuneÂ 30,Â 2024, 2023 and 2022, respectively. At JuneÂ 30,Â 2024, there was $2,788 of unrecognized compensation expense related to the RSUs, which will be recognized over a weighted-average period of 4.1 years.Stock OptionsThere was no stock-based compensation expense related to employee stock options in the periods included in the consolidated financial statements, and there was no stock option activity during 2024.â€‹â€‹â€‹10.Â Â Â Â Â Related Party TransactionsCertain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to the Company as employees or consultants and received aggregate compensation and benefits of $1,590, $1,924 and 101 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)$2,203 during 2024, 2023 and 2022, respectively. Mr.Â Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.â€‹â€‹â€‹11.Â Â Â Â Â Employee Benefit PlansDomestic Pension PlanWe maintain a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to DecemberÂ 31, 2013, who meet certain requirements of age, length of service and hours worked perÂ year. We amended the plan to eliminate credit for future service and compensation increases, effective September 2016. Plan benefits are based uponÂ years of service and average compensation, as defined. The measurement dates for the plan were as of JuneÂ 30,Â 2024 and 2023.In July 2023, we entered into an annuity purchase agreement to irrevocably transfer a portion of the pension benefit obligation to a third-party insurance company. The annuity purchase price was $26,381 and was approximately equal to the benefit obligation transferred. The annuity purchase was funded from pension assets. We recognized a partial settlement of the pension plan, resulting from the recognition of net pension losses previously included in Accumulated other comprehensive loss. We recorded $10,674 of expense in selling, general and administrative expenses in our consolidated statement of operations during the year ended June 30, 2024.Changes in the projected benefit obligation were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Change in projected benefit obligationâ€‹â€‹â€‹â€‹â€‹â€‹Projected benefit obligation at beginning of year â€‹$ 60,673Â $ 63,079Interest cost â€‹Â 1,775Â â€‹ 2,608Benefits paid â€‹Â (954)Â â€‹ (2,865)Actuarial gain â€‹Â (1,852)Â â€‹ (2,149)Settlement paymentâ€‹â€‹ (26,381)â€‹â€‹ â€”Projected benefit obligation at end of year â€‹$ 33,261Â $ 60,673Â â€‹The discount rate used for the projected benefit obligation at JuneÂ 30,Â 2024 and 2023, was 5.4% and 5.0%, respectively.The projected benefit obligation for the year ended JuneÂ 30,Â 2024 decreased due to the agreement to irrevocably transfer a portion of the pension benefit obligation to a third-party insurance company, as well as actuarial gains at the annual remeasurement period due to a higher discount rate, partially offset by losses derived from other actuarial assumptions. The discount rate used each period is determined with reference to current long-term bond market rates. The projected benefit obligation also increases each year by the interest cost due to the passage of time and decreases each year by the benefits paid to plan participants.Changes in the plan assets and funded status of the plan were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Change in plan assetsâ€‹â€‹â€‹Â Â â€‹â€‹Â Â Fair value of plan assets at beginning of year â€‹$ 58,387â€‹$ 61,286Actual return on plan assets â€‹Â (28)â€‹Â (34)Benefits paid â€‹Â (954)â€‹Â (2,865)Settlement paymentâ€‹â€‹ (26,381)â€‹â€‹ â€”Fair value of plan assets at end of year â€‹$ 31,024â€‹$ 58,387Liability funded status at end of year â€‹$ (2,237)â€‹$ (2,286)Â â€‹The actual return on plan assets for the year ended JuneÂ 30,Â 2024 was lower than expected due to a reduction in the market value of fixed income securities. Benefits paid decreased compared with the prior year as the pension settlement reduced the number of participants receiving benefits. Our investment strategy is to hold a significant portion of our plan assets in fixed income securities with maturities and amounts approximately matching projected future benefit payments.102 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)The funded status is included in other liabilities in the consolidated balance sheets at JuneÂ 30,Â 2024 and 2023, respectively. We seek to maintain an asset balance that meets the long-term funding requirements identified by actuarial projections while also satisfying ERISA fiduciary responsibilities. We do not expect to contribute to the domestic pension plan during 2025.Accumulated other comprehensive loss related to the plan was:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Accumulated other comprehensive loss related to pension planÂ â€‹â€‹Â Â â€‹â€‹Â Â Balance at beginning of period â€‹$ (23,996)â€‹$ (24,208)Amortization of net actuarial lossâ€‹â€‹Â 370â€‹â€‹Â 721Current period net actuarial lossâ€‹â€‹Â (60)â€‹â€‹Â (509)Settlement expense recognizedâ€‹â€‹â€‹ 10,674â€‹â€‹â€‹ â€”Net change â€‹â€‹Â 10,984â€‹â€‹Â 212Balance at end of period â€‹$ (13,012)â€‹$ (23,996)Â â€‹Net periodic pension expense was:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Interest cost on benefit obligationâ€‹$ 1,775â€‹$ 2,608â€‹$ 1,675Expected return on plan assetsâ€‹â€‹Â (1,884)â€‹â€‹Â (2,624)â€‹â€‹Â (3,413)Amortization of net actuarial loss and prior service costsâ€‹â€‹Â 370â€‹â€‹Â 721â€‹â€‹Â 480Settlement expenseâ€‹â€‹â€‹ 10,674â€‹â€‹â€‹ â€”â€‹â€‹â€‹ â€”Net periodic pension expense (income)â€‹$ 10,935â€‹$ 705â€‹$ (1,258)Â â€‹Significant actuarial assumptions used for the net periodic pension expense for the plan were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â Discount rate for interest costÂ 5.0%Â Â 4.3%Â Â 2.2%Expected rate of return on plan assetsÂ 5.8%Â Â 4.4%Â Â 4.4%Discount rate for benefit obligationÂ 5.1%Â Â 4.6%Â Â 2.9%Â â€‹The plan used the Aon AA Bond Universe as a benchmark for its discount rate as of JuneÂ 30,Â 2024, 2023 and 2022. The discount rate is determined by matching the planâ€™s timing and amount of expected cash outflows to a bond yield curve constructed from a population of AA-rated corporate bond issues that are generally non-callable and have at least $250 million par value outstanding. From this, the discount rate that results in the same present value is calculated.103 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Estimated future benefit payments, based on the benefit obligation as of JuneÂ 30,Â 2024 are:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Years Ending JuneÂ 30Â Â Â Â â€‹â€‹2025â€‹$ 1,3882026â€‹Â 1,6002027â€‹â€‹ 1,8092028â€‹â€‹â€‹ 1,9552029â€‹â€‹â€‹ 2,1132030 â€” 2034â€‹Â 11,486Â â€‹The planâ€™s target asset allocation for 2025 and the weighted-average asset allocation of plan assets as of JuneÂ 30,Â 2024 and 2023 are:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

(Continued)Components of the provision for income taxes were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Current provision:Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Federalâ€‹$ 3,037â€‹$ 9,801â€‹$ 4,874State and localâ€‹Â 1,718â€‹Â 1,810â€‹Â 1,468Foreignâ€‹Â 15,740â€‹Â 12,750â€‹Â 17,613Total current provisionâ€‹Â 20,495â€‹Â 24,361â€‹Â 23,955Deferred provision (benefit):â€‹Â â€‹â€‹Â â€‹â€‹Â Â Â Federalâ€‹Â (4,755)â€‹Â (6,151)â€‹Â (75)State and localâ€‹Â (1,523)â€‹Â (266)â€‹Â 251Foreignâ€‹Â (4,468)â€‹Â 3,424â€‹Â 23Change in foreign valuation allowancesâ€‹Â (1,249)â€‹Â 97â€‹Â (1,002)Total deferred benefitâ€‹Â (11,995)â€‹Â (2,896)â€‹Â (803)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Provision for income taxesâ€‹$ 8,500â€‹$ 21,465â€‹$ 23,152Â â€‹Reconciliations of the federal statutory rate to the Companyâ€™s effective tax rate were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Year Ended JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€‹U.S. federal statutory income tax rateÂ 21.0%Â Â 21.0%Â Â 21.0%Â Â State and local taxes, net of federal benefitÂ (1.1)â€‹ 2.0â€‹ 2.0â€‹Higher taxes on non-U.S. incomeÂ 9.9â€‹ 8.9â€‹ 4.8â€‹Changes in uncertain tax positionsâ€‹ 30.7â€‹ 5.1â€‹ 4.4â€‹Global Intangible Low-Taxed IncomeÂ 18.3â€‹ 3.3â€‹ 0.3â€‹Recognition of federal and foreign tax creditsâ€‹ (10.6)â€‹ (3.1)â€‹ (0.9)â€‹Change in valuation allowance â€‹ (11.4)â€‹ 0.2â€‹ (1.4)â€‹Foreign derived intangible incomeâ€‹ (3.8)â€‹ (3.7)â€‹ (2.1)â€‹Non-U.S. withholding and related taxes, net, on planned repatriationâ€‹ 28.4â€‹ â€”â€‹ â€”â€‹Impact of foreign tax credit regulations and related changesâ€‹ (20.0)â€‹ 1.9â€‹ â€”â€‹Non-deductible operating expensesâ€‹ 11.3â€‹ 0.9â€‹ 0.8â€‹Non-deductible acquisition costsâ€‹ 4.3â€‹ â€”â€‹ â€”â€‹OtherÂ 0.9â€‹ 3.2â€‹ 3.1â€‹Effective income tax rateÂ 77.9%Â Â 39.7%Â Â 32.0%Â â€‹We record the Global Intangible Low-Taxed Income (â€œGILTIâ€) aspects of comprehensive U.S. income tax legislation as a period expense. The provision for income taxes for the years ended JuneÂ 30,Â 2024, 2023 and 2022, included $2,003, $1,775 and $207 of federal tax expense from the effects of GILTI, respectively.The Company benefits from certain tax holidays in Israel; the impact of which are included within Higher taxes on non-U.S. income.106 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)The tax effects of significant temporary differences that comprise deferred tax assets and liabilities were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Deferred tax assets:â€‹â€‹â€‹â€‹â€‹â€‹Employee-related accruals â€‹$ 6,620â€‹$ 5,461Inventory â€‹Â 1,521â€‹Â 2,864Environmental remediation â€‹Â 767â€‹Â 1,733Net operating loss carry forwardsâ€“domestic â€‹Â 777â€‹Â 839Net operating loss carry forwardsâ€“foreign â€‹Â 3,813â€‹Â 4,389Operating lease liabilitiesâ€‹â€‹ 6,788â€‹â€‹ 6,521R&D cost capitalizationâ€‹â€‹ 7,227â€‹â€‹ 4,283Unrealized foreign exchangeâ€‹â€‹ 1,470â€‹â€‹ â€”Carried foreign interest expenseâ€‹â€‹ 4,518â€‹â€‹ â€”Other â€‹â€‹ 7,224â€‹Â (1,311)â€‹â€‹Â 40,725â€‹Â 24,779Valuation allowance â€‹Â (1,288)â€‹Â (2,598)â€‹â€‹Â 39,437â€‹Â 22,181Deferred tax liabilities:â€‹Â â€‹â€‹Â â€‹Property, plant and equipment and intangible assets â€‹â€‹ (5,282)â€‹â€‹ (6,286)Operating lease ROU assetsâ€‹â€‹ (6,441)â€‹â€‹ (6,280)Unrealized foreign exchangeâ€‹â€‹ â€”â€‹â€‹ (1,906)Non-U.S. withholding and related taxes, net, on planned repatriationâ€‹â€‹ (2,828)â€‹â€‹ â€”Other â€‹Â (6,182)â€‹Â (712)â€‹â€‹Â (20,733)â€‹Â (15,184)â€‹â€‹â€‹â€‹â€‹â€‹Net deferred tax asset â€‹$ 18,704â€‹$ 6,997Â â€‹Deferred taxes are included in the consolidated balance sheets as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Other assets â€‹$ 19,371â€‹$ 8,711Other liabilities â€‹Â (667)â€‹Â (1,714)â€‹â€‹$ 18,704â€‹$ 6,997Â â€‹The valuation allowance established against deferred tax assets was:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Balance at beginning of periodâ€‹$ 2,598â€‹$ 2,618â€‹$ 3,709(Benefit) provision for income taxesâ€‹â€‹ (1,310)â€‹Â (20)â€‹Â (1,091)Balance at end of periodâ€‹$ 1,288â€‹$ 2,598â€‹$ 2,618Â â€‹The Company records valuation allowances against certain foreign and state deferred tax assets when, after considering all of the available evidence, it is more likely than not that these assets will not be realized.The Company has $17,250 of state net operating loss carry forwards. $9,320 that will expire in 2024 through 2043, and $7,930 that do not expire, and $16,208 of foreign net operating loss carry forwards of which most are in jurisdictions that have no expiration.If amounts are repatriated from certain of our foreign subsidiaries, we could be subject to additional non-U.S. income and withholding taxes. We expect to repatriate approximately $80,000 of non-U.S. earnings, which will be subject to applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes. As of June 30, 2024 we recorded a liability of $2,828 related to the planned repatriation of international earnings. We consider all other undistributed earnings of such foreign subsidiaries to be indefinitely reinvested. At JuneÂ 30,Â 2024, our cash and cash equivalents and short-term investments included $111,890 held by our international subsidiaries. We do not provide 107 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)income taxes for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would reduce our effective income tax rate.Reconciliations of the beginning and ending amounts of gross unrecognized tax benefits are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Unrecognized tax benefitsâ€“beginning of period â€‹$ 9,449â€‹$ 7,832â€‹$ 5,311Tax position changesâ€“current period â€‹Â 2,066â€‹Â 2,181â€‹Â 5,333Tax position changesâ€“prior periods, including settlements with tax authoritiesâ€‹Â 615â€‹Â 193â€‹Â (1,175)Lapse of statute of limitationsâ€‹Â (58)â€‹Â (194)â€‹Â (1,071)Effect of changes in exchange ratesâ€‹Â (211)â€‹Â (563)â€‹Â (566)Unrecognized tax benefitsâ€“end of period â€‹Â 11,861â€‹Â 9,449â€‹Â 7,832Interest and penaltiesâ€“end of period â€‹Â 1,689â€‹Â 981â€‹Â 427Total liabilities related to uncertain tax positionsâ€‹$ 13,550â€‹$ 10,430â€‹$ 8,259Â â€‹We recognize interest and penalties associated with uncertain tax positions as a component of the provision for income taxes. We recognized and recorded interest and penalties expense of $740, $589 and $74 for 2024, 2023 and 2022, respectively.Income tax returns for the following periods are no longer subject to examination by the relevant tax authorities:â—U.S. federal and significant states, through JuneÂ 30, 2019;â—Brazil, through DecemberÂ 31, 2018; andâ—Israel, through JuneÂ 30, 2020, for certain subsidiaries and through June 30, 2021, for certain subsidiaries.â€‹â€‹13.Â Â Â Â Commitments and ContingenciesEnvironmentalOur operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, â€œEnvironmental Lawsâ€). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination, and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the period during which such costs are likely to be incurred are difficult to predict.While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We 108 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based on our experience, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.The United States Environmental Protection Agency (the â€œEPAâ€) oversees remediation of contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (â€œOmega Chemical Siteâ€), which is upgradient of the Santa Fe Springs, California facility of our subsidiary, Phibro-Tech, Inc. (â€œPhibro-Techâ€). The EPA entered into a settlement agreement and court-approved consent decree (the â€œConsent Decreeâ€) with a group of companies, including Phibro-Tech and certain other subsidiaries of PAHC due to groundwater contamination from Phibro-Techâ€™s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In February 2023, Phibro-Tech signed a definitive settlement agreement that provided for a â€œcash-outâ€ settlement, with contribution protection, for Phibro-Tech and its affiliates releasing Phibro-Tech and its affiliates from liability for contamination of the groundwater plume affected by the Omega Chemical Site (with certain exceptions). The settlement agreement does not constitute an admission of liability on the part of Phibro-Tech or its affiliates. As part of the settlement, Phibro-Tech also resolved all claims for indemnification and contribution between Phibro-Tech and the successor to the prior owner of the Phibro-Tech site. The EPA, the Department of Justice and the district court have approved the definitive settlement agreement and the Consent Decree. The district courtâ€™s order can be appealed within 60 days, which period will expire on September 10, 2024. As of June 30, 2024, Phibro-Tech and one of its affiliates have made settlement payments totaling $5,019, which represents all cash payments required by the definitive settlement agreement. Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites to be approximately $4,282 and $8,505 at JuneÂ 30,Â 2024 and 2023, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries are liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.Claims and LitigationPAHC and its subsidiaries are party to various claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.Employment and Severance AgreementsWe have entered into employment agreements with certain executive management and other employees that specify severance benefits of up to 15 monthsÂ of the employeeâ€™s compensation.109 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Purchase CommitmentsAs of JuneÂ 30,Â 2024, we have agreements to purchase goods and services totaling approximately $2,000 that are enforceable and legally binding and include amounts for future purchases. Payments for these obligations are expected to be approximately $2,000 in 2025.â€‹â€‹14. DerivativesWe monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are recorded in accumulated other comprehensive income (loss).We routinely assess whether the derivatives used to hedge transactions are effective. If we determine that a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see â€œNote 15â€” Fair Value Measurements.â€We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating portion of our interest obligation on that amount of debt to a fixed interest rate of 0.61% through June 2025. We designated the interest rate swap as a highly effective cash flow hedge.We are a party to foreign currency option contracts used to hedge cash flows related to monthly inventory purchases. The individual option contracts mature monthly through December 2024. The forecasted inventory purchases are probable of occurring and the individual option contracts were designated as highly effective cash flow hedges.The consolidated balance sheet includes the net fair values of our outstanding foreign currency option contracts within the respective line items, based on the net financial position and maturity date of the individual contracts. The consolidated balance sheet includes the net fair values of our outstanding interest rate swap within the respective balance sheet line items, based on the expected timing of the cash flows. The consolidated balance sheet includes assets and liabilities for the fair values of outstanding derivatives that are designated and effective as cash flow hedges as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Other current assetsÂ â€‹Â Â Â â€‹Â Â Foreign currency option contracts, netâ€‹$ 39â€‹$ 333Interest rate swapâ€‹Â 13,151â€‹Â 14,031Other assetsâ€‹â€‹â€‹â€‹â€‹â€‹Foreign currency option contracts, netâ€‹â€‹ â€”â€‹â€‹ â€”Interest rate swapâ€‹â€‹ â€”â€‹â€‹ 10,225Accrued expense and other current liabilitiesâ€‹Â â€‹â€‹Â â€‹Foreign currency option contracts, netâ€‹Â (41)â€‹Â â€”Interest rate swapsâ€‹Â â€”â€‹Â â€”Total Fair Valueâ€‹Â â€‹â€‹Â â€‹Foreign currency option contracts, netâ€‹Â (2)â€‹Â 333Interest rate swapâ€‹Â 13,151â€‹Â 24,256â€‹110 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Notional amounts of the derivatives as of the balance sheet date were:â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Interest rate swapâ€‹$ 300,000Brazil Real-USD call optionsâ€‹R$ 36,000Brazil Real-USD put optionsÂ R$ (36,000)USD-Israel shekel call optionsâ€‹$ (3,043)USD-Israel shekel put optionsâ€‹$ 3,043Â â€‹The consolidated statements of operations and statements of other comprehensive income (â€œOCIâ€) for the years ended JuneÂ 30,Â 2024 and 2023 included the effects of derivatives as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024Â Â Â Â 2023Foreign currency option contracts, netâ€‹â€‹Â Â Â â€‹Â Â (Income) expense recorded in consolidated statements of operationsâ€‹$ (1,126)â€‹$ 1,237Consolidated statement of operations - total cost of goods soldâ€‹$ 704,587â€‹$ 679,652Consolidated statement of operations - total selling, general and administrative expensesâ€‹$ 259,777â€‹$ 226,390(Income) expense recorded in comprehensive incomeâ€‹$ 380â€‹$ 270Interest rate swapâ€‹Â â€‹â€‹Â â€‹(Income) expense recorded in consolidated statements of operationsâ€‹$ (14,503)â€‹$ (9,870)Consolidated statement of operations - total interest expense, netâ€‹$ 18,536â€‹$ 15,321(Income) expense recorded in comprehensive incomeâ€‹$ 11,105â€‹$ (3,968)Â â€‹We recognize gains and losses related to certain foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold. Inventory as of JuneÂ 30,Â 2024 included realized net gains of $1,142 related to matured contracts. We anticipate the net gains included in inventory will be recognized in cost of goods sold within the next 12 months.â€‹â€‹15.Â Â Â Â Fair Value MeasurementsFair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Financial assets and liabilities are measured at fair value using the three-level valuation hierarchy for disclosure of fair value measurements. The determination of the applicable level within the hierarchy of a particular asset or liability depends on the inputs used in the valuation as of the measurement date, notably the extent to which the inputs are market-based (observable) or internally derived (unobservable). Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs based on a companyâ€™s own assumptions about market participant assumptions developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:Level 1 â€” Quoted prices in active markets for identical assets or liabilities.Level 2 â€” Significant observable inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly through corroboration with observable market data.Level 3 â€” Unobservable inputs for which there is little or no market data available, and that are significant to the overall fair value measurement, are employed that require the reporting entity to develop its own assumptions.In assessing the fair value of financial instruments at JuneÂ 30,Â 2024 and 2023, we used a variety of methods and assumptions that were based on estimates of market conditions and risks existing at the time.111 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)Short-Term InvestmentsOur short-term investments consist of cash deposits held at financial institutions. We consider the carrying amounts of these short-term investments to be representative of their fair value.Current Assets and LiabilitiesWe consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.DebtWe record debt, including term loans and revolver balances, at amortized cost in our consolidated financial statements. We believe the carrying value of the debt is approximately equal to its fair value, due to the variable nature of the instruments and our evaluation of estimated market prices.DerivativesWe determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation rates.Non-Financial AssetsOur non-financial assets, which

primarily consist of goodwill, other intangible assets, property and equipment, and lease-related ROU assets, are not required to be measured at fair value on a recurring basis, and instead are reported at carrying value in the consolidated balance sheet. Assets and liabilities may be required to be measured at fair value on a non-recurring basis, either upon initial recognition or for subsequent accounting or reporting, including the initial recognition of net assets acquired in a business combination. These fair value measurements involve unobservable inputs that reflect estimates and assumptions that represent Level 3 inputs.Fair Value of Assets (Liabilities)â€‹As of â€‹JuneÂ 30,Â 2024â€‹JuneÂ 30,Â 2023â€‹Â Â Â Â LevelÂ 1Â Â Â Â LevelÂ 2Â Â Â Â LevelÂ 3Â Â Â Â LevelÂ 1Â Â Â Â LevelÂ 2Â Â Â Â LevelÂ 3Short-term investmentsâ€‹$ 44,000â€‹$ â€”â€‹$ â€”â€‹$ 40,000â€‹$ â€”â€‹$ â€”Foreign currency derivativesâ€‹$ â€”â€‹$ (2)â€‹$ â€”â€‹$ â€”â€‹$ 333â€‹$ â€”Interest rate swapâ€‹$ â€”â€‹$ 13,151â€‹$ â€”â€‹$ â€”â€‹$ 24,256â€‹$ â€”Â â€‹There were no transfers between levels during the periods presented. There were no changes in the fair value of the Level 3 liabilities.For a detailed discussion on the fair value of our pension plan assets, see â€œNote 11 â€” Employee Benefit Plans.â€â€‹â€‹16. Business SegmentsWe evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to a segment or segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the other segments because they are not used to evaluate the segmentsâ€™ operating results or financial position. Corporate costs include certain costs related to executive management, information technology, legal, finance, human resources and business development. The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.We evaluate performance of our segments based on Adjusted EBITDA. We calculate Adjusted EBITDA as net income plus (a)Â interest expense, net, (b)Â provision for income taxes or less benefit for income taxes, (c) depreciation and amortization, (d)Â other expense or less other income, as separately reported on our consolidated statements of operations, 112 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)including foreign currency (gains) losses, net and (e)Â certain items that we consider to be unusual, non-operational or non-recurring.â€‹ForÂ theÂ YearÂ EndedÂ JuneÂ 30â€‹2024â€‹2023â€‹2022Net salesÂ â€‹Â Â Â â€‹Â Â Â â€‹Â Â Animal Health â€‹$ 706,482â€‹$ 659,851â€‹$ 607,055Mineral Nutrition â€‹Â 243,663â€‹Â 242,656â€‹Â 259,512Performance Products â€‹Â 67,534â€‹Â 75,382â€‹Â 75,694Total segments â€‹$ 1,017,679â€‹$ 977,889â€‹$ 942,261â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Depreciation and amortizationâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Animal Health â€‹$ 30,194â€‹$ 27,714â€‹$ 26,759Mineral Nutrition â€‹Â 2,427â€‹Â 2,638â€‹Â 2,616Performance Products â€‹Â 1,688â€‹Â 1,780â€‹Â 1,717Total segments â€‹$ 34,309â€‹$ 32,132â€‹$ 31,092Adjusted EBITDAâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Animal Health â€‹$ 145,606â€‹$ 136,139â€‹$ 124,106Mineral Nutrition â€‹Â 16,449â€‹Â 17,417â€‹Â 24,038Performance Products â€‹Â 7,662â€‹Â 9,346â€‹Â 8,706Total segments â€‹$ 169,717â€‹$ 162,902â€‹$ 156,850Reconciliation of income before income taxes to Adjusted EBITDAâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Income before income taxes â€‹$ 10,916â€‹$ 54,071â€‹$ 72,327Interest expense, net â€‹Â 18,536â€‹Â 15,321â€‹Â 11,875Depreciation and amortization â€“ Total segmentsâ€‹Â 34,309â€‹Â 32,132â€‹Â 31,092Depreciation and amortization â€“ Corporate â€‹Â 1,869â€‹Â 1,880â€‹Â 1,613Corporate costsâ€‹â€‹ 58,480â€‹â€‹ 50,149â€‹â€‹ 45,767Acquisition-related cost of goods soldâ€‹Â 521â€‹Â â€”â€‹Â 316Acquisition-related transaction costsâ€‹Â 6,405â€‹Â â€”â€‹Â 279Pension settlement costâ€‹â€‹ 10,674â€‹â€‹ â€”â€‹â€‹ â€”Brazil employment taxesâ€‹â€‹ 4,202â€‹â€‹ â€”â€‹â€‹ â€”Stock-based compensationâ€‹Â 475â€‹Â â€”â€‹Â â€”Phibro Forward income growth initiatives implementation costsâ€‹â€‹ 366â€‹â€‹ â€”â€‹â€‹ â€”Insurance proceedsâ€‹â€‹ (899)â€‹â€‹ â€”â€‹â€‹ â€”Environmental remediation costsâ€‹â€‹ â€”â€‹â€‹ 6,894â€‹â€‹ â€”Gain on sale of investmentâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (1,203)Foreign currency (gains) losses, net â€‹Â 23,863â€‹Â 2,455â€‹Â (5,216)Adjusted EBITDA â€“ Total segments â€‹$ 169,717â€‹$ 162,902â€‹$ 156,850Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Identifiable assetsÂ â€‹Â Â Â â€‹Â Â Animal Health â€‹$ 684,407â€‹$ 698,522Mineral Nutrition â€‹Â 67,088â€‹Â 75,814Performance Products â€‹Â 50,862â€‹Â 49,678Total segments â€‹Â 802,357â€‹Â 824,014Corporate â€‹Â 179,827â€‹Â 147,383Total â€‹$ 982,184â€‹$ 971,397Â â€‹The Animal Health segment includes all goodwill of the Company. Corporate assets include cash and cash equivalents, short-term investments, debt issuance costs, income tax related assets and certain other assets.113 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)The geographic location of property, plant and equipment, net was:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of JuneÂ 30Â Â Â Â 2024Â Â Â Â 2023Property, plant and equipment, netÂ â€‹Â Â Â â€‹Â Â United States â€‹$ 87,526â€‹$ 79,404Israel â€‹Â 60,395â€‹Â 61,304Brazil â€‹Â 30,348â€‹Â 30,359Irelandâ€‹â€‹ 19,038â€‹â€‹ 18,900Other â€‹Â 5,993â€‹Â 5,601â€‹â€‹$ 203,300â€‹$ 195,568Â Â Â â€‹17. Subsequent Event â€“ 2024 Credit AgreementIn July 2024, we entered into the 2024 Credit Agreement with a group of lenders. Initial borrowings were used to refinance all our outstanding debt, to pay fees and expenses of the transaction, and for ongoing working capital requirements and general corporate purposes. Borrowings under the Delayed Draw Term A-1 and A-2 Loans will be used to finance the purchase price of the Proposed Acquisition upon completion of the acquisition (the â€œClosing Dateâ€).Under the 2024 Credit Agreement, there are (i) Initial Term A-1 Loans in an initial aggregate principal amount of $162,000 (the â€œInitial Term A-1 Loansâ€), (ii) Delayed Draw Term A-1 Loans in an initial aggregate principal amount of $189,000 (the â€œDelayed Draw Term A-1 Loansâ€ and, together with the Initial Term A-1 Loans, the â€œTerm A-1 Loansâ€) (iii) Initial Term A-2 Loans in an initial aggregate principal amount of $138,000 (the â€œInitial Term A-2 Loansâ€), (iv) Delayed Draw Term A-2 Loans in an initial aggregate principal amount of $161,000 (the â€œDelayed Draw Term A-2 Loansâ€ and, together with the Initial Term A-2 Loans, the â€œTerm A-2 Loansâ€), and (v) Revolving Credit Commitments in an initial aggregate principal amount of $310,000 (the â€œRevolving Credit Commitmentsâ€ and, together with the Term A-1 Loans and Term A-2 Loans, the â€œ2024 Credit Facilitiesâ€). The 2024 Credit Facilities mature in July 2029 in the case of the Term A-1 Loans and the Revolving Credit Commitments and in July 2031 in the case of the Term A-2 Loans.Borrowings under the 2024 Credit Facilities bear interest at rates based on the ratio of the Company and its subsidiariesâ€™ net consolidated indebtedness to the Company and its subsidiariesâ€™ consolidated EBITDA (the â€œNet Leverage Ratioâ€). The interest rates per annum for loans under the 2024 Credit Facilities are based on a fluctuating rate of interest as selected by the Company plus an applicable rate as set forth in the table below: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Revolving Credit and Term A-1 Loansâ€‹Term A-2 LoansNet Leverage Ratioâ€‹Base rateSOFRâ€‹Base rateSOFRâ‰¥ 4.00:1.00Â 1.75%2.75%Â Â 2.25%3.25%â‰¥ 3.50:1.00 and < 4.00:1.00â€‹1.50%2.50%â€‹2.00%3.00%â‰¥ 2.25:1.00 and < 3.50:1.00â€‹1.25%2.25%â€‹1.75%2.75%< 2.25:1.00â€‹1.00%2.00%â€‹1.50%2.50%Â â€‹The Company may receive patronage from the lenders providing the Term A-2 Loans, to the extent eligible under such lenderâ€™s patronage program, as determined by such lender in its sole discretion.Pursuant to the terms of the 2024 Credit Agreement, the 2024 Credit Facilities are subject to various covenants that, among other things and subject to the permitted exceptions described therein, restrict us and our subsidiaries with respect to: (i)Â incurring additional debt; (ii)Â making certain restricted payments or making optional redemptions of other indebtedness; (iii)Â making investments or acquiring assets; (iv)Â disposing of assets (other than in the ordinary course of business); (v)Â creating any liens on our assets; (vi)Â entering into transactions with affiliates; (vii)Â entering into merger or consolidation transactions; and (viii)Â creating guarantee obligations; provided, however, that we are permitted to pay distributions to stockholders out of available cash subject to certain annual limitations and a quarterly maximum Net Leverage Ratio of 4.0x and so long as no default or event of default under the 2024 Credit Facilities shall have occurred and be continuing at the time such distribution is declared. Indebtedness under the 2024 Credit Facilities is collateralized 114 Table of ContentsNOTES TO CONSOLIDATED FINANCIAL STATEMENTS â€” (Continued)by a first priority lien on substantially all assets of Phibro and certain of our domestic subsidiaries. The 2024 Credit Agreement contains an acceleration clause should an event of default (as defined) occur. The 2024 Credit Agreement requires, among other things, compliance with financial covenants that permit: (i)Â a maximum Net Leverage Ratio and (ii)Â a minimum interest coverage ratio, each calculated on a trailing four-quarter basis, as follows: â€‹â€‹â€‹â€‹â€‹Periodmaximum Net Leverage Ratioâ€‹minimum interest coverage ratioPrior to the Closing Date4.00:1.00â€‹3.00:1.00First fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date4.75:1.00â€‹2.50:1.00Eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date4.50:1.00â€‹2.75:1.00Thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date4.25:1.00â€‹3.00:1.00After the forty-two month anniversary of the Closing Date4.00:1.00â€‹3.00:1.00Â â€‹We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025. We have designated the interest rate swap as a highly effective cash flow hedge. For additional details, see â€œNote 14 â€” Derivatives.â€â€‹â€‹â€‹â€‹115 Table of ContentsItemÂ 9.Â Â Â Changes in and Disagreements with Accountants on Accounting and Financial DisclosureNone.â€‹Item 9A.Â Controls and ProceduresDisclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our periodic reports that we file or submit under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) are recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (â€œCEOâ€) and Chief Financial Officer (â€œCFOâ€), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures as of JuneÂ 30,Â 2024. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of JuneÂ 30,Â 2024 to provide the reasonable assurance described above. Managementâ€™s Annual Report on Internal Control Over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including the CEO and the CFO, we carried out an evaluation of the effectiveness of our internal control over financial reporting as of JuneÂ 30,Â 2024 using the criteria established in â€œInternal Control-Integrated Frameworkâ€ (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, management concluded that our internal control over financial reporting was effective as of JuneÂ 30,Â 2024.The effectiveness of our internal control over financial reporting as of JuneÂ 30,Â 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included under â€œItem 8 â€” Financial Statements and Supplementary Data.â€â€‹Changes in Internal Control Over Financial Reporting There have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ItemÂ 9B.Â Â Â Other InformationNone.â€‹ItemÂ 9C.Â Â Â Disclosure Regarding Foreign Jurisdictions that Prevent InspectionsNone.â€‹116 Table of Contentsâ€‹PART IIIItemÂ 10. Directors, Executive Officers and Corporate GovernanceThe information required by this item is incorporated by reference to our 2024 Proxy Statement to be filed with the SEC within 120Â days of the year ended JuneÂ 30,Â 2024.Our Board of Directors has adopted a Code of Business Conduct and Ethics applicable to all officers, directors and employees, which is available on our website (investors.pahc.com) under â€œCorporate Governance.â€â€‹ItemÂ 11. Executive CompensationThe information required by this item is incorporated by reference to our 2024 Proxy Statement to be filed with the SEC within 120Â days of the year ended JuneÂ 30,Â 2024.â€‹ItemÂ 12. Security Ownership of Certain Beneficial Owners and Management Related Stockholder MattersThe information required by this item is incorporated by reference to our 2024 Proxy Statement to be filed with the SEC within 120Â days of the year ended JuneÂ 30,Â 2024.â€‹ItemÂ 13. Certain Relationships and Related Transactions, and Director IndependenceThe information required by this item is incorporated by reference to our 2024 Proxy Statement to be filed with the SEC within 120Â days of the year ended JuneÂ 30,Â 2024.â€‹ItemÂ 14. Principal Accountant Fees and ServicesThe information required by this item is incorporated by reference to our 2024 Proxy Statement to be filed with the SEC within 120Â days of the year ended JuneÂ 30,Â 2024.â€‹117 Table of ContentsPART IVItemÂ 15. Exhibits, Financial Statement Schedules(a)We have filed the following documents as part of this Annual Report on Form 10-K:(1)Consolidated Financial Statements:Report of Independent Registered Public Accounting FirmConsolidated Statements of Operations for the fiscalÂ years ended JuneÂ 30,Â 2024, 2023 and 2022Consolidated Statements of Comprehensive Income for the fiscalÂ years ended JuneÂ 30,Â 2024, 2023 and 2022Consolidated Balance Sheets at JuneÂ 30,Â 2024 and 2023Consolidated Statements of Cash Flows for the fiscalÂ years ended JuneÂ 30,Â 2024, 2023 and 2022Consolidated Statements of Changes in Stockholdersâ€™ Equity for the fiscalÂ years ended JuneÂ 30,Â 2024, 2023 and 2022Notes to Consolidated Financial Statements(2)Schedules: None(3)The exhibits filed are listed in the Index to Exhibits immediately preceding the signature page of this Annual Report on Form 10-K.â€‹118 Table of Contentsâ€‹(b)Exhibits â€‹â€‹â€‹Exhibit NumberExhibit Descriptionâ€‹â€‹Exhibit 2.1Purchase and Sale Agreement, dated April 28, 2024, among Phibro Animal Health Corporation, Phibro Animal Health S.A. and Zoetis Inc.â€‹â€‹Exhibit 3.1Amended and Restated Certificate of Incorporation of Phibro Animal Health Corporation (incorporated by reference to Exhibit 3.1 to Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q filed on May 13, 2014 (File No. 001-36410)).â€‹â€‹Exhibit 3.2Amended and Restated Bylaws of Phibro Animal Health Corporation (incorporated by reference to Exhibit 3.2 of Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q filed on May 13, 2014 (File No. 001-36410)).â€‹â€‹Exhibit 4.1Registration Rights Agreement between Phibro Animal Health Corporation and BFI Co., LLC, dated as of April 16, 2014 (incorporated by reference to Exhibit 4.9 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1/A filed on March 31, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 4.2Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 of the Phibro Animal Health Corporationâ€™s 2019 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on August 27, 2019 (File No. 001-36410)).â€‹â€‹Exhibit 10.1Debt Commitment Letter, dated April 28, 2024, among Phibro Animal Health Corporation, Phibro Animal Health S.A., CoÃ¶peratieve Rabobank U.A., New York Branch, Compeer Financial, PCA and Citibank, N.A.â€‹â€‹Exhibit 10.2Credit Agreement dated July 3, 2024, among Phibro Animal Health Corporation, the guarantors party thereto, CoÃ¶peratieve Rabobank U.A., New York Branch (â€œRabobankâ€), as Administrative Agent, Collateral Agent and Letter of Credit Issuer, and each lender party thereto (incorporated by reference to Exhibit 10.1 to Phibro Animal Health Corporationâ€™s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 9, 2024 (File No. 001-36410)).â€‹â€‹Exhibit 10.3Unprotected Lease Agreement, dated January 26, 2011, by and between Samaria Carpets Ltd. and ABIC Biological Laboratories Ltd. (translated from Hebrew) (incorporated by reference to Exhibit 10.17 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.4Employment Agreement, dated March 27, 2014, by and between Jack C. Bendheim and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.18 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1/A filed on March 31, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.5Employment Offer Letter, dated May 2, 2008, by and between Larry L. Miller and Phibro Animal Health Corporation, including confidentiality and nondisclosure, employee invention, and noncompetition and nonsolicitation agreements dated as of May 2, 2008 (incorporated by reference to Exhibit 10.20 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹119 Table of ContentsExhibit 10.6Clarifying Amendment to Employment Offer Letter, dated December 21, 2009, by and between Larry L. Miller and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.21 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.7â€¡Amendment to Employment Offer Letter, dated December 15, 2011, by and between Larry L. Miller and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.22 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.8â€¡Phibro Animal Health Corporation 2008 Incentive Plan (incorporated by reference to Exhibit 10.23 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.9 â€¡Phibro Animal Health Corporation Management Incentive Plan (incorporated by reference to Exhibit 10.24 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1/A filed on March 31, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.10â€¡Phibro Animal Health Corporation Retirement Income and Deferred Compensation Plan, as amended and restated as of April 15, 2009 (incorporated by reference to Exhibit 10.25 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.11Phibro Animal Health Corporation Executive Income Deferred Compensation Agreement, dated as of March 1, 1990 (incorporated by reference to Exhibit 10.26 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1 filed on March 10, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.12Form of 2009 Stock Option Grant Agreement (incorporated by reference to Exhibit 10.28 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1/A filed on March 31, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.13Form of 2013 Stock Option Grant Agreement (incorporated by reference to Exhibit 10.29 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1/A filed on March 31, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.14Form of

Indemnification Agreement (incorporated by reference to Exhibit 10.32 of Phibro Animal Health Corporationâ€™s registration statement on Form S-1/A filed on April 4, 2014 (File No. 333-194467)).â€‹â€‹Exhibit 10.15*Intellectual Property Purchase Agreement dated January 20, 2015 by and between MJ Biologics, Inc. and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.33 to Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 11, 2015).â€‹â€‹Exhibit 10.16*First Amendment, dated July 31, 2018 to the Intellectual Property Purchase Agreement, drafted as of January 20, 2015, by and among MJ Biologics, Inc. and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.18 to Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2018 (File No. 001-36410)).â€‹â€‹Exhibit 10.17Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to Phibro Animal Health Corporationâ€™s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 7, 2018 (File No. 13-1840497)).â€‹â€‹120 Table of ContentsExhibit 10.18Executive Long-Term Incentive Agreement dated May 11, 2015, by and between Phibro Animal Health Corporation and Richard G. Johnson (incorporated by reference to Exhibit 10.34 to Phibro Animal Health Corporationâ€™s 2015 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 10, 2015 (File No. 001-36410)).â€‹â€‹Exhibit 10.19Executive Long-Term Incentive Agreement dated July 5, 2023 by and between Phibro Animal Health Corporation and Larry L. Miller (incorporated by reference to Exhibit 10.18 to Phibro Animal Health Corporationâ€™s 2023 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on August 30, 2023 (File No. 001-36410)).â€‹â€‹Exhibit 10.20Employment Offer Letter, dated September 14, 2020, by and between Damian L. Finio and Phibro Animal Health Corporation, including confidentiality and nondisclosure, employee invention, and noncompetition and nonsolicitation agreements (incorporated by reference to Exhibit 10.1 to Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 4, 2020 (File No. 001-36410)).â€‹â€‹Exhibit 10.21Continuing Employment Letter, dated November 2, 2020, by and between Richard G. Johnson and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.2 to Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 4, 2020 (File No. 001-36410)).â€‹â€‹Exhibit 10.22General Release and Separation Agreement, dated November 16, 2020, by and between Richard G. Johnson and Phibro Animal Health Corporation. (incorporated by reference to Exhibit 10.24 to Phibro Animal Health Corporationâ€™s 2021 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on August 25, 2021 (File No. 001-36410)).â€‹â€‹Exhibit 10.23Severance Protection Letter, dated February 7, 2022, by and between Damian Finio and Phibro Animal Health Corporation (incorporated by reference to Exhibit 10.25 to Phibro Animal Health Corporationâ€™s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on February 9, 2022 (File No. 001-36410)).â€‹â€‹Exhibit 10.24Employment Offer Letter, dated May 6, 2019, by and between Rob Aukerman and Phibro Animal Health Corporation, including confidentiality and nondisclosure, employee invention, and noncompetition and nonsolicitation agreements (incorporated by reference to Exhibit 10.18 to Phibro Animal Health Corporationâ€™s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on August 26, 2020 (File No. 001-36410).â€‹â€‹Exhibit 10.25Employment Offer Letter, dated October 10, 2023, by and between Glenn David and Phibro Animal Health Corporation, including noncompetition and nonsolicitation agreement.â€‹â€‹Exhibit 19.1Phibro Animal Health Corporation Insider Trading and Disclosure of Confidential Information Policy.â€‹â€‹Exhibit 21.1List of Subsidiaries of Phibro Animal Health Corporation.â€‹â€‹Exhibit 23.1Consent of Independent Registered Public Accounting Firm.â€‹â€‹Exhibit 31.1Chief Executive Officer-Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302.â€‹â€‹Exhibit 31.2Chief Financial Officer-Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302.â€‹â€‹Exhibit 32.1**Chief Executive Officer-Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906.â€‹â€‹Exhibit 32.2**Chief Financial Officer-Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906.â€‹â€‹121 Table of ContentsExhibit 97.1Phibro Animal Health Corporation Clawback Policy.â€‹â€‹Exhibit 101.INSInline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentâ€‹â€‹Exhibit 101.SCHInline XBRL Taxonomy Extension Schema Document.â€‹â€‹Exhibit 101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.â€‹â€‹Exhibit 101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.â€‹â€‹Exhibit 101.LABInline XBRL Taxonomy Extension Label Linkbase Document.â€‹â€‹Exhibit 101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.â€‹â€‹Exhibit 104Cover Page Interactive Data File (embedded within the inline XBRL and contained in Exhibit 101)â€‹*Confidential treatment of certain provisions of this exhibit has been requested with the Securities and Exchange Commission. Omitted material for which confidential treatment has been requested has been filed separately with the Securities and Exchange Commission.**This certification is deemed not filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.â€‹Item 16. Form 10-K SummaryNot applicable.â€‹â€‹122 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.â€‹â€‹Phibro Animal Health Corporationâ€‹â€‹August 28, 2024By:/s/ Jack C. Bendheimâ€‹â€‹Jack C. Bendheimâ€‹â€‹Chairman, President and Chief Executive Officerâ€‹Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.â€‹â€‹Phibro Animal Health Corporationâ€‹â€‹August 28, 2024By:/s/ Jack C. Bendheimâ€‹â€‹Jack C. Bendheimâ€‹â€‹Chairman, President and Chief Executive Officerâ€‹â€‹August 28, 2024By:/s/ Glenn C. Davidâ€‹â€‹Glenn C. Davidâ€‹â€‹Chief Financial Officerâ€‹â€‹August 28, 2024By:/s/ Daniel M. Bendheimâ€‹â€‹Daniel M. Bendheimâ€‹â€‹Director and Executive Vice President,â€‹â€‹Corporate Strategyâ€‹â€‹August 28, 2024By:/s/ Jonathan Bendheimâ€‹â€‹Jonathan Bendheimâ€‹â€‹Director and President, MACIE Region andâ€‹â€‹General Manager of Israel Operationsâ€‹â€‹August 28, 2024By:/s/ Alejandro Bernalâ€‹â€‹Alejandro Bernalâ€‹â€‹Directorâ€‹â€‹August 28, 2024By:/s/ E. Thomas Corcoranâ€‹â€‹E. Thomas Corcoranâ€‹â€‹Directorâ€‹â€‹August 28, 2024By:/s/ Sam Gejdensonâ€‹â€‹Sam Gejdensonâ€‹â€‹Directorâ€‹â€‹August 28, 2024By:/s/ Mary Lou Malanoskiâ€‹â€‹Mary Lou Malanoskiâ€‹â€‹Directorâ€‹â€‹August 28, 2024By:/s/ Carol A. Wrennâ€‹â€‹Carol A. Wrennâ€‹â€‹Directorâ€‹â€‹â€‹123 EX-2.1 2 pahc-20240630xex2d1.htm EX-2.1 Exhibit 2.1EXECUTION VERSIONâ€‹â€‹PURCHASE AND SALE AGREEMENTBY AND AMONGPHIBRO ANIMAL HEALTH CORPORATION,PHIBRO ANIMAL HEALTH S.A.ANDZOETIS INC.Dated as of April 28, 2024â€‹â€‹TABLE OF CONTENTSâ€‹â€‹PageARTICLE I DEFINITIONS1Section 1.1Definitions1Section 1.2Other Defined Terms15â€‹â€‹ARTICLE II PURCHASE AND SALE; CLOSING19Section 2.1Purchase and Sale19Section 2.2Purchase Price19Section 2.3Closing Date19Section 2.4Purchased Assets19Section 2.5Excluded Assets22Section 2.6Assumed Liabilities24Section 2.7Retained Liabilities26Section 2.8Closing Deliveries27Section 2.9Adjustment to Base Purchase Price29Section 2.10Purchase Price Allocation32Section 2.11Transferred Marketing Authorizations34Section 2.12Bulk Sales36Section 2.13Withholding36â€‹â€‹ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER36Section 3.1Organization and Standing36Section 3.2Purchased Entities; Capital Structure36Section 3.3Authority; Enforceability37Section 3.4No Conflicts; Consents38Section 3.5Governmental Authorizations38Section 3.6Proceedings39Section 3.7Financial Statements; Absence of Undisclosed Liabilities39Section 3.8Absence of Changes or Events40Section 3.9Title to Assets; Sufficiency of Assets40Section 3.10Intellectual Property41Section 3.11Information Technology; Data Protection42Section 3.12Real Property43Section 3.13Contracts44Section 3.14Significant Customers; Significant Suppliers46Section 3.15Transferred Marketing Authorizations; Recalls46Section 3.16Compliance with Applicable Laws; Permits47Section 3.17Environmental Matters48Section 3.18Taxes49Section 3.19Benefit Plans50Section 3.20Labor Matters52Section 3.21Intercompany Arrangements53Section 3.22Insurance53Section 3.23Inventory; Accounts Payable; Accounts Receivable53Section 3.24Brokers54â€‹-i-Section 3.25International Trade54Section 3.26No Other Representations or Warranties54â€‹â€‹ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASERS55Section 4.1Organization and Standing55Section 4.2Authority; Enforceability55Section 4.3No Conflicts; Consents56Section 4.4Governmental Authorizations56Section 4.5[Reserved]56Section 4.6Financing56Section 4.7Proceedings58Section 4.8Brokers58Section 4.9Solvency58Section 4.10Securities Laws59Section 4.11Acknowledgment of No Other Representations or Warranties59â€‹â€‹ARTICLE V COVENANTS60Section 5.1Efforts60Section 5.2Covenants Relating to Conduct of Business63Section 5.3Confidentiality67Section 5.4Access to Information69Section 5.5Publicity70Section 5.6Intercompany Accounts and Intercompany Arrangements71Section 5.7Financing72Section 5.8Financing Cooperation74Section 5.9Financial Obligations76Section 5.10Trademark Matters77Section 5.11Global Separation Sublicenses79Section 5.12Background IP License79Section 5.13Insurance80Section 5.14Litigation Support80Section 5.15Third-Party Consents81Section 5.16Non-Solicitation of Employees; Non-Competition81Section 5.17Payments; Misallocated Assets84Section 5.18R&W Insurance Policy85Section 5.19Delivery of Financial Statements85Section 5.20Exclusivity87Section 5.21Certain Matters87Section 5.22Resignations87Section 5.23Restricted Cash87Section 5.24Additional Business Products.88Section 5.25Additional Business Product Marks89Section 5.26Expired Marks89Section 5.27Omitted Marks90Section 5.28Intellectual Property Chain of Title Corrections90Section 5.29Assignment of Business Registered IP90Section 5.30Transition Services91â€‹-ii-â€‹â€‹ARTICLE VI EMPLOYEE MATTERS91Section 6.1Transfer of Business Employees91Section 6.2Compensation and Employee Benefits92Section 6.3Seller Benefit Plans94Section 6.4Purchased Entity Benefit Plans95Section 6.5U.S. Defined Contribution Plans95Section 6.6Short-Term Incentive Compensation96Section 6.7Labor Matters96Section 6.8Workersâ€™ Compensation97Section 6.9Immigration Compliance97Section 6.10Assignment and Transfer of Business Contingent Worker97Section 6.11Communications98Section 6.12Employee Restrictive Covenants98Section 6.13Third-Party Beneficiary Rights98â€‹â€‹ARTICLE VII CERTAIN TAX MATTERS98Section 7.1Cooperation and Exchange of Information98Section 7.2Tax Sharing Agreements99Section 7.3Tax Treatment of Payments99Section 7.4Elections99Section 7.5Transfer Taxes and VAT/GST99Section 7.6Italian VAT Receivable100Section 7.7Straddle Period100Section 7.8Certain Tax Refunds100â€‹â€‹ARTICLE VIII CONDITIONS PRECEDENT101Section 8.1Conditions to Each Partyâ€™s Obligations to Close101Section 8.2Conditions to Obligations of Purchasers to Close101Section 8.3Conditions to Obligations of Seller to Close102â€‹â€‹ARTICLE IX TERMINATION; EFFECT OF TERMINATION103Section 9.1Termination103Section 9.2Effect of Termination104Section 9.3Notice of Termination104â€‹â€‹ARTICLE X INDEMNIFICATION104Section 10.1Survival104Section 10.2Indemnification by Seller105Section 10.3Indemnification by Purchasers105Section 10.4Procedures106Section 10.5Exclusive Remedy and Release107Section 10.6Additional Indemnification Provisions108Section 10.7Mitigation108â€‹â€‹ARTICLE XI GENERAL PROVISIONS109Section 11.1Entire Agreement109Section 11.2Disclosure Schedules109Section 11.3Assignment109Section 11.4Amendments and Waivers110â€‹-iii-Section 11.5No Third-Party Beneficiaries110Section 11.6Notices110Section 11.7Specific Performance111Section 11.8Governing Law and Jurisdiction111Section 11.9Waiver of Jury Trial112Section 11.10Severability112Section 11.11Counterparts112Section 11.12Expenses113Section 11.13Interpretation; Absence of Presumption113Section 11.14Waiver of Conflicts Regarding Representation; Nonassertion of Attorney-Client Privilege114Section 11.15Financing Provisions115â€‹EXHIBITSExhibit AForm of Transition Services AgreementExhibit BForm of Assignment Agreement and Bill of SaleExhibit CAllocation Scheduleâ€‹â€‹â€‹-iv-PURCHASE AND SALE AGREEMENTThis PURCHASE AND SALE AGREEMENT, dated as of April 28, 2024 (this â€œAgreementâ€), is by and among Zoetis Inc., a Delaware corporation (â€œSellerâ€), Phibro Animal Health Corporation, a Delaware corporation (â€œPurchaser 1â€), and Phibro Animal Health S.A., a Belgian company (â€œPurchaser 2â€, and each of Purchaser 1 and Purchaser 2, a â€œPurchaserâ€, and collectively, the â€œPurchasersâ€, and together with Seller, the â€œPartiesâ€ and each, a â€œPartyâ€).WHEREAS, Seller and certain of its Subsidiaries are engaged in, among other things, the Business; andWHEREAS, on the terms and subject to the conditions set forth herein, the Seller Entities shall sell, assign, transfer and convey to the Purchasers, and the Purchasers shall purchase, acquire and accept from the Seller Entities, all of their right, title and interest in and to the Purchased Assets, and the Purchasers shall assume the Assumed Liabilities (the â€œTransactionâ€).NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, on the terms and subject to the conditions of this Agreement, the Parties hereby agree as follows:ARTICLEÂ IDEFINITIONSSectionÂ 1.1Definitions. As used herein, the following terms have the meanings set forth below:â€œAcquisition Proposalâ€ means, other than the transactions contemplated hereby, any inquiry, proposal or offer for (a) any direct or indirect sale, lease, transfer or other disposition, in one or a series of related transactions, of all or more than 50% of the Purchased Assets or the Business, taken as a whole, by any Person or group of related Persons, or (b) any acquisition by any Person or group of related Persons, in one or a series of related transactions, of more than 50% of the total equity securities (determined by either total voting power or fair market value) of any of the Purchased Entities.â€œAdditional Business Productsâ€ means collectively or individually the medicated feed products in the U.S. or any foreign jurisdiction (including water soluble and solid feed additives) that (i) are owned by Seller or its Subsidiaries (including the Purchased Entities), (ii) were maintained, manufactured, distributed or sold by Seller or its Subsidiaries (including the Purchased Entities) within the 5 year period prior to the Closing, (iii) have the same active pharmaceutical ingredients as the Business Products and (iv) were distributed or sold under the same trademark as the Business Products; provided, that Additional Business Products shall in no event include any Business Products or ALBACÂ®.â€œAffiliateâ€ means, with respect to any Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. For purposes of this definition, â€œcontrolâ€ (including, with correlative meanings, the terms â€œcontrolled byâ€ and â€œunder common control withâ€), as used with respect to any Personâ€‹â€‹â€‹means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by Contract or otherwise; provided that, from and after the Closing, (a) none of the Purchased Entities shall be considered an Affiliate of Seller or any of its Affiliates, and (b)Â none of Seller or its Affiliates shall be considered an Affiliate of any Purchased Entity.â€œAncillary Agreementsâ€ means the Transition Services Agreement, the Assignment Agreement and Bill of Sale, the Distribution Agreements and each other agreement, instrument or certificate entered into in connection with the transactions contemplated hereby, including all exhibits, schedules, annexes, supplements and amendments to any of the foregoing.â€œBusinessâ€ means, subject to the following sentence, the business, operations, products, services and activities related to manufacturing, distribution, marketing and selling of the Business Products, or otherwise exclusively relating to the medicated feed additive business (including liquid and solid feed additives) as carried on by Seller (directly or indirectly through its Subsidiaries, including the business, operations, products, services and activities of the Purchased Entities), in each case as conducted immediately prior to the Closing by Seller and its Subsidiaries. Seller and each Purchaser agree that the â€œBusinessâ€ shall not include (a)Â the businesses, operations, products, services and activities set forth on SectionÂ 1.1(a) of the Seller Disclosure Schedules or (b) any other businesses, operations, products, services or activities of Seller or its Subsidiaries (clauses (a) and (b) collectively, the â€œRetained Businessâ€).â€œBusiness Contingent Workerâ€ means each individual who is an independent contractor, consultant, any other non-employee worker or third-party agency worker who is actively providing services to a member of the Seller Group or a Purchased Entity immediately prior to the Closing and set forth on SectionÂ 1.1(b) of the Seller Disclosure Schedules, each of whom primarily dedicates his or her working time to the Business, which schedule may be updated by Seller from time to time prior to the Closing, with the prior written approval of the Purchasers if such approval is otherwise required under SectionÂ 5.2(b).â€œBusiness Dayâ€ means any day, other than a Saturday, Sunday or any other day on which commercial banks are required or authorized to be closed in New York, New York.â€œBusiness Employeeâ€ means each employee of any member of the Seller Group or a Purchased Entity who is either (a)Â set forth on Section 3.20(a)(i) of the Seller Disclosure Schedules, each of whom primarily dedicates his or her working time to the Business or (b) set forth on Section 3.20(a)(ii) of the Seller Disclosure Schedules, either of which schedule in clausesÂ (a) and (b) may be updated by Seller from time to time prior to the Closing with the prior written approval of the Purchasers if such approval is otherwise required under SectionÂ 5.2(b), and in each case, may include, for the avoidance of doubt, an individual who is not actively working as of the Closing as a result of an illness, injury or leave of absence approved by the applicable human resources department or otherwise taken in accordance with applicable Law (including long-term disability).â€œBusiness Material Adverse Effectâ€ means any event, change, state of facts, occurrence, circumstance, development or effect that has had or would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of theâ€‹-2-Business taken as a whole; provided, however, that no such event, change, state of facts, occurrence, circumstance, development or effect resulting or arising from or in connection with any of the following matters shall be deemed, either alone or in combination, to constitute or contribute to, or be taken into account in determining whether there has been, a Business Material Adverse Effect: (a)Â general conditions or trends in the industries in which the Business operates; (b)Â general political, economic, business, monetary, financial or capital or credit market conditions (including interest rates, exchange rates, tariffs, trade wars and credit markets), including with respect to government spending, budgets and related matters; (c)Â any (i)Â geopolitical conditions, military conflict or actions, outbreak of hostilities, acts of war (whether or not declared), acts of foreign or domestic terrorism, rebellion or insurrection, acts of espionage or (ii) acts of cyberterrorism or any escalation or general worsening of any of the foregoing specified in clausesÂ (i) and (ii), or any action taken by any Governmental Entity in response to any of the foregoing specified in clauses (i) and (ii); (d) earthquakes, hurricanes, tsunamis, typhoons, lightning, hail storms, blizzards,

tornadoes, droughts, floods, cyclones, arctic frosts, mudslides, wildfires, epidemics, pandemics (including any escalation, general worsening, easing, or other change in the state of Covid-19), disease outbreaks or acts of God, or any other conditions resulting from natural or manmade disasters or weather developments; (e)Â the failure of the financial or operating performance of the Seller Group, the Purchased Entities or the Business to meet internal or external (including Purchasers or analyst) projections, forecasts or budgets for any period (provided that this clause (e) shall not be construed as implying that Seller is making any representation or warranty herein with respect to any such projections, forecasts or budgets and no such representations or warranties are being made; provided, further, that the exception in this clause (e) shall not prevent or otherwise affect a determination that any underlying change that is the cause of such failure has resulted in a Business Material Adverse Effect); (f) any matter set forth on Section 1.1(c) of the Seller Disclosure Schedules; (g) any action taken or omitted to be taken by Seller or its Subsidiaries solely to the extent such action or omission was at Purchasersâ€™ express written request in accordance with and subject to the terms of this Agreement; (h) compliance with the covenants and other express terms of this Agreement (including the impact on or any loss of Business Employees, customers, suppliers, relationships with Governmental Entities or other business relationships resulting from any of the foregoing); (i)Â the execution, announcement, pendency or consummation of this Agreement, the Transaction or the other transactions contemplated hereby solely as a result of the identity of either Purchaser or their Affiliates (including the impact on or any loss of customers, suppliers, relationships with Governmental Entities or other business relationships resulting from any of the foregoing) (provided that this clause (i) shall not apply with respect to the representations and warranties in SectionÂ 3.4 or SectionÂ 3.5 or any condition to any Partyâ€™s obligation to consummate the Transaction relating to such representations and warranties); (j) changes in any Law (including any proposed Law) or GAAP or other applicable accounting principles or standard or any interpretations of any of the foregoing, in each case, following the date hereof; or (k) any Excluded Assets or Retained Liabilities; provided that any adverse events, changes, state of facts, occurrences, circumstances, developments or effects resulting from the matters described in clauses (a), (b), (c) and (d) may be taken into account in determining whether there has been a Business Material Adverse Effect to the extent, and only to the extent, that they have a materially disproportionate adverse effect on the Purchased Entities and the Business, taken as a whole, relative to businesses that operate in the industries or geographic areas in which the Businessâ€‹-3-operates (in which case only such incremental materially disproportionate adverse effect may be taken into account in determining whether there has been a Business Material Adverse Effect).â€œBusiness Productsâ€ means, collectively or individually, the products (including all raw materials and ingredients) that are or were manufactured, distributed or sold by Seller or its Subsidiaries (including the Purchased Entities) set forth on SectionÂ 1.1(d) of the Seller Disclosure Schedules.â€œBusiness Technology Deliverablesâ€ means Technology that (a) are exclusively related to, exclusively used in or exclusively held for use in the Business, (b) are located at the Transferred Real Property and used in, and necessary for, the operation of the Business as of the Closing, or (c) constitute the know-how of the Business Employees to the extent related to the Business; provided that Business Technology Deliverables does not include Information Technology and any books and records.â€œCashâ€ means an amount equal to the sum of, without duplication, (a) all cash and cash equivalents, bank and other depositary accounts and safe deposit boxes, demand accounts, certificates of deposit, time deposits, marketable securities, short-term deposits, securities and brokerage accounts (including, in each case, any accrued interest thereon), in each case of the Purchased Entities, plus (b) deposits in transfer, wires, drafts and checks in transit issued to or received by the Purchased Entities but not yet posted (net of outstanding but uncleared wires, drafts and checks written or issued by the Purchased Entities), in each case, such amounts calculated in a manner consistent with the Transaction Accounting Principles.â€œChinese Purchased Entityâ€ means Zoetis Suzhou Manufacturing Co., Ltd.â€œClosing Cashâ€ means the Cash of the Purchased Entities as of the Closing; provided, that â€œClosing Cash â€ shall not include any Cash held by the Chinese Purchased Entity as of the Closing in excess of the Chinese Operating Cash Amount (such excess amount, the â€œExcess Restricted Cashâ€).â€œClosing Gross Profitâ€ means the Gross Profit of the Business for the fiscal year ended December 31, 2023, derived from the Audited Financial Statements for the fiscal year ended December 31, 2023, delivered by Seller pursuant to SectionÂ 5.19(a).â€œClosing Indebtednessâ€ means the Indebtedness of the Purchased Entities as of the Closing.â€œClosing Purchase Priceâ€ means (a)Â the Base Purchase Price, plus (b)Â the Estimated Closing Cash, plus (c) the Estimated WC Adjustment Amount (which may be a positive or negative number, or zero), minus (d) the Estimated Closing Indebtedness, plus (e) the Estimated Gross Profit Adjustment Amount (which may be a negative number or zero, but not a positive number).â€œClosing Working Capitalâ€ means the Working Capital of the Business as of the Closing.â€œCodeâ€ means the U.S. Internal Revenue Code of 1986, as amended.â€‹-4-â€œCollective Bargaining Agreementâ€ means any collective bargaining agreement or other Contract with any labor organization, union, or associations, works council or other agency or employee representative body.â€œCombined Tax Returnâ€ means any combined, consolidated, affiliated or unitary Tax Return that includes any member of the Seller Group, on the one hand, and any of the Purchased Entities, on the other hand.â€œCompleted Phase I Reportsâ€ means Phase I Environmental Site Assessments satisfying the All Appropriate Inquiry standard as defined in 40 C.F.R. Â§ 312.20 for the following properties: (a) 601 Beam Street, Salisbury, Maryland; (b) 1020 Northwest 10th Street, Eagle Grove, Iowa; and (c) 400 State Street, Chicago Heights, Illinois.â€œContaminationâ€ means the emission, discharge or release of any Hazardous Material to, on, onto or into the environment.â€œContractâ€ means any written or oral legally binding contract, agreement, sales order, purchase order, tender, lease, license, commitment, loan or credit agreement, indenture or agreement, or any other legally binding contractual obligation, commitment or understanding, other than any Seller Benefit Plan, any Collective Bargaining Agreement or any Permit.â€œCovered Lossesâ€ means losses, Liabilities, claims, fines, deficiencies, damages, payments (including those arising out of any settlement or Judgment relating to any Proceeding), Taxes, penalties and reasonable attorneysâ€™ and accountantsâ€™ fees and disbursements, in each case that are due and payable; provided that Covered Losses shall not include any consequential, special or punitive damages except (a) to the extent actually awarded against an Indemnified Party in connection with a Third-Party Claim or (b) solely in respect of consequential or special damages, to the extent reasonably foreseeable.â€œCovid-19â€ means SARS-CoV-2 or Covid-19, and any evolutions thereof or related or associated epidemics, pandemics or disease outbreaks.â€œData Protection Lawsâ€ means in each case to the extent relating to the protection, use, transmission, or processing of Personal Data, data privacy or cybersecurity in any relevant jurisdiction: (a) all applicable Laws; and (b) Contracts to which the Purchased Entities (or with respect to the Business, Seller and its Subsidiaries) have entered into or are otherwise bound.â€œEnvironmental Lawsâ€ means, collectively, any and all Laws and Judgments relating to Contamination, Hazardous Materials, public or worker health or safety, pollution or protection of the environment.â€œERISAâ€ means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.â€œERISA Affiliateâ€ means, with respect to any entity, trade or business, any other entity, trade or business that is, or was at any relevant time, a member of a group described in SectionÂ 414(b), (c), (m) or (o) of the Code or SectionÂ 4001(b)(1) of ERISA that includes or included the first entity, trade or business, or that is, or at any relevant time, a member of theâ€‹-5-same â€œcontrolled groupâ€ as the first entity, trade or business pursuant to SectionÂ 4001(a)(14) of ERISA.â€œExcluded Informationâ€ means any (a) description of all or any portion of the Financing, including any â€œdescription of notesâ€, â€œplan of distributionâ€ and information customarily provided by investment banks or their counsel or advisors in the preparation of an offering memorandum for private placements of non-convertible bonds pursuant to Rule 144A under the Securities Act, (b) risk factors relating to, or any description of, all or any component of the financing contemplated thereby, (c) historical financial statements or other information required by RuleÂ 3-05, Rule 3-09, Rule 3-10, Rule 3-16, Rule 13-01 or Rule 13-02 of Regulation S-X under the Securities Act; any compensation discussion and analysis or other information required by Item 10, Item 402 and Item 601 of Regulation S-K under the Securities Act or XBRL exhibits; or any information regarding executive compensation or related persons related to SEC Release Nos. 33-8732A, 34-54302A and IC-27444A, (d) other information customarily excluded from an offering memorandum for private placements of non-convertible high-yield bonds pursuant to Rule 144A under the Securities Act in a â€œRule 144A-for-lifeâ€ offering, (e)Â financial statements or other financial data (including selected financial data) for any period earlier than the year ended December 31, 2022, (f)Â financial information that Seller or its Subsidiaries do not maintain in the ordinary course of business, (g) information not reasonably available to Seller or its Subsidiaries under their respective current reporting systems, or (h) (x)Â footnote disclosures or (y)Â pro forma financial information or pro forma financial statements (other than, in the case of clauses (c), (f), (g) and (h)(x), to the extent specifically enumerated in and required by Section 5.19).â€œExcluded Taxesâ€ means any Taxes (a) imposed with respect to the Excluded Assets, the Retained Liabilities or any Combined Tax Return or (b) imposed on or payable by any member of the Seller Group (other than any Transfer Taxes).â€œEx-Im Lawsâ€ means all U.S. and non-U.S. Laws relating to export, reexport, transfer, and import controls, including the Export Administration Regulations, the customs and import Laws administered by U.S. Customs and Border Protection, and the EU Dual Use Regulation.â€œFDAâ€ means the United States Food and Drug Administration.â€œFDA Lawsâ€ means all Laws applicable to the operation of the Business related to the research, investigation, development, production, marketing, distribution, storage, shipping, transport, advertising, labeling, promotion, sale, export, import, use handling and control, safety, efficacy, reliability or manufacturing of animal drugs and medicated feeds including, without limitation the FDCA and the rules and regulations promulgated and enforced by FDA thereunder and all comparable state, federal or foreign Laws relating to any of the foregoing.â€œFDCAâ€ means the U.S. Federal Food, Drug, and Cosmetic Act.â€œFilingsâ€ means any registrations, applications, declarations, reports, submissions or other filings with, or any notices to, any Person (including any third party or Governmental Entity).â€‹-6-â€œFinancing Informationâ€ means the Business Financial Information; provided, that notwithstanding anything to the contrary in this definition or otherwise, nothing herein shall require Seller or its Subsidiaries to provide (or be deemed to require Seller or its Subsidiaries to prepare) any reviewed or audited financial statements or other financial information other than as expressly set forth in SectionÂ 3.7(a) or SectionÂ 5.19, nor any Excluded Information whatsoever. If Seller shall in good faith believe that the Financing Information has been delivered to the Purchasers, Seller may deliver to the Purchasers a written notice to that effect (stating when it believes the delivery of the Financing Information to the Purchasers was completed), in which case Seller shall be deemed to have complied with such obligation to furnish the Financing Information and the Purchasers shall be deemed to have received the Financing Information, unless the Purchasers in good faith reasonably believes that Seller has not completed delivery of the Financing Information and not later than 5:00 p.m. (New York City time) two (2) Business Days after the delivery of such notice by Seller, delivers a written notice to Seller to that effect (stating with specificity which such Financing Information Seller has not delivered); provided, that notwithstanding the foregoing, the delivery of the Financing Information shall be satisfied at any time which (and so long as) the Purchasers shall have actually received the Financing Information, regardless of whether or when any such notice is delivered by Seller. Sellerâ€™s or its Subsidiariesâ€™ filing with the SEC pursuant to the Securities Act, the Exchange Act and the rules and regulations of the SEC promulgated thereunder of any required audited financial statements with respect to it that is publicly available on Form 10-K or required unaudited financial statements with respect to it that is publicly available on Form 10-Q, in each case, will satisfy the requirements of this definition.â€œFinancing Partiesâ€ means each debt provider (including each agent and arranger) that commits to provide a Purchaser or any of its Subsidiaries Financing pursuant to the Commitment Letter (the â€œFinancing Entitiesâ€), and their respective Representatives; provided, that neither Purchaser nor any Affiliate thereof shall be a Financing Party.â€œFormer Employeeâ€ means any individual whose employment with the Seller Group or a Purchased Entity (to the extent such individual employed by a Purchased Entity was not primarily dedicated to the Business) is terminated prior to the Closing.â€œGAAPâ€ means U.S. generally accepted accounting principles, as in effect from time to time.â€œGovernmental Entityâ€ means any national, state, provincial, local, regional, supranational or foreign government or any court of competent jurisdiction, administrative agency or commission or other national, state, provincial, local, supranational or foreign governmental authority or instrumentality, or any arbitral body (public or private), or any other entity or body with administrative, executive, judicial, regulatory, taxing or similar authority of any nature.â€œGross Profitâ€ means an amount equal to (a) revenue of the Business minus (b) cost of sales of the Business, calculated in a manner consistent with the illustrative example set forth in the Sample Closing Statement.â€‹-7-â€œGross Profit Adjustment Amountâ€ means (a) the Closing Gross Profit minus (b) the Target Gross Profit; provided that the Gross Profit Adjustment Amount shall be deemed zero if the Closing Gross Profit is greater than or equal to $109,678,500 (the â€œLower Boundâ€); provided, further, that if the Closing Gross Profit is less than the Lower Bound, the Gross Profit Adjustment Amount shall equal (i) the incremental amount by which the Closing Gross Profit is less than the Lower Bound, (ii) multiplied by two (2). For illustrative purposes, if the Closing Gross Profit is equal to: (y) $115,000,000 or $109,678,500, the Gross Profit Adjustment Amount shall be zero; and (z) $108,000,000, the Gross Profit Adjustment Amount shall be -$3,357,000.â€œHazardous Materialâ€ means any substance, pollutant, contaminant, material or waste for which Liability or standards of conduct may be imposed under Environmental Law or that is otherwise classified in any applicable Environmental Law as â€œhazardous,â€ â€œtoxic,â€ â€œdangerous,â€ a â€œpollutant,â€ a â€œcontaminantâ€ or words of similar meaning, including asbestos, asbestos-containing materials, polychlorinated biphenyls, petroleum or petroleum products, radioactive materials, per- or polyfluoroalkyl substances, lead, mold, noise, odor and radon gas.â€œHSR Actâ€ means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations thereunder.â€œIncome Taxâ€ means any Tax imposed on or measured by reference (in whole or in part) to gross or net income, profits, or capital gains (however denominated).â€œIndebtednessâ€ means, as of any time, an amount equal to the sum of, without duplication, the following obligations of a Person, in each case calculated in a manner consistent with the Transaction Accounting Principles: (a) the outstanding indebtedness for borrowed money (other than trade payables arising in the ordinary course of business); (b) all obligations evidenced by bonds (other than letters of credit, surety bonds or bank guarantees), debentures or notes; (c) all outstanding obligations in respect of letters of credit, surety bonds or bank guarantees, in each case solely to the extent funds have been drawn and are payable thereunder; (d) all guarantees by such Person of indebtedness of other Persons for borrowed money or evidenced by bonds, debentures, notes or similar instruments, in each case solely to the extent such guarantees are actually called upon and funds are payable thereunder; (e) the Separate Company Accrued Tax Amount; (f) [reserved]; (g) leases recorded as capital or finance leases under GAAP or recorded as such in the Business Financial Information (other than lease obligations classified as operating leases in the Business Financial Information); and (h) with respect to the foregoing clausesÂ (a) through (c), all accrued but unpaid interest thereon and any termination fees, prepayment penalties, â€œbreakageâ€ cost or reimbursements payments associated with the repayments of such Indebtedness, in each case, solely to the extent due and payable on the Closing or as a result of the Transaction; provided, however, that in no event shall Indebtedness include (i) any Retained Liabilities, (ii) any Indebtedness to the extent owing from any of the Purchased Entities to any of the other Purchased Entities to the extent reconciled or eliminated in the consolidated financial statements of the Business at or prior to Closing or (iii) any Liabilities to the extent repaid or extinguished in connection with the Closing (including any Liabilities in respect of intercompany balances or accounts to be settled pursuant to SectionÂ 5.6).â€œInformation Technologyâ€ means any computer systems (including computers, screens, servers, workstations, routers, hubs, switches, networks, data communications lines andâ€‹-8-hardware), all software, data and databases embedded therein, and all peripheral equipment, and telecommunications systems, in each case, that are used by or for, or otherwise owned by the Seller Group or a Purchased Entity as of the Closing.â€œIntellectual Property Rightsâ€ means any and all intellectual property, common law or statutory rights anywhere in the world arising under or associated with the following, whether registered or unregistered: (a) patents, patent applications, statutory invention registrations, registered designs, utility models, and similar or equivalent rights in inventions and designs and extensions, divisionals, continuations, continuations-in-part, reexaminations, and reissues thereof (â€œPatentsâ€), (b)Â trademarks, service marks, trade dress, trade names, slogans, logos, corporate names and other designations of origin (including all goodwill associated with the foregoing) (â€œMarksâ€), (c) rights in domain names and uniform resource locators, social media identifiers and accounts, and other names and locators associated with Internet addresses and sites, (d)Â copyrights, copyright registrations and applications, and any other equivalent rights in works of authorship (including rights in software as a work of authorship) and any other related rights of authors (â€œCopyrightsâ€), (e) trade secrets, industrial secret rights and rights in know-how, or confidential information (including in formulas, inventions, protocols, processes, methods, techniques, research and development information), in each case, that derive independent economic value from not being generally known (â€œTrade Secretsâ€), (f) other similar or equivalent intellectual property rights, and (g) applications and registrations of any of the foregoing clausesÂ (a) through (f).â€œInternational Business Employeeâ€ means each Business Employee who provides services primarily outside the United States.â€œItalian Purchased Entityâ€ means Zoetis Medolla Manufacturing S.r.l., an Italian societÃ a responsabilitÃ limitata.â€œItalian VAT Receivableâ€ means the value added tax receivable reflected on the books and records of the Italian Purchased Entity as of the date hereof.â€œJudgmentâ€ means any judgment, injunction, writ, order, ruling, directive or decree of any Governmental Entity.â€œKnowledgeâ€ means, with respect to Seller, the actual knowledge of any Person listed in SectionÂ 1.1(e) of the Seller Disclosure Schedules, and, with respect to the Purchasers, the actual knowledge of any Person listed in SectionÂ 1.1(a) of the Purchaser Disclosure Schedules.â€œLawâ€ means FDA Laws and any national, state, provincial, local, supranational or foreign law, statute, code, act, common law, Judgment, ordinance, rule, regulation or treaty (including any Tax treaty) or other requirements of any kind, in each case enacted, issued, enforced, entered or promulgated by a Governmental Entity.â€œLiabilitiesâ€

means all debts, liabilities, guarantees, assurances, commitments and obligations of any kind, whether fixed, contingent or absolute, asserted or unasserted, matured or unmatured, liquidated or unliquidated, accrued or not accrued, known or unknown, due or to become due, whenever or however arising (including whether arising out of any Contract or tort based on negligence or strict liability).â€‹-9-â€œLienâ€ means any mortgage, lien, pledge, right of first offer or first refusal, security interest, charge, easement, or similar encumbrance of any kind.â€œMultiemployer Planâ€ means any â€œmultiemployer planâ€ within the meaning of SectionÂ 4001(a)(3) of ERISA for the benefit of U.S. Business Employees.â€œNon-Commercialized Business Productâ€ means collectively or individually the antibiotic and coccidiostat medicated feed products in the U.S. or any foreign jurisdiction (including water soluble and solid feed additives) that (i) are owned by Seller or its Subsidiaries (including the Purchased Entities) and (ii) were maintained, manufactured, distributed or sold by Seller or its Subsidiaries (including the Purchased Entities) prior to the Closing.â€œPermitsâ€ means permits, approvals, authorizations, consents, licenses, registrations, filings or certificates issued or granted by any Governmental Entity.â€œPermitted Liensâ€ means the following Liens: (a) Liens for Taxes, assessments or other governmental charges or levies that are not yet due or payable or that are being contested by appropriate Proceedings for which an adequate reserve has been established and reflected in the Business Financial Information; (b) statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, materialmen, workmen, repairmen and other Liens imposed by Law in the ordinary course of business; (c)Â Liens incurred or deposits made in the ordinary course of business in connection with workersâ€™ compensation, unemployment insurance or other types of social security; (d) Liens incurred in the ordinary course of business securing Liabilities that do not materially impair the use of or materially detract from the value of a Purchased Asset; (e)Â with respect to real property, (i) defects or imperfections of title, (ii) easements, declarations, covenants, rights-of-way, restrictions and other charges, instruments or encumbrances of record affecting title, (iii) zoning ordinances, variances, conditional use permits and similar regulations, permits, approvals and conditions regulating the use or occupancy of such real property or the activities conducted thereon which are imposed by any Governmental Entity having jurisdiction over such real property or (iv) Liens not created by Seller or any of its Subsidiaries that affect the underlying fee interest of any leased real property, including master leases or ground leases; provided, however, that with respect to this clauseÂ (e), any such item does not materially interfere with the ordinary conduct of the Business or materially impair the continued use and operation of such real property for the purpose for which it is used as of immediately prior to the Closing; (f) Liens set forth on Section 1.1(f) the Seller Disclosure Schedules; (g) with respect to any securities of any Person, any Liens created under securities Laws or expressly set forth in the governing documents of such Person; (h) Liens in the Purchasersâ€™ favor deemed to be created by any of the Transaction Documents; or (i)Â non-exclusive licenses of Transferred Intellectual Property granted in the ordinary course of business.â€œPersonâ€ means any individual, firm, corporation, partnership, limited liability company, trust, Governmental Entity or other entity.â€œPersonal Dataâ€ means any information about an identifiable natural person that alone or in combination with other information identifies, or could be used to identify, directly or indirectly, a natural person or household, and includes information that is defined as â€œpersonal data,â€ â€œpersonally identifiable information,â€ â€œindividually identifiable health information,â€â€‹-10-â€œprotected health informationâ€ or â€œpersonal informationâ€ or a similar term under any applicable Law.â€œPre-Closing Tax Periodâ€ means any taxable period ending on or before the Closing Date and the portion through the end of the Closing Date for any Straddle Period.â€œProceedingâ€ means any judicial, administrative or arbitral action, suit, litigation, charge, complaint, audit, inquiry, demand, investigation, claim, petition, or proceeding by or before any Governmental Entity or other body of competent jurisdiction.â€œPurchased Entity Benefit Planâ€ means each Seller Benefit Plan that is (a) solely sponsored or maintained by a Purchased Entity, (b) maintained or contributed to by Seller or any of its Subsidiaries solely for the benefit of the Business Employees or (c)Â identified as a Purchased Entity Benefit Plan on Section 3.19(a) of the Seller Disclosure Schedules.â€œPurchaser Disclosure Schedulesâ€ means those certain Purchaser Disclosure Schedules, dated as of the date of this Agreement, provided by the Purchasers to Seller.â€œPurchaser Material Adverse Effectâ€ means any event, change or effect that, individually or in the aggregate, materially impairs, hinders or delays the ability of the Purchasers and their respective Subsidiaries to perform their respective obligations under this Agreement and the other Transaction Documents or to consummate the transactions contemplated hereby and thereby.â€œRegistered IPâ€ means all U.S., international or foreign (a) issued Patents and Patent applications, (b) registered Marks and applications to register Marks, (c) registered Copyrights and applications for Copyright registration and (d) registrations for domain names.â€œRegulatory Approvalsâ€ means all approvals, rulings, consents, exemptions, clearances, written confirmations of no intention to initiate a Proceeding and waiting period terminations or expirations from Governmental Entities that are required under applicable Law (including pursuant to any Regulatory Law or FDA Law) (i) to permit the consummation of the Transaction and the other transactions contemplated by this Agreement or (ii) for the Purchasers to manufacture, sell or distribute the Business Products.â€œRegulatory Lawsâ€ means statutes, rules, regulations, orders, decrees, administrative and judicial doctrines and other Laws of any jurisdiction that are designed or intended to (a) prohibit, restrict or regulate actions that may have the purpose or effect of creating a monopoly, lessening competition or restraining trade, or (b) prohibit, restrict or regulate foreign investments.â€œRepresentativesâ€ of a Person means such Personâ€™s Affiliates and any officer, director or employee of such Person or its Affiliates or any investment banker, attorney, accountant or other advisor or representative of such Person or its Affiliates.â€œRetained Claimâ€ means any claim, cause of action, defense, right of offset or counterclaim, or settlement agreement (in any manner arising or existing, whether choate or inchoate, known or unknown, contingent or non-contingent) (a) to the extent related to theâ€‹-11-Excluded Assets, the Retained Liabilities or the Retained Business or (b) set forth on SectionÂ 1.1(g) of the Seller Disclosure Schedules.â€œSale Processâ€ means all matters relating to the sale or separation of the Business and the review of strategic alternatives with respect to the Business and all activities in connection therewith, including matters relating to (a)Â the solicitation of proposals from and negotiations with third parties in connection with the sale of the Business or (b)Â the drafting, negotiation or interpretation of any of the provisions of this Agreement or the other Transaction Documents, or the determination of the allocation of any assets or Liabilities pursuant to the foregoing agreements or the transactions contemplated thereby.â€œSanctioned Countryâ€ means any country or region or government thereof that is, or has been in the last five years, the subject or target of a comprehensive embargo under Trade Controls (including Cuba, Iran, North Korea, Syria, Venezuela, the Crimea region of Ukraine, the so-called â€œDonetsk Peopleâ€™s Republic,â€ and the so-called â€œLuhansk Peopleâ€™s Republicâ€).â€œSanctioned Personâ€ means any Person that is the subject or target of sanctions or restrictions under Trade Controls including: (i) any Person listed on any U.S. or non-U.S. sanctions- or export-related restricted party list, including the U.S. Department of the Treasury Office of Foreign Assets Controlâ€™s (â€œOFACâ€) List of Specially Designated Nationals and Blocked Persons, or any other OFAC, U.S. Department of Commerce Bureau of Industry and Security, or U.S. Department of State sanctions- or export-related restricted party list; (ii)Â any Person located, organized, or resident in a Sanctioned Country; or (iii) any Person that is, in the aggregate, 50 percent or greater owned, directly or indirectly, or otherwise controlled by a Person or Persons described in clausesÂ (i)-(ii).â€œSanctionsâ€ means all U.S. and non-U.S. Laws relating to economic or trade sanctions, including the Laws administered or enforced by the United States (including by OFAC or the U.S. Department of State) and the United Nations Security Council.â€œSECâ€ means the U.S. Securities and Exchange Commission.â€œSecurities Actâ€ means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.â€œSeller Benefit Planâ€ means any employee benefit plan (within the meaning of SectionÂ 3(3) of ERISA, whether or not subject to ERISA) and any bonus, stock option, stock purchase, restricted stock, incentive, deferred compensation, retiree health or life insurance, retirement, pension, superannuation, gratuity, jubilee, provident fund, employment, severance, retention, termination, change in control, welfare, post-employment, profit-sharing, disability, health, vacation, sick leave benefits, fringe benefits or other benefit plan, program, agreement or arrangement, that is sponsored, maintained, contributed to or required to be maintained or contributed to by Seller or any of its Subsidiaries (but excluding any such plan, program or arrangement mandated by or maintained solely pursuant to applicable Law or any Multiemployer Plan solely for purposes of SectionÂ 3.19), in each case, providing benefits to any Business Employee.â€‹-12-â€œSeller Disclosure Schedulesâ€ means those certain Seller Disclosure Schedules dated as of the date of this Agreement, provided by Seller to the Purchasers.â€œSeller Employeeâ€ means each employee of the Purchased Entities who does not meet the definition of a Business Employee.â€œSeller Entitiesâ€ means Seller and all of its Subsidiaries that transfer Purchased Assets (including Purchased Entity Shares) or Assumed Liabilities to the Purchasers or any of their respective Subsidiaries pursuant to this Agreement.â€œSeller Fundamental Representationsâ€ means the representations and warranties made by Seller contained in SectionÂ 3.1(a) (Organization and Standing), SectionÂ 3.2 (Purchased Entities; Capital Structure), SectionÂ 3.3 (Authority; Enforceability), and SectionÂ 3.24 (Brokers).â€œSeller Groupâ€ means Seller and its Subsidiaries (other than the Purchased Entities).â€œSeparate Company Accrued Tax Amountâ€ means an amount (which shall not be less than zero) equal to the aggregate unpaid Income Taxes of the Purchased Entities (and any unpaid Taxes required to be withheld from payments made or deemed made or transactions between a Purchased Entity and Seller or any of its Subsidiaries (including pursuant to Section 5.6)) for any Pre-Closing Tax Period for which the applicable annual Tax Return first becomes due after the date hereof, which amount shall (a)Â not include any Income Taxes with respect to a Combined Tax Return for which the Purchased Entities are liable solely as a result of being a member of the applicable group filing such Combined Tax Return, (b) not be expressed as a negative number in the aggregate or be computed by reference to a negative number in respect of any Tax Return, (c) exclude any deferred Tax liabilities or deferred Tax assets and any accruals for contingent Tax liabilities (in each case, taken into account for financial accounting purposes), (d) be computed in accordance with the past practices of the Purchased Entities except to the extent prohibited by applicable Law, (e) take into account any estimated Income Tax payments and overpayments of Income Taxes with respect to any Pre-Closing Tax Period as reductions in the amount of unpaid Income Taxes, but only to the extent that such payments have the effect of reducing (not below zero) the particular unpaid Income Taxes in respect of which such payments were made, (f) exclude any Income Taxes attributable to any transaction entered into by the Purchasers or any of their Affiliates (including, after the Closing, the Purchased Entities) after the Closing (limited, in the case of actions taken on the Closing Date after the Closing, to actions taken outside the ordinary course of business), (g) in the case of any Straddle Period, be determined in accordance with SectionÂ 7.7 and (h) treat as taxable income in a Pre-Closing Tax Period any taxable income shifted from a Pre-Closing Tax Period to a taxable period (or portion thereof) that begins after the Closing Date by reason of any change in method of accounting made or adopted after December 31, 2023 and prior to the Closing.â€œShared Contractâ€ means any Contract pursuant to which Seller or its Subsidiaries is bound to sell any Business Products in combination with one or more products which itself is not a Business Product.â€œStraddle Periodâ€ means any Tax period that begins on or before the Closing Date and ends after the Closing Date.â€‹-13-â€œSubsidiaryâ€ means, with respect to any Person, any corporation, partnership, limited liability company or other entity, whether incorporated or unincorporated, of which such first Person directly or indirectly owns or controls at least a majority of the securities or other interests having by their terms ordinary voting power to elect a majority of the board of directors or others performing similar functions; provided that, from and after the Closing, no Purchased Entity shall be deemed to be a Subsidiary of any Seller Entity.â€œTangible Personal Propertyâ€ means machinery, office equipment, operating supplies, equipment, hardware, furniture, fixtures, tools and all other tangible personal property, it being understood that Tangible Personal Property shall not include any Intellectual Property Rights.â€œTarget Gross Profitâ€ means $121,865,000.â€œTarget Working Capitalâ€ means $198,625,000.â€œTaxâ€ means any U.S. federal, state, local or non-U.S. tax or similar charge imposed by any Taxing Authority, including any income, gross receipts, property, sales, use, capital stock, social security, value added, goods and services, profits, license, withholding, payroll, employment, excise, premium, property, capital gains, transfer, stamp, environmental, customs, duties, alternative or add-on minimum, estimated, capital, capital gains, franchise and occupation tax, together with any interest and penalties imposed by any Taxing Authority with respect to such amounts.â€œTax Proceedingâ€ means any audit, examination, contest, litigation or other Proceeding with or against any Taxing Authority.â€œTax Returnâ€ means any return, declaration, report, claim for refund or information return or statement required to be filed with any Taxing Authority with respect to Taxes, including any amendment thereof.â€œTaxing Authorityâ€ means any Governmental Entity responsible for the administration or the imposition of any Tax.â€œTechnologyâ€ means embodiments of Intellectual Property Rights, including in the form of documentation, materials, product specifications, hardware, prototypes, data, databases and software; provided that Technology does not include any Intellectual Property Rights in such Technology.â€œTerritoryâ€ means the countries set forth on SectionÂ 1.1(h) of the Seller Disclosure Schedules.â€œTransaction Documentsâ€ means this Agreement and the Ancillary Agreements.â€œTransfer Taxesâ€ means any federal, state, local, non-U.S. and other transfer (including real property transfer), registration, documentary, stamp, stamp duty, land, recording, conveyance or similar Taxes (but, for the avoidance of doubt, excluding any Income Taxes and Taxes imposed directly or indirectly on gain and withholding Taxes in respect of the foregoing) imposed on the sale and transfer, or recording of transfer, of the Purchased Assets (including, forâ€‹-14-the avoidance of doubt, the Purchased Entity Shares) and the assumption of the Assumed Liabilities contemplated by this Agreement; provided that â€œTransfer Taxesâ€ shall not include any VAT/GST.â€œU.S. Business Employeeâ€ means each Business Employee who provides services primarily inside the United States.â€œU.S. Purchased Entity Benefit Planâ€ means each Purchased Entity Benefit Plan in which U.S. Business Employees are eligible to participate or receive benefits.â€œVAT/GSTâ€ means any (i) Tax imposed in accordance with Directive 2006/112/EC and any permitted derogations therefrom, as well as any equivalent or similar Tax imposed under the laws of any jurisdiction that is not a member state of the European Union, or any goods and services or similar Taxes, and (ii) any sales or use Tax imposed by a state or local Taxing Authority in the United States, in each case, imposed on the sale and transfer, or recording of transfer, of the Purchased Assets and the assumption of the Assumed Liabilities. For the avoidance of doubt, VAT/GST shall exclude any Income Taxes and Taxes imposed directly or indirectly on gain and withholding Taxes in respect of the foregoing.â€œWARN Actâ€ means the Worker Adjustment and Retraining Notification Act of 1988, as amended, or any similar Laws.â€œWC Adjustment Amountâ€ means (a) the Closing Working Capital minus (b)Â the Target Working Capital.â€œWorking Capitalâ€ means, as of any time, (a) the current assets of the Business that are included in the specific line items of current assets specifically identified in the Sample Closing Statement reduced by (b)Â the current liabilities of the Business that are included in the specific line items of current liabilities specifically identified in the Sample Closing Statement, in each case, without duplication and without giving effect to the Transaction, and calculated in accordance with the Transaction Accounting Principles; provided, however, that in no event shall Working Capital include (i) any amount included within the definition of Cash or Indebtedness, (ii) any Excluded Assets or Retained Liabilities, (iii) any Liabilities to be repaid or extinguished pursuant to this Agreement in connection with the Closing (including any Liabilities in respect of intercompany balances or accounts to be settled pursuant to SectionÂ 5.6) or (iv) any amounts with respect to Income Tax assets or Income Tax Liabilities or deferred Tax assets or deferred Tax liabilities.SectionÂ 1.2Other Defined Terms. In addition, the following terms shall have the meanings ascribed to them in the corresponding section of this Agreement:TermÂ Â Â Â SectionAdditional Business Product Marksâ€‹-5.25Agreementâ€‹-PreambleAllocationâ€‹-2.10(c)Allocation Scheduleâ€‹-2.10(a)Alternative Financingâ€‹-5.7(c)â€‹-15-Anti-Corruption Lawsâ€‹-3.16(b)Approval Productsâ€‹-5.10(c)(i)Assignment Agreement and Bill of Saleâ€‹-2.8(a)(vi)Assumed Liabilitiesâ€‹-2.6Audited Financial Statementsâ€‹-5.19(a)Balance Sheet Dateâ€‹-3.7(d)Base Purchase Priceâ€‹-2.2Business Contingent Worker Contractsâ€‹-6.10Business Financial Informationâ€‹-3.7(a)Business Registered IPâ€‹-3.10(a)Cash Incentive Compensationâ€‹-6.6Chinese Operating Cash Amountâ€‹-5.23Closingâ€‹-2.3Closing Dateâ€‹-2.3Closing Statementâ€‹-2.9(b)Commitment Letterâ€‹-4.6(a)Comparability Periodâ€‹-6.2(a)Competing Businessâ€‹-5.16(c)Confidential Business Informationâ€‹-5.3(b)Confidential Retained Business Informationâ€‹-5.3(c)Confidentiality Agreementâ€‹-5.3(a)Copyrightsâ€‹-See definition of Intellectual Property Rights, 1.1Covered Intellectual Propertyâ€‹-5.28Current Representationâ€‹-11.14(a)Deferred Closingâ€‹-2.11(a)Deferred Closing Dateâ€‹-2.11(a)Deferred Marketing Authorizationâ€‹-2.11(a)Deferred Marketing Authorization Liabilityâ€‹-2.11(a)Definitive Agreementsâ€‹-5.7(a)Designated Personâ€‹-11.14(a)Dispute Noticeâ€‹-2.9(e)Dispute Resolution Periodâ€‹-2.9(e)Distributed Excess Restricted Cashâ€‹-5.23Distributed Excess Restricted Cash Transferâ€‹-5.23Distribution Agreementâ€‹-2.8(a)(iv)Estimated Closing Cashâ€‹-2.9(b)Estimated Closing Indebtednessâ€‹-2.9(b)Estimated Gross Profit Adjustment Amountâ€‹-2.9(b)Estimated WC Adjustment Amountâ€‹-2.9(b)Excess Restricted Cashâ€‹-See definition of Closing Cash, 1.1Excess Restricted Cash Distributionâ€‹-5.23Exchange Actâ€‹-3.5Excluded Assetsâ€‹-2.5Expired Marksâ€‹-5.26Fair Valueâ€‹-4.9Final Purchase Priceâ€‹-2.9(g)â€‹-16-Financial Statementsâ€‹-5.19(a)Financingâ€‹-4.6(a)Financing Amountsâ€‹-4.6(d)Financing Entitiesâ€‹-See definition of Financing Parties, 1.1fraudâ€‹-9.2Global Separation Licensesâ€‹-5.11Guaranteesâ€‹-5.9Indemnified Partyâ€‹-10.4(a)Indemnifying Partyâ€‹-10.4(a)Independent Accounting Firmâ€‹-2.9(e)Initial Allocationâ€‹-2.10(b)Inside Dateâ€‹-2.3International Transferred Employeeâ€‹-6.1(d)Inventoryâ€‹-2.4(n)IRSâ€‹-2.10(c)Leased Real Propertyâ€‹-2.4(g)Lendersâ€‹-4.6(a)Litigating Partyâ€‹-5.14(a)Lower Boundâ€‹-See definition of Gross Profit Adjustment Amount, 1.1Marksâ€‹-See definition of Intellectual Property Rights, 1.1Material Contractsâ€‹-3.13(a)New Plansâ€‹-6.2(c)Non-U.S. Purchased Entity Benefit Planâ€‹-3.19(k)OFACâ€‹-See definition of Sanctioned Person, 1.1Offer Employeesâ€‹-6.1(b)Old Plansâ€‹-6.2(c)Original Seller Groupâ€‹-5.16(d)Outside Dateâ€‹-9.1(d)Owned Real Propertyâ€‹-2.4(g)Partiesâ€‹-PreamblePartyâ€‹-PreamblePatentsâ€‹-See definition of Intellectual Property Rights, 1.1Post-Closing Representationâ€‹-11.14(a)Post-Closing Statementâ€‹-2.9(d)Pre-Closing Restricted Cash Distributionâ€‹-5.23Product Claimsâ€‹-2.6(c)Prohibited Modificationâ€‹-5.7(b)Proposed Initial Allocationâ€‹-2.10(b)Purchased Assetsâ€‹-2.4Purchased

Entitiesâ€‹2.4(a)Purchased Entityâ€‹2.4(a)Purchased Entity Sharesâ€‹2.4(a)Purchaserâ€‹PreamblePurchaser 1â€‹PreamblePurchaser 2â€‹PreamblePurchaser DC Plansâ€‹6.5(a)â€‹-17-Purchaser FSA Planâ€‹6.2(e)Purchaser Indemnified Partiesâ€‹10.2(a)Purchasersâ€‹PreamblePurchasersâ€™ Allocation Noticeâ€‹2.10(c)Purchasersâ€™ Initial Allocation Noticeâ€‹2.10(b)R&W Insurance Policyâ€‹5.18Remedy Actionsâ€‹5.1(d)Required Approvalsâ€‹8.1(a)Retained Businessâ€‹See definition of Business, 1.1Retained Liabilitiesâ€‹2.7Retained Marksâ€‹5.10(a)Retained Seller Benefit Plansâ€‹6.3Sample Closing Statementâ€‹2.9(a)Sellerâ€‹PreambleSeller Change of Controlâ€‹5.16(d)Seller Covered Personâ€‹5.16(a)Seller DC Plansâ€‹6.5(a)Seller FSA Planâ€‹6.2(e)Seller Indemnified Partiesâ€‹10.3Sellerâ€™s Allocationâ€‹2.10(c)Severance Capâ€‹6.2(c)Significant Customersâ€‹3.13(a)(i)Significant Suppliersâ€‹3.13(a)(ii)Specified Business Contractsâ€‹2.4(f)Specified Dateâ€‹9.1(d)Suballocationâ€‹2.10(d)Surviving Obligationsâ€‹9.2Tax Benefitâ€‹10.6Third-Party Claimâ€‹10.4(a)Third-Party Consentsâ€‹5.15Trade Controlsâ€‹3.25(a)Trade Secretsâ€‹See definition of Intellectual Property Rights, 1.1Transactionâ€‹RecitalsTransaction Accounting Principlesâ€‹2.9(a)Transferred Employeesâ€‹6.1(d)Transferred FSA Balancesâ€‹6.2(e)Transferred Information Technologyâ€‹2.4(j)Transferred Intellectual Propertyâ€‹2.4(h)Transferred Leasesâ€‹2.4(g)Transferred Marketing Authorizationsâ€‹3.15(a)Transferred Packagingâ€‹5.10(c)(i)Transferred Permitsâ€‹2.4(o)Transferred Real Propertyâ€‹2.4(g)Transferred Tangible Personal Propertyâ€‹2.4(k)Transition Services Agreementâ€‹2.8(a)(iii)U.S. DC Employeesâ€‹6.5(a)â€‹-18-U.S. LTD Employeeâ€‹6.1(c)U.S. Transferred Employeeâ€‹6.1(d)Waiver of Subrogation Provisionâ€‹5.18willful and material breachâ€‹9.2Workersâ€™ Compensation Eventâ€‹6.8â€‹ARTICLEÂ IIPURCHASE AND SALE; CLOSINGSectionÂ 2.1Purchase and Sale. Subject to the terms and conditions of this Agreement, at the Closing, (a) Seller shall, and shall cause the other Seller Entities to, sell, assign, transfer and convey to Purchaser 1 and Purchaser 2, as applicable, (b) Purchaser 1 shall purchase and acquire from Seller and the other Seller Entities, all of Sellerâ€™s and the other Seller Entitiesâ€™ right, title and interest as of the Closing in and to the Purchased Assets (other than the Purchased Assets that are the subject of SectionÂ 2.4(a)Â â€“ 2.4(e)), free and clear of all Liens, other than Permitted Liens, and (c) Purchaser 2 shall purchase and acquire from Seller and the other Seller Entities, all of Sellerâ€™s and the other Seller Entitiesâ€™ right, title and interest as of the Closing in and to the Purchased Assets that are the subject of SectionÂ 2.4(a)Â â€“ 2.4(e), free and clear of all Liens, other than (i) in the case of the Purchased Entity Shares, Liens arising under applicable securities Laws, this Agreement or the governing documents of the Purchased Entities and (ii) in the case of all other Purchased Assets, Permitted Liens.SectionÂ 2.2Purchase Price. In consideration for the Purchased Assets and the other obligations of Seller pursuant to this Agreement, at the Closing, the Purchasers shall (a)Â pay (or cause the applicable portion to be paid by Purchaser 1 or Purchaser 2, as applicable) to Seller (or one or more of Sellerâ€™s Subsidiaries designated by Seller in accordance with SectionÂ 2.8(a)(i)) three hundred and fifty million U.S. dollars ($350,000,000) in cash (the â€œBase Purchase Priceâ€) as adjusted in accordance with SectionÂ 2.9 and paid in the manner set forth in SectionÂ 2.8 and SectionÂ 2.9; and (b)Â assume the Assumed Liabilities.SectionÂ 2.3Closing Date. The closing of the Transaction (excluding any transactions to be consummated at any Deferred Closing) (the â€œClosingâ€) shall take place by remote exchange of signatures and documentation, at 8:00 a.m. (New York City time) on the fourth (4th) Business Day following the date on which the last of the conditions set forth in ArticleÂ VIII (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at the Closing) have been satisfied (or, to the extent permitted, waived by the Party entitled to the benefits thereof) or at such other place, time and date as may be agreed in writing between Seller and the Purchasers; provided that, notwithstanding anything set forth herein to the contrary, the Closing shall not occur prior to the fourth (4th) Business Day following the date that is seventy five (75) days following the date of this Agreement without the prior, express written consent of each of Seller and the Purchasers (the â€œInside Dateâ€); provided, further, that, upon Sellerâ€™s prior written request, the Inside Date shall be extended by an additional fourteen (14) Business Days. The date on which the Closing occurs is referred to in this Agreement as the â€œClosing Date.â€SectionÂ 2.4Purchased Assets. Subject to the terms and conditions of this Agreement, on the Closing Date and at the Closing, Seller shall, and shall cause the other Seller Entities to,â€‹-19-sell, assign, transfer and convey to the applicable Purchaser, and each such Purchaser shall purchase, acquire and accept from the Seller Entities, all of the Seller Entitiesâ€™ right, title and interest as of the Closing in the following (the â€œPurchased Assetsâ€):(a)All of the equity interests (the â€œPurchased Entity Sharesâ€) in the entities listed on SectionÂ 2.4(a) of the Seller Disclosure Schedules (each, a â€œPurchased Entity,â€ and, collectively, the â€œPurchased Entitiesâ€);(b)Any and all accounts receivable of the Purchased Entities as of the Closing, in each case to the extent included in the calculation of the Closing Working Capital;(c)All Cash of the Purchased Entities as of the Closing to the extent included in the calculation of Closing Cash (which, for the avoidance of doubt, shall exclude the Excess Restricted Cash);(d)Except as set forth in ArticleÂ VI, any and all assets of the Purchased Entity Benefit Plans (other than any assets that are controlled by a third party or Governmental Entity);(e)All rights of the Purchased Entities under the Transaction Documents;(f)(i) Each Contract to which Seller or any Seller Entity or any Subsidiary thereof is a party that exclusively relates to, is exclusively held for use by or is exclusively used in connection with the Business and (ii) the Business Contingent Worker Contracts (collectively, the â€œSpecified Business Contractsâ€);(g)(i) The owned real property listed on SectionÂ 2.4(g)(i) of the Seller Disclosure Schedules, together with all improvements, fixtures and appurtenances thereto (the â€œOwned Real Propertyâ€) and (ii) the leases with respect to the leased real property listed on SectionÂ 2.4(g)(ii) of the Seller Disclosure Schedules (such leases, including all amendments, extensions, renewals, guaranties and other agreements with respect thereto, the â€œTransferred Leases,â€ and such leased real property, the â€œLeased Real Property,â€ and together with the Owned Real Property, the â€œTransferred Real Propertyâ€);(h)(i) The Registered IP listed in SectionÂ 2.4(h)(i) of the Seller Disclosure Schedules, including the goodwill appurtenant to the Marks included in the foregoing and (ii) the Intellectual Property Rights (other than Registered IP) owned by the Seller Group (or any of the Purchased Entities) as of the Closing and exclusively used, or held exclusively for use, in the operation of the Business (collectively, the â€œTransferred Intellectual Propertyâ€), including the right to damages for the past or future infringement or violation of the Transferred Intellectual Property;(i)The Business Technology Deliverables;(j)Any and all Information Technology (including all software loaded thereon but only to the extent such software is transferable to the Purchasers pursuant to the terms of this Agreement or the Purchasers independently have their own license forâ€‹-20-such software), in each case exclusively used, or held exclusively for use, in the operation of the Business (the â€œTransferred Information Technologyâ€);(k)Any and all Tangible Personal Property owned or leased by the Seller Entities and exclusively related to, exclusively used, or held exclusively for use, in the operation of the Business (the â€œTransferred Tangible Personal Propertyâ€);(l)Any and all other current assets of the Business as of the Closing, in each case to the extent included in the calculation of the Closing Working Capital;(m)Any and all credits, prepaid assets, prepaid expenses, deposits (including security deposits) and other amounts deposited with third parties in each case of the Business and to the extent included in the calculation of the Closing Working Capital;(n)Any and all Business Products, raw materials, bulk substances, ingredients, work-in-process, finished goods, goods in transit, supplies and other inventories and related packaging materials or similar items, in each case exclusively used, or held exclusively for use, by the Business, and in each case to the extent included in the calculation of the Closing Working Capital (collectively, the â€œInventoryâ€);(o)All Permits that are exclusively related to, exclusively held for use or exclusively used in connection with the Business, including those listed in SectionÂ 2.4(o) of the Seller Disclosure Schedules, other than marketing authorizations (the â€œTransferred Permitsâ€);(p)The Transferred Marketing Authorizations;(q)Any and all goodwill of the Business;(r)Any and all claims, causes of action, defenses, rights of offset or counterclaims, or settlement agreements (in any manner arising or existing, whether choate or inchoate, known or unknown, contingent or non-contingent), in each case, exclusively related to the Business, other than any Retained Claims;(s)Copies of any and all (x) documents, instruments, papers, books, records, books of account, files and data (including customer, distributor and supplier lists, pricing lists, and repair and performance records, testing and clinical data, market research reports, marketing plans and other marketing-related information and materials, quality control, pharmacovigilance and regulatory records), catalogs, brochures, sales literature, promotional materials, certificates and other documents, in each case, exclusively related to the Business and in the possession of the Seller Entities or any of their Subsidiaries and (y) personnel and employment records of Transferred Employees and any other employees of the Purchased Entities, other than (i) any books, records or other materials that the Seller Entities are required by Law to retain (copies of which, to the extent permitted by Law, will be made available to the Purchasers upon the Purchasersâ€™ reasonable request), (ii) personnel and employment records for employees and Former Employees who are not Transferred Employees or employees of a Purchased Entity and for Transferred Employees if prohibited by Law, (iii) any books, records or otherâ€‹-21-materials that may be located in a facility of the Business (including the Transferred Real Property) to the extent not exclusively related to the Business, (iv) Tax Returns and other books and records related to Taxes and (v) records prepared in connection with the Transaction, including bids received from other Persons and analyses relating to the Business; provided that, with respect to any such books, records or other materials that are Purchased Assets pursuant to this clauseÂ (s), the Seller Entities shall be permitted to keep (A)Â copies of such books, records or other materials to the extent required to demonstrate compliance with applicable Law or pursuant to internal compliance procedures, (B)Â copies of such books, records or other materials to the extent they are relevant to any Excluded Assets or the Retained Business and (C) such books, records or other materials in the form of so-called â€œback-upâ€ electronic tapes in the ordinary course of business; provided, further, that the obligation to sell, assign, transfer and convey any such books, records or other materials that are Purchased Assets pursuant to this clauseÂ (s) is only to the extent permitted by Data Protection Laws and the foregoing shall not include any materials that constitute Technology;(t)The assets set forth on SectionÂ 2.4(u) of the Seller Disclosure Schedules;(u)Additional Business Products in accordance with SectionÂ 5.24; and(v)All other assets, Contracts, rights and properties not addressed by clausesÂ (a) to (u), whether tangible or intangible, personal or mixed, wherever located and whether or not reflected on the books and records of any Seller Entities, exclusively related to, exclusively held for use or exclusively used in the Business; provided, that, for the avoidance of doubt, if any categories of assets, Contracts, rights and properties are specifically addressed by clausesÂ (a) to (u), the terms of clausesÂ (a) to (u) shall govern.The transfer of any assets of the Purchased Entities that constitute Purchased Assets shall be effected solely by virtue of the transfer of the Seller Entitiesâ€™ right, title and interest in the Purchased Entity Shares and not through the direct transfer of such assets, and Seller and its Subsidiaries shall not be required to transfer any such assets of the Purchased Entities other than through the transfer of the Seller Entitiesâ€™ right, title and interest in the Purchased Entity Shares. Subject to SectionÂ 2.11, the Parties acknowledge and agree that no member of the Seller Group will retain after the Closing any direct or indirect right, title and interest in any Purchased Asset.The Parties acknowledge and agree that a single asset may fall within more than one of clausesÂ (a) through (v) in this SectionÂ 2.4; such fact does not imply that (i) such asset shall be transferred more than once or (ii) any duplication of such asset is required.SectionÂ 2.5Excluded Assets. Notwithstanding anything in this Agreement to the contrary, the Purchasers expressly understand and agree that the following assets, Contracts, rights and properties of the Seller Entities and their Subsidiaries (the â€œExcluded Assetsâ€) shall be retained by the Seller Group, shall be excluded from the Purchased Assets and may be transferred out of the Purchased Entities prior to the Closing, notwithstanding any other provision of this Agreement:â€‹-22-(a)Any and all legal and beneficial interest in the share capital or equity interest of any Person, other than the Purchased Entity Shares;(b)Any and all Contracts, other than the Specified Business Contracts and the Transferred Leases;(c)Any and all owned and leased real property and other interests in real property, other than the Transferred Real Property;(d)Any and all Intellectual Property Rights, other than the Transferred Intellectual Property;(e)Any and all Technology, other than the Business Technology Deliverables in the form transferred;(f)Any and all Information Technology, other than the Transferred Information Technology;(g)Any and all Tangible Personal Property, other than the Transferred Tangible Personal Property;(h)Any and all raw materials, work-in-process, finished goods, supplies and other inventories, other than the Inventory;(i)Any and all Permits, other than the Transferred Permits;(j)Any and all marketing authorizations, other than the Transferred Marketing Authorizations;(k)Any Retained Claim;(l)Any and all documents, instruments, papers, books, records, books of account, files and data, catalogs, brochures, sales literature, promotional materials, certificates and other documents not specifically identified as Purchased Assets in SectionÂ 2.4;(m)Except as set forth in ArticleÂ VI, any and all assets of the Seller Benefit Plans (other than the assets of the Purchased Entity Benefit Plans);(n)Any and all loans and advances if any, by the Seller Entities to any of their Affiliates or otherwise to the Business;(o)The Italian VAT Receivable;(p)Shared Contracts;(q)Any and all prepaid Taxes, and any and all refunds, credits, overpayments or similar items or recoveries, of or against Excluded Taxes;â€‹-23-(r)Tax Returns and other books and records related to Taxes paid or payable by Seller, the Seller Entities, or any of their respective Affiliates with respect to a Combined Tax Return or with respect to Excluded Taxes;(s)Any and all Cash, (i) excluding any Cash of the Purchased Entities as of the Closing to the extent included in the calculation of the Closing Cash and (ii) including the Excess Restricted Cash;(t)Any and all accounts receivable (other than those of the Purchased Entities as of the Closing to the extent included in the calculation of the Closing Working Capital) and any and all trade receivables, other current assets, prepaid expenses and security deposits (in each case, other than those of the Business as of the Closing to the extent included in the calculation of the Closing Working Capital);(u)Any and all insurance policies and binders and interests in insurance pools and programs and self-insurance arrangements, whether or not related to the Business, for all periods before, through and after the Closing, including any and all refunds and credits due or to become due thereunder and any and all claims, rights to make claims and rights to proceeds on any such insurance policies, binders and interests for all periods before, through and after the Closing;(v)All rights to receive payments of Seller or any of its Affiliates pursuant to a hedging or other currency exchange agreement existing before, on or after the Closing Date;(w)All intercompany assets between members of the Seller Entities and their Subsidiaries (other than the Purchased Entities), on the one hand, and any other members of the Seller Entities and their Subsidiaries (other than the Purchased Entities), on the other hand;(x)The assets set forth on Section 2.5(x) of the Seller Disclosure Schedules; and(y)Except for those assets expressly identified as Purchased Assets in clausesÂ (a) through (v) of SectionÂ 2.4, any and all assets, business lines, properties, rights, Contracts and claims of Seller or any of its Subsidiaries not exclusively used, or held exclusively for use, in the operation of the Business (including all assets, business lines, properties, rights, Contracts and claims constituting ownership interests in, or that are used or held for use in or related to, the Retained Business), wherever located, whether tangible or intangible, real, personal or mixed.The Parties acknowledge and agree that neither Purchaser nor any of their respective Subsidiaries will acquire, and no Purchased Entity may retain after the Closing, any direct or indirect right, title and interest in any Excluded Assets.SectionÂ 2.6Assumed Liabilities. Subject to the terms and conditions of this Agreement, at the Closing, each Purchaser shall, as applicable, (x) assume and hereby agrees to pay, satisfy, discharge and perform all of the Liabilities of the Seller Entities solely to the extentâ€‹-24-related to or arising out of the Purchased Assets and (y)Â cause the Purchased Entities to pay, satisfy, discharge and perform all of their respective Liabilities (the â€œAssumed Liabilitiesâ€), in each case, whether accruing or arising prior to, on or after the Closing, including the following (but excluding the Liabilities identified as Retained Liabilities in clausesÂ (a) through (l) of SectionÂ 2.7):(a)Any and all Liabilities to the extent relating to or arising out of the Specified Business Contracts or the Transferred Leases;(b)Any and all Liabilities arising under Environmental Laws to the extent arising out of or relating to in any way any past, current or future businesses, operations, products or properties of or associated with the Purchased Assets or the Business;(c)Any and all Liabilities and obligations to the extent arising from or relating to (i) any return, repair, warranty or similar obligations relating to products and services of the Business that were designed, manufactured or sold on, or prior to or after the Closing Date or that were held in the Inventory as of the Closing Date, (ii)Â infringement, dilution, misappropriation or other violation of any rights in respect of Transferred Intellectual Property, (iii) alleged or actual hazard or defect in design, manufacture, materials or workmanship, including any failure to warn or alleged or actual breach of express or implied warranty or representation or (iv)Â lawsuits or other claims, regardless of when commenced or made and irrespective of the legal theory asserted, with respect to the design, manufacture, testing, advertising, marketing, distribution or sale of the products and services of the Business, whether prior to or after the Closing (collectively, â€œProduct Claimsâ€);(d)Any and all Liabilities relating to or arising out of the ownership, use or conduct of, or associated with the realization of the benefits of the Business, the Purchased Assets or the Purchased Entities, whether accruing or arising before, on or after the Closing, whether known or unknown, fixed or contingent, asserted or unasserted, and not satisfied or extinguished as of the Closing, including any and all Liabilities in respect of any Proceedings related thereto, other than the Liabilities identified as Retained Liabilities in clausesÂ (a) through (l) of SectionÂ 2.7;(e)Any and all Liabilities in respect of or relating to Business Employees, other than those expressly retained by Seller pursuant to ArticleÂ VI;(f)Any and all Liabilities of the Purchased Entities, other than with respect to Seller Employees and Former Employees;(g)Any and all Liabilities to the extent relating to or arising out of (i) the Seller Benefit Plans (other than Purchased Entity Benefit Plans) with respect to or relating to Business Employees but only to the extent expressly assumed by a Purchaser pursuant to ArticleÂ VI or (ii) the Purchased Entity Benefit Plans;(h)Any and all Liabilities for which the Purchasers or their Subsidiaries expressly have responsibility pursuant to this Agreement, including pursuant to SectionÂ 5.7;â€‹-25-(i)Any and all Liabilities to the extent included in the calculation of Closing Indebtedness; and(j)Any and all accounts payable of the Purchased Entities and other Liabilities of the Business to the extent included in the calculation of the Closing Working Capital.With respect to Assumed Liabilities that are Liabilities of the Purchased Entities, the applicable Purchaser shall cause the Purchased Entities to pay, satisfy, discharge and perform all of such Liabilities.The Parties acknowledge and agree that a single Liability may fall within more than one of clausesÂ (a) through (j) in this SectionÂ 2.6; such

fact does not imply that (i) such Liability shall be transferred more than once or (ii) any duplication of such Liability is required.SectionÂ 2.7Retained Liabilities. The Seller Entities shall retain, and the Purchasers shall not assume, the following Liabilities (the â€œRetained Liabilitiesâ€):(a)Except as set forth in SectionÂ 2.6(f) and SectionÂ 2.6(i), any Indebtedness of the Seller Entities and their Subsidiaries;(b)Liabilities for which any Seller Entity (other than the Purchased Entities) expressly has responsibility pursuant to this Agreement;(c)Liabilities to the extent arising out of or related to the Excluded Assets (other than any Liabilities for which the Purchasers or any of their Subsidiaries expressly have responsibility pursuant to the terms of this Agreement or any Transaction Document);(d)Except as expressly assumed by a Purchaser as set forth in ArticleÂ VI, Liabilities to the extent relating to or arising out of any Seller Benefit Plan (other than a Purchased Entity Benefit Plan);(e)Any and all accounts payable (other than those of the Purchased Entities as of the Closing to the extent included in the calculation of the Closing Working Capital);(f)Liabilities for Excluded Taxes;(g)Fees and expenses of brokers, finders, outside counsel, financial advisors, accountants, consultants and other professional advisors incurred by Seller or any of its Subsidiaries prior to the Closing in connection with the negotiation, execution and performance of this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby;(h)Any and all Liabilities in respect of (i) any transaction, retention or change in control bonuses or nonqualified deferred compensation obligations payable to any Business Employee or other individual service provider of the Business or the Purchasedâ€‹-26-Entities or of Seller and any of its Subsidiaries upon and solely by reason of the consummation of the transactions contemplated hereby, together with the employer portion of any payroll, social security, unemployment or similar Taxes related thereto, and (ii) any Taxes related to any equity or equity-based payments or benefits (including, any cancellation or accelerated vesting of any equity or equity-based arrangements) due or payable to any Person in connection with the consummation of the transactions contemplated hereby;(i)Any and all Liabilities in respect of or to the extent relating to Former Employees or Seller Employees regardless of when they arise;(j)Subject to Section 5.21 (with respect to Shared Contracts only), any and all Liabilities (including rebates) related to Shared Contracts (other than Liabilities with respect to Business Products sold by Purchasers or their Affiliates following the Closing under such Shared Contracts, which shall be covered by SectionÂ 2.6(c));(k)All Liabilities prior to the Closing associated with workers compensation claims to the extent retained by the Seller Entities pursuant to Section 6.8; and(l)All intercompany Liabilities or intercompany payables between members of the Seller Entities and their Subsidiaries (other than the Purchased Entities), on the one hand, and any other members of the Seller Entities and their Subsidiaries (other than the Purchased Entities), on the other hand.SectionÂ 2.8Closing Deliveries.(a)At the Closing, the Purchasers shall deliver, or cause to be delivered, to Seller (or one or more other Seller Entities designated by Seller) the following:(i)payment, by wire transfer(s) to one or more bank accounts designated in writing by Seller (such designation to be made by Seller at least two (2) Business Days prior to the Closing Date), an amount in immediately available funds equal to the Closing Purchase Price;(ii)the certificate to be delivered pursuant to SectionÂ 8.3(c);(iii)a counterpart of the Transition Services Agreement, in substantially the form attached as Exhibit A hereto (the â€œTransition Services Agreementâ€), duly executed by the Purchasers;(iv)a counterpart of one or more distribution agreements entered into pursuant to SectionÂ 2.11 (if any), in customary form for a transaction similar to this Transaction and on terms mutually agreed between the Parties in good faith (which terms shall generally be consistent with those applicable to the relevant services under the Transition Services Agreement) (each, a â€œDistribution Agreementâ€), duly executed by the applicable Purchaser(s);(v)a fully executed and binding copy of the R&W Insurance Policy;â€‹-27-(vi)with respect to any Purchased Asset (other than the Purchased Entity Shares) or Assumed Liability that is not held by a Purchased Entity, a counterpart of an Assignment and Assumption Agreement and Bill of Sale providing for the transfer of the Seller Entitiesâ€™ right, title and interest as of the Closing in and to the Purchased Assets (other than the Purchased Entity Shares) and the assumption by the applicable Purchaser of the Assumed Liabilities in accordance with and subject to this Agreement, by and between the applicable Seller Entities and Purchasers, in substantially the form attached hereto as Exhibit B (the â€œAssignment Agreement and Bill of Saleâ€), duly executed by the Purchasers; and(vii)any other instruments necessary and appropriate to evidence the applicable Purchaserâ€™s assumption of the Assumed Liabilities pursuant to and in accordance with this Agreement, in each case duly executed by such Purchaser, to the extent applicable.(b)At the Closing, Seller shall deliver, or cause to be delivered, to the Purchasers the following:(i)the certificate to be delivered pursuant to SectionÂ 8.2(c);(ii)a counterpart of the Transition Services Agreement, duly executed by the Seller Entity named as a party thereto;(iii)a counterpart of each Distribution Agreement (if any), duly executed by the Seller Entity named as a party thereto;(iv)certificates evidencing the Purchased Entity Shares, to the extent that such Purchased Entity Shares are in certificated form, duly endorsed in blank or with stock powers duly executed in proper form for transfer, and, to the extent that such Purchased Entity Shares are not in certificated form, other evidence of ownership or assignment in form and substance reasonably satisfactory to the Purchasers;(v)a completed and duly executed IRS Form W-9 of Seller;(vi)with respect to any Purchased Asset (other than the Purchased Entity Shares) or Assumed Liability that is not held by a Purchased Entity, a counterpart of the Assignment Agreement and Bill of Sale duly executed by each Seller Entity named as a party thereto;(vii)customary documentation (x) evidencing the release or termination of any Lien on any Purchased Asset securing indebtedness for borrowed money and (y) and the termination of any UCC financing statements in respect of any such Lien;(viii)the Completed Phase I Reports and corresponding reliance letters or other documentation sufficient to allow Purchaser to establish the Phase I reports for the benefit of Purchasers, in each case prepared at the Purchasersâ€™ sole cost and expense (provided, that the Parties hereby agree that Sellerâ€™s obligation to provide such Completed Phase I Reports and corresponding reliance letters or other documentationâ€‹-28-under this clause (viii) is conditioned on the Purchasersâ€™ prompt reimbursement of any costs and expense); and(ix)any other instruments of transfer necessary and appropriate to evidence the transfer of the Seller Entitiesâ€™ right, title and interest in the Purchased Assets pursuant to and in accordance with this Agreement duly executed by each Seller Entity named as a party thereto, to the extent applicable.SectionÂ 2.9Adjustment to Base Purchase Price.(a)SectionÂ 2.9(a) of the Seller Disclosure Schedules sets forth an illustrative calculation (the â€œSample Closing Statementâ€) of (i)Â the Working Capital of the Business and the Cash and Indebtedness of the Purchased Entities, in each case, as of December 31, 2023, including the current asset and current liability line items included in the calculation of Working Capital, in each case prepared in accordance with the accounting principles, practices, procedures, methodologies and policies set forth on SectionÂ 2.9(a) of the Seller Disclosure Schedules (collectively, the â€œTransaction Accounting Principlesâ€) and (ii) the Gross Profit of the Business for the fiscal year ended December 31, 2023.(b)At least four (4) Business Days prior to the Closing Date, Seller shall cause to be prepared and delivered to the Purchasers a closing statement (the â€œClosing Statementâ€) setting forth a good-faith estimate of (i)Â the WC Adjustment Amount (such estimate, the â€œEstimated WC Adjustment Amountâ€), (ii)Â the Closing Cash (such estimate, the â€œEstimated Closing Cashâ€), (iii)Â the Closing Indebtedness (such estimate, the â€œEstimated Closing Indebtednessâ€), and (iv)Â the Gross Profit Adjustment Amount (such estimate, the â€œEstimated Gross Profit Adjustment Amountâ€), together with reasonable supporting calculations and documentation used by Seller in determining the amounts set forth therein. The Closing Statement shall set forth the calculations of such amounts in a format consistent with the Sample Closing Statement and, in the case of the Estimated WC Adjustment Amount, the Estimated Closing Cash and the Estimated Closing Indebtedness, be prepared in accordance with the Transaction Accounting Principles, including the use of the same line item categories (and specific line items within those categories) set forth on and used in the preparation of the Sample Closing Statement.(c)The Estimated WC Adjustment Amount, the Estimated Closing Cash, the Estimated Closing Indebtedness and the Estimated Gross Profit Adjustment Amount shall be used to calculate the Closing Purchase Price to be paid by the Purchasers to Seller at the Closing. The Purchasers agree that, following the Closing through the date that the Post-Closing Statement becomes final and binding in accordance with this SectionÂ 2.9, they will not take any actions with respect to any accounting books, records, policies or procedures on which the Sample Closing Statement or the Closing Statement is based, or on which the Post-Closing Statement is to be based, that would impede or prevent the final determination of the Post-Closing Statement. The Purchasers, their Subsidiaries and their respective Representatives shall have the right to review and comment on the Closing Statement, and Seller shall (and shall cause its Subsidiaries and its and their respective Representatives to) reasonably cooperate in connection with such review and Seller shall consider any comments proposed by or on behalf of the Purchasers in good faith (provided that, for the avoidance of doubt, no failure by theâ€‹-29-Purchasers to object to, or comment on, any item set forth in the Closing Statement shall prejudice the Purchasers with respect to any post-Closing adjustments pursuant to SectionÂ 2.9(d) or the resolution thereof). Seller shall promptly provide, or cause to be provided, to the Purchasers and their Representatives with reasonable access to, upon advance written request, during normal business hours, the relevant personnel involved in the preparation of the Closing Statement, and to the books, records, documents, work papers and other information in the possession or control of Seller Group or its Representatives (subject to customary access letters and confidentiality undertakings) for purposes of assisting the Purchasers and their Representatives in their review of the Closing Statement.(d)Following the Closing Date, Seller shall provide to the Purchasers reasonable access (subject to customary access letters), upon advance written request, during normal business hours, to the accounting advisors and other personnel involved in the preparation of the Closing Statement and to the books and records of the Seller Entities and any other document or information reasonably requested by the Purchasers or their Representatives in order to allow the Purchasers and their Representatives to prepare the Post-Closing Statement. Within one hundred (100) days after the Closing Date, the Purchasers shall prepare or cause to be prepared, and will provide to Seller, a written statement (the â€œPost-Closing Statementâ€), setting forth a good-faith calculation of the WC Adjustment Amount, the Closing Cash, the Closing Indebtedness and the Gross Profit Adjustment Amount, together with reasonable supporting calculations and documentation used by the Purchasers in determining the amounts set forth therein. The Post-Closing Statement shall set forth in reasonable detail the Purchasersâ€™ calculations of such amounts in a format consistent with the Sample Closing Statement and, in the case of the WC Adjustment Amount, the Closing Cash and the Closing Indebtedness, shall be prepared in accordance with the Transaction Accounting Principles, including the use of the same line item categories (and specific line items within those categories) set forth on and used in the preparation of the Sample Closing Statement.(e)Within forty-five (45) days following receipt by Seller of the Post-Closing Statement, Seller shall deliver written notice to the Purchasers of any dispute Seller has with respect to the calculation, preparation or content of the Post-Closing Statement (the â€œDispute Noticeâ€); provided, however, that if Seller does not deliver any Dispute Notice to the Purchasers within such forty-five (45)-day period, the Post-Closing Statement will be final, conclusive and binding on the Parties. The Dispute Notice shall set forth in reasonable detail (i) any item on the Post-Closing Statement that Seller disputes and (ii) the amount of such item that Seller believes is correct. Upon receipt by the Purchasers of a Dispute Notice, the Purchasers and Seller shall negotiate in good faith to resolve any dispute set forth therein. If the Purchasers and Seller, such good-faith effort notwithstanding, fail to resolve any such dispute within thirty (30) days after delivery of the Dispute Notice (the â€œDispute Resolution Periodâ€), then the Purchasers and Seller jointly shall engage, within ten (10) Business Days following the expiration of the Dispute Resolution Period, Deloitte or, if Deloitte is unavailable or conflicted, another nationally recognized independent accounting firm selected jointly by Seller and the Purchasers (the â€œIndependent Accounting Firmâ€) to resolve any such dispute; provided that, if Deloitte is unavailable or conflicted and Seller and the Purchasers are unable to agree on the Independent Accounting Firm, then each of Seller and the Purchasers shall select a nationally recognized independent accounting firm, and require that the two (2) firms mutually select a third (3rd) nationally recognized independent accounting firm to serve as the Independent Accounting Firm.â€‹-30-As promptly as practicable, and in any event not more than fifteen (15) days following the engagement of the Independent Accounting Firm, the Purchasers and Seller shall each prepare and submit a presentation detailing such Partyâ€™s complete statement of proposed resolution of each issue still in dispute to the Independent Accounting Firm (and such presentation, and all other communications with the Independent Accounting Firm, will be simultaneously made or delivered to the other Party). The Purchasers and Seller shall instruct the Independent Accounting Firm to, as soon as practicable after the submission of the presentations described in the immediately preceding sentence and in any event not more than twenty (20) days following such presentations, make a final determination in writing setting forth such calculation along with its analysis in reasonable detail of the basis and quantification of the appropriate amount of each of the line items that remain in dispute as indicated in the Dispute Notice (and that have not been thereafter resolved by written agreement of the Parties). With respect to each disputed line item, such determination, if not in accordance with the position of either Seller or the Purchasers, shall not be in excess of the higher, nor less than the lower, of the amounts advocated by Seller or the Purchasers, as applicable, in the Dispute Notice and the Post-Closing Statement, respectively. The scope of the disputes to be resolved by the Independent Accounting Firm shall be limited to those line items that remain in dispute as indicated in the Dispute Notice (and that have not been thereafter resolved by written agreement of the Parties) and whether any disputed determinations of the WC Adjustment Amount, the Closing Cash and the Closing Indebtedness were properly calculated in accordance with the Transaction Accounting Principles and the provisions of this Agreement, and not based on independent review beyond the aforementioned scope. The Independent Accounting Firm shall act as an expert and not as an arbitrator. Neither the Purchasers, Seller nor any of their respective Subsidiaries or Representatives shall have any ex parte conversations or meetings with the Independent Accounting Firm in connection with any dispute submitted by the Purchasers or Seller to the Independent Accounting Firm pursuant to this SectionÂ 2.9(e) without the prior consent of the other Party. All fees and expenses relating to the work, if any, to be performed by the Independent Accounting Firm shall be borne by Seller and the Purchasers in proportion to the allocation of the dollar value of the amounts in dispute between Seller and the Purchasers resolved by the Independent Accounting Firm, such that the party prevailing on the greatest dollar value of such disputes pays the lesser proportion of the fees. For example, if Seller submits a Dispute Notice to the Independent Accounting Firm for $1,000, and if the Purchasers contest to the Independent Accounting Firm only $500 of the amount claimed by Seller, and if the Independent Accounting Firm ultimately resolves the dispute by awarding Seller $300 of the $500 contested, then the costs and expenses of the Independent Accounting Firm will be allocated 60% (i.e., 300/500) to the Purchasers and 40% (i.e., 200/500) to Seller. All determinations made by the Independent Accounting Firm, and the Post-Closing Statement, as modified by the Independent Accounting Firm and to reflect any items resolved by written agreement of the Parties, will be final, conclusive and binding on the Parties absent manifest error.(f)For purposes of complying with the terms set forth in this SectionÂ 2.9, from and after delivery of the Post-Closing Statement until the earlier of the delivery of a Dispute Notice and the finalization of the Final Purchase Price in accordance with the terms hereof, each of Seller and the Purchasers shall reasonably cooperate with and make available to each other, the Independent Accounting Firm and each of their respective Representatives all information, records, data and working papers, in each case to the extent related to the Purchased Assets, Assumed Liabilities, Business, or Purchased Entities, and shall permit access to its andâ€‹-31-their facilities and personnel, as may be reasonably required in connection with the preparation, analysis and review of the Post-Closing Statement and the resolution of any disputes thereunder.(g)The â€œFinal Purchase Priceâ€ means the Base Purchase Price, plus (i)Â the Closing Cash, plus (ii) the WC Adjustment Amount (which may be a positive or negative number, or zero), minus (iii) the Closing Indebtedness, plus (iv) the Gross Profit Adjustment Amount (which may be a negative number or zero, but not a positive number), in the case of each of clauses (i), (ii), (iii) and (iv), as finally determined pursuant to SectionÂ 2.9(e).(h)If the Closing Purchase Price shall exceed the Final Purchase Price, then Seller shall pay or cause to be paid an amount in cash equal to such excess to the Purchasers by wire transfer of immediately available funds to an account or accounts designated in writing by the Purchasers to Seller; or if the Final Purchase Price shall exceed the Closing Purchase Price, then Purchasers shall pay an amount in cash equal to such excess to Seller by wire transfer of immediately available funds to an account or accounts designated in writing by Seller to the Purchasers. Any such payment is to be made within five (5) Business Days of the date on which the WC Adjustment Amount, the Closing Cash, the Closing Indebtedness and the Gross Profit Adjustment Amount are finally determined pursuant to this SectionÂ 2.9.(i)The process set forth in this SectionÂ 2.9 (and in SectionÂ 2.10) shall be the sole and exclusive remedy of any of the Parties and their respective Affiliates for any disputes related to the Closing Working Capital, the WC Adjustment Amount, the Closing Cash, the Closing Indebtedness, the Gross Profit Adjustment Amount, the Closing Purchase Price, the Final Purchase Price and the calculations and amounts on which they are based or set forth in the related statements and notices delivered in connection therewith; provided, that, for the avoidance of doubt, the foregoing shall not limit the Purchasersâ€™ rights of recovery under the R&W Insurance Policy.SectionÂ 2.10Purchase Price Allocation.(a)Seller and the Purchasers agree to allocate and, as applicable, to cause their relevant Subsidiaries to allocate, the Final Purchase Price (as finally determined pursuant to SectionÂ 2.9) any other items that are treated as additional consideration for U.S. federal income Tax purposes among the Purchased Assets (and any other assets that, for U.S. federal income Tax purposes, are treated as assets purchased by the applicable Purchaser (or its relevant Subsidiaries) pursuant to this Agreement and any other Transaction Document) in accordance with Exhibit C attached hereto (the â€œAllocation Scheduleâ€).(b)To the extent necessary to prepare bills of sale, transfer agreements, or to otherwise timely comply with the requirements of applicable Law in respect of the sale of any of the Purchased Assets (or other assets), no later than ten (10) days prior to the Closing, Seller shall deliver a draft of the allocation of the Base Purchase Price and any other items that are treated as additional consideration for U.S. federal income Tax purposes among each applicable Seller Entity (or other Subsidiary of Seller) that sells, transfers or assigns any relevant Purchased Assets (or other assets) determined in a manner consistent with the Allocation Schedule (the â€œProposed Initial Allocationâ€). If the Purchasers reasonably disagree with any item

on the Proposed Initial Allocation, the Purchasers may, within five (5) days after delivery of theâ€‹-32-Proposed Initial Allocation, deliver a written notice (the â€œPurchasersâ€™ Initial Allocation Noticeâ€) to Seller to such effect, specifying those items as to which the Purchasers disagree and setting forth the Purchasersâ€™ proposed allocation of such items. During the three (3) days following the Purchasersâ€™ delivery of a Purchasersâ€™ Initial Allocation Notice, the Purchasers and Seller negotiate in good faith to resolve such dispute. The Proposed Initial Allocation, as prepared by Seller if no Purchasersâ€™ Initial Allocation Notice has been given or as agreed to by Seller and the Purchasers following delivery of Purchasersâ€™ Initial Allocation Notice (the â€œInitial Allocationâ€), shall be conclusive and binding on the Parties. The Initial Allocation or, in the event that the Initial Allocation has not become final pursuant to this SectionÂ 2.10 by the Closing, the Proposed Initial Allocation, shall be used for the purpose of determining the amount of any payments made on the Closing Date to the applicable Seller Entities.(c)No later than ninety (90) days after the date on which the Final Purchase Price is finally determined pursuant to SectionÂ 2.9, Seller shall deliver to the Purchasers a proposed allocation of the Final Purchase Price and any other items that are treated as additional consideration for U.S. federal income Tax purposes among the Purchased Assets (including among the Purchased Entity Shares and among any other assets that, for U.S. federal income Tax purposes, are treated as assets purchased by the applicable Purchaser (or its relevant Subsidiaries) pursuant to this Agreement and any other Transaction Document), as of the Closing Date, determined in a manner that incorporates, reflects and is consistent with the Allocation Schedule, the Initial Allocation, and Sections 338 and 1060 of the Code and the Treasury Regulations promulgated thereunder (â€œSellerâ€™s Allocationâ€). If the Purchasers disagree with Sellerâ€™s Allocation (other than with respect to any Initial Allocation reflected in Sellerâ€™s Allocation), the Purchasers may, within thirty (30) days after delivery of Sellerâ€™s Allocation, deliver a written notice (the â€œPurchasersâ€™ Allocation Noticeâ€) to Seller to such effect, specifying those items as to which the Purchasers disagree and setting forth the Purchasersâ€™ proposed allocation of such items. If the Purchasers deliver a Purchasersâ€™ Allocation Notice, Seller and the Purchasers shall, during the thirty (30) days following such delivery, negotiate in good faith to resolve such dispute within thirty (30) days after delivery of the Purchasersâ€™ Allocation Notice. If Seller and the Purchasers are unable to reach such agreement, they shall promptly thereafter cause the Independent Accounting Firm (who shall be promptly engaged if not previously engaged pursuant to SectionÂ 2.9 in accordance with the procedures described in SectionÂ 2.9) to resolve any remaining disputes. The Purchasers and Seller shall each request that the Independent Accounting Firm make a final determination as to the disputed items, in a manner that is consistent with the Allocation Schedule and the Initial Allocation, within thirty (30) days after such engagement. All fees and expenses relating to the work, if any, to be performed by the Independent Accounting Firm shall be borne equally by Seller and the Purchasers. The allocation, as prepared by Seller if no Purchasersâ€™ Allocation Notice has been duly and timely delivered, as adjusted pursuant to any agreement between Seller and the Purchasers or as determined by the Independent Accounting Firm in accordance with this SectionÂ 2.10(c) (the â€œAllocationâ€), shall be final, conclusive and binding on the Parties absent manifest error. The Allocation shall be adjusted (other than with respect to amounts allocated to the Purchased Entity Shares pursuant to Exhibit C), as necessary, to reflect any adjustments to the purchase price under this Agreement in a manner consistent with the Allocation Schedule. Each of Seller and the Purchasers shall (and shall cause their respective Subsidiaries to) prepare and file its Tax Returns (including Internal Revenue Service (â€œIRSâ€) Form 8594) on a basis consistent with the Allocation and shall (and shall cause its respective Subsidiaries to) take noâ€‹-33-position inconsistent with the Allocation on any Tax Return (including IRS Form 8594) or in any Tax Proceeding or otherwise, in each case, except to the extent otherwise required pursuant to a â€œdeterminationâ€ within the meaning of Section 1313(a) of the Code (or any analogous provision of state, local or non-U.S. Law). In the event that the Allocation is disputed by any Taxing Authority, the Party receiving notice of the dispute shall promptly notify the other Party hereto, and both Seller and the Purchasers agree to use their commercially reasonable efforts to defend such Allocation in any Tax Proceeding.(d)If, in connection with the applicable Deferred Closing, an allocation of the relevant portion of the purchase price among the assets and liabilities transferred in such Deferred Closing is required by applicable Law, and the Allocation has not become final pursuant to this SectionÂ 2.10 at the time of such Deferred Closing, the Parties shall agree on an allocation of the relevant portion of the purchase price and any other items that are treated as additional consideration for U.S. federal income Tax purposes among the applicable Deferred Marketing Authorizations and Deferred Marketing Authorization Liabilities (each, a â€œSuballocationâ€). Any such Suballocation shall be consistent with the Initial Allocation. If Seller and the Purchasers are unable to mutually agree on any such Suballocation, such disagreement shall be referred to the Independent Accounting Firm promptly for review and resolution (in accordance with the procedures set forth in SectionÂ 2.9).SectionÂ 2.11Transferred Marketing Authorizations.(a)Notwithstanding anything to the contrary herein, if, the sale, assignment, transfer, conveyance or delivery of any of the Transferred Marketing Authorizations or the purchase, acquisition, acceptance and assumption of any Assumed Liabilities relating thereto as contemplated by this ArticleÂ II shall not have been consummated as of the Closing because a Regulatory Approval (other than a Required Approval) has not been received (each, a â€œDeferred Marketing Authorizationâ€ or a â€œDeferred Marketing Authorization Liability,â€ as applicable), then, notwithstanding anything to the contrary in this Agreement, such Deferred Marketing Authorizations and Deferred Marketing Authorization Liabilities shall not be transferred to the Purchasers at the Closing (but the Closing shall otherwise occur with respect to the Purchased Assets (other than any Deferred Marketing Authorizations) and Assumed Liabilities (other than any Deferred Marketing Authorization Liabilities)). Such Deferred Marketing Authorizations and Deferred Marketing Authorization Liabilities shall be transferred to the Purchasers on the second (2nd) Business Day following the receipt, satisfaction or waiver of such Regulatory Approval (each, a â€œDeferred Closingâ€ and such date, a â€œDeferred Closing Dateâ€) with respect to such Deferred Marketing Authorizations and Deferred Marketing Authorization Liabilities, as applicable; provided that the receipt, satisfaction or waiver of such Regulatory Approval allows the Purchasers or any of their Subsidiaries to manufacture, distribute and market the applicable Business Products in the applicable jurisdictions in substantially the same manner as, and consistent with, the practice of the Business prior to Closing. If the Purchasers or any of their Subsidiaries obtain a new marketing authorization (including any re-registration) that enables the Purchasers or any of their Subsidiaries to manufacture, distribute and market the applicable Business Products in the applicable jurisdictions in substantially the same manner as, and consistent with, the practice of the Business prior to Closing with respect to each such Deferred Marketing Authorizations (in which case Seller and its Subsidiaries shall, subject to prior consultation with and receipt of written confirmation from the Purchasers, be entitled toâ€‹-34-withdraw or terminate such Deferred Marketing Authorizations), or if the Purchasers or any of their Subsidiaries obtain a Deferred Marketing Authorization from an authorized third party (e.g., an importer, manufacturer or distributor) that holds such Deferred Marketing Authorization and confirms the same in writing to Seller, then Seller and its Subsidiaries shall be released of their obligations hereunder to transfer such Deferred Marketing Authorizations to the Purchasers. In no event shall the Closing Purchase Price payable by the Purchasers at the Closing or the Final Purchase Price be reduced or deferred in respect of any Deferred Marketing Authorizations or Deferred Marketing Authorization Liabilities and the Cash, Indebtedness, Working Capital and Gross Profit of or relating to any Deferred Marketing Authorizations and Deferred Marketing Authorization Liabilities will be included in determining the Closing Cash, the WC Adjustment Amount, the Closing Indebtedness, the Closing Gross Profit and the Gross Profit Adjustment Amount pursuant to SectionÂ 2.9.(b)With respect to any Deferred Marketing Authorizations or Deferred Marketing Authorization Liabilities, from the Closing Date until the earliest of (i) the applicable Deferred Closing Date, (ii) the date on which the Purchasers or any of their Subsidiaries obtain a new marketing authorization (including any re-registration) that enables the Purchasers or any of their Subsidiaries to manufacture, distribute and market the applicable Business Products in the applicable jurisdictions in substantially the same manner as, and consistent with, the practice of the Business prior to Closing with respect to each such Deferred Marketing Authorizations (in which case Seller and its Subsidiaries shall, subject to prior consultation with the Purchasers, be entitled to withdraw or terminate such Deferred Marketing Authorizations and be released of their obligations hereunder to transfer such Deferred Marketing Authorizations) and (iii) the date the Purchasers or any of their Subsidiaries obtain a Deferred Marketing Authorization from an authorized third party (e.g., an importer, manufacturer or distributor) that holds such Deferred Marketing Authorization (in which case Seller and its Subsidiaries shall be released of their obligations hereunder to transfer such Deferred Marketing Authorizations), (w) the Purchasers shall, at their sole cost, use reasonable best efforts to obtain, or cause to be obtained the applicable Regulatory Approval or a new marketing authorization (including any re-registration) that enables the Purchasers or their Subsidiaries to manufacture, distribute and market the applicable Business Products in the applicable jurisdictions in substantially the same manner as, and consistent with, the practice of the Business prior to Closing, (x) Seller shall use commercially reasonable efforts to assist the Purchasers in obtaining such Regulatory Approvals, (y) Seller (or its designated Subsidiary) and the Purchasers (or their designated Subsidiary) shall enter into a distribution agreement in substantially the form of the Distribution Agreement, and (z)Â the Parties shall treat the applicable Purchaser as the owner of any such Deferred Marketing Authorizations and Deferred Marketing Authorization Liabilities for Tax purposes as of the Closing Date. For so long as Seller or any member of the Seller Group holds any Deferred Marketing Authorizations or assumes any Deferred Marketing Authorization Liabilities following the Closing and provides the applicable Purchaser or its Subsidiaries any claims, rights and benefits of any such Deferred Marketing Authorizations or Deferred Marketing Authorization Liabilities pursuant to an arrangement described in this SectionÂ 2.11, the Purchasers shall indemnify and hold Seller and its Subsidiaries harmless from and against all Covered Losses incurred or asserted as a result of post-Closing direct or indirect ownership, management or operation of any such Deferred Marketing Authorizations or Deferred Marketing Authorization Liabilities by Seller or any member of the Seller Group.â€‹-35-SectionÂ 2.12Bulk Sales. Each Purchaser on behalf of itself and its Subsidiaries acknowledges that Seller and its Subsidiaries have not taken, and do not intend to take, any actions required to comply with any applicable â€œbulk transfer lawâ€ or â€œbulk sales lawâ€ (or any similar Law) of any jurisdiction. Each Purchaser on behalf of itself and its Subsidiaries waives compliance by Seller and its Subsidiaries with the provisions of any â€œbulk transfer lawâ€ or â€œbulk sales lawâ€ (or any similar law) of any jurisdiction in connection with the Transaction and the other transactions contemplated by this Agreement.SectionÂ 2.13Withholding. The Purchasers and Seller shall be entitled to deduct and withhold (or cause to be deducted and withheld) from any amount payable pursuant to this Agreement such amounts as are required to be deducted and withheld under applicable Law; provided, that the Purchasers and Seller shall each use commercially reasonable efforts to provide the other Party with written notice of the Purchasersâ€™ or Sellerâ€™s (as applicable) intention to withhold at least five (5) Business Days prior to any such withholding and the Purchasers and Seller shall cooperate in good faith to minimize any such Taxes. Amounts withheld pursuant to this SectionÂ 2.13 and paid over to the appropriate Taxing Authority shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made.ARTICLEÂ IIIREPRESENTATIONS AND WARRANTIES OF SELLERExcept as disclosed in, or qualified by any matter set forth in, the Seller Disclosure Schedules, Seller hereby represents and warrants to the Purchasers as follows:SectionÂ 3.1Organization and Standing.(a)Seller and each other Seller Entity is a corporation, partnership or other legal entity duly organized, validly existing and, where applicable, in good standing (or other local equivalent) under the Laws of the jurisdiction of its organization, except where the failure to be so organized, existing or in good standing would not have, individually or in the aggregate, a Business Material Adverse Effect or materially impair, hinder or delay the ability of Seller and its Subsidiaries to perform their respective obligations under this Agreement and the other Transaction Documents or to consummate the transactions contemplated hereby and thereby.(b)Seller has made available to the Purchasers correct and complete copies of the governing documents of each Purchased Entity, which are in full force and effect, and no Purchased Entity is in breach or in violation of any such governing documents.SectionÂ 3.2Purchased Entities; Capital Structure.(a)Each of the Purchased Entities is a corporation, partnership or other legal entity duly organized and validly existing, with corporate or other similar applicable power and authority to own, lease and operate its properties and assets and to carry on its respective business, as currently conducted. Each of the Purchased Entities is duly qualified to do business and, where applicable, in good standing (or other local equivalent) in each jurisdiction where the nature of its business or properties makes such qualification necessary, except where the failure to be so qualified or in good standing would not be or reasonably expected to be, individually orâ€‹-36-in the aggregate, material to the Business and the Purchased Entities, taken as a whole. No vote of any stockholders or other equity holders of a Purchased Entity or any of its Affiliates is required for the execution of this Agreement or any other Transaction Document or the consummation of the Transaction or the other transactions contemplated hereby and thereby.(b)All of the outstanding equity interests of each of the Purchased Entities are validly issued, fully paid and, in the case of any Purchased Entity which is a corporation, non-assessable. There are no outstanding warrants, options, agreements, subscriptions, convertible or exchangeable securities or other commitments pursuant to which any of the Purchased Entities is or may become obligated to issue, sell, purchase, return, redeem or otherwise acquire any equity interests of the Purchased Entities. The Seller Entities own of record or beneficially all of the Purchased Entity Shares free and clear of all Liens, except for restrictions arising under applicable securities Laws, those that are expressly set forth in the governing documents of the Purchased Entities or those that will be discharged and released at or prior to the Closing. None of the issued and outstanding equity interests of the Purchased Entities were issued in violation of any preemptive rights, rights of first refusal, transfer restrictions or similar rights or any applicable Laws or are subject to any Liens (other than restrictions arising under applicable securities Laws, those that are expressly set forth in the governing documents of the Purchased Entities or those that will be discharged and released at or prior to the Closing). None of the Purchased Entities is party to, nor are the issued and outstanding equity securities of the Purchased Entities subject to, any equityholders, stockholders, voting trust or similar agreement or any other Contract related to the voting, transfer, redemption or repurchase of, or that otherwise provides for any rights in respect of, any such equity securities, except for the organizational documents of the Purchased Entities. None of the Purchased Entities owns any equity securities in any other Person or is subject to any obligation or requirement to make any investment (in the form of a loan, capital contribution or otherwise) in any other Person.(c)SectionÂ 3.2(c) of the Seller Disclosure Schedules sets forth (as may be updated prior to the Closing pursuant to clause (iii)), as of the date hereof, (i)Â the name and the jurisdiction of organization of each of the Purchased Entities, (ii)Â the record owners of the outstanding equity interests of each of the Purchased Entities, (iii)Â the number and type of authorized, issued and outstanding equity interests of the Purchased Entities (provided, that, Seller may update SectionÂ 3.2(c)(iii) of the Seller Disclosure Schedules from time to time prior to the Closing) and (iv) the percentage interest held by each Seller Entity. None of the Purchased Entities has any Subsidiaries.SectionÂ 3.3Authority; Enforceability.(a)Seller has all requisite corporate power and authority to execute and deliver this Agreement and each other Transaction Document to which it is or will be a party and to perform its obligations hereunder and thereunder. The execution and delivery by Seller of this Agreement and each such Transaction Document, and the performance by Seller of its obligations hereunder and thereunder, have been, or will have been as of the Closing, duly authorized by all requisite corporate action. Each other Seller Entity has, or will have as of the Closing, all requisite corporate or other similar applicable power and authority to execute and deliver each Transaction Document to which it will be a party and to perform its obligations thereunder. The execution and delivery by each other Seller Entity of each Transactionâ€‹-37-Document to which it will be a party, if applicable, and the performance by it of its obligations thereunder, have been, or will have been as of the Closing, duly authorized by all requisite corporate or other similar applicable action.(b)Seller and each other Seller Entity has, or will have as of the Closing, all requisite corporate or other similar applicable power and authority to carry on its respective business as it pertains to the Business as currently conducted and to own, lease and operate its properties and assets related to the Business, except where the failure to have such power and authority would not materially impair, hinder or delay the ability of Seller and its Subsidiaries to perform their respective obligations under this Agreement and the other Transaction Documents or to consummate the transactions contemplated hereby and thereby.(c)This Agreement has been duly executed and delivered by Seller and, assuming this Agreement has been duly executed and delivered by the Purchasers, constitutes a valid and binding obligation of Seller, and each other Transaction Document will be as of the Closing duly executed and delivered by each Seller Entity that will be a party thereto and will, assuming such Transaction Document has been duly executed and delivered by each other party thereto, constitute a valid and binding obligation of such Seller Entity, in each case enforceable against such Seller Entity in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditorsâ€™ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).SectionÂ 3.4No Conflicts; Consents. The execution, delivery and performance of this Agreement and the other Transaction Documents to which Seller or any other Seller Entity will be a party by Seller or such other Seller Entity and the consummation of the transactions contemplated hereby and thereby by Seller or such other Seller Entity do not and will not (a)Â violate any provision of the certificate of incorporation, bylaws or other organizational documents of Seller, any of the other Seller Entities or any of the Purchased Entities, (b)Â subject to obtaining the consents set forth in SectionÂ 3.4(b) of the Seller Disclosure Schedules, conflict with, constitute a default under, or result in the breach or termination, cancellation or acceleration (whether after the giving of notice or the lapse of time or both) of any right or obligation of the Seller Entities or the Purchased Entities under, or to a loss of any benefit of the Business to which any of the Seller Entities or the Purchased Entities is entitled under any Material Contract or any other Contract that constitutes a Purchased Asset

and (c)Â assuming compliance with the matters set forth in SectionÂ 3.5 and SectionÂ 4.4, violate or result in a breach of or constitute a default under any Law or other restriction of any Governmental Entity to which any Seller Entity or Purchased Entity is subject; except, with respect to clausesÂ (b) and (c), as would not, individually or in the aggregate, be or reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole.SectionÂ 3.5Governmental Authorizations. The execution, delivery and performance of this Agreement by Seller does not require any Regulatory Approval of, or Filing with, any Governmental Entity, except for (a)Â compliance with (i) the applicable requirements of the HSR Act and (ii)Â any other applicable Regulatory Law, (b) compliance with the applicable requirements of the Securities Act and the U.S. Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the â€œExchange Actâ€),â€‹-38-(c)Â compliance with the rules and regulations of the New York Stock Exchange, (d)Â compliance with any applicable foreign or state securities or blue sky Laws and (e)Â Regulatory Approvals and Filings which if not obtained or made would not, individually or in the aggregate, be or reasonably expected to be material to the Purchased Entities and the Business, taken as a whole.SectionÂ 3.6Proceedings.(a)There is no, and during the past three (3) years there has not been any, Proceeding pending or, to the Knowledge of Seller, threatened against a Purchased Entity, Seller or any of its Subsidiaries relating to the Business or any properties or rights of a Purchased Entity, other than Proceedings which would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole or which would not, individually or in the aggregate, have a Business Material Adverse Effect.(b)As of the date of this Agreement, none of the Purchased Entities or the Seller Entities (relating to the Business) is subject to any outstanding Judgment other than those which would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole or which would, individually or in the aggregate, have a Business Material Adverse Effect.SectionÂ 3.7Financial Statements; Absence of Undisclosed Liabilities.(a)SectionÂ 3.7(a) of the Seller Disclosure Schedules sets forth correct and complete copies of the unaudited statement of assets and liabilities of the Business and related income statement as of and for the fiscal year ended December 31, 2023 (collectively, the â€œBusiness Financial Informationâ€).(b)The Business Financial Information (i) has been derived from the financial statements of Seller and its Subsidiaries, which have been prepared in accordance with GAAP, consistently applied during the periods involved, and (ii) fairly presents in all material respects (A) the financial condition, assets and liabilities of the Business as of the dates therein specified and (B) the results of operations of the Business for the periods indicated therein; provided, that the Business Financial Information does not include footnote disclosures (which if presented would not materially change the financial position and results of operations of the Business), is unaudited, may not include all adjustments that an audit may require and may include certain normalized adjustments that audited or unaudited financial statements may not require as set forth on Section 3.7(b) of the Seller Disclosure Schedules; provided, further, that the Business Financial Information and the foregoing representations and warranties are qualified by the fact that the Business has not operated as a separate standalone entity and has received certain allocated charges and credits which do not necessarily reflect amounts that would have resulted from armâ€™s-length transactions or that the Business would incur on a standalone basis.(c)Seller and its Subsidiaries maintain systems of internal accounting controls designed to provide reasonable assurances (i) regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP in all material respects, (ii) the receipts and expenditures of the Business are being made in accordance with appropriate authorizations of management of the Seller Group andâ€‹-39-(iii)Â regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Business that could have a material effect on the financial statements of the Business, it being understood that Sellerâ€™s policies and procedures are designed and implemented giving effect to Sellerâ€™s entire business and therefore levels of materiality and other determinations made with respect to Seller may not be the same as if the Business were operated on a standalone basis.(d)Except as set forth on SectionÂ 3.7(d) of the Seller Disclosure Schedule, as of the date hereof, the Business does not have any Liabilities that would be required by GAAP to be reflected on a balance sheet of the Business, other than Liabilities that: (i) are specifically reflected and adequately reserved against in the most recent balance sheet and included in the Business Financial Information (â€œBalance Sheet Dateâ€), (ii) were incurred since the Balance Sheet Date in the ordinary course of business (none of which is a Liability resulting from breach of contract, breach of warranty, tort, infringement or misappropriation or violation of Law), (iii)Â are Retained Liabilities, (iv) are disclosed in SectionÂ 3.7(d) of the Seller Disclosure Schedules, or (v) would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole.(e)As of the date hereof, the Business meets the requirements for abbreviated financial statements set forth in Rule 3-05(e)(1)(i), (ii), (iii) and (iv) of Regulation S-X under the Securities Act.SectionÂ 3.8Absence of Changes or Events. (a) Since the Balance Sheet Date through the date of this Agreement, the Business has been conducted in all material respects in the ordinary course of business, (b) since the Balance Sheet Date, there has not been any Business Material Adverse Effect and (c) since Balance Sheet Date through the date of this Agreement, no Seller Entity or Purchased Entity has, in relation to the Purchased Entities or the conduct of the Business, taken any action set forth in clauses (ii), (iii), (iv), (v), (vi), (viii), (ix), (x), (xii), (xiii), (xiv), (xix) or (xxiii) (to the extent clause (xxiii) relates to any of the foregoing clauses of SectionÂ 5.2(b)) of SectionÂ 5.2(b), that, if taken following the execution of this Agreement until the Closing, would require the consent of the Purchasers.SectionÂ 3.9Title to Assets; Sufficiency of Assets.(a)Except as would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole, the Seller Entities or the Purchased Entities will (assuming all Regulatory Approvals as may be required in connection with the consummation of the Transaction and the other transactions contemplated by this Agreement have been obtained) have as of the Closing good title to, or other legal rights to possess, use, and transfer, all of the Purchased Assets (other than any Deferred Marketing Authorizations) as conducted immediately prior to the Closing, free and clear of all Liens other than Permitted Liens.(b)Except as set forth on SectionÂ 3.9(b) of the Seller Disclosure Schedules, the Purchased Assets (assuming all Regulatory Approvals as may be required in connection with the consummation of the Transaction and the other transactions contemplated by this Agreement have been obtained and assuming that any Deferred Marketing Authorizations are transferred toâ€‹-40-the Purchasers at the Closing), together with the services, rights and benefits to be provided pursuant to the Transaction Documents, shall, in the aggregate, constitute all of the rights, materials, goods, services, properties and assets (tangible or intangible) in all material respects necessary for the Purchasers and their Subsidiaries (including the Purchased Entities) to conduct the Business immediately following the Closing in substantially the same manner as conducted by Seller and its Subsidiaries as of the date of this Agreement.SectionÂ 3.10Intellectual Property.(a)SectionÂ 3.10(a) of the Seller Disclosure Schedules lists all Registered IP included in the Transferred Intellectual Property, as of the date of this Agreement (the â€œBusiness Registered IPâ€).(b)Except as would not, individually or in the aggregate, reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole: (i) the applicable Seller Entities or the Purchased Entities are current in the payment of all registration, maintenance and renewal fees with respect to the Business Registered IP, except in each case as Seller or any of its Subsidiaries has elected in its reasonable business judgment to abandon or permit to lapse a registration or application for any Intellectual Property Rights, (ii) the Business Registered IP and all Transferred Intellectual Property are solely owned by the Seller Entities or the Purchased Entities free and clear of all Liens, other than Permitted Liens, (iii) the Business Registered IP is subsisting, valid and, to the Knowledge of Seller, not unenforceable and (iv) as of the Closing, Purchasers or their Subsidiaries (including the Purchased Entities) will be the sole and exclusive owner of all Transferred Intellectual Property and, taking into account the services, rights and benefits to be provided pursuant to the Transaction Documents, will have the right or license to use all other Intellectual Property Rights necessary for the Purchasers and their Subsidiaries (including the Purchased Entities) to conduct the Business immediately following the Closing in substantially the same manner as conducted by Seller and its Subsidiaries as of the date of this Agreement.(c)Except as would not reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole: (i) none of the Transferred Intellectual Property is subject to any Judgment adversely affecting the use thereof or rights thereto by Seller and its Subsidiaries or the Purchased Entities; (ii)Â there is no opposition or cancellation Proceeding pending against Seller and its Subsidiaries or the Purchased Entities as of the date of this Agreement concerning the ownership, validity or enforceability of any Business Registered IP; (iii) as of the date of this Agreement, none of Seller, its Subsidiaries or the Purchased Entities, has received any written notice within the three (3)-year period prior to the date of this Agreement alleging that the conduct of the Business infringes, misappropriates, or violates the Intellectual Property Rights of any other Person; (iv) none of Seller, its Subsidiaries, the Purchased Entities as of the date hereof or within the three (3)-year period prior to the date of this Agreement has alleged (including by initiating any claim or action) that a third Person is infringing, misappropriating, or violating the Transferred Intellectual Property; and (v) since the date that is three (3) years prior to the date hereof, the conduct of the Business has not infringed, misappropriated, or violated the Intellectual Property Rights of any other Person.â€‹-41-(d)Except as would not reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole, (i) Seller or its Subsidiaries, and the Purchased Entities, as applicable, have taken commercially reasonable measures to protect and maintain the confidentiality of Trade Secrets included in the Transferred Intellectual Property, (ii) there have been no material unauthorized uses or disclosures of any such Trade Secrets within the three (3)-year period prior to the date of this Agreement, except in the ordinary course of business pursuant to a written confidentiality, non-use, and non-disclosure agreement with the Purchased Entities, and (iii) to the Knowledge of Seller, there have been no breaches of any such agreements.(e)Except as would not reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole, all current and former officers and employees of, and consultants and independent contractors to, Seller and its Subsidiaries, or the Purchased Entities, as applicable, that were involved in the conception, creation, authoring, reduction to practice, or development of Transferred Intellectual Property have agreed to, or are subject to policies, restricting the disclosure and use of any confidential information (except for use for the benefit of Seller and its Subsidiaries) and have assigned either by operation of law, or by granting an assignment, to Seller or any of its Subsidiaries, or the applicable Purchased Entity, of all rights in and to any Transferred Intellectual Property conceived, created, authored, reduced to practice, or developed pursuant to services performed for the Business by such Persons for the Business.SectionÂ 3.11Information Technology; Data Protection.(a)Except as would not reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole, during the three (3)-year period immediately prior to the date of this Agreement, there have not been any material vulnerabilities or defects that have resulted in any security breaches or unauthorized access or other security access incidents involving the unauthorized processing, access, deletion, exfiltration, use, loss, destruction, compromise, transfer, or disclosure of any Personal Data or Trade Secrets collected or received by the Purchased Entities, or adversely affecting, including resulting in a partial or complete loss of control of, the Transferred Information Technology.(b)Except as would not reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole, (i) Seller, its Subsidiaries and the Purchased Entities are and have been during the three (3) year period immediately prior to the date of this Agreement in compliance in all material respects with all applicable Data Protection Laws with respect to the Business, as well as their own rules, policies and procedures, relating to privacy, data protection and the collection, retention, protection, transfer, use and processing of Personal Data with respect to the Business; (ii) none of Seller, its Subsidiaries or the Purchased Entities is party to any pending or threatened Proceedings, or has, during the three (3) year period immediately prior to the date of this Agreement, received any written notice from any applicable Governmental Entity or been party to any Proceeding, in each case, alleging a violation of any Data Protection Laws with respect to the Business or otherwise in connection with the processing of Personal Data; (iii)Â the Purchased Entities (and the Seller Entities with respect to Personal Data collected or used in connection with the Business) have taken appropriate actions (including implementing reasonable technical, physical or administrativeâ€‹-42-safeguards) to protect the Transferred Information Technology, Trade Secrets, and all Personal Data in their possession or under their control against any unauthorized use, access or disclosure; and (iv) during the three (3) year period immediately prior to the date of this Agreement, there have been no successful phishing incidents, ransomware or malware attacks or any unauthorized use, loss, access, destruction, processing, acquisition, compromise, transfer, or disclosure of any Personal Data or Trade Secrets collected or received by the Purchased Entities, or other security incident of or involving Personal Data collected by or used in connection with the Business.(c)Except as would not reasonably be expected to be material to the Purchased Entities and the Business, taken as a whole, (i) the Purchased Entities own, lease, license, or otherwise have the legal right to use all Transferred Information Technology, and (ii)Â all Transferred Information Technology (A) is free from any material defect, bug, virus or programming, design or documentation error or corruptant that permit, or are designed to permit, unauthorized access to any Transferred Information Technology, (B) operates and runs in a reasonable and efficient business manner, and (C) is sufficient for the current and currently contemplated needs of the Business.SectionÂ 3.12Real Property.(a)Except as would not be or reasonably be expected to be, individually or in the aggregate, material to the Purchased Entities and the Business, taken as a whole:(i)Seller, a Seller Entity or a Purchased Entity has good and valid fee simple title to the applicable Owned Real Property, free and clear of any Liens, other than Permitted Liens. Except as set forth in SectionÂ 3.12(a)(i) of the Seller Disclosure Schedules, as of the date hereof, (A) none of Seller, a Seller Entity or a Purchased Entity has leased or otherwise granted to any Person the right to use or occupy such Owned Real Property or any portion thereof and (B) the Purchased Entities are not a party to any agreement or option to purchase any real property or interest therein. None of the Owned Real Property is subject to any first refusal, purchase option, right to purchase or other similar right.(ii)Seller, a Seller Entity or a Purchased Entity has a legal, valid, binding, enforceable and in full force and effect leasehold estate (as lessee) in all Leased Real Property as lessee or sublessee, in each case free and clear of all Liens, other than Permitted Liens. Seller has delivered to the Purchasers a true and complete copy of each such Transferred Lease as in effect as of the date hereof. Except as set forth in SectionÂ 3.12(a)(ii) of the Seller Disclosure Schedules, with respect to each of the Transferred Leases, as of the date hereof: (A) none of Seller, a Seller Entity or a Purchased Entity has subleased, licensed or otherwise granted any Person the right to use or occupy such Leased Real Property or any portion thereof, and (B) none of Seller, a Seller Entity or a Purchased Entity has collaterally assigned or granted any other security interest in such Transferred Lease or any interest therein.(b)Except as would not have, individually or in the aggregate, a Business Material Adverse Effect, (i) all improvements located on the Owned Real Property have received all necessary Regulatory Approvals of Governmental Entities (including licenses and permits)â€‹-43-required in connection with the use thereof being made as of the date of this Agreement, (ii)Â there are no judicial or administrative Proceedings pending or, to the Knowledge of Seller, threatened in writing under any condemnation, environmental, zoning, eminent domain, land-use or other Law applicable to the Owned Real Property which, if adversely decided, would interfere with the present use in the Business of the Owned Real Property, (iii) there are no outstanding unpaid assessment notices against any of the Owned Real Property and (iv) all buildings, structures, improvements, fixtures, building systems and equipment, and all components thereof, included in the Owned Real Property are in good condition and repair and sufficient for the operation of the Business. The Owned Real Property and the Leased Real Property comprise all of the real property exclusively used in the Business.SectionÂ 3.13Contracts.(a)SectionÂ 3.13(a) of the Seller Disclosure Schedules sets forth the following Contracts to which any Purchased Entity or any Seller Entity (with respect to the Business) is a party to or bound by as of the date hereof (other than sales or purchase orders, statements of work, standard terms and conditions and similar instruments entered into or used in the ordinary course of business) (the â€œMaterial Contractsâ€):(i)the Contracts with the ten (10) largest customers of the Business (measured by aggregate dollar amounts received by the Business in the applicable region in the fiscal year ended December 31, 2023) (such counterparties, the â€œSignificant Customersâ€) for the provision of Business ProductsÍ¾(ii)the Contracts with the ten (10) largest suppliers of the Business (measured by dollar amounts spent by the Business in the fiscal year ended DecemberÂ 31, 2023) (such counterparties, the â€œSignificant Suppliersâ€) for the supply of services, products or materials for use in the Business;(iii)each Contract providing for (A) the acquisition or disposition by the Business of any business or assets (whether by merger, sale of stock, sale of assets or otherwise), excluding ordinary course commercial Contracts, in the last three (3) years and (B) continuing earn-out, indemnification, deferred or contingent purchase price or other similar obligations following the date of this AgreementÍ¾(iv)each Contract providing for a joint venture or other joint development agreement involving future payments or capital commitments or similar partnership agreement or arrangement with a third party;(v)each Contract providing for indebtedness for borrowed money in excess of $250,000 owed to a Person that is currently outstanding, or otherwise granting a Lien to secure indebtedness for borrowed money, in each case, other than (A)Â any such indebtedness to the extent owing from any of the Purchased Entities to any of the other Purchased Entities to the extent reconciled or eliminated in the consolidated financial statements of the Business at or prior to Closing or (B) any such indebtedness to be repaid or extinguished at or prior to the Closing;â€‹-44-(vi)each Contract requiring future capital expenditure obligations of the Business in excess of $250,000;(vii)each Contract relating to (A) the licensing of Intellectual Property Rights that are material to the Purchased Entities and the Business, taken as a whole, including any license granted (x)Â on an exclusive basis to any third party with respect to any Transferred Intellectual Property, or (y)Â to any of the Purchased Entities or Seller Entities with respect to Intellectual Property Rights of third parties, or (B) the Businessâ€™s ability to own, enforce, license or disclose any material Transferred Intellectual Property or relating to the acquisition, divestiture or development of any material Transferred Intellectual Property; excluding, in each case, licenses for commercially-available software or other Technology that involved aggregate annual payments less than $250,000 in the fiscal year ended December 31, 2023;(viii)each Transferred Lease;(ix)each Contract that by its express terms materially limits or materially impairs the ability of the Seller

Entities (with respect to the Business) or the Purchased Entities to compete in any line of business or with any Person or in any geographic area (including through non-compete or exclusivity provisions), other than customary exclusive distribution agreements for the Business Products entered into in the ordinary course of business consistent with past practice;(x)(A) each material Contract that contains any â€œmost favored nationâ€ or similar provision or (B) each Contract that contains minimum order or purchase requirements in excess of $250,000;(xi)any Contract of lease of any personal property requiring future payments in excess of $250,000 for any successive calendar year; and(xii)each Contract that is a settlement, conciliation or similar agreement with (A) any Governmental Entity, (B) entered into in the last three (3) years or (C)Â pursuant to which the Business or the Purchased Entities will have any material outstanding obligation after the date of this Agreement.(b)(i) Each Material Contract is valid and binding on the Seller Entity or Purchased Entity that is a party thereto and, to the Knowledge of Seller, each other party thereto, and is in full force and effect, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditorsâ€™ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law), and (ii) no Seller Entity or Purchased Entity or, to the Knowledge of Seller, any other party thereto, is in breach of, or default under, any such Material Contract. No Seller Entity or Purchased Entity has received any written, or to the Knowledge of Seller, other claim or notice of any other partyâ€™s intention to terminate, modify or allow to expire, any such Material Contract, and to the Knowledge of Seller, there is not, and in the past three (3) years has not been, any dispute with respect to any Material Contract, in each case, which would be or reasonably expected to be material to the Business and the Purchased Entities, taken as aâ€‹-45-whole. Except for any Shared Contracts, correct and complete copies of each Material Contract in effect as of the date hereof have been made available to the Purchasers.SectionÂ 3.14Significant Customers; Significant Suppliers.(a)SectionÂ 3.14(a) of the Seller Disclosure Schedules lists the names of each of the Significant Customers. To the Knowledge of Seller, none of the Significant Customers has modified, allowed to expire or terminated its relationship with the applicable Seller Entity or Purchased Entity. No member of the Seller Group or Purchased Entity has received any written notice that any Significant Customer has ceased or will cease to be a customer of the Business or that such Significant Customer intends to terminate, allow to expire or materially modify any existing Material Contract with any Seller Entity or Purchased Entity, as applicable. No Seller Entity or Purchased Entity has been engaged in the past three (3) years, or is currently engaging, in a material dispute with any Significant Customer.(b)SectionÂ 3.14(b) of the Seller Disclosure Schedules lists the names of each of the Significant Suppliers. To the Knowledge of Seller, none of the Significant Suppliers has modified, allowed to expire or terminated its relationship with the applicable Seller Entity or Purchased Entity. No member of the Seller Group or Purchased Entity has received any written notice that any Significant Supplier has ceased or will cease to act as a supplier of the Business or that such Significant Supplier intends to terminate, allow to expire or materially modify any existing Material Contract with any Seller Entity or Purchased Entity, as applicable. No member of the Seller Group or Purchased Entity has been engaged in the past three (3) years, or is currently engaging, in a material dispute with any Significant Supplier.SectionÂ 3.15Transferred Marketing Authorizations; Recalls.(a)SectionÂ 3.15(a) of the Seller Disclosure Schedules sets forth, as of the date of this Agreement, a list of (i) the marketing applications, regulatory or marketing approvals, clearances or other authorizations used to sell, distribute or market the Business Products and granted by any Governmental Entity, (ii) any Investigational New Animal Drug (INAD) files, data, information or applications that are part of the Business or related to Business Products and (iii) any Veterinary Master File (VMF) related to the Business or Business Products (â€œTransferred Marketing Authorizationsâ€).(b)Except as would not, individually or in the aggregate, be or reasonably expected to be material to the Purchased Entities and the Business, taken as a whole, Seller or its Subsidiaries have exclusive ownership, or have obtained beneficial use, of all Transferred Marketing Authorizations, and all such Transferred Marketing Authorizations are and, to the extent freely transferrable by Seller and its Subsidiaries, will be immediately after the Closing, valid and in full force and effect. No Proceedings with respect to Transferred Marketing Authorizations are (i)Â pending against any member of the Seller Group or, to the Knowledge of Seller, against any third-party holding a Transferred Marketing Authorization, or (ii) to the Knowledge of Seller, threatened in writing to revoke, suspend, or modify any Transferred Marketing Authorization;â€‹-46-(c)For the past twelve (12) months, none of Seller or any other member of the Seller Group has distributed, used, sold, marketed, manufactured, licensed, labeled, packaged, authorized any use of, offered a right of reference to, or letter of authorization for, any Additional Business Product corresponding to sales in excess of $2,000,000 during such period;(d)For the past three (3) years, there has not been conducted or requested in writing, nor, to the Knowledge of Seller, is there any current consideration by Seller or any of its Subsidiaries or any Governmental Entity of, any recall in respect of any Business Product; and(e)Except for ordinary course inquiries by Governmental Entities, there are not pending, or, to the Knowledge of Seller, threatened in writing, any Product Claims with respect to which liability is reasonably anticipated to exceed $500,000.SectionÂ 3.16Compliance with Applicable Laws; Permits.(a)None of the Seller Entities or the Purchased Entities is in violation of any Law applicable to the conduct of the Business as presently conducted, except for violations that would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole.(b)(i) Within five (5) years prior to the date of this Agreement, none of the Seller Entities or the Purchased Entities or any of their respective officers, employees, or directors, nor, to the Knowledge of Seller, any of their agents or third party representatives, in each case, with respect to the Business, has made, paid, authorized, promised, received, or accepted any gift, bribe, payoff or kickback to or from any person in violation of any applicable Law relating to anti-bribery, anti-money laundering, or anti-corruption, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (collectively, â€œAnti-Corruption Lawsâ€) or otherwise been in violation of Anti-Corruption Laws and (ii) to the Knowledge of Seller, none of the Seller Entities or the Purchased Entities, in each case with respect to the Business, is under Governmental Entity investigation for, or has received any written notice from a Governmental Entity regarding, any violation of any Anti-Corruption Laws.(c)The Seller Entities and/or the Purchased Entities hold all material Permits necessary for the conduct of the Business as presently conducted. The Seller Entities and the Purchased Entities, in each case with respect to the Business, are in compliance in all material respects with such Permits. The Seller Entities and/or the Purchased Entities hold all Permits required by all applicable FDA Laws and state animal feed regulations or animal remedies regulations, which Permits are in full force and effect, and no material suspension, cancellation, withdrawal, or revocation thereof is pending or, to the Knowledge of Seller, threatened.(d)Each Seller Entity and Purchased Entity has complied in the past three (3) years in all material respects with all FDA Laws applicable to the Business Products and all other U.S. federal and state statutes and regulations governing the research, development manufacturing, packaging, labeling, storage, distribution, marketing and/or advertising of the Business Products. To the Knowledge of Seller, each of the Seller Entities and/or Purchased Entities has not in the past three (3) years introduced or caused the introduction into commerce of any Business Products, and does not hold any inventory, which is/are or was/were in anyâ€‹-47-material respect â€œadulterated,â€ â€œmisbranded,â€ an article which may not be introduced into interstate commerce under any provision of the FDCA, or otherwise violative within the meaning of the FDCA and/or under any other applicable legal requirement that would reasonably be expected to result in any material liability to the Business and the Purchased Entities, taken as a whole, under the FDA Laws applicable to the Business Products.(e)Within the past three (3) years, there have been no pending or, to the Knowledge of Seller, threatened recalls, market withdrawals, stock recovery or public notifications, field notifications, food safety alerts, or similar actions with respect to any Business Products or other similar federal, state, or private actions with respect to such Business Products and, to the Knowledge of Seller, no facts or circumstances exist that would reasonably be expected to (i) result in the recall, market withdrawal or stock recovery of any Business Product, (ii) cause, as a result of any regulatory action by any Governmental Entity, (x) a material change in the research or development status or labeling of any Business Product or (y) a termination or suspension of the research, development, marketing, labeling or distribution of any Business Product, or (iii) result in any material liability to the Business and the Purchased Entities, taken as a whole, under the FDA Laws applicable to the Business Products.(f)Except as set forth on SectionÂ 3.16(f) of the Seller Disclosure Schedules, in the past three (3) years, none of the Seller Entities and/or Purchased Entities has received any FDA Form 483, FDA Warning Letter, Federal Trade Commission Letter, or any written notice of an action brought by the United States under FDA Laws or the U.S. Federal Trade Commission Act with respect to any Business Products, nor has any Seller Entity or Purchased Entity received any comparable written warnings or notices from any other Governmental Entity and to the Knowledge of Seller, there are no such pending or threatened actions, in each case with respect to any Business Products.(g)Each Seller Entity and Purchased Entity possesses, in all material respects, any required certification, and adequate substantiation, for any claims, promises, and affirmations of fact made with respect to any Business Product, including on the product labeling and in promotional materials.SectionÂ 3.17Environmental Matters.(a)(i)Â The Seller Entities and the Purchased Entities are, and for the past three (3) years have been, in compliance in all material respects with all Environmental Laws applicable to the conduct of the Business or the occupation of the Businessâ€™s properties or facilities, (ii)Â the Seller Entities and the Purchased Entities have obtained, maintained and are, and for the past three (3) years have been, in compliance in all material respects with all Permits pursuant to Environmental Laws required for the operation of the Business or the occupation of the Businessâ€™s properties or facilities, (iii)Â as of the Closing Date and for the past three (3) years (or earlier to the extent unresolved), the Seller Entities and the Purchased Entities have not received any written notice, report or other information and there are and have been no Proceedings pending, or to the Knowledge of Seller threatened, against the Seller Entities or the Purchased Entities, in each case alleging a material violation of, or material Liability under, Environmental Laws with respect to the Business or the Businessâ€™s properties or facilities, and (iv) there has been no storage, handling, treatment, transportation, disposal, arranging for orâ€‹-48-permitting the disposal, or release of, exposure of any Person to, or ownership or operation of any property or facility contaminated by, any Hazardous Material (or products or other items containing any Hazardous Material), in each case that would give rise to material Liability of the Seller Entities or Purchased Entities with respect to the Business and the Purchased Assets, taken as a whole, under Environmental Laws.(b)Seller has made available to the Purchasers copies of all material environmental, health or safety audits, assessments and reports and other material environmental, health or safety documents for the past five (5) years relating to the current or former properties, facilities or operations of the Business, Purchased Assets or Purchased Entities, which are in its possession or under its reasonable control.SectionÂ 3.18Taxes.(a)Except with respect to (1) Taxes of any member of the Seller Group or (2)Â any Tax Return of any consolidated, combined, affiliated or unitary group that includes any member of the Seller Group, including any Combined Tax Return, (i)Â all material Tax Returns required to be filed by the Purchased Entities have been timely filed (taking into account extensions) and all such Tax Returns are correct and complete in all material respects; (ii) all material amounts of Taxes shown to be due on such Tax Returns have been paid; (iii) there is no pending Tax Proceeding by any Taxing Authority with respect to any material Taxes of the Purchased Entities; (iv)Â each of the Purchased Entities has complied in all material respects with all applicable Laws relating to the withholding of Taxes; and (v) there are no Liens for Taxes upon any of the Purchased Assets or any assets of a Purchased Entity other than Permitted Liens.(b)The Purchased Entities have not been a member of an affiliated group within the meaning of Section 1504(a) of the Code (or any similar group defined under a similar provision of state, local, or foreign Law) filing a consolidated, affiliated or unitary income Tax Return, and the Purchased Entities do not have any liability for the Taxes of any Person under Treasury Regulations Section 1.1502-6 or any similar provision of Law, by contract (other than agreements not primarily related to Taxes), or as a transferee or successor.(c)No closing agreements, private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into with or issued by any Taxing Authority with respect to the Purchased Entities.(d)The Purchased Entities will not be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting made prior to the Closing; (ii) use of an improper method of accounting prior to the Closing; (iii) â€œclosing agreementâ€ as described in Code Section 7121 (or similar or corresponding provision of Law) executed prior to the Closing; (iv) installment sale made prior to the Closing; or (v) prepaid amount received prior to the Closing outside the ordinary course of business.(e)Each Purchased Entity is classified as an entity disregarded as separate from its owner for U.S. federal income Tax purposes.â€‹-49-(f)For the past three (3) years, the Purchased Entity Shares have been owned by a â€œcontrolled foreign corporationâ€ as defined in Section 957 of the Code.SectionÂ 3.19Benefit Plans.(a)Section 3.19(a) of the Seller Disclosure Schedules sets forth a list, as of the date of this Agreement, of each material Seller Benefit Plan and identifies each such plan that is a Purchased Entity Benefit Plan.(b)With respect to each material Purchased Entity Benefit Plan, Seller has made available to the Purchasers, to the extent applicable (i) the summary plan description, and the written document evidencing each Purchased Entity Benefit Plan or, with respect to any such plan that is not in writing, a written description of the material terms thereof, and all material amendments or material supplements to any Purchased Entity Benefit Plan, (ii)Â for any U.S. Purchased Entity Benefit Plan, the annual report (Form 5500), if any, filed with the IRS for the last plan year, and the most recently received IRS determination letter or prototype opinion letter, (iii)Â any related trust agreements, insurance contracts or documents of any other funding arrangements relating to a Purchased Entity Benefit Plan, (iv) the applicable portions of the most recently prepared actuarial report or financial statement relating to a U.S. Purchased Entity Benefit Plan, and (v) all material nonroutine correspondence with a Governmental Entity with respect to any U.S. Purchased Entity Benefit Plans within the past three (3) years. With respect to each Seller Benefit Plan that is not a Purchased Entity Benefit Plan, Seller has made available to the Purchasers the most recent summary plan description or a written description of the planâ€™s material terms.(c)No Purchased Entity Benefit Plan is subject to TitleÂ IV of ERISA and with respect to each Seller Benefit Plan, (i) there does not exist any failure to meet the â€œminimum funding standardâ€ of SectionÂ 412 of the Code or 302 of ERISA (whether or not waived), (ii) such plan is not in â€œat-riskâ€ status for purposes of Section 430 of the Code and (iii) no reportable event within the meaning of Section 4043(c) of ERISA has occurred.(d)Except as would not, individually or in the aggregate result in a material Liability to the Purchased Entities and the Business, taken as a whole, each Purchased Entity Benefit Plan that is intended to be qualified within the meaning of SectionÂ 401(a) of the Code has received a favorable determination letter as to its qualification or is covered by a prototype plan opinion letter, and nothing has occurred that would reasonably be expected to adversely affect the qualification of such U.S. Purchased Entity Benefit Plan.(e)Each Purchased Entity Benefit Plan has been operated in all material respects in compliance with its terms and applicable Law and no event has occurred and no condition exists with respect to such Purchased Entity Benefit Plan, that has subjected, or would reasonably be expected to subject, any Purchased Entity to any material Liability imposed by ERISA, the Code or any other applicable Law.(f)No Purchased Entity Benefit Plan is a Multiemployer Plan and, in the six (6) years prior to the date hereof, no Purchased Entity or an ERISA Affiliate of the Purchased Entities has withdrawn from a Multiemployer Plan to which the Purchased Entities or theirâ€‹-50-ERISA Affiliates contribute in respect of Business Employees in a â€œcomplete withdrawalâ€ or a â€œpartial withdrawalâ€ as defined in SectionsÂ 4203 and 4205 of ERISA, respectively, so as to result in a Liability of the Purchased Entities or their ERISA Affiliates that has not been fully paid.(g)Except as would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole, there is no pending or, to the Knowledge of Seller, any threatened claim, action, suit, audit, Proceeding, investigation, litigation, inquiry, or other disputes on behalf or relating to each Purchased Entity Benefit Plan (other than routine claims for benefits thereunder), and no Purchased Entity Benefit Plan has within the three (3) years prior to the date hereof been the subject of an examination, investigation or audit by a Governmental Entity.(h)Except as required by applicable Law, neither the execution of this Agreement nor the consummation of the Transaction will (either alone or in combination with any other event) (i)Â result in any material payment becoming due to any Business Employee or other individual service provider of the Business or the Purchased Entities under any Purchased Entity Benefit Plan or Seller Benefit Plan, (ii)Â materially increase the amount or value of, any compensation or benefits payable to any Business Employee or other individual service provider of the Business or the Purchased Entities under any Purchased Entity Benefit Plan, (iii)Â result in the acceleration of the time of payment, funding or vesting of any compensation or benefits of any Business Employee or other individual service provider of the Business or the Purchased Entities under any Purchased Entity Benefit Plan or Seller Benefit Plan, or (iv) result in any â€œparachute paymentâ€ (as such term is defined in Section 280G of the Code).(i)Each Purchased Entity Benefit Plan that constitutes in any part a â€œnonqualified deferred compensation planâ€ (within the meaning of Section 409A of the Code) has been established, operated and maintained at all times in all material respects in operational and documentary compliance with Section 409A of the Code and applicable guidance thereunder and no amount under any such Purchased Entity Benefit Plan has been, is or could reasonably be expected to be, subject to material interest or additional Tax under Section 409A of the Code.(j)Neither the Seller Entities nor the Purchased Entities maintain any obligations to indemnify, gross-up or reimburse any Business Employee or other individual service provider of the Business or the Purchased Entities for any Taxes or related interest or penalties incurred by such individual under Sections 409A or 4999 of the Code.(k)With respect to each Purchased Entity Benefit Plan that is subject to the Laws of a jurisdiction other than the United States (whether or not United States law also applies) (a â€œNon-U.S. Purchased Entity Benefit Planâ€): (i) all material employer and employee contributions to each Non-U.S. Purchased Entity Benefit Plan required by law or by the terms of such Purchased Entity Benefit Non-U.S. Plan have been timely made, or, if applicable, accrued in accordance with normal accounting practices, (ii) each Purchased Entity Benefit Non-U.S. Plan required to be registered has been registered and has been maintained in good standing with applicable regulatory authorities, except where any failure to comply would not, individually or in the aggregate,

be reasonably expected to result in a material Liability to the Purchased Entities and the Business, taken as a whole, (iii) no Non-U.S. Purchased Entity Benefit Plan is a defined benefit plan (as defined in ERISA, whether or not subject to ERISA), and (iv) there are noâ€‹-51-material unfunded or underfunded material Liabilities withÂ respect to any Non-U.S. Purchased Entity Benefit Plan.SectionÂ 3.20Labor Matters.(a)Section 3.20(a) of the Seller Disclosure Schedules sets forth each Business Employee, and for each: (i) employee identification number; (ii) job title; (iii) primary work location (including country and state); (iv) hourly wage or base salary (as applicable); (v) target annual incentive compensation opportunity; (vi) exempt or non-exempt status (for U.S. Business Employees); (vii) active or inactive status (and as applicable, type of leave and anticipated return date); (viii) full-time or part-time status; (ix) visa status (as applicable); (x) union or non-union status; (xi) date of hire; (xii) employing entity; and (xiii) accrued unused paid time off. The Business Employees are sufficient in number and skill to operate the Business in substantially the same manner as conducted by the Purchased Entities and Seller Group prior to the Closing. Other than the Business Employees, there are no employees of the Seller Group that primarily provide services to the Business.(b)Section 3.20(b) of the Seller Disclosure Schedules sets forth a list of each Collective Bargaining Agreement to which any Purchased Entity or Seller Entity (with respect to the Business) is a party or bound. Seller has made available to the Purchasers a copy of each such Collective Bargaining Agreement, including any national or industry contractor arrangement. Other than the Collective Bargaining Agreements set forth on Section 3.20(b) of the Seller Disclosure Schedules, there are no Collective Bargaining Agreements that pertain to any Business Employees, and none are currently being negotiated; and no Business Employees are represented by any labor union, labor organization, works council, employee representative or group of employees. There are no pre-signing legal or contractual requirements to provide notice or information to, bargain with, enter into any consultation procedure with, or obtain consent from, any labor union, works council, labor organization or employee representative, which is representing any Business Employees, or any applicable labor tribunal, in connection with the execution of this Agreement.(c)To the Knowledge of Seller, in the past three (3) years, (i) there has been no organizational effort made or threatened by, or on behalf of, any Business Employees, labor organization, union, or association, works council, or other employee representative body with respect to any Business Employees, and (ii) no application, request or demand for recognition or certification of any Business Employees has been made by, or on behalf of, any Business Employees, labor organization, union, or association, works council, or other employee representative body.(d)Except as would not, individually or in the aggregate, be material to the Purchased Entities and the Business, taken as a whole, (i) in the past three (3) years, there have been no actual or, to the Knowledge of Seller, threatened, unfair labor practice charges, labor grievances, labor arbitrations, strikes, work stoppages, slowdowns, picketing, hand billing, lockouts, or other labor disputes involving Business Employees or against or affecting the Purchased Entities or the Business and (ii) in the past three (3) years, there have been no unfair labor practice charges, strikes, or lockouts impacting the Business Employees.â€‹-52-(e)Each Purchased Entity and Seller Entity (with respect to the Business) has promptly, thoroughly, and impartially investigated all sexual harassment, or other harassment, discrimination, or retaliation allegations made during the past three (3) years relating to employees with an annual base compensation in excess of $150,000, officers or directors of such entities and of which the Seller has Knowledge. With respect to each such allegation with potential merit, the applicable Purchased Entity or Seller Entity has taken prompt corrective action reasonably calculated to prevent further improper action. No Purchased Entity or Seller Entity (with respect to the Business) (i)Â reasonably expects to incur any material Liability with respect to any such allegation or (ii)Â is aware of any such allegations that would indicate a breach of fiduciary duty or that, if known to the public, would bring the Business or any Purchased Entity into material disrepute.SectionÂ 3.21Intercompany Arrangements. Except for (a) any Contracts that will be terminated at or prior to the Closing, (b) the Transaction Documents and (c) the organizational documents of the Purchased Entities, there are no Contracts in effect as of the date of this Agreement that are solely between or among the Seller Group, on the one hand, and the Purchased Entities, on the other hand.SectionÂ 3.22Insurance. Except as would not reasonably be expected to be, individually or in the aggregate, material to the Purchased Entities and the Business, taken as a whole, (a) the Seller Entities and the Purchased Entities collectively own or hold policies of insurance, or are self-insured, in amounts providing reasonably adequate coverage against all risks customarily insured against by companies in similar lines of business as the Business and (b) as of the date hereof, all such insurance policies are in full force and effect, except for any expiration thereof in accordance with the terms thereof, no written notice of cancellation or modification has been received other than in connection with ordinary renewals, and there is no existing default or event (or failure to take action) which, with the giving of notice or lapse of time or both, would constitute a breach or default, by any insured thereunder, or otherwise would permit termination or modification of any of the insurance policies. As of the date hereof, no written notice of cancellation or termination has been received by any member of the Seller Group or a Purchased Entity with respect to any of the insurance policies applicable to the Business, and there are no material claims pending under any of such policies for which coverage has been denied or disputed by the applicable insurance carrier (other than a customary reservation of rights notice).SectionÂ 3.23Inventory; Accounts Payable; Accounts Receivable. Except as would not be or reasonably be expected to be, individually or in the aggregate, material to the Purchased Entities and the Business, taken as a whole, (a) all Inventory, whether or not reflected in the Business Financial Information, consists of a quality and quantity usable and salable in the ordinary course, except for obsolete or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established, in each case, in accordance with GAAP, and is fit for its intended use in all respects, (b) all Inventory is owned by a member of the Seller Group or a Purchased Entity, free and clear of all Liens (other than Permitted Liens), and no Inventory is held on a consignment basis, (c) all accounts payable of the Purchased Entities that are reflected in the Business Financial Information (except as specifically set forth therein) and all accounts payable of the Purchased Entities arising since the Balance Sheet Date are valid obligations and have arisen only from bona fide armâ€™s length transactions in the ordinary course of business, and all such accounts payable have either been paid, are not yetâ€‹-53-due and payable in the ordinary course of business, are being contested by the Purchased Entities in good faith (and appropriate reserves established therefor), and if not paid, have been properly recorded, (d) all accounts receivables of the Purchased Entities that are reflected in the Business Financial Information (except as specifically set forth therein) and all accounts receivables of the Purchased Entities arising since the Balance Sheet Date are valid obligations and have arisen only from bona fide armâ€™s length transactions in the ordinary course of business and are not subject to defenses, credits, setoffs or counterclaims, (e) no reasonable basis exists for the assertion of any claim of the repayment of any payments heretofore received by the Purchased Entities on account of any accounts receivable and (f) all of the outstanding receivables deemed uncollectible have been reserved against in the Business Financial Information in accordance with GAAP.SectionÂ 3.24Brokers. No broker, investment banker, or financial advisor is entitled to any brokerâ€™s, finderâ€™s, financial advisorâ€™s or other similar fee or commission in connection with the Transaction and the other transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller or its Subsidiaries for which the Purchasers or any of their Subsidiaries (including, following the Closing, the Purchased Entities) would have any Liability.SectionÂ 3.25International Trade.(a)None of the Purchased Entities nor any of their respective officers, directors or employees, nor to the Knowledge of Seller, any agent or other third party representative acting at the direction of any of the Purchased Entities, is currently, or has in the last five (5) years: (i) been a Sanctioned Person; (ii) been engaging in any dealings or transactions with or for the benefit of any Sanctioned Person or in any Sanctioned Country; or (iii) otherwise been in violation of Sanctions, Ex-Im Laws, or U.S. anti-boycott Laws (collectively, â€œTrade Controlsâ€).(b)In the past five (5) years, none of the Purchased Entities has: (i) received from any Governmental Entity or any Person any written or, to the Knowledge of Seller, oral notice, inquiry, or internal or external allegation; (ii) made any voluntary or involuntary disclosure to a Governmental Entity; or (iii) conducted any internal investigation or audit concerning any actual or potential violation or wrongdoing, in each case, related to Trade Controls or Anti-Corruption Laws.SectionÂ 3.26No Other Representations or Warranties. Except for the representations and warranties contained in this ArticleÂ III and in any certificate delivered in connection with this Agreement, neither Seller nor any of its Affiliates, Representatives or any other Person makes any express or implied representation or warranty with respect to Seller, the other Seller Entities, the Purchased Entities or any of their respective Affiliates, the Purchased Assets, the Business or with respect to any other information provided, or made available, to the Purchasers or any of their Affiliates or Representatives in connection with the Transaction or the other transactions contemplated by this Agreement. Neither Seller nor any of its Affiliates, Representatives or any other Person has made any express or implied representation or warranty with respect to the prospects of the Business or its profitability for the Purchasers, or with respect to any forecasts, projections or business plans or other forward looking information delivered toâ€‹-54-the Purchasers or any of their Affiliates or Representatives in connection with the Purchasersâ€™ review of the Business and the negotiation and execution of this Agreement, including as to the accuracy or completeness thereof or the reasonableness of any assumptions underlying any such forecasts, projections or business plans or other information. Neither Seller nor any of its Affiliates, Representatives or any other Person will have, or be subject to, any Liability or other obligation to the Purchasers or any of their Affiliates or Representatives or any other Person resulting from the use by the Purchasers or any of their Affiliates or Representatives of, any information, including information, documents, projections, forecasts, business plans or other material (including any Evaluation Material (as defined in the Confidentiality Agreement)) made available to the Purchasers, their Affiliates or Representatives in any virtual data room, confidential information memorandum, management presentations, offering materials, site tours or visits, diligence calls or meetings or any documents prepared by, or on behalf of, Seller or any of its Affiliates or Representatives, or the Purchasers or their Affiliates or Representatives or any of the Purchasersâ€™ potential financing sources (including the Financing Parties) in connection with the Purchasersâ€™ financing activities with respect to the transactions contemplated by this Agreement. Each of Seller and its Affiliates disclaims any and all representations and warranties, whether express or implied, except for the representations and warranties contained in this ArticleÂ III and in any certificate delivered in connection with this Agreement. Notwithstanding anything in this Agreement to the contrary, neither Seller nor any of its Affiliates makes any express or implied representation or warranty with respect to the Excluded Assets or the Retained Liabilities.ARTICLEÂ IVREPRESENTATIONS AND WARRANTIES OF PURCHASERSExcept as set forth in the Purchaser Disclosure Schedules, each Purchaser hereby represents and warrants, jointly and severally, to Seller as follows:SectionÂ 4.1Organization and Standing. Each Purchaser is a corporation duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation, except where the failure to be so organized, existing or in good standing would not have, individually or in the aggregate, a Purchaser Material Adverse Effect.SectionÂ 4.2Authority; Enforceability.(a)Each Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and each such Transaction Document to which it is or will be a party, and to perform its obligations hereunder and thereunder. The execution and delivery by each Purchaser of this Agreement and each other Transaction Document to which it is or will be a party, and the performance by each Purchaser of its obligations hereunder and thereunder, have been, or, with respect to Transaction Documents to which it will be a party, will have been as of the Closing, duly authorized by all requisite corporate or other similar applicable action. No vote of any stockholders or other equity holders of either Purchaser or any of its Subsidiaries is required for the execution of this Agreement or any other Transaction Document or the consummation of the Transaction or the other transactions contemplated hereby and thereby.â€‹-55-(b)Each Purchaser has all requisite corporate or other similar applicable power and authority to carry on its business as it is now being conducted and to own, lease and operate its properties and assets, except where the failure to have such power and authority would not have, individually or in the aggregate, a Purchaser Material Adverse Effect.(c)This Agreement has been duly executed and delivered by each Purchaser and, assuming this Agreement has been duly executed and delivered by Seller, constitutes a valid and binding obligation of each Purchaser, and each other Transaction Document will be duly executed and delivered by each Purchaser and will, assuming such Transaction Document has been duly executed and delivered by each Seller Entity that will be a party thereto, constitute a valid and binding obligation of each Purchaser, in each case enforceable against each Purchaser in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditorsâ€™ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).SectionÂ 4.3No Conflicts; Consents. The execution, delivery and performance by each Purchaser of this Agreement and the other Transaction Documents to which such Purchaser will be a party, and the consummation by each Purchaser of the transactions contemplated hereby and thereby, do not and will not (a)Â violate any provision of the certificate of incorporation, bylaws or other organizational documents of such Purchaser or any of its Affiliates, (b)Â conflict with, constitute a default under, or result in the breach or termination, cancellation or acceleration (whether after the giving of notice or the lapse of time or both) of any right or obligation of such Purchaser or any of its Affiliates under any Contract to which such Purchaser or any of its Affiliates is a party or is subject or (c)Â assuming compliance with the matters set forth in SectionÂ 3.5 and SectionÂ 4.4, violate or result in a breach of or constitute a default under any Law or other restriction of any Governmental Entity to which such Purchaser or any of its Affiliates is subject, except, with respect to clausesÂ (b) and (c), as would not have, individually or in the aggregate, a Purchaser Material Adverse Effect.SectionÂ 4.4Governmental Authorizations. The execution, delivery and performance of this Agreement by each Purchaser does not require any Regulatory Approval of, or Filing with, any Governmental Entity, except for (a)Â compliance with (i) the applicable requirements of the HSR Act and (ii) any other applicable Regulatory Law, (b)Â the Regulatory Approvals and Filings set forth in SectionÂ 4.4 of the Purchaser Disclosure Schedules and (c)Â the Regulatory Approvals and Filings which if not obtained or made would not have, individually or in the aggregate, a Purchaser Material Adverse Effect.SectionÂ 4.5[Reserved].SectionÂ 4.6Financing.(a)Purchaser 1 is a party to that certain Debt Commitment Letter, dated as of the date hereof (together with all exhibits, schedules, annexes and amendments thereto, together with the fee letter referred to therein, the â€œCommitment Letterâ€), pursuant to which the lenders party thereto (collectively, the â€œLendersâ€) have agreed, subject to the terms and conditions thereof, to provide debt financing in the amounts set forth therein. The debt financing committedâ€‹-56-pursuant to the Commitment Letter is collectively referred to in this Agreement as the â€œFinancing.â€(b)The applicable Purchaser has delivered to Seller a true, complete and correct copy of the executed Commitment Letter and any fee letters related thereto, subject, in the case of the fee letter, to redaction solely of fee, â€œmarket flexâ€, other economic provisions or other commercially sensitive information that are customarily redacted in connection with transactions of this type, in each case, so long as no such redaction adversely affects any term in respect of the conditionality, enforceability, availability, termination or aggregate principal amount of the Financing (other than through operation of additional original issue discount).(c)Except as expressly set forth in the Commitment Letter, there are no conditions precedent to the obligations of the Lenders to provide the Financing or any contingencies that would permit the Lenders to reduce the aggregate principal amount of the Financing below the Financing Amounts, including any condition or other contingency relating to the amount or availability of the Financing pursuant to any â€œflexâ€ provision. As of the date hereof, neither Purchaser has any reason to believe that it will be unable to satisfy on a timely basis all terms and conditions to be satisfied by it in the Commitment Letter on or prior to the Closing Date, nor does either Purchaser have Knowledge that any Lender will not perform its obligations thereunder. As of the date hereof, there are no side letters, understandings or other agreements, contracts or arrangements of any kind relating to the Commitment Letter or the Financing that could reasonably be expected to affect the conditionality, enforceability, availability, termination or amount of the Financing, other than as expressly contained in the Commitment Letter.(d)The Financing, when funded in accordance with the Commitment Letter and giving effect to any â€œflexâ€ provision in the fee letter or related to the Commitment Letter (including with respect to fees and original issue discount), together with the Purchasersâ€™ other available sources of funds, shall provide the Purchasers with cash proceeds on the Closing Date sufficient to provide the Purchasers with the funds necessary for it to fund all the Closing Purchase Price, the Final Purchase Price and any fees and expenses of or payable by each Purchaser or its Affiliates and all other amounts earned, due and payable pursuant to this Agreement on the Closing Date (such amounts, collectively, the â€œFinancing Amountsâ€).(e)As of the date hereof, the Commitment Letter constitutes the legal, valid, binding and enforceable obligations of Purchaser 1 and, to each Purchaserâ€™s Knowledge, all the other parties thereto and is in full force and effect, in each case, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditorsâ€™ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). As of the date hereof, no event has occurred which (with or without notice, lapse of time or both) constitutes, or would constitute, a default, breach or failure to satisfy a condition by the Purchasers under the terms and conditions of the Commitment Letter. As of the date hereof, the Purchasers do not have any reason to believe that any of the conditions to the Financing will not be satisfied by the Purchasers on a timely basis or that the Financing will not be available to the Purchasers on the Closing Date. Purchaser 1 has paid in full any and all commitment fees or other fees required to be paid pursuant to the terms of the Commitment Letter on or before the date of this Agreementâ€‹-57-and will pay in full any such amounts due on or before the Closing Date as and when due, in each case, pursuant to the terms of the Commitment Letter. The Commitment Letter will not be amended, modified or altered at any time through the Closing, except as permitted by SectionÂ 5.7(b) (with any such modification, amendment or alteration promptly notified in writing to Seller), and none of the respective commitments under the Commitment Letter has been terminated, reduced, withdrawn or rescinded in any respect, and, to the Knowledge of the Purchasers, no termination, reduction, withdrawal, modification, amendment, alteration or rescission thereof is contemplated.(f)In no event shall the receipt or availability of

any funds or financing (including the Financing) by the Purchasers or any of their Affiliates or any other financing or other transactions be a condition to any of the Purchasersâ€™ obligations under this Agreement.SectionÂ 4.7Proceedings. There is no, and in the past three (3) years there has not been, any Proceeding pending or, to the Knowledge of the Purchasers, threatened against either Purchaser or any of their Subsidiaries, other than Proceedings that would not have a Purchaser Material Adverse Effect. As of the date of this Agreement, neither Purchaser nor any of their Subsidiaries is subject to any outstanding Judgment that would have a Purchaser Material Adverse Effect.SectionÂ 4.8Brokers. No broker, investment banker or financial advisor is entitled to any brokerâ€™s, finderâ€™s, financial advisorâ€™s or other similar fee or commission in connection with the Transaction and the other transactions contemplated by this Agreement based upon arrangements made by or on behalf of any Purchaser or its Subsidiaries for which Seller or any of its Subsidiaries would have any Liability.SectionÂ 4.9Solvency. No transfer of property is being made, and no obligation is being incurred in connection with the transactions contemplated by this Agreement or the other Transaction Documents with the intent to hinder, delay or defraud either present or future creditors of any Purchaser, any Seller Entity or any Subsidiary thereof (including any Purchased Entity). Immediately after giving effect to the consummation of the transactions contemplated by this Agreement (including the Financing and any other financings being entered into in connection therewith), in each case, assuming the satisfaction of the conditions to Closing set forth in SectionÂ 8.1 and SectionÂ 8.2:(a)the Fair Value of the assets of the Purchasers and their Subsidiaries, taken as a whole, shall be greater than the total amount of the Purchasersâ€™ and their Subsidiariesâ€™ liabilities (including all liabilities, whether or not reflected in a balance sheet prepared in accordance with GAAP, and whether direct or indirect, fixed or contingent, secured or unsecured, disputed or undisputed), taken as a whole;(b)the Purchasers and their Subsidiaries, taken as a whole, shall be able to pay their debts and obligations in the ordinary course of business as they become due; and(c)the Purchasers and their Subsidiaries, taken as a whole, shall have adequate capital to carry on their businesses and all businesses in which they engage.â€‹-58-For the purposes of this SectionÂ 4.9, â€œFair Valueâ€ means the amount at which the assets (both tangible and intangible), in their entirety, of the Purchasers and their Subsidiaries would change hands between a willing buyer and a willing seller, within a commercially reasonable period of time, each having reasonable knowledge of the relevant facts, with neither being under any compulsion to act.SectionÂ 4.10Securities Laws. The Purchasers are acquiring the Purchased Entity Shares solely for the purpose of investment and not with a view to, or for sale in connection with, any distribution thereof in violation of the Securities Act or any other applicable state or foreign securities Laws. The Purchasers acknowledge that the Purchased Entity Shares are not registered under the Securities Act, any applicable state securities Laws or any applicable foreign securities Laws, and that such Purchased Entity Shares may not be transferred or sold, except pursuant to the registration provisions of the Securities Act and applicable state and foreign securities Laws or pursuant to an applicable exemption therefrom. The Purchasers have sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risks of their investment in the Purchased Entity Shares and are capable of bearing the economic risks of such investment.SectionÂ 4.11Acknowledgment of No Other Representations or Warranties. (a)Except for the representations and warranties contained in this ArticleÂ IV and in any certificate delivered in connection with this Agreement, neither Purchaser nor any of their Affiliates, Representatives or any other Person makes any express or implied representation or warranty with respect to either Purchaser or any of their respective Affiliates, or with respect to any other information provided, or made available, to Seller or any of its Affiliates or Representatives in connection with the Transaction or the other transactions contemplated by this Agreement. Any such other representation or warranty is hereby expressly disclaimed by each Purchaser on behalf of itself and its Affiliates.(b)Each Purchaser acknowledges and agrees that, except for the representations and warranties contained in ArticleÂ III and in any certificate delivered in connection with this Agreement, neither Seller nor any of its Affiliates, Representatives or any other Person makes any express or implied representation or warranty with respect to Seller, the other Seller Entities, the Purchased Entities or any of their respective Affiliates, the Purchased Assets, the Business or with respect to any other information provided, or made available, to the Purchasers or any of their Affiliates or Representatives in connection with the transactions contemplated hereby. Each Purchaser acknowledges and agrees that neither Seller nor any of its Affiliates, Representatives or any other Person has made any express or implied representation or warranty with respect to the prospects of the Business or its profitability for the Purchasers, or with respect to any forecasts, projections or business plans or other forward looking information delivered to the Purchasers or any of their Affiliates or Representatives in connection with the Purchasersâ€™ review of the Business and the negotiation and execution of this Agreement, including as to the accuracy or completeness thereof or the reasonableness of any assumptions underlying any such forecasts, projections or business plans or other information. Each Purchaser acknowledges and agrees that neither Seller nor any of its Affiliates, Representatives or any other Person will have, or be subject to, any Liability or other obligation to any Purchaser, its Affiliates or Representatives or any other Person resulting from the sale and purchase of theâ€‹-59-Purchased Assets or the Business to the Purchasers or their Affiliates or either Purchaserâ€™s use of, or the use by any of its Affiliates or Representatives, of any information, including information, documents, projections, forecasts, business plans or other material (including any Evaluation Material (as defined in the Confidentiality Agreement)) made available to the Purchasers, their Affiliates or Representatives in any virtual data room, confidential information memorandum, management presentations, offering materials, site tours or visits, diligence calls or meetings or any documents prepared by, or on behalf of, Seller or any of its Affiliates or Representatives, or either Purchaser or its Affiliates or Representatives or any of such Purchaserâ€™s potential financing sources (including the Financing Parties) in connection with such Purchaserâ€™s financing activities with respect to the transactions contemplated by this Agreement. Each Purchaser acknowledges and agrees that it is not relying on any representation or warranty of Seller or any of its Affiliates or Representatives or any other Person, other than those representations and warranties specifically set forth in ArticleÂ III and in any certificate delivered in connection with this Agreement. Each Purchaser acknowledges and agrees that each of Seller and its Affiliates disclaims any and all representations and warranties, whether express or implied, except for the representations and warranties contained in ArticleÂ III and in any certificate delivered in connection with this Agreement.(c)Each Purchaser acknowledges that it has conducted to its satisfaction an independent investigation of the financial condition, results of operations and projected operations of the Business and the nature and condition of its properties, assets, liabilities and businesses and, in making the determination to proceed with the transactions contemplated hereby, has relied solely on the results of its own independent investigation and the representations and warranties set forth in ArticleÂ III and in any certificate delivered in connection with this Agreement.ARTICLEÂ VCOVENANTSSectionÂ 5.1Efforts.(a)From and after the date hereof, the Purchasers and Seller shall, and shall cause their respective Affiliates to, use their respective reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and shall cooperate with each other to take and do, all things necessary, proper or advisable under any applicable Law to consummate and make effective as promptly as practicable the Transaction and the other transactions contemplated by this Agreement, including (i)Â preparing and filing of all forms, registrations, Filings and notices required to be filed to satisfy the conditions precedent to this Agreement and to consummate the Transaction and the other transactions contemplated by this Agreement as soon as practicable, (ii) defending through litigation on the merits any claim asserted in any Proceedings by any Governmental Entity to avoid entry of, or to have vacated or terminated, any decree, order or judgment (whether temporary, preliminary or permanent) that would prevent the Closing from occurring prior to the Outside Date and (iii) the executing and delivering of any additional instruments necessary to consummate the Transaction and the other transactions contemplated by this Agreement and to fully carry out the purposes of this Agreement. Without limiting the foregoing, the Purchasers and Seller shall, and shall cause their respective Affiliates to, use reasonable best efforts to take all actions necessary to obtain (and shall cooperate withâ€‹-60-each other in obtaining) any Regulatory Approvals (which actions shall include furnishing all information required in connection with such Regulatory Approvals) required to be obtained or made by the Purchasers, Seller, the other Seller Entities or the Purchased Entities or any of their Affiliates in connection with the Transaction or the other transactions contemplated by this Agreement. Additionally, the Purchasers and Seller shall not, and shall cause their respective Affiliates not to, acquire or agree to acquire, by merger, consolidation, stock or asset purchase or otherwise, any business or corporation, partnership or other business organization or division thereof, or merge or consolidate with any other Person, if such transaction would reasonably be expected to materially impair or materially delay the obtaining of, or result in not obtaining, any Regulatory Approval necessary to be obtained prior to the Closing.(b)Prior to the Closing, the Purchasers and Seller shall each keep the other apprised of the status of matters relating to the completion of the Transaction and the other transactions contemplated by this Agreement and work cooperatively in connection with obtaining all required Regulatory Approvals. In that regard, prior to the Closing, subject to the Confidentiality Agreement and SectionÂ 5.3, each Party shall promptly consult with the other Party to provide any necessary information with respect to (and, in the case of correspondence, provide the other Party (or its counsel) copies of (other than Filings made pursuant to the HSR Act)) all substantive Filings made by such Party or any of its Affiliates with any Governmental Entity or any other information supplied by such Party or any of its Affiliates to, or correspondence with, a Governmental Entity in connection with this Agreement, the Transaction and the other transactions contemplated by this Agreement. Subject to the Confidentiality Agreement and SectionÂ 5.3, each Party shall promptly inform the other Party and, if in writing, furnish the other Party with copies of (or, in the case of oral communications, advise the other Party orally of) any communication received by such Party or any of its Affiliates or Representatives from any Governmental Entity regarding the Transaction and the other transactions contemplated by this Agreement, and permit the other Party to review and discuss in advance, and consider in good faith the views of the other Party in connection with, any proposed substantive communication with any such Governmental Entity regarding the Transaction and the other transactions contemplated by this Agreement. If either Party or any Affiliate or Representative of such Party receives a request for additional information or documentary material from any Governmental Entity with respect to the Transaction or the other transactions contemplated by this Agreement, then such Party will make, or cause to be made, promptly and after consultation with the other Party, an appropriate response to such request. No Party to this Agreement shall participate in any substantive meeting with any Governmental Entity in connection with this Agreement and the Transaction or the other transactions contemplated by this Agreement (or make substantive oral submissions at meetings or in telephone or other conversations), unless it consults with the other Party in advance and, to the extent not prohibited by such Governmental Entity, gives that Party the opportunity to attend and participate thereat. Subject to the Confidentiality Agreement and SectionÂ 5.3, each Party shall furnish the other Party with copies of all substantive correspondence and Filings (other than Filings made pursuant to the HSR Act) between it or any of its Affiliates or Representatives, on the one hand, and any Governmental Entity, on the other hand, with respect to this Agreement and the Transaction or the other transactions contemplated by this Agreement, and furnish the other Party with such necessary information and reasonable assistance as the other Party may reasonably request in connection with its preparation of Filings to any such Governmental Entity. the Purchasers and Seller may, as each deems advisable and necessary, reasonably designate anyâ€‹-61-competitively sensitive material provided to the other under this Agreement as â€œoutside counsel only.â€ Such materials and the information contained therein shall be given only to the outside legal counsel and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (a Purchaser or Seller, as the case may be) or its legal counsel; provided, however, that materials provided pursuant to this Agreement may be redacted (i) to remove references concerning the valuation of or future plans for the Business or the Sale Process, (ii)Â as necessary to comply with contractual obligations or applicable Law and (iii) as necessary to address reasonable privilege concerns.(c)Without limiting the foregoing, the Purchasers and Seller shall, and shall cause their respective Affiliates to, file, as promptly as practicable, but in any event no later than ten (10) Business Days after the date of this Agreement, notifications under the HSR Act, provided that there are no changes in the applicable regulations under the HSR Act between the date hereof and the date of filing pursuant to the HSR Act, in which instance Purchasers and Seller shall use reasonable best efforts to file notifications under the HSR Act as promptly as commercially practicable thereafter, and the Purchasers and Seller shall, and shall cause their respective Affiliates to, file as promptly as practicable any other Filings under applicable Regulatory Laws listed on SectionÂ 8.1(a) of the Seller Disclosure Schedules, but in any event, any such other Filings or initial drafts thereof shall be submitted no later than twenty (20) Business Days after the date of this Agreement.(d)In furtherance of the foregoing, and notwithstanding anything in this Agreement to the contrary, the Purchasers shall, and shall cause their Affiliates to, take all such actions as may be necessary, proper or advisable to avoid or eliminate each and every impediment under any applicable Law with respect to the Transaction or the other transactions contemplated hereby and to resolve such objections, if any, as any Governmental Entity or any other Person may assert under any applicable Law with respect to the Transaction or the other transactions contemplated hereby, so as to enable the Closing to occur as soon as reasonably possible (and in any event prior to the Outside Date). In furtherance of the foregoing, the Purchasers shall, and shall cause their Affiliates to, and shall permit the Seller Entities (provided, that, the Parties shall consult and cooperate in all respects with one another, and consider in good faith the views of one another regarding the appropriate course of action), proffer, negotiate and agree to, by consent decree, hold separate order, or otherwise, (i) sell, divest, lease, license, transfer, dispose of or otherwise encumber or hold separate any assets, licenses, operations, rights, product lines, businesses or interests therein of the Business or of the Purchasers or their Subsidiaries; (ii)Â make any changes (including through a licensing arrangement) to or create any restrictions on, or other impairment of any Purchaserâ€™s or its Subsidiariesâ€™ ability to own, retain or operate, any such assets, licenses, product lines, businesses or interests of the Business or of the Purchasers or their Subsidiaries; (iii) create, terminate, unwind, divest or assign, subcontract or otherwise secure substitute parties for relationships, ventures, and contractual or commercial rights or obligations of the Business or of the Purchasers or their Subsidiaries; and (iv) make any changes to or create any restrictions on Purchaserâ€™s or its Subsidiariesâ€™ ability to acquire any assets or businesses in the future (the actions referred to in clauses (i), (ii), (iii) and (iv), â€œRemedy Actionsâ€); provided, however, notwithstanding anything to contrary this Agreement, that the Purchasers shall not be required to take any Remedy Actions if any such Remedy Actions, individually or in the aggregate, would require the divestiture, holding separate (or anyâ€‹-62-other remedy) of or with respect to any assets of Purchasers or their Subsidiaries or the Business representing in the aggregate more than fifteen (15%) of annual gross revenue generated by the Business between January 1, 2023 and December 31, 2023. Notwithstanding anything in this Agreement to the contrary, Seller and its Affiliates shall not be obligated to take or agree or commit to take any action that is not conditioned on the occurrence of the Closing or to the extent related to any Excluded Assets or the Retained Business; and in no event shall Seller or any of its Affiliates be required to be the licensing, selling, divesting, leasing, transferring, disposing or encumbering party under any such agreements unless required by the relevant Governmental Entity or applicable Law, and, in any case, Seller and its Affiliates shall have no direct or indirect obligation or Liability in respect of any such agreements, transactions or relationships, including any indemnification obligations, for which Seller and its Affiliates are not fully indemnified by the Purchasers. (e)The Purchasers shall be responsible for filing fees to any Governmental Entity in connection with Filings made pursuant to the HSR Act and any other required Regulatory Approvals pursuant to this Agreement.SectionÂ 5.2Covenants Relating to Conduct of Business.(a)Except (A) as set forth in SectionÂ 5.2(a) of the Seller Disclosure Schedules, (B) as required by applicable Law, (C) as otherwise expressly permitted by the terms of this Agreement, (D) to the extent primarily related to the Excluded Assets, the Retained Liabilities or the Retained Business and does not have a materially adverse and disproportionate or material effect on the Business, Business Products or Purchased Entities relative to the business of the Seller Entities, taken as a whole, or (E) as otherwise consented to by the Purchasers (such consent not to be unreasonably withheld, conditioned or delayed), from the date of this Agreement to the Closing, Seller shall, and shall cause each of its Subsidiaries, including each Purchased Entity to, use commercially reasonable efforts to (i) maintain and preserve intact the current organization, material assets, material Permits, relationships and goodwill of employees, customers, suppliers, regulators and others having material business relationships with the Business and (ii) conduct the Business in all material respects in the ordinary course; provided, however, that no action by Seller or its Subsidiaries with respect to matters specifically addressed by SectionÂ 5.2 shall be deemed a breach of this SectionÂ 5.2(a) unless such action would constitute a breach of such other provision.(b)Except (A) as set forth in SectionÂ 5.2(b) of the Seller Disclosure Schedules, (B) as required by applicable Law, (C) as otherwise expressly permitted by the terms of this Agreement, (D)Â to the extent primarily related to the Excluded Assets, the Retained Liabilities or the Retained Business and does not have a materially adverse and disproportionate or material effect on the Business, Business Products or Purchased Entities relative to the business of the Seller Entities, taken as a whole, or (E) as otherwise consented to by the Purchasers (such consent not to be unreasonably withheld, conditioned or delayed), from the date of this Agreement to the Closing, Seller shall not, and shall cause each of its Subsidiaries, including each Purchased Entity, not to, in each case with respect to the Business, do any of the following without the prior consent of the Purchasers (such consent not to be unreasonably withheld, conditioned or delayed):â€‹-63-(i)except (A) as may be required by any Seller Benefit Plan, including any Purchased Entity Benefit Plan, or any Collective Bargaining Agreement, or (B) for any grant or award to any Business Employee or other individual service provider of the Business or the Purchased Entities with annual compensation of $150,000 or less for which the Seller or any of its Subsidiaries (including the Purchased Entities) shall be solely obligated to pay, (I)Â grant or promise to grant to any Business Employee or other individual service provider of the Business or the Purchased Entities with an annual base compensation in excess of $150,000 any increase in compensation or benefits under

any Purchased Entity Benefit Plan, (II) grant or promise to grant any incentive awards, bonuses, change in control payments, deferred compensation, severance, retention or equity or equity-based rights to any Business Employee or other individual service provider of the Business or the Purchased Entities, (III) take any action to accelerate the vesting, funding or payment of any compensation payable or benefit provided to any Business Employee or other individual service provider of the Business or the Purchased Entities, (IV) hire, terminate (other than for cause), furlough or temporarily lay off any Business Employee (or individual who would be a Business Employee upon hire) or other individual service provider of the Business or the Purchased Entities with annual base compensation in excess of $150,000, or (V)Â adopt, enter into, modify, terminate or amend any Purchased Entity Benefit Plan (or any plan, program, policy, arrangement, agreement, or Contract that would be a Purchased Entity Benefit Plan if it were in existence as of the date of this Agreement);(ii)adopt or effect any amendment to, or change, the organizational documents of any Purchased Entity, or form a Subsidiary of any Purchased Entity;(iii)(A) split, combine or reclassify the outstanding equity interests of any of the Purchased Entities or (B) declare, set aside or pay any non-cash dividend or non-cash distribution to any Person;(iv)issue, sell or grant, pledge, dispose or transfer or propose to issue, sell or grant, pledge, dispose or transfer any equity interests of any of the Purchased Entities, or securities convertible into, or exchangeable or exercisable for, or options with respect to, or warrants to purchase, or rights to subscribe for, equity interests of any of the Purchased Entities, in each case other than the granting of Permitted Liens;(v)incur, create or assume (A) any indebtedness for borrowed money, or issue or sell any debt securities or warrants or other rights to acquire any debt security of the Purchased Entities, in each case, in excess of $250,000 in the aggregate, in each case, other than (x)Â between or among any of the Purchased Entities to the extent reconciled or eliminated in the consolidated financial statements of the Business at or prior to Closing orÂ (y) that will be settled, repaid or extinguished at or prior to Closing, or (B) any Lien, other than Permitted Liens, with respect to any material asset of the Business, other than any Lien that will be released or discharged at or prior to the Closing;â€‹-64-(vi)acquire any assets or dispose of any assets of the Business with a value in excess of $500,000 in the aggregate, in each case, outside of a sale of inventory or products in the ordinary course of business;(vii)(A) amend in any material respect, or waive any material right under, or voluntarily terminate (other than upon expiration in accordance with its terms), any Material Contract, or (B) enter into any Contract that, if in effect on the date hereof, would be a Material Contract, other than, in each case of clausesÂ (A) and (B), (x) in the ordinary course of business, or (y) for the automatic renewal or extension of any Material Contract pursuant to its terms; provided, that no Selling Entity or Purchased Entity may, without the prior written consent of the Purchasers, enter into a Contract that would be required to be disclosed pursuant to SectionÂ 3.13(a)(ix) or SectionÂ 3.13(a)(x) if entered into before the date hereof; provided, further, that a Selling Entity or Purchased Entity may, without the prior written consent of the Purchasers, amend or renew a Contract that would be required to be disclosed pursuant to SectionÂ 3.13(a)(x) if such Contract was effective on or before the date hereof and included such a provision;(viii)settle or compromise any Proceeding, or enter into any consent decree or settlement agreement with any Governmental Entity, against or pertaining to the Business or any Purchased Entity, other than settlements or compromises of any Proceeding where the amount paid in settlement or compromise does not exceed $500,000 individually or $2,500,000 in the aggregate (excluding any amounts covered by insurance or amounts Seller or another member of the Seller Group agrees to pay) and that do not impose any equitable relief, fines or criminal penalties on the Purchased Entities or the Business following the Closing; (ix)with respect to any Purchased Entity, (A)Â make (except in the ordinary course of business), change or revoke any material Tax election, (B)Â change or adopt any annual accounting period or Tax accounting or transfer pricing policy or practice, (C)Â change or adopt any material method of accounting for Tax purposes, or (D)Â settle or compromise any claim or assessment in respect of Taxes or enter into any Tax closing agreement, (E) file an amended Tax Return, (F) surrender or abandon any right to claim a Tax refund, offset or other reduction in liability or (G) consent to any extension or waiver of the limitations period applicable to any Tax claim or assessment, in each case, except for any such action that would not result in more than a de minimis increase in the Tax liability of the Purchasers and their Subsidiaries (including, after the Closing, the Purchased Entities) after the Closing;(x)(A) make any material change in any method of financial accounting or accounting practice or auditing practice or policy applicable to the Business, other than such changes as are required by GAAP or applicable Law or otherwise apply on an enterprise-wide basis to Seller and its Subsidiaries, or (B) make any material change to any of the practices, policies, procedures or timing of the collection of accounts receivable, billing of customers, payment terms, cash collections, cash payments, pricing or similar terms applicable to the Business, other than such changes as are required by GAAP or applicable Law, in the ordinary course of business or otherwise apply on an enterprise-wide basis to Seller and its Subsidiaries;â€‹-65-(xi)except as set forth in the capital budget of the Business made available to the Purchasers, commit or authorize any commitment to make any capital expenditures in excess of $100,000 individually or $500,000 in the aggregate (other than any such commitments which will be satisfied at or prior to Closing);(xii)dissolve, or authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution or restructuring any Purchased Entity, or merge or consolidate any Purchased Entity with any other Person;(xiii)(A) materially modify, extend, terminate or enter into any Collective Bargaining Agreement or (B) recognize or certify any labor union, labor organization, works council or group of employees as the bargaining representative for any Business Employees;(xiv)implement or announce any employee layoffs, furloughs, reductions in force, plant closings, reductions in compensation or other similar actions that would trigger notice obligations under the WARN Act; (xv)waive or release any noncompetition, nonsolicitation, nondisclosure or other restrictive covenant obligation of any current or former employee or independent contractor of the Purchased Entities or the Business, including any Business Employee;(xvi)transfer, modify or reassign the duties of (A) a Business Employee such that he or she no longer meets the definition of a Business Employee or (B) any other employee of any Seller Entity such that he or she would become a Business Employee;(xvii)transfer, modify or reassign the duties of (A) a Business Contingent Worker such that he or she no longer meets the definition of a Business Contingent Worker or (B) any other individual service provider of any Seller Entity such that he or she would become a Business Contingent Worker;(xviii)transfer any employee or individual service providers into or out of a Purchased Entity other than as contemplated by SectionÂ 6.1(a) or SectionÂ 6.10;(xix)designate any individual as a Business Employee who does not primarily provide services to the Business;(xx)amend, modify, extend, renew or terminate any Transferred Lease and shall not enter into any new lease, sublease, license or other agreement for the use or occupancy of any real property other than in the ordinary course of business;(xxi)enter into, amend, modify, extent, renew or terminate any Shared Contract, other than any amendments, modifications, extensions or renewals in the ordinary course of business;â€‹-66-(xxii)(A) sell, transfer, assign, exclusively license, or otherwise dispose of any material Transferred Intellectual Property, other than nonexclusive licenses granted by any of the Purchased Entities to customers or vendors in the ordinary course of business, or (B) disclose any material Trade Secrets to any Person except pursuant to valid and appropriate written non-disclosure agreements in the ordinary course of business; or(xxiii)authorize any of, or commit or agree to take, whether in writing or otherwise, or do any of, the foregoing actions.(c)Nothing contained in this Agreement shall be construed to give to the Purchasers, directly or indirectly, rights to control or direct the Businessâ€™s operations prior to the Closing. Prior to the Closing, Seller and its Subsidiaries shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision of the operations of the Business. Notwithstanding anything in this Agreement to the contrary, the Parties acknowledge and agree that nothing in this SectionÂ 5.2 or elsewhere in this Agreement shall limit the transfer (whether to or from Seller or any of its Subsidiaries, or otherwise) of any Excluded Asset or any Retained Liability; provided, that, other than in the case of the Italian VAT Receivable and the Pre-Closing Restricted Cash Distribution, which are governed by Section 7.6 and Section 5.23, respectively, (i) reasonable advance notice of any such transfer must be provided to the Purchasers, (ii) the Purchasers shall have the right to review and comment on any documentation in connection with any such transfer; provided, that such period of review shall in no event be longer than five (5) Business Days, and (iii) Seller shall reasonably cooperate in connection with such review and Seller shall consider any comments proposed by or on behalf of Purchasers in good faith.SectionÂ 5.3Confidentiality.(a)Each Purchaser acknowledges that the information being provided to it in connection with the Transaction and the other transactions contemplated hereby is subject to the terms of that certain confidentiality agreement between Phibro Animal Health Corporation and Zoetis Services LLC, dated as of November 15, 2023 (the â€œConfidentiality Agreementâ€), the terms of which are incorporated herein by reference in their entirety and shall survive the Closing. Effective upon, and only upon, the Closing, the Confidentiality Agreement shall terminate solely with respect to information relating to the Business; provided, however, that such Purchaser acknowledges that its obligations of confidentiality and non-disclosure with respect to any and all other information provided to it by or on behalf of Seller, the other Seller Entities, the Purchased Entities or any of their respective Affiliates or Representatives, concerning the Retained Business, Seller, the other Seller Entities or any of their respective Affiliates (other than solely with respect to the Business) shall continue to remain subject to the terms and conditions of the Confidentiality Agreement for the term thereof. The Parties expressly agree that, notwithstanding any provision of the Confidentiality Agreement to the contrary, including with respect to termination thereof, if, for any reason, the Closing does not occur and this Agreement is terminated, and the remaining term of the Confidentiality Agreement is less than twenty-four (24) months, the Confidentiality Agreement shall continue in full force and effect for a period of twenty-four (24) months following termination of this Agreement and otherwise in accordance with its terms, and this Agreement shall constitute theâ€‹-67-requisite consent of the Parties and their Affiliates, if applicable, to amend the Confidentiality Agreement accordingly.(b)Seller hereby agrees with the Purchasers that it shall not, and shall not permit its Subsidiaries or their respective Representatives to, for a period of four (4) years after the Closing Date, without the prior written consent of the Purchasers, use or disclose to any third party (other than Sellerâ€™s Affiliates and its and their respective Representatives) any nonpublic information that is proprietary or competitively sensitive included in the Purchased Assets or relating to the Business (â€œConfidential Business Informationâ€); provided, however, that the term â€œConfidential Business Informationâ€ will not include any information that (i) becomes available to Seller or its Affiliates or their respective Representatives from and after the Closing, from a third-party source that is not known by Seller to be under any obligations of confidentiality in respect of such information, (ii)Â is or becomes generally available to, or known by, the public (other than as a result of disclosure in violation hereof), (iii) is or was derived independently by Seller, its Affiliates or any of their respective Representatives without use of Confidential Business Information or (iv)Â constitutes Excluded Assets. Notwithstanding the foregoing, the foregoing shall not prohibit Seller, its Affiliates or any of their respective Representatives (A)Â from disclosing Confidential Business Information for the sole purpose of complying with the terms of this Agreement or any of the Transaction Documents or (B) from disclosing Confidential Business Information that Seller, any of its Affiliates or its or their Representatives are required by Law (by oral questions, interrogatories, requests for information, subpoena, civil investigative demand, or similar process) or requested by any Governmental Entity with jurisdiction over such Person to disclose (provided that Seller will, to the extent not legally prohibited, provide the Purchasers with prompt written notice of such request so that the Purchasers may seek, at their sole expense, an appropriate protective order or waive compliance with this SectionÂ 5.3(b)). Furthermore, the provisions of this SectionÂ 5.3(b) will not prohibit any retention of copies of records or any disclosure in connection with the preparation and filing of financial statements or Tax Returns of Seller or its Affiliates or any disclosure made in connection with the enforcement of any right or remedy relating to this Agreement, the other Transaction Documents or the transactions contemplated hereby and thereby.(c)Each Purchaser hereby agrees with Seller that it shall not, and shall not permit its Affiliates (including the Purchased Entities following the Closing) or their respective Representatives to, for a period of three (3) years after the Closing Date, without the prior written consent of Seller, use or disclose to any third party (other than such Purchaserâ€™s Affiliates and its and their respective Representatives) any nonpublic information that is proprietary or competitively sensitive to the extent relating to the Retained Business (â€œConfidential Retained Business Informationâ€); provided, however, that the term â€œConfidential Retained Business Informationâ€ will not include any information that (i) becomes available to a Purchaser or its Affiliates or their respective Representatives from and after the Closing, from a third-party source that is not known by such applicable Purchaser to be under any obligations of confidentiality in respect of such information, (ii) is or becomes generally available to, or known by, the public (other than as a result of disclosure in violation hereof), (iii) is or was derived independently by a Purchaser, its Affiliates or any of their respective Representatives without use of Confidential Retained Business Information or (iv) constitutes Purchased Assets. Notwithstanding the foregoing, the foregoing shall not prohibit any Purchaser, its Affiliates or any of their respective Representatives (A) from disclosing Confidential Retained Businessâ€‹-68-Information for the sole purpose of complying with the terms of this Agreement or any of the Transaction Documents or (B) from disclosing Confidential Business Information that such Purchaser, any of its Affiliates or its or their Representatives are required by Law (by oral questions, interrogatories, requests for information, subpoena, civil investigative demand, or similar process) or requested by any Governmental Entity with jurisdiction over such Person to disclose (provided that such Purchaser will, to the extent not legally prohibited, provide Seller with prompt written notice of such request so that Seller may seek, at its sole expense, an appropriate protective order or waive compliance with this SectionÂ 5.3(c)).SectionÂ 5.4Access to Information.(a)Seller shall, and shall cause its Affiliates to, afford to each Purchaser, its Affiliates and their respective Representatives reasonable access, upon reasonable notice during normal business hours, so long as consistent with applicable Law and in accordance with the procedures established by Seller, during the period prior to the Closing, and only for purposes of integration planning and in furtherance of the Transaction and the other transactions contemplated by this Agreement, to the Business Employees and the facilities, properties, books, Contracts and records of Seller and its Subsidiaries to the extent related to the Business and the Purchased Assets; provided, however, that (i)Â neither Seller nor any of its Affiliates shall be required to violate any obligation of confidentiality to which it or any of its Affiliates may be subject in discharging their obligations pursuant to this SectionÂ 5.4 (it being agreed that, in the event that the restrictions set forth in this clause (i) apply, Seller shall inform such Purchaser as to the general nature of what is being withheld and shall cooperate in good faith to attempt to design and implement alternative disclosure arrangements to enable such Purchaser to evaluate any such information without violating an obligation of confidentiality to any third party); (ii)Â Seller shall not be required to make available, or cause its Subsidiaries to make available, Business Employee personnel files prior to the Closing and, with respect to any Business Employees, only if and when such Purchaser provides Seller with notice that the applicable Business Employees have provided such Purchaser with a release permitting transfer of those files (provided that Seller shall not be required to make, or cause to be made, available medical records, workers compensation records or the results of any drug testing; and that such Purchaser shall indemnify and hold Seller and its Affiliates (including the other Seller Entities) harmless from any Liabilities arising out of or relating to the access to and/or transfer of such personnel files); and (iii)Â prior to the Closing Date, the Purchasers shall not conduct any Phase II Environmental Site Assessment or conduct any invasive testing or any sampling of soil, sediment, surface water, ground water or building material at, on, under or within any facility on the Transferred Real Property, or any other property of Seller, the other Seller Entities, the Purchased Entities or any of their respective Affiliates without the prior written consent of Seller.(b)Each Purchaser agrees that any investigation undertaken pursuant to the access granted under SectionÂ 5.4(a) shall be conducted in such a manner as not to unreasonably interfere with the operation of the Business, and neither Purchaser or any of their Affiliates or Representatives shall communicate with any of the Business Employees without the prior written consent of Seller, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding anything in this Agreement to the contrary, neither Seller nor any of its Affiliates shall be required to provide access to or disclose information where, such access or disclosure would (i) reasonably be expected to jeopardize attorney-client or other applicableâ€‹-69-privilege or protection, or contravene any applicable Laws or contractual obligations (it being agreed that, in the event that the restrictions set forth in this clause (i) apply, Seller shall inform the Purchasers as to the general nature of what is being withheld and shall cooperate in good faith to attempt to design and implement alternative disclosure arrangements to enable the Purchasers to evaluate any such information without violating an obligation of confidentiality to any third party, jeopardizing the attorney-client or other applicable privilege or protection or contravening any Laws or contractual obligations), or (ii) such information concerns the valuation of the Business or the Sale Process. In addition, no access hereunder shall be permitted for a purpose relating to a dispute or potential dispute between or among the Parties or their respective Affiliates.(c)At and after the Closing for a period of ten (10) years (except to the extent relating to Tax matters (access, cooperation and procedures with respect to which are governed exclusively by ArticleÂ VII)), each Purchaser shall, and shall cause its Affiliates to, afford Seller, its Affiliates and their respective Representatives, during normal business hours, upon reasonable notice, reasonable access to the facilities, properties, books, Contracts, records and employees of the Business and the Purchased Entities to the extent that such access may be reasonably requested by Seller, including in connection with financial statements, taxes, reporting obligations and compliance with applicable Laws; provided, however, that nothing in this Agreement shall limit any of Sellerâ€™s or any of its Affiliatesâ€™ rights of discovery. Notwithstanding anything in this Agreement to the contrary, neither Purchaser nor any of their Affiliates shall be required to provide access to or disclose information where such access or disclosure would reasonably be expected to jeopardize attorney-client or other applicable privilege or protection, or contravene any applicable Laws or contractual obligations (it being agreed that, in the event that the restrictions set forth in this sentence apply, such Purchaser shall inform Seller as to the general nature of what is being withheld and shall cooperate in good faith to attempt to design and implement alternative disclosure arrangements to enable Seller to evaluate any such information without violating an obligation of confidentiality to any third party, jeopardizing the attorney-client or

other applicable privilege or protection or contravening any Laws or contractual obligations). In addition, no access hereunder shall be permitted for a purpose relating to a dispute or potential dispute between or among the Parties or their respective Affiliates.(d)Except for Tax Returns and other documents governed by SectionÂ 7.1, each Purchaser agrees to hold all the books and records of the Business existing on the Closing Date and not to destroy or dispose of any thereof for a period of ten (10) years from the Closing Date or such longer time as may be required by Law, and thereafter, if it desires to destroy or dispose of such books and records, to offer first in writing at least sixty (60) days prior to such destruction or disposition to surrender them to Seller. Seller agrees to hold all the books and records of the Business existing on the Closing Date but not transferred to the Purchasers and not to destroy or dispose of any thereof for a period of ten (10) years from the Closing Date or such longer time as may be required by Law, and thereafter, if it desires to destroy or dispose of such books and records, to offer first in writing at least sixty (60) days prior to such destruction or disposition to surrender them to the Purchasers.SectionÂ 5.5Publicity. The initial press release with respect to the Transaction shall be a joint press release agreed upon by Seller and the Purchasers. Other than such joint pressâ€‹-70-release, neither Party nor any Affiliate or Representative of such Party shall issue or cause the publication of any press release or public announcement in respect of this Agreement, the Transaction or the other transactions contemplated by this Agreement without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by applicable Law or stock exchange rules, in which case the Party required to publish such press release or public announcement shall use reasonable efforts to provide the other Party a reasonable opportunity to comment on such press release or public announcement in advance of such publication; provided that the foregoing shall not apply to any press release or public announcement so long as any statements contained therein concerning the Transaction or the other transactions contemplated by this Agreement are consistent in all material respects with previous releases or announcements made by the applicable Party with respect to which such Party has complied with the provisions of this SectionÂ 5.5.SectionÂ 5.6Intercompany Accounts and Intercompany Arrangements.(a)At or prior to the Closing, Seller shall cause, and shall cause each member of the Seller Group to cause, all intercompany balances and accounts between members of the Seller Group, on the one hand, and the Purchased Entities, on the other hand, to be settled or otherwise eliminated in such a manner as Seller shall determine in its sole discretion (including, if so determined by Seller, by the Seller Entities or any of their Affiliates removing from any Purchased Entity any or all cash, cash equivalents or funds from cash pools by means of dividends, distributions, contribution, the creation or repayment or refinancing of intercompany debt, increasing or decreasing of cash pool balances or otherwise). Intercompany balances and accounts solely among any of the Purchased Entities shall not be affected by the above provisions of this SectionÂ 5.6. Immediately prior to the Closing, except for the Transaction Documents, all arrangements, understandings or Contracts, including all obligations to provide goods, services or other benefits, between the members of the Seller Group, on the one hand, and the Purchased Entities, on the other hand, shall automatically be terminated without further payment or performance and cease to have any further force and effect, such that no party thereto shall have any further obligations or Liabilities therefor or thereunder.(b)Except for any claim for fraud or to the extent provided to the contrary in this SectionÂ 5.6 or pursuant to ArticleÂ X, effective as of the Closing, each Purchaser, on behalf of itself and its Affiliates, including the Purchased Entities, hereby (i) agrees not to, and agrees to cause its Affiliates not to, assert any claim against Seller or its Affiliates, and (ii) releases Seller and each of its Affiliates (and their respective officers, directors and employees, acting in their capacities as such) from any Liability, obligation or responsibility to any of them for any and all past actions or failures to take action prior to the Closing directly or indirectly relating to or arising out of the Business, the Retained Business, or the operations of the Purchased Entities prior to the Closing, or relating to or arising out of Sellerâ€™s or its Affiliateâ€™s ownership of the Purchased Assets, in each case of clause (i) and (ii), except for any obligation pursuant to the provisions of this Agreement or the other Transaction Documents.(c)Except for any claim for fraud or to the extent provided to the contrary in this SectionÂ 5.6 or pursuant to ArticleÂ X, effective as of the Closing, Seller, on behalf of itself and its Affiliates, hereby (i) agrees not to, and agrees to cause its Affiliates not to, assert anyâ€‹-71-claim against Purchasers or their Affiliates, and (ii) releases the Purchased Entities (and their respective officers, directors and employees, acting in their capacities as such) from any Liability, obligation or responsibility to any of them for any and all past actions or failures to take action prior to the Closing directly or indirectly relating to or arising out of the Business, the Retained Business, or the operations of the Purchased Entities prior to the Closing, or relating to or arising out of the Purchased Entitiesâ€™ ownership of the Purchased Assets, in each case of clause (i) and (ii), except for any obligation pursuant to the provisions of this Agreement or the other Transaction Documents.SectionÂ 5.7Financing.(a)Purchaser 1 shall use its reasonable best efforts, and shall cause each of its Subsidiaries to use reasonable best efforts to, take, or cause to be taken, all actions, and do, or cause to be done, all things necessary, proper or advisable to (x) obtain funds sufficient to fund the Financing Amounts on or prior to the date on which the Transaction is required to be consummated pursuant to the terms hereof and (y) extend the Expiration Date (as defined in the Commitment Letter) in the Commitment Letter to 11:59 p.m. (New York City time) on a date no earlier than July 28, 2025 or obtain replacement financing that does not include any Prohibited Modification the term of which runs through 11:59 p.m. (New York City time) on a date no earlier than July 28, 2025; provided that, under no circumstances shall such Purchaserâ€™s requirement to pursue an extension under this clause (y) require such Purchaser to (i) pay a materially higher amount (taken as a whole) of interest rate or fees (it being agreed that accruing ticking fees shall not be â€œfees that are higherâ€) relative to the interest rate and fees set forth in the Commitment Letter and fee letter as of the date hereof or (ii) instate a more onerous financial covenant than the financial covenant set forth in the Commitment Letter as of the date hereof. In furtherance and not in limitation of the foregoing, Purchaser 1 shall use its reasonable best efforts to take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to obtain the proceeds of the Financing on the terms and subject only to the conditions described in the Commitment Letter prior to the date on which the Transaction is required to be consummated pursuant to the terms hereof, including by (i)Â maintaining in effect the Commitment Letter, subject to permitted amendments and/or replacements as set forth herein, (ii) negotiating and entering into definitive agreements with respect to the Financing (the â€œDefinitive Agreementsâ€) consistent with the terms and conditions contained therein (including, as necessary, any â€œflexâ€ provisions contained in the Commitment Letter or any related fee letter) or on other terms agreed to in writing by the Seller, and without any Prohibited Modification and (iii)Â satisfying on a timely basis (or obtaining a waiver of) no later than the Closing all conditions applicable to it in the Commitment Letter and the Definitive Agreements and complying with its obligations thereunder, subject to any amendments and/or replacements permitted hereunder.(b)Neither Purchaser 1 nor any of its Subsidiaries shall, without the prior written consent of Seller: (i)Â permit, consent to or agree to any amendment, replacement, supplement, termination, modification, or waiver of any provision or remedy under the Commitment Letter or the Definitive Agreements if such amendment, replacement, supplement, termination, modification, waiver or remedy (A) adds new (or adversely modifies any existing) conditions to the consummation of all or any portion of the Financing, (B) reduces the aggregate principal amount of the Financing such that the aggregate amount of Financing at the Closing is less than the aggregate amount of the Financing Amounts, (C) adversely affects the ability ofâ€‹-72-such Purchaser to enforce its rights against other parties to the Commitment Letter or the Definitive Agreements as so amended, replaced, supplemented or otherwise modified or (D) would otherwise reasonably be expected to prevent or delay the Closing (the effects described in clauses (A) through (D), collectively, the â€œProhibited Modificationsâ€); or (ii) terminate or cause the termination of the Commitment Letter or any Definitive Agreement; in each case, other than (A) any amendment to the Commitment Letter solely to join lenders, lead arrangers, bookrunners, syndication agents or similar entities who have not executed the Commitment Letter as of the date of this Agreement and who have voted to or are required by the terms of such amendment to vote to amend the Purchasersâ€™ credit agreement in the manner contemplated by the Commitment Letter or (B) any replacement and related termination of the Commitment Letter with a committed financing (including as a committed delayed draw term loan under the Purchasersâ€™ credit facilities) and the definitive documentation of such replacement financing, solely to the extent that such amendment or replacement or the addition of such additional parties would not constitute a Prohibited Modification. Purchaser 1 shall promptly deliver to Seller copies of any amendment, replacement, supplement, termination, modification or waiver to the Commitment Letter and/or the Definitive Agreements.(c)In the event that any portion of the Financing becomes unavailable on the terms contemplated in the Commitment Letter, regardless of the reason therefor, Purchaser 1 shall (i) promptly notify Seller in writing of such unavailability and the reason therefor and (ii)Â after giving effect to any other funds of such Purchaser available for application towards the Financing Amounts, use reasonable best efforts, and cause each of its Subsidiaries to use their reasonable best efforts, to arrange and obtain, as promptly as practicable following the occurrence of such event, alternative financing for any such unavailable portion from the same or alternative sources (the â€œAlternative Financingâ€) in an amount sufficient, when taken together with the available portion of the Financing, to consummate the Transaction and the other transactions contemplated by this Agreement and to pay the Financing Amounts and, without limiting the foregoing, shall use reasonable best efforts to cause such Alternative Financing to include terms and conditions that are not materially less favorable, taken as a whole, to such Purchaser than the terms and conditions set forth in the Commitment Letter; provided that, under no circumstances shall such Purchaserâ€™s requirement to pursue Alternative Financing require such Purchaser to (i) pay an interest rate or fees that are higher by more than a material amount, taken as a whole, relative to the interest rate and fees set forth in the Commitment Letter and fee letter as of the date hereof or (ii) instate a more onerous financial covenant than the financial covenant set forth in the Commitment Letter as of the date hereof. Purchaser 1 shall provide Seller with prompt oral and written notice of any actual or threatened (in writing) breach, default, cancellation, termination or repudiation by any party to the Commitment Letter and a copy of any written notice or other written communication from any Lender or other financing source with respect to any actual breach, default, cancellation, termination or repudiation by any party to the Commitment Letter of any provision thereof. Purchaser 1 shall keep Seller reasonably informed on a current basis of the status of its efforts to consummate the Financing, including any Alternative Financing.(d)The foregoing notwithstanding, compliance by the Purchasers with this SectionÂ 5.7 shall not relieve any Purchaser of its obligations to consummate the transactions contemplated by this Agreement whether or not the Financing or any Alternative Financing is available. To the extent a Purchaser obtains Alternative Financing or amends, replaces,â€‹-73-supplements, terminates, modifies or waives any of the Financing, in each case pursuant to this SectionÂ 5.7 and without any Prohibited Modification, references to the â€œFinancing,â€ â€œFinancing Parties,â€ â€œCommitment Letterâ€ and â€œDefinitive Agreementsâ€ (and other like terms in this Agreement) shall be deemed to refer to such Alternative Financing, the commitments thereunder and the agreements with respect thereto, or the Financing as so amended, replaced, supplemented, terminated, modified or waived.(e)At all times prior to the Closing, the Purchasers shall maintain no less than $25,000,000 in unrestricted cash to be used to pay amounts due hereunder.SectionÂ 5.8Financing Cooperation.(a)Seller shall use its commercially reasonable efforts to provide, and shall cause the Seller Entities and Purchased Entities to use commercially reasonable efforts to provide, and each of them shall use their commercially reasonable efforts to cause their respective Representatives to use their commercially reasonable efforts to provide, customary cooperation, to the extent reasonably requested by the Purchasers in writing, necessary for the arrangement of the Financing (provided that such requested cooperation does not unreasonably interfere with the ongoing operations of Seller or any of its Affiliates), including using commercially reasonable efforts to:(i)participate in a reasonable number of meetings, presentations, due diligence sessions and sessions with rating agencies, at reasonable times and with reasonable advance notice, and in each case which shall be virtual unless otherwise agreed to by Seller;(ii)to the extent required by the Financing, facilitate the pledging of collateral of the Purchased Entities effective no earlier than the Closing;(iii)provide reasonable and customary assistance to the Purchasers and the Lenders in the preparation of customary lender presentations, syndication memoranda, ratings agency presentations and other bank marketing materials for the Financing;(iv)cooperate with the Lendersâ€™ due diligence, to the extent customary and reasonable; and(v)assist in the preparation of, and in the execution and delivery at Closing of, any pledge and security documents, other definitive financing documents (including credit agreements) and schedules and certificates (including a perfection certificate), in each case, as may be reasonably requested in writing by the Purchasers.(b)The foregoing notwithstanding, neither Seller nor any of its Affiliates shall be required to take or permit the taking of any action pursuant to this SectionÂ 5.8 that would: (i)Â require Seller or its Affiliates or any Persons who are officers or directors of such entities to pass resolutions or consents to approve or authorize the execution of the Financing or enter into, execute or deliver any certificate, document, instrument or agreement or agree to any change or modification of any existing certificate, document, instrument or agreement (other than, withâ€‹-74-respect to the Purchased Entities only, resolutions that are contingent on the Closing), (ii) cause any representation or warranty in this Agreement to be breached by Seller or any of its Affiliates, (iii)Â require Seller or any of its Affiliates to pay any commitment or other similar fee or incur any other expense, liability or obligation in connection with the Financing or otherwise incur any obligation under any agreement, certificate, document or instrument, (iv) reasonably be expected to cause any director, officer, employee or stockholder of Seller or any of its Affiliates to incur any personal liability, (v)Â reasonably be expected to conflict with the organizational documents of Seller or any of its Affiliates or any Laws, (vi)Â reasonably be expected to result in a material violation or breach of, or a default (with or without notice, lapse of time, or both) under, any Contract to which Seller or any of its Affiliates is a party, (vii) provide access to or disclose information that Seller or any of its Affiliates determines would jeopardize any attorney-client privilege or other applicable privilege or protection of Seller or any of its Affiliates (provided that, upon a Purchaserâ€™s reasonable written request, Seller shall provide written notice to such Purchaser that information is being withheld on this basis), (viii) require the delivery of any opinion of counsel, (ix) require Seller to prepare any financial statements or information that are not available to it and prepared in the ordinary course of its financial reporting practices or (x)Â require Seller to prepare or deliver any Excluded Information. Nothing contained in this SectionÂ 5.8 or otherwise in this Agreement shall require (A) Seller or any of its Affiliates (other than the Purchased Entities) to be an issuer or other obligor with respect to the Financing or (B)Â the Purchased Entities, prior to Closing, to be an issuer or other obligor with respect to the Financing. The Purchasers shall, promptly on request by Seller, reimburse Seller and each of its Affiliates for all reasonable out-of-pocket costs incurred by them or their respective Representatives in connection with such cooperation (other than the preparation of financial statements in the ordinary course of business of the Seller and/or the Purchased Entities) and shall reimburse, indemnify and hold harmless Seller and its Affiliates and their respective Representatives from and against any and all losses suffered or incurred by them in connection with the arrangement of the Financing, any action taken by them at the request of the Purchasers or their Representatives pursuant to this SectionÂ 5.8 and any information used in connection therewith, other than to the extent such losses are a direct result of the Seller acting in bad faith through the knowing, intentional and material breach of the Sellerâ€™s respective obligations under this SectionÂ 5.8 or through the knowing and intentional delivery of information under this SectionÂ 5.8 that is, when taken as a whole, materially inaccurate.(c)The Parties acknowledge and agree that the provisions contained in this SectionÂ 5.8 represent the sole obligation of Seller and its Affiliates with respect to cooperation in connection with the arrangement of any financing (including the Financing) to be obtained by the Purchasers with respect to the transactions contemplated by this Agreement and the Commitment Letter, and no other provision of this Agreement (including the Exhibits and Schedules hereto) or the Commitment Letter shall be deemed to expand or modify such obligations. In no event shall the receipt or availability of any funds or financing (including the Financing) by the Purchasers or any of their Affiliates or any other financing or other transactions be a condition to any of the Purchasersâ€™ obligations under this Agreement. Notwithstanding anything to the contrary in this Agreement, the Sellerâ€™s breach of any of the covenants required to be performed by it under this Section 5.8 shall not be considered in determining the satisfaction of the condition set forth in Section 8.2(b), unless (i) Purchaser provides written notice of a breach of this Section 5.8 to the Seller (which notice specifies such breach in reasonable detail), (ii) Seller fails to materially cureâ€‹-75-such breach within thirty (30) days of such notice and (iii) the failure to obtain the Financing was primarily caused by such breach.(d)Prior to the Closing, if requested in writing by the Purchasers, Seller shall (i) provide to the Purchasers (A) the Financing Information and (B) the information necessary or proper for the applicable Purchaser to prepare the pro forma financial statements required by paragraph 3 of Exhibit C to the Commitment Letter, (ii) use commercially reasonable efforts to provide to the Purchasers executed, customary authorization letters authorizing the distribution of information to prospective lenders, and (iii) if requested in writing by the Purchasers at least ten (10) Business Days prior to the Closing Date, to furnish to the Purchasers, at least four (4) Business Days prior to the Closing Date, a certification regarding beneficial ownership and information regarding the Purchased Entities that is required by U.S. regulatory authorities under applicable â€œknow your customerâ€ and anti-money laundering rules and regulations, including the USA PATRIOT Act and 31 C.F.R. Â§Â 1010.230. All non-public or otherwise confidential information regarding Seller or any of its Affiliates obtained by the Purchasers or their Representatives pursuant to this SectionÂ 5.8 shall be kept confidential in accordance with the Confidentiality Agreement.SectionÂ 5.9Financial Obligations. At or prior to the Closing, the Purchasers shall at their sole expense arrange for substitute letters of credit, surety bonds, Purchaser guarantees, advance payment guarantees, and other obligations to replace the outstanding letters of credit, surety bonds, guarantees, advance payment guarantees and other contractual obligations entered into by or on behalf of Seller or any of its Affiliates (other than the Purchased Entities) in connection with or relating to the Business, the Purchased Assets or the Assumed Liabilities set forth on SectionÂ 5.9 of the Seller Disclosure Schedules (together, the â€œGuaranteesâ€), and assume all

obligations under each Guarantee, obtaining from the creditor or other counterparty a full and irrevocable release of Seller and its Affiliates that are liable, directly or indirectly, for reimbursement to the creditor or fulfillment of other Liabilities to a counterparty in connection with amounts drawn under the Guarantees. Each Purchaser further agrees that to the extent Seller or any of its Affiliates incurs any cost or expense, or is required to make any payment, or is subject to any claim or Proceeding, in connection with such Guarantees on or after the Closing, such Purchaser shall, jointly and severally, indemnify and hold harmless Seller and its Affiliates against, and reimburse Seller and its Affiliates for, any and all Liabilities incurred or amounts paid, including costs or expenses in connection with such Guarantees, including Sellerâ€™s and any of its Affiliatesâ€™ expenses in maintaining such Guarantees, whether or not any such Guarantee is drawn upon or required to be performed, and shall in any event promptly reimburse, upon written demand therefor from Seller, Seller and any of its Affiliates to the extent that any Guarantee is called upon and Seller or any of its Affiliates makes any payment or incurs any Liability in respect of any such Guarantee; provided, that in no event shall Purchasersâ€™ obligation to indemnify or reimburse Seller pursuant to this sentence exceed $50,000, individually or in the aggregate. For any Guarantees for which a Purchaser or any of its Affiliates, as applicable, is not substituted in all respects for Seller and its Affiliates (or for which Seller and its Affiliates are not fully released) effective as of the Closing and that cannot otherwise be terminated effective as of the Closing (with Seller and its Affiliates to be fully released in respect thereof), such Purchaser shall and shall cause its Affiliates to continue to use their commercially reasonable efforts to effect such substitution or termination and release after the Closing. Without limiting the foregoing, neither Purchaser nor any of their respective Affiliates shall extend or renew anyâ€‹-76-Contract containing or underlying a Guarantee unless, prior to or concurrently with such extension or renewal, such Purchaser or its Affiliates are substituted in all respects for Seller and its Affiliates, and Seller and its Affiliates are fully released, in respect of all Liabilities under such Guarantees.SectionÂ 5.10Trademark Matters.(a)No Purchaser nor any of their Affiliates (including the Purchased Entities) shall acquire any rights in, or use, or have the right to use, the â€œZoetisâ€ names or any confusingly similar variations or derivatives thereof or any Marks of Seller or any of its Affiliates that are not included in the Purchased Assets (collectively, the â€œRetained Marksâ€) or any name or Mark that is confusingly similar to or derivative of the Retained Marks, except for the limited right to use such Retained Marks as expressly set forth in SectionÂ 5.10(c)(i).(b)Within ten (10) Business Days of Closing, the Purchasers shall make all filings necessary to change the legal names, corporate names and business names of the Purchased Entities to remove any reference to the Retained Marks, and shall promptly take any and all follow-up actions that may be required or requested by any Governmental Entity to effect such changes as soon as practicable.(c)Subject to compliance with the quality control provisions and other terms of this SectionÂ 5.10, the Business may continue to temporarily use the Retained Marks following the Closing, solely to the extent and in the same manner as used immediately prior to the Closing, so long as the Purchasers shall, and shall cause their Affiliates (including the Business), to (i) immediately after the Closing cease to hold itself out as having any affiliation with Seller or any of its Affiliates and (ii) use commercially reasonable efforts to minimize and eliminate use of the Retained Marks by the Business from and after the Closing; provided, that:(i)the Business shall be permitted to use such Retained Marks for a period of up to two (2) years following the Closing (A) with respect to any finished goods Inventory in the Purchasersâ€™ possession as of the Closing, until the expiration of the applicable shelf lives of such Inventory or the supply is exhausted, (B) with respect to any packaging included in Working Capital (â€œTransferred Packagingâ€), until the supply of such Transferred Packaging is exhausted, and (C) with respect to any Business Products for which such Retained Marks are required to be used under a Transferred Marketing Authorization or any other Regulatory Approval or Permit related to the Business Products (such products, the â€œApproval Productsâ€), the use of such Retained Marks is no longer required under such Transferred Marketing Authorization and the use of the Retained Marks is no longer required under any Regulatory Approval or Permit; provided that the Purchasers shall coordinate with Seller and take all steps reasonably necessary to obtain or change the applicable Transferred Marketing Authorization, Regulatory Approval or Permit with respect to such Approval Products to eliminate any required use of such Retained Marks as soon as practicable after the Closing Date; provided, further, that if any Transferred Packaging has not been exhausted by the expiration of the two (2)-year period, or if the Purchasers will not be able to eliminate required use of such Retained Marks with respect to such Approval Products by the expiration of the two (2)-year period despite Purchasersâ€™ diligent efforts to obtain orâ€‹-77-change the applicable Transferred Marketing Authorization, Regulatory Approval or Permit and due to circumstances outside the Purchaserâ€™s reasonable control, then the Purchasers shall notify Seller in writing that the Transferred Packaging has not been exhausted, and of the specific jurisdictions for which the Retained Marks are still required to be used under any Transferred Marketing Authorization, Regulatory Approval or Permit (as applicable), and such period shall automatically be extended for up to twoÂ (2) additional periods of six (6) months each so long as the Purchasers remain diligent with respect to such transition during such extension. Notwithstanding the forgoing, with respect to the specific Retained Marks, the specific Approval Products and specific jurisdictions set forth on SectionÂ 5.10 of the Seller Disclosure Schedules, the Business shall be permitted to use such specific Retained Marks (including to use any Transferred Packaging in such specific jurisdictions) until the earlier of (x) the time period set forth set forth next to the specific Approval Products and specific jurisdictions on SectionÂ 5.10 of the Seller Disclosure Schedules and (y) such time that the Transferred Packaging is exhausted and the use of such Retained Marks is no longer required under such Transferred Marketing Authorization and the use of the Retained Marks is no longer required under any Regulatory Approval or Permit; provided that the Purchasers shall coordinate with Seller and take all steps reasonably necessary to obtain or change the applicable Transferred Marketing Authorization, Regulatory Approval or Permit with respect to such Approval Products to eliminate any required use of such Retained Marks as soon as practicable after the Closing Date.(ii)for all other uses of the Retained Marks (subject to SectionÂ 5.10(b)), as soon as practicable after the Closing Date (and in any event within sixty (60) days thereafter), the Purchasers shall, and shall cause their Affiliates (including the Purchased Entities and the Business), to cease and discontinue use of all Retained Marks and complete the removal of the Retained Marks from all products, signage, vehicles, properties, technical information and promotional or other marketing materials and other assets.(d)Notwithstanding the foregoing, the Purchasers and their Subsidiaries (including the Purchased Entities) may use the Retained Marks after the Closing (i) in a manner that constitutes fair use, or as permitted or required by Law, and (ii) for purposes of regulatory filings or describing the past ownership or affiliation of the Business; provided, that such use does not give rise to a likelihood of confusion as to the source or origin of any goods or services or imply any endorsement by, or ongoing association with, Seller or any of its Subsidiaries.(e)To comply with Sellerâ€™s quality control standards, the Purchasers and their Affiliates shall: (i) use the Retained Marks in the same form and manner, and at least the same high level of quality, in effect for the Retained Marks as of the Closing, (ii) comply with all applicable Laws and regulations pertaining to any Business Products bearing the Retained Marks; (iii) adhere to Sellerâ€™s reasonable instructions regarding use and appearance of the Retained Marks (which, to the extent applicable, shall be consistent with Sellerâ€™s generally applicable instructions for other licensees of the Retained Marks); and (iv)Â not use the Retained Marks in any manner that would damage the goodwill associated therewith or the reputation of Seller or any of its Affiliates. Seller may terminate the rights granted under SectionÂ 5.10(c)(i) if the Purchasers or any of their Affiliates fail to comply with the foregoing quality controlâ€‹-78-provisions or otherwise materially breach the terms of this SectionÂ 5.10 and such failure or material breach is not cured to Sellerâ€™s reasonable satisfaction within thirtyÂ (30) days of receiving written notice of such failure.(f)The Purchasers, jointly and severally, shall indemnify and hold harmless Seller and its Affiliates for Third Party Claims arising from or relating to any use of the Retained Marks by such Purchaser or its Affiliates. All goodwill arising from the use of the Retained Marks as described in this Section shall inure to the sole and exclusive benefit of Seller and Sellerâ€™s Subsidiaries.SectionÂ 5.11Global Separation Sublicenses. Seller and the Purchasers shall cooperate with each other and use their respective commercially reasonable efforts to obtain consent from the counterparty to certain Contracts listed in SectionÂ 5.11 of the Seller Disclosure Schedules (collectively, the â€œGlobal Separation Licensesâ€) to enter into a sublicense or new Contract that extends the rights to a Purchaser, and allows such Purchaser to assume the obligations, under such Global Separation Licenses to the extent related to the operations or conduct of the Business. Neither Seller nor any of its Affiliates shall have (a)Â any obligation under this SectionÂ 5.11 with respect to such consents that are not obtained on or prior to one hundred twenty (120) days following the Closing Date; and (b) any obligation to make any payments or other concession, or incur any other Liability, or commence or participate in any Proceeding to obtain any such consents, and the failure to receive any such consents shall not be taken into account in determining whether any condition to the Closing set forth in ArticleÂ VIII shall have been satisfied. All reasonable and documented third-party legal and administrative fees, and other similar costs and expenses, payable in connection with obtaining any such consents shall be borne by Seller.SectionÂ 5.12Background IP License.(a)License to the Purchasers. Effective as of the Closing, and subject to the provisions hereof, Seller and its Subsidiaries hereby grant, and agree to grant, to the Purchasers and their Subsidiaries, including the Purchased Entities, a worldwide, irrevocable, non-exclusive, fully paid, royalty-free, non-sublicenseable, non-transferable (except as provided in SectionÂ 5.12(c)) license under: (i) Patents owned by the Seller Group as of the Closing to the extent practiced by, or absent a license thereto or ownership thereof, would be infringed by, the Business immediately prior to the Closing, to make, have made, import, use, offer to sell, sell, and otherwise provide any product or service of the Business and any natural evolutions and extensions thereof; and (ii) Intellectual Property Rights (other than Registered IP) owned by the Seller Group as of the Closing to the extent used in and related to the Business immediately prior to the Closing, to use, reproduce, distribute, disclose, make, modify, improve, display and perform, create derivative works of and otherwise exploit the Purchased Assets, in each case, solely with respect to the conduct of the Business and any natural evolutions and extensions thereof; it being understood that the foregoing license does not and shall not require the delivery or disclosure to the Purchasers of any tangible or intangible assets that are not Purchased Assets.(b)Term. The licenses granted under this SectionÂ 5.12 will continue until the expiration of the last-to-expire of the Intellectual Property Rights licensed therein.â€‹-79-(c)Transfer of License. Except as expressly set forth herein, no Purchaser may assign or transfer the license granted in SectionÂ 5.12(a) directly or indirectly, in whole or in part, whether voluntarily or involuntarily or by operation of Law or otherwise, without Sellerâ€™s prior written consent. Notwithstanding the foregoing, a Purchaser may assign such license to a third party, or permit a third party to assume such license, in connection with the acquisition of such Purchaser (whether by equity or asset sale or merger or otherwise) or the sale of all or substantially all of the assets of any such Purchaser to which this Agreement relates; provided that the resulting, surviving or transferee Person or acquirer of such Purchaser assumes all of the applicable obligations of such Purchaser by operation of Law or by express assignment, as the case may be. Any assignment in violation of this SectionÂ 5.12(c) shall be null and void ab initio. (d)Confidentiality. The Purchasers agree on behalf of themselves and their Subsidiaries that (i) they (and each of their Subsidiaries) shall treat the Trade Secrets and confidential information licensed under SectionÂ 5.12(a) with at least the same degree of care as they treat their own similar Trade Secrets and confidential information, but in no event with less than reasonable care, and (ii)Â neither they (nor any of their Subsidiaries) may use or disclose such Trade Secrets or confidential information, as applicable, except in accordance with the license granted in SectionÂ 5.12(a).SectionÂ 5.13Insurance. Each Purchaser acknowledges and agrees that, from and after the Closing, the Business, the Purchased Entities, the Purchased Assets, the Assumed Liabilities, and the operations and assets and Liabilities in respect thereof, shall cease to be insured by Sellerâ€™s or its Affiliatesâ€™ insurance policies or by any of their self-insured programs, and neither Purchaser nor any of their Affiliates (including the Business and the Purchased Entities) shall have any access, right, title or interest to or in any such insurance policies (including to all claims and rights to make claims and all rights to proceeds) to cover the Business, the Purchased Entities, the Purchased Assets, the Assumed Liabilities, or the operations or assets or Liabilities in respect thereof. Seller or its Affiliates may amend any insurance policies in the manner it deems appropriate to give effect to this SectionÂ 5.13. From and after the Closing, the Purchasers shall be responsible for securing all insurance they consider appropriate for the Business, the Purchased Entities, the Purchased Assets, the Assumed Liabilities, and the operations and assets and Liabilities in respect thereof. From and after the date hereof and for the first six (6) months following the Closing, Seller and its Subsidiaries shall use their respective commercially reasonable efforts to cooperate with the Purchasers, upon a Purchaserâ€™s reasonable request, in seeking assistance to secure such insurance. Each Purchaser further covenants and agrees not to seek to assert or to exercise any rights or claims of, or in respect of, the Business, the Purchased Entities, the Purchased Assets, the Assumed Liabilities, and the operations and assets and Liabilities in respect thereof, under or in respect of any past or current insurance policy under which any of the foregoing is a named insured.SectionÂ 5.14Litigation Support. (a)From and after the Closing, in the event that and for so long as a Party or any of its Affiliates (in such capacity, a â€œLitigating Partyâ€) is prosecuting, contesting or defending any Proceeding, investigation, charge, claim or demand by or against a third party or otherwise addressing, negotiating, disputing, investigating, complying with, mitigating, discharging or otherwise performing or managing any obligation, Liability or loss in connectionâ€‹-80-with (i) the Transaction or any of the other transactions contemplated under this Agreement, or (ii) any fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action, failure to act, or transaction relating to, in connection with or arising from the Business, the Purchased Entities, the Purchased Assets or the Assumed Liabilities, the other Party shall, and shall cause its Affiliates (and its and their officers, employees and other Representatives) to, reasonably cooperate with the Litigating Party and its counsel in such prosecution, contest, defense or other action, including making available its personnel, participating in meetings and providing such testimony and access to its books and records and taking such other actions as shall be reasonably necessary in connection with such prosecution, contest, defense or other action. Notwithstanding anything in this Agreement to the contrary, Seller shall retain full control of prosecuting, contesting, defending, compromising, settling or taking any other action related to or in connection with any Proceeding, investigation, charge, claim or demand by or against a third party related to the Retained Business, any Excluded Asset or Retained Liability, whether arising before or after the Closing, and neither Purchaser nor their Affiliates shall have any rights in connection therewith, other than the right to indemnification for Retained Liabilities pursuant to ArticleÂ X.(b)The Purchasers agree to the matters set forth on SectionÂ 5.14(b) of the Seller Disclosure Schedules.SectionÂ 5.15Third-Party Consents. Seller and the Purchasers shall, and shall cause their respective Subsidiaries to, cooperate and use their commercially reasonable efforts to obtain any consents from third parties under the Material Contracts required in connection with the consummation of the Transactions (the consents of third parties referred to in this SectionÂ 5.15, collectively, the â€œThird-Party Consentsâ€). Notwithstanding anything to the contrary contained herein, (a) Seller and its Affiliates shall not have any further obligation under this SectionÂ 5.15 with respect to any consents of third parties (including the Third-Party Consents) that are not obtained on or prior to one hundred twenty (120) days following the Closing Date; and (b)Â neither Seller nor any of its Affiliates shall have any obligation to make any payments or other concession, or incur any other Liability, or commence or participate in any Proceeding to obtain any consents of third parties (including Third-Party Consents) or effect any of the transfers or arrangements contemplated by this SectionÂ 5.15, and the failure to receive any such consents or to effect any such transfers or arrangements shall not be taken into account in determining whether any condition to the Closing set forth in ArticleÂ VIII shall have been satisfied. Notwithstanding anything in this Agreement to the contrary, none of Seller, the other Seller Entities or any of their respective Affiliates shall under any circumstance be required to pay or commit to pay any amount or incur any obligation in favor of or offer or grant any accommodation (financial or otherwise, regardless of any provision to the contrary in the underlying Contract, including any requirements for the securing or posting of any bonds, letters of credit or similar instruments, or the furnishing of any guarantees) to any Person to obtain any approval.SectionÂ 5.16Non-Solicitation of Employees; Non-Competition.(a)For a period of three (3) years from the Closing Date, without the prior written consent of the Purchasers, as to any Business Employee as of immediately prior to the Closing who shall have become employed by the Purchasers or their Subsidiaries as ofâ€‹-81-immediately following the Closing (a â€œSeller Covered Personâ€), Seller agrees that none of Seller or any of its Subsidiaries will solicit for employment any Seller Covered Person; provided that Seller and its Subsidiaries shall not be precluded from soliciting, or taking any other action with respect to, any such individual (i) whose employment with the Purchasers or any of their Subsidiaries ceased prior to commencement of employment discussions between Seller or its Subsidiaries and such individual, (ii) who responds to solicitation not specifically targeted at employees of the Purchasers or any of their Subsidiaries or (iii) who initiates discussions regarding such employment without any solicitation by Seller or its Subsidiaries in violation of this Agreement; and provided, further, that Seller and its Subsidiaries shall not be restricted from engaging in general solicitations or advertising not specifically targeted at any such Persons described above.(b)For a period of three (3) years from the Closing Date, without the prior written consent of Seller, each Purchaser agrees that neither such Purchaser nor any of its Subsidiaries will solicit for employment any employee of Seller or its Subsidiaries with whom the Purchasers or any of their Subsidiaries had contact during their evaluation of the transactions contemplated by this Agreement or in connection with the services provided pursuant to the Transition Services Agreement or the Distribution Agreements; provided that such Purchaser and its Subsidiaries shall not be precluded from soliciting, or taking any other action with respect to, any such individual (i) whose employment with Seller or any of its Subsidiaries ceased prior to commencement of employment discussions between such Purchaser or its Subsidiaries and such individual, (ii) who responds to solicitation not specifically targeted at employees of Seller or any of its Subsidiaries or (iii) who initiates discussions regarding such employment without any solicitation by such Purchaser or its Subsidiaries in violation of this Agreement; and provided, further, that such Purchaser and its Subsidiaries shall not be restricted from engaging in general solicitations or advertising not specifically targeted at any such

Persons described above.(c)For a period of three (3) years from the Closing Date, without the prior written consent of the Purchasers, Seller agrees not to, and agrees to cause its Subsidiaries not to, (i) acquire, finance, own any interest in, manage, control, participate in, consult with, render services for, operate or engage in, directly or indirectly, any business that manufactures, distributes, markets and sells medicated products added in feed or drinking water that compete with the Business Products in the Territory (a â€œCompeting Businessâ€), or (ii) intentionally solicit or intentionally entice, or attempt to solicit or entice, any Person that, to the knowledge of Seller, was a supplier of the Business as of immediately prior to the Closing to cease doing business with the Business or intentionally interfere in a materially adverse manner with the relationship between the Business and any Person that, to the knowledge of Seller, was a supplier of the Business as of immediately prior to the Closing; provided, however, that nothing herein shall preclude Seller or its Subsidiaries from:(i)owning seven and a half percent (7.5%) or less of the outstanding stock or other securities of any Person;(ii)acquiring and, after such acquisition, owning an interest in any Person (or its successor) that is engaged in a Competing Business and operating such Competing Business if such Competing Business generated less than seven and a halfâ€‹-82-percent (7.5%) of actual revenue received by such Person in the last completed fiscal year of such Person;(iii)acquiring and, after such acquisition, owning an interest in any Person (or its successor) that is engaged in a Competing Business and operating such Competing Business if (A) such Competing Business generated seven and a half percent (7.5%) or more of actual revenue received by such Person in the last completed fiscal year of such Person and (B) Seller or its applicable Subsidiary, within eighteen (18) months after the consummation of such acquisition, causes the divestiture of a sufficient portion of the Competing Business of such Person such that the restrictions set forth in this SectionÂ 5.16(c) would not have operated to restrict such ownership assuming the completion of such divestiture had occurred prior to such acquisition;(iv)exercising its rights, performing or complying with its obligations under this Agreement or any of the other Transaction Documents;(v)engaging in the Retained Business; or(vi)engaging in the activities set forth on SectionÂ 5.16(c) of the Seller Disclosure Schedules.(d)If the final judgment of a court of competent jurisdiction declares that any term or provision set forth in this SectionÂ 5.16 is invalid or unenforceable, the Parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this SectionÂ 5.16 shall be enforceable as so modified after the expiration of the time within which the judgment may be appealed. The Parties intend that the agreements, covenants and obligations set forth in this SectionÂ 5.16 shall be deemed to be a series of separate covenants, one for each county or province of each and every state, commonwealth, territory or jurisdiction of each county or province anywhere in the world and one for each month of the applicable period of time (if any), as applicable. In the event of a breach or violation of any of the covenants, agreements or obligations in this SectionÂ 5.16, the period applicable to such breached or violated covenants, agreements or obligations shall be tolled until such breach or violation has been duly cured, to the extent such breach or violation is curable. Notwithstanding the foregoing, this SectionÂ 5.16 (x) shall not restrain or prohibit the consummation of any transaction or series of related transactions that results in a change of control of Seller, or involves the sale or transfer of a majority of the assets of the Seller Group or the equity of Seller, including any transaction following which the equity holders of Seller immediately prior to such transaction, in their capacity as such (and excluding any cross-ownership they may have in the equity of any counterparty to such transaction), cease to own a majority of the equity or voting power of Seller or the surviving entity in such transaction or its ultimate parent company immediately following such transaction (the â€œSeller Change of Controlâ€); provided, that, following the consummation of any Seller Change of Control, Seller and its Subsidiaries that were bound by this SectionÂ 5.16 prior to the Seller Change of Control (the â€œOriginal Seller Groupâ€) shall continue to be bound by the terms of this SectionÂ 5.16 in accordance with theâ€‹-83-terms hereof; provided, however, that, for the avoidance of doubt, Sellerâ€™s Affiliates (other than the Original Seller Group) shall in no event be bound by this SectionÂ 5.16; and (y) shall not restrain or prohibit any activities, actions or conduct of any Person that Seller or its Subsidiaries have an equity interest in as of the date hereof but is not directly or indirectly controlled by Seller or its Subsidiaries, including any such joint ventures, partnerships or co-investment vehicles that neither Seller nor any of its direct or indirect Subsidiaries controls.SectionÂ 5.17Payments; Misallocated Assets.(a)Seller shall, or shall cause its applicable Subsidiary to, promptly pay or deliver to the Purchasers (or their designated Subsidiaries) any monies or checks that have been sent to Seller or any of its Subsidiaries after the Closing by customers, suppliers or other contracting parties of the Business to the extent that they constitute a Purchased Asset. The Purchasers shall, or shall cause their applicable Subsidiary (including the Purchased Entities) to, promptly pay or deliver to Seller (or its designated Subsidiaries) any monies or checks that have been sent to a Purchaser or any of its Subsidiaries (including the Purchased Entities) after the Closing by customers, suppliers or other contracting parties of the Retained Business to the extent that they constitute an Excluded Asset.(b)Subject to SectionÂ 5.13, if, at any time after the Closing, any asset held by a Purchaser or any of its Subsidiaries (including the Purchased Entities) is ultimately determined to be an Excluded Asset or such Purchaser or any of its Subsidiaries is found to be subject to a Retained Liability, (i)Â such Purchaser shall return or transfer and convey (at such Purchaserâ€™s sole cost and expense (other than Transfer Taxes which shall be borne pursuant to SectionÂ 7.5) and without further consideration) to Seller or the appropriate Subsidiary of Seller such Excluded Asset or Retained Liability; (ii)Â Seller shall, or shall cause its appropriate Subsidiary to, assume (without further consideration) such Retained Liability; and (iii)Â Seller and such Purchaser shall, and shall cause their appropriate Subsidiaries to, execute such documents or instruments of conveyance or assumption and take such further acts as are reasonably necessary or desirable to effect the transfer of such Excluded Asset or Retained Liability back to Seller or its appropriate Subsidiary, in each case such that each Party is put into the same economic position as if such action had been taken on or prior to the Closing Date.(c)Subject to SectionÂ 5.13, if, at any time after the Closing, any asset held by any of the Seller Entities or any of their Subsidiaries is ultimately determined to be a Purchased Asset or any of the Seller Entities or any of their Subsidiaries is found to be subject to an Assumed Liability, (i)Â Seller shall transfer and convey (at Sellerâ€™s sole cost and expense (other than Transfer Taxes which shall be borne pursuant to SectionÂ 7.5) and without further consideration) to the applicable Purchaser such Purchased Asset or Assumed Liability; (ii)Â such Purchaser shall assume (without further consideration) such Assumed Liability; and (iii)Â Seller and such Purchaser shall, and shall cause their appropriate Subsidiaries to, execute such documents or instruments of conveyance or assumption and take such further acts as are reasonably necessary or desirable to effect the transfer of such Purchased Asset or Assumed Liability to such Purchaser, in each case such that each Party is put into the same economic position as if such action had been taken on or prior to the Closing Date.â€‹-84-SectionÂ 5.18R&W Insurance Policy. The Purchasers shall use reasonable best efforts to take all actions necessary to complete the applicable conditions in the conditional binder (other than the condition that Closing has occurred, to which this sentence does not apply) to the representations and warranties insurance policy with respect to the transactions contemplated hereby (the â€œR&W Insurance Policyâ€) within the times set forth therein. Upon its final issuance, the Purchasers shall deliver a copy of the R&W Insurance Policy to Seller. The R&W Insurance Policy shall include a provision whereby the insurer expressly waives, and irrevocably agrees not to pursue, directly or indirectly, any subrogation rights in connection with this Agreement, the other Transaction Documents, and the transactions contemplated hereby and thereby (other than in respect of fraud) against Seller, its Subsidiaries or any of their respective direct or indirect past or present shareholder, partner, stockholder, manager, member, director, officer or employee (the â€œWaiver of Subrogation Provisionâ€) and such Persons shall be express third-party beneficiaries of such provision. In addition, the Purchasers agree not to amend or waive the Waiver of Subrogation Provision in any manner that is adverse to Seller, its Subsidiaries or any of their respective direct or indirect past or present shareholder, partner, stockholder, manager, member, director, officer or employee without Sellerâ€™s prior written consent (which consent shall be in the sole and absolute discretion of Seller). Seller shall, and shall use commercially reasonable efforts to cause its Representatives to, reasonably cooperate with the Purchasers and use commercially reasonable efforts with respect to any reasonable requests made by the Purchasers or their Subsidiaries or Representatives in connection with the Purchasersâ€™ procurement of the R&W Insurance Policy, including responding to and facilitating any additional reasonable diligence investigation and providing to the Purchasers and their Representatives, as well as the applicable insurers, any additional diligence information reasonably requested in connection with binding such policy or removing or limiting any exclusions under the R&W Insurance Policy.SectionÂ 5.19Delivery of Financial Statements.(a)Seller shall prepare and deliver as soon as reasonably practicable following the date hereof (and in any event no later than five (5) Business Days prior to the Closing) (x) audited financial statements of the Business, consisting of the audited statements of assets acquired and liabilities assumed as of December 31, 2023 and 2022, and the related audited statements of revenues and direct expenses for the twelve (12)-month periods then ended (the â€œAudited Financial Statementsâ€), and (y) an unaudited statement of assets acquired and liabilities assumed of the Business and related statement of revenues and direct expenses for the three (3) month-period ended March 31, 2024, together with the comparative period for the prior year, reviewed in accordance with SAS 100 review procedures by independent accountants for the Business, in each case together with the notes thereto and prepared in accordance with the requirements for abbreviated financial statements set forth in Rule 3-05(e) of Regulation S-X under the Securities Act. Seller shall prepare and deliver to the Purchasers as soon as reasonably practicable and not later than ninety (90) days or, with respect to annual results, one hundred and five (105) days, following the end of any fiscal quarter or fiscal year, as applicable, ending between the date hereof and the Closing Date (even if such delivery date occurs after the Closing Date), (i) as of the end of such quarterly period, an unaudited statement of assets acquired and liabilities assumed of the Business and related statement of revenues and direct expenses for the applicable year-to-date period, in each case, reviewed in accordance with SAS 100 review procedures by independent accountants for the Business and (ii) as of the end of such annualâ€‹-85-period, an audited statement of assets acquired and liabilities assumed of the Business and related statement of revenues and direct expenses for the applicable period, in each case together with the comparative period for the prior year and the notes thereto and prepared in accordance with the requirements for abbreviated financial statements set forth in Rule 3-05(e) of Regulation S-X under the Securities Act, and with respect to each such annual period (including with respect to the Audited Financial Statements), audited pursuant to the standards set forth by the American Institute of Certified Public Accountants and accompanied by an independent auditorsâ€™ report for the Business, and in each case (A) solely to the extent such additional financial statements are required by Item 9.01 of Form 8-K with respect to financial statements of the business acquired if included on a Form 8-K (or amendment thereto) filed by Purchaser 1 pursuant to the requirements of the Exchange Act and (B) which would satisfy the requirements of Item 9.01 of Form 8-K with respect to financial statements of the business acquired if included on a Form 8-K (or amendment thereto) filed by Purchaser 1 pursuant to the requirements of the Exchange Act (collectively with the Audited Financial Statements, the â€œFinancial Statementsâ€). For the avoidance of doubt, Seller shall not be required to deliver any financial statements of the Business for any fiscal quarter or fiscal year, as applicable, ending between the date hereof and the Closing Date if any previously delivered financial statements are not required to be filed on a Form 8-K pursuant to the prior two sentences (provided that Seller shall provide such cooperation as set forth in clauseÂ (b) below). The annual and quarterly Financial Statements shall be prepared from and in accordance with the books of account and financial records of the Business and in accordance with GAAP, consistently applied throughout the periods indicated, and present fairly in all material respects the assets acquired, liabilities assumed, revenues and direct expenses of the Business as of the times and for the periods referred to therein.(b)Following the Closing, upon the Purchasersâ€™ request, (i) solely to the extent required to be included by Purchaser 1 in a filing with the SEC, Seller will use its commercially reasonable efforts to cause the independent accountants for the Business to provide their written consent for the filing of the Audited Financial Statements with the SEC (provided that such Purchaser shall be required to provide the independent accountants for the Business with customary representations and letters in connection therewith as requested by such independent accountants), and (ii) if the Closing Date does not coincide with the last day of a fiscal quarter for which Seller delivered financial statements to the Purchasers pursuant to SectionÂ 5.19(a), Seller shall prepare and deliver, as soon as reasonably practicable and within sixty (60) days after the Closing Date (provided that in no event will such information be delivered less than fifteen (15) days before the due date for Purchaser 1â€™s quarterly report (or annual report in the case of Purchaser 1â€™s Form 10-K) initially required to be filed by Purchaser 1 following the Closing Date under applicable SEC rules), such financial information (which will not be reviewed or audited by the independent accountants) for the Business for the period subsequent to the end of the fiscal quarter for which financial statements were delivered to the Purchasers pursuant to SectionÂ 5.19(a) up to the Closing Date that is required by Purchaser 1 to establish an opening balance sheet for the Business as of the close of business on the Closing Date or that is reasonably requested for purposes of preparing (i) financial statements of the Business for any quarter(s) ending after the most recent quarter for which financial statements were delivered pursuant to SectionÂ 5.19(a) through the Closing Date and (ii) pro forma financial statements (which financial information need not be reviewed as set forth above); provided, however, that in no event shall Seller be obligated to deliver any such financial information relating to the Business that would be in excess of the information required to prepareâ€‹-86-abbreviated financial statements for the portion of such fiscal year in accordance with the requirements set forth in Rule 3-05(e)(2) of Regulation S-X (as if financial statements of the Business for such portion of the fiscal year were required to be filed); provided, further, that in no event shall Seller be obligated to deliver any such financial information relating to the Business for any period after the Closing Date.(c)The Purchasers shall reimburse Seller for all documented out-of-pocket costs incurred by Seller or its Affiliates in connection with fulfilling its obligations pursuant to this SectionÂ 5.19; provided that such costs shall not exceed (i) $2,000,000 in the aggregate for the Audited Financial Statements and the unaudited financial statements corresponding to the fiscal quarter ended March 31, 2024 and (ii) $350,000 for each additional quarter required to be prepared and provided by Seller pursuant to this SectionÂ 5.19.SectionÂ 5.20Exclusivity. During the period from the date of this Agreement until the earlier to occur of (a) the Closing and (b) the termination of this Agreement in accordance with its terms, Seller shall not, and shall not permit any of its Subsidiaries (including the Purchased Entities) or their respective Representatives to, directly or indirectly, (i) solicit, knowingly encourage or initiate any Acquisition Proposal, or (ii) institute, pursue or engage in any discussions or negotiations with, or enter into any Contract with, or provide any information relating to the Business, the Purchased Assets, the Assumed Liabilities, or any of the Purchased Entities, to, any Person of group of Persons (other than the Purchasers and their Representatives) in furtherance of an Acquisition Proposal. For the avoidance of doubt, Seller, its Subsidiaries or their respective Representatives shall not be restricted in any way with respect to or in connection with any disposition, merger, sale, change of control or other transaction (i) involving all or a majority of the assets or equity of Seller and its Subsidiaries (other than with respect to the Business or the Purchased Entities) on a consolidated basis, (ii) involving any business of Seller other than the Business or (iii) not prohibiting the consummation of the Transaction.SectionÂ 5.21Certain Matters. The Parties agree to the matters set forth on Section 5.21 of the Seller Disclosure Schedules.SectionÂ 5.22Resignations. On the Closing Date, Seller shall use commercially reasonable efforts to cause to be delivered to the Purchasers duly signed resignations, effective immediately after the Closing, of all of the directors and officers of the Purchased Entities in office as of the Closing Date identified by the Purchasers in writing at least five (5) Business Days prior to the Closing, or shall take such other action as is necessary to cause such persons to no longer be directors or officers of the Purchased Entities as the case may be, immediately after the Closing.SectionÂ 5.23Restricted Cash. On or prior to the Closing, Seller shall, and shall cause the Chinese Purchased Entity to, use reasonable best efforts to distribute or otherwise transfer all Cash in excess of five million dollars ($5,000,000) (the â€œChinese Operating Cash Amountâ€) from the Chinese Purchased Entity to a member of the Seller Group (the â€œPre-Closing Restricted Cash Distributionâ€). To the extent that, notwithstanding the foregoing,Â the Chinese Purchased Entity holds any Excess Restricted Cash following the Closing, then following the Closing, the Purchasers shall (i) use reasonable best efforts to cause the Chinese Purchased Entity to distribute or otherwise transfer any such portion of the Excess Restricted Cash to its direct ownerâ€‹-87-(or, to the extent the Chinese Purchased Entity and its direct owner are organized in the same jurisdiction, to its first indirect owner organized in another jurisdiction) (any such distribution or other transfer, an â€œExcess Restricted Cash Distributionâ€ and any Excess Restricted Cash so distributed or otherwise transferred, the â€œDistributed Excess Restricted Cashâ€), (ii) transfer to Seller or its designated Subsidiaries such Distributed Excess Restricted Cash, net of any Taxes or other reasonable and documented third-party costs borne by the Purchasers and their Affiliates in connection with such transfer imposed on the Excess Restricted Cash Distribution (each such transfer, a â€œDistributed Excess Restricted Cash Transferâ€), and (iii) reasonably cooperate with the Seller Group to structure and effect any Excess Restricted Cash Distribution and Distributed Excess Restricted Cash Transfer in a manner that seeks to minimize any Taxes imposed on such distribution or transfer, if such structure does not adversely affect Purchasers or any of their Affiliates in a more than de minimis manner. For the avoidance of doubt, any such Excess Restricted Cash Distribution or Distributed Excess Restricted Cash Transfer shall be effected without any corresponding payment, distribution or transfer to the Purchasers or any other party.SectionÂ 5.24Additional Business Products.(a)Notwithstanding anything in this Agreement to the contrary, for a period of two (2) years following the Closing Date, each Purchaser shall have an option to provide Seller notice of its desire to acquire any Additional Business Products (as well as associated marketing approvals, product development approvals, applications, clearances or other authorizations used to sell, distribute, research or develop or market the Additional Business Product) identified with reasonable specificity by such Purchaser. As soon as

reasonably practicable following such notice, the Seller or its Affiliates shall use their commercially reasonable efforts to contribute, grant, assign, transfer, convey or deliver, as applicable, such Additional Business Product to the applicable Purchaser (or, in the sole discretion of the Purchasers, any Affiliate thereof) on the terms set forth in this Agreement for no additional consideration, except the Purchasers shall reimburse Seller for all reasonable third-party costs associated with the transfer of any Additional Business Product. The Purchasers shall, and shall cause their Affiliates to, reasonably cooperate with Seller in connection with the foregoing.(b)Following the date hereof, unless this Agreement is validly terminated pursuant to ArticleÂ IX, Seller and its Affiliates shall not at any time (i) use, sell, divest, assign, distribute, manufacture, produce the Additional Business Products or Non-Commercialized Business Products; (ii) withdraw any drug master files or animal drug applications made with any regulatory or government agency related to the Additional Business Products or Non-Commercialized Business Products; and (iii) grant, authorize or permit any other Person the right to use, sell, distribute, manufacture, produce, or have a right to reference the Additional Business Products or Non-Commercialized Business Products, or exploit any Intellectual Property Rights that are exclusively used by or exclusively embedded in the Additional Business Products or Non-Commercialized Business Products in the exercise of the forgoing.(c)Following the Closing, (i) Purchaser and its Affiliates shall have the right to reference any drug master file or animal drug application made with any regulatory or government agency for any Additional Business Product, and (ii) until the second (2nd) anniversary of the Closing Date Seller shall use commercially reasonable efforts to provide anyâ€‹-88-such documentation needed for a right to reference, on behalf of or directly to Purchaser and its Affiliates.(d)The Purchasers shall, and shall cause their Affiliates to, reasonably cooperate with Seller in connection with the foregoing and the Purchasers shall reimburse Seller for any Transfer Taxes, VAT/GST and all reasonable and documented third-party costs incurred by Seller or its Affiliates in connection with fulfilling its obligations pursuant to this Section 5.24.SectionÂ 5.25Additional Business Product Marks. Subject to the terms and conditions of this Agreement, effective only upon the Closing, Seller, on behalf of itself and the other Seller Entities, hereby quitclaim, sell, assign, transfer and convey to the Purchasers all of Sellerâ€™s and the other Seller Entitiesâ€™ right, title and interest as of the Closing in, to and under the Marks listed in SectionÂ 5.25 of the Seller Disclosure Schedules (which may be updated prior to the Closing pursuant to Section 5.28) (collectively, â€œAdditional Business Product Marksâ€), together with all of the goodwill appurtenant thereto and including the right to damages for the past or future infringement, misappropriation or violation of the Additional Business Product Marks, and to recover or collect royalties, damages, proceeds, and profits in connection therewith. If any renewal, maintenance, or other fees relating to the registration or application for any Additional Business Product Marks become due and payable prior to Closing, Seller shall, at the Purchasersâ€™ reasonable request, make any such payment at the Purchasersâ€™ cost (or shall notify, authorize and assist the Purchasers to make any such payment directly with the relevant intellectual property office). Notwithstanding anything in this Agreement to the contrary, the Additional Business Product Marks are transferred to the Purchasers solely on an â€œas is, where isâ€ basis and no representations or warranties whatsoever, whether express, implied or statutory, are made with respect to any of the Additional Business Product Marks. Without limiting the foregoing, the Additional Business Product Marks shall not be considered within the definition of Transferred Intellectual Property.SectionÂ 5.26Expired Marks. Subject to the terms and conditions of this Agreement, effective only upon the Closing, Seller, on behalf of itself and the other Seller Entities, hereby quitclaim, sell, assign, transfer and convey to the Purchasers all of Sellerâ€™s and the other Seller Entitiesâ€™ right, title and interest (and only to the extent Seller and the other Seller Entities have any right, title and interest) as of the Closing in, to and under the Expired Marks set forth in SectionÂ 5.26 of the Seller Disclosure Schedules (which may be updated prior to the Closing pursuant to Section 5.28) (collectively, the â€œExpired Marksâ€), together with the goodwill appurtenant thereto and including the right to damages for the past or future infringement, misappropriation or violation of the Expired Marks, and to recover or collect royalties, damages, proceeds, and profits in connection therewith; provided, that Seller makes no, and disclaims any, representation or warranty of any kind with respect to the Expired Marks, including whether such Expired Marks are entitled to protection as Marks, are distinctive, are capable of being registered with the United States Patent and Trademark Office or any other Governmental Entity, are owned by Seller or any of its Affiliates or may be used without infringing the rights of others. Without limiting the foregoing, the Expired Marks shall not be considered within the definition of Transferred Intellectual Property.â€‹-89-SectionÂ 5.27Omitted Marks. If, prior to the Closing, the Purchasers notify Seller of a Mark omitted from Sections 2.4(h)(i), SectionÂ 5.25 or SectionÂ 5.26 of the Seller Disclosure Schedules, which the Purchasers reasonably believe is (a) owned by the Seller Entities as of the date hereof, and (b) exclusively used, or held exclusively for use, in the operation of the Business, then the Parties shall promptly discuss in good faith whether such omitted Mark should be added to the Additional Business Product Marks or the Expired Marks and, if agreed, SectionÂ 5.25 or SectionÂ 5.26 of the Seller Disclosure Schedules shall be updated accordingly prior to the Closing. Notwithstanding the requirement of good faith discussions in the foregoing, if such omitted Mark is a foreign counterpart to a Mark listed in Sections 2.4(h)(i), SectionÂ 5.25 or SectionÂ 5.26 of the Seller Disclosure Schedules as of the date hereof, then such omitted Mark shall be presumed to be entitled to be added, as the case may be, to the Additional Business Product Marks or the Expired Marks.SectionÂ 5.28Intellectual Property Chain of Title Corrections. Prior to the Closing, Seller shall use commercially reasonable efforts to cooperate with the Purchasersâ€™ reasonable request to file any required name change documentation at the United States Patent and Trademark Office and intellectual property offices or agencies in any other jurisdictions as may be necessary and required to correct the named owner in the public record of any Patents set forth on Section 5.28 of the Seller Disclosure Schedules or other Transferred Intellectual Property where the aggregate sales of Business Products branded under such Transferred Intellectual Property in the jurisdiction where such Transferred Intellectual Property is registered meet or exceed $500,000 on an annual basis (each Transferred Intellectual Property meeting this criteria, a â€œCovered Intellectual Propertyâ€) to the extent the title records at the applicable intellectual property offices and agencies do not reflect ownership of such Covered Intellectual Property in the name of a Purchased Entity or a current Seller Entity as of the date hereof. Seller shall provide, upon the Purchasersâ€™ reasonable request, the documentation and filings made in connection with the foregoing prior to the Closing. In the event that any such filing to update the title records at the applicable intellectual property offices to name a Purchased Entity (or a current Seller Entity, as applicable) as the owner of record of a Covered Intellectual Property has not been filed at or prior to the Closing, Seller shall use commercially reasonable efforts to execute and deliver such further instruments and documents (but excluding making any filings, which shall be the responsibility of Purchaser) as Purchaser may reasonably request, at the sole cost and expense of Seller, as necessary for Purchaser to complete such name change or correction following Closing. Notwithstanding anything to the contrary contained herein, if Sellerâ€™s commercially reasonable efforts prior to the Closing were unsuccessful in correcting the named owner of any Covered Intellectual Property, such failure shall not be taken into account in determining whether any condition to the Closing set forth in ArticleÂ VIII shall have been satisfied and as of and following the Closing, Seller shall have no responsibility to take any further action.SectionÂ 5.29Assignment of Business Registered IP. Promptly following the Closing, Seller or the applicable Seller Entity, as assignor, will execute and deliver to the applicable Purchaser, as assignee, a short-form recordable deed of assignment as may be required, and that is sufficient, to evidence the transfer, sale, assignment, and conveyance of the Seller Entitiesâ€™ right, title and interest in the Business Registered IP pursuant to and in accordance with this Agreement. Without limiting the foregoing, Seller shall use reasonable best efforts following the Closing to take such further action (including the execution and delivery of such otherâ€‹-90-instruments of conveyance) as the Purchasers may reasonably request and provide any additional information that may be reasonably requested by Purchasers and required to effectuate the transfer of the Business Registered IP. Purchaser shall be solely responsible for, and shall bear all costs related to, any filings or recordings to effectuate such transfer. For the avoidance of doubt, as of and following the Closing, Seller will have no responsibility to take any action to maintain any of the Business Registered IP, or further prosecute or seek issuance of any applications included in the foregoing, including payment of fees, responses to any office action or other inquiries from agents of Governmental Entities or registrars, or otherwise.SectionÂ 5.30Transition Services. Seller and the Purchasers agree, as soon as reasonably practicable following the date hereof and prior to the Closing, to amend and finalize in good faith the terms of the schedules to the Transition Services Agreement consistent with the general terms set forth on in the schedules attached to the Transition Service Agreement as of the date hereof (including, for the avoidance of doubt, the schedule of services and the costing methodology set forth in the Transition Services Agreement).ARTICLEÂ VIEMPLOYEE MATTERSSectionÂ 6.1Transfer of Business Employees.(a)Transfer of Business Employees Generally. Except as otherwise provided in this SectionÂ 6.1, the applicable member of the Seller Group shall transfer the employment, employment Contracts and, subject to applicable Law and any required employee consents, accrued unused vacation of each Business Employee based in a jurisdiction where there is a Purchased Entity to a Purchased Entity no later than immediately prior to the Closing. The applicable member of the Seller Group shall transfer the employment and employment Contracts of each Seller Employee to a member of the Seller Group no later than as of immediately prior to the Closing. To the extent required by Law, Seller Group shall timely pay out any accrued unused vacation for such Seller Employees in connection with such transfer, or shall obtain any required employee consents to roll over such amounts to the Seller Group. For the avoidance of doubt, the Seller Group shall assume and retain all Liabilities with respect to any Seller Employees.(b)Offers to Certain Business Employees. No later than thirty (30) days prior to the Closing Date, the Purchasers shall, or shall cause one of their Subsidiaries to, offer employment, (i)Â on terms and conditions consistent with the requirements of this ArticleÂ VI and applicable Law and (ii) in a position that is substantially comparable to such individualâ€™s position immediately prior to the time of offer including level of responsibility, authority and geographical location (i.e., same city or within thirty (30) miles of the current primary office location), to each Business Employee not employed by a Purchased Entity (the â€œOffer Employeesâ€) other than any U.S. LTD Employee. Each such offer shall be subject to the prior review and reasonable comment of Seller. Other than the U.S. LTD Employees, the Seller Entities shall terminate the employment of each Offer Employee as of the Closing, provided that the Purchasers shall be responsible for any associated severance or other liability. The Seller Entities shall not discourage the Offer Employees from accepting such Purchaserâ€™s or itsâ€‹-91-Subsidiaryâ€™s offers of employment and shall cooperate with respect to the Business Employeesâ€™ transition to such Purchaser and its Subsidiaries.(c)U.S. LTD Employees. If any U.S. Business Employee who is receiving long-term disability benefits as of the Closing Date (each, a â€œU.S. LTD Employeeâ€) is, within twelve (12) months following the Closing Date or such longer time required by applicable Law, able to return to work, Purchaser 1 shall offer employment to such employee on terms consistent with those applicable to Business Employees generally under this ArticleÂ VI. Notwithstanding the foregoing, Purchaser 1 shall return to work any inactive employee of the Business who is subject to a Collective Bargaining Agreement and who is receiving long-term disability benefits as of the Closing Date, but who subsequently becomes able to return to work within the period provided in the Collective Bargaining Agreement that applied to him or her immediately prior to the Closing Date. Unless otherwise specified in this Agreement, for any U.S. LTD Employee, references in this Agreement to the â€œClosingâ€ and â€œClosing Dateâ€ shall be treated as references to the first day and time at which the applicable U.S. LTD Employee is released to return to work but shall not otherwise extend the Comparability Period under SectionÂ 6.2(a).(d)Definitions. For purposes of this Agreement, (i)Â any U.S. Business Employee whose employment transfers (including any Offer Employee who commences employment with Purchaser 1 or its Subsidiaries) pursuant to this SectionÂ 6.1 shall be referred to as a â€œU.S. Transferred Employee,â€ and (ii)Â any International Business Employee whose employment transfers (including any Offer Employee who commences employment with Purchaser 2 or its Subsidiaries) pursuant to this SectionÂ 6.1 shall be referred to as an â€œInternational Transferred Employeeâ€ (collectively, the â€œTransferred Employeesâ€).SectionÂ 6.2Compensation and Employee Benefits.(a)Compensation and Benefits Comparability. For a period of one (1) year following the Closing, or such shorter period a Transferred Employee is employed (the â€œComparability Periodâ€), the Purchasers shall, or shall cause their Subsidiaries (including the Purchased Entities) to, provide to each Transferred Employee during his or her employment with such Purchaser and its Subsidiaries (including the Purchased Entities) (i)Â annual base salary or wage rates (as applicable) that are not less than those in effect for each such Transferred Employee immediately prior to the Closing, (ii) annual or short-term cash incentive compensation (including cash bonus opportunities) opportunities that, in each case, are no less favorable than those in effect for each such Transferred Employee immediately prior to the Closing, (iii) severance benefits (including termination indemnity, redundancy or similar termination payments or benefits) that are no less favorable than the severance benefits (including termination indemnity, redundancy or similar termination payments or benefits) that would have been payable to each such Transferred Employee under the Seller Benefit Plan in which such Transferred Employee participated, or was eligible for, immediately prior to the Closing, and (iv) other employee benefits (excluding nonqualified deferred compensation) that are substantially comparable to those employee benefits provided to similarly situated employees of the Purchasers. In addition, Purchasers shall, or shall cause their Subsidiaries (including the Purchased Entities) to, provide to each Transferred Employee who immediately prior to Closing was otherwise eligible to receive equity compensation from Seller during the Comparability Period with a cash retention award with a value equal to the target value of the portion of suchâ€‹-92-Transferred Employeeâ€™s Seller equity incentive compensation opportunity that would have been subject to vesting within 12 months from the grant date of such award, which retention award shall be subject to such terms, including vesting, as reasonably determined by the Purchaser (provided that the vesting period shall not exceed 12 months).(b)Severance or Other Termination Liabilities. The Purchasers and their Subsidiaries shall be solely responsible for any severance, termination indemnity, redundancy or similar termination payments or benefits that may become payable to any Business Employee arising out of or in connection with the transactions contemplated by this Agreement, including any amounts paid or payable to any Business Employee who does not become an employee of the Purchasers or their Subsidiaries because such Business Employee rejects or does not accept an offer of employment or transfer of employment or refuses to transfer employment or otherwise challenges such transfer of employment pursuant to SectionÂ 6.1, provided that the Purchasersâ€™ and their Subsidiariesâ€™ obligation pursuant to this sentence shall be limited to an aggregate amount specified in Section 6.2(b) of the Seller Disclosure Schedule (the â€œSeverance Capâ€); provided, however, that the Severance Cap shall not apply to the extent a Liability arises out of or in connection with the Purchasersâ€™ or their Subsidiariesâ€™ noncompliance with applicable Law or the terms of this Agreement. In addition, to the extent that Seller or its Affiliates (other than the Purchased Entities) become liable for, or are legally required to make, severance, redundancy, termination indemnity or other termination payments, contributions or benefits to any Business Employee as a result of the transactions contemplated by this Agreement, the Purchasers shall, or shall cause their Affiliates to, reimburse Seller, as soon as practicable but in any event within thirty (30) days of receipt from Seller of an invoice, for all payments, costs and expenses for which the Purchasers or their Subsidiaries are liable pursuant to the immediately preceding sentence that are actually paid by Seller or its Affiliates (other than the Purchased Entities), including any employment, social security or other Taxes or any employer contributions, as required by applicable Law, Contract, Collective Bargaining Agreement or Seller Benefit Plan.(c)Service Credit. For (i) all employment purposes including the calculation of all service-related entitlements under applicable Law (such as the calculation of severance (including termination, indemnity, redundancy or similar termination payments or benefits) pay and benefits eligibility) and (ii) purposes of determining vesting, eligibility to participate and, with respect to paid time off, vacation and severance, the level of benefits under the employee benefit plans of the Purchasers and their Subsidiaries (other than plans providing defined benefit pension or post-employment health or welfare benefits or perquisites) under which any Business Employees may be eligible to participate after the Closing (the â€œNew Plansâ€), each Business Employee shall be credited with his or her years of service with Seller and its Subsidiaries and their respective predecessors prior to the Closing, to the same extent and for the same purpose as such Business Employee was entitled, prior to the Closing, to credit for such service under any similar Seller Benefit Plan in which such Business Employee participated or was eligible to participate immediately prior to the Closing; provided that the foregoing shall not apply for purposes of benefit accrual under any defined benefit pension plan, retiree medical plan (except with respect to any Purchased Entity Benefit Plan or as otherwise required by applicable Law) or to the extent that its application would result in a duplication of benefits for the same period of service. In addition, and without limiting the generality of the foregoing, the Purchasers shall allow each Business Employee to be immediately eligible to participate, without any waitingâ€‹-93-time, in any and all New Plans to the extent coverage under such New Plan is comparable to a Seller Benefit Plan in which such Business Employee participated immediately before the Closing (such plans, collectively, the â€œOld Plansâ€).(d)Welfare Plans. For purposes of each New Plan providing medical, dental, pharmaceutical and/or vision benefits to any Business Employee, the Purchasers shall use commercially reasonable efforts to cause all pre-existing condition exclusions and actively-at-work requirements of such New Plan to be waived for such employee and his or her covered dependents, unless such conditions would not have been waived under the comparable Seller Benefit Plans in which such employee participated immediately prior to the Closing, and the Purchasers shall cause any eligible expenses incurred by such employee and his or her covered dependents during the portion of the plan year of the Old Plans ending on the date such employeeâ€™s participation in the corresponding New Plan begins to be taken into account under such New Plan for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee and his or her covered dependents for the applicable plan year as if such amounts had been paid in accordance with such New Plan.(e)Flexible Spending Accounts. Seller and the Purchasers shall take all actions necessary or appropriate so that, effective as of the Closing Date, (i)Â the account balances (whether positive or negative) (the â€œTransferred FSA Balancesâ€) under the applicable flexible spending plan of Seller or its

Subsidiaries (collectively, the â€œSeller FSA Planâ€) of the Transferred Employees who are participants in the Seller FSA Plan shall be transferred to one or more comparable plans of the Purchasers (collectively, the â€œPurchaser FSA Planâ€); (ii)Â the elections, contribution levels and coverage levels of such Transferred Employees shall apply under the Purchaser FSA Plan in the same manner as under the Seller FSA Plan; and (iii)Â such Transferred Employees shall be reimbursed from the Purchaser FSA Plan for claims incurred at any time during the plan year of the Seller FSA Plan in which the Closing Date occurs that are submitted to the Purchaser FSA Plan from and after the Closing Date on the same basis and the same terms and conditions as under the Seller FSA Plan. As soon as practicable after the Closing Date, and in any event within tenÂ (10) Business Days after the amount of the Transferred FSA Balances is determined, Seller shall pay the applicable Purchaser the net aggregate amount of the Transferred FSA Balances, if such amount is positive, and the applicable Purchaser shall pay Seller the net aggregate amount of the Transferred FSA Balances, if such amount is negative.(f)Accrued PTO. Seller shall timely make any payments to any Business Employees in respect of earned but unused paid time off that become due under applicable Law as a result of any transfer or termination of employment contemplated by SectionÂ 6.1. Subject to applicable law and any required employee consents, the applicable Purchaser will recognize and/or assume (as applicable and to the extent reflected in Working Capital) all other accrued but unused paid time off for Transferred Employees as of the Closing.SectionÂ 6.3Seller Benefit Plans. From and after the Closing, the Transferred Employees shall cease to be active participants in the Seller Benefit Plans that are not Purchased Entity Benefit Plans (collectively, the â€œRetained Seller Benefit Plansâ€). Except as set forth in this ArticleÂ VI, Seller shall indemnify and hold harmless the Purchasers and their Affiliates and their officers, directors, employees, and agents from and against any and all costs, damages,â€‹-94-losses, expenses, or other Liabilities arising out of or related to the Retained Seller Benefit Plans. Notwithstanding anything in this ArticleÂ VI to the contrary, Seller and the Purchasers hereby agree that Seller and its Subsidiaries shall retain any obligation to provide long-term disability benefits to any Business Employee who (i) as of the Closing Date is receiving or entitled to receive short-term disability benefits and who subsequently becomes eligible to receive long-term disability benefits, or (ii) as of the Closing Date is receiving or entitled to receive long-term disability benefits. At least thirty (30) days prior to the Closing Date, Seller shall provide the Purchasers or their Subsidiaries, with any information requested by the Purchasers or their Subsidiaries necessary to effectuate the enrollment of the Business Employees in the New Plans effective as of the Closing Date, to the extent allowed under applicable Law.SectionÂ 6.4Purchased Entity Benefit Plans. The applicable Purchaser and its Subsidiaries shall assume all Liabilities related to all Purchased Entity Benefit Plans. Each such Purchaser shall, severally and jointly, indemnify and hold harmless Seller and its Affiliates and their officers, directors, employees, and agents from and against any and all costs, damages, losses, expenses, or other Liabilities arising out of or related to the Purchased Entity Benefit Plans.SectionÂ 6.5U.S. Defined Contribution Plans.(a)Effective as of the Closing, the applicable Purchaser shall create or designate defined contribution plans (collectively, the â€œPurchaser DC Plansâ€) for the benefit of the U.S. Transferred Employees who participated in one or more of the defined contribution plans maintained by Seller or its Subsidiaries (other than the Purchased Entities) that are intended to be qualified under Section 401(a) of the Code immediately prior to the Closing (collectively, the â€œSeller DC Plansâ€). Such U.S. Transferred Employees are referred to hereinafter as the â€œU.S. DC Employees.â€ The U.S. DC Employees shall be given credit under the respective Purchaser DC Plan for all service with and compensation from Seller and its Subsidiaries and their respective predecessors as if it were service with and compensation from such Purchaser for purposes of determining eligibility, vesting and the amount of any benefits or benefit accruals under each respective Purchaser DC Plan. Effective as of the Closing Date, Seller shall take all actions necessary to 100% fully vest each U.S. DC Employee in his or her account balances under the Seller DC Plans.(b)As of the Closing Date, the Seller Group shall retain, and no Purchased Entity shall assume or retain sponsorship of, or any assets or Liabilities with respect to, the Seller DC Plans, other than with respect to the rollover of account balances described in SectionÂ 6.5(c).(c)Each Purchaser DC Plan will provide for the receipt from the U.S. DC Employees of â€œeligible rollover distributionsâ€ (as such term is defined under Section 402 of the Code), including notes corresponding to loans. The Purchasers and Seller will work together in order to facilitate any such distribution or rollover and to effect an eligible rollover distribution for those U.S. DC Employees who elect to roll over their account balances, including notes, directly into a Purchaser DC Plan. At least thirty (30) days prior to the Closing Date, Seller shall provide the Purchasers or their Subsidiaries, with any information regarding any plan loans associated with any U.S. DC Employees under the Seller DC Plans.â€‹-95-SectionÂ 6.6Short-Term Incentive Compensation. The Purchasers shall, or shall cause their Subsidiaries to, pay to each Transferred Employee any cash incentive compensation payable under the incentive compensation plan or arrangement in which such Transferred Employee participates in respect of the calendar year in which the Closing occurs (or any portion thereof) (the â€œCash Incentive Compensationâ€), and Seller and its Subsidiaries shall not have any Liability for the Cash Incentive Compensation. All Cash Incentive Compensation shall be governed by plans, programs or arrangements maintained by the Purchasers and their Subsidiaries (including the Purchased Entities) on terms and conditions no less favorable than those that applied to each such Transferred Employee prior to the Closing Date, including with respect to target incentive opportunities, applicable performance metrics and service requirements; provided that the amount of Cash Incentive Compensation actually paid by the Purchasers and their Subsidiaries (including the Purchased Entities) to Transferred Employees shall be not less than the accrued amount of Cash Incentive Compensation included in Closing Working Capital.SectionÂ 6.7Labor Matters.(a)Seller shall, and shall cause its Subsidiaries to take all steps, on a timely basis, as are required under applicable Law or any Collective Bargaining Agreement to notify, provide information to, consult or bargain with, or negotiate the effect, impact, terms or timing of the transactions contemplated by this Agreement with each works council, union, labor organization, labor board, employee group or representative, or Governmental Entity (with respect to labor and similar matters) where so required under applicable Law and the Purchasers shall reasonably cooperate with the foregoing. Seller shall regularly review with the Purchasers the progress of the notifications, consultations and negotiations with each works council, union, labor organization, labor board, employee group or representative and such Governmental Entity regarding the effect, impact or timing of the transactions contemplated by this Agreement. Prior to the Closing, Seller shall, and shall cause its Subsidiaries to, timely comply with all applicable Laws, directives and regulations relating to the Business Employees and any Collective Bargaining Agreements, and the Purchasers shall reasonably cooperate with respect to the foregoing. The Purchasers or their applicable Subsidiaries shall, subject to bargaining with the unions to the extent required by applicable Law, assume the Collective Bargaining Agreements set forth on Section 3.20(b) of the Seller Disclosure Schedules effective as of the Closing, and shall, or shall cause their Subsidiaries to, be responsible for all Liabilities arising thereunder. The Purchasers shall, or shall cause their Subsidiaries to, be responsible for all Liabilities arising under and otherwise honor any Collective Bargaining Agreements which any Purchased Entity is party to, until its expiration, modification or termination in accordance with its terms or applicable Law. The Purchasers shall, or shall cause its Subsidiaries to, join any industrial, employer or similar association or federation if membership is required for the applicable Collective Bargaining Agreement to continue to apply. Seller shall use commercially reasonable efforts to negotiate a one-year extension with each applicable union with respect to each Collective Bargaining Agreement set forth on Section 3.20(b) of the Seller Disclosure Schedules. Notwithstanding anything in this Agreement to the contrary, the terms and conditions of employment for any Transferred Employee covered by a Collective Bargaining Agreement will be governed by the applicable Collective Bargaining Agreement until its expiration, modification or termination in accordance with its terms or applicable Law.â€‹-96-(b)On the Closing, Seller shall provide the Purchasers with a list setting forth termination date and work location, the job title of each employee or former employee of the Seller Entities who have suffered an â€œemployment lossâ€ under the WARN Act at any site of employment where a Business Employee is located within the ninety (90) days immediately preceding the Closing Date.SectionÂ 6.8Workersâ€™ Compensation. Seller and its Subsidiaries (other than the Purchased Entities) shall be responsible for all workersâ€™ compensation benefits payable to or on behalf of the Transferred Employees based on a Workersâ€™ Compensation Event that occurs prior to the Closing Date. The Purchasers or their Subsidiaries (including, after the Closing Date, the Purchased Entities) shall be responsible for all workersâ€™ compensation benefits payable to or on behalf of the U.S. Business Employees based on a Workers Compensation Event that occurs on or after the Closing Date. Claim for workersâ€™ compensation benefits shall be deemed to be incurred when the event giving rise to the claim occurs (a â€œWorkersâ€™ Compensation Eventâ€). Notwithstanding the foregoing or anything to the contrary in this Agreement, with respect to any facts, events, circumstances or occurrences, known or unknown, related to or arising out of the Business Employees or Business Contingent Workers that occurred (in whole or in part) at or prior to the Closing that are covered by or insured under any employment practices liability insurance policies of Seller or any of its Subsidiaries, the Purchasers and their Subsidiaries (including, for the avoidance of doubt, from and after the Closing, the Purchased Entities) may make claims, to the extent such claims relate to or arise out of facts, events, circumstances or occurrences occurring at or prior to the Closing, under any such policies and programs, and Seller shall, and shall cause its Subsidiaries to, (i)Â take such actions as may be requested by a Purchaser in connection with the tendering of such claims to the applicable insurers under such policy or program, the pursuit of such claims or the collection of any losses, to the extent available under such policy or program, and (ii) provide the Purchasers or an Subsidiary thereof designated in writing by the Purchasers with the proceeds it realizes with respect to such claims.SectionÂ 6.9Immigration Compliance. The applicable Purchaser and Seller shall, or shall cause their respective Subsidiaries to, cooperate to ensure that any foreign national who requires a visa in order to work for Seller or its Subsidiaries in his or her current position may continue to work in such position as a Transferred Employee on and following the Closing Date. To the extent any such visas cannot be transferred as of Closing, the applicable Purchaser and Seller will enter into an employee leasing arrangement such that such Purchaser may benefit from the services of any such Business Employee until their visa is transferred to a Purchaser or one of its Subsidiaries.SectionÂ 6.10Assignment and Transfer of Business Contingent Worker. Effective as of no later than the Closing Date, the Parties shall use commercially reasonable efforts to take such actions as are necessary to ensure that the Contract of services of each Business Contingent Worker located in a jurisdiction where there is a Purchased Entity is transferred to a Purchased Entity no later than immediately prior to the Closing Date. Each of the Parties agrees to execute, and to seek to have the applicable Business Contingent Worker execute, such documentation, if any, as may be necessary to reflect such assignment and/or transfer. Each Contract of services of each Business Contingent Worker located in a jurisdiction where there is not a Purchased Entity (collectively, the â€œBusiness Contingent Worker Contractsâ€) shall constitute a Specified Business Contract and be transferred in accordance with SectionÂ 2.4.â€‹-97-SectionÂ 6.11Communications. Prior to the Closing, any employee notices or communication materials (including website postings) from a Purchaser or its Subsidiaries to the Business Employees, including notices or communication materials with respect to employment, compensation or benefits matters addressed in this Agreement or related, directly or indirectly, to the transactions contemplated by this Agreement or employment thereafter, shall be subject to the prior review of Seller.SectionÂ 6.12Employee Restrictive Covenants. Seller agrees that, notwithstanding the terms of any noncompetition, customer non-solicit or other restrictive covenant obligation between Seller or its Subsidiaries and a Transferred Employee, such Transferred Employee shall be permitted to provide services to the Purchasers and their Subsidiaries following the Closing, and Seller and its Subsidiaries will not seek to enforce the terms of any such restrictive covenant following the Closing with respect to such Transferred Employeeâ€™s services to the Purchasers and their Subsidiaries, in each case solely with respect to the Business.SectionÂ 6.13Third-Party Beneficiary Rights. This ArticleÂ VI is included for the sole benefit of the parties to this Agreement and their respective transferees and permitted assigns and does not and shall not create any right in any Person, including any current or former employee of Seller or any of its Subsidiaries, any Business Employee, any Former Employee or any Transferred Employee, who is not a party to this Agreement. Nothing contained in this Agreement (express or implied) is intended to confer upon any individual any right to employment for any period of time, or any right to a particular term or condition of employment. No current or former employee of Seller or any of its Subsidiaries, nor any Business Employee, Former Employee or Transferred Employee, including any beneficiary or dependent thereof, or any other Person not a party to this Agreement, shall be entitled to assert any claim against any Purchaser, Seller or any of their respective Subsidiaries under this ArticleÂ VI.ARTICLEÂ VIICERTAIN TAX MATTERSSectionÂ 7.1Cooperation and Exchange of Information.(a)From and after the Closing, each Party shall, and shall cause its Subsidiaries to, provide to the other Party such cooperation, documentation and information relating to the Purchased Entities or the Purchased Assets as either of them may reasonably request in (i)Â filing any Tax Return, amended Tax Return or claim for refund, (ii) determining a liability for Taxes or a right to refund of Taxes, or (iii) conducting any Tax Proceeding. Such cooperation and information shall include providing copies of all relevant portions of relevant Tax Returns, together with all relevant portions of relevant accompanying schedules and relevant work papers, relevant documents relating to rulings or other determinations by Taxing Authorities and relevant records concerning the ownership and Tax basis of property and other information, which any such Party may possess. Notwithstanding anything to the contrary in this Agreement, such cooperation shall not include disclosure of, and neither the Purchasers nor any of their Subsidiaries shall be entitled to, any Tax Return (or copy thereof) of Seller, any Seller Entity or any of their respective Subsidiaries (other than a Purchased Entity) or the Seller Group. Each Party shall make its employees reasonably available on a mutually convenient basis at its cost to provide an explanation of any documents or information so provided.â€‹-98-(b)Each Party shall retain all Tax Returns, schedules and work papers, and all material records and other documents relating to Tax matters, of the relevant entities for their respective Pre-Closing Tax Periods until the later of (i) the expiration of the statute of limitations for the Tax periods to which the Tax Returns and other documents relate, or (ii) eight (8) years following the due date (without extension) for such Tax Returns. Thereafter, the Party holding such Tax Returns or other documents may dispose of them after offering the other Party reasonable notice and opportunity to take possession of such Tax Returns and other documents at such other Partyâ€™s own expense.SectionÂ 7.2Tax Sharing Agreements. Seller shall terminate or cause to be terminated, on or before the Closing Date, the rights and obligations of the Purchased Entities pursuant to all Tax sharing agreements or arrangements (other than this Agreement), if any, to which any of the Purchased Entities, on the one hand, and Seller or any of its Subsidiaries (other than the Purchased Entities), on the other hand, are parties such that neither Seller nor any of its Subsidiaries (other than the Purchased Entities), on the one hand, nor any of the Purchased Entities, on the other hand, shall have any rights or obligations to each other after the Closing in respect of such agreements or arrangements.SectionÂ 7.3Tax Treatment of Payments. Except to the extent otherwise required pursuant to a â€œdeterminationâ€ (within the meaning of Section 1313(a) of the Code or any similar provision of state, local or non-U.S. Law), Seller, the Purchasers, the Purchased Entities and their respective Subsidiaries shall treat any and all payments under SectionÂ 2.9 and ArticleÂ X (and any other indemnity payments under this Agreement) as an adjustment to the purchase price for Tax purposes.SectionÂ 7.4Elections. Notwithstanding anything herein to the contrary, the Purchasers shall not and shall cause their Subsidiaries (including, after the Closing, the Purchased Entities) not to (a) make any election with respect to any Purchased Entity (including any entity classification election pursuant to Treasury Regulations Section 301.7701-3), or change any method of Tax accounting or any Tax accounting period of any Purchased Entity, which election or change would be effective on or prior to the Closing Date or (b) take any other action or engage in any transaction that would reasonably be expected to increase Taxes included as a liability in the Separate Company Accrued Tax Amount or the WC Adjustment Amount.SectionÂ 7.5Transfer Taxes and VAT/GST. Notwithstanding anything in this Agreement to the contrary, (a) each of Seller, on the one hand, and the Purchasers, on the other hand, shall be responsible for fifty percent (50%) of any Transfer Taxes and (b) Purchasers shall be responsible for any VAT/GST. The Party responsible under applicable Law for filing the Tax Returns with respect to any such Transfer Taxes (or paying any such Transfer Taxes) shall prepare and timely file such Tax Returns (and pay such Transfer Taxes) and promptly provide a copy of such Tax Return to the other Party and such other Party shall reimburse the filing Party for its share of any such Transfer Taxes paid by the filing Party that are required to be borne by the other Party pursuant to clause (a) of the preceding sentence. Purchasers shall pay to Seller (or its relevant Affiliates), in addition to the consideration otherwise payable, any VAT/GST upon receipt from Seller of a proper invoice. Seller and the Purchasers shall, and shall cause their respective Subsidiaries to, cooperate (y) to timely prepare and file any Tax Returns or other filings relating to Transfer Taxes or VAT/GST imposed on any transaction or supplyâ€‹-99-contemplated by this Agreement, including any available claim for exemption or exclusion from the application or imposition of any Transfer Taxes or any such VAT/GST, and (z) to structure any transaction or supply contemplated by this Agreement so as to minimize Transfer Taxes and VAT/GST.SectionÂ 7.6Italian VAT Receivable. Seller shall have the right to control any claim for refund and any Tax Proceeding, in each case, relating to the Italian VAT Receivable, and the Purchasers shall provide Seller with any information and cooperation reasonably required in connection with any such claim for refund or Tax Proceeding, including by causing the Italian Purchased Entity to provide Seller with a power of attorney to represent the Italian Purchased Entity in any such Tax Proceeding. In connection with any such Tax Proceeding, Seller shall timely provide the Purchasers with copies of all written communications and documents received, provide the Purchasers with a reasonable advance opportunity to comment on any written submissions, and allow the Purchasers to participate in any such Tax Proceeding at the Purchasersâ€™ sole cost and expense. Any Taxes incurred by Purchasers or any of their Affiliates (including the Purchased Entities) in connection with obtaining or transferring the benefit of the Italian VAT Receivable to Seller shall be the responsibility of Seller.SectionÂ 7.7Straddle Period. In the case of any Straddle Period of a Purchased Entity, (i) the amount of any Income Taxes which relate to the Pre-Closing Tax Period will be determined based on an interim closing of the

books as of the close of business on the Closing Date and (ii) the amount of Taxes other than Income Taxes which relate to the Pre-Closing Tax Period will be deemed to be the amount of such Tax for the Straddle Period multiplied by a fraction, the numerator of which is the number of days in the portion of the Straddle Period ending on the Closing Date and the denominator of which is the total number of days in such Straddle Period.SectionÂ 7.8Certain Tax Refunds. If a Purchaser or a Purchased Entity receives after the Closing Date a refund in cash (or a credit against Income Taxes otherwise payable, in lieu of a refund in cash) from a Taxing Authority that is specifically identified on SectionÂ 7.8 of the Seller Disclosure Schedule(which Seller shall be permitted to update prior to the Closing), in each case, such Purchaser shall (or shall cause the applicable Purchased Entity) pay to the applicable Seller Entity no later than thirty (30) days after receipt the amount of such refund that it actually receives in cash (or applies such credit to reduce Income Taxes otherwise payable), in each case, net of any third-party out-of-pocket costs or expenses (including Tax costs) incurred in connection with obtaining, claiming or paying over such amount. If any such refund or credit paid over to a Seller Entity is subsequently disallowed by a Taxing Authority within the two (2) year period ending after the payment of an associated amount to a Seller Entity pursuant to this paragraph, the Seller Entities shall return such amount to the applicable Purchaser or the applicable Purchased Entity within thirty (30) days of notification of such disallowance. Notwithstanding the forgoing, no Seller Entity shall be entitled to any refund to the extent that it (i) is attributable to the carryback of any Tax attribute generated in a taxable period (or portion thereof) beginning after the Closing Date, (ii) arises from an adjustment that results in an increase in Taxes imposed on Purchaser and its Subsidiaries, or a reduction of Tax benefits, in each case, in any Tax period or portion thereof beginning after the Closing or (iii) is received by a Purchaser or a Purchased Entity following the second (2nd) anniversary of the Closing Date.â€‹-100-For the avoidance of doubt, this SectionÂ 7.8 shall not apply to the Italian VAT Receivable or Tax refunds that are Excluded Assets.ARTICLEÂ VIIICONDITIONS PRECEDENTSectionÂ 8.1Conditions to Each Partyâ€™s Obligations to Close. The respective obligations of Seller and Purchasers to effect the Closing are subject to the satisfaction or (to the extent permitted by Law) waiver by Seller and Purchasers at or prior to the Closing of the following conditions:(a)Regulatory Approvals. Any waiting period under the HSR Act applicable to the consummation of the Transaction or the other transactions contemplated by this Agreement shall have expired or been terminated, and any other Regulatory Approvals required to be obtained prior to the Closing under the Regulatory Laws of the jurisdictions listed on SectionÂ 8.1(a) of the Seller Disclosure Schedules shall have been obtained (or any applicable waiting period thereunder shall have expired or been terminated) (collectively, the â€œRequired Approvalsâ€).(b)No Injunctions or Restraints. No Law or Judgment issued by any Governmental Entity of competent jurisdiction shall have been promulgated or entered and remain in effect which prevents, prohibits or restrains the consummation of the Closing.SectionÂ 8.2Conditions to Obligations of Purchasers to Close. The obligation of Purchasers to effect the Closing is subject to the satisfaction (or waiver by Purchasers) at or prior to the Closing of the following additional conditions:(a)Representations and Warranties.(i)The representations and warranties made by Seller contained in SectionÂ 3.2(b) and SectionÂ 3.2(c) (Purchased Entities; Capital Structure) shall be true and correct in all respects other than de minimis inaccuracies as of the Closing Date as if made on and as of the Closing Date (or, in the case of representations and warranties that are made as of a specific date, as of such date).(ii)(A) The Seller Fundamental Representations (other than those contained in SectionÂ 3.2(b) and SectionÂ 3.2(c) (Purchased Entities; Capital Structure)) that are qualified by â€œmaterialityâ€ or â€œMaterial Adverse Effectâ€ limitations shall be true and correct in all respects as of the Closing Date as if made on and as of the Closing Date (or, in the case of representations and warranties that are made as of a specific date, as of such date) and (B) the Seller Fundamental Representations that are not qualified by any â€œmaterialityâ€ or â€œMaterial Adverse Effectâ€ limitations shall be true and correct in all material respects as of the Closing Date as if made on and as of the Closing Date (or, in the case of representations and warranties that are made as of a specific date, as of such date).(iii)The representations and warranties of Seller contained in ArticleÂ III (other than the Seller Fundamental Representations and other than as set forthâ€‹-101-in the following sentence) shall be true and correct (without giving effect to any â€œmaterialityâ€ or â€œBusiness Material Adverse Effectâ€ limitations set forth therein) as of the Closing Date as if made on and as of the Closing Date (or, in the case of representations and warranties that are made as of a specific date, as of such date), except where the failure of such representations and warranties to be true and correct would not have, individually or in the aggregate, a Business Material Adverse Effect. The representation and warranty of Seller set forth in SectionÂ 3.8(b) shall be true and correct in all respects as of the Closing Date as if made on and as of the Closing Date.(b)Performance of Obligations of Seller. The covenants and agreements of Seller to be performed or complied with on or before the Closing in accordance with this Agreement shall have been performed and complied with in all material respects.(c)Officerâ€™s Certificate. The Purchasers shall have received a certificate, dated as of the Closing Date and signed on behalf of Seller by an executive officer of Seller, stating that the conditions specified in SectionÂ 8.2(a), SectionÂ 8.2(b) and Section 8.2(d) have been satisfied.(d)No Business Material Adverse Effect. Since the date of this Agreement, there shall not have been a Business Material Adverse Effect that is continuing as of the Closing Date.SectionÂ 8.3Conditions to Obligations of Seller to Close. The obligation of Seller to effect the Closing is subject to the satisfaction (or waiver by Seller) at or prior to the Closing of the following additional conditions:(a)Representations and Warranties. The representations and warranties of the Purchasers contained in ArticleÂ IV (other than as set forth in the following sentence) shall be true and correct as of the Closing Date as if made on and as of the Closing Date (or, in the case of representations and warranties that are made as of a specific date, as of such date), except where the failure of such representations and warranties to be true and correct would not have, individually or in the aggregate, a Purchaser Material Adverse Effect. The representations and warranties of the Purchasers set forth in SectionÂ 4.1, SectionÂ 4.2 and SectionÂ 4.8 shall be true and correct in all material respects as of the Closing Date as if made on and as of the Closing Date (or, in the case of representations and warranties that are made as of a specific date, as of such date).(b)Performance of Obligations of Purchasers. The covenants and agreements of the Purchasers to be performed or complied with on or before the Closing in accordance with this Agreement shall have been performed and complied with in all material respects.(c)Officerâ€™s Certificate. Seller shall have received a certificate, dated as of the Closing Date and signed on behalf of the Purchasers by an executive officer of the Purchasers, stating that the conditions specified in SectionÂ 8.3(a) and SectionÂ 8.3(b) have been satisfied.â€‹-102-ARTICLEÂ IXTERMINATION; EFFECT OF TERMINATIONSectionÂ 9.1Termination. Notwithstanding anything to the contrary in this Agreement, this Agreement may be terminated and the Transaction and the other transactions contemplated by this Agreement abandoned at any time prior to the Closing:(a)by mutual written consent of Seller and the Purchasers;(b)by Seller, if the Purchasers shall have materially breached any of its representations, warranties, covenants or agreements contained in this Agreement, and such breach would give rise to the failure of a condition set forth in SectionÂ 8.3(a) or SectionÂ 8.3(b) and has not been cured by the earlier of (i) the date that is thirty (30) days after the date that Seller has notified the Purchasers of such breach stating Sellerâ€™s intention to terminate this Agreement pursuant to this SectionÂ 9.1(b) and the basis for such termination and (ii) the Outside Date; provided that Seller shall not be permitted to terminate this Agreement pursuant to this SectionÂ 9.1(b) if Seller has breached any of its representations, warranties, covenants or agreements contained in this Agreement, in each case, such that any condition set forth in SectionÂ 8.2(a) or SectionÂ 8.2(b) would not be satisfied;(c)by the Purchasers, if Seller shall have materially breached any of its representations, warranties, covenants or agreements contained in this Agreement, and such breach would give rise to the failure of a condition set forth in SectionÂ 8.2(a) or SectionÂ 8.2(b) and has not been cured by the earlier of (i) the date that is thirty (30) days after the date that the Purchasers have notified Seller of such breach stating the Purchasersâ€™ intention to terminate this Agreement pursuant to this SectionÂ 9.1(c) and the basis for such termination and (ii) the Outside Date; provided that the Purchasers shall not be permitted to terminate this Agreement pursuant to this SectionÂ 9.1(c) if the Purchasers have breached any of its representations, warranties, covenants or agreements contained in this Agreement, in each case such that any condition set forth in SectionÂ 8.3(a) or SectionÂ 8.3(b) would not be satisfied;(d)by Seller or by the Purchasers, subject to SectionÂ 11.7, if the Closing shall not have occurred on or prior to 11:59 p.m. (New York City time) on January 28, 2025 (the â€œOutside Dateâ€); provided that if all of the conditions set forth in ArticleÂ VIII, other than the conditions set forth in SectionÂ 8.1(a) or SectionÂ 8.1(b) (solely if the Law or Judgment relates to any Regulatory Laws), shall have been satisfied or waived or shall be capable of being satisfied on such date if Closing were to take place on such date, then the Outside Date shall automatically be extended to 11:59 p.m. (New York City time) on April 28, 2025, which date shall thereafter be deemed to be the Outside Date; provided, that, the Purchasers and Seller shall amend the Outside Date to a date no earlier than July 28, 2025 if the Purchasers are able to obtain the extension under the Commitment Letter pursuant to Section 5.7(a)(y); provided, further, that (x) if all of the conditions set forth in ArticleÂ VIII shall have been satisfied or waived (or in the case of conditions that by their nature are to be satisfied at the Closing, are then capable of being satisfied if the Closing were to take place on such date) on a date that occurs on or prior to the Outside Date but (y) the Closing would thereafter occur in accordance with SectionÂ 2.3 on a date (the â€œSpecified Dateâ€) that occurs after such Outside Date, then the Outside Date shall automatically be extended to such Specified Date (which, for the avoidance of doubt, will not beâ€‹-103-greater than four (4) Business Days after Closing pursuant to SectionÂ 2.3) and the Specified Date shall become the Outside Date for purposes of this Agreement; provided, further, that the right to terminate this Agreement pursuant to this SectionÂ 9.1(d) shall not be available to any Party whose failure to perform any covenant or agreement under this Agreement has been the primary cause of, or resulted in, the failure of the Closing to occur on or before such date; or(e)by Seller or by the Purchasers, if a Judgment issued by a Governmental Entity of competent jurisdiction shall have become final and nonappealable, permanently enjoining or otherwise permanently preventing the consummation of the Transaction; provided that the right to terminate this Agreement pursuant to this Section 9.1(e) shall not be available to any Party whose failure to perform any covenant or agreement under this Agreement has been the primary cause of, or resulted in, the issuance of such Judgment.SectionÂ 9.2Effect of Termination. If this Agreement is terminated as described in SectionÂ 9.1, this Agreement shall become null and void and of no further force and effect, without any Liability or obligation on the part of any Party or its Affiliates; provided that the last sentence of SectionÂ 5.8(d) and the provisions of SectionÂ 5.1(e), SectionÂ 5.3(a), SectionÂ 5.8(b), SectionÂ 5.19(c), this SectionÂ 9.2, SectionÂ 9.3 and ArticleÂ XI shall remain in full force and effect (the â€œSurviving Obligationsâ€); and provided, further, that nothing in this SectionÂ 9.2 shall release or relieve any Party from any Liability for any fraud or willful and material breach by such Party occurring prior to the termination of this Agreement. For the purposes of this Agreement, â€œwillful and material breachâ€ means a willful and material breach of this Agreement that is the consequence of an intentional act or intentional failure to act by a Party with the actual knowledge that the taking of such act or failure to take such action would be a material breach of this Agreement. For the purposes of this Agreement, â€œfraudâ€ means an actual and intentional common law fraud (and not constructive fraud or negligent or reckless misrepresentation or a similar theory) under Delaware law with respect to the representations and warranties set forth in ArticleÂ III or ArticleÂ IV of this Agreement and in any certificate delivered in connection with this Agreement.SectionÂ 9.3Notice of Termination. In the event of termination by Seller or the Purchasers pursuant to SectionÂ 9.1, written notice of such termination shall be given by the terminating Party to the other Party.ARTICLEÂ XINDEMNIFICATIONSectionÂ 10.1Survival.(a)The representations and warranties of Seller contained in this Agreement and in any certificate delivered hereunder (and any rights arising out of any breach of such representations and warranties) shall not survive the Closing and shall terminate at the Closing, and, following the Closing, neither Seller nor any of its Affiliates or any other Person shall have any Liability with respect to any of such representations or warranties.(b)The representations and warranties of the Purchasers contained in this Agreement and in any certificate delivered hereunder (and any rights arising out of any breach ofâ€‹-104-such representations and warranties) shall not survive the Closing and shall terminate at the Closing, and, following the Closing, neither the Purchasers nor any of their Affiliates or any other Person shall have any Liability with respect to any of such representations or warranties.(c)The covenants and agreements contained in this Agreement that require performance prior to the Closing (and any rights arising out of any breach of such covenants and agreements) shall not survive the Closing and shall terminate at the Closing, and, following the Closing, neither Party nor any of its respective Affiliates or any other Person shall have any Liability with respect to any breach of any such covenants and agreements. The covenants and agreements in this Agreement that by their terms apply or are to be performed, in whole or in part, after the Closing (and any rights arising out of any breach of such covenants and agreements), in each case, shall survive the Closing for the period provided in such covenants and agreements, if any, or until fully performed. The obligation of Seller to retain, and indemnify and hold harmless the Purchaser Indemnified Parties for, any Retained Liabilities, and the obligation of the Purchasers to assume, and indemnify and hold harmless the Seller Indemnified Parties for, any Assumed Liabilities, as well as any covenants and agreements of the Parties that by their terms provide for indemnification or reimbursement or allocate fees, payments, costs or expenses as between the Parties, shall survive the Closing indefinitely.(d)No Person shall be entitled to indemnification, and no Proceeding seeking to recover Covered Losses or other relief shall be commenced or maintained, after the end of the relevant survival period set forth herein, unless a claim for indemnification with respect thereto has previously been made in accordance with this Agreement. Notwithstanding anything to the contrary set forth in this Agreement or in any Ancillary Agreement, nothing in this Agreement or in any Ancillary Agreement shall limit or prevent any claims in respect of fraud.SectionÂ 10.2Indemnification by Seller.(a)Subject to the provisions of this ArticleÂ X, effective as of and after the Closing, Seller shall indemnify and hold harmless the Purchasers and their Affiliates and their respective Representatives (collectively, the â€œPurchaser Indemnified Partiesâ€), from and against any and all Covered Losses incurred or suffered by any of the Purchaser Indemnified Parties to the extent resulting from (i)Â any breach of any covenant or agreement of Seller contained in this Agreement that survives the Closing, for the period it survives or (ii) any Retained Liabilities.(b)Seller shall not be required to indemnify or hold harmless any Purchaser Indemnified Party against, or reimburse any Purchaser Indemnified Party for, any Covered Losses to the extent that such Covered Losses are reflected, reserved, accrued, recorded or included in the Closing Working Capital or the Closing Indebtedness as finally determined pursuant to this Agreement.SectionÂ 10.3Indemnification by Purchasers. Subject to the provisions of this ArticleÂ X, effective as of and after the Closing, the Purchasers shall, severally and jointly, indemnify and hold harmless Seller and its Affiliates and their respective Representatives (collectively, the â€œSeller Indemnified Partiesâ€), from and against any and all Covered Losses incurred or suffered by any of the Seller Indemnified Parties to the extent resulting from (i) any breach of anyâ€‹-105-covenant or agreement of a Purchaser contained in this Agreement that survives the Closing, for the period it survives or (ii) any Assumed Liabilities.SectionÂ 10.4Procedures.(a)Any Person entitled to be indemnified under this ArticleÂ X (the â€œIndemnified Partyâ€) shall promptly give written notice to the Party from whom indemnification may be sought (the â€œIndemnifying Partyâ€) of any pending or threatened Proceeding against the Indemnified Party that has given or would reasonably be expected to give rise to such right of indemnification with respect to such Proceeding (a â€œThird-Party Claimâ€), indicating, with reasonable specificity, the nature of such Third-Party Claim, the basis therefor, a copy of any documentation received from the third party, the amount and calculation of the Covered Losses for which the Indemnified Party is entitled to indemnification under this ArticleÂ X (and a good-faith estimate of any such future Covered Losses relating thereto), and the provision(s) of this Agreement in respect of which such Covered Losses shall have occurred, and the Indemnified Party shall promptly deliver to the Indemnifying Party any information or documentation related to the foregoing reasonably requested by the Indemnifying Party. A failure by the Indemnified Party to give notice and to tender the defense of the Proceeding in a timely manner pursuant to this SectionÂ 10.4(a) shall not limit the obligations of the Indemnifying Party under this ArticleÂ X, except to the extent such Indemnifying Party is materially prejudiced thereby.(b)With respect to any Third-Party Claim, the Indemnifying Party under this ArticleÂ X shall have the right, but not the obligation, to assume the control and defense, at its own expense and by counsel of its own choosing, of such Third-Party Claim and any Third-Party Claims related to the same or a substantially similar set of facts; provided that the Indemnifying Party shall not be entitled to assume the control and defense of such Third-Party Claim if such Third-Party Claim seeks (i) an order, injunction or other equitable relief or relief other than monetary damages against the Indemnified Party that the Indemnified Party reasonably determines, after conferring with its outside counsel, cannot be separated from any related claim for monetary damages, or (ii) a finding or admission of violation of Law (including any Third-Party Claim seeking to impose criminal fines, penalties or sanctions) or any Judgment of a Governmental Entity against the Indemnified Party. If the Indemnifying Party so undertakes to control and defend any such Third-Party Claim, it shall notify the Indemnified Party of its intention to do so, and the Indemnified Party shall cooperate fully with the Indemnifying Party and its counsel in the defense against, and settlement of, any such Third-Party Claim; provided, however, that the Indemnifying Party shall not settle any such Third-Party Claim without the written consent of the Indemnified Party (not to be unreasonably withheld, conditioned or delayed) unless such settlement does not involve any injunctive relief against or any finding or admission of any violation of Law or wrongdoing by the Indemnified Party, and any money damages are borne solely by the Indemnifying Party. Subject to the foregoing, the Indemnified Party shall have the right to employ separate legal counsel and to participate in but not control the defense of such Proceeding at its own cost and expense; provided that, subject to the provisions of this ArticleÂ X, the Indemnifying Party shall bear the reasonable fees of one firm of legal counsel (and one additional firm of legal counsel in each jurisdiction implicated in such Proceeding) representing all Indemnified Parties in such Proceeding and all related Proceedings, if, but only if, the defendants in such Proceeding include both an Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have reasonably concluded, based on theâ€‹-106-advice of legal counsel, that there is a material conflict of interest between the Indemnifying Party and the Indemnified Party with respect to such Proceeding. In

any event, the Indemnified Party shall cause its legal counsel to reasonably cooperate with the Indemnifying Party and its legal counsel and shall not assert any position in any Proceeding inconsistent with that asserted by the Indemnifying Party. No Indemnified Party may settle any Third-Party Claim without the written consent of the Indemnifying Party (not to be unreasonably withheld, conditioned or delayed). If the Indemnifying Party does not assume the control and defense of a Third-Party Claim, it shall nevertheless be entitled to participate in the defense of such Proceeding at its own cost and expense, and the Indemnified Party shall cooperate fully with the Indemnifying Party and its counsel in the defense against, and settlement of, any such Third-Party Claim. Anything herein to the contrary notwithstanding, Seller shall have the exclusive right to control any Proceeding relating to Excluded Taxes.(c)In the event that any Indemnified Party has or may have an indemnification claim against any Indemnifying Party under this ArticleÂ X that does not involve a Third-Party Claim, the Indemnified Party shall promptly give written notice thereof to the Indemnifying Party indicating, with reasonable specificity, the nature of such claim, the basis therefor, the amount and calculation of the Covered Losses for which the Indemnified Party is entitled to indemnification under this ArticleÂ X (and a good-faith estimate of any such future Covered Losses relating thereto), and the provision(s) of this Agreement in respect of which such Covered Losses shall have occurred, and the Indemnified Party shall promptly deliver to the Indemnifying Party any information or documentation related to the foregoing reasonably requested by the Indemnifying Party. A failure by the Indemnified Party to give notice in a timely manner pursuant to this SectionÂ 10.4(c) shall not limit the obligations of the Indemnifying Party under this ArticleÂ X, except to the extent such Indemnifying Party is materially prejudiced thereby. If the Indemnifying Party disputes its liability with respect to such claim, the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute and, if not resolved through negotiations, such dispute shall be resolved by litigation in the appropriate court of competent jurisdiction set forth in SectionÂ 11.8.SectionÂ 10.5Exclusive Remedy and Release. The Purchasers and Seller acknowledge and agree that, except with respect to claims under any Ancillary Agreement (which shall be governed exclusively by such Ancillary Agreement), claims seeking specific performance or other equitable relief with respect to covenants or agreements to be performed after the Closing, and claims for fraud, following the Closing, the indemnification provisions of SectionÂ 10.2 and SectionÂ 10.3 shall be the sole and exclusive remedies of the Purchasers and Seller, respectively, and any of their respective Affiliates, for any Liabilities (including in respect of any claims for breach of contract (including for breach of any representation, warranty, covenant or agreement), warranty, tortious conduct (including negligence), under Law or otherwise and whether predicated on common law, statute, strict liability, or otherwise) that each Party may at any time suffer or incur, or become subject to, as a result of or in connection with this Agreement, the Transaction or the other transactions contemplated by this Agreement, including any breach of any representation or warranty in this Agreement by any Party, or any breach of or failure by any Party to perform or comply with any covenant or agreement in this Agreement and the other Transaction Documents. Other than claims in respect of fraud, the Purchasers acknowledge and agree that they are relying exclusively on, and their sole recourse for any actual or alleged breach of any representation or warranty will be, the R&W Insurance Policy. In furtherance of theâ€‹-107-foregoing, and subject to the indemnification provisions of this ArticleÂ X or with respect to fraud, from and after the Closing, the Parties hereby waive, on behalf of themselves and their Affiliates, to the fullest extent permitted by applicable Law, any and all other rights, claims and causes of action (including rights of contribution, if any) known or unknown, foreseen or unforeseen, which exist or may arise in the future, that they may have against Seller or any of its Affiliates, or the Purchasers or any of their Affiliates, as the case may be, as a result of or in connection with this Agreement, the Transaction or the other transactions contemplated by this Agreement, whether arising under or based upon breach of contract (including for breach of any representation, warranty, covenant or agreement), warranty, tortious conduct (including negligence), under Law or otherwise and whether predicated on common law, statute, strict liability, or otherwise. Without limiting the generality of the foregoing, the Parties hereby irrevocably waive any right of rescission they may otherwise have or to which they may become entitled.SectionÂ 10.6Additional Indemnification Provisions. With respect to each indemnification obligation contained in this Agreement, all Covered Losses shall be net of any (a) net cash Tax benefit actually recognized by a Purchased Entity in the country of its organization during the taxable year of the Covered Loss or the immediately succeeding taxable year (a â€œTax Benefitâ€) and (b) third-party insurance or indemnity, contribution or similar proceeds that have been recovered (net of the deductible for such insurance policy, costs of enforcement and any Taxes or other expenses incurred in connection with such recovery) by the Indemnified Party or its Affiliates in connection with such Covered Loss (it being agreed that if third-party insurance or indemnification, contribution or similar proceeds in respect of such Covered Loss are received subsequent to the Indemnifying Partyâ€™s making of an indemnification payment in satisfaction of its applicable indemnification obligation, such proceeds shall be promptly remitted to the Indemnifying Party to the extent of the indemnification payment made), and the Indemnified Party shall use, and causes its Affiliates to use, reasonable best efforts to seek full recovery under all insurance and indemnity, contribution or similar provisions covering such Covered Loss to the same extent as it would if such Covered Loss were not subject to indemnification hereunder. To the extent any indemnification payment made to any Indemnified Party does not take into account any Tax Benefit that is subsequently realized by such Indemnified Party, such Indemnified Party shall pay the amount of such Tax Benefit to the Indemnifying Party. Upon making any payment to the Indemnified Party for any indemnification claim pursuant to this ArticleÂ X, the Indemnifying Party shall be subrogated, to the extent of such payment, to any rights which the Indemnified Party may have against any third parties with respect to the subject matter underlying such indemnification claim, and the Indemnified Party shall assign any such rights to the Indemnifying Party and otherwise cooperate with the Indemnifying Party in seeking recovery thereunder.SectionÂ 10.7Mitigation. Each of the Parties agrees to use, and to cause its Affiliates to use, its commercially reasonable efforts to mitigate its respective Covered Losses upon and after becoming aware of any event or condition that would reasonably be expected to give rise to any Covered Losses that are indemnifiable hereunder (provided, however, that the foregoing shall not require any party to initiate or pursue any Proceeding against third parties, other than taking the relevant administrative steps to file for or make ordinary course claims under insurance policies, in respect of such Covered Losses).â€‹-108-ARTICLEÂ XIGENERAL PROVISIONSSectionÂ 11.1Entire Agreement. This Agreement and the other Transaction Documents, and the Schedules and Exhibits hereto and thereto, and the Confidentiality Agreement, along with the Seller Disclosure Schedules and Purchaser Disclosure Schedules, constitute the entire agreement and understanding between the Parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, whether written or oral, relating to such subject matter. In the event of a conflict between the terms of this Agreement and the terms of any Transaction Document, the terms of this Agreement shall control.SectionÂ 11.2Disclosure Schedules. The Seller Disclosure Schedules and the Purchaser Disclosure Schedules, and all schedules attached thereto, and all Exhibits attached to this Agreement shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein. Any capitalized terms used in any Exhibit or in the Seller Disclosure Schedules or the Purchaser Disclosure Schedules but not otherwise defined therein shall be defined as set forth in this Agreement. Any information, item or other disclosure set forth in any Section of the Seller Disclosure Schedules or the Purchaser Disclosure Schedules, as the case may be, shall be deemed to be disclosed with respect to any other Section of this Agreement (or to have been set forth in any other Section of the Seller Disclosure Schedules or the Purchaser Disclosure Schedules, as the case may be), if the relevance of such disclosure to such other Section is reasonably apparent on its face, notwithstanding the omission of a reference or a cross-reference with respect thereto and notwithstanding any reference to a Section of the Seller Disclosure Schedules or the Purchaser Disclosure Schedules, as applicable, in such Section of this Agreement.SectionÂ 11.3Assignment. Neither this Agreement nor any of the rights and obligations hereunder may be assigned or transferred by either Party (whether by operation of Law or otherwise) without the prior written consent of the other Party. Any attempted assignment in violation of this SectionÂ 11.3 shall be void. Notwithstanding anything to the contrary contained herein, (a) either Party may assign its rights and obligations (in whole or in part) under this Agreement to any of its Subsidiaries (and for the avoidance of doubt, in the case of each Purchaser, to any Subsidiary of Purchaser 1) or, following the Closing, to any third party who purchases directly or indirectly a majority of the equity interests or assets of Purchasers or the Purchased Entities without prior written consent, and (b) each Purchaser may make a collateral assignment of all or any part of its rights and obligations under this Agreement to any of its Subsidiaries, financing sources (or agent therefor) without prior written consent (provided that any assignment of obligations pursuant to this sentence shall only release the assigning party from such obligations to the extent actually performed and shall not impede or delay the consummation of the Transaction or the other transactions contemplated hereby). In the event any such assignment by a Purchaser results in any incremental withholding of Taxes from the consideration payable to Seller, Purchasers shall pay such additional amounts as are necessary to ensure that Seller receives the amounts it would have received absent such incremental withholding. Any attempted assignment in violation of this SectionÂ 11.3 will be void. Notwithstanding anything to the contrary contained herein, the Purchasersâ€™ potential financing sources will be express third-party beneficiaries of, and will be entitled to rely on and may enforce, the provisions of this SectionÂ 11.3. Subject to the preceding sentences, this Agreementâ€‹-109-shall be binding upon and shall inure to the benefit of the Parties and their respective successors and assigns.SectionÂ 11.4Amendments and Waivers. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties. By an instrument in writing, Purchasers, on the one hand, or Seller, on the other hand, may waive compliance by the other with any term or provision of this Agreement that the other Party was or is obligated to comply with or perform. Such waiver or failure to insist on strict compliance with such term or provision shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure of compliance.SectionÂ 11.5No Third-Party Beneficiaries. Except for SectionÂ 5.7, SectionÂ 10.2 SectionÂ 10.3 and Section 11.15, which are intended to benefit, and to be enforceable by, the Persons specified therein, this Agreement, together with the other Transaction Documents and the Exhibits and Schedules hereto and thereto are not intended to confer in or on behalf of any Person not a party to this Agreement (and their successors and assigns) any rights, benefits, causes of action or remedies with respect to the subject matter or any provision hereof.SectionÂ 11.6Notices. All notices and other communications to be given to any Party hereunder shall be sufficiently given for all purposes hereunder if in writing and delivered by hand, courier or overnight delivery service, or five (5) days after being mailed by certified or registered mail, return receipt requested, with appropriate postage prepaid, or when given in the form of an email transmission (unless the sender receives a non-delivery message), and shall be directed to the address set forth below (or at such other address or email address as such Party shall designate by like notice):(a)if to Purchasers:Phibro Animal Health Corporation300 Frank W. Burr Blvd., Suite 21Teaneck, NJ 07666Attention:Â Â Â Daniel Bendheim, Judith WeinsteinEmail:Â Â Daniel.Bendheim@pahc.comÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Judith.Weinstein@pahc.comwith a copy (which shall not constitute notice) to:Kirkland & Ellis LLP601 Lexington AvenueNew York, NY 10022Attention:Â Â Â Daniel Wolf, P.C.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Keri Schick Norton, P.C.Email:Â Â Â Daniel.Wolf@kirkland.com Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Keri.SchickNorton@kirkland.comâ€‹-110-(b)if to Seller:Zoetis Inc.10 Sylvan WayParsippany, New Jersey 07054Attention:Â Â Â General Counsel E-mail: LegalNotices@zoetis.comwith a copy (which shall not constitute notice) to:Wachtell, Lipton, Rosen & Katz51 West 52nd StreetNew York, New York 10019Attention:Â Â Â Igor Kirman, Esq.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Meng Lu, Esq.Email:Â Â Â IKirman@wlrk.comÂ Â Â Â Â Â Â Â Â Â Â Â Â Â MLu@wlrk.comSectionÂ 11.7Specific Performance. The Parties agree that irreparable damage, for which monetary damages (even if available) would not be an adequate remedy, would occur in the event that the Parties do not perform any provision of this Agreement in accordance with its specified terms or otherwise breach such provisions. Accordingly, the Parties acknowledge and agree that each of the Parties shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which such Party is entitled in Law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that the other Party has an adequate remedy at Law or that any such award is not an appropriate remedy for any reason at Law or in equity. Any Party seeking an injunction or injunctions to prevent breaches or threatened breaches of this Agreement or to enforce specifically the terms and provisions of this Agreement shall not be required to provide any bond or other security in connection with such remedy. The foregoing is in addition to any other remedy to which any Party is entitled at law, in equity or otherwise. The Parties further agree that nothing set forth in this SectionÂ 11.7 shall require any Party hereto to institute any Proceeding for (or limit any Partyâ€™s right to institute any Proceeding for) specific performance under this SectionÂ 11.7 prior to or as a condition to exercising any termination right under ArticleÂ IX (and pursuing damages after such termination).SectionÂ 11.8Governing Law and Jurisdiction. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. In addition, each of the Parties (a)Â in the event that any dispute (whether in contract, tort or otherwise) arises out of this Agreement or the Transaction or the other transactions contemplated hereby, submits to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware, or in the event (but only in the event) that such court does not have subject matter jurisdiction over the applicable Proceeding, any state or federal court within the State ofâ€‹-111-Delaware; (b)Â agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; (c)Â agrees that it will not bring any Proceeding relating to this Agreement or the Transaction or the other transactions contemplated hereby in any court other than the above-named courts; and (d) agrees that it will not seek to assert by way of motion, as a defense or otherwise, that any such Proceeding (i) is brought in an inconvenient forum, (ii) should be transferred or removed to any court other than the above-named courts, (iii) should be stayed by reason of the pendency of some other proceeding in any court other than the above-named courts or (iv) that this Agreement or the subject matter hereof may not be enforced in or by the above-named courts. Each Party agrees that service of process upon such Party in any such Proceeding shall be effective if notice is given in accordance with SectionÂ 11.6.SectionÂ 11.9Waiver of Jury Trial. EACH PARTY TO THIS AGREEMENT WAIVES TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY ANY OF THEM AGAINST THE OTHER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT, OR ANY OTHER AGREEMENTS EXECUTED IN CONNECTION HEREWITH OR THE ADMINISTRATION THEREOF OR THE TRANSACTION OR ANY OF THE OTHER TRANSACTIONS CONTEMPLATED HEREIN OR THEREIN. NO PARTY TO THIS AGREEMENT SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDING, COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON, OR ARISING OUT OF, THIS AGREEMENT OR ANY RELATED INSTRUMENTS. NO PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN WAIVED. EACH PARTY TO THIS AGREEMENT CERTIFIES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT OR INSTRUMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH ABOVE IN THIS SECTIONÂ 11.9. NO PARTY HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS SECTIONÂ 11.9 WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.SectionÂ 11.10Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other competent authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. Upon such a determination, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the Transaction and the other transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.SectionÂ 11.11Counterparts. This Agreement may be executed in two (2) or more counterparts, all of which shall be considered an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one (1) or more such counterparts have been signed by each Party and delivered (by facsimile, email, or otherwise) to the other Party. Signatures to this Agreement transmitted by facsimile transmission, by electronic mail in â€œportable document formatâ€ from, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, willâ€‹-112-have the same effect as physical delivery of the paper document bearing the original signatures. This Agreement has been executed in the English language. If this Agreement is translated into another language, the English language text shall in any event prevail.SectionÂ 11.12Expenses. Except as otherwise provided in this Agreement, whether or not the Closing takes place, all costs and expenses incurred in connection with this Agreement, the Transaction and the other transactions contemplated hereby shall be paid by the Party incurring such expense.SectionÂ 11.13Interpretation; Absence of Presumption. It is understood and agreed that the specification of any dollar amount in the representations and warranties or covenants and agreements contained in this Agreement or the inclusion of any specific item in the Seller Disclosure Schedules or Purchaser Disclosure Schedules is not intended to imply that such amounts or higher or lower amounts, or the items so included or other items, are or are not material, and no Party shall use the fact of the setting of such amounts or the fact of the inclusion of any such item in the Seller Disclosure Schedules or Purchaser Disclosure Schedules in any dispute or controversy between the Parties as to whether any obligation, item or matter not described in this Agreement or included or not included in the Seller Disclosure Schedules or Purchaser Disclosure Schedules is or is not material for purposes of this Agreement. Nothing herein (including the Seller Disclosure Schedules and the Purchaser Disclosure Schedules) shall be deemed an admission by either Party or

any of its Affiliates, in any Proceeding or action, that such Party or any such Affiliate, or any third party, is or is not in breach or violation of, or in default in, the performance or observance of any term or provisions of any Contract or any Law. For the purposes of this Agreement, (a) words in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires; (b) references to the terms Article, Section, paragraph, Exhibit and Schedule are references to the Articles, Sections, paragraphs, Exhibits and Schedules to this Agreement unless otherwise specified; (c) the terms â€œhereof,â€ â€œherein,â€ â€œhereby,â€ â€œhereto,â€ and derivative or similar words refer to this entire Agreement, including the Schedules and Exhibits hereto and the words â€œdate hereofâ€ refer to the date of this Agreement; (d) references to â€œDollarsâ€ or â€œ$â€ shall mean U.S. dollars; (e) the word â€œincludingâ€ and words of similar import when used in this Agreement and the Transaction Documents shall mean â€œincluding, without limitation,â€ unless otherwise specified; (f) the word â€œorâ€ shall not be exclusive; (g) references to â€œwrittenâ€ or â€œin writingâ€ include in electronic form; (h) provisions shall apply, when appropriate, to successive events and transactions; (i) the headings contained in this Agreement and the other Transaction Documents are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement and the other Transaction Documents; (j) Seller and Purchasers have each participated in the negotiation and drafting of this Agreement and the other Transaction Documents and if an ambiguity or question of interpretation should arise, this Agreement and the other Transaction Documents shall be construed as if drafted jointly by the Parties or the parties thereto, as applicable, and no presumption or burden of proof shall arise favoring or burdening any party by virtue of the authorship of any of the provisions in this Agreement or the other Transaction Documents; (k) a reference to any Person includes such Personâ€™s successors and permitted assigns; (l) any reference to â€œdaysâ€ means calendar days unless Business Days are expressly specified; (m) when calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded and ifâ€‹-113-the last day of such period is not a Business Day, the period shall end on the next succeeding Business Day; (n) any Law defined or referred to in this Agreement or in any agreement or instrument that is referred to herein means such Law as from time to time amended, modified or supplemented, including (in the case of statutes) by succession of comparable successor Laws and the related regulations thereunder and published interpretations thereof, and references to any Contract or instrument are to that Contract or instrument as from time to time amended, modified or supplemented; provided that, for purposes of any representations and warranties contained in this Agreement that are made as of a specific date or dates, references to any Law shall be deemed to refer to such Law, as amended, and the related regulations thereunder and published interpretations thereof, in each case, as of such date; (o) to the extent that this Agreement or any other Transaction Document requires a Subsidiary or an Affiliate of any Party to take or omit to take any action, such covenant or agreement includes the obligation of such Party to cause such Subsidiary or Affiliate to take or omit to take such action; (p) the words â€œmade available to Purchasersâ€ or â€œdelivered to Purchasersâ€ or words of similar import refer to materials posted to the virtual data room hosted by Intralinks located at intralinks.com (Project Delta) at least one (1) Business Day prior to the date of this Agreement; (q) the word â€œextentâ€ in the phrase â€œto the extentâ€ shall mean only the degree to which a subject or other thing extends, and such phrase shall not mean simply â€œifâ€; (r) any reference to â€œfiscal yearâ€ or â€œyear ended December 31â€ with respect to the Business or the Purchased Entities shall be to the twelve (12) months ended December 31 in the case of U.S. entities and November 30 in the case of non-U.S. entities; (s) any reference to Purchasers shall mean any or all of the Purchasers unless the context otherwise requires; and (t) whenever the words â€œordinary course of businessâ€ are used in this Agreement, they shall be deemed to be followed by the words â€œconsistent with past practiceâ€.SectionÂ 11.14Waiver of Conflicts Regarding Representation; Nonassertion of Attorney-Client Privilege.(a)Each Purchaser waives and will not assert, and agrees to cause its Affiliates, including, following the Closing, the Purchased Entities, to waive and not assert, any conflict of interest arising out of or relating to the representation, after the Closing (the â€œPost-Closing Representationâ€), of Seller or any of its Affiliates, or any shareholder, officer, employee or director of Seller or any of its Affiliates (any such Person, a â€œDesignated Personâ€) in any matter involving the negotiation, documentation and consummation of this Agreement, the other Transaction Documents or any other agreements or transactions contemplated hereby or thereby, by any legal counsel currently representing any Designated Person in connection with the negotiation, documentation and consummation of this Agreement, the other Transaction Documents or any other agreements or transactions contemplated hereby or thereby, including Wachtell, Lipton, Rosen & Katz (any such representation, the â€œCurrent Representationâ€).(b)Each Purchaser waives and will not assert, and agrees to cause its Affiliates, including, following the Closing, the Purchased Entities, to waive and not assert, any attorney-client or other applicable legal privilege or protection with respect to any communication between any legal counsel and any Designated Person occurring during the Current Representation or in connection with any Post-Closing Representation, including in connection with a dispute with such Purchaser or its Affiliates (including, following the Closing, any Purchased Entity), including in respect of any claim for indemnification by a Purchaser Indemnified Party, it being the intention of the Parties that all such rights to such attorney-clientâ€‹-114-and other applicable legal privilege or protection and to control such attorney-client and other applicable legal privilege or protection shall be retained by Seller and its Affiliates and that Seller, and not any Purchaser or its Affiliates or the Purchased Entities, shall have the sole right to decide whether or not to waive any attorney-client or other applicable legal privilege or protection. Accordingly, from and after the Closing, none of Purchasers or their Affiliates, including the Purchased Entities, shall have any access to any such communications or to the files of the Current Representation, all of which shall be and remain the property of Seller and not of any Purchaser or its Affiliates (including the Purchased Entities), and none of Purchasers nor their Affiliates, including, following the Closing, the Purchased Entities, or any Person acting or purporting to act on their behalf shall seek to obtain the same by any process on the grounds that the privilege and protection attaching to such communications and files belongs to either Purchaser or their Affiliates, including, following the Closing, the Purchased Entities, or does not belong to Seller. Notwithstanding the foregoing, in the event that a dispute arises between a Purchaser or its Affiliates, including, following the Closing, the Purchased Entities, on the one hand, and a third party other than Seller or its Affiliates, on the other hand, such Purchaser or its Affiliates, including, following the Closing, the Purchased Entities, may assert the attorney-client privilege, the expectation of client confidence and all other rights to any evidentiary privilege to prevent disclosure of confidential communications by the Current Representation.SectionÂ 11.15Financing Provisions. Notwithstanding anything in this Agreement to the contrary, Seller, on behalf of itself, its Subsidiaries and each of its controlled Affiliates, hereby: (a) agrees that any legal action, whether in law or in equity, whether in contract or in tort or otherwise, involving the Financing Parties, arising out of or relating to, this Agreement or the Financing, shall be subject to the exclusive jurisdiction of any federal or state court in the Borough of Manhattan, New York, New York, so long as such forum is and remains available, and any appellate court thereof and each party hereto irrevocably submits itself and its property with respect to any such legal action to the exclusive jurisdiction of such court, (b) agrees that any such legal action shall be governed by the laws of the State of New York (without giving effect to any conflicts of law principles that would result in the application of the laws of another state), except as otherwise provided in any agreement relating to the Financing and except to the extent relating to the interpretation of any provisions in this Agreement (including any provision in the Commitment Letter or in any definitive documentation related to the Financing that expressly specifies that the interpretation of such provisions shall be governed by and construed in accordance with the law of the State of Delaware), (c) knowingly, intentionally and voluntarily waives to the fullest extent permitted by applicable law trial by jury in any such legal action brought against the Financing Parties in any way arising out of or relating to, this Agreement or the Financing, (d)Â agrees that none of the Financing Parties shall have any liability to Seller or any of its Subsidiaries or any of their respective controlled Affiliates or representatives relating to or arising out of this Agreement or the Financing, and (e)Â agrees that the Financing Parties are express third party beneficiaries of, and may enforce, any of the provisions of this SectionÂ 11.15 and that this SectionÂ 11.15 may not be amended in a manner materially adverse to the Financing Parties without the written consent of the Financing Entities (such consent not to be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, nothing in this SectionÂ 11.15 shall in any way limit or modify the rights and obligations of any Purchaser under this Agreement, or any Financing Partyâ€™s obligations to the Purchasers under the Commitment Letter.[Remainder of page intentionally left blank]â€‹â€‹â€‹-115-IN WITNESS WHEREOF, Seller and the Purchasers have duly executed this Agreement as of the date first written above.â€‹ZOETIS INC.â€‹â€‹â€‹By:/s/ Kristin Peckâ€‹Name:Kristin C. Peckâ€‹Title:Chief Executive Officer and Directorâ€‹â€‹[Signature Page to Purchase and Sale Agreement]â€‹â€‹PHIBRO ANIMAL HEALTH CORPORATIONâ€‹â€‹â€‹By:/s/ Jack Bendheimâ€‹Name:Jack Bendheimâ€‹Title:President & Chief Executive Officerâ€‹â€‹PHIBRO ANIMAL HEALTH S.A.â€‹â€‹â€‹By:/s/ Jack Bendheimâ€‹Name:Jack Bendheimâ€‹Title:Directorâ€‹[Signature Page to Purchase and Sale Agreement] EX-10.1 3 pahc-20240630xex10d1.htm EX-10.1 Exhibit 10.1â€‹Execution VersionSTRICTLY CONFIDENTIALâ€‹COÃ–PERATIEVE RABOBANK U.A., NEW YORK BRANCH245 Park AvenueNew York, NY 10167COMPEER FINANCIAL, PCA2600 Jenny Wren TrailPO Box 810Sun Prairie, Wisconsin 53590â€‹â€‹CITIBANK, N.A.388 Greenwich StreetNew York, New York 10013â€‹CONFIDENTIALâ€‹April 28, 2024â€‹Phibro Animal Health CorporationGlenpointe Centre East, 3rd Floor300 Frank W. Burr Boulevard, Suite 21Teaneck, New Jersey 07666-6712Attention:Glenn DavidChief Financial Officer Project DeltaCommitment LetterLadies and Gentlemen:Reference is hereby made to the Amended and Restated Credit Agreement, dated as of April 22, 2021 (as amended by Amendment No. 1, dated as of November 8, 2022, Amendment No. 2, dated as of June 16, 2023 and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the â€œExisting Credit Agreementâ€), among Phibro Animal Health Corporation, a Delaware corporation (the â€œBorrowerâ€ or â€œyouâ€), Bank of America, N.A. (â€œBank of Americaâ€), as Administrative Agent, Collateral Agent and L/C Issuer and each lender from time to time party thereto.You have advised CoÃ¶peratieve Rabobank U.A., New York Branch (â€œRabobankâ€), Compeer Financial, PCA (â€œCompeerâ€), Citibank, N.A. (â€œCitibankâ€, together with Rabobank and Compeer, â€œweâ€, â€œusâ€, or the â€œCommitment Partiesâ€), Wells Fargo Bank, National Association (â€œWells Fargoâ€) and Bank of America that you intend to (i) consummate the Transactions described in the Transaction Description attached hereto as Exhibit A (the â€œTransaction Descriptionâ€) and (ii) seek certain amendments to the Existing Credit Agreement as set out more particularly on Annex I-A to Exhibit B hereto (the â€œProposed Amendmentsâ€).Capitalized terms used but not defined herein shall have the meanings assigned to them in the Existing Credit Agreement, the Transaction Description, the Summary of Principal Terms and Conditions attached hereto as Exhibit B (the â€œTerm Sheetâ€) and the Summary of Additional Conditions attached hereto as Exhibit C; this commitment letter, the Transaction Description, the Term Sheet and the Summary of Additional Conditions attached hereto as Exhibit C (collectively, this â€œCommitment Letterâ€).1.Commitments.â€‹In connection with the Transactions, each of Rabobank, Compeer and Citibank, severally but not jointly (each in such capacity, an â€œIncremental Lenderâ€ and collectively, the â€œIncremental Lendersâ€), is pleased to advise you of its respective commitment to provide the percentage set forth opposite such Incremental Lenderâ€™s name on Schedule 1 hereto of the aggregate principal amount of the Incremental Term Facility (as defined in Exhibit B), subject only to the applicable Closing Conditions (as defined below).Each of the Incremental Lenders, Bank of America and Wells Fargo, on behalf of themselves and their affiliates and their respective affiliatesâ€™, managed funds and accounts that are Lenders under the Existing Credit Agreement on the date hereof (or that become Lenders under the Existing Credit Agreement after the date hereof and prior to the date of effectiveness of, and initial funding under, the Incremental Term Facility (the â€œIncremental Effective Dateâ€)) (in such capacity referred to herein as the â€œConsenting Lendersâ€), which collectively constitute the Required Lenders as defined in and under the Existing Credit Agreement as of the date hereof, is pleased to advise you of its commitment to irrevocably consent to the Proposed Amendments.Each of the Consenting Lenders party hereto hereby agrees that, if at any time prior to the Incremental Effective Date, such Consenting Lender assigns or sells any participation of any portion of their Commitments and/or Loans under the Existing Credit Agreement, such assignment and/or participation shall be subject to the relevant Assignee or Participant, as applicable, agreeing to the Proposed Amendments.2.Titles and Roles.It is agreed that: (i) each of Rabobank, Compeer and Citibank will act as a joint lead arranger for the Incremental Term Facility (each in such capacity, a â€œLead Arrangerâ€ and collectively, the â€œLead Arrangersâ€), (ii) each of Rabobank, Compeer and Citibank will act as a joint bookrunner for the Incremental Term Facility (each in such capacity, a â€œBookrunnerâ€ and collectively, the â€œBookrunnersâ€) and (iii) in connection with the Incremental Term Facility, Bank of America will continue to act as administrative agent and collateral agent under the Existing Credit Agreement and will also act as administrative agent and collateral agent with respect to the Incremental Term Facility.You agree that no other agents, co-agents, arrangers, bookrunners, managers or co-managers will be appointed, no other titles will be awarded and no compensation (other than compensation expressly contemplated by this Commitment Letter and the Arranger Fee Letter (as defined below) referred to below) will be paid to any Lender (as defined below) by you or any of your affiliates in order to obtain its commitment to participate in the Incremental Term Facility unless you and the Lead Arrangers shall so agree.3.[Reserved].4.Information.You hereby represent and warrant that (in the case of Information and Projections regarding the Target Companies and their subsidiaries and their and their respective businesses provided prior to the date of the consummation of the Acquisition, to your knowledge), (a) all written information and written data (such information and data, other than (i) the financial estimates, forecasts and other projections delivered to the Commitment Parties by you (the â€œProjectionsâ€) and (ii) information of a general economic or industry specific nature, the â€œInformationâ€) that has been or will be made available to the Commitment Parties directly or indirectly by, or at the request of, you or by any of your representatives, in each case, on your behalf in connection with the transactions contemplated hereby, when taken as a whole, is or will be, whenâ€‹-2furnished, correct in all material respects and does not or will not, when furnished and when taken as a whole, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not materially misleading in light of the circumstances under which such statements are made (after giving effect to all supplements and updates thereto through the date of the consummation of the Acquisition) and (b) the Projections have been or will be prepared in good faith based upon assumptions that are believed by you to be reasonable at the time such Projections are so furnished to the Commitment Parties; it being understood that the Projections are as to future events and are not to be viewed as facts, the Projections are subject to significant uncertainties and contingencies, many of which are beyond your control, that no assurance can be given that any particular Projections will be realized and that actual results during the period or periods covered by any such Projections may differ significantly from the projected results and such differences may be material. Â You agree that, if at any time prior to the Incremental Effective Date, you become aware that any of the representations and warranties in the preceding sentence would be incorrect in any material respect if the Information and the Projections made available to the Commitment Parties directly or indirectly by, or at the request of, you or any of your representatives, and such representations and warranties were being made, at such time, then you will promptly inform the Commitment Parties thereof and will (or, with respect to the Information and such Projections relating to the Target Companies and their subsidiaries, will use commercially reasonable efforts to) promptly supplement the Information and such Projections such that such representations and warranties are correct in all material respects under those circumstances (or, in the case of the Information and Projections relating to the Target Companies and their subsidiaries and its and their respective businesses, to your knowledge, such representations and warranties are correct in all material respects under those circumstances). Â The Commitment Parties (i) will be entitled to use and rely on the Information and the Projections without responsibility for independent verification thereof and (ii) assume no responsibility for the accuracy or completeness of the Information or the Projections.5.Fees.As consideration for (i) the commitments of the Incremental Lenders hereunder and (ii) the agreements of the Lead Arrangers and the Bookrunners to perform the services described herein, you agree to pay (or cause to be paid) the fees set forth in the (x) Term Sheet and (y) the Fee Letter dated the date hereof and delivered herewith with respect to the Incremental Term Facility (the â€œArranger Fee Letterâ€), if, when and to the extent due and payable. Once paid, such fees shall not be refundable, except as expressly set forth therein or as otherwise separately agreed to in writing by you and the Commitment Parties.6.Conditions.The agreements of the Consenting Lenders hereunder with respect to the Proposed Amendments are subject only to entry into definitive documents related thereto consistent with Exhibit B and subject to the 6th paragraph of Section 10 hereof.The commitments of the Incremental Lenders hereunder to fund the Incremental Term Facility on the Incremental Effective Date and the agreements of the Lead Arrangers and the Bookrunners to perform the services described herein are subject solely to the conditions set forth in Exhibit C hereto (such conditions, the â€œClosing Conditionsâ€), and upon satisfaction (or waiver by all Incremental Lenders) of such conditions, the initial funding of the Incremental Term Facility shall occur; it being understood and agreed that there are no other conditions (implied or otherwise) to the commitments hereunder, including compliance with the terms of this Commitment Letter, the Arranger Fee Letter and the documentation for the Incremental Term Facility (the â€œIncremental Term Facility Documentationâ€).Notwithstanding anything to the contrary in this Commitment Letter (including each of the exhibits attached hereto), the Arranger Fee Letter, the Incremental Term Facility Documentation or any other letterâ€‹-3agreement or other undertaking concerning the Transactions or the financing of the Transactions to the contrary, (i) the only representations and warranties the making and accuracy of which shall be a condition to the availability and funding of any of the Incremental Term Facility on the Incremental Effective Date shall be (A) such of the representations and warranties made by, or with respect to, the Target Companies and their subsidiaries in the Purchase Agreement as are material to the interests of the Incremental Lenders, but only to the extent that you

(or your affiliate) have the right (taking into account any applicable cure provisions) to terminate your (or its) obligations under the Purchase Agreement or decline to consummate the Acquisition (in each case, in accordance with the terms thereof) as a result of a breach of any such representations and warranties in the Purchase Agreement, (to such extent, the â€œSpecified Purchase Agreement Representationsâ€) and (B) the Specified Representations (as defined below) made in the Incremental Term Facility Documentation and (ii) the terms of the Incremental Term Facility Documentation and the Closing Deliverables (as defined in Exhibit C) shall be in a form such that they do not impair the availability or funding of the Incremental Term Facility on the Incremental Effective Date if the applicable Closing Conditions are satisfied (or waived by all Incremental Lenders) (provided that, any guarantee by the Target Companies or their subsidiaries and any security interest in any Collateral (as defined in the Existing Credit Agreement) relating to the assets of the Target Companies or their subsidiaries (including creation or perfection thereof) shall be delivered and/or perfected after the Incremental Effective Date in accordance with Section 6.11 of the Existing Credit Agreement). For purposes hereof, â€œSpecified Representationsâ€ means the representations and warranties of the Loan Parties, after giving effect to the Transactions, to be set forth in the Incremental Term Facility Documentation relating to organizational existence; power and authority, due authorization, execution, delivery, in each case only as they relate to the entering into and performance of the Incremental Term Facility Documentation; the enforceability of the Incremental Term Facility Documentation; solvency as of the Incremental Effective Date (after giving effect to the Transactions) of the Borrower and its subsidiaries on a consolidated basis; Federal Reserve margin regulations; the use of loan proceeds not violating the USA Patriot Act, the OFAC regulations and other applicable sanctions laws; and the United States Foreign Corrupt Practices Act (â€œFCPAâ€) and other applicable anti-corruption laws; the Investment Company Act; no conflicts between the Incremental Term Facility Documentation and the organizational documents of the Loan Parties (in each case, as they relate to the entering into and performance of the Incremental Term Facility Documentation); and subject to permitted liens and the limitations set forth in the prior sentence creation, validity, and perfection of security interests in the Collateral provided on the Incremental Effective Date. This paragraph, and the provisions herein, shall be referred to as the â€œLimited Conditionality Provisionsâ€.7.Indemnity.To induce the Commitment Parties and the Consenting Lenders to enter into this Commitment Letter and the Arranger Fee Letter, as applicable, and to proceed with the Incremental Term Facility Documentation, you agree to indemnify and hold harmless the Commitment Parties, the Consenting Lenders and each of their affiliates and their respective officers, directors, employees, agents, advisors, controlling persons and other representatives and successors (each an â€œIndemnified Partyâ€) from and against (and will reimburse each Indemnified Party within thirty (30) days after demand therefor as the same are incurred) any and all claims, damages, losses, liabilities and reasonable and documented or invoiced out-of-pocket expenses (including, without limitation, the reasonable fees, disbursements and other charges of one counsel for all Indemnified Parties and, if necessary, one firm of local counsel in each appropriate jurisdiction (which may include a single special counsel acting in multiple jurisdictions) for all Indemnified Parties) that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or by reason of (including, without limitation, in connection with any investigation, litigation or proceeding or preparation of a defense in connection therewith) any aspect of the Transactions, or any use made or proposed to be made with the proceeds of the Incremental Term Facility, except to the extent such claim, damage, loss, liability or expense (i) is found in a final, nonappealable judgment by a court of competent jurisdiction to have resulted from such Indemnifiedâ€‹4Partyâ€™s (or any of its affiliate's) gross negligence, bad faith or willful misconduct, (ii) is found in a final, nonappealable judgment by a court of competent jurisdiction to have resulted from a material breach of the definitive documents with respect to the Incremental Term Facility by such Indemnified Party or one of its Affiliates or (iii) arises from any dispute to the extent such dispute does not arise from any act or omission of the Borrower or any of its affiliates and that is brought by an Indemnified Party against any other Indemnified Party (other than claims against a Commitment Party or a Consenting Lender in its capacity as an administrative agent, arranger or similar role for the Incremental Term Facility). In the case of an investigation, litigation or proceeding to which the indemnity in this paragraph applies, such indemnity shall be effective whether or not such investigation, litigation or other proceeding is brought by you, your equity holders or creditors or an Indemnified Party, whether or not an Indemnified Party is otherwise a party thereto and whether or not any aspect of the Transactions is consummated. You also agree that no Indemnified Party shall have any liability (whether direct or indirect, in contract or tort or otherwise) to you or your subsidiaries or affiliates or to your or their respective equity holders, directors, partners, or creditors arising out of, related to or in connection with any aspect of the Transactions, except to the extent of your direct, as opposed to special, indirect, consequential or punitive, damages determined in a final nonappealable judgment by a court of competent jurisdiction. Notwithstanding any other provision of this letter agreement, no Indemnified Party shall be liable for any damages arising from the use by others of information or other materials obtained through electronic telecommunications or other information transmission systems.If the foregoing indemnification is for any reason unavailable or insufficient to hold any Indemnified Party harmless other than by virtue of the exceptions set forth in clauses (i), (ii) and (iii) of the prior paragraph, the Borrower shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, claim or damage in such proportion as is appropriate to reflect the relative benefits received by the Borrower on the one hand and each Indemnified Party on the other arising out of the matters contemplated by this letter agreement.By executing this letter agreement, you agree to reimburse the Commitment Parties, the Consenting Lenders and their respective affiliates from time to time on demand for all reasonable and documented out-of-pocket fees and expenses (including but not limited to out-of-pocket expenses of the Commitment Partiesâ€™ and the Consenting Lendersâ€™ due diligence investigation, travel expenses, but limited, in the case of legal fees and expenses, to the reasonable fees, disbursements and other charges of Davis Polk & Wardwell LLP, as counsel to the Commitment Parties and the Consenting Lenders and, if necessary, of a single local counsel to the Commitment Parties and the Consenting Lenders in each relevant jurisdiction) incurred in connection with the Transactions, the Incremental Term Facility and the preparation of the Incremental Term Facility Documentation. Â Upon Borrowerâ€™s request, the Commitment Parties and the Consenting Lenders will present the documentation and invoice(s) supporting the costs, expenses and charges in the foregoing sentence.8.Sharing of Information, Absence of Fiduciary Relationships, Affiliate Activities.You acknowledge that the Commitment Parties, the Consenting Lenders and their respective affiliates may be providing debt financing, equity capital or other services (including, without limitation, financial advisory services) to other persons in respect of which you, the Target Companies, the Seller and your and their respective subsidiaries and affiliates may have conflicting interests regarding the transactions described herein and otherwise. Â In addition, you acknowledge that the Commitment Parties and the Consenting Lenders may be arranging or providing (or contemplating arranging or providing) a committed form of acquisition financing to other potential purchasers of the Target Companies and that, in such capacity, such Commitment Parties and Consenting Lenders may acquire information about the Target Companies and their subsidiaries, the sale thereof, and such other potential purchasers and their strategies and proposals, but such Commitment Parties and Consenting Lenders shall have no obligation to discloseâ€‹5to you the substance of such information or the fact that such Commitment Parties or Consenting Lenders are in possession thereof.The Commitment Parties, the Consenting Lenders and their respective affiliates will not use or disclose confidential information obtained from you, the Target, the Investors, the Seller or any of your or their respective subsidiaries or affiliates by virtue of the transactions contemplated by this Commitment Letter or their other relationships with you, the Borrower, the Target or any of your or their respective subsidiaries or affiliates in connection with the performance by them or their affiliates of services for other persons, and the Commitment Parties, the Consenting Lenders and their respective affiliates will not furnish any such information to other persons, except to the extent permitted below. Â You also acknowledge that the Commitment Parties, the Consenting Lenders and their respective affiliates do not have any obligation to use in connection with the transactions contemplated by this Commitment Letter, or to furnish to you, confidential information obtained by them from other persons.As you know, the Commitment Parties, the Consenting Lenders and their respective affiliates may be full service securities firms engaged, either directly or through their affiliates, in various activities, which may include securities trading, commodities trading, investment management, financing and brokerage activities and financial planning and benefits counseling for both companies and individuals. Â In the ordinary course of these activities, the Commitment Parties, the Consenting Lenders and their respective affiliates may actively engage in commodities trading or trade the debt and equity securities (or related derivative securities) and financial instruments (including bank loans and other obligations) of you, the Borrower, the Target Companies and their subsidiaries, the Target Companiesâ€™ customers or competitors and other companies which may be the subject of the arrangements contemplated by this Commitment Letter for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities. Â The Commitment Parties, the Consenting Lenders and their respective affiliates may also co-invest with, make direct investments in, and invest or co-invest client monies in or with funds or other investment vehicles managed by other parties, and such funds or other investment vehicles may trade or make investments in securities of you, the Borrower, the Target Companies, the Target Companiesâ€™ subsidiaries or other companies which may be the subject of the arrangements contemplated by this Commitment Letter or engage in commodities or other trading with any thereof.In connection with all aspects of the Transactions, you acknowledge and agree, and acknowledge your affiliatesâ€™ understanding, that: (i) in connection with the process leading to the Transactions, each Lead Arranger is and has been acting solely as a principal and is not the financial advisor, agent or fiduciary, for you or any of your affiliates, stockholders, creditors or employees or any other party; (ii) the Lead Arrangers have not assumed nor will assume an advisory, agency or fiduciary responsibility in your or your affiliatesâ€™ favor with respect to the Transactions or the process leading thereto (irrespective of whether such Lead Arranger has advised or is currently advising you or your affiliates on other matters) and the Lead Arrangers have no obligation to you or your affiliates with respect to the Transactions except those obligations expressly set forth in this Commitment Letter; (iii) The Lead Arrangers and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from yours, the Borrowerâ€™s, the Target Companiesâ€™ and your affiliates and the Lead Arrangers have no obligation to disclose any of such interests by virtue of any advisory, agency or fiduciary relationship; and (iv) the Lead Arrangers have not provided any legal, accounting, regulatory or tax advice with respect to the Transactions and you have consulted your own legal, accounting, regulatory and tax advisors to the extent you have deemed appropriate. You hereby waive and release, to the fullest extent permitted by law, any claims that you may have against the Lead Arrangers with respect to any breach or alleged breach of agency or fiduciary duty in connection with the arranging and other services described herein.9.Confidentiality.â€‹6You agree that you will not disclose, directly or indirectly, the Arranger Fee Letter or the contents thereof or this Commitment Letter, the Term Sheet, the other exhibits and attachments hereto or the contents of each thereof, or the activities of any Commitment Party or Consenting Lender pursuant hereto or thereto, to any person or entity without prior written approval of the Commitment Parties and the Consenting Lenders (such approval not to be unreasonably withheld or delayed), except (a) to your affiliates and your and your affiliatesâ€™ officers, directors, employees, agents, attorneys, accountants, advisors, controlling persons and equity holders and to actual and potential investors who are informed of the confidential nature thereof, in each case, on a confidential and need-to-know basis, (b) if the Commitment Parties and the Consenting Lenders consent in writing (such consent not to be unreasonably withheld or delayed) to such proposed disclosure, (c) pursuant to the order of any court or administrative agency or in any pending legal, judicial or administrative proceeding, or otherwise as required by applicable law, rule or regulation or compulsory legal process or to the extent requested or required by governmental and/or regulatory authorities, in each case based on the reasonable advice of your legal counsel (in which case you agree, to the extent practicable and not prohibited by applicable law, rule or regulation, to inform the Commitment Parties and the Consenting Lenders promptly thereof prior to disclosure) or (d) as required, in connection with the enforcement of our rights hereunder or under the Arranger Fee Letter, based on the reasonable advice of counsel; provided that (i) you may disclose this Commitment Letter and the contents hereof and the Arranger Fee Letter redacted in a customary manner to the Seller and its affiliates, the Target Companies and their subsidiaries and its and their respective officers, directors, employees, agents, attorneys, accountants, advisors, controlling persons and equity holders, in each case, on a confidential and need-to-know basis, (ii) you may disclose the Commitment Letter and its contents (including the Term Sheet and other exhibits and attachments hereto) (but not the Arranger Fee Letter or the contents thereof) in connection with any public or regulatory filing requirement relating to the Transactions, (iii) you may disclose the Term Sheet and the other exhibits and attachments to the Commitment Letter, and the contents thereof, to potential Lenders and to rating agencies, (iv) you may disclose the aggregate fee amount contained in the Arranger Fee Letter as part of Projections, pro forma information or a generic disclosure of aggregate sources and uses related to fee amounts related to the Transactions to the extent customary or required in marketing materials for the Incremental Term Facility or in any public or regulatory filing relating to the Transactions (and then only to the extent aggregated with all other fees and expenses of the Transactions and not presented as an individual line item unless required by applicable law, rule or regulation) and (v) if the fee amounts payable pursuant to the Arranger Fee Letter have been redacted (including the portions thereof addressing fees payable to the Commitment Parties and/or the Incremental Lenders) in a customary manner reasonably acceptable to the Lead Arrangers, you may disclose the Arranger Fee Letter and the contents thereof to the Target Companies and their subsidiaries and their and their respective officers, directors, employees, agents, attorneys, accountants, advisors, controlling persons and equity holders, in each case, on a confidential and need-to-know basis.Each Commitment Party, Consenting Lender and each of their respective affiliates will use all non-public information provided to any of them or such affiliates by or on behalf of you hereunder or in connection with the Acquisition and the related Transactions solely for the purpose of providing the services and/or commitments, as the case may be, that are the subject of this Commitment Letter and negotiating, evaluating and contemplating the transactions contemplated hereby and shall treat confidentially all such information received by it in accordance with Section 10.08 of the Existing Credit Agreement, the provisions of which are hereby incorporated herein, mutatis mutandis; it being understood and agreed that, for purposes hereof, (i) references to â€œInformationâ€ in such section shall be construed to include the Information and Projections and (ii) each Commitment Party, Consenting Lenders and each of their respective affiliates shall be permitted to disclose such non-public information to (x) their respective investment committee members on a confidential basis and (y) to current and potential providers of leverage to or investors in a Commitment Party or a Consenting Lender on a confidential basis. Â For the avoidance of doubt, the Arranger Fee Letter may not be disclosed to any party to this Commitment Letter that is not a Lead Arranger, Bookrunner or the Borrower.â€‹710.Miscellaneous.This Commitment Letter and the commitments hereunder shall not be assignable by any party hereto without the prior written consent of each other party hereto (such consent not to be unreasonably withheld or delayed) (and any attempted assignment without such consent shall be null and void). This Commitment Letter and the commitments hereunder are intended to be solely for the benefit of the parties hereto (and Indemnified Persons to the extent expressly set forth herein) and do not and are not intended to confer any benefits upon, or create any rights in favor of, any person other than the parties hereto (and Indemnified Persons to the extent expressly set forth herein). Â Each Commitment Party reserves the right to employ the services of its respective affiliates or branches (other than a Disqualified Lender) in providing services contemplated hereby and to allocate, in whole or in part, to their affiliates or branches certain fees payable to such Commitment Party in such manner as such Commitment Party and its respective affiliates or branches may agree in their sole discretion and, to the extent so employed, such affiliates and branches shall be entitled to the benefits and protections afforded to, and subject to the provisions governing the conduct of, such Commitment Party hereunder. Â This Commitment Letter may not be amended or any provision hereof waived or modified except by an instrument in writing signed by each of the Commitment Parties, the Consenting Lenders (to the extent that the Proposed Amendments are affected) and you.This Commitment Letter shall become effective as of the date hereof. This Commitment Letter contains the entire understanding of the parties relating to the matters contemplated hereby, superseding all prior agreements or understandings with respect thereto. This Commitment Letter may be executed in counterparts, each of which shall be an original, but all of which taken together shall constitute the same instrument. Delivery of an executed counterpart of this Commitment Letter by facsimile or other electronic transmission shall constitute an original for purposes hereof. For the avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by the parties hereto of a manually signed paper document which has been converted into electronic form (such as scanned into PDF format), or an electronically signed document converted into another format, for transmission, delivery and/or retention. Â For purposes hereof, â€œElectronic Recordâ€ and â€œElectronic Signatureâ€ shall have the meanings assigned to them, respectively, by 15 USC Â§7006, as it may be amended from time to time.EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM BROUGHT BY OR ON BEHALF OF ANY PARTY RELATED TO OR ARISING OUT OF THIS COMMITMENT LETTER OR THE ARRANGER FEE LETTER OR THE PERFORMANCE OF SERVICES HEREUNDER OR THEREUNDER.This Commitment Letter shall be governed by, and construed in accordance with, the laws of the State of New York; provided that, notwithstanding the foregoing, it is understood and agreed that (a) the interpretation of the definition of Business Material Adverse Effect (as defined in the Purchase Agreement) (and whether or not a Business Material Adverse Effect has occurred), (b) the determination of the accuracy of any Specified Purchase Agreement Representations and whether as a result of any inaccuracy thereof you (or your affiliate) have the right (taking into account any applicable cure provisions) to terminate your (or its) obligations under the Purchase Agreement or decline to consummate the Acquisition

and (c) the determination of whether the Acquisition has been consummated in accordance with the terms of the Purchase Agreement, in each case shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. Each of the parties hereto hereby irrevocably and unconditionally submits to the exclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in the Borough of Manhattan in New York City in respect of any suit, action or proceeding arising out of or relating to the provisions of this Commitment Letter, the Transactionsâ€‹8and the other transactions contemplated hereby and thereby and irrevocably agrees that all claims in respect of any such suit, action or proceeding may be heard and determined in any such court. Each of the parties hereto waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceedings brought in any such court, and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.Any Lead Arranger or Bookrunner may, with your approval, place customary advertisements in financial and other newspapers and periodicals or on a home page or similar place for dissemination of customary information on the Internet or worldwide web as it may choose, and circulate similar promotional materials, in each case, after the Incremental Effective Date, in the form of â€œtombstoneâ€ or otherwise describing the name of the Borrower and the amount, type and Incremental Effective Date of the Transactions, all at the expense of such Lead Arranger or Bookrunner.Each of the parties hereto agrees that (i) this Commitment Letter is a binding and enforceable agreement with respect to the subject matter contained herein, including an agreement of each party to negotiate in good faith the Incremental Term Facility Documentation and documentation related to the Proposed Amendments in a manner consistent with this Commitment Letter, it being acknowledged and agreed that the commitments and agreements provided hereunder are subject only to conditions precedent as expressly provided herein, and (ii) the Arranger Fee Letter is a legally valid and binding agreement of the parties thereto with respect to the subject matter set forth therein.The Lead Arrangers hereby notify you that pursuant to the requirements of the USA PATRIOT Act, Title III of Pub. L. 107-56 (signed into law October 26, 2001) (the â€œActâ€) and the requirements of 31 C.F.R. Â§ 1010.230 (the â€œBeneficial Ownership Regulationâ€), the Lead Arrangers subject to the Act and Beneficial Ownership Regulation are required to (i) obtain, verify and record information that identifies you, which information includes your name and address and other information that will allow the Lead Arrangers, as applicable, to identify you in accordance with the Act and (ii) obtain a certification regarding beneficial ownership from you under the Incremental Term Facility in compliance with the Beneficial Ownership Regulation.The indemnification, reimbursement, jurisdiction, governing law, venue, waiver of jury trial, and confidentiality provisions contained herein and in the Arranger Fee Letter and the provisions of Section 8 of this Commitment Letter shall remain in full force and effect regardless of whether the Incremental Term Facility Documentation shall be executed and delivered and notwithstanding the termination or expiration of this Commitment Letter or each Incremental Lenderâ€™s commitments hereunder; provided that your obligations under this Commitment Letter (and other than your obligations with respect to the confidentiality of the Arranger Fee Letter and the contents thereof) shall automatically terminate and be superseded, in each case to the extent covered thereby, by the provisions of the Incremental Term Facility Documentation upon the initial funding thereunder, and you shall automatically be released from all liability in connection therewith at such time. Â You may terminate this Commitment Letter and/or the Incremental Lendersâ€™ commitments with respect to all or a portion of any of the Incremental Term Facility hereunder (on a pro rata basis with respect to the commitments of the applicable Incremental Lenders hereunder) at any time subject to the provisions of the preceding sentence. Â In addition, in the event that a lesser amount of indebtedness is required to fund the Transactions for any reason, you may reduce the Incremental Lendersâ€™ commitments with respect to the Incremental Term Facility (on a pro rata basis amongst the Incremental Lenders) in a manner consistent with the allocation of purchase price reduction described under paragraph 2 of Exhibit C.Section headings used herein are for convenience of reference only and are not to affect the construction of, or to be taken into consideration in interpreting, this Commitment Letter.â€‹9If the foregoing correctly sets forth our agreement, please indicate your acceptance of the terms of this Commitment Letter and of the Arranger Fee Letter by returning to the Commitment Parties (or their legal counsel) and the Consenting Lenders (or their legal counsel) on behalf of the Commitment Parties and the Consenting Lenders, as applicable, executed counterparts hereof and of the Arranger Fee Letter not later than 11:59 p.m., New York City time, on April 28, 2024 (such date of your acceptance of this Commitment Letter and the Arranger Fee Letter, the â€œSigning Dateâ€). Â The Incremental Lendersâ€™ respective commitments and the obligations of the Commitment Parties and the Consenting Lenders hereunder will expire at such time in the event that Commitment Parties (or their legal counsel) and the Consenting Lenders (or their legal counsel) have not received such executed counterparts in accordance with the immediately preceding sentence. Â If you do so execute and deliver to the Commitment Parties and the Consenting Lenders, as applicable, this Commitment Letter and the Arranger Fee Letter at or prior to such time, the Commitment Parties and the Consenting Lenders agree to hold our commitments and all agreements and undertakings hereunder until the earliest of (i) after execution of the Purchase Agreement and prior to the time of the consummation of the Acquisition, the valid termination of the Purchase Agreement in accordance with its terms (other than with respect to provisions therein that expressly survive termination) in the event that the Acquisition is not consummated, (ii) the consummation of the Acquisition with or without the initial funding of the Incremental Term Facility and (iii) five business days after the Outside Date (as defined in the Purchase Agreement as in effect on the date hereof) (but in any event no later than 11:59 p.m., New York City time, April 28, 2025), without giving effect to any extension to a date later than April 28, 2025 set forth in the Purchase Agreement (regardless of whether any party thereto pursues a claim of specific performance)) (such earliest time, the â€œExpiration Dateâ€). Â Upon the occurrence of any of the events referred to in the preceding sentence, this Commitment Letter and the commitments of the Commitment Parties and the Consenting Lenders hereunder and the agreement of the Commitment Parties and the Consenting Lenders to provide the services described herein shall automatically terminate unless the Commitment Parties and the Consenting Lenders shall, in their sole discretion, agree to an extension in writing.[Remainder of this page intentionally left blank]â€‹â€‹10The Commitment Parties are pleased to have been given the opportunity to assist you in connection with the financing for the Transactions.â€‹COÖPERATIEVE RABOBANK U.A., NEW YORK BRANCHâ€‹â€‹By:/s/ Eric Rogowskiâ€‹Name:Eric Rogowskiâ€‹Title:Managing Directorâ€‹â€‹By:/s/ Joost Le Blanschâ€‹Name:Joost Le Blanschâ€‹Title:Vice Presidentâ€‹â€‹[Signature Page to Incremental Commitment Letter]â€‹COMPEER FINANCIAL, PCAâ€‹â€‹By:/s/ Corey J. Waldingerâ€‹Name:Corey J. Waldingerâ€‹Title:Managing Director, Capital Marketsâ€‹â€‹[Signature Page to Incremental Commitment Letter]â€‹CITIBANK, N.A.â€‹â€‹By:/s/ Matthew Marzicolaâ€‹Name:Matthew Marzicolaâ€‹Title:SVP & Authorized Signorâ€‹â€‹[Signature Page to Incremental Commitment Letter]â€‹WELLS FARGO BANK, NATIONAL ASSOCIATION, as Consenting Lenderâ€‹â€‹By:/s/ Jonathan Antonioâ€‹Name:Jonathan Antonioâ€‹Title:Portfolio Managerâ€‹â€‹[Signature Page to Incremental Commitment Letter]â€‹â€‹BANK OF AMERICA, N.A., as Consenting Lenderâ€‹â€‹By:/s/ Dilcia P. Hillâ€‹Name:Dilcia P. Hillâ€‹Title:Senior Vice Presidentâ€‹â€‹[Signature Page to Incremental Commitment Letter]â€‹â€‹Accepted and agreed to as ofâ€‹the date first above written:â€‹â€‹PHIBRO ANIMAL HEALTH CORPORATIONâ€‹â€‹By:/s/ Jack Bendheimâ€‹Name:Jack Bendheimâ€‹Title:President & Chief Executive Officerâ€‹â€‹[Signature Page to Incremental Commitment Letter]EXHIBIT AIncremental Term FacilityTransaction DescriptionCapitalized terms used but not defined in this Exhibit A shall have the meanings set forth in the other Exhibits to the Commitment Letter to which this Exhibit A is attached (the â€œCommitment Letterâ€) or in the Commitment Letter. Â In the case of any such capitalized term that is subject to multiple and differing definitions, the appropriate meaning thereof in this Exhibit A shall be determined by reference to the context in which it is used.Phibro Animal Health Corporation, a Delaware corporation (â€œPurchaser 1â€), and Phibro Animal Health S.A., a Belgian company (â€œPurchaser 2â€, and together with Purchaser 1, â€œPurchasersâ€), intend to acquire (the â€œAcquisitionâ€) all of the Purchased Assets of the entities previously identified to the Lead Arrangers as â€œDeltaâ€ (the â€œTarget Companiesâ€), from Zoetis Inc., a Delaware corporation (the â€œSellerâ€). Â Borrower intends to consummate the Acquisition pursuant to that certain Purchase and Sale Agreement, dated as of the Signing Date (together with all exhibits and schedules attached thereto, collectively, as modified, amended, supplemented, consented to or waived, the â€œPurchase Agreementâ€) by and between Purchasers and the Seller pursuant to which the Seller will receive cash in exchange for the Acquisition (collectively, the â€œPurchase Considerationâ€).Substantially contemporaneously with the consummation of the Acquisition, the Borrower will, pursuant to SectionÂ 2.14 of the Existing Credit Agreement, obtain a senior secured incremental first lien term loan facility described in Exhibit B to the Commitment Letter in an aggregate principal amount of $325 million (the â€œIncremental Term Facilityâ€).In connection with the Incremental Term Facility, the Borrower will also obtain the Proposed Amendments to the Existing Credit Agreement.The proceeds of the Incremental Term Facility and cash on hand at Borrower on the Incremental Effective Date will be applied (i) as described above to pay the Purchase Consideration and (ii) to pay the fees and expenses incurred in connection with the Transactions (such fees and expenses, the â€œTransaction Costsâ€) (the amounts set forth in clauses (i) and (ii) above, collectively, the â€œAcquisition Fundsâ€)The transactions described above (including the payment of Transaction Costs) are collectively referred to herein as the â€œTransactionsâ€.â€‹â€‹A-1EXHIBIT Bâ€‹Amendment No. 3Incremental Term FacilitySummary of Principal Terms and Conditions1â€‹See attached.â€‹â€‹â€‹â€‹1All capitalized terms used but not defined herein shall have the meaning given them in the Commitment Letter to which this Term Sheet is attached, including Exhibit A and Exhibit C thereto.â€‹â€‹B-1Project Delta$325 Million Incremental Term Loan A FacilitySummary of Principal Terms and ConditionsSet forth below is a summary of the principal terms and conditions for the Incremental Term Loans (as defined below).Â All capitalized terms used but not otherwise defined herein shall have the meaning assigned to such terms in the Existing Credit Agreement (as defined below).Borrower:Phibro Animal Health Corporation (the â€œBorrowerâ€).â€‹â€‹Guarantors:Same as the Existing Credit Agreement and including, after consummation of the Acquisition (as defined in Exhibit A to the Commitment Letter), the Target Companies that meet the criteria to be guarantors.â€‹â€‹Transactions:As set forth in Exhibit A to the Commitment Letter.â€‹â€‹Administrative Agent andCollateral Agent:Bank of America, N.A. will act as Administrative Agent and Collateral Agent (in such capacity, the â€œAdministrative Agentâ€) for the banks, financial institutions and other entities reasonably acceptable to the Borrower (excluding Disqualified Lenders) with respect to the Incremental Term Loans and will perform the duties customarily associated with such roles.â€‹â€‹Lead Arrangers and Bookrunners:CÃ¶operatieve Rabobank, U.A., New York Branch, Compeer Financial, PCA and Citibank, N.A. will act as joint lead arrangers and joint bookrunners for the Incremental Term Loans (each, a â€œLead Arrangerâ€ and together, the â€œLead Arrangersâ€), and will perform the duties customarily associated with such roles.â€‹â€‹Incremental Term Loan Facility:A senior secured incremental term loan A facility denominated in dollars (the â€œIncremental Term Loan Facilityâ€) in an aggregate principal amount of $325 million (the loans thereunder, the â€œIncremental Term Loansâ€).â€‹â€‹Purpose:The proceeds of borrowings under the Incremental Term Loan Facility will be used by the Borrower on the date of the initial funding of the Incremental Term Loan Facility (the â€œIncremental Effective Dateâ€) to finance all or a portion of (a) the Purchase Consideration (as defined in Exhibit A to the Commitment Letter) and (b) the Transaction Costs (as defined in Exhibit A to the Commitment Letter).â€‹â€‹Availability:The Incremental Term Loan Facility will be available in a single drawing on the Incremental Effective Date. Amounts borrowed under the Incremental Term Loan Facility that are repaid or prepaid may not be reborrowed.â€‹â€‹Incremental Facilities:Substantially consistent with the Existing Credit Agreement, subject to the modifications set forth in Annex I-A hereto.â€‹â€‹1Interest Rates:As set forth in Annex I hereto.â€‹â€‹Default Rate:Same as the Existing Credit Agreement.â€‹â€‹Final Maturity and Amortization:The Incremental Term Loan Facility will mature, and lending commitments thereunder will terminate on the same Maturity Date as the Term A Loans under the Existing Credit Agreement. The Incremental Term Loan Facility will amortize in quarterly installments equal to 2.500% of the initial aggregate principal amount of the Incremental Term Loans made on the Incremental Effective Date; provided that the aggregate principal amount of all Incremental Term Loans outstanding on the Maturity Date of the Incremental Term Loan Facility shall be repaid on such date.â€‹â€‹Guarantees:Same as the Existing Credit Agreement and, after consummation of the Acquisition, guarantees from the Target Companies that meet the criteria to be guarantors.â€‹â€‹Security:Same as the Existing Credit Agreement and, after consummation of the Acquisition, assets of the Target Companies that meet the criteria to be collateral.â€‹â€‹Mandatory Prepayments:Same as the Existing Credit Agreement, to be shared on a pro rata basis with the Term A Loans.â€‹â€‹Voluntary Prepayments andReductions in Commitments:Same as the Existing Credit Agreement, to be shared on a pro rata basis with the Term A Loans.â€‹â€‹Documentation Principles:The definitive documentation for the Incremental Term Loan Facility will be in the form of an incremental facility amendment (the â€œIncremental Facility Documentationâ€) to that certain Amended and Restated Credit Agreement, dated as of April 22, 2021 (the â€œOriginal Closing Dateâ€) among the Borrower (as defined below), the other loan parties from time to time party thereto, the lenders from time to time party thereto and Bank of America, N.A., as the Administrative Agent (as amended by that certain Amendment No. 1, dated November 8, 2022, that certain Amendment No. 2, dated as of June 16, 2023 and as further amended, restated, supplemented and/or otherwise modified from time to time prior to the date hereof, the â€œExisting Credit Agreementâ€) and will contain only those terms, conditions to borrowing, mandatory prepayments and other terms and provisions expressly set forth herein (including the modifications to the Existing Credit Agreement set forth in Annex I-A hereto).â€‹â€‹Representations and Warranties:Same as the Existing Credit Agreement, but subject to the Limited Conditionality Provisions (as defined in the Commitment Letter).â€‹â€‹Conditions to Borrowing:The availability of the Borrowing under the Incremental Term Loan Facility on the Incremental Effective Date will be subjectâ€‹2â€‹solely to the satisfaction or waiver of the conditions set forth in Exhibit C to the Commitment Letter.â€‹â€‹Affirmative Covenants:Same as the Existing Credit Agreement.â€‹â€‹Negative Covenants:Same as the Existing Credit Agreement.â€‹â€‹Financial Maintenance Covenant:The Incremental Facility Documentation will contain the following financial covenants with regard to the Borrower and its restricted subsidiaries on a consolidated basis, which covenants shall be tested on a trailing four quarter basis as of the last day of any fiscal quarter of the Borrower for which financial statements have been delivered, commencing with the first full fiscal quarter following the Incremental Effective Date:â€‹â€‹â€‹(i) A maximum First Lien Net Leverage Ratio not to exceed 4.50 to 1.00; provided that, on and after the Incremental Effective Date, no step-ups in the maximum permitted First Lien Net Leverage Ratio shall be permitted in connection with an acquisition.â€‹â€‹â€‹(ii) A minimum Consolidated Interest Coverage Ratio of not less than 2.50 to 1.00.â€‹â€‹Unrestricted Subsidiaries:Same as the Existing Credit Agreement.â€‹â€‹Events of Default:Same as the Existing Credit Agreement.â€‹â€‹Voting:Same as the Existing Credit Agreement; provided, that the Incremental Term Loan Facility shall be deemed to be a separate Class from the Term A Loans and the 2023 Incremental Term Loans for purposes of the class voting rights set forth in the Existing Credit Agreement.â€‹â€‹Cost and Yield Protection:Same as the Existing Credit Agreement.â€‹â€‹Assignments and Participations:Same as the Existing Credit Agreement.â€‹â€‹Expenses and Indemnification:Same as the Existing Credit Agreement.â€‹â€‹Governing Law and Forum:New York.â€‹â€‹Counsel to the Administrativeand the Lead Arrangers:Davis Polk & Wardwell LLP.â€‹3Annex Iâ€‹Interest Rates:The interest rate under the Incremental Term Loan Facility will be, at the option of the Borrower, Term SOFR (as defined in the Existing Credit Agreement), Base Rate (as defined in the Existing Credit Agreement) or Daily SOFR (as defined in the Existing Credit Agreement), in each case, plus a margin determined in accordance with the table set forth below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹First LienNet Leverage RatioBase RateTerm SOFRDaily SOFRâ€‹â‰¥ 4.00:1.002.25%3.25%3.25%â€‹â‰¥ 3.50:1.00 and < 4.00:1.002.00%3.00%3.00%â€‹â‰¥ 2.25:1.00 and < 3.50:1.001.75%2.75%2.75%â€‹< 2.25:1.001.50%2.50%2.50%â€‹â€‹Calculation of interest shall be as per the Existing Credit Agreement.â€‹â€‹â€‹â€‹Interest shall be payable as per the Existing Credit Agreement.â€‹â€‹1ANNEX I-A TO EXHIBIT Bâ€‹â€‹â€‹â€‹TermAgreed Modification to Existing Credit Agreement1.Definition of â€œConsolidated EBITDAâ€Include add-back for other add-backs and adjustments with respect to the Transactions reflected in the model agreed with the Lead Arrangers on April 16, 2024 (the â€œModelâ€).2.Definition of â€œConsolidated First Lien Net Debtâ€Replace the reference to â€œobligations in respect of Capitalized Leases and Indebtedness incurred pursuant to Section 7.03(f)â€ with â€œobligations in respect of Capitalized Leases and Indebtedness of the type described in Section 7.03(f)â€3.Definition of â€œIncremental Facilities Capâ€; Section 2.14(a)Increase the ratio incurrence tests in the unlimited prong to (i) 3.70x First Lien Net Leverage Ratio or, solely in the case of Incremental Facilities incurred to finance a Permitted Acquisition, (ii) 4.50x 4.Section 2.14The incurrence of the Incremental Term Loan Facility and the funding of the Incremental Term Loans shall be deemed permitted under Section 2.14 5.Section 4.02The incurrence of the Incremental Term Loan Facility and the funding of the Incremental Term Loans shall not be subject to the requirements set forth in Section 4.02(a) (other than with respect to the Specified Representations (as defined in the Commitment Letter)) and (b) 6.Section 7.02(j)The Acquisition shall be deemed to be a â€œPermitted Acquisitionâ€ for all purposes of the Existing Credit Agreement and shall not be subject to the provisions of Section 7.02(j)â€‹â€‹â€‹â€‹1EXHIBIT CAmendment No. 3Incremental Term FacilitySummary of Additional Conditions2â€‹Subject in all respects to the Limited Conditionality Provisions, the initial borrowings under the Incremental Term Facility shall be subject solely to the satisfaction or waiver by all Commitment Parties of the following conditions:1.Since the date of the Purchase Agreement, there shall not have been a Business Material Adverse Effect (as defined in the Purchase Agreement (as in effect on the date hereof)) that is continuing as of the Closing Date (as defined in the Purchase Agreement).2.The Acquisition shall have been consummated, or substantially simultaneously with the initial borrowings under the Incremental Term Facility, shall be consummated, in all material respects in accordance with the terms of the Purchase

Agreement, without any amendment, modification or waiver to the Purchase Agreement or any consent thereunder that is materially adverse to the Commitment Parties in their capacities as such without the prior written consent of the Commitment Parties (such consent not to be unreasonably withheld, delayed or conditioned); provided, that, with respect to any amendment, modification or waiver to, or consent under, the Purchase Agreement requiring the consent of the Commitment Parties, such consent shall be deemed given if the Commitment Parties have not responded to such proposed amendment, modification or waiver to, or consent under, the Purchase Agreement within five (5) Business Days (as defined in the Purchase Agreement) of being provided a copy of such amendment, modification, waiver Â or consent by the Borrower or its counsel (it being understood that any modification, amendment, supplement, consent, waiver or request by you (or your affiliate) to the definition of Business Material Adverse Effect shall be deemed to be materially adverse to the interests of the Commitment Parties); provided, that, without limiting any other rights and/or obligations of this ExhibitÂ C, including rights under paragraphÂ 1 above, any reduction in the Base Purchase Price (as defined in the Purchase Agreement) (other than as set forth in the Purchase Agreement as of the date hereof) shall not, in and of itself, be deemed to be materially adverse to the interests of the Â Commitment Parties so long as any such reduction above $25,000,000 shall be applied to reduce the amount of commitments in respect of the Incremental Term Facility on a dollar for dollar basis.3.The Lead Arranger shall have received the Financial Statements (as defined in the Purchase Agreement).4.The Administrative Agent and the Lead Arrangers shall have received, at least three business days prior to the Incremental Effective Date, all documentation and other information about the Loan Parties and the Target Companies that shall have been reasonably requested by the Administrative Agent and the Lead Arrangers in writing at least 10 business days prior to the Incremental Effective Date and that the Administrative Agent and each Lead Arranger reasonably determines is required by regulatory authorities under applicable â€œknow your customerâ€ and anti-money laundering rules and regulations, including without limitation the PATRIOT Act (including, for the avoidance of doubt, a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation).2Capitalized terms used in this Exhibit C shall have the meanings set forth in the other Exhibits attached to the Commitment Letter to which this Exhibit C is attached (the â€œCommitment Letterâ€). In the case of any such capitalized term that is subject to multiple and differing definitions, the appropriate meaning thereof in this Exhibit C shall be determined by reference to the context in which it is used.â€‹C-15.(x) The execution and delivery by the Borrower of the Incremental Term Facility Documentation, which shall be in accordance with the terms of the Commitment Letter and the Term Sheet (y) delivery to the Administrative Agent of the following (the â€œClosing Deliverablesâ€): (i) customary legal opinions, customary officerâ€™s closing certificates (which shall not require certification of no default or bringdown of representations and warranties), organizational documents, customary evidence of authorization and good standing certificates in jurisdictions of formation/organization (except, in the case of any Loan Parties other than the Borrower, where the failure of such Loan Parties to be in good standing could not reasonably be expected to have a Material Adverse Effect (as defined in the Existing Credit Agreement)), in each case with respect to the Loan Parties (to the extent applicable) (as such terms are defined in Exhibit B), (ii) a customary borrowing request and (iii) a certificate attesting to the Solvency (as defined in the Existing Credit Agreement) of the Borrower and its Subsidiaries (on a consolidated basis) dated as of the Incremental Effective Date and after giving effect to the Transactions, substantially in the form of AnnexÂ I attached to this ExhibitÂ C, of a senior authorized financial executive or officer with equivalent duties of the Borrower (or, at the option of the Borrower, a third party opinion as to the solvency of the Borrower and its subsidiaries on a consolidated basis by a nationally recognized firm).6.All fees required to be paid on the Incremental Effective Date pursuant to the Arranger Fee Letter and reasonable out-of-pocket expenses required to be paid on the Incremental Effective Date pursuant to the Commitment Letter, and with respect to expenses, to the extent invoiced at least three business days prior to the Incremental Effective Date (except as otherwise reasonably agreed by the Borrower), shall, upon the initial borrowings under the Incremental Term Facility, have been, or will be substantially simultaneously, paid (which amounts may be offset against the proceeds of the Incremental Term Facility).7.The Specified Purchase Agreement Representations and the Specified Representations shall be true and correct in all material respects on and as of the Incremental Effective Date.8.The Incremental Effective Date shall not occur prior to July 12, 2024.â€‹C-2ANNEX 1 TO EXHIBITÂ CFORM OF SOLVENCY CERTIFICATE[____][__], 20[__]â€‹This Solvency Certificate (this â€œCertificateâ€) is being delivered pursuant to Section [__] of that certain Amendment No. [â—] (the â€œAmendmentâ€).â€‹I, [â—], solely in my capacity as a [â—] of the Borrower, do hereby certify on behalf of the Borrower that, as of the date hereof, before and after giving effect to the consummation of the transactions on the Amendment No. [â—] Effective Date:â€‹7.the fair value of the property (for the avoidance of doubt, calculated to include goodwill and other intangibles) of the Borrower and its Subsidiaries is greater than the total amount of liabilities, including contingent liabilities, of the Borrower and its Subsidiaries;8.the present fair salable value of the assets of the Borrower and its Subsidiaries is not less than the amount that will be required to pay the probable liability of the Borrower and its Subsidiaries on its debts as they become absolute and matured;9.the Borrower and its Subsidiaries do not intend to, and do not believe that they will, incur debts or liabilities beyond the Borrower and its Subsidiariesâ€™ ability to pay such debts and liabilities as they mature; and10.the Borrower and its Subsidiaries are not engaged in business or a transaction, and are not about to engage in business or a transaction, for which the Borrower and its Subsidiariesâ€™ property would constitute an unreasonably small capital.For purposes of this Certificate, the amount of contingent liabilities at any time has been computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.â€‹[Remainder of this page intentionally left blank]â€‹â€‹C-1IN WITNESS WHEREOF, I have executed this Solvency Certificate on the date first written above.â€‹[BORROWER]â€‹â€‹By:â€‹Name:â€‹Title:â€‹[Signature page to Solvency Certificate] EX-10.25 4 pahc-20240630xex10d25.htm EX-10.25 Exhibit 10.25â€‹October 10, 2023â€‹Glenn David3 Spring Hill Ln.Morristown, NJ 07960Email: gcd1_98@msn.comâ€‹Dear Glenn,â€‹I am pleased to present to you an offer of employment with Phibro Animal Health Corporation (the â€œCompanyâ€) as its Chief Financial Officer (CFO), reporting directly to me.â€‹Our offer to you is as follows:â€‹Start DateYour anticipated start date with the Company will be agreed upon by you and the Company but will be no later than February 12, 2024, (â€œStart Dateâ€)1 subject to you having satisfactorily cleared the pre-employment background check and substance abuse test referred to below.â€‹LocationYou will be based out of our corporate headquarters office located in Teaneck, New Jersey.â€‹CompensationYou will be compensated at the semi-monthly base salary rate of $27,084 (equivalent to $650,000 annually) less applicable deductions as required by law. Your compensation is subject to periodic review per Company policy.â€‹You will be eligible to participate in the Phibro Animal Health Corporation Management Incentive Plan (â€œMIPâ€). Your target bonus under the MIP will be 50% of your base salary (the MIP currently provides for a maximum payout of 75% of your base salary). Notwithstanding the foregoing, for fiscal year 2024 (beginning on July 1, 2023): (a) if your Start Date is on or before February 12, 2024, you will be only be eligible for a prorated bonus for the period of time between your start date and January 31, 2024 divided by 365 days or (b) if your Start Date is February 13, 2024 or later, you will not be eligible for any annual bonus for fiscal year 2024. Bonuses under the MIP are subject to corporate performance, contingent on satisfactory individual performance and subject to the approval of the Companyâ€™s Compensation Committee and the Companyâ€™s Board of Directors. In order to receive any bonus under the MIP, you must be employed by the Company on the date the applicable bonus is paid; provided, however, that if your employment with the Company has been involuntarily terminated without â€œCauseâ€ or you have resigned for â€œGood Reasonâ€ (each defined below) prior to such payment date, you will remain eligible to receive a pro-rated MIP bonus, payable approximately 3 months following the end of the fiscal year to which the bonus relates.â€‹Restricted Stock Units (RSUs): Subject to approval by the Board of Directors, on or as soon as reasonably practicable following your Start Date, the Company will grant to you an aggregate of 300,000 restricted stock units (â€œthe RSU Grantâ€) that will vest as follows: (i) 150,000 RSUs will be subject to time vesting (collectively, the1Employee and Company will determine whether the Employee will start as CFO, or with another title, dependent upon the fiscal reporting cycle for the most recent quarter of FY2024.â€‹â€‹HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD.Â®â€‹Glenpointe Centre East / 3rd Floor / 300 Frank W. Burr Blvd., Ste. 21 / Teaneck, NJ 07666-6712Direct: 201-329-7300 / Fax: 201-329-7399â€‹October 10, 2023â€‹Page 2â€‹â€œTime Vesting RSUsâ€) and (ii) 150,000 RSUs will be subject to performance vesting (collectively, the â€œPerformance Vesting RSUsâ€); provided, however that you must be employed on the date of such vesting unless your employment has been involuntarily terminated without â€œCauseâ€ or you have resigned for â€œGood Reason.â€ The RSU Grant shall be subject to the terms and conditions of the Phibro Animal Health Corporation 2008 Incentive Plan (the â€œPlanâ€) and the Restricted Stock Unit Award Agreement (attached hereto).Additional Compensation:You will have the option of either being provided with a Company-leased vehicle for your business and personal use pursuant to the Companyâ€™s Fleet Policy or you will be provided with a car allowance of up to $800/month toward a vehicle (including gas reimbursement) to be used for your business and personal use.You will receive a signing bonus in the gross amount of $135,000, less applicable deductions as required by law, payable on or about September 15, 2024; provided you are still employed by the Company on the applicable payment date. If your employment with the Company has been involuntarily terminated without â€œCauseâ€ or you have resigned for â€œGood Reasonâ€ (each defined below) prior to payment of the signing bonus, you will receive payment of the signing bonus on or before September 15, 2024.â€‹Separation Payâ€‹In the event the Company terminates your employment without â€œCauseâ€ or you terminate for â€œGood Reason,â€ as these terms are defined below, and the Company wishes to hold you to some or all of the one year non-compete restrictions set forth in Section 1(a) of the your NonCompetition and NonSolicitation Agreement, the Company will continue to pay your then Base Salary and the cost of your medical benefits under COBRA for the period of time the Company wishes you not to compete up to the maximum of one (1) year.â€‹Definitions: â€‹The Term â€œCauseâ€ shall mean: (A) any willful or repeated failure by you to substantially perform your material duties hereunder, other than a failure resulting from your complete or partial incapacity due to physical or mental illness or impairment; (B) a material and willful violation of a federal or state law or regulation applicable to the business of the Company or that adversely affects the image of the Company; (C) commission of a willful act by you which constitutes gross misconduct and is injurious to the Company; (D) material breach or material violation of any company policy including but not limited to the Companyâ€™s Code of Business Conduct and Ethics; or (E) your material violation of any provision of any agreement(s) between the you and the Company and/or its Affiliates relating to the Companyâ€™s standard forms of Confidentiality and NonDisclosure, Employee Invention Agreements or NonCompetition and NonSolicitation Agreement.â€‹The term â€œGood Reasonâ€ shall mean: (A) a material adverse change in your duties, responsibilities or authority or compensation (defined as base salary plus target bonus) from those in effect on the date of this Agreement without your written consent; provided that before you assert a claim for Good Reason to resign, you must provide the Company with written notice that identifies the manner in which you believe the Company has created a material adverse change in your duties, responsibilities or authority and a 30-day period for the Company to respond to such claims; or (B) a relocation of your principal place of employment more than 50 miles from Teaneck, New Jersey, without your consent. The acquisition of the assets or capital stock of the Company by another or any other Change in Controls (as defined in the Plan) shall not, by itself, constitute â€œGood Reason.â€â€‹Benefit Planâ€‹HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD.Â®â€‹October 10, 2023â€‹Page 3â€‹You will be eligible to participate in the Companyâ€™s benefit plans, which includes health, dental, life and disability insurance after a 30-day waiting period, and the Companyâ€™s 401(k) Retirement and Savings Plan. Participation in these plans is subject to the terms and conditions of the plans, and they are subject to change at any time at the sole discretion of the Company. Please see the Summary of Insurance and Benefits for more details.â€‹VacationYou are eligible for 20 vacation days per year and will begin to accrue that time on a monthly basis with your Start Date. Your first-year entitlement will be prorated according to your Start Date.â€‹HolidaysCurrently the Company provides employees with 8 holidays and 3 floating holidays each year, for which you are eligible as of your start date.â€‹Contingencies:This offer is contingent upon:â€‹Â·A satisfactory result on a pre-employment background check and substance abuse test.Â·Your signed acceptance of, and agreement to be bound by, the Companyâ€™s standard forms of Confidentiality and Nondisclosure, Noncompetition and Nonsolicitation, and Employee Invention agreements, and any other agreement between you and the Company or any of its affiliates related to restrictive covenants.Â·Your signed agreement to abide by the Companyâ€™s Code of Business Conduct and Ethics.Â·The approval by the Board of your appointment as the Chief Financial Officer and the terms of your compensation.â€‹Prior Employment AgreementsYou agree that you have fully disclosed to the Company any post-termination obligations you may have with your current and prior employers, that your employment with the Company will not violate any such obligations, and that as a condition of your employment you will strictly comply with any such obligations, including any obligation to maintain the confidentiality of your current and prior employersâ€™ confidential information.â€‹Employment-At-WillYour employment status with the Company will be that of an at-will employee. Nothing in this offer of employment at-will shall be deemed to create a contract of employment. This offer of employment is not for a fixed duration and may be terminated at any time by either you or the Company with or without cause.â€‹This offer expires October 17, 2023.â€‹Glenn, I am excited about your future at the Company and the potential of your leadership, and I look forward to working with you. If you agree with the above terms, please sign and date and return to me at your earliest convenience a copy of this letter; the Confidentiality and Nondisclosure, Noncompetition and Nonsolicitation, and Employee Invention agreements; and your agreement and written acknowledgement to abide by the Companyâ€™s Code of Business Conduct and Ethics.â€‹â€‹HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD.Â®â€‹October 10, 2023â€‹Page 4â€‹If you have any questions regarding your employment with Phibro, please feel free to call me at 201-707-8272.â€‹Sincerely,â€‹/s/ Jack C. Bendheimâ€‹Jack C. BendheimChief Executive Officerâ€‹Offer Accepted:/s/ Glenn Davidâ€‹Glenn Davidâ€‹â€‹â€‹10/12/2023â€‹Dateâ€‹â€‹HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD.Â®â€‹â€‹PHIBRO ANIMAL HEALTH CORPORATIONâ€‹NONCOMPETITION AND NONSOLICITATION AGREEMENTâ€‹In consideration of my employment by PHIBRO ANIMAL HEALTH CORPORATION, or any of its subsidiaries or affiliates (collectively â€œPAHCâ€), my access to and provision with PAHCâ€™s confidential information and trade secrets under the terms and conditions of my Confidentiality and Nondisclosure Agreement with PAHC, and for other good and sufficient consideration, I hereby acknowledge and agree:â€‹1.During my employment with PAHC and for a period of one year after my separation of employment regardless of the reason, I shall not:â€‹a.Directly or indirectly (i) own, (ii) be engaged to perform work in a capacity similar to the position(s) I held with PAHC on behalf of, any firm engaged in any business: (A) similar to, or competitive with, PAHCâ€™s business in those geographic regions or territories in which PAHC marketed its products or had sales during the twelve-month period prior to the separation of my employment at PAHC, or (B) which PAHC has plans to enter during the twelve-month period following the separation of my employment with PAHC of which I was aware during the term of my employment with PAHC.â€‹b.Directly or indirectly, or in any capacity, on my own behalf or on behalf of another, undertake or assist in the servicing or solicitation of any customer or prospective customer for the purpose of selling products or services of the type for which I had (i) responsibility, or (ii) access to confidential information and trade secrets, while employed by PAHC. This restriction shall apply only to those customers or prospective customers of PAHC with whom I came into contact during the 12-month period prior to the date of my separation of employment with PAHC. For the purposes of this section, the term â€œcontactâ€ means interaction between the customer and me which takes place to further the business relationship, or making sales to or performing services for the customer on behalf of PAHC.â€‹c.Directly or indirectly solicit any employee of PAHC to leave the employ of PAHC or to violate the terms of his or her employment arrangement with PAHC. This restriction shall apply only to those employees of PAHC with whom I came into contact during the 24-month period prior to the date of my separation of employment with PAHC.â€‹The restrictions in (a) above shall not apply (other than for termination of my employment for cause), except to the extent that PAHC makes any severance or other payments to me or on my behalf in connection with the termination of my employment (otherâ€‹â€‹Revised Noncompete tied to severance (G. David)(Oct. 2023)â€‹â€‹â€‹than base salary and bonus actually earned through the date of termination) equivalent to my base salary for some or all of the period of one year after my termination of employment. The portion of the one-year period in which this restriction shall continue to apply shall be proportionate to the portion of my annual base salary represented by such payments made by PAHC. The Term â€œCauseâ€ shall mean: (A) any willful or repeated failure by you to substantially perform your material duties, other than a failure resulting from your complete or partial incapacity due to physical or mental illness or impairment; (B) a material and willful violation of a federal or state law or regulation applicable to the business of the Company or that adversely affects the image of the Company; (C) commission of a willful act by you which constitutes gross misconduct and is injurious to the Company; (D) material breach or material violation of any company policy including but not limited to the Companyâ€™s Code of Business Conduct and Ethics; or (E) your material violation of any provision of any agreement(s) between the you and the Company and/or its Affiliates relating to the Companyâ€™s standard forms of Confidentiality and NonDisclosure, Employee Invention Agreements or this NonCompetition and NonSolicitation Agreement.â€‹2.For the purposes of this Agreement, I understand that, as of October, 2023, PAHC is engaged in businesses which include but are not limited to manufacturing and/or marketing of pharmaceutical and nutritional products for animals (including but not limited to medicated and non-medicated feed additives and vaccines), plant nutrition products, manufacturing and/or marketing specialty chemicals including products used in ethanol-production, surface finishing and coating materials, and personal care ingredients and manufacture and/or marketing and sale of microbial products and bioproducts for environmental, industrial and agricultural applications. I further understand that, for the purposes of this Agreement, from

time to time the businesses engaged in by PAHC may change from this description.â€‹3.For a period of one year following the separation of my employment from PAHC, regardless of reason, I shall notify any future or prospective employer of mine of the existence of this Agreement, and I further agree that PAHC may inform any future or prospective employer of mine of the existence of this Agreement.â€‹4.The unenforceability of any provision or portion of this Agreement shall not impair or affect the enforceability of any other provision or portion of this Agreement. If any provision or portion of this Agreement is declared illegal or unenforceable by any court of competent jurisdiction, that provision or portion shall be deemed modified so as to render it enforceable.â€‹5.THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF NEW JERSEY WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES. ANY ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT AND MY EMPLOYMENT SHALL BE BROUGHT EXCLUSIVELY IN THE STATE OR FEDERAL COURTS OF NEW JERSEY. I EXPRESSLY CONSENT TO VENUE IN, AND THE PERSONAL JURISDICTION OF, THE STATE AND FEDERAL COURTS LOCATED IN NEW JERSEY FOR ANY LAWSUIT ARISING FROM OR RELATING TO THIS AGREEMENT.â€‹6.This Agreement does not alter the status of my employment as an at-will employee of PAHC.â€‹7.I understand PAHC is engaged in a highly competitive business and that its competitive position depends upon its ability to maintain the confidentiality of its confidential information, proprietary information, and trade secrets, which were developed, compiled and acquired by PAHC at its great effort and expense. I further acknowledge and agree that compliance with the provisions of this Agreement and PAHCâ€™s Confidentiality and Nondisclosure Agreement is necessary to protect the confidential information, proprietary information, and trade secrets,â€‹Revised Noncompete tied to severance (G. David)(Oct. 2023)- 2 -â€‹â€‹business and goodwill of PAHC, and that any breach of this Agreement will result in irreparable and continuing harm to PAHC, for which money damages may not provide adequate relief. Accordingly, in the event of a breach or threatened breach of this Agreement,PAHC shall have full rights to injunctive relief, in addition to any other existing rights and remedies, without requirement of posting bond.â€‹8.The terms of this Agreement shall survive my separation of employment with PAHC.â€‹9.This Agreement shall inure to the benefit of PAHC, its successors and assigns.â€‹10.This Agreement constitutes the entire agreement between PAHC and me with respect to the subject of this Agreement and supersedes all prior agreements between us relating to the same subject matter, except the Confidentiality and Nondisclosure Agreement between PAHC and me, which is incorporated herein by reference. Any waiver of a breach of any provision of this Agreement by PAHC shall not be construed as a waiver of any other breach of this Agreement, and no failure or delay by PAHC in exercising any right under this Agreement shall operate as a waiver of any breach by me. This Agreement cannot be changed except by written agreement of PAHC and me, wherein specific reference is made to this Agreement.â€‹I have read, understand and consent to the above Agreement.â€‹By: /s/ Glenn Davidâ€‹â€‹Name: Glenn Davidâ€‹â€‹Date: January 31, 2024â€‹â€‹Revised Noncompete tied to severance (G. David)(Oct. 2023)- 3 -â€‹ EX-19.1 5 pahc-20240630xex19d1.htm EX-19.1 â€‹Exhibit 19.1â€‹INSIDER TRADING AND DISCLOSURE OF CONFIDENTIAL INFORMATION POLICYThis Policy (the â€œInsider Trading Policyâ€) has been adopted by the Board of Directors of Phibro Animal Health Corporation, a Delaware corporation (the â€œCompanyâ€). In adopting this Insider Trading Policy, the Board is mindful that the Company has responsibilities to several constituencies and has various objectives and that the manner in which the Companyâ€™s directors and employees trade in the Companyâ€™s securities can affect those responsibilities and objectives. Consequently, while all Company personnel are required to comply with applicable law, this Insider Trading Policy is broader than mere compliance with applicable securities laws and may prohibit conduct that is permitted by applicable law. Compliance with this Insider Trading Policy is required of all directors, officers and employees of the Company and its subsidiaries and includes all members of the â€œimmediate family and householdâ€ of the foregoing and entities controlled by a person covered by this Insider Trading Policy. As used in this Insider Trading Policy, the term â€œimmediate family and householdâ€ means a spouse, children, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws, and anyone else who lives in your household, and any family members who do not live in your household but whose transactions in the Companyâ€™s securities are directed by you or are subject to your influence or control, such as parents or children who consult with you before they trade in the Companyâ€™s securities.This Insider Trading Policy should not be interpreted to modify any agreements the Company and Company personnel may have entered into regarding the disclosure of confidential information.1.Prohibition Against Trading and Tipping While Aware of Material, Non-Public Information.It is a violation of Company policy for any person to engage in transactions in securities of the Company if he or she is aware of material, non-public information concerning the Company or its securities. It also violates this Insider Trading Policy for any director or employee in possession of material, non-public information to recommend that another person buy or sell the Companyâ€™s securities or to otherwise improperly disclose such information to others outside the Company who may trade on, or make recommendations to others to trade on, the basis of that information. In that case, both the â€œtippeeâ€ and the â€œtipperâ€ may be liable for a violation of insider trading laws.Information is material if a reasonable investor would consider that information important in making a decision to buy, sell or hold securities. There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances. Although it is not possible to list all types of information that might be deemed material under particular circumstances, information concerning the following subjects is often found material:â€‹â€‹Insider Trading and Disclosure of Confidential Information PolicyRev. August 1, 2024â€‹â€‹â€‹â€‹(i) internal forecasts or budgets; (ii) significant acquisitions or dispositions (including mergers, tender offers and asset purchase or sale transactions); (iii) major product changes or introductions; (iv) special dividends or changes in dividend policy; (v) changes in debt ratings; (vi) significant write-downs of assets or additions to reserves for bad debts or contingent liabilities; (vii) liquidity problems; (viii) extraordinary management developments; (ix) significant financing transactions; (x) major price or marketing changes; (xi) labor negotiations; (xii) significant cybersecurity incidents; and (xiii) significant litigation or investigations by governmental bodies. Information about a company generally is not material if its public dissemination would not have any impact on the price of the Companyâ€™s securities. It should be noted that either positive or adverse information may be material.It should also be noted that materiality may depend on the type of securities involved in the analysis. Materiality can frequently be uncertain and, since your actions will be judged with hindsight, caution should be exercised. If you have any questions in this area, you should contact the Companyâ€™s General Counsel or Chief Financial Officer at +1 (201) 329-7300.Information is non-public if it has not been disclosed to the public and, even after disclosure has been made (e.g., SEC filings, press releases or publicly accessible conference calls), until a reasonable time has passed after it has been disclosed by means likely to result in widespread public awareness. By contrast, information would likely not be considered widely disseminated if it is available only to the Companyâ€™s employees, or if it is only available to a select group of analysts, brokers and institutional investors. These prohibitions against trading while in possession of material, non-public information also apply to material, non-public information about any other company with which the Company does business, including a customer or supplier of the Company, or that is involved in a potential transaction or business relationship with the Company that has been obtained in the course of a personâ€™s work for the Company.This Insider Trading Policy continues to apply to your transactions in Company securities even after you have terminated employment or other services to the Company or a subsidiary. If you are aware of material, non-public information when your employment or service relationship terminates, you may not trade in Company securities until that information becomes public or is no longer material.2.Restrictions on Selective Disclosure of Material, Non-Public Information.It is a violation of Company policy to disclose in any manner any material, non-public information to any person who may trade on, or make recommendations to others to trade on, the basis of that information except as follows: (i)Â disclosure to a person who has signed an appropriate agreement to hold such information in confidence; (ii)Â disclosure to Senior Personnel (as defined below) of the Company; (iii)Â disclosure to personnel who need the information to carry out their services to the Company and who agree to hold the information in confidence; (iv)Â disclosure to the Companyâ€™s legal counsel, accountants or advisors if the information disclosed is related to a matter on which they are involved; or (v)Â as approved by the Chief Executive Officer, Chief Operating Officer, Chief Financial Officer or the General Counsel of the Company. All communications with investors, investor representatives, securities analysts and securities professionals shall be made solely by the Companyâ€™s Chief Executive Officer, Chief Financial Officer or a person specifically designated by either of them. All requests forâ€‹â€‹Insider Trading and Disclosure of Confidential Information PolicyRev. August 1, 2024-2-â€‹â€‹â€‹â€‹information about the Company from stockholders, the financial press, investment analysts and others in the media or financial communities, whether or not involving confidential or non-public information, should be directed to the Companyâ€™s Chief Financial Officer at +1 (201) 329-7300, or a person designated by him or her from time to time. If any person subject to this Insider Trading Policy should inadvertently selectively disclose any material, non-public information to any person not covered by the exceptions above, this Insider Trading Policy requires that such inadvertent disclosure be reported as soon as possible to the Chief Executive Officer, Chief Operating Officer, General Counsel, or Chief Financial Officer of the Company. Such inadvertent disclosure may arise because of a mistaken belief about the materiality or non-public nature of the disclosed information, the identity of the recipient of such disclosure, the applicability of a confidentiality agreement or numerous other reasons. Applicable law (Regulation FD, in particular) generally requires that the Company publicly and promptly disclose the information that had been inadvertently disclosed.3.Window Periods and Pre-Clearance Procedures.It is not permissible for any member of the board of directors, officers, any employees with the title of vice president or higher, any finance employees who assist with SEC filings, legal department employees, any employees on the Companyâ€™s disclosure committee, and any other persons designated by the General Counsel as being subject to these procedures, as well as the immediate family and household, and controlled entities of such persons (â€œSenior Personnelâ€) to engage in any transaction in the Companyâ€™s securities (including the cashless exercise of any stock option that involves a market sale to generate cash to pay the exercise price or tax liability of such stock option, to the extent permitted, but excluding the exercise of a stock option and cash payment to the Company or the exercise of withholding by the Company of the exercise price or tax liability of a stock option) without first obtaining pre-clearance of the transaction from the General Counsel or Chief Financial Officer, or, if the transaction involves the Chief Financial Officer, from the General Counsel or if the transaction involves the General Counsel, from the Chief Financial Officer. The officer providing such pre-clearance is referred to herein as the â€œPre-Clearance Officer.â€ A request for pre-clearance should be submitted to the Pre-Clearance Officer at least two business days in advance of the proposed transaction. Normally, the Pre-Clearance Officer will clear, to the extent consistent with Company policy, any transaction that complies with this Insider Trading Policy and applicable securities law and occurs inside a period in which transactions are permitted (a â€œWindow Periodâ€). When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic information about the Company. The requestor, if subject to Section 16 of the Securities Exchange Act of 1934, as amended, should also indicate whether he or she has effected any non-exempt â€œopposite-wayâ€ transactions within the past six months. The requestor should also be prepared to comply with Section 16 of the Exchange Act and file Form 4 or Form 5 and SEC Rule 144 and file Form 144, if applicable, at the time of any sale.However, the Pre-Clearance Officer is under no obligation to approve, and may determine not to permit, any transaction submitted for pre-clearance, even if the transaction falls inside a â€œWindow Periodâ€. If pre-clearance is denied, such denial must be kept confidential by the person requesting pre-clearance. Unless otherwise provided, pre-clearance of a transaction is valid for three business days. If the transaction is not executed within that time, the person requesting pre-clearance must request pre-clearance again.â€‹â€‹Insider Trading and Disclosure of Confidential Information PolicyRev. August 1, 2024-3-â€‹â€‹â€‹â€‹Quarterly Permitted Period. The â€œWindow Periodâ€ shall include the period beginning two full business days following the release of the Companyâ€™s quarterly or annual financial results for the immediately preceding fiscal quarter or year and ending immediately preceding the 15th calendar day before the end of the then-current fiscal quarter. The release of quarterly or annual financial results invariably has the potential to have a material effect on the market for the Companyâ€™s securities. As such, a quarterly blackout period is imposed to avoid even the appearance of insider trading.Event-specific Blackout Period. From time to time, an event may occur that is material to the Company and is known by certain parties. So long as the event remains material and non-public, directors, officers, and such other persons as are designated by the Pre-Clearance Officer may not trade in the Companyâ€™s securities. The existence of an event-specific blackout will not be announced. If, however, a person whose trades are subject to pre-clearance requests permission to trade in the Companyâ€™s securities during an event-specific blackout, the Pre-Clearance Officer will inform the requester of the existence of a blackout period, without disclosing the reason for the blackout. Any person made aware of the existence of an event-specific blackout should not disclose the existence of the blackout to any other person. The failure of the Pre-Clearance Officer to designate a person as being subject to an event-specific blackout will not relieve that person of the obligation not to trade while aware of material non-public information. A person in possession of material, non-public information about the Company may not engage in any transaction involving the Companyâ€™s securities either outside or inside the Window Period.The foregoing procedures do not apply to the purchase or sale of securities in a â€œblindâ€ trust, mutual fund, â€œwrapâ€ account or similar arrangement, provided that there are no discussions with the trustee, money manager or other investment advisor who has discretion over the funds. Senior Personnel should consider asking their advisors to refrain from trading in Company securities to prevent any future misunderstanding or embarrassment. Further, the requirement for pre-clearance, the quarterly trading restrictions and event-driven trading restrictions do not apply to transactions conducted pursuant to approved Rule 10b5-1 plans, described under the heading â€œPrearranged Trading Plans.â€Employee Benefit Plan Blackout Periods. Section 306 of the Sarbanes-Oxley Act of 2002 and Regulation BTR prohibit executive officers and directors of a public company from directly or indirectly acquiring or disposing of any equity securities of a public company received in connection with such personâ€™s service or employment as a director or executive officer during an individual account plan â€œblackout period.â€ â€œIndividual account plansâ€ include 401(k) plans, profit sharing plans, stock bonus plans and money purchase pension plans sponsored by the Company. An individual account plan â€œblackout periodâ€ exists whenever the Company or any plan fiduciary temporarily suspends for more than three consecutive business days the ability of 50% or more of the plan participants or beneficiaries under all individual account plans maintained by the Company to acquire or dispose of any of the Companyâ€™s equity securities held in the plans. This Insider Trading Policy extends this prohibition to all Senior Personnel.4.Prearranged Trading Plans.Rule 10b5-1 under the Exchange Act provides an affirmative defense to insider trading allegations under federal law. In order to be eligible to rely on this defense, a person subject to thisâ€‹â€‹Insider Trading and Disclosure of Confidential Information PolicyRev. August 1, 2024-4-â€‹â€‹â€‹â€‹Insider Trading Policy must enter into a Rule 10b5-1 plan for transactions in Company securities that meets the conditions specified in the Rule (a â€œRule 10b5-1 Planâ€). If the plan meets the requirements of Rule 10b5-1, Company securities may be purchased or sold without regard to certain insider trading restrictions described in this Insider Trading Policy.To comply with the Policy, the adoption, modification or early termination of a Rule 10b5-1 Plan must be approved by the Pre-Clearance Officer, and all Rule 10b5-1 Plans must meet the requirements of Rule 10b5-1. Any Rule 10b5-1 Plan must be submitted for approval five business days prior to the entry into the Rule 10b5-1 Plan, and any proposed modifications or terminations thereof must be submitted for approval at least three business days prior to the consummation of such actions (or in each case such shorter period as shall be agreed by the Pre-Clearance Officer). No further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required.In addition, a Rule 10b5-1 Plan may be entered into or modified in any material respect only (i) at a time when the person entering into or modifying the plan is not aware of material nonpublic information about the Company or Company securities and (ii) in the case of Covered Senior Persons, during an open â€œWindow Period.â€ Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.Once a Rule 10b5-1 Plan is pre-cleared and is adopted or modified, it is subject to a â€œcooling-offâ€ period before execution of the first trade. The â€œcooling-offâ€ period for directors and officers subject to Section 16 of the Exchange Act ends on the later of: (1) 90 days following the Rule 10b5-1 Plan adoption or modification or (2) two business days following the disclosure in Form 10-Q or Form 10-K of the Companyâ€™s financial results for the fiscal quarter in which the Rule 10b5-1 Plan was adopted or modified (however, the cooling-off period will not exceed 120 days following plan adoption or modification). For all other individuals, a 30-day cooling-off period is required.A person may not enter into overlapping Rule 10b5-1 Plans (subject to certain exceptions) and may only enter into one single-trade Rule 10b5-1 Plan during any 12-month period (subject to certain exceptions). Directors and officers subject to Section 16 of the Exchange Act must include a representation in their Rule 10b5-1 Plan certifying that: (i) they are not aware of any material nonpublic information and (ii) they are adopting the Rule 10b5-1 Plan in good faith and not as part of a plan or scheme to evade the prohibitions in Rule 10b-5.All persons entering into a Rule 10b5-1 Plan must act in good faith with respect to that plan.5.Prohibition Against Short Selling.It violates this Insider Trading Policy for any person subject to this Insider Trading Policy to sell any equity security of the Company if such person either (a)Â does not own the security sold or (b)Â does not deliver the security against such sale within twenty days thereafter or does notâ€‹â€‹Insider Trading and Disclosure of Confidential Information PolicyRev. August 1, 2024-5-â€‹â€‹â€‹â€‹within five days after such sale deposit the security in the mails or other usual channels of transportation.6.Prohibition Against Trading in Derivatives.It violates this Insider Trading Policy for any Senior Personnel to purchase, sell or engage in any other transaction involving any derivative securities related to any equity securities of the Company. A â€œderivative securityâ€ includes any option, warrant, convertible security, stock appreciation right or similar security with an exercise or conversion price or other value

related to the value of any equity security of the Company. This prohibition does not, however, apply to any derivative security received pursuant to a Company compensatory or benefit plan, contract or arrangement.7.Annual Certification.All Senior Personnel of the Company are required to execute and deliver an annual statement to the Chief Financial Officer or General Counsel of the Company, certifying that such person has complied with this Insider Trading Policy at all times from the date hereof (or such lesser time as such person has been covered hereby).8.Implementation.The Board of Directors may adopt such reasonable procedures as it deems necessary or desirable in order to implement this Insider Trading Policy.Where appropriate for this Insider Trading Policy, references to the General Counsel may include an individual designated by the General Counsel to aid the General Counsel in the performance of his or her duties.*Â Â *Â Â *Â Â *If you have any doubt as to your responsibilities under these guidelines, please seek clarification and guidance from the Chief Financial Officer or the General Counsel of the Company at +1 (201) 329-7300 before you act. Do not try to resolve uncertainties on your own.The Company expects strict compliance with the foregoing policies by all persons subject to this Insider Trading Policy. Any failure to observe these guidelines may result in serious legal difficulties for you and the Company. Furthermore, any failure to follow this Insider Trading Policy will be considered a matter of extreme seriousness and may serve as a basis for termination of employment or service.â€‹Insider Trading and Disclosure of Confidential Information PolicyRev. August 1, 2024-6-â€‹â€‹ EX-21.1 6 pahc-20240630xex21d1.htm EX-21.1 EXHIBIT 21.1PHIBRO ANIMAL HEALTH CORPORATION LIST OF SUBSIDIARIESâ€‹SUBSIDIARY JURISDICTION 8861 Dice Road LLCâ€‹Californiaâ€‹First Dice Road Company, A California Limited Partnership California Western Magnesium Corp. California Phibro Animal Health Holdings, Inc. Delaware Prince Agri Products, Inc. Delaware Phibro-Tech, Inc. Delaware PhibroWood, LLCâ€‹Delawareâ€‹PMC Quincy, Inc.â€‹Illinoisâ€‹C P Chemicals, Inc. New Jersey Phibrochem, Inc. New Jersey OmniGen Research, LLC Oregon Phibro Animal Health de Argentina SRL Argentina Phibro Animal Health PTY Limited Australia Phibro Animal Health S.A. Belgium Phibro Saude Animal Internacional Ltda. Brazil Phibro Saude e Nutricao Animal Ltda.(1) Brazil Quimica Real Ltda.â€‹Brazilâ€‹Phibro Animal Health Ltd. Canada Phibro Animal Health Holdings, Inc. Chile Limitada Chile Phibro Animal Health (Shanghai) Co., Ltd.â€‹Chinaâ€‹Phibro Animal Health Colombia S.A.S. Colombia Phibro Animal Health de Republica Dominicana, SRL Dominican Republic Phibro Animal Health (Egypt) LLC Egypt Phibro Animal Health For Trading (Egypt) S.A.E.â€‹Egyptâ€‹Phibro Corporation Limited Hong Kong Phibro Animal Health Limited Ireland Abic Biological Laboratories Ltd. Israel Abic Veterinary Products Ltd. Israel Phibro Animal Health Ltd.(2) Israel Phibro Animal Nutrition Ltd.(3) Israel Phibro Israel Holdings Ltd.â€‹Israelâ€‹pHi-Tech Animal Health Technologies Ltd.(4) Israel Phibro Corporation (M)Â Sdn. Bhd. Malaysia PB Animal Health de Mexico S. de R.L. de C.V. Mexico PBAH Peruana S.A.C. Peru Phibro Animal Health (Philippines), Inc. PhilippinesPhibro Animal Health (Poland) sp. z.o.o. Poland Phibro Animal Health (Proprietary) Limited South Africa Phibro Animal Health (Thailand) Limited Thailand Phibro Hayvan Sagligi Urunleri Sanayi ve Ticaret A.S Turkey Ferro Metal and Chemical Corporation Ltd. United Kingdom Phibro Animal Health SRLâ€‹Uruguayâ€‹Phibro Animal Health de Venezuela, C.A. Venezuela California Water Technologies LLC(5) Michigan North Field Extension, LLC(5) New Jersey Marion Bio-Tech, LLC(5) Delaware Hannibal Bio-Tech, LLC(5) Delaware â€‹(1)Formerly known as Planalquimica Industrial Ltda.(2)Formerly known as Koffolk (1949) Ltd.(3)Formerly known as Agrozan Ltd.(4)Formerly known as Target Point-Technologies Ltd.(5)We directly or indirectly own 50% of the entity. EX-23.1 7 pahc-20240630xex23d1.htm EX-23.1 EXHIBIT 23.1CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMWe hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-198809) of Phibro Animal Health Corporation of our report dated AugustÂ 28, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K./s/ PricewaterhouseCoopers LLPFlorham Park, New JerseyAugust 28, 2024 EX-31.1 8 pahc-20240630xex31d1.htm EX-31.1 EXHIBIT 31.1CERTIFICATIONSI, Jack C. Bendheim, certify that:1.I have reviewed this Annual Report on Form 10-K for the year ended JuneÂ 30, 2024, of Phibro Animal Health Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Dated: AugustÂ 28, 2024 /s/ Jack C. Bendheimâ€‹â€‹â€‹Jack C. Bendheimâ€‹â€‹â€‹â€‹Chairman, President and Chief Executive Officerâ€‹â€‹ EX-31.2 9 pahc-20240630xex31d2.htm EX-31.2 EXHIBIT 31.2CERTIFICATIONSI, Glenn C. David, certify that:1.I have reviewed this Annual Report on Form 10-K for the year ended JuneÂ 30, 2024, of Phibro Animal Health Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Dated: AugustÂ 28, 2024 /s/ Glenn C. Davidâ€‹â€‹â€‹Glenn C. Davidâ€‹â€‹â€‹â€‹Chief Financial Officerâ€‹â€‹ EX-32.1 10 pahc-20240630xex32d1.htm EX-32.1 EXHIBIT 32.1CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this periodic report fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this periodic report fairly presents, in all material respects, the financial condition and results of operations of the issuer.â€‹â€‹â€‹â€‹â€‹Dated: AugustÂ 28, 2024â€‹/s/ Jack C. Bendheimâ€‹â€‹â€‹â€‹Jack C. Bendheimâ€‹â€‹â€‹â€‹Chairman, President and Chief Executive Officerâ€‹â€‹ EX-32.2 11 pahc-20240630xex32d2.htm EX-32.2 EXHIBIT 32.2CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this periodic report fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this periodic report fairly presents, in all material respects, the financial condition and results of operations of the issuer.â€‹â€‹â€‹â€‹â€‹â€‹Dated: AugustÂ 28, 2024â€‹/s/ Glenn C. Davidâ€‹â€‹â€‹â€‹Glenn C. Davidâ€‹â€‹â€‹â€‹Chief Financial Officerâ€‹â€‹ EX-97.1 12 pahc-20240630xex97d1.htm EX-97.1 â€‹Exhibit 97.1â€‹CLAWBACK POLICYPHIBRO ANIMAL HEALTH CORPORATIONPURPOSEPhibro Animal Health Corporation (the â€œCompanyâ€) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Companyâ€™s pay-for-performance compensation philosophy. The Companyâ€™s Board of Directors (the â€œBoardâ€) has therefore adopted this policy, which provides for the recoupment of certain executive compensation in the event that the Company is required to prepare an accounting restatement of its financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws (this â€œPolicyâ€). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), the rules promulgated thereunder, and the listing standards of the national securities exchange on which the Companyâ€™s securities are listed.ADMINISTRATIONThis Policy shall be administered by the Compensation Committee of the Board (the â€œCompensation Committeeâ€). Any determinations made by the Compensation Committee shall be final and binding on all affected individuals.COVERED EXECUTIVESThis Policy applies to the Companyâ€™s current and former executive officers (as determined by the Compensation Committee in accordance with Section 10D of the Exchange Act, the rules promulgated thereunder, and the listing standards of the national securities exchange on which the Companyâ€™s securities are listed) and such other senior executives or employees who may from time to time be deemed subject to this Policy by the Compensation Committee (collectively, the â€œCovered Executivesâ€). This Policy shall be binding and enforceable against all Covered Executives.RECOUPMENT; ACCOUNTING RESTATEMENTIn the event that the Company is required to prepare an accounting restatement of its financial statements due to the Companyâ€™s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement (i) to correct â€‹â€‹â€‹Clawback Policyâ€‹Last Revised: November 6, 2023â€‹â€‹â€‹â€‹an error in previously issued financial statements that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (each an â€œAccounting Restatementâ€), the Compensation Committee will reasonably promptly require reimbursement or forfeiture of the Overpayment (as defined below) received by any Covered Executive (x) after beginning service as a Covered Executive, (y) who served as a Covered Executive at any time during the performance period for the applicable Incentive-Based Compensation (as defined below), and (z) during the three (3) completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the Companyâ€™s fiscal year) within or immediately following those three (3) completed fiscal years.INCENTIVE-BASED COMPENSATIONFor purposes of this Policy, â€œIncentive-Based Compensationâ€ means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure, including, but not limited to: (i) non-equity incentive plan awards that are earned solely or in part by satisfying a financial reporting measure performance goal; (ii) bonuses paid from a bonus pool, where the size of the pool is determined solely or in part by satisfying a financial reporting measure performance goal; (iii) other cash awards based on satisfaction of a financial reporting measure performance goal; (iv) restricted stock, restricted stock units, stock options, stock appreciation rights, and performance share units that are granted or vest solely or in part based on satisfaction of a financial reporting measure performance goal; and (v) proceeds from the sale of shares acquired through an incentive plan that were granted or vested solely or in part based on satisfaction of a financial reporting measure performance goal.Compensation that would not be considered Incentive-Based Compensation includes, but is not limited to: (a) salaries; (b) bonuses paid solely based on satisfaction of subjective standards, such as demonstrating leadership, and/or completion of a specified employment period; (c) non-equity incentive plan awards earned solely based on satisfaction of strategic or operational measures; (d) wholly time-based equity awards; and (e) discretionary bonuses or other compensation that is not paid from a bonus pool that is determined by satisfying a financial reporting measure performance goal.A financial reporting measure is: (i) any measure that is determined and presented in accordance with the accounting principles used in preparing financial statements, or any measure derived wholly or in part from such measure, such as revenues, EBITDA, Adjusted EBITDA or net income or (ii) stock price and total shareholder return. Financial reporting measures include, but are not limited to: revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates); net assets or net asset value per share; earnings before interest, taxes, depreciation and amortization; funds from operations and adjusted funds from operations; liquidity measures (e.g., working capital, operating cash flow); return measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales is subject to an accounting restatement; revenue per user, or average revenue per user, where revenue is subject to an accounting restatement; cost per employee, where cost is subject to an accounting restatement; any of such financial reporting measures relative to a peer group, whereâ€‹Clawback Policyâ€‹Last Revised: November 6, 2023â€‹â€‹â€‹2â€‹â€‹the Companyâ€™s financial reporting measure is subject to an accounting restatement; and tax basis income.OVERPAYMENT: AMOUNT SUBJECT TO RECOVERYThe amount to be recovered will be the amount of Incentive-Based Compensation received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts, and must be computed without regard to any taxes paid (the â€œOverpaymentâ€). Incentive-Based Compensation is deemed received in the Companyâ€™s fiscal period during which the financial reporting measure specified in the incentive-based compensation award is attained, even if the vesting, payment or grant of the incentive-based compensation occurs after the end of that period.For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the exchange on which the Companyâ€™s securities are listed.METHOD OF RECOUPMENTThe Compensation Committee will determine, in its sole discretion, the method or methods for recouping any Overpayment hereunder which may include, without limitation:â—requiring reimbursement of cash Incentive-Based Compensation previously paid;â—seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards granted as Incentive-Based Compensation;â—offsetting any or all of the Overpayment from any compensation otherwise owed by the Company to the Covered Executive;â—cancelling outstanding vested or unvested equity awards; and/orâ—taking any other remedial or recovery action permitted by law, as determined by the Compensation Committee.LIMITATION ON RECOVERY; NO ADDITIONAL PAYMENTSThe right to recovery will be limited to Overpayments received during the three (3) completed fiscal years prior to the date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the Companyâ€™s fiscal year) within or immediately following those three (3) completed fiscal years. In no event shall the Company be required to award Covered Executives an additional payment if the restated or accurate financial results would have resulted in a higher Incentive-Based Compensation payment.â€‹Clawback Policyâ€‹Last Revised: November 6, 2023â€‹â€‹â€‹3â€‹â€‹NO INDEMNIFICATIONThe Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive-Based Compensation.INTERPRETATIONThe Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and the applicable rules or standards adopted by the Securities and Exchange Commission or any national securities

exchange on which the Companyâ€™s securities are listed.EFFECTIVE DATEThis Policy shall be effective as of the date it is adopted by the Board (the â€œEffective Dateâ€) and shall apply to Incentive-Based Compensation (including Incentive-Based Compensation pursuant to arrangements existing prior to the Effective Date). Notwithstanding the foregoing, this Policy shall only apply to Incentive-Based Compensation received (as determined pursuant to this Policy) on or after the effective date of NASDAQ Listing Rule 5608 (October 2, 2023).AMENDMENT; TERMINATIONThe Board may amend this Policy from time to time in its discretion. The Board may terminate this Policy at any time.OTHER RECOUPMENT RIGHTSThe Board intends that this Policy will be applied to the fullest extent of the law. The Compensation Committee may require that any employment or service agreement, cash-based bonus plan or program, equity award agreement, or similar agreement entered into on or after the adoption of this Policy shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, cash-based bonus plan or program, or similar agreement and any other legal remedies available to the Company.IMPRACTICABILITYThe Compensation Committee shall recover any Overpayment in accordance with this Policy except to the extent that the Compensation Committee determines such recovery would be impracticable because:â€‹Clawback Policyâ€‹Last Revised: November 6, 2023â€‹â€‹â€‹â€‹â€‹(A) The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered;(B) Recovery would violate home country law of the Company where that law was adopted prior to November 28, 2022; or(C) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.SUCCESSORSThis Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.Clawback Policyâ€‹Last Revised: November 6, 2023â€‹â€‹â€‹â€‹â€‹ GRAPHIC 13 pahc-20240630x10k009.jpg GRAPHIC begin 644 pahc-20240630x10k009.jpg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

[_XO^)G\4>(1I<;X@M_P"%\'A1_LCN>YKW>^F33M-GFVXC@B9[]#'"C.!^ M5.L;+.&UMHEAMX4"1QH,!5' %>2_&'X^:)X0T^]TNT9=3U62-HC'&_P"[MBR,$NWMZ"NK+LNE27+#WIO5ON_\ (YZM>C@X>TKRLOQ?H>1:5^V3CW=FF MG7,UXDX\JY9T#B(,#\XQ@D@%11ZE;S:%H:6K/EV5U:3 MX8@9/MBOD1MN/45[BG@X15*K4O4Z\MK=+VO_%O8=;
YK5E/%X7"N&'T5C7#YGFF%C^[PU%R[OF?X/3\#YY\-?!#X:O<+=^+?B" M^NW1.75'95)_WCDUSOC3X1_#ZPUZ>;2_$/FZ5,DKP16_S&&099(VSR5/"[A7 MU1_PS3X#_P"@;-_X$O\
XUQ>I_LXZ7J-YJ\MEI4NGV5E#+':1&8M)>3[3M8Y_M/RH#C'I]!7UQ>R^%OV22/-NYL<+GN3^@K.T*W MG^"6AVTMP%_X18P++=AR!)83;06.?XD)S[@]*\$B@UK]L;XI^?(MQ@^])D*
MJ";QF/FYUGO*71=%'R]/F7?A M-X"UC]I3X@3?$#QC&1X?MY,6EFV=DNT\(H_N#N>YK[(CC6*-410B*JC] M*J:+HUEX>TJUTW3K:.TLK6,10PQ#"HH' J[7FUZ[K2TTBMVE/7G+F?D%%%%< MQ
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A .,CITHQ2 MT4 (!T&/I2T44 %9VOZ)#XATN:PN'E2"; ?R7VL5!!*Y]#C!]C6C133:=T3 M**DG%[,R(_#&GPWEE<1VXB-G;O:PQH $6-
BN1C_@ KGI?@SX2N(KV&;1X98; MF4S;&'^J8]=A'*@GG'3=Q15JK..TF82PU&?Q03^7R/"-> _93TF64SZ#]=UI M,XY4%MR@_7@UA_V1\9/AK\MK=#Q'IZ= 6\QL?0 .^IKZ3I",UVQQU6UJEI+S
M7ZGE3R;#)\U!NF_[KM^&Q\XG]IV\MK:?3M?T.;2+]D*K,8RR@^I1L9T->!^ M)O"><C>-]6O\ 6])N[7PJ]UNC:PC=MI<1EV? QA'8;0HZ$U]W>+M/TN[T2Y_J M:5'JUM&I8V[0"5F/HH/>O
M0_9PBUF^T^Y-F^B#4;B0-:6I\Q;*(1,4WDYRQ M8+GMS@5Z.$Q&&5Y6Y'ZW1YU52^'UL')*C453;=6>ZWMIY>E_EY_P' / 'Q9US2 M6_L#QS)!?6+".YL+NZ;?
%G[GW@1M('!Z&NH_L3]I;>FIVNIA?\ II&V?S5: MF\._L[^*K.:\&F>()&U6V8!R"\<%_]5J$>L1K MT#LDN?S -:5)0G\DH/U5CMH9OB:-->WPTO56E_E;T.;_P"$_P#VBM''^E>&
M8;P#^Y$IS_WRU0WO[0/Q6CLY[36_AM)<6\R-'*BP2892,$<9[5U?_"\/B3X; M.-:\&"Y1>KQ1O&3^(W#]*M3?M6Z;=:7=V\NF7>C;JT3+%)*HDC23'RD]\ ^U_M9>QJ/7V,7Z/_ "9TQS[O2?NOS37_
/)O"7[67B'X>65'UH]_X7NIH8EWV4-X MSB6WC_NL6&64= 32>&=8^.GC75+[6]'TMK.XU15 U"X4(L<\ YZ MUW7@SXJ^&[2"XN=1N(KO7=0OQ'JU[>1;Q$+N_C_M9PHZ^=W9?*W+:-
M]V85I^R7XU\9R"Y\<>.9YG9YC_M /LJUYYXH\7^.;_5]1+Z,NDS74*-?6T$9"2 .-CNI)PV< '@FHIY?5D[5&E\ MT>9B,_HPCS44Y?\ ;K^6Y]7:@OA^3Q9IGVE8&UY$D:U./WJIC#\CHOUXS[UT M-
?)GA#5OBS/>ZK?:99037\TQ2\FGA0S(PZ(3G[-;I[>5& M*B> :=O:1^;+I9U[2/,Z,WVM'1]Y]%TA.*^=6?X[R#&Z%?<)$*3[+\=Y!_Q] M0IGVBX_2H^I?]/8_>;_VOVP]3_P'_@GM?_"
<:6(]9+2M&^E!WNH77#JJ@G<% M[]0.#WJ27QCIL5]IMGYK276H*)(8(UW.$QG>P_A7W-?*WC:P^);LH' :EY% M/J$%C,9C;>7O2V*G>)"H^Z0#@'OTJUX2T;XI/K\FG:I'::I)'&\BSM$))(@
MOR%2RG* =AP*ZO[/AR\WM%]_ /+6>5G5]G["6_;7[K[]-_/R/KL'(I:^^A7S%CF&WSDQDM&?X@.A]*\1_X0;XWX_P*1 MF7_O^O\ \37*^)O"'Q/DUK3+&\\0"_U4/Y\$44V9(!T,A('RKVZ\UI3P5.3L
MZL?Q_P CGKYO6A'FCAYKU2_S/HN+XBZ5/I^BW,)EFDUA4>UM43,Q1L?,5SPH M!Y-=4IXKXT\$V_Q%T2]L7TF>-)]0LHFM'N0C>;"!\L:,P[#^$&O01XZ^-.C? M\?7AZ"^](,Y_P"^6JJN
Y96IS7S9&&SMRCS5J4UZ1NOZ>Y]%9I:^=%_:-\9 M:2V-5\"2$?Q&,R)C\U:M&T_:VT8$]J.A:C9R]PNU@=S/(Z5SO+\1TC?T:9VQ MSS O24^7U37Z'O.:,BOG[5/VEM%35;,4]-
O[J2VP(KO2KF':"N?]9&W9QGD' M@CTQ6->?M+1_8KJRCOKCS+C4;DB^6(%K>TWGRPB\9?;@#/3J::R_$.WNDRSS M QO[ZT]/Z_K4^FLTM?.TW[4-]J 2#WPX4O-1(43W+')/J0@(_45$?%/QL\5
M\6>EQ:-$W\7DJI'XN2:/J%5?&U'U:&\[PTM**E-_W8M_CL?1I8#J:\\^(GB^ MWT%X-2L_$-G#<6:L)--FG4).!OO0K,\@ M'_!A:;?_LIVT-[86=O>7EV)27NK^4JD<*#'"H,DL<\9.!S6M.AAH2]^K?T6
MGWLYJ^,Q(J:#]EAFEW?<-EY"!U(4=:U+3]GBTTN[U2[L=.MWG MM+M7T^&_ FAN8?*0,D@.<9;=@XR#[5()X=M((](M2FEQ:2[QAFM415\ILKQ:1 WWE215(_P"^03^M?1FW% &Y_KBC_#I17RO
M^9Z']DRJ?Q\1.7SLOP/ESQ'^SSXCCAMQ=^(;S6=1NI!%&B[S&AZEG9CPH'YT MRX_9?NHYM6AL+V=;NSMX)+:X<;4N)&#>8H/;&%_.OJ;;FDV"K698A:)F3X?P M4G=I_>_Z_D?
+N@6'Q@\':7#=Z?+-JEESNM+KYI$(.",-SVX()S6]I7[4=QI M%TEGXM\.W.GR]&DB4@_7:W7\#7T)MJCJ^@:;K]JUMJ5C;WUNW6.XB5Q^HJ7B MZ=5_OJ2]5HRHY7B,-%?5<0U;I+WE_FCG/#/Q?
\)>*P@L=9MQ*W2&=O+?Z8-= M>]Q'$H9Y%520 2< D]*\?\2_LM^$=8+R:>;C19CR/L[;T'_6_H17GNN?!;X MD5*@,FL-+U@ZWHYP5MC(2/7%"3QR.ZHZLR# '.T^]?*GA/XF^+;(QOIV
ME:J(;+6(+673?MJUQLWO&XJ'DT+ (.F2PKZ5*^%K3PM8-!;M)/-*YEN+J=M MTL\AZNQJ?T%<^(PSPUE-ZOL=N!S!8^\J<;);W .*QM44E+7&>N?+?[9'_"&? M#/\ U[S?^A+11^V1_P AGPS_ -
>\W_H2T4 >X_!O_DE?A;_KPB_E7C'AE/$? MAO\ ;B;1=1\6ZEKNGZCX)N=5-G<$);02?V@D:".-1@;4^7)R3R2>:]G^#?\ MR2KPM_UX1_RKRY_V?O\GQ[@^);_ !"LC-#:-
I"V(T+M:TOQ!XT"75Y9_:;B=BO+$,R MJN> >N:[GQ/^RCK6ICQKX?T?QW)HWP_\9W,,&K=^X?,/NP0\:Y']M MK5[W2?!GAO['+-&9]2\MUA]>Q_"KX<:;\)/A_HOA+27EELM,A\H
M33G,DS$EGD8_WF8EC]:Y;X_?##4?B;I6B0::T*S6-Z;@F8X &QER/<9K*KS\ MC]F]3HH5:=&I[2M'FBKZ+KH[>FO7IN??%5XEW;68@-Y?_&I "7%TV]N2=I;/
M3GI7J_PM_:M@^&W@RVT/4],GO[^*21VGGN&0$,Q*CE&/ P*LWOP#UN/6M0TM M8HI[NVTU+[9&^6<,\BC![L2AX^E<5\?A_9?%+:Z_:$M]@OX]HE4< M':>H(/45Z>
H87%T7I*FXI%%4]WDKM_Z%_2N M&NOA9:>!)S;^,?!,TMKG'VRSF9./7<,J?TKI?#WPU^#?CW$>FZ]J6BWC=+>] ME4G/L2 #^=1B,GDES4\1*W?EC)?A8][@LO9V4)]I1U_%G._%+XG_ ! ^
M)?A2XTC4I-(>Q=TE,5G&0[%3D8)KBO#GA+37\)3><2I)Y^7EF'!CQVYZ8[_C M7L'BW]B^S\-Z'!?,:2[0(@7ZJ?RQUKB=%_9*\;:]X9FU.*[2.& M7=++#:3LR2W"C[K$'H6'0'VS7@5?Y^7TCS+$NBJ%.:
MA%-/W5;4Y;PQXC\%Z)]I>43QB%PJ+;Q;YK@8Y()P%';)/X5UFF_%[5;M_+\- M:/%H5L_RQN 9[R7W+DW/J_6W1'P^/QM7,Z\L-A9-O[&^&_@SX4UAH[SQCXGNI ^)'T^
MSLK@98\GS)"F3^&/J:]IT"T^$?AK2)].T^RC@AGC,4K_ &"RC BBVF\V+K5W>>!'T1M\W_ (EK0FW-J-/GV>7C M&W'E],5\DG5H?V=OBA<2Z8SZWX U<[+BVF@D0&)NJ$.HRZ9R#W'UK[WKFOB'
MX"TOXD^%;S0)6A$EO.IV/CYHG_A=3V(-&'KJFW&>L9;K]3NA/E9\4?%'P)HV MC7 \6?"_49+W3;Q=UQI(MI2
IY.W*X9?;.1VKCO#GC**2Y66S9K:=3E[9B\O!:QV&M8,LEK&=L=R>N5[!C^1KFK4'@G*'CST9[QZ-=UV:/1QM M'#YY3C1QLN2M'^'56Z\I]X_D~^&W[0U_IL,<6J]^IZ<,+YH_UL1^O?Z&O6YO
MCQX-CBB9=3:1G90R+!)E >YR,<=\$U\-^!O'NH>$=L:1]=_+<:5$]I9N5"P2MN9&(&1GTSG%?.XV.*RVC[?!2]K M1D[*]W*+[.WZGR+K8C UI8+,(\M6/W27\T7U3/3_ !_X^'Q.\20:=%<2V7AN
M&0!I_*=]WJY503]!BO4-)^)/@'P1H<-G!J)L[2$8!>TF7KB:SPV A[2KUZ1BN\GLDCTOX MR?M3W&J1RV.A2/IFF'*F<_Z^X^@_A'ZUYU\-_ARGC[4A>^+[^YT#05;=]F%M M,]Q=]^H4A0?7\O6O?
O@M^RE8>%)8M<\6M'K>N\,D+#,%L?8?Q'WKZ%(VIA<# MC]!7KU<3*K'V=-IA\'1P$;3E[;$?SM>[#RIQ?\ Z4]>R1XC M9^' (*V=K%
NC6;+&H4%],G9CCU)3TOR+0+SX5>%=16_TFQM]/O%4H)X--G5 M@#U&?+K9T7XBRZ3JLNA^,3;Z5J*IZEO>[MEM>1CNC'HP'52<]QQ7&/\ M2^% MCXHG#:W8VOAZSWO-
X9YKN7MY:J.$'/)ZJSCA9-^Y#;LCOEB,34334IMI^;/ M0O\ A;GA7_H(R_\ @%/_/$4?\+<]!&7_ , I_P#XBO*M: ;;\"V!9;&' M4-28<#;$$!_.UR_[9?B#6G,?AKP#=WK'[K.'?/X*M=4<%B'KRV]=#G5*?
8] M]_X6YX5_Z",O @%/_P#5S=E^T+X:36M0L-8DDTH1R$V=S)!*8[N+&=RG8"& M'=2./4UX_P#\)A^T9XV/?A:)#H%N_P!UWB6,C_OHD_I7(2?"/XI?%GQ3-H6M M^)?MEO8-NN[C>6@MI<8L8
R^"<@=!UK>&#BK^UFEZ.[*5-?:8_XR_%BX_:" M\;P>$] O)+7P?;2C[1>K"[++@\RLJC.T?PC')KZ.\ >(? 'PX\,6FAZ/=2Q6 MD"\LUE/OD;N['R^2:Y[X*>&+/X#W7_":(E:K'<5[I66)JII4J?P+;S\Q3E]E;"?
\ "W/"O_01E_\ *?_.(H_P"%N>%? M^@C+_P" 4_\ \178T5PB\)QW_MSPK_T$9?_"G_P#B*/\ A;GA7_H(R_\ M@%/_/$5V-% ''?\+<*_P#01E_\ I__(BC_A;GA7_H(R_^ 4__,178T4
M<=_PMSPK_P!!&7_P"G_^(X6YX5_P"@C+_X!3__!%=C10!QW_"W/"O_01E M_P# *?\ ^(H_X6YX5_Z",O\ X!3_/Q%=C10!QW_MSPK_T$9?_"G_P#B M*/\ A;GA7_H(R_\ @%/_/$5V-% ''?\+
<* P#01E_\ KC_.(H_P"%N>%3 M_P Q&7_P"G_^(KD?VA/CI%\(-(B@MH#^%?[3 M/B/P5XIGO-9NI]:TR^DWW<$C9*$_QQ^F/3I7L8;*\1B:+K06G3S]#S*^84:%
M54I?/R/L_P#X6YX5_P"@C+_X!3__!%'_"W/"O\ T$9?_*?_P"(KH=!UBV\ M0Z/9ZG:,S6MW$LT9=2IVD9&0>E:%>0TT[,]).ZNCCO\ A;GA7_H(R_\ @%/_M /$4?\+<*_]!&7_ ,
I_P#XBNQHI#._P"%N>%?^@C+_P" 4_\ \11_PMSP MK_T$9?\ P"G_/B*[&B@#CO^%N>%?^@C+_X!3_\ Q%'_MSPK_T$9?_"G_P#B*[&B@#CO^%N>%?\ H(R_^ 4__P 11_PMSPK_-!&7_P"G_\
B*[&B@#C MO^%N>%?^@C+_. 4_P#\11_PMSPK_P!!&7_P"G_^(KL:*_P"%N>%?^@C+_M_P" 4_\ \11_PMSPK_T$9?\ P"G_/B*[&B@#CO^%N>%?^@C+_X!3_\ Q%'_M MSPK_T$9?_"G_P#B*
[&B@#CO^%N>%?\ H(R_^ 4__P 11_PMSPK_-!& M7_P"G_\ B*[&B@#CC\6_"AZZA+_X!7'_,11_P +;*?]!"7_P KC_XBNQH MH XX?%KPH#_R$)?_ "N/_B*/^%M^%?^@A+_ .5Q_\ $5V-%
'''XM^%#_S M$)? !G_P#B*Q-;\9?#O4K:5[NWCOB%)V7*6;V&8^M>P4546XNZ(G",U: M2N?).H>&/!WB&X@U*>WETH75VD?]G6MK,#:VV&R[G9@OG;TR!TYKHO!&E#K M3C-
I^LZ6+B6V_P!7J8LIS'=)V)7;E7'<8QZ5]*45VRQM:4>6^GJ>/#)\+3G[M113?6Z6O]>6WH>56>]J"VPQY%E;1D=_[+F/_+3K9M_B)X&M,>3(D./[FFS#
M^4==Y17&YRENSUHT:9MXP\$#Q$FM17]Q M;WNPQRF*SN%69>V\>7SCL:V_^%N>%?\ H(R_^ 4__P 178T4FV]RHPC"_*K7 M.._X6YX5_P"@C+_X!3__!%!^+?A4_\ ,0E_\ I__B*[&BD6>:Q^+?
$<.J1 M>>[+J9?[66LK@M*&!!!.S.,' :GW/C/P'PP+>5;*X#(,8VYV< MCVKT>BKYY=S+V5/;E7]:_F<%?^@C+_P" 4_\ \178T4_<=_PMSPK_-!&7_P"G_\ B*/%%N>%?^@C+_X! M3_\
Q%=C10!QW_"W/"O_$$9?_*?_XBC_A;GA7_*"_O_@%/_\ $5V-% '' M?\+<*_]!&7_ , I_P#XBLOQ'\3-#U/21;_3]=DT^>0JIN/[/G9E3/S;?DZX_MS@[]]%HIIV=R914DXOJ>4>'?"WA'Q)]B?
V;*;NUMK&6VN+>>UD5Y6E=&\TR. M!ELQ^YY[5W7A71;WP_:2V=QJ#:C;H_\ HKRK\2/'"LW\1'//IBMVBM)59S5 MI.YSPPU*E+F@K,****R.H^6_VR/^0SX9_P"O>;_T):*/VR/^0SX9_P"O>;_T M):*
/$7^][.@ HHHH **** .)M1G MXT:I_P!B_:?^E-S7AO[2OPEO_"6NQ?$[PF67M+^UD66^B@'0C_EJ!W!Z,.AZ^ MM>Y6O_):=3_[%^T_]*;FNRG@CN87BE19(W4JR,,A@>H(KKPN)EA:G/'5=5W7
M8YL10CB(%>//#FK?LK?$Z#Q9X?B:?PGJ+E9K4$[5R M;"%+&Q>'QD$Y1[_)H^:O%'PG^(_@[2+FQL[UO$>@/@M;!BQ7!R MK!#RI! .5/;*Q-6^.?BS4H-,TM89;3Q%"DED\H&&D\S: =O9^,9]\C%?
6OB M!=2;2YDTAH$OFPJ/<9V)DX+8'4@9('F^7!5)*+M=-W6_1[Z;^11^"?P M4A\!6W]K:H1=^(;D9>1OF$ /55/KZFO6@,5@>$M.U;2)K+4KM+Z"%@MI<' M(E:/'23MD=,CK705Y-
>I*K4&H1ITX\J7WW\^X4445@=P44F:6@ M#RO]H'X*6?QA\)-$@6WUVR!DL;K'?O&W^RWZ'!KS?]EOXUW;32?#KQ>[0:[I MQ,-I)E>CAZD:D?J]79[/L_P#(V@TUR2-_]I7X(:)XU\+WWB5%&G^(M-
)MWN8[R) ?-" MLD'\0XX/4?I7Q=H&O336_F71$3CYA(.-P'.<>U?8GPP^+ MS?'?X0:]I6Q/^$MAL);;>T+!1,Q0JL@ST#'@^A_"OFEOV7_BTTKR'PR,LACQ M]MM\ 'L/GKS_&D\MQ+?*W?1JUT_-
H>A4RREGN!>#Q,I.TH^42)]; MZ+M?55OAQV]8^-OC*30+*Y2]Z[+[1=W,G+F/-OASXNU2[\3:2+"SDL#!#(;B M*8CEU0C$XP#7U(S!%+,0 !DDUESRQ$O;5+MOOT\DC/$4Z>706783E5.(
RKW4&O!C[^S?XW9O$GA;;IOBJ#$@$;>6MR1T MR1T?T;Z9]1F_3]H^75;X>#?' .F>)+=O)CGN/D$[#C8V>C_ ,YQ6PU/$0> M(PG3XH]5YKNBJ5>=":H8CY/O_P $^CJ*0'-+7C'JA1104 4444
%%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444
%%%% 'RW^V1_R&?#/_7O- P"A+11^V1_R&?#/_7O- P"A M+10![C\&O^25^%O^O"+^5=G7&?!K_KPB_E79T %%%% !1110!Q-K_R M6G4_^Q?M/_Z7FYKMJXFU_Y+3J?
_8OVG_I3H/9@>Q!Y!KY\ ^)-5_97^)T_A3Q!)))X3U&?7! M?BJ$IVJTOCCMY^1WMM<1W<"30NLD4BAE=3D,"@BI:^6?V:/BW?^%];F^&/C M)C;WUI(8K"68X/'_"R)/4=U/OCTKZE'-
<^*PTL+4<):KH^Z[F^'KQQ$.=;] M5V8M%%17-U#9PM+/*D,2C+/(P4 >Y-[T+]/RS7EMQ_PNC]HJ-XC&OA; MPU<@J4(,2/&?4GYWX_ ^E>K1RZI)*I6?)#N]/N6YYU7&PB^2E[TNR_4Y_P") M?
[7'B#5_%$_AB8Z=HUC+F.-U!-UZF0>A*]\ ?M2>#/$^@6]JQF1OZJ]. ML]K<$C:PZE3W!KPGQ3^Q;XCTO4]*M]$U"/5K2YPESOB_]*E",6_\ MW?YW/+P MW]H*1)R7W[?*QZ!;?
&?P/=X\KQ1IK9]9P/YUJ6_CSPU>C$.OZ7+GL+N,G\LU MY)=?L6_#V;/E?VI;?[EWG'Y@UD77[#7A!LFVUW6X&]Y(F'_H _G7D^RR][59 M+_MW_)GI>TQJWII_,X/VX>"[CX+>.[?XE^
IXSI[RYO;6VD#)&6/S @?\LW_ M $./:O3M2_;&\(V7A_0KZ!)KZYO]IN+2+AK09P^[/<$<#O7*WW["EK+&R6_C M2\C4_P_UF)!^CK7S1\4_A3KGP:\2-IVJ()K>7+6UW&/WGZ)!JFT<@^QKY)^-?[4VN?
$^XFT/PIX-F:'(WE_NO\ 7W0]\<@'T'XT_P"!W[*. ML?$62VUGQ+YND>'SB18L8GN1V"C^%3_>/X#O7V;X4^C7A;P1 D6BZ'9V&U0I MD2(&1OJQY/XFN!0!X*I[MYM?
<=2]I"GK;G^]+_,^)OA%X'^)^CQ-+X7\,C3[MV8$-JU[%E53V4O]T?0,'$R77COQK--D[OL\3M+M^F<*/P%?5H M4 8 Q145,VJN7-2BHOO:[^]GG/!*H[UYN?J]/N1\G?$3]BJ*WT>VD\'WCR7T
M;!9H;U^>)5)^\"!P1Z5R?@>YU+]DWXI-9>)+.&ZTC4T6/^TXH^0F?O(>O!/S+ M]/:OMW&:Y+XG?#32/BEX7N-&U6(8(W07 'SP28X=?\.XJZ6:UX)KV.*?-![_ M7Y&%&3+H1?M6J?
='=AL0L1':TENNS)****X3K"BBB@ HHHH **** "BBFLZHI M9B% Y)+ #J^<_P!I_P#:#O/ !_X1G0HY8-8N(?,DOF7"Q1MTV9ZMUY[5H_%[M]JK2/!SRZ1X:B7Q#XA)\M5CRT,3?
[1'WC_LC\Q7G.@_LW^-/C5>3>)/B'K$^ MFR2Q$6T"J&E0G.WY.B("<[>I]NM>]@L+"BUB,;I#HGN_EV/&Q6(E53H87675 MK9?,\:\-_&_QUH&A7&@:7K-P8KV7Y6;,DR,QYV,' M6?
%4I\I2S)B9DN,M"K'GD'ES_O5-\"/V7;3X;WK:SK\D.JZXKD6WEC]S;KT# M#/5SZ]N@]:]^'2M\QS&#DZ>#T3W:TN98+ R24\3JULGT&PPJ;Q+'&BQQJ,*J MC]*?117S1[P4444
%>,_'O]GC3_BM9MJ5AY>G>)H$S%=*,";'17Q^C=1Q MVKV:BMJ-!AYJI3=FC&K2A0X35T?+GP6 .;$U'POK\ P@OQ(WV6H6Q$,%_< M<$^BN>^>S=Z^H4=74,I#*1D$=#7F?QL^!>C_
!@T8B7%EK<"'[J"+EE/96] M5)[=NU>+?"CXU:[\&/$ \"?$A94M(R$M-0<$^4O09;^*,]CU'\O6J4:>.BZV M&5IKXH_K' (\Z%6>#DJ5=WCTE^C_ ,SZWHKDO#?Q4\,>+=?OM&TK5K>\0[,
MR1QMU'JI_BQWQ76=:\;<)0=IJS/5C.,U>+N+1114%!1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110!M_MD?AGPS_U[S?^A+11^V1_R&?#/_7O- Z$M% 'N/P:_P"2 M5^%O^O"+^5=G7&?!K_DE?A;_*\(OY5V= !1110 4444 <3:_P#):=3_.Q?
MM/\ TIN:[:N)M?\ DM.I_P#8OVG_*4W-=M0 4444 >"?M._]O'&EKXET&/ MRO$VF+Y@,?RM<(O._WAC(_*O.O_P"VM-9VNA6&O:6TRQJ8=0OT;YS@X5U7 MZ?>'Y5].?
$/P>/'O@_4]#:]GT\7D6S[1;MAE/4?4'H1W&:_/CQ^%O%7ACQO M'X?73)KJJG?%J*DQSKG[P/8>N>E?699[#&470Q3OR[=&EUU/F\?[;#555PZ MMS;^;]#Z5\;?MFZ8DO\
9_@G2KC7]1D.R.5XV6,L>F$'S-]."YRW^#_Q;^-L MB7/C76'\Z5*=WV(<-M]/+7@?\" *O6_V?\ X%6WPCT.22Z:.[UR\(>>;:" (ML#[B'KCGD]Z]='%>?
4QE'"R<,%%:?:>K^71'9##5<0E+%2_[=6B^9YC\OV= M?!?P\6-[735OKY!S=WH$CD^H!X'X5Z<% %+17D5*M2M+FJ2N_,]2G3A2 M7+!60F*6BBLC0**** (;QI4M9F@C$LX0E$9MH9L<
GM7GFE?">+Q!Y'1>.HX M-Y! @*YM[-,Y$<0/IQENI->DT5<9RA\([V.+\$^&]9\'ZC22[R@<@]1C'-=I112E)R=V#=PHHHJ1!1110!Y[\9?@_IGQ=\,M,26-
TJPZA$"UG>8^:)_0^JGN*\/^!7Q=U7X5^)V^&GC[=:>5((:*\E;Y4S]U M=%=&XVGMT^GUE7E'Q\^!MA\7?#*Y)4MO$%JI:TN^F[_IF_J|.0UZN$Q.'!X; M$? ^O\K[K]3S<30DI?
6*'QK\5V_R/5@<@I]#W%?38.17)B<-/"U.2?R?1KNCIH5XXB'-YKL+1117 M*=(444F: %HKR7XZ?'[3/A)IIMH3'?>(9U)@L\Y"?[;^@]N]>(6?[:&OW7A2
M'3H='2[\6S/Y_ N%R0W^P/X1^M>KXI:*\FK6J5Y MN=1W9Z5.E^C'D@K(****Q-0HHHH **** "BBB@ KYX_:+\(:IX@\#6EYIND1 M7\=A*9;JX1"UQ#%CJH'5>
[>F.],U]#TUU#]58!E(P0>AKIPU=X:M&K%7L85Z M*KTY4WU/RN\,W^]Z5KUA<:$UPFK+*HMA: M(SDX"@#DYZ8[U]06G[7GB[PS! M##XH\W45DEMBQ]<,[Y[]]V*_!'PCX-
\6W_B+2],6'4;LY&3E(.CYO M+&/ESW_H.*[MD5U(8!@>"#7O8S- MU8$7FAZ?%:%2>IA!C/_(Z17G^TR^?Q4Y1] M&G^9V\F-CM.+]5:\BQ8_'GX>ZE TL'C#2 JJ6VS72Q/CV5\$_3%>6Z3^V=H%
M]X^23)[5[7PXY$4&J/G=OSIYU(?S'4^T_CC]C+PEJ.D7+>'2M&E:H!NAWS& M2$G^ZP/.#ZYKY:TKX,>*]5\=MX372Y8M3C?$S2*1'&G _#T+=-N.GK7J8/!Y M=7C.7.]%UTMY^C?^*Q..I2BN5?
+6_D?I/#>07$:R1S1NC#:-+7/V;XC7?L#+*/_9]\OZKA M'MB%_P" L]#ZQB5O1_%'U1D>M&:^5O\ AFIX]6A_T:XB3"3-Q*/ZU#=?!?X MY:?;RO!XZ>Z*J2(Q=-EO89%'U*@]L1'\0^MU5O1?
X'N.N?"PCX>\=VOA.]U M-(]4GP">L<3G[J.W12W;/MGK7? @C@YK\]=7T_4K76[FUU**X75?.*S1S F4 MR$\Y[DD_G7TMX5OOVA_#'A^PCM-.&HV:O*8H[Q%DE5,9 8[@>!ZFO1Q631HQ M@Z=17?
=VOYHXI]@^5\I_\+Y^-6BG_(FG@ 7&.ODP._] M\EJE3]K_.36)_XFGP]O(<==H<8_-:\W^R\2_AL_22_S.[^T*"^*Z]4SZGI. M@=Z^9;?]MW2DQ]N\,ZC:^N"#C\Z\E^(/[5GB?
O#XSM=2T*>32=+L7S;V9.1- MZF4=\CC':M:63XNI+E<;>:(J9GAX1NG<^],TM>6IY\MB#@@]P<''TKT>O)TIT9NG45FCTJ=2-6*G!W3"BBBLC0**** "B MBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHI#Q0 M%8UQXQT6U\00:'-[59O]\Z&2.S9Q MYC*.X%;--IK>\^//@#XF^#FL-
X^&5S.]M&2\^E@EG5>X_C7VZBN]U*.9:5? MG<^M!2UKK$_VEM&^)]I29]31_$B_*;60X6 M8CJ8R>_^R>?K7M((->36H5,/-TZJLSTJ5:%;//3=T+1116!L%%%% !1110 4 M444 %%%%)D4
+17B7Q]_:+L/A;;MI>F-'?^)9!D0YRELI_BD]_1:N_;IH'3? MBSIPL[IH['Q' N9K0G E_CC]1ZCJ*[7@JZH?6,7W?ZU]#D^MT75]CS>\>P4 M4F:,UQ'6+1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !116 M1XF\6:1X.TR34-9U"#3[1.LD[XR?0#]3[*FDY.T5=B;45=FO7FGQX=V*_]_P M/?7UI-9OK! 2VMIY0"23@L%ZM@+ M+?[P7HH]V_2K7@?]DF[UN]37/B3JTVKZA(=
[V22EE!ZX9^_T'%>U3P4,/IC M967\N[?RZ'E3O%5_/HO\SY-O_%.K;KSZW<;S>=X;.00>V M.V*_03]GOQ?XF\9?#RTOO%%B;:[!V17##:UU&!Q(5[$_D>]HK.N?V7_!$_C2S MU]-/$$=NHSIT?
$$CKC:Q'MCIWKUR.-8D5$4*JC & !71F>8T.73A"E"UNO; MR1C@,%5PTY2G+3_?1117SA[A\M_MD?\AGPS_U[S?\ H2T4?MD?\AGPS_U[MS?\ H2T4 >X_!K_DE?A;_KPB_E79UQGP:_Y)7X6_Z\
(OY5V=_'PW\4?AK\(_MO&WQ1^)_CCX1^_B#X2GU1-8_M:>2&6_L+1((48)%(O(5D9\S76^$O"7A+ M]HF[]IKXMR^-+=M/%>DZ-H^6OVAZ=]LO2EAM+>[MY9I9HXVX221MO[P88;_1B
MO6O&/[-.@>/[R_7Q!KGB74]#OYO.N?#\V]OJ@EYSL,?79D#Y,[?:I?&O[-WA MGQ?XK?Q);7VL^&-9FL$TNZN?#U^UH;]V0G9('%X,W<=I&" >#0!@_L2WIY>?
ML[:##=W4MZMA=7VG6MQ.Y=Y+;"ZEBA)8]?D11GVKVO5+Y]L9+B.UEO'7&(8 M -[<]LUG>"?!FC_#OPIIGAO0+-;#1]-A6"VMT).U1ZD\DGJ2>]-:E 'DMMXM MNQ\6]1N/^$>U(NVAVT?
D;5W@">><[NO0YQ^!KKO\ A-KW_H6-5_[Y3_&]MK_R_M6G4_^Q?M/_2FYKMJ_3_.$VO?\ H6-5_P"^7A_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_*%C5?\ OE\:/\ A-KW_H6-5_[Y3_&\NLHH Y/\ X3:]_P"A8U7_+Y3_&C_
(3:]_Z%C5?^^4_QKK** .3_.$VO?\ MH6-5_P"^4_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_*%C5?\ OE\:/\ A-KW_H6-5_[Y3_&\NLHH Y/\ X3:]_P"A8U7_+Y3_&C_
(3:]_Z%C5?^^4_QKK** .3_.$VO?\ MH6-5_P"^4_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_*%C5?\ OE\:/\ MA-KW_H6-5_[Y3_&\NLHH Y/\ X3:]_P"A8U7_+Y3_&C_(3:]_Z%C5?^^4_QKK**
.3_.$VO?\ H6-5_P"^4_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_M *%C5?\ OE\:/\ A-KW_H6-5_[Y3_&\NLHH Y/\ X3:]_P"A8U7_+Y3_&L7 MQ?+:_=*N=(UCP=]=W93CYE94RI[.ISP1V-
>C4549.+4HNS0FE)6>QYUX1GM M_^A6VD:/X-U*SLK=<*BJN6/=F.>2>Y-:/\ PFU[_P!"QJO_'RG^-=911*3 MDW*3NP2459:')_\ ";?O_0L:K_WRG^-'_";?O_0L:K_WRG^-=914C.3_.$V MO?\ H6-

5_P"^4_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_*%C5?\ OE/\ M:/\ A-KW_H6-5_[Y3_&NLHH Y/\ X3:]_P"A8U7_+Y3_&C_(3:]_Z%C5?^ M^4_QKK** .3_ .$VO?\ H6-5_P"^4_QH_P"$VO?
^A8U7_OE/\:ZRB@#D_P#A M-KW_*%C5?\ OE/\:/\ A-KW_H6-5_[Y3_&NLHH Y/\ X3:]_P"A8U7_+Y3 M_&C_(3:]_Z%C5?^^4_QKK** .3_ .$VO?\ H6-5_P"^4_QH_P"$VO?^A8U7
M_OE/\:ZRB@#D_P#A-KW_*%C5?\ OE/\:/\ A-KW_H6-5_[Y3_&NLHH Y/\ MX3:]_P"A8U7_+Y3_&C_(3:]_Z%C5?^^4_QKK** .3_ .$VO?\ H6-5_P"^ M4_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_
*%C5?\ OE/\:/\ A-KW_H6- M5_[Y3_&NLHH Y/\ X3:]_P"A8U7_+Y3_&C_(3:]_Z%C5?^^4_QKK** .3_ M .$VO?\ H6-5_P"^4_QH_P"$VO?^A8U7_OE/\:ZRB@#D_P#A-KW_*%C5?\ MOE/\:/\ A-KW_H6-
5_[Y3_&NLHH Y/\ X3:]_P"A8U7_+Y3_&C_(3:]_Z% MC5?^^4_QKK** .3_ .$VO?\ H6-5_P"^4_QH_P"$VO?^A8U7_OE/\:ZRB@#D M_P#A-KW_*%C5?\ OE/\:#XUO3_S+&J_]\K_(UUE%
'S!\:O@O!\0II=:T/ MPWJ>B>)0?,\Z-56.=AW;!X;_&A61X%_:8\1?#"\'AGXFZ;=O-H-[C]ZPZ M#=V8?[7YU];5PWQ<^'>@^/?"=['K&E2:B]O"\D!M0!96PKA)UL.^677L_4CB^+5O-
9V=VFD7C6UXP6WE#Q[96/0 M*=W)]JT?^$WO?^A8U7_OE/\ &OS4GU+4K9(K%[J[BALIF:"VED8>0V><#C#< M#/3I7T/X"_:@^)TGAZ&ULO"X\4-;?NCJ!AE=F] VPX)QWKT,1D52E%2IR3]=
M/0XZ.;PJ/EG%KTU/J3_A-KW_*%C5?\ OE/\:/\ A-KW_H6-5_[Y3_&OGW_A M?WQPNO\ 4_#J.,'H387']7H_X6Y^T!<_ZOP7%%];)A_-J_^RZRWE%?]O([/ M[0I=(R^YGT%_PFU[_P!"QJO_
'RG^-8/C#XX6'@+3EOM=TC4+"W=MB%PN6/H M!G)KQH^.?VC[D?N_#L,7_;M&/YM7A'QHU+QS?^*$_P"$\2:'45B'E0NH6-4] M4 X^N*Z\+E'M:JC.I&WD[LYL1F7LX-
P@[^:LC[ML/BBNIZ7%J5MH=_-82H)$ MN%*;"I[YW5R/B#]JCPGX9=L:9 +'OZ5]*>&/V// .A%'O(;O6YAU>]FPI_X"N!45L'@\ M)4<*U5M]DOS>Q=+%8G$P4J4$EW;_
$.9UK]MG3;AA;>&/#=_JUXWW1(-H_(9 M)_*L&^^('Q^\@[00JI M_/%;6!6'UO#4OX-%>LG?\-C7ZM7J?Q:K]%H?GEXM_9_^(%M8W.O:C8W6HWDC MO/>';N<9Y+9_B.<]*M^$?
V=?'DUA!K5I%?:/J"D26IC!1\8^]N!!4^U?H$5! M!!&0: H%=#SO$NGR67W=.UMC%9304^;7^NMSX_TF?]HWPTH 2;5(4Z+=K'(2 M/KP?UK53]ISXC^%&V^)O
,LD:_>E@1T_'H17U93'B24$.BN#V89%NOYGSIIO[;_A">$?;=+U*RF'#)M5\'Z@T[Q%^VEX8M MM!FGTBSNKK4&4K!%* J[O5N>!7L>O_"[PEXG#%?VGX>T^[8_QO N[\QS7S=\? M/V3X=/LFU[P-
:LL<*DW6E*2Q(_OQD\\=U_*NG#K+J]6,9)Q^=U]^YA7>.HTV MXM2^6IV?P?\ VK(?&\4&E:EI(B#\EKC9,!W7)Z^WM7K?_F][_T+&J_] M\I_C7QS\'_V5_$'Q%TMM9N]2]2PPO:$9M)&@,DLIS]
[;N7:OOGGTKT1OV9/BGH M6?[$^(^]!T62:>'/X#>E_N/H+_M (3>]_Z%C5?^^4_QH_X3:]_Z%C5?^^4_QKY_P"$+_:,T$9M]>AU%%[?:$?/ M_?2@TG_";_M&:$/W_A^'4%7O]F1_P#?#?
UQ_P!G]_Z%C5?^^4_QJM8_$EM321K30=0N5C9_"#XT:U\(]>%U:N]WID M[@WE@[?+*.[#T?T/YUV0R.O.E*?,K]$M;_,Y9YM2C44.W5]OD??'_";7O\ MT+&J_P#?*_XT)M>\
0L:K_P!\I_C7GFD_MA?#K40HEO;NP<]1IS'_";7O_$+&J_\ ?*?XT?\ ";7O_0L: MK_WRG^-9O@GXW^$?B!KNH:1H^IK/>6C$;7&T3*.K1G^(_]Q77:CKVG:1$TM] M?6]I&O+--*%_,U:+NC#_P"$VO?
^A8U7_OE/\:/^$VO? M^A8U7_OE/\:YK7OVE_AUX?WB7Q'!=.O\%F#,3^*\?K7G>M_MO:#&6CT'P[J]> MLS= 9"($/Y!C^E==/ 8JK\--E^9SSQF'I_%-?G^1[0_CF[C4LWAG5%4#))" M ?G7
6G[6/A&\UFXTQ(;H7$&[Q&?^ @9KYRTK0K_7=6@TNQM);G4)Y/*2W13O+>F.WO M7N83)HSC)UYI-=FG;S9Y&)S24915&.GFM_0^N?%W[8W]J,FE>!-#N=2U>8E% M>9,JI]E'+?RKC=/^"GC?
XC^(/[9^),>KW48P8[6VVGCKM'.$'T&:]_\ @'\(M(/AAX,LXKVSLO[?D4M=7,"98Y.0I8]<#CC_G7J]=>?/&4\->G@XV_O;M^G8[M886>(M/%._\ =V2]>YYIX.AT_P
Z4FGZ%X&O]/MQRWEQIND/JS9RQ^M;_\ MPFU[_P!"QJO_'RG^-=917C2DYMRD[MGJ1BHJT59&/H>O3ZO)*LVDWFG! "& MN0 &]A@UL445)04444 ?+?[9'_(9\,_]>\W_*$M%'[9'_(9\,_]>\W_*$M
M% 'N/P:_Y)7X6_Z\(OY5V=<9\&O^25^%O^O"+^5=G0 4444 %%%% '$VO_): M=3_[%^T_]*;FNVKB;7_DM.I_]B_:?^E-S7;4 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !2'FEHH \5^+'[+^@?
$S7[75XYFTF[,H-Z8%&+ ME._T;_:KU/PMX5TSP9HEOI.D6J6EE ,+&@Z^I)[D^M:]%=$\15J0C3G)N*V1 MA"A3IS=2,;-A28I:*YS<*Y/XA_##0/B=IB66NV8G2-MT^&ZC/>NLH
MJX3E3DI0=FB91C-.,E=&=H/A_3_#&DV^FZ9:QV=E;KLCBC& !_C6C114MMN[M&DDK(****0PHHHH **** "DI:* $ & ,"EHHH **** ,+QGX,TKQYH,^CZQ M:K=6W5\%\07Z,)T*4YJI*-VC@-3^
O@+6 ?M'AFR!/4QIL/Z5QNK_M +'GP\U(,8;2ZL7/0P3G__U[C15PQF(I_#4:^9$L+0G\4%]Q\OWG[$=O92- M)H'B[4-.D/(WKT_%2#7%_$KX&?%'P9X0OID\477B'2%7_2;6*5]_E]VVDG(' M?
FOM2D*AA@\CTKMAFV)C).;4DNZ1RSRV@TU!./HV?EMX(TC7-=\3V%EX:$YU MB1\0-;,59>.6+#H .I]*^I=)_8MEU9HKGQ=XMO=1N" S1PDD]QNZOE'4Q%:K_$FW\SUH4*5/X(I?(0BN
M[&);E4&X^N/0GN1UKI**Q4I1NHNUS5Q4K-K8****DH**** "BBB@ HHHH ^6 M_P!LC_D,^&?^O>;_-"6BC]LC_D,^&?^O>;_-"6B@#W'X-?\DK\+?\ 7A%_ M*NSKC/@U_P DK\+?]>$7\J[.@
HHHH **** .)M?^2TZG_V+]I_Z4W-=M7$V MO_):=3_[%^T_]*;FNVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** /EO M]LC_)#/AG_KWF_]"6BC]LC_)#/AG_KWF_]"6B@#W'X-?\ )*_"W_7A%_*N MSKC/@U_R2OPM_P!>$7\J[.@ HHHH **** .)M?\ DM.I_P#8OVG_*4W-
=M7 M$VO_"6G4_\ L7[3_P!*;FNVH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /EO\ ;(_Y#/AG_KWF_P#0EHH_;(_Y#/AG_KWF_P#0EHH]Q^#7_)*_"W_M %X1?RKLZXSX-?\ )*_"W_7A%_*NSH ***X_QU\8/!?PRFMH?%/B2PT6:X4O
M%%_2@#L**J:3JUEKVF6VHZ==17UC$7\J[.@ KYC^'L>FW_P"V MI\=E\1);RW,&BZ FFK?!2!9&*X,QC#?P^;][''?&:^G*X/X@_OP'\5-0MK_Q M3X;M=5OK:,PQW+,\=I)'7B@#S_]AX;?V?-.6(EM-75-
4&FG MG;]C^VS>1M_V?+VX]L5[CJCWJ64C:>D,EV,;%N'*H>>I)Z 4 >=6\WBT?%K4'%CI7VDZ);*P-Q)Y>SSY\8.S.[.+]+U+ M2;)]+TAWU&9X4=;J7"%8WDRWR=,(1]2*T_M/C3_GPT3_,"I?
_B*E*_$'PO MX\EG70=9LM6EM"#*EO(&>/(X)'4 \X/0UTM '*_:?&G_#X:)_X%2_\ Q%'V MGQI_SX:)_P"!4O\ \17544 2"WF5V4 XW8],]QQ0 S[3XT_Y\-$_\"I?_(BC[3XT_P"?#1/_*E M_P#B*ZJB@#E?
M/C3_GPT3_P*E_\ B*/M/C3_)\-$_\ J7_.(KJJ* .$\0 M>)/&'A[2I;Z72](F2-D4I'=2[CN8*/X/>M$77C0C/V#1?_J7_XBETWXE^$= M?\07'A^R\0:=>:Q 662QCG5I 4.& 'N.F.:ZF@#E?M/C3_GPT3_P*E_\
MB*/M/C3_)\-$_\ J7_.(KJJ* .5^T^-/^?#1/_J7_P"(JKJVL^,=)TJ\ MOGTW1Y$MH7F9$NI=S!5)('R=>*[2N8E^)7A-?%'_C,FOZ>-<8[/[/>=1(6
MQG;@]3@YQUQ0!3TS5_&6IZ=:WB:;HT:7$2RJKW4N0& .#\G7FK/VGQI_SX:) M_P"!4O\ \174JH4 8 Z 4M '*_:?&G_#X:)_X%2_\ Q%'VGQI_SX:)_P"! M4O\ \17544 D017<0E6.6
MZEW*#V/R5JZQ\3_">@>((-#U+Q!86.K3;=EI/,%O:NF1%C4*B MA5'0 8 H Y?[3XT_Y\-$_P# J7_XBC[3XT_Y\-$_\"I?_B*ZJB@#E?M/C3_G MPT3_ ,"I?_B*#=>- /\ CPT7_P "I?\
XBNJK/N]>TZQU:QTNXOH(-1OTD>U MM9' DG6/;YA0=]N](O&&O6!NHM,TB)1+)%MDNI6%I>WT%IYD""29\[(P3U8X.!0!R.F>+O%VI^(-9TE-*TE M)=+\GS)'NI=K^8F\;?D[#@UK_:?
&G_/AHG_@5+_\173JB!F=5 9NI Y-/H Y M7[3XT_Y\-$_\"I?_(BC[3XT_P"?#1/_*E_P#B*ZJB@#E?M/C3_GPT3_P* ME_\ B*R8/%?B^?Q/=:(-*TD306L=T93=2;"KLR@#Y.HV'\Q78ZYKNG^&M+GU
M+5;R'3["#'FW-PX1$RP49)X')_&K<8CD(E3:Q91AUP:>=2T'48-4MDD:!I83DHXQN1@>5/3@^U;M '*_:?&G_/AHG_@5+_\ $4?: M?&G_ #X:)_X%2_\ Q%=510!ROVGQI_SX:)_X%2_
!%9VI>)/&&FZEI5F^EZ M0[ZA,*,MU+A"L;29;Y.F$(^IKL[^_M]+LI[N[GCMK6!#)+-*P5$4#))Z " ML3PCX]\-_$"*>?0-5MM56TD$6.WD#% (O$GB_PYH]QJ,VEZ1-'#MRD5U+N.6"\?)[UW=)?
$=SX=L-&$UNQEUU58MIPF4RX !8;>^ 02.P-= M$ % & * .6^T^-/^?#1/_J7_XBC[3XT_Y\-$_\"I?_(BNJHH Y7[3XT_Y M\-$_\"I?_B*!P N&B?^!4O_ ,1755SU]\0?#6F^);;P]=:W90:W8"5R02
!ZD D#J<4 8OASQ)XP\2:#I^JPZ7I$,5[DZQRW4NY0P! /R=>: MT?M/C3_GPT3_ ,"I?_B*ZA$6- J@*H& , 4Z@#E?M/C3_GPT3_P*E_^(H^T M^-/^?#1/_J7_P"(KJJ* .5-UXT' $5D^'?%%?
B[Q'%?20Z5I, M(M+V:R8274OS-&VTL/DZ'M6_X@^(/AOPIJ=CIVL:W9:=?7S!;:WN)@KR$MM& M![L<]SQ6]&BQ@[5"@G)P.I]: .8^T^-/^?#1/\ P*E_^(H^T^-/^?#1/_J M7_XBNJHH Y7[3XT_Y\-
$_P# J7_XBC[3XT_Y\-$_\"I?_B*ZJL#Q=X^\.> H M()O$6LV>CQ3L5B:[E";R.3CV&1D]!GF@#G](\5>+]8U#5[2/2M)C?3;@@6[L] MU+AR45\K\G3# ?A6K]I\:?\
/AHG_@5+_P#$5TT!BD02Q%624!PZ8(8$<'/? MBI* .5^T^-/^?#1/_J7_P"(H^T^-/\ GPT3_P "I?\ XBNJHH Y7[3XT_Y\ M-$_\"I?_(BLRT\4>+[SQ!J.DKI>D++91PR/(UU+M82;L ?)VV'/U%=3XD\3
M:5X/T>?5=:OX-,TV#;YMUPLX?.LI;N.>SF=Q\CQH5.Y1U\P'\#7652TK4K'7;"UU/ M3[B&]L[F(2074#!TD1L$%6'4'BKM !1110!\M_MD?\AGPS_U[S?\ Z$M%
'N/P:_P"25^%O^O"+^5=G7&?!K_DE?A;_*\(OY5V= !1 M17.>/?'5A\/M .IWL5Q=L\\5I;6=HH::YGE<)%$@) RS,!DD =20!0!T#RI& M5#,JECA03C)]J^:-=\>WOQ9\2V^@7EJ?_B;1?
$,UQX8OM4@,^G:TL/F0LI& M5.XJSY7(8?*RYKFO&VOV'COXCZAXB\9Z%KMMX4TRV30-1LB[?:?#%^I-PM[B MW=@T4T-Q$#*I.SR1G@G'H_PGTRT^-7PQU?1_$TS>*=&T[6'MM'\0L#'+?01I
M%)%=(XP0ZL[Q^8O4Q$]Z ,7X(> M>*_&C7=35+R&+55N9_$NVV>UTN6\#QB MU:TB=B!7=R!CZ2IJJ$4#DX[FG4 %,DE2(NZH"< L<9/I6-XW\9Z M5\//">J^(]:G-OIFFV[7,[JI9MH[*HY))P
!U)%?-/Q.\<1?$'QQIZ>(__B M)=)\.VK3ZUX=E :Y2WNCBVU*%;>1O-$;6\R,JG>NXG:<#(!L_%'Q[_PL?Q'X MF^'?B"UG\&V=CKMA_P (YXLE3S:3M!?A]
MXKTK]H]O$MR'75;Q3;>()M,L7M-(ELTMO]'";V8RS><5._J &7H!G5^"[:=\ M4-.\;^"[NZ_X3WX_Z7IT6 MD:;:6,!=H;:)84,CEV*J,#)/)/'4T 6J**JZGJ5MH^G7-]>2B&UMHGFED;HJ M*I9C^ !-
$\LJ0H7D=8T'5F. *\$^.?Q)MIM=\0_#CQ)IUYIG@K6- CAD\86 MV3%9W-R]Q$(Y.RC;&K!ONY;#8!&>2^*7Q&N/BK<>&8%\#:U>:3 #KSZ%>.E:M !2,RHI9B%4VM7\RYM(V5]\9>(,Z;U4/L]":
.K^,_Q3 M\3:'M,BN=7EO9I8I[N&97+BT*@KN2-6.6X+8''6O.[SPEX MGMM'T'P\OAV:Z\;>%Y;<^%O&>A[8XY+8[0%O1D&,&'7VM?#OP)J^I0^&?$V@WT.I:7?V\IG\+78"JA99,%0Y=QY1/)7*\9-?
1/PN^ M%]E\,M'FACN[G5M5O76;4=5O6W37#])TR]_LS1FUR[NM6ED2*:,P$$)0'Y MSL8EB<+\O!SQQOQC^-2^,O#FL>%O#NFZJBZCJ4GAJS\2 HEC)J<3D/:,P?S4
M#M%)!YFS:&)&:XK0=5TO_A*=)\,^"8]5T5O$?GZ/XG\"ZA!+YNCHUM+_*&-1/PMMO#]MX8O=5D3<&YR#]A:.+P:39#4#&;_R$^T&+[GF;1NV^VI))/->E4 %%(2 ,DX% M>(?
&/XSI%IOBGPWI=GJT!B5=(N?%%HL9MM*O+E%$!<%Q(P!EC+%%.T,/P .G M^)'C_P 1:=XG\/>%O!^G6%YK&L07EU]OU5Y!96T=MY096,8+&1FF0*O'"N?X M<'Y]\,SS>,_!-U.)+C6(TT:97U31-
4639.J'*NR+,FZ.9.4X# M BI?"^NV?@'6_#46@V>H>$/B M[;:?K?@6=I;B#4HG8)+X/AAX6C\:.DOBQ-.A74W3;\T^P;R=ORYSUV\9SCBNNHHHH *X;XG^- M-6\.6NC6?ANSM;_6=7U)--
B>\+FVM"8I)#)-L^;:%C(&,LRC(SFL+XF_'[3 MOA_=:S;)HFK:Y%H=BFHZW=Z6L133+9]^V1][J7.(Y&VH&.U"?3/S;9S_/"G M?
#EL0^I67QCTK:8703S6OCE"WWT/S*S2J02.&B8_W1D@'8:1)K6KW'BO4/$G MA&P\6>'?$&I3Z+XDT.R_>307MNHA^T6N_#20R1HA*9#QD97/./=?@+I>O:)\ M,].L?$!O#/;R31V@U*3S+M;,2-
]G6=LG=((M@8DDY'/.:R? G[/UCX4\=ZSX MHO\ 5;K6IY]2NK_3;2?Y8--\\YEV*/O.3D;SSC@8KUF@ HHKS[X@_&"#P5K5 MOHEAH&J^+-=ELI-2?3='6,R16L;!&D8R.B\LP55!W,0<#@T
:'Q/\:WO@[P_M%+H]C%J>L7=[;:=;0S.5BCDGD"+),5!81KG)P,\8'6O(3X,M_P!H34+Z7QQO* M?#_C7P'J5QHNGZGH%T8TAN)X[.YCNK75-
0\,>,-0:;7O#'B]XYIK+7;>8F:WMI$&07"LL30$!^,IG/'MWPV^"4NJ^ M*3\0_$ES>0S:O-:^((_"LHVQ:9J#6<$4I$WEAD1W<:GY)MA_U;,.J<@'.#BNHHHH *Y'XJ>/3\-_>M>
M((K"35[JQ@$D5A"V'E9F"+D\[5W,"S8. "<'&*A\?_$R'P1=:5IUOI-[XAUW M5#*+/2].,8DD6-0TCEI&55505R2>K #K7S"VK>']6U+6O%'BJXU?PB^MW;W_M (<\AZAH4?QO\5ZQX,^+-A8VFH>$
MX;76;._T.\DC@*7BSQ13([X>*:*2WEPP(YVD=2*];^&%CXOT;3+W2O%UU;ZL M]C,(K#68CB6_M]H(>:, !)0-M<'K.NZ#XO\ &FO>+O&L.M:/X?OI%L+'7%D=+CPC
MJ%KF&>TG\IF5%:11,LO*,92&.-N>V\)_"^_/FD>O[WBC7[E["UM;[2KNVM M(3;IKMNMY_H\[GAECD2%)"@ #;_[O! /4/A1X?\ %G@\WNA:QJ<7B+PY;(C: M+K,LF;UHCG]S<#H[(
,2@_",C()/HE1V\$=K!'#$@CBC4(B*,!0!@ 5)0 5 M7O;V*Q@:21N0I*H/O.0,X4=S[5B>/_'6G_#KPU-K.H)-<()H+6&UME#37$\\ MR0PQ("0-SR2(HR0!G)( )KY>\:>+M)^(/Q*U35/&?AG7H-
"T*WCT35K%',ES MX9O& N(K[%NS;H9H9DS*A.SRQD ;B #LW\1:I\=+31/"7C_1;"R\&^/--?4[M2VLI91=Q1VTUO,;:Z#KM/F1N ^W&/G7G(:O0/A1X*U[X=:E+HMGJB:[\.6M_
M.TB2ZG,EWIQW#%J'Y\V#:248G6>!/!.J_'*Q@:Y\8WT_A_PWND M6FNVUL89?$&ES0VLO^L."I213 TJ##^4^,9-?3&D:3::#I5GIMA EK8VD*00 M0H,+&B@!5'L !0!]
M&I),D0R[J@R!ECCD]!7S'X@^)^L?$?4?"%GKNBV^F>"/$GC&71+!HY'&IP7> MG37$\4LT;H8S%*VFR#:.0LB')YQD_$KQBGQ ^(5I)XE\$Z\^A>'[)AK7AV21 M6NK..Y8&VU6)+=V\X+Y,L;(#O3<6
.WE/#G@:Y^.D,&CZ-X\OKSPQX/\00:M MHWBF*'?/-'+975O/9&1L;I(Q<-B4#*[E!RP)H Z7PAJGBFU_:.^(FE^&?#T1 MT?4=3T^]O-=N3MLTMH[...41[?\ 63M(C1X& NPECP ?I&L?PCX3TOP-X=L=
M#T:V%IIUFFR*,$D\DEF)/)8L2Q)Y))-;% !3))4A0L[*BCJ6.!5/7=$1.Q:2"66)_()K/7-+O=)M8/ "Z]:>& MKZ7S734F>9X0MQ$"IC,8DEC&UL[E#?0S7VL>(M"_:\2Z=X0\.K>W.KZ9I$3
M:E,NVPM(X9+KSY)F7&9 KHJQCYB2O0 DT"+XR6WB/P#X/\77_@RW.FZ MUIVNO"TDVD745T':Q8R@%FQ$K!6YCSAOX17TOX#\":7\._#T6DZ4LK1AVFFN
M+B0R37$K'+RR.>69CR30!T*Y"C/6EHILDBQ(69@JCJ2<4 #NL:EG8*HZDG % M?/?QX^)>OR:'X]L+?1[1O!NDVT5CK4\MQ)%>W$-U&!(]H5&T%$DR"Q.Y@1QC M)Y_XF?
&=/C%H/A_3=!\+ZU>:9J\PU?3#,4AM_$UC;D//!$P?$ M],USNG65C\2;[6/AIX#UG4!X0\0Z-<37EM?V2QS MF(E?ES0!T_C6#7/AY\>?!MGX(T(ZW?_"%76@P3NH2UBE%U9LLMVR !52-& M?
&3O(4[G(+L>@X 48 KK* "D) !)X H9@HR2 />OG'XR_%F MY\=^'[[PMX=T74E74-2;1[+6994ALKZ]MY"TMDS*_FQK((98?,VXSG\0#J/B MO\7?
%N@ZQK5EX.T;3+^/0=!_X2&]N=6ED2.ZCW2@6]NR CS,0.2S<+N3@[CC MS#5PG@;1/@#?>!- O_$_D13RVEL60702ZL9# MS(!\D99OFD/_///)JIH$^B MZEK\'A+P7_:^A0>)K:ZTGQ+X'OX)/-
T57MY!]K0MD(%;"Y5BDF\%3D5[O\$? M@K:_"'P_'%-J,NO^()K:WM[W6+A=K2K"FV-$3)$<:@G:@Z9/)))H [;PN-87 MP]IX\0-:/K7DK]L-@K"#S 3R?;I6I12$A023@#N: %KS;XD^//
M$EAXE\/^%_!NGZ?=ZOJUO>7?V[5FD%E;I;&$,C&,%C([3KM'''N>V#R/QI^, M?VK0_%/A?1K;5[%I3_PC[>+;98_LNF:A+;&]U/4+[6UL?"US_IT-]/YJS$3(%P4 %%%>4?$OX_Z;
MX"NM:MAHNL:Q;Z'.)>ZW?Z9'&T>EP.&*R/O=2Y"JSE8PQ"KDCD @&_\ $[QG MJWARWT2R\.6=K?:SK.I+IL+WK,+:U/DRRM)-LRV L1 ZLRC(SFO#K#1]'\< M> ?
$VJ^(K/6+37&\8,NJP>&)V:9[VT*PAK1]HE6(K&DF!\XY]ZX.QF?X-^'+ M!"VHZ?\ &?1_+1K?=--;>-QN ,D9.5=I5.[LT3'G"CGZ&^'/[.FG>"?'.M^) M[S5;O6[BZU2\U+3;6X.V'33&6NM
M*L$U359KJVLK>WD6;:J@[F(.!P2/F67Q#H4.FZGXMEU34/#/B M?6))O$GA'Q>8[B2TUJSN";BUM)$&X;E1TA,! ;"@H.> #T!O#]KX]MOB[_PG M.GSIKTI]'_9ZT_Q'I^B:\NL
M7.L7&BR:FSZ"OB*5I=1CLS&F1,[_#G]YYA7>2P4@&N=^'/P2D\1^*(_B5XG MDO[.YUN.PUL^#YW_'.EZA]DBC?S"/\ 6NFW:!DYKWF@ HHKB_'3K
M7P%+HUC'I]SKNO:U/);Z;I%B\:S7#)&TLC9D9555122Q/=1U(H M?$WQR/AY MX'US7H[*35KG3K1[F/3H#^\G(X '4@9(R<' R:\>;0[_,;^-O%\/Q$M[.TU MG1_";V<-WH$[-;R66I.V "3#B9'T\@-
P"&''8>=WFM^'/$NO:YXK\7Q:WX5M M]6NV.B^,4WB30[B#_1Y].N@A=(F2>&0C.8Y-Q&-=4 MG6*\TVWM;_0X+9K:#4I+.YN3;W3JWSK'(LOFB$@8WC=G& =#^S3X;U+PRVO
M6MLOB.V\#1P6,.BV/BF=Y;JWD1'6<)O)98<>0%4G *OM !%>X4@& !2T %%9O MB'6XO#VBW^H21R7'V6WEN/L\(W2RA%+%47NQQP*RO'_CVS^'VCP7ES;W%_<7 M5U%8V=A9[3-
ZYXA\;Z+KFE^'T$ M>D_V@LS"Y\)ZA""SB00NP$#I_%6B06LS2[/(DM6-I="50"Q-S "PPI^<8X!/3?LQ^ ?'_@>:Y;5[MR&+P'J%IYVC>&WNS<3: /,)CMQ+@^:K(Y.=Y$>Q47<,&N<\&_"_4OCS%X?
U_M6_%ES=:5HL>J>'VN[2W,!\1Z=+-:R12EN-JG[,%H,/@D$ _3MC90:906E MM$L%M!&L442#"HJC 'H *)Z**PO&OC'3_?AN\UK4O,:WMPO[J!=TDC,P1 M$0=V9F4#W- &U)*D6-[JNXX&XXR?
2OG"?XK^(_B/!I>D:UX>L;'P7\09-5\. MV/[V1=1M98X;DJUPC+MPZVTIPIRI*\GG',?$7Q-#X]^(PU'Q7X0UT>&M L_L M&LZ*S[KK2))V$EOJ<:V[L)8RJNC%263;D#&ZK?A7P+=?'73[.QLO'5_=^'O!
M_B W&E>)K=,S:A:36,L,MOYIQET^T,OG $\?WLD $G[+GPY^)GA?4M(UF:2T MT'P1=V\D=[X,%PL@MKORT\R\A958*'FCD_<*RJHE+=25'U569X9\-Z=X/T"P MT72+9;/3;*(0P0IT51]>I[D]R:TZ
"BBB@#Y;_;(_P"0SX9_Z]YO_0EHH_;(M_P"0SX9_Z]YO_0EHH]Q^#7_ "2OPM_UX1?RKLZXSX-?\DK\+?\ 7A%_*MC7 MO$<=DES8V%Q8S>(FMI)+/3KFX$9F<*2H.,L%)QD@' SQ0!G_!5\"[X=>
M(?%=Q;/>Q:19O=M;QG!<+[]AW)[$]J^?OB7X\U2P\3>%-7\9>%(EGM9//MI M=,F-Y9:G*5F>-. 1<1>4LT?'S>6P4\XJ'5M N?$WA^U\?#Q=IGAK6;O6KA; MB?Q<\-
O;F)XCIDML)41]K@@C(!V[N2>=SX#?!R?Q%X0\&Z[J6N:K::';3C M5+;P>HC-A!%/ 'BK5OC#XC\2VVMV]K MX"UB^LM=MY[!\SZEMLH(HXF/181Y18XY?>!P <^\@8IL,*6\211(L<: *J*, M!0.@ I]
!5#7=630M%O]1>*2=;2WDN##"-SN$4L54=R<8 HU'7=/TJ6**[OK M:UGFXBCGE5"Y]@3S7S#K>BZMX\AU[QM>^*;+PEXATO7["&%K^:=X-#6W\H3V M[1*Z+*D[[FYV[TN!DC:N "I\1_B-K/C?
P=X8UG7O"UB-+U4Q3:5-!=_:+*]2 M=0#I]WD (TR-L5^5$FSI767'@CQ-\4?B[9^-/#FLKH?@76?#.GVEW>H9NHV$#DYK ^#_P4E^)/A!Y=2\17VG^&)=9D>\\.Z-'&FD: MHUO=;X[FW$JO-
;1RLBLT<@1I)J>H6VGH[;5:YE6,,?09- %]F [@$],U\\7?Q(L?CS;ZQX2>VNO"O MBBSO;N;P]/=_ZG43:S20F2,]'1MKI)&>=CGL0:R?B'HU[\7;WQ\^H:O#X:U' MP[I7V6R2:YF2+3I3))*FKQM&5\Q6A,>
>CP.A.-U;?PTMV^/6A^(M(\:IIVN MP^'-81-(\6>'XI;!;IO)CE\Z']XS1R1O(T;%7*L5/N* ,^Y*^)OB=J?@+6? M!-Q:^$-,M-+O-"U<;,W&ED2Q"2*!.F\&!D!/ !#8/%?1>GV8T^QM[8223"&- M8_,F;
<[X&,L>Y/K3X+>.V0K&@0$EC@=2>I/J3ZU+0 4A(R3CZU5U'5;+1[? MS[Z[@LX0(N?3)KPKQWIEU\4_'NMZ#K$T-A8:5I%QVFCP?$.*75M*T'*>+_"L!,T(2 M<1BPOA<--'=@AF9&95=?*8\9Y -
#1HM6^*GP@TBP\#G26\3:+XFL]>DNI5,= MOJ<9E9EO6 Y\QC\TB]1+%(IKZ:\M=/O]8NM>OEW27&H7>-\LC,6 M8@#A5R2%4= *J_#3X;Z7\+?"=IH6EM-.D+32RW=T5,UQ-
+,\TTCE0!EI99& MPH"C=@ # KJZ "D) !)X%,N+F*T@>:>1(84&YI';"J/4FO&/B/#5O#/A M2VO+>'P[K=[#OU."Y)CNVB??/8.R6ZG&>0"/XJ?&^_P!"U;Q7 MI.F:'8ZM8^'=)34M62\O?
(DGMY%D)$ QAB%C;D\9XKRKPCWO[$:N##/=0P7$:^1='KYL!B$#MR<"-OXA3+#P[X-O/B7XR^'-KHYO MM=M-:":-(MHMX=!M7M+::29S-E1")9&*QL2"S$*/3Z4^&GPV@^'VF72RW\NM M:Q?
W4M]?ZKD:K=+IM]K=$M8R,Z&-6V1.?N2/CA#7K7P>\)^)/#VB277 MS4UNM8O5BW6%J?\ 1-/C12$AASR<_,YY8^@Q6UX+^'.@_#^UN;70[,V=E-= M/>):[RT5O(XPPA4\1J>3M7 RQXKIJ
"BD)P*\L^.'CFXLOASK#>&]5MK>61 M7T^XUB&4.=',L;1QW3*Y$460QJ^PXVR1N/XA7*W\6M? 7Q^G_",^(-'OK+5)-(@E\&71N+N\N2 MTC13WD$K2_NF;S"QRK!A;@DJ22?H;1/ASX?
\.^(=7UK3K 6MYJSQRW:H[>2\ MJ;@)1'G:LA#8+@ L N2<"@#S7]EOX5>,/AWX%T6'QIJZRWUCI5OI-OH]BW^A MVL42A=_3+RN1DL> #@#U]PHHH *X/XL_$2Z\.6.BQ:;907NJ:UJ*:7:"[F\J
MW25E9@9'P< [" .I8@=ZE\>_$J#PMH.I:AIJ1:Y-I!2;4K&TEW7$-J#^]D5! MDLR+EMO?:0.<5\J_%7P+=>!_]KJL7B/0/$9O?#(EO\ 1]3>[N9/%MXLBR>9 M;;95\B;
[HCE0,0TP!7"K0!WVD^.X]#^/O)XGT1M$U>]"0W=K.?@AGDVP0W MMI+_,\Y<)!(.,()IFC:>?W;1RW#R M?:)V/+2'< %'"@=R:T_'P1?0]RLVM-,MM;6W)T^)VC=U+Q
MQ*TSYBC&^0L1L'K^(;6$S1:.]TL&1I>H6L.+I[=C,3Q;X4QX*TGQ=;^,O#T,VMV>HR:C+XGCN;NWUF.0[XK9K<2H%**-N1 MRA!"K7IGP@^"DD]IX/\ $NNZ[KE_:V=@9]-
\,:OY$L>E/<0;)8_.$0FE"JS(MHE9L \Y., $OPK^%WC#1/B%XBU#4]1AT_P ,#7=0U6QLK!\OJ3W+,1+<'''H MC*JH.Z;B>E>Y 8H VC Z4M !6=XAU=-!T+4M1?!6SM9+DJ3C(12W]*JZ[XGM M-
,:2QAN[%M=DB9K.PN;D1M/)@[5[G!(QD U\Q?V1?ZGI]I\3&\(+G3-9MQ8,1CP?%/P[X%^(_B#1A MHWB^*TD5S8LT*31,'CVLN26A<;951\E25[@Y]:CC6) J *H& !T H 4#%+15 M#4-
;LM/FCMI;RVAO)\B"&>4(9&[#J?PH O%@#@GFOE>3XCCX_\ ABTFN/#U MQH'CK2X&U2U\/:@W[K6],@?"B-?C]X$T[M6?
&^C69U;0M;NHM,UC2A+:QW(MYVC2\MCN,D<&M>ATCP#K^@Z<+B[MO^/YQ#)-(+=,\1AO.&YCR-I7&3Q]&*-H IL, M*6\2QQHJ(O 51@#*?0 4R201H6/8=!U-4]3U[3=%: 7]_;V1G<1Q">4)O;T
M&>IKYR\;Z!JGQ.O/B!>:MK4'A75O#\,5KIRS7$HATMUF>1=1!0KYBRPF+@]& M1TSC)H QO'OQ;U7XF?"K3_$U_P"'+>U*7LJW6F:O;W?G?8)N_#FK%AB[TEENH#+!$G3S, MP&,$\
+N&>,XOPP^$^H?%#_A.8)O%LVG:-<:DUGJLGA6VCBTKQ'&T2/)*D4X ME:WERYCD>&3#$$_>Y'UC:6<-C (H(UCC'91C)]3[T +:VXM;:*(,TGEH$WN< MLV!C)/V\
(Z5J=SISZOI]P7U#3;BTG*_:I(,0:M_$;1[SXN^- M/$NFWNJ0Z;8:+H-R^GVOVR6.*62?RS;:D'C()$?ESH1SM."/O9KD?A7\/=<^
M(/B#Q8D/Q#DMYX;>SM[SQ/X1M8X[774DB8.EQ!)K789[51PZE6W1]B)E)Z&OI MGP[HH\/:%8:;]KN=0^R0K#]JO9-\TN!C<[=V/4FH/!WA'2_GA?2?#^C6_V7#M3-
+LX;&VC+%F6**-8XP6/+$*JC)YK9H *0L%&20!ZFJVI:G::/9O=7UU#9V MR?>FG<(J_4FO%O&TZ?%/XDZ)X5OIX!X;$4NJV\45R_D:[$(C&R>9&1AH9G1B MF2"KJW4<

$_C'XNZ#K/CWQ!\,/$^G7NG;12YGBWB#S!S%* 5* MGN<8.<"N-U'POXM\0>#=.\->'%TRV\=>$/$T5Y?37" M/#=SX4\-V>G7NKW6O7L8+3ZA>8\R:0G+' X49)PHZ# K>HJ*ZNH;*W>>XE2"
M&.;GDD8*JCU)- $A.!D\"O'OBW\<;'P!XWL/#6MZ' MAE2%?._@;>V2/NA23QS4?Q2U.;QGXE*^&%N8H/"NKW"3_VC;7#&._1TRYNY?DUF MPCN86BDDE&=[*L(B=^3\]$_>%>^_#?
POK/ACPZ(O$6N2;_K=S(US=W.W9$LC M8S'"G\,:XP 35KP9X"T/X?Z3'IFA6?V.QA:0PPF1G$*NVXHFXG:F>B#@ M8& *Z&@ HILDBQ(SNP1%&2S']37D'QE\4W&NZ)I.F:'J=O#H>MWBZ==Z[:
M7))M9/-C98B4Y5946:(N"'K-'Z]2 *[\0?BOK>C _!"T_P &>%)%M-5UB?2Y M-$;[?= _9TEA241LD1P=T@+ GLH*YZUX?H-U;>,O#/Q:\ Z5ICZ)XC\2Z5?6E
M@M\H$T4RQ/YFGROW\LW&~/L8ILKPAQ#XI^',VD_$VP\-:?XCL9;"Y\19T[3- M+\[^V #BO; M,HP:CK=YXIU_4[A M;F\U6_AAB=V6(1(%CB1$0!!C@9.3DG- $?PE\->)]'TJYO\ QA]BWFMZBR2/
M8VQ_T33D486"'(RV ?F<\L>>!@5WE%(3B@!:\V^*_P 4-2\&;[X3\/:'I<&H MZWXDFN([62^F,-K'Y,?F,KR 'YV!^5>IVL?X357XV>/);+X?:LOAW5+6.YD5 M[&YU*&<,^DB6-XX[HJN-
;6U^.VJ_VOX?;1]8U M ?8I#=8DETRZE'F>4LG\5M=*#$(R.!)#(O!85U7[*OPK\9 #OX>>'+;OOJRO M?Z9H=GHEOH]B^;2UB@B1-Y,.O*Y3<6Z ':,Y/6?#OX/MX/UK4=;UGO/]?C76 M[NWM[-;
[6(K9'AMX&D>) L$4:EMTSDN1DDCH!BO1] "BBN*\= _$FW\,:1]5Q MIGV:6M0TO1<7FEPS@W(MU8>G6A'FSO+*L85<]_F[UYA!XIT'5?&'ASXG:3MU#PY?W TW5(+]%A=:- MJ&TP13%#\T38=
[>5"/XHV_A)/F>]:?KWP7T#PUXST3Q[H&HZ]+X5>:]M]0:Y MOE\97N^&0S1+YJB)S@*$CJ&Q]I*[-JKCZATOX;Z%:>++WQ7!8O9:KJELL5_ D MI\BX8%6622+.QI5V[1)C."1DC&
#@/@U*O%WAOQ1K=_X@U5;71X=:U>ZTO2 M-/;]W<)=WL\ YBV)&6?;*]A!PNTDGDCVS&*.E+0 5SOQ#4OX)\!^(_$$-0] MMFTG3KB^2USCS6CC9PG'//)7'XTOB?
O.VFV.H0Z0MKJOB&"W::#2&N5CDG(&= MOG>*;^R\=SZ;-I^]>%Y8;?Q;X7U ;Y+6 $0%=*! MU,+DNDJ\.C2CKTZ3P7* %]M\8?%NLW>KOZ=X/N]875[6UL3^^U"0VT,0$['
M[L:>6<*!0@DX&*Z/P#X?L/BEH'@7XC^(O#7]A^,9]&BEG@5V5XA/"#);29 TWI %BEHK*U;7[6PE%BEY9K]\;&UM+B<(96P<#' M7&1U - %:QYXLA\"^#-
<\0SP2746EV4UZT$/WY!&A8@?E7S9\4?'&KW_ /PB MFL^*?"UL=\BOIEWI5S]LT_4H)=CO92G P[B-'C;H9(D /."[5M&U#QKI-IX^ MG\3V/A'Q#*X@AB9M:::6+18XXQ%/8/"LB).'E#=U#K*&SP*L?
CX.3^.?!&E MWVH:W?Z7X8359+D^%=-2.;3=26UTWDW-J94;X@MY3&DPA$F.0 <=0#I-\;#> M) '/Q?N_&.A: !8?#SO!8:7?&\LB3=W@A5RD"YX2.^9N9NI"'-?00&*;##' M;0I%$BQO(JH@P% Z
"GT %%%% !1110!\M MD?\AGPS_P!>\W_H2T4?MD?\ MAGPS_P!>\W_H2T4 >X_!K_DE?A;_ *\(OY5X)\9?!NO>%OBTVLW46K'P3K=V M+FY\1^&;]6?5]*E6V6)("L:/(+=F4-NC4X)8, #D^]_!K_DE?
A;_ *\(OY5V M76@#Q#]GSP%]_P#8%Y]_BIIKI=8(D?3M7LECD=XY)%CO(R/WZA9RB;2U;6;0 MI+]]E$X^QW,\4@#+(H,B LH+)MSVKZ%(S2T 1P01VT*10QI%$@VJB*%51Z # MI4E%%
%/6=231](OK^0 I;P/.P)QD*I8_A7@'@[6O"?[3EJ/&-S;2QWUGH4 MMC>^#]9@'G6,LNV592C?WE VR+PRD8/!%?1+HLB,CJ&1A@]1D$5RFK?#+1=4 M\8Z)XI2.2PUK2U:%;BS81_:
(&4@P2C&'CR0P!Z$ C% 'AWL(/ M[)N]/TG1="32)!1U-"CZT3'B2,1.-WE1R 8D;&Y@X4%3D_3%I9P6%ND%M!':MP(.+%$@55^@' J2.-(4"(H1!T51@"G4 %%% '"?$7X76'CL[4M.O]2E:6VTZ
MUNXA821"6&1Y54"0IW9-IQC^\;\+^"?@G4-7\7Z6NC^)/$&J>&O"lK.);ZGK M^DR66_M&>!-<\=> H!X;2VN]9TB_BU6WTN^.+743&KC[/-VVM MOR"> RH3P*]2H6
^.OA9X6U[OQKOAZQBN/%UC'IMC]MOSXDTM[5=#U:)XA\' M:,R*KI(C7",D1:/R\VA;1)=4.-;TK1[2X_LO2DBMC):W\5Q)&D;7'V@1*%CSE7<$?(Q' MVA28% &7I7ANQT]\N[^*UMTU.^$9O;N.
(*]PR*%!8I3@#CTK5HHH *\)^+OQ M2TC6/%&M"75FO\ PY%JVG10P>*8TS:1W,_F:+=WZ1R,L;%0W#_-&U#2M9TVWU#3[^/RKF&9,B1>V3UR.QZ@\B@#Y\56FG^&OC?XN\"
M:'X3:_/BCPWI4<.F6D306F%FO5GO))5&V,1KY0S]YF:,*">1]&^$?"YT#1]- MCOYTU?6K>TCMKC6)(%2>Z*]!O8@=3C)'3-/&^$X?!GAS3](BO+O4A90BW\ MU&7SKEXP3M#R8RV <9/)OSDY-;E
!1110!0UW3#K6B:AIZW,MFUW;R0"X@,) M(BRE=ZGU& N]F$9B4NKN7+.I5<'GBOL.DP* .6\"^ ;7P;H>GV$CKJ3M7"YSSCFNJHHH *0]*6B@#X:\0^%/'7PQ\5>*-/=?$EA,EF_A/6O" M>EM?
+K5X]Q/*8M0*HV&&Z!-LQ6/:'8,,_%GX/ZAX:AN_[8O4M=+G M\0RZO:>+=(M;NXUV%W9Y4MPD,;]&Q&&)V[,+.C.*^PJ3% *'B]?;^U]I?@NVN M?
$]O&JYJ0AU272:B!673:OXU^T"/W0T@,FW^%G?'\X]7QBEHH *X7XU2$[_ M (5!X N/$JZ3V%E'IMF1YJP]S>0VP6//!;,V0.^,<=;[JHKBVAND59 MHDE565P'4$!E(*GGN" 0>Q% 'R!\:M.\,7_P4\9_%:1-
4?6)M4\2Z%K%KJ'V M=FNM'CBN],@FA4 %TV"&9F3 (+R CK7LWPG\-7'B.^\0>+M4T(;'IGB26.YZ M\/WJ+(Y**%2[E4C$)4O[2)L M6US(IXG;/IYN/E+#D@#.<"NMH 15"*%4!5 P .@I:** "O$?CY\
(=$\0:/XH M\0ZO]=_8F2WT\+>Z=8/>76GI;W)D=[=(U9]SAL$JIQC=T%>W4E '@?[/ A#5 MM:GUSQ)KMW?:GI#+#8VQUS3A;IZM91F-K:ZGA8 JZL:B,P5GC$3%1Q7O4, M,=M$D44:O1(
]H@P]@= !V%. O2T %%% 'SE^U-X%\3S:GI_C'P_ITFO6MO M:+INH6-M$)VSMVN8I)+RR0@AIU177;U.5*Y*[2GP/\ "&HZ_P"+[[Q$-4UZ M^\-6Q-C:S^*-/>"YU2S>+
<\,B3(DA$4X4I(Z@X,BC(.:^C2,T 8H BM+*WT^ MW2WM8(K:!!A(H4'*H]@.!4U%% !7D?QM^&6M>./$7A7Q!I$6G:N-%2[AGT'6 MBPM+M9UC'F94-B2/R_E.T\.X[YKURDZT ?)/[-/PWN:W5[BY@O\
4#IFBW2W M5E=76GW%M&AN7N#?:7$EPJR-;(OV;;N'#*^.00/JZQTVTTN 065K#:0@DB," M,(N3U. *L 8I: "D)P*6DZT > VOCSPU^T+XR/A74?/T74/"GB&XG&6W\8,.
MN00>=;&2+/$L8=LL!DHZ+D<@GC/AC:W/BCO)JO@W0=$NM/M _OC&]U!]/=/M(+R)[.ZL;D7MEJ%B1% M<6DP;)>-P.-W(8'(8$@@YKJHX4BW,552QW.0,9/K0!!8Z9:::CK:6D%]';>X
MAC";F]3@#O".O^((/LDFJW=][]-K-HDEOIVAMM,EM/;3/&]LZRB M(!49@X,F0 #7UC8Z5:V#R316UO%=3X,\T42HTK>K$&K74'TJYU2QEM8[R/DQ,RD!L=QGJ/3-?)^C^'0%6JZDWAC5=)
MU_0]>N!8%KJ7AO3]/D'ATZ6>#ZUU33(I[: MO>]M9;9;JW.)(2Z%=Z^,Y'N*TJ* /AO6OA/X@\#ZUX$TRY@MDU_3-.72;> M/P_874T7B2-YK>.9K]O+\F-1"DS%7#=_"T[3Y'&]2Z3758I: "BBB@#S?
XR?&_2O@L_AAM6M M:FZMM8OWM97M(S(UG"D$DLETZ@9\I-BAR/N[P:\<\4:%X>^ VA_"CO%IYNO% MU_B6[1=5T^$7%]K"W=EJ,L<+.O#AW\@;F(7Y%8X KZEFM(+AE:6&.5E#*"Z M@D
C!'X]ZYGP-\-&^'D- ;Z-&\&FW-XU[%I[-N@LW8 ,L"X_=H3EMHX!9L8 M!QO!B?I_X?2^&O^D":UIMG;W+7,E[:Z9'B>/2?,.YK>&0@$]K$D8 S@< 5Z M-T!>E% !1110!W?&+X1:#X72#O/>^}
$&C:@_B6;5%UC0!*EOKY3+;RQI;? MNHI&6 9XW+MR$&#M4N;<:G MK'AZU:XUC1EB@E51$BJS^4\C1%FB!9<-P0V1]244 >#_ +/G@?5[FQU76_$< MM[?6>IR/ D&O6 AN+Z&*3%K>3Q,
8Y3&2K!E#.%C)"GBO=HXTAC6.-%1% 55 M48 Z "G44 %%%% !1110 4444 ?+?[9'_(9_]>\W_*$M%'[9'_(9_] M>\W_*$M% 'N/P; Y)7X6_Z\(OY5V=<9\&O^25^%O^O"+^5=G0 4444 %%%% M
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+?[9' _(9_]>\W
M_H2T4?MD?\AGPS_U[S?^A+10![C\&O\ DE?A;_KPB_E79UQGP;_Y)7X6_P"O M"+^5=G0 4444 %%%% !1110 4444 %%%% !112,P49) 'O0 M%,\Z/\ OK^= MBK_7M5PA*!)0@KMD2G&"(_B!
M#X*\1>$M3\&^(;K36U:QBO9H;B*[MT94D*21,PW*77*G!P'=:_;%U3X3Q6=VE_90.4U9]OV2XN4CCEEM8SGD)2,5&(_WO0UUOACXHV?B2*.MXF>-/!D-G/#>>>&%LVGN7(\N;[1%YB[0:>!P^&6N>
M$K:ZA:6"_N;BWN8A@ [)?*B_MG0 ^BO$OBU^U+HGPD\6?V#>X2\3>W_D)/YMRL!<-G Y/M6=\/ P!L'0/B#RPT MWP_::+]%I/?.46:9D**0I/.#[5SO$4E+D^FW<]^HIG
MGQ \|% .LSQ1XGL/"'AG5M>U&4IlVF6LMY<.@W%8XT+M@#[< \5T'DFM17E' MPA^-6L %6/2]1?P!JNA^&]7L5U#3]8N;NVE22-@K1AXTHC48_MC72S&%I/LFW=Y0=3SNR%YOB@#Z/HKS
M#XQ_&N3X5:OX/T>S\-7OBC6/%%Y-:6=I9W$4&#'$9'9GD(&!5WX1?&*T^*T M?B"V.DWWAA_7?#!]_9^J:1J&PRVI177#(2KJRL"&4X- 'H5%>'WO[16N7GQ$
M\5>%/"_PTU7O0WANXAMKV_AU&TMXP\D0D 597#*"MUQ6U\0?CJWA?X@6?@7P M[X9OO&7BV;3FU>:QM)XK=+6T#^6))))" "SY55\)P>@H l6HKP>#K/2-5\+
M>&+K1O#VJ:GXG\0:C=;3;^&2T<5S#';T6.J:1>NCO [('1U="5='4Y##T([4 >B4444 %%(2%Z MD#ZTF]?[P_.@!U%8OBSQ;8>#]&EU*^H(R*R56#FZ:>JUL*_0LT4WS%_O#\ZX#X]_&*Q^ ?
PEUJQ[J-A,->T M_P!0KM66TN+J;R<2@GCRW!##KP:]_O/&>@Z=]B:;=:S86^H.0%MI;A%D)/ M0;2<]Z -]BL]_P#%>?C:7]5OI]YJMG:WUQ@0VTTZK))GIA2%M M!U?5[^ST5M5LX;I(;JY5<>8@;:"
<9QG&<5KZIXHT?1-/CO\ 4-3M+*RD("?$ M\RHC9Z8).#F@##4HJGINL6.L1R26%Y!>1QL$=H) X5BH;!([X93]"\F\1?M# MW!\>ZWX1\$^"M4\>:EH B&L365Q!;6]E)(N](3),RAY"A#%5SC(R10!
[+17+ M67Q"TV/PSIFK:\?^$4DO8PQL=9D2&:%^Z-S@D'T)%:UOXFTBULK:\FU.TBM+ MEQ'!.\RA)6()"JV<$\!IZ&@#3HKG1\1?"S6*W@\1;6;1I/*$WVN/87_NYSU]
MJN:EXLT71E#7^JV=FIB\\&>=4S'D#=R>F2!GWH UJ*IZ;]=IK%G%=V-S%>6L MHW)- X=&']*.#5]@ HHI&95^0\)0/]: %HIGG1_P!]?SK!TCQM8:KK.I:2V^TU M&Q?YH+C"F2, _=E3GYD/KVZ'!II-[
[=#17/Z!XTL/$NI:E;V!::"Q<1/>#'DO M)SN1& B*X&<<9./6MWSH_P"^OYT--.S':P^BO\ XV_%N+X,^#(-=;2+G79; MG4;33+>QM)$C>6:XE6)/F8,3DKN&S
M^]E03QV%5K;Q7HU[JLNF6^JV;_LGV/S,./D&_?Y?3C&>IKU'XB>+] M8\(Z=:R;'X3O_%U]<3>4MI9310B.;22\DDC!57C'(D%E;"E.N6&.T >ZT5X?X3 M_:7N-5\3^$=+\1^!=8\'VOBZ-
VT._OYH9$G=8_-$4BHQ:&1H\L%;T(Z@UDW/ M[8%G!8S>)$\(:I-\.(=5_LF3Q>L\)DAA-Y+3B+=O.(DXWXZ/L6Y^>)B"VL=VDD?S"0.$*JJ!R6)4\5:A*6R,)UZ=-VG)(ZRBJFG7WVVPMYY
M(VMGDC5VAE(WH2,[3CN*LB16. P)IC4VL;)IJZ'45XSK?[0E)?"B3PWX3\" MZIXRD\-M#']T]G=6\ ADD02"-97#2-L(/&!R!G-/^*/O]NO!GQ&T?P'H/AU
M=>\2ZAI4^MM]MOTL+6&UB=8V)E96W.68?*!P,DD"D,]CHKRGP\\?]\ ''[. MZ?%I-*O++3O[)N=6?3I2IF"P"0N@/0\LX/0@@UROP^_:SC\4W'P_,O>"-9\ M(Z9X\@CE\ZI=S07%O*M'XU>X@T
M_5+.^FMN)H[>=7.?\ >*CTOQEH.MWTEGI^LV-[=QV+P6]PCNN8'- &S16* M?&F@"]EM/[9L?M44==P_V[IWFVB> M9<)]]3,2^K#/ H W:*RHO%6C3Z- .:\>J6SBI-$\1Z7XEM3 MM &C1110
4444 %%%% !1110 4444 %%%% 'RW M^V1_R&?#/ 7O- Z$M%'[9'_(9_]>\W_H2T4 >X_!K_))7X6_Z\(OY5V=< M9\&O^25^%O\ KPB_E79T %%%% !1110 4444 %%%% !1110 5YM\;_AGK/O+
MTJPMM(\0S:"]O*7D\K)01@ X(/%>DT5K2J2HS4X;RKJ4U8N$MF?*__ R? MXV_Z*:]6EF^)IS4G9\D>;4RRA,+BKKYL^+/AI^RQXWU'PU#?MX@D\,?:_P!Z M+)2V ;CAG (P2.WTS76?\,G^-O\
HH=Q^SY1^/'PH\2>&/V-_'WAZ75KWQ/JMRUN\!BC:21!]J@X1>2<8+5V M6F_"Q/A!::S\4==UW6_'GB?3- FAM3>1KN@@"B5H88HU'+LBY."3@"O?*3%> M54G*K-
SENSTH05,*A'9'Y_7OP4^+/@GX+>%O&S6VDW/B+PUK:^/:I+2*9M3N MI;AF:\MSSAB896CV@)]%L+BST1[.73+V6O M2<&S&[.;BIX/ITKZWQ1BLRS\\M#^#7B:T^
GBL:1H^]:K<=#OC3>^)8M,N0 MS76K65O<[3M+8\UF1BXA93CDU]>PKU7%&* %HHHH Y#XK>#M1\>>^W1M+U>71+R8 MH5NXNH 8$]<>G1:R_AS\ M*?%/B7QII>G06VHZ))-(0+]
[:1!#\I.2<#'I^-?IUM%&T5Q/+X<_-?0^FCO9 MB(T/9.FKVM?];6M\CY-_X9$\< \ 11KC_QJ3 P"*KO/A]\+-4^#GACQ9=^*= M8O\ QKIL]F=^EP0-<.Z -O"QDDNS
XVCK7N])79##TX2YEOZGSN(S;%8FFZ5 M1]S _+J7Y(^)/A/]$FB?&C2=/^!3^(K_.'LNE7\NM:-KEC=6^G:7<(B_9(X M'N$4JS2$J8U) 4$]!7BOA.Y\1>#+RS\?:#H>O^*?C=JB70\3>"=2T*X1;:_D
MW9N[67RQ##L(4:@QWKCG)K1<"C_I*Z3QCX2U/2O$7Q/T3]EI:+7O$,&L64] MW!JVOS:8\5W:7*V)64ROS)A29 RY(P>Q-?4?PD^$&G_"6PU:R-0O=:U?6;LW M^J:OJ+AI[R::$#' "J % P.*[W
]*6@#XK .:0/@A+SQX_@R'QE8_&J[*BR MBT6OOH_M5XB*L,F[9Y#18VY8MC:#6W_;^I_S]HY?&?Q%L[UM.\2^"-/T^?6 M-+T^:\@M]3MG=IH&6%&90_F%E)&#C'8U]<6#1!0@>E 'P/X3T?6?
AQXR^'?Q@ M\0:!]]CX9N/$7BFZO+86,DMSIMOJ30FUFE@12Z@BW^;@E3(,U[K^S7;7/B?X MI_&+XE1V5Y8^'_%%WIUKI(OK9[>2YBL[=D:X$;@,JNTI W $[,XZ5]!X'I1C M% "T444 <7\2/!.I>.
[>SCT_5Y-+,#,7"9QD)8<&<5/FUK@_^%%^)/^ALE_-O M\:]PHKS*^6X?$3=2HG=^;TZD:?,NSX[\:;3JVE:U7>JQVS %RKE2V.< M ^E;'PX*ZWXPN+BQCU>[TO[/&'C5PX4KG!],<5]5>6OH#^%
11T %>++#A^ M$:WM74;7:7;M>]S+V.M[GB/_HOQ)_T-DOYM_C7"?MB^ MI:MXU'Q:T;/PE_97B"QU.$:5:V7AN>YOM4@B$HOO>A=D:C#C M:(\O&"2 ?T3P/2C]*|L^) C;/;^"?CG?>
(_#.GW/B_QKJ+Z1:7/A#5-!N) MX[E5,86XLKO9Y<&O)&9SN"AHFW8/7@/B/8Z'9?#_/:1\->*_ FM:Y\4]6U# M6+K29X-(GN7N.;:2V_P!#N(;A5V)#&O!3>"-C#:2VVOT7P/2C]* /BSXKZU/ M;+X-\-
ZGX=@M;-_ ULT&L7/#5XFS(*-81$,(W "L=V,[Q_=-86A:>OA3 MPW^S5JWQ*T34+SP5IWA2>POX9&^[O8EPI8$^8^]>4_!>>^\6?&WX)>{K;0%T>6&,_CUNQT
MWPU/IT.CR36+M]CFFD53,P>,CN,IG(W+G[^P/2C% 'R%X6^%5E:? 3X\:NWA MP_\'57^I^,/)N9+8FYDC>>Z$8C)&=K*1@#@YXZUA-\!]$'Q2_97" ")#[' + MH6IC7F^SMMED%C;21B[/1\X,0'_
(LU]M8'I1B@#XINUO?AAX4^.5G9>$%O M/#\CNT%E8SZ=)<6EI:S0VC3720(,R)'(TCD*,9!]#71_LQKZSP*,4 +1110 4444 %%%% M!1110 4444 %%%% 'RW^V1_R&?#/ 7O- P"A+11^V1_R&?
#/ 7O- P"A+10! M[C\&O^25^%O^O"+^5=G7RKX%^-OB'1?"&D6%Q9&'WMTC0O$Q: '<[JW?^& M?$ __#RT_P#[\50!]&T5\Y?\ #0/B?_GEI_\WY;__*H_P"&@?$__/+3 M_P#ORW_Q5
'T;17SE_PT#XG_.>6G\ ?EO_(JC_AH'Q/\ \\M/_P"_+?\ MQ5 'T;17SE_PT#XG_P">6G_]^6_^*H_X:!\3_P#/+3_^_+?_ !5 'T;17SE_MPT#XG_YY:?\ ]^6_^*H_X:!\3_\/+3_ /ORW_Q5 'T;17SE_P -
^)_^>6G M_P#?EO\ XJC_(:!\3_\\M/_._+?_%4 ?1M%?.7_#0/B?\ YY:?_P!^6_\ MBJ/^&@?$_P#SRT__+\M_P#%4 ?1M%?.7_#0/B?_)Y:?_WY;_XJC_AH'Q/_M_\M/_[\M_\%4 ?1M%?.7_#0/B?
_GEI_P#WY;_XJC_AH'Q/_P \M/\ ^_+?_M_%4 ?1M%?.7_T#XG_YY:?_-^6_P#BJ\ AH'Q/_SRT__[\M_\50!]&T5\Y?\-^)_^>6G_/?EO_BJ/^&@?$__SRT__ORW_P 50!]&T5\Y?\-^_M)_\GEI__?
EO_BJ/^&@?$__SRT__ORW_P 50!]&T5\Y?\-^)_^>6G_/?E MO_BJ/^&@?$__#RT_P#[\M_\50!]&T5\Y?\ #0/B?_GEI_\WY;__*H_P"&@?$__/+3_P#ORW_Q5 'T;17SE_PT#XG_.>6G_\?EO_
(JC_AH'Q/\ \\M/_P"_+?\ Q5 'T;17SE_PT#XG_P">6G_]^6_^*H_X:!\3_P#/+3_^_+?_ !5 M'T;17SE_PT#XG_YY:?\ ]^6_^*H_X:!\3_\/+3_ /ORW_Q5 'T;17SE_P - M_^)_^>6G_M_P#?EO\ XJC_(:!\3_\\M/_._+?_%4 ?1M%?.7_#0/B?\ YY:?_M_P!^6_\ MBJ/^&@?$_P#SRT__+\M_P#%4 ?1M%?.7_#0/B?_GEI_P#WY;_XJC_AH'Q/_P \M/\ ^_+?_M_%4 ?
1M%?.7_T#XG_YY:?_-^6_P#BJ/\ AH'Q/_SRT__[\M_\50!]&T5\Y?\-^)_P#GEI__'Y;_P"*H_X:!\3__//+3_\ ORW_,50!]&T5\Y?\-^)_\GEI__?EO_BJ/^&@?$__SRT__ORW_P 50!]&T5\Y?\-^)_^
M>6G__/?EO_BJ/^&@?$__#RT_P#[\M_\50!]&T5\Y?\ #0/B?_GEI_\WY;__M_*H_P"&@?$__/+3_P#ORW_Q5 'T;17SE_PT#XG_.>6G_\?EO_(JC_AH' MQ/\ \\M/_P"_+?\ Q5
'T;17SE_PT#XG_P">6G_]^6_^*H_X:!\3_P#/+3_^_+?_ !5 'T;17SE_PT#XG_YY:?\ ]^6_^*H_X:!\3_\/+3_ /ORW_Q5 'T;17SE_P - ^)_^>6G_M_P#?EO\ XJC_(:!\3_\\M/_._+?_%4 ?1M%?.7_#0 M/B?__)Y:?_WY;_XJC_AH'Q/_\M/_[\M_\%4 ?1M%?.7_#0/B?_GEI_P#W MY;_XJC_AH'Q/_P \M/\ ^_+?_%4 ?1M%?.7_T#XG_YY:?_-^6_P#BJ/\ MAH'Q/_SRT_\
[\M_\50!]&T5\Y?\-^)_P#GEI__'Y;_P"*H_X:!\3__//+ M3_\ ORW_,50!]&T5\Y?\-^)_\GEI__?EO_BJ/^&@?$__SRT__ORW_P 5 M0!]&T5\Y?\-^)_^>6G_/?EO_BJ/^&@?$__#RT_P#[\M_\50!]&T5\Y?\ #0/B?_GEI_\WY;__*H_P"&@?$__/+3_P#ORW_Q5 'T;17SE_PT#XG_.>6G_\?EO_(JC_AH'Q/\ \\M/_P"_+?\ Q5 'T;17SE_P - ^)_^>6G_M_P#?EO\ XJC_(:!\3_\\M/_._+?_%4 ?1M%?.7_#0/B?\ YY:?_M_P!^6_\ MBJ/^&@?$_P#SRT__+\M_P#%4 ?1
MM%?.7_#0/B?_)Y:?_WY;_XJC_AH'Q/_\M/_[\M_\%4 9'9'_(9_ \ E7O- Z$M%>_<_'X@:GXUOM)EU!;=6@CD5/)0J,$C. GRAPHIC begin 644 pahc-20240630xex10d25001.jpg GRAPHIC begin 644 pahc-
20240630xex10d25001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!#_" @," @,# P,$ P,$!0@%!00$ M!0H'!P8(#_H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&$!(4%13_ MVP!# 0,$!
4$!0D%'0D4@0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P 1" V *8# 2(A$! 0$! \0 M'P 04! 0$! 0$ $" P0%!@<(^0H+ \0 M1 @$# P(% P4% M! 0
%! 0(# 01!1(A,4$&$%U%A!RJQ%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7]#A(6AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& M0)C)RM+3U-76U]C9VN'BX^3EYN?
HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+ \0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-
$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H_$ MA8:'B(F*DL4E9:7F)F:HJ.DI::GJ*FJLK.TM::WN+FZPL/$O<;'R,G*TM/4 MU=:.7V-G:XN/DY>:GZ.GJ\O/T]?:W^/GZ_]H # _! (1 Q$
/P#]4Z\& ,:J\ M$>*/'.HZ/#HNF2WMG:PNS.DB*-[-R,.PZ!%_,O>: /'X_P# _40\=?#KXQ^ M*?#'AS3?#]QI&DW9M(Y;VVF>5F0 2;BLJC[^X=.@J_[&J9Y"6%@['=7K;9KO< MX5\&$Z?)4;2?8ZW_
(4!X]_Z%Z;__+_1?_%T?*\>_]"]- W^B_^+KQ'_AZ M)\5O^@/X5_.?__/U)! P5&^*23*TNB>%I8P>46TG4G\?.KC_.(:5/YG M_P"!+_(\;ZIA?YI?A_D>U?\ "@'/O_0O3?\ ?Z+_.+H_P"% >/?^A>F_P"_
MT7_Q=>E?LH_MJZ3^T9=7&@W^F#P_XKMX3\ 9DE\R"ZC!PS1D@$$9&5.>#D$ MX./"OV@_^"AWKXK;_&3Q3X7\.;:X?N-(TFZ^R1RWMO+)*S*H$FXK*H^_N'3H M!7#3X
]I7EAKR4HJ^K6WK8T>_PRBI_]"]- W^B_^+KJ_P!B/]JQW^TAKGB<>)+#1[32M)MH2CZ;;RQNTTC M'):1AC:C\8]*^MJX.5P=0P=5T:LY_X4!X]_Z%_\71_PH#0[_P!"]-
_W^B_^+KZ8_:_^*4WP8^#'B;Q?:+!)?6$*"UCN M03&\SR+&@8 @D9;. 1TK\^A_P5#^*Q(^]C^%?_*?_X_7=@N HX^#]49.R=M M60\ (SG@,/3=I2?X?Y'MO_"@/'O_$+TW_?Z+_XNC_A0'CW_
*%Z;_O]%_\ M%UT7[0G[6_C/X+__P"6OI9:-)XO\3P+/?'_ASPW%I'A@-JVH0664LY]P$DBJ2/W_8$FM:/A[[:DZT) MOE5^ZJ;!!/ X:+Y7) A_D??_,)_#,OA#X?:/IEQ#Y%U'$7FCR"5=F+$$CCD
M./PKKJ**[J5.-&G&E':*2^X]^$5"*@MD%%%%:EA1110 4444 %%%% %75-1A MTC3+N_N6V6]K"\\C>BJI8G\A7X'>+->F\4^*=8UFXSY^HWDUW)G^](Y8_J:_M9C]L#Q?_,(3^S9X\U!9?
*FFT\V$3#KNG80\>^)"?PK\4CR:_1.%]-J=6MW:_M7W:_J>9BY:J)].?L(?JL[^'OC_P"-_$[-T4>Y(%?5*G4IXB=>]4]QI)+HN[.2Z<5%+4]E_8&BFC_M
&EM#U%9&AL]+L[V^O9!T6!:;0,3[991^(KP[OCX@E\6^+=:UR?)FU*]FO'W M==TCES^IK]-_9];ID'])DIXD^)M=GA?OQK>E_V>YA8,MFDS")84;^)LON8C
M@E0!D+D_G1]X^YKEP5;GB\15Q%+5*T4^]KM_G^!52+A%1?]?;/[)7[2'@G]E MKX'7U[]PFUCQ/XAU)YH=*L"OF+;O*[(TK$X12_FXZD\X!'->P_#[_@]#X1\3 M^)[/2]?\+7OAJTN15B&HB\6YCB).
T@V(0OJ1G'I7S)\<_V6O#_P<_9H\">, MIM1OY/&&O2P-/:R%?(6.6!I2]KC<"F$!))R2>!Q7S;HFE3:[K-CIML-UQ>3! M;Q@U9V"C]2*X%EN S'VF(=VVWK=]UM-.EEYFGM:E*T3]?/VS_BC\.O G@/2=
M.^(V@7WBC2-9N_W=AI\OEL6B_:>3YB' ++W[BODOPAX__97\9^*!'T#3_@SK M_P!NU.BLX=]Z^T/(X4$XN:J_P#!.93^Q'YGQ(\^$TE,J:%HJLY)_Y:2M M@Y]LI49_&O.OV!O"' "6_M/>%BZIX-
+$VI2#&<>7&=A_[^-'7!@L%"AEGUB4_MY)V\.VJA+30=&C41]>$>5B<# M_@"Q5XO^REXM\,_#[XV:-XK\6W36VD:)'->[((HS))-*(V6-$4=6+LIY('!)(MQ3?VM?%_"/=360RPKJ$[_P!"]-

$*X]L1Y_&O4?V&?V4-#_ &AKCQ'] MOBJ:\30]*\NWBALI!&TT[@DY8@X"] <#]6'ISZ\52P>5*-=M1Y5>V_O;V\[L MQ=YUO=[GNTG_5;\.C5/+C\ ZFVG;L?:&OXQ-M]?+V$9]M_XU]0:3^T-X1U M_P""=]\4-.N):OP]9V>%_V#_B/;>:8X-9\2VFFP9/ M\7EK+*!]4B4'ZUY6-R+"F;KJ[!?0+//9V_E@V0).$DZT\ MSR^;$A(W+N$94L!G@'&>]7BRJK$;2>^#D9]] M^Q_^"46MWI7/O!T@R,VF*EI=K&?
NI*3(I([V4#/^X/2C-.GPM/!_6\,G&UG: M^Z=N_74*->;GR3/T-HHHKX,]$^+O^"I'B\Z5\'_#OA^-P)-6U7SG7UCAC)/_ M ()'^5?F!UK]E_VD?V2]" .;4U71KO7/$.IZ4NDP21Q6]B(]IWL"SG
@P_XK+Q!GCM:_/Q%?H.49M@L%A(PKW8TC;MZ/O_E8\VM1[5)M MK8]D_9+^$VB^':?V=/ L% H=A=?/7&GK?327%JCV,HR2,\!P/PKW6\3Z
M1%:V\5M$.B0H$7\A4>E6%OH^F6=A:@);6T"0Q*.R*H4?H!5D.K8PP.1D8/45 M\-7K2KU)5)/=M_>>A&*BDCXT_P""HOB\Z1\&=!T"-]LFL:])'7/+10H2?_'G MCK\VO
/AF3QIXX\/Z!$&:35+^"S&WK^\D5?ZU^O7[2/[)V@_M*ZCHMSKGB'4 MM*328I8H8+'R]I+D%F,Y3SA5_*N$^%/_ 3Q\$?"WX@:'XNL_$NKZG<:5<>? M#;W7D^4[@$+G:H/!(/!Z@5]IEF;83
X'V3;YJ7L]^GZ':5HSJ5+]#P[_(*F M>)8H?$'@'P=:$);Z=82WC0KT42,(XQ^ A:\Z^??V,O! _": M+^!:-HA+#;7 MO]H2YZ!8%,HS_P "11^-?H7\>OV'?" Q[^(,_BS6_%6K:?
I)/N35K]GW]B+PE^SYXYD\4:3KNIZO?/9R6<<=]Y6Q S*68;5!SA< M?1C3HYOA$GS\KZ/=WZ_,)49R]\SVN?G-^V+XP_X3?]I3QW?K+YL,%^ M;"(@Y 6!1#0[90G\:]W_.";=C'X7L?
BK\1;I%%OH>C^4DC=^'F<#\(4_,O7 MM5_X)C>!M9U.]U"Z\<:_)2[U% +^TJK*BE0 NW&U".1_&:TQ6;8*>"6$I2?V4]'LK7_4 M*-15,=H_';4+V74K^YN[AM\\\C2R-ZL3DG\S7U]^R_\
M>>$_@'-SKXJT/[- M>R>-KF\GN+()(X@89&>&-(W9\\!"I)'7CCKOJ[9_PZR\ !5;_A--?VDX!V?!/ MI]RK_P 2_P#@F7X((\7\-SX8UZX*2I!'%-;"W6XA=E4+Y@7:>5\ #+,[$_J2;^F?VF? M"-Q\%O@1\)?
AU>(8=9N1=>)-7A)Y2:7:D:D>JHK(?=37VA\!OV"O /P3UNW\ M07]['+XKU^W:?:3WR+'!;N/XTB!/S]"O,.H /-:'[0/[%7AK]H?QW#XDUOQ1 MJVGW"6B64-K9^5Y81"S'&Y2^,OC>PU.-
X[Z7+6+HR:ORVZ5F#?1 M@0^PB^B/V/(VH/!7[/'@GVOB$73:S>/%/8P6\!?[5L1P([XX3YFZM@8;VK M[3 ;"_9+^'/[0NEMPI:K,VC^(DC$8U?3I46211T653E7 Z\-CC_6 M2 M?:\ \+//V7/W?[-3?
CZ^=C]*^B_MG+<=A%0Q4G':ZUZ=FKZ')[*I3GS0U/@3 M7]9NO%'B#4=6NSYE[]%S)=3$?Q2.Q9OU)K]7_P#@G[\"KIX/?"*;4M:MFM->_N\I7_2@=52(48=F^9V(I;P#R*M?!7]A[X5?!S4K>
5RS>)]<@(>*\U>5 M&2%0[R1* H([%MQ'8BOJ**[@G;;'-(W7"L":\K,.[I8RG]6PWP]7WMLDNQO M0H_!17Z O=2BMMOEM^B/-WU-NT^&/C[P]XH;P1=ZI[^H:UJ.A:?X5M
M+D2RO6]KIJ&>25,A=^^6*U"LPYW2MC 5<[G[_ C:!!^*WA'PWJEIY|X/"L>B MV]U&.R)1]N7(M0Z _-P"0!QI6[;Z=?ZQ%X'US0(;"\S
M(>#=1TJZ^R.@M+B>ZNKB.26;RK=!#GRBD0SZN>IHHK5.\%Y-K\4OR;)ZEOX: MQ:\9=$^'.EZYH-K>OI&OZKJ.K3WF)3=N89KIXTR/N-+-%D-U$0KHO@MX.\3
M:/#?:FVMPWEY;>!)!3TN!HQ''97FI32W$F&5=S*##&-S98#(P!117)B6X,< M%MI^,I7^\N,MG_6R/*;B3P[XB\!?#VRTKPM;P0>(-/OM!C^U2\RZX5@A74KG M"GS"BF9E;EPS]NHUM5\
:W::EK>L27UF;W7['6';,3KR(.MVC-(_#/BZX\46MU8#Q#XB MMM0&BWB*Z2Q376H1V:&\DY,]0QB-T '#%P1T:BBN>E4E4HTW-WYM_O?^1324
MG;H:G@GX26EG<^&/#OB;2=*UB#POKGB"]D5V><2QPVT;)$&D7<5:6<2,&[H. MME^(M"TJZBMKOQ%:Z/[_BFTU1IG_T2"&*:^NHXOERLDUS)M;'#1@9 M/&***]$I2E/F?2_SN_Z\O-
62M_6Q['^R;X!U3P=X\UJSU/44U&R\-Z';)8$, MQ<-J 6\NBV0! K8\ ^F,UX_K^JR:QK=_?2$[[F=YFSZL23_.BBOQGCROZ%#>WK1O;UHHK\K/##>WK7M'P*T>>[\%?$2\M3'
M]N.E/:6YD9D"M(KX)*C(&44Y'-%%?1\,I2S2C?O^C._ I/$1^2Y,R?'_,'O M&>L:=7PK]M--2_L(&_$*FL?\ @&_ ^%' "JO&G_0:JQ_X!O_A6 MD/\ @JM9D#/PWN@?3^UE_P#C=?3OI-7QW?\ :'\
3^*AH,GA^W6]DLXH9+D3 MF38%W/D*N!EB,>U75X+=="/4DTOD*&##HS=HS9\H?*]\:?\ 0J:Q_P" ; X4 M?*\:?]"IK' @&_^%?H/FN;^)7CBW^&O@#Q!XJNXS/;Z192WC0AMIDV+D(# MV).!^-
%J,FDJCOZ(U>6TUJY,^'/\ A57C3_H5-8_\ W_PH_X55XT_Z%36 M/_-_P#"M)?^"JUF0"?AO<@^G]K+_P#&Z]R^':?[6T/C?]G[Q5\5;OPU+H^G: M(TZI9M=B1KDQJIX;;-N68+T-
=M3@J5))SD^W0QC@Z$M%-GSW_P *]\:?]"IK M' _& P#A7JW[-7PSUW3/B2-3UG1;W3>SM)&CDNX&0-(V% &>^'$KJ_P#1 P!A9?\ XW7T_P#LV_'- P!H;X>R>*QH+^'[?
[;+:1027(G,@0+E M\A5QR2> J1O%1NT6NV_R-:&%HJHG&3;1ZM1117O'M!1110 4444 % M%%% !1110 5^-?[8_B\^-/VEO'-X'WPVMV-.B(/&V!!&^N)+J1CU+.Y8_SKZ3 M):=YSJ=E;
[_^&/.QDM%$?H.CS^(M=TW2;49NK^ZBM(N, /(X0?]:]R_:4_8[MU]F[1-*UB]U^PUW3K^Y-INMXFADCDVEAE6)R"%/(/:I7DOPR\9I\,OB%X>\ M4OIR:O\
V/=I>+922^6LK+D]"V#@9P>AZ5Z!^T;^U-XG ;1OM. M>TM=(TG3 M2SVNFV99E#L,&1W;EFP,#@ #/'-?0U/;NM'D^#[<$>3D=]^AXS7V _Q#OM. _MX)]PZ7<3L6U#Q
VCVH8\ 9UE\Y@/8;6'TXKY2\,^&=5\9^(+#0M#LI=1U>_E M$-M:0C+.O_D!U)Z FOJ#]M?PW#\'OA]\/A1;S+-)I-C/[=(G26XE8*S?] M]>;CVK/$\LZE*D][W^XJG>,92\K'R8O"@D!!S7ZT?
L]>+/!G[. [.O@"\V8> M(=.\,3W6P+]H[R8+*TS&?*T]]YN& R!VK\G;.RGU.\M[.U@>YNKB188H(UW- M(("']W)) KT/X[_ Z^?(2@'Q3922$BW>+6-2M%FWW>X2;]RN$5!M)"!.!=@
MZ<5.,H1Q7+2E*WT8Z,W2O-*Y^M_@+]H7X;_ !0U(Z=X7\9:7JVH8+"TCE*3 M,!U*HX!;\!6;^TUX?T7Q\(]4\.:[XPM(!%EK#QVYU*[9 #M<2&-0[*"2$]>
MF: &WPKJ=]HGBK1=0TN:2WU.UO89;:6(X=9 XQC'Y?C7V]_P5,\7&>[^' A= ML!DBGU2>,'(!.V-/Y28_&0$GEJHXFG&G+?7TL=BQ'/3DY+8Y@_L2_"<#) ;% MT?' _&[? ']$_ :7\.Z9^SY^POI/@?
1M8768=7OXHTU%5"?:T>1KEY 2,$* MHX)XQ7Y]Z'K=&^ACX]A&WYUZ%6G4^L4J/? ?[.OL?@>QU%_B?3/#] _<:6E.5NOFS*C-TIR2N?KE\/OCEX!^
M*LTL/A/Q9INMW,2[GMH)<3*OKY;8;'OBM[Q1XX\.^"8K>3Q#KNG:)'<,5A;4 M+E(1(0,D+N(SC(Z5^&WA'Q:J/@'O3I?B32+E[34M,N$N8I8S@_*%-2]V5 M_70[8XJ\')K5'WQ_POKX;?\
0^^& P#P:0 _!56_%/QB\"^"-2@T_O!XOT7 M1KZ$O#^]_$KX]>']/U, MW=U?Z_JMO!+'3+BUB5-6U6V.)(!O ^O?%?OQ8 M>']$@?4]>U24A3-)R3@LSR.>@ !))KCPV5^TI^UK2Y8_H:U.3RRY8*
[/UVL/ MVPO@QJ5RL$/Q$T<2,<#SG>)<_P"\Z@?K7&K:K9:W8QJ7NG7EO?V(/@;XUE\+>)1;M]"P1W:R6(;I:"[T[G)NB21^(YD\'\+!L D=02#VK>ME4/9>U MH3OI?
U)ABGS>$/#4.YFU'4GO)40$G9#'@9QVW2C\]_'R9 M?^>,O_?!_P *^URB'\A^;N_^ >-BW>I;L>[_ +*W[*EQ^TS<>(_^)\?#UIHZ MP@SBT^T>;))\N^7&I<8"Y_$5])Z1_P2MTF*X5M4^(=]"

G)"Q]MS.^/R MKNO^":?@_P#L'X"WFLR1&.?6]5FE!9<$QQ 1+^JO^=?6E>5C,PKQKSA3E9+3 MH=5&A!P3DM3RSX+_ +, @#X#0.?"^D8U*5=DVJWK^===R+Z;S]T>R@"OS< ;V M\7?
\)9^TYXE1'+P:1%!IB#/0HFYQ_P!IR-7ZY7-Q':6\L\K:8HD+NWH ,DU^ M%'CWQ!<^-/'7B/Q!+'*SZIJ-Q=YV$\/(Q';T(K7*>;K6G5F[M+_^&)Q5HP4 M8GI_[%7A+_A.?VFO!4#+NAL)WU.3(X A0LO_
(_LKM_^"D'BW_A(?VBVTQ'# MPZ'ID%K&G'@.^96_1UKM_^"7/@YKOQ_XR\2S0L$T_3XK&)W4C#RON;'_8A^= M?+_QV\3R^._C3XWUX)*\5YJUP8CL)'EJY1,>VU17JQ_>8]O^6-OFSE?NT$N[M-
+]F'PA_PG/[0?@+2#'YD+:I'A5-[_P#CTC5V'_!-7PK]M^->L^(KJ-H[:(0=!'D?S'4@!Y6" GL5Z^ M:?B'XBN?&WC_,2^(98Y7?5-2N+O.P]'D8K^F*U7OXQO^6-OF_\@$OW:2\V M>E?L7>$3XR_::\6Y3?
#97+ZG+D< 0H77_Q[96G^W?XN'BW]IWQ2$?=!I2P: M8@ST,: N/^^W:O5?^"8OAE4\<^-_%UY$T=KI&EI;"1U(VM(Q=CS_+,7ZU\C M^-M>N?&/C37]>FCE:34]0N+PG83]^1F';T(J8?O,;)_RI+
[]1OW:*7=GJO[$ MGA1/%W[3O@N"50T-E++J3_]8V9?_'MM>U_\%1_&DD\^_!WA:&97;3+*6^ MN$4_<>9@J ^AVOD_1A7RI[X,T[O]X&T:/XG>&$U'2[.PO&T_^V:->8)3&*588
M.%*MC)&"3BN6USQ+JWCOQ%PJW0]IB ME7OI%6^9?_RT^2VY<\ ^$[GOYXY\>'+-#))OVCO&;P$&TTZX32;< Y 2WC6+C_{$K5]0_L3_LO7_PML]0^+OCVQ;3
MKNRL]M+TNX7L>PEYY5_A8]"IJ>0"2<9%?![&KZA=Z_]]JEQ',T]]<274A M*'.YW+'M[T4ZL:^(DXNZBK?-[_D$HN%-)]3W7]A'X>6GQ$_:,T:/4;,.^TW2 M;>;4YH9E#(60!8]P/!
=U.#Z"OUJO[6RAMVNI;."4VBF9^8U4]"RS^/?%$T3)@6^F0LZXS]Z23'_D/]* 0!T61&5@&5A@@]*^9S6K MSXEKHK+]3TL+&U, <_!KQ7KUUXJ\5:UK5([TUWJ-[-=2NW4L[EOZU]>?\$O/
M"L.H_%#O:K\L8=]+TN.WA)_A.:0[B\ @,1'XUY!^T_^S%XF^!GC?5)1IMS> M^#[JX>?3]6@C+Q+&$$B.4CICKG'. < CK7G/PY^,WBOX176HW'A#Q%+H4]_"
M+>Y:'8=Z@DCA@<$$G!'(R;^GJ16+PSC1>Z/-B_95+S6QZC^W5XRA\9_M->*7 MM!):.6L.EJRG(W1)^_)VT@C+Q65Z-2N6'1(H!O) M)[?,%'UKAO!/PZ\8?%K7?LGAO1-
1\0ZA<2%/)8HRRAF.2\DI^5>3DEC7ZD? ML??LI6_[.WARYO\ 59H=0\9ZIBB\N(>8[:_ MR30*UE_F:4H2K5.?H?1-%%%?$'M'G&K_]S\):9\4?\ A KDW$FM)82:A+,L M :V@1$,AC>0GB38-^W'3!
[UR.G_M=_#O5?"MCK]I;ZC/:7EC/?I$MFOFHD5RE MEMM9=W#O)(H0=QD\5XKXD^%UFGAW3_&XUC63X@\2#7);^5KH&,M- \+%(RNU M-L:]JX' 49S6I<_!C0- ^)'B!+%[N"U?5-
"VH=#%&J1FXV*-O"M+#&S#N5[M5[2PM)+6_P#PSL_ST./VDFSVFZ_:H\!6$&H_OKMI;+QGA3[+# IDGOF*\1K MN^9!N)+<8VGVS9U#]ISP7INM>,I-=K^23P;9&^U&>.W!BD"G:\
<+9^=U8A". M,.<9KP67]GSPOX4\&>"_ 'ED!^WB.YN+>_DFGF5T-PD_!K3/ OA:WDT[5]:DDUCPU:SWK7ETL_F2/?0W#MAD(&Z3)8 8.3O36$ MHR=E<'5FE<^O/%WQ*TCP3HFB:EJRSPQ:O?
6NG6\6U0XFG.%#9K!0!DL<\!3U MK@6 :@\'SZS::5I>BZOK=Y=3744^6%M 0RV]O]G>4%Y%!0R9"D9))Q7+7%@ MGQ@\+ "&;Q@5UO'>_P!1N=:XAB\BYEPCM1'YD84*0N<@ #D#.:\/T7P[:^_
M&7@IM.6*:[+X?MQ;B^L[>X\A@)KCS(R\9,;F1R2R$=%':LJ6&@T^;=7],J_0 MJ4W?38^]+[]ICP1I.M>,],/VTOX.LFOM2FAMAY4@4@/'"V1O=6(4CC#'&;=X
MD^/FC>&/&%GX\NK#^TUGM[&)H$MP%,LC.9!@1[U#<=3@9KYH\>?! MK3/ OA6WDT[5]:DDUGPU!/>M>72S^9(]!U.C6NH:1;Z:ZV 2(QQ"P.2F%^\QD8DG.2;\:O=5UO6?AA\V=EU^\LN UMKSPQ:RP16ZB*SFBBB;:OE8#A4&'QD9/6IAAZ;9K M5G:PB\^RWTFG*T7H&M;3K!*MN58ESYC*HR "37EK?!'PUX2\06GB.Q2Y;4]$\
M5VNFVAGD$D8MX;!8XD9"NT[2/,#8W!R2#VJS]OP'\)>$/V9K7Q)I-I+;>)(+ M>SU-M69Q+--*EPD^'#@KL:0!F55 .!Z4_84+I:ZV_$7/,](N_P!JSPDNF203 M^%_$CWXN;NSN]!.GQ-

1"DTS2+YFS8(Y$.0Q^]CK4EK\4_A/X;\1^!8M*\ M.00:MXQMTN]/ET_1XHY(HY%W1M,P ,>\@JHYR0?2O#M2^"NA^,/"EWJNMW>H MWNIW'A>]\1-
<^M+XRTVTCMX)Q'9QV\"]D4*PA=!8(]X[Y=N>:IX>DEI?K]X*/$VEPK]PT)I]0LHTC%YSOBR)3]Q0S-Q@ 'J>*RKK]L?XZ=H.IZS? MZ3KNGV%I90:G;OFZ]X8\"Z?.,#,<5R'PD\ V?
C^P*ZAXAN[K5&; M6+;1#!((EA^QV-K.8(=BH!C=(S-W)QV&*2P]&SDT[+ -_P"0^>=TCZ1D^/'A M:WT7Q+JD$=U-8Z%=06<\L,2A9I98HY5$1S\V%E3.<8.1VKEO^&OO! \ T#M8 M_P"_,?\
\77C:>$K;P,^S%HFDVEU=W$5WK]S/<3W3AY964NJ[F P_J@<=%% M>< V5%_?D_,?X5^;YIFF(P.-EA\,URI+==3S\1BZL))1ML?25$G[77@V:-HY- M+U>2-AAE:",@CW&^N:E^-
GP;GF,TGP_ADF)R9&T:U+9^N:^?/[*B_OR?F\ M^C^RHO[\GYC_KP%Q#F$=I+[CE^NUWO;[C

$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$
/P#]4*\=_:@L M]9UCP'::5HVF7>I2W-XC3+:1&0JB GG'0%MM>Q5\Q?M*?MOV'[._CZV\+'PO M-XAN)+%+V66.]6 1;F8*N"C9X7.?>L:F"GF%.6&AO)?A\S*ORNFU)V3/%?\ MA57C3_H5-8_\
W_PH_X55XT_Z%36/_-_P#"M+_AZM9_]$WNO_!LO_QNC_AZ MM9_]$WN?_!LO_P ;KP?]1:G=_P#DO^9XWU7#_P [,W_A57C3_H5-8_\ -_\ M*/\ A57C3_H5-8_\
W_PKN?!'_!3P#3K>J0B3PBX0?^-ZOKUF91:=B\VFT'_[)LW9ZZ3OM0\"S2'%X'X8L7NQ@=%0U9[#KT6$T%]?,:!Q1::5=0EXFQ9[,[+:<GNLA^\WE]DLXH9+D3 MF38%W/D*N!EB,>U75X+=".//4DTOD*&#HS=HS9\H?*J\:?\ 0J:_P" ;_X4 M,NC2Y*E_
@&_^%'_A57C3_H5-8_\ -_\ M*/\ A57C3_H5-8_\ -_\ M*/\ A57C3_H5-8_\ W_PH_X55XT_Z%36/_ ;KP?]1:G=_P#DO^9XWU7#_P [,W_A57C3_H5-8_\ -_\ M*/\ A57C3_H5-8_\ W_PH_X55XT_Z%36/_ M/_ - P#"M)?^JU:_]$WN?_!LO_P ;K0[[16
J\:?\ 0J:_P" ;_X4 ?\ A57C3_H5-8_\ W_PH_X55XT_Z%36/_ ;KP?]1:G=_P#DO^9XWU7#_P [,W_A57C3_H5-8_\ -_\ M/\ A57C3_H5-8_\

G)"Q]MS.^/R MKNO^":?@_P#L'X"WFLR1&.?6]5FE!9<$QQ 1+^JO^=?6E>5C,PKQKX0MZH-(RSX+_+,_@#X#0.?"^D8U*5=DVJWK^==R+Z;S]T>R@"OS<_;V M\7?
\)9^TYXE1'+P:1%!IB#/0HFYQ_P!]R-7ZY7-Q':6\L\K;8HD+NWH ,DU^ M%'CWQ!<^-/'7B/Q!+'*SZIJ-Q=YV$\/(Q';T(K7*>:K6G5F[M+_^&)Q5HP4 M8GI_[%7A+_A,?VFO!4#+NAL)WU.3(X A0LO_
(_LKM_^"D'BW_A(?VBVTQ'# MPZ'ID%K@'@.^96_1UKM_^"7/@@YKOQ_XR\2S0L$T_3XK&)W4C#RON;'_8A^= M?+_QV\3R^._C3XWUX)*\5YJUP8CL)'EJY1,>VU17JQ_>8]O^6-OFSE?NT$N[_M-
+]F'PA_PG/[0?@+2#'YD+:I'A5-[_P#CTC5V'_!-7PK]M^->L^(KJ-H[;0='D?S'S4@!Y6"_GL5Z^_M:?B'XBN?&WC__,2^(98Y7?5-2N+O.P]'D8K^F*U7OXQO^6-OF_\ @$OW:2V@V!\V M>E?L7>$3C3X]R:S::,::\$6Y3?
#97+ZG+D<_0H77_Q[96G^W?XN'BW]IWQ2$?=!I2P:_M8@ST,:_N/^^W:O5?^"8OAE4\<^-_%UY$T=KI&EI;"1U(VM(Q=CS_+,7ZU\C M^-M>N?&/C37]>FCE:34]0N+PG83]^1F';T(J8?O,,)_RI+
[]1OW:*7=GJO[$ MGA1/%W[3O@N"50T-E++J3_]Q8,8V9?_'MM>U_\%1_&D6H^_!WA:&97;3+*6^ MN$4_<>>9@J^AVQD_1A7R[X,T[Q]X&T:/XG>&$U'2'2[.PO&T_^V;->8)3&"588
M.%*MC)&"3BN6USQ+JWCOQ%PJW0]IB ME7OI%6^9//RT^2VY<\ ^$[GQYXY\/>'+-#))OVCO&;P$&TTZX32;< Y 2WC6+C_($K5]0_L3_LO7_PML]0^+OCVQ;3
MKNRL)IM+TNX7L>PEYY5_A8J"JJ>0"2<9%?!&KZA=Z_J]_JEQ',T]]<274A M*'.YW+'M[T4ZL:^(DXNZBK?-[_D$HN%-)]3W7]A'X>6GQ$_:,T:/4;..^TW2 M;>;4YH9E#(60!8]P/!
=U.#Z"OUJO[6RAMVNI;."4VBF9"8U)4J"RS^/?%$T3)@6^F0LZXS]Z23'_D/]*_0!T61&5@&5A@@]"*^9S6K MSXEKHK+]3TL+&U._<_!KQ7KUUXJ\5:UK5[(TUWJ-[-=2NW4L[EOZU]>?\$O/
M"L.H_%#Q;K\L8=]+TN.WA)_A::0[B/\ @,1'XUY!^T_^S%XF^!GC??5)1IMS> M^#[JX>?3]6@C+Q+&S$B.4C[CKG'.<_CK7G/PY^,WBBOX176HW'A#Q%%+H4]_"
M+>Y:'8=Z@DCA@<$$G!'(R:^GJ16+PSC8ZW5XRA\9_M->*ZC^W5XRA\9_M->*7 MMI!);:6L.EJRG(W1)^_)VT@C+Q65Z-2N6'1(H!O) M)[?,%'U(KAO!/PZ\8?%K7?7LGAO1-
1\0ZA<2%I)8HRRAF.2\DI^5>3DEC7ZD? ML??LI6_[.WARYO\ 59H=0\9ZJBB\N(>8[:, MR3O*UE_F:4H2K5.?H?1-%%%?$'M'G&K_!S\):9\4?\ A KDW$FM)82:A+,L M :V@1$,AC>0GB38-^W'3!
[UR.G_M=_#O5?"MCK]I;ZC/:7EC/?I$MFOFHD5R MEMM9=W#O)(H0=QD\5XKXD^%UFGAW3_&XUC63X@\2#7);^5KH&,M- \+%(RNU M-L:JJX' 49S6I<_!C0-^)'B!+%[N"U?5-
"VH=#%&J1FXV*-O"M+#&S#N5[M5[2PM)+6_P#PSL_ST./VDFSVFZ_:H\!6$&H_OKMI;+Q(GA3[+# IDGOF*\1K MN^9!N)+<8VGVS9U#]ISP7INM>.]-=K^23P;9&^U&>.W!BD"G:\
<+9^=U8A". M,,<9KP67]GSPOX4\&>"_'ED]^WB.YN+>_DFGF5T-PD_!K3/ OA:WDT[5]:DDUCPU;SWK7ETL_F2/?0W#MAD(&Z3)8 8.3Q36$ MHR=E<'5FE<^Q/%WQ*TCP3HFB:EJRSPQ:Q?
6NG6\6U0XFG.%#Y8!0!DL<\!3U MK@6_:@\'SZS::5I>BZOK=Y=3744*6%M 0RV]Q]G>4%Y%!0R9"D9))Q7+7%@ MGQ@\+_"&;Q@5UQ'>_P!1N+:XAB\BYECMY1'YD84*0N<@ #D#.:\/T7P[:^_
M&7@IM.6*;[+X?MQ;B^L[>X\A@)KCS(R\9,;F1R2R$=%':LJ6&@T^;=7+J_0 MJ4W???38^J+[[]ICP1[IM>.]./VTOX.LFOM2FAMAY4@4@/'"V1O=6(4CC#&&:=X
MD^/FC>&/&%GX\NK#^TUGM[&)H$MP%,LC,9!@1[U#<=3@9KYH\>?! MK3/ OA6WDT[5]:DDUGPU!/>M>72S^9(]]!U.C6NH:1:Z:ZV 2(QQ"P.2F%^\QD8DG.2:\:O=5UO6?AA\/M>EU^\AU.UN
MKSPQ;RP16ZB*SFBBB;:OE8#A4&'QD9/6IAAZ:9K M5G:PB\^RWTFG*T&HM;3K!*MN58ESYC*HR "37EK?!'PUX2\06GB.Q2Y;4]$\
M5VNFVAGD$D8MX;!8XD9"NT[2/,#8W!R2#VJSJOP'\)>$/V9K7Q)I-I+;>)(+ M>SU-M69Q+--*EPD^'#@KL:0!F55 .!Z4_84+I:ZV_$7/,[](N_P!JSPDNF203 M^%_ $CWXN;NSN]!!.GQ-

1"DTS2+YFS8(Y$.0Q^]CK4EK\4_A/X;\1^!8M*\ M.00:MXQMTN]/ET_1XHY(HY%W1M,P ,>\@JHYR0?2O#M2^"NA^./"EWJNMW>H MWNIW'A>]\1-
<^M+XRTVTCMX)Q'9QV\"JD4*PA=H10[X[Y=N>:IX>DEI?K]X*'/$VEPKJPT)I]0LHTC%YSOBR)3]Q0S-Q@ 'J>*RKK]L?X?Z=H.IZS? MZ3KNGV%I90:G;OFZ]X8\"Z?.,#.<5R'PD\ V?
C^P*ZAXAN[K5&; M6+;1#!((EA^QV-K.8(=BH!C=(S-W)QV&*2P]&SDT[+_-_P"0^>=TCZ1D^/'A M:WT7Q+JD$$=U-8Z%%=06<\L,2A9I98HY5$1S\V%E3.<8.1VKEO^&OO!_\ T#M8 M_P"_,?\
\77C:>$K;P;^S%HFDVEU=W$5WK]S/<3W3AY964NJ[F P J@<=%% M><_V5%_?D_,?X5^:Y[FF(P.-EA\.URI+==3S\1BZL))1ML?5$G[77@V:-HY- M+U>2-AAE:",@CW&^N:E^-
GP;GF,TGP_ADF)R9&T:U+9^N:^?/[*B_OR?F/\ M"C^RHO[\GYC_KP%Q#F$=I+[CE^NUWO;[CZBL?VKO NEVRVV]EHFI6ENOW8H M+6)%'T ?%7[#]K'PIJ5_:V<&F:PT]Q*D,8\F/EF(
_C]37R=_947]^3\Q_A7 M9_!K1+>?XJ>&%D+NJWBR;21@E02.WJ!6M'/&X[:/ LX>\H-:>)"/MS^;;:^ EX-101.SCH 18 pahc-20240630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom
Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940204 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Net Income Per Share and Weighted Average Shares (Details) link:presentationLink link:calculationLink link:definitionLink 99940405 - Disclosure - Statements of Operations-Additional Information - Interest Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99940407 - Disclosure - Statements of Operations-Additional Information - Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940408 - Disclosure - Statements of Operations-Additional Information - Depreciation and Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Balance Sheets-Additional Information - Accounts Receivable, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - Balance Sheets-Additional Information - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Tabular Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 99940507 - Disclosure - Balance Sheets-Additional Information - Intangibles, Net - Total (Details) link:presentationLink link:calculationLink link:definitionLink 99940509 - Disclosure - Balance Sheets-Additional Information - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940510 - Disclosure - Balance Sheets-Additional Information - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940512 - Disclosure - Balance Sheets-Additional Information - Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940513 - Disclosure - Balance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 99940605 - Disclosure - Debt - Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 99940606 - Disclosure - Debt - Classification (Details) link:presentationLink link:calculationLink link:definitionLink 99940607 - Disclosure - Debt - Aggregate Maturities of Long-Term Debt and Revolver (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Leases - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Leases - Composition of Net Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 99940705 - Disclosure - Leases - Maturities of Future Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940706 - Disclosure - Leases - Gross Difference (Details) link:presentationLink link:calculationLink link:definitionLink 99941106 - Disclosure - Employee Benefit Plans - Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 99941107 - Disclosure - Employee Benefit Plans - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 99941108 - Disclosure - Employee Benefit Plans - Net Periodic Pension Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Income Taxes - Income (Loss) before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Rate to Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 99941205 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99941206 - Disclosure - Income Taxes - Deferred Taxes Included in Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 99941211 - Disclosure - Income Taxes - Liabilities Related To Uncertain Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 99941303 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 99941402 - Disclosure - Derivatives - Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 99941605 - Disclosure - Business Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 995200500 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Accounts Receivable and Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Property, Plant and Equipment and Capitalized Software (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Derivative Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 99940205 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - New Accounting Standards (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Proposed Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Statements of Operations-Additional Information - Net Sales by Product Type (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - Statements of Operations-Additional Information - Net Sales by Region (Details) link:presentationLink link:calculationLink link:definitionLink 99940506 - Disclosure - Balance Sheets-Additional Information - Intangibles, Net - Weighted-Average Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Debt - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Debt - Interest Rates - Stated Rates (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Debt - Interest Rates - Weighted Average Rates (Details) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - Debt - Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Leases - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Common Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock - Tabular Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Common Stock, Preferred Stock and Dividends - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Stock Incentive Plan - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Stock Incentive Plan - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940904 - Disclosure - Stock Incentive Plan - Cost Not yet Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Employee Benefit Plans - Annuity Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99941111 - Disclosure - Employee Benefit Plans - Estimated Future Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 99941112 - Disclosure - Employee Benefit Plans - Asset Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 99941113 - Disclosure - Employee Benefit Plans - Fair Values of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941114 - Disclosure - Employee Benefit Plans - Change in Fair Value of Level 3 Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941208 - Disclosure - Income Taxes - Net Operating Loss Carry Forwards (Details) link:presentationLink link:calculationLink link:definitionLink 99941209 - Disclosure - Income Taxes - Repatriation (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Derivatives - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941403 - Disclosure - Derivatives - Notional Amounts (Details) link:presentationLink link:calculationLink link:definitionLink 99941404 - Disclosure - Derivatives - Effects of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 99941405 - Disclosure - Derivatives - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - Fair Value Measurements - Fair Value of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941602 - Disclosure - Business Segments - Net Sales (Details) link:presentationLink link:calculationLink link:definitionLink 99941603 - Disclosure - Business Segments - Depreciation and Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 99941604 - Disclosure - Business Segments - Adjusted EBITDA (Details) link:presentationLink link:calculationLink link:definitionLink 99941606 - Disclosure - Business Segments - Identifiable Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941607 - Disclosure - Business Segments - Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99941701 - Disclosure - Subsequent Event - 2024 Credit Agreement - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941702 - Disclosure - Subsequent Event - 2024 Credit Agreement - Interest Rates (Details) link:presentationLink link:calculationLink link:definitionLink 99941703 - Disclosure - Subsequent Event - 2024 Credit Agreement - Financial Covenants (Details) link:presentationLink link:calculationLink link:definitionLink 99941704 - Disclosure - Subsequent Event - 2024 Credit Agreement - Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 995200505 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Proposed Acquisition link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Statements of Operations-Additional Information link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Balance Sheets-Additional Information link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Common Stock, Preferred Stock and Dividends link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Stock Incentive Plan link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Commitments and Contingencies

link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995211601 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 995211701 - Disclosure - Subsequent Event - 2024 Credit Agreement link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Statements of Operations-Additional Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Balance Sheets-Additional Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Common Stock, Preferred Stock and Dividends (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Employee Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 99931403 - Disclosure - Derivatives (Tables) link:presentationLink link:calculationLink link:definitionLink 99931503 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99931603 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 99931703 - Disclosure - Subsequent Event - 2024 Credit Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Statements of Operations-Additional Information - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 99940404 - Disclosure - Statements of Operations-Additional Information - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940406 - Disclosure - Statements of Operations-Additional Information - Capitalized Software (Details) link:presentationLink link:calculationLink link:definitionLink 99940409 - Disclosure - Statements of Operations-Additional Information - Research and Development Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Balance Sheets-Additional Information - Reserve for Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 99940505 - Disclosure - Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940508 - Disclosure - Balance Sheets-Additional Information - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 99940511 - Disclosure - Balance Sheets-Additional Information - Insurance Premium Financing (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - Leases - Other Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Common Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Common Stock, Preferred Stock and Dividends - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Stock Incentive Plan - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Employee Benefit Plans - General Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941103 - Disclosure - Employee Benefit Plans - Change in Projected Benefit Obligation - Tabular Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 99941104 - Disclosure - Employee Benefit Plans - Change in Projected Benefit Obligation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941105 - Disclosure - Employee Benefit Plans - Change in Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941109 - Disclosure - Employee Benefit Plans - Actuarial Assumptions - Tabular Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 99941110 - Disclosure - Employee Benefit Plans - Actuarial Assumptions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941115 - Disclosure - Employee Benefit Plans - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 99941116 - Disclosure - Employee Benefit Plans - 401(k) Retirement Savings Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99941117 - Disclosure - Employee Benefit Plans - Other Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99941204 - Disclosure - Income Taxes - Global Intangible Low-Taxed Income (Details) link:presentationLink link:calculationLink link:definitionLink 99941207 - Disclosure - Income Taxes - Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 99941210 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 99941212 - Disclosure - Income Taxes - Uncertain Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Commitments and Contingencies - Environmental (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - Commitments and Contingencies - Employment and Severance Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99941502 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis, Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 99941503 - Disclosure - Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 99941601 - Disclosure - Business Segments - General Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 19 pahc-20240630_cal.xml EX-101.CAL EX-101.DEF 20 pahc-20240630_def.xml EX-101.DEF EX-101.LAB 21 pahc-20240630_lab.xml EX-101.LAB Cover [Abstract] Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Common Class A [Member] Common Class A Common Class B [Member] Common Class B Document Information [Line Items] Document Type Document Annual Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Entity Listing, Par Value Per Share Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Interactive Data Current Entity Emerging Growth Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Entity Public Float Entity Well-known Seasoned Issuer Entity Voluntary Filers Auditor Name Auditor Firm ID Auditor Location Income Statement [Abstract] Revenue from Contract with Customer, Excluding Assessed Tax Net sales Cost of Goods and Services Sold Cost of goods sold Consolidated statement of operations - total cost of goods sold Gross Profit Gross profit Selling, General and Administrative Expense Consolidated statement of operations - total selling, general and administrative expenses Selling, general and administrative expenses Operating Income (Loss) Operating income Interest Income (Expense), Nonoperating, Net Interest expense, net Interest expense, net Foreign Currency Transaction Gain (Loss), before Tax Foreign currency (gains) losses, net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income before income taxes Income before income taxes Income Tax Expense (Benefit) Provision for income taxes Provision for income taxes Net income Earnings Per Share, Diluted [Abstract] Net income per share Earnings Per Share, Basic basic (in dollars per share) Earnings Per Share, Diluted diluted (in dollars per share) diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average number of shares Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic basic (in shares) Weighted average number of shares - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average number of shares - diluted (in shares) diluted (in shares) Statement of Comprehensive Income [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax, Portion Attributable to Parent, Total (Income) expense recorded in comprehensive income Change in fair value of derivative instruments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent, Total Foreign currency translation adjustment Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Pension settlement recognition Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Unrecognized net pension gains (losses) Unrecognized net pension gains (losses) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent (Provision) benefit for income taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total Comprehensive income (loss) Comprehensive income (loss) Statement of Financial Position [Abstract] Assets [Abstract] Assets ASSETS Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Short-term Investments Short-term investments Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventories, net Inventory, net Other Assets, Current Other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net Property, plant and equipment, net Finite-Lived Intangible Assets, Net Total Intangibles, net Goodwill Balance at end of period Balance at beginning of period Goodwill Other Assets, Noncurrent Other assets Other assets, total Assets Total assets Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Loans Payable, Current Current portion of long-term debt Accounts Payable, Current Accounts payable Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current Accrued expenses and other current liabilities Accrued expenses and other current liabilities, total Liabilities, CurrentTotal current liabilities Long-term Line of Credit, NoncurrentRevolving credit facility Loans Payable, NoncurrentLong-term debt Other Liabilities, NoncurrentOther liabilitiesOther liabilities, total LiabilitiesTotal liabilities Commitments and Contingencies.Commitments and contingencies (Note 13) Common Stock, Value, OutstandingCommon stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at June 30, 2024, and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at June 30, 2024, and June 30, 2023 Additional Paid in Capital, Common StockPaid-in capital Accumulated deficitRetained earnings Accumulated Other Comprehensive Income (Loss), Net of TaxAccumulated other comprehensive lossAccumulated other comprehensive loss Stockholders' Equity Attributable to ParentTotal stockholders' equity Liabilities and EquityTotal liabilities and stockholders' equity Statement [Table] Statement [Line Items] Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]Common stock Common Stock, Par or Stated Value Per ShareCommon stock, par value (in dollars per share) Common Stock, Shares AuthorizedCommon stock, shares authorized (in shares) Common Stock, Shares, IssuedBalance (in shares)Balance (in shares)Common stock, shares issued (in shares) Common Stock, Shares, OutstandingCommon stock, shares outstanding (in shares) Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]Preferred stock Preferred Stock, Par or Stated Value Per SharePreferred stock, par value (in dollars per share) Preferred Stock, Shares AuthorizedPreferred stock, shares authorized (in shares) Preferred Stock, Shares IssuedPreferred stock, shares issued (in shares) Preferred Stock, Shares OutstandingPreferred stock, shares outstanding (in shares) Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract]OPERATING ACTIVITIES Net Income (Loss), Including Portion Attributable to Noncontrolling InterestNet income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Adjustments to reconcile net income to net cash provided by operating activities: Depreciation, Depletion and AmortizationDepreciation and amortizationDepreciation and amortization Amortization of Debt Issuance CostsAmortization of debt issuance costs Deferred Income Taxes and Tax CreditsDeferred income taxes Foreign Currency Transaction Gain (Loss), UnrealizedForeign currency (gains) losses, net Represents amount of business acquisition related items.Acquisition Related ItemsAcquisition-related items Pension Expense (Reversal of Expense), NoncashPension settlement cost Foreign Employment TaxesForeign Employment TaxesBrazil employment taxes Share-Based Payment Arrangement, Noncash ExpenseStock-based compensation Gain on Sale of InvestmentsGain on sale of investment Other Noncash Income (Expense)Other Increase (Decrease) in Operating Capital [Abstract]Changes in operating assets and liabilities, net of business acquisition: Increase (Decrease) in Accounts ReceivableAccounts receivable, net Increase (Decrease) in InventoriesInventories, net Increase (Decrease) in Prepaid Expense and Other AssetsOther current assets Increase (Decrease) in Other Noncurrent AssetsOther assets Increase (Decrease) in Accounts PayableAccounts payable Increase (Decrease) in Accrued Liabilities and Other Operating LiabilitiesAccrued expenses and other liabilities Net Cash Provided by (Used in) Operating ActivitiesNet cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract]INVESTING ACTIVITIES Payments to Acquire Short-term InvestmentsPurchases of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-term InvestmentsMaturities of short-term investments Payments to Acquire Productive AssetsCapital expenditures Payments to Acquire Businesses, Net of Cash AcquiredBusiness acquisition, net of cash acquired Proceeds from Sale of Investment ProjectsSale of investment Payments for (Proceeds from) Other Investing ActivitiesOther, net Net Cash Provided by (Used in) Investing ActivitiesNet cash used by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract]FINANCING ACTIVITIES Proceeds from Long-term Lines of CreditRevolving credit facility borrowings Repayments of Long-term Lines of CreditRevolving credit facility repayments Proceeds from Issuance of Other Long-Term DebtProceeds from long-term debt Repayments of Other Long-Term DebtPayments of long-term debt Payments of Debt Issuance CostsDebt issuance costs Payment for Contingent Consideration Liability, Financing ActivitiesPayment of contingent consideration Proceeds from Insurance Premium Financing and Other Short-term Debt, Financing ActivitiesProceeds from Insurance Premium Financing and Other Short-term Debt, Financing ActivitiesProceeds from insurance premium financing and other short-term debt Payments for Insurance Premium Financing and Other Short-term Debt, Financing ActivitiesPayments for Insurance Premium Financing and Other Short-term Debt, Financing ActivitiesPayments of insurance premium financing and other short-term debt Payments of Ordinary Dividends, Common StockDividends paid Net Cash Provided by (Used in) Financing ActivitiesNet cash (used) provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsEffect of exchange rate changes on cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNet increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsCash and cash equivalents at end of periodCash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract]Supplemental cash flow information Interest Paid, Excluding Capitalized Interest, Operating ActivitiesInterest paid, net Income Taxes Paid, NetIncome taxes paid, net Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Other Noncash Investing and Financing Items [Abstract]Non-cash investing and financing activities Capital Expenditures Incurred but Not yet PaidProperty, plant and equipment Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Parent [Member] Common Stock [Member]Common Stock Additional Paid-in Capital [Member]Paid-in Capital Retained Earnings [Member]Retained Earnings (Accumulated Deficit) AOCI Attributable to Parent [Member]Accumulated Other Comprehensive Income (Loss) Increase (Decrease) in Stockholders' Equity [Roll Forward]Increase (Decrease) in Stockholders' Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling InterestBalanceBalance Dividends, Common Stock, CashDividends declaredDividends declared and paid Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period RecognitionStock-based compensation expense Stock Transactions, Parenthetical Disclosures [Abstract]Dividends declared Common Stock, Dividends, Per Share, DeclaredDividends declared (in dollars per share) Description of Business Nature of Operations [Text Block]Description of Business Summary of Significant Accounting Policies and New Accounting Standards Basis of Presentation and Significant Accounting Policies [Text Block]Summary of Significant Accounting Policies and New Accounting Standards Proposed Acquisition Asset Acquisition [Text Block]Proposed Acquisition Statements of Operations-Additional Information Revenue from Contract with Customer [Text Block]Disaggregated Revenue, Deferred Revenue and Customer Payment Terms Additional Financial Information Disclosure [Text Block]Additional Information Balance Sheets-Additional Information Supplemental Balance Sheet Disclosures [Text Block]Balance Sheets-Additional Information Debt Debt Disclosure [Text Block]Debt Leases Lessee, Operating Leases [Text Block]Leases Common Stock, Preferred Stock and Dividends Stockholders' Equity Note Disclosure [Text Block]Common Stock, Preferred Stock and Dividends Stock Incentive Plan Disclosure of Compensation Related Costs, Share-based Payments [Text Block]Stock Incentive Plan Related Party Transactions Related Party Transactions Disclosure [Text Block]Related Party Transactions Employee Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block]Employee Benefit Plans Income Taxes Income Tax Disclosure [Text Block]Income Taxes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block]Commitments and Contingencies Derivatives Derivative Instruments and Hedging Activities Disclosure [Text Block]Derivatives Fair Value Measurements Fair Value Disclosures [Text Block]Fair Value Measurements Business Segments Segment Reporting Disclosure [Text Block]Business Segments Subsequent Event - 2024 Credit Agreement Subsequent Events [Text Block]Subsequent Event - 2024 Credit Agreement Basis of Accounting, Policy [Policy Text Block]Principles of Consolidation and Basis of Presentation Concentration Risk, Credit Risk, Policy [Policy Text Block]Risks and Uncertainties Use of Estimates, Policy [Policy Text Block]Use of Estimates Revenue from Contract with Customer [Policy Text Block]Revenue Recognition Cash and Cash Equivalents, Policy [Policy Text Block]Cash and Cash Equivalents Investment, Policy [Policy Text Block]Short-term Investments Accounts Receivable [Policy Text Block]Accounts Receivable Credit Loss, Financial Instrument [Policy Text Block]Reserve for Credit Losses Inventory, Policy [Policy Text Block]Inventories Property, Plant and Equipment, Policy [Policy Text

Block]Property, Plant and Equipment Lessor, Leases [Policy Text Block]Leases Internal Use Software, Policy [Policy Text Block]Capitalized Software Costs Deferred Charges, Policy [Policy Text Block]Debt Issuance Costs Business Combinations Policy [Policy Text Block]Business Combinations Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]Long-Lived Assets and Goodwill Foreign Currency Transactions and Translations Policy [Policy Text Block]Foreign Currency Translation Comprehensive Income, Policy [Policy Text Block]Comprehensive Income Derivatives, Policy [Policy Text Block]Derivative Financial Instruments Environmental Costs, Policy [Policy Text Block]Environmental Liabilities Income Tax, Policy [Policy Text Block]Income Taxes Advertising Costs, Policy [Policy Text Block]Advertising Research and Development Expense, Policy [Policy Text Block]Research and Development Expenditures Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]Stock-Based Compensation Earnings Per Share, Policy [Policy Text Block]Net Income per Share and Weighted Average Shares New Accounting Pronouncements, Policy [Policy Text Block]New Accounting Standards Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]Schedule of net income per share and weighted average shares Disaggregation of Revenue [Table Text Block]Schedule of revenues disaggregated by major product category and geographic region Tabular disclosure of interest expense, net.Schedule of Interest Expense, Net [Table Text Block]Schedule of interest expense, net Tabular disclosure of depreciation and amortization.Schedule of Depreciation and Amortization [Table Text Block]Schedule of depreciation and amortization Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]Schedule of amortization of intangible assets Tabular disclosure of research and development expense.Schedule of Research and Development Expense [Table Text Block]Schedule of research and development expense Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]Schedule of accounts receivable, net Accounts Receivable, Allowance for Credit Loss [Table Text Block]Schedule of reserve for credit losses Schedule of Inventory, Current [Table Text Block]Schedule of inventories Property, Plant and Equipment [Table Text Block]Schedule of property, plant and equipment, net Schedule of Finite-Lived Intangible Assets [Table Text Block]Schedule of intangibles, net Schedule of Goodwill [Table Text Block]Schedule of goodwill Schedule of Other Assets, Noncurrent [Table Text Block]Schedule of other assets Tabular disclosure of accrued expenses and other current liabilities.Accrued Expenses and Other Liabilities, Current [Table Text Block]Schedule of accrued expenses and other current liabilities Other Noncurrent Liabilities [Table Text Block]Schedule of other liabilities Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]Schedule of accumulated other comprehensive loss Schedule of Long-term Debt Instruments [Table Text Block]Schedule of long term debt Schedule of Maturities of Long-term Debt [Table Text Block]Schedule of aggregate maturities of long term debt Lease, Cost [Table Text Block]Summary of operating lease information Lessee, Operating Lease, Liability, Maturity [Table Text Block]Summary of maturities of future lease liabilities Schedule of Stock by Class [Table Text Block]Schedule of preferred shares and common shares Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]Schedule of changes in projected benefit obligation, plan assets and the funded status Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]Schedule of accumulated other comprehensive (income) loss related to the pension plan Schedule of Net Benefit Costs [Table Text Block]Schedule of net periodic pension expense Schedule of Assumptions Used [Table Text Block]Schedule of significant actuarial assumptions Schedule of Expected Benefit Payments [Table Text Block]Schedule of estimated future benefit payments, including benefits attributable to future service Schedule of Allocation of Plan Assets [Table Text Block]Schedule of weighted-average asset allocation of plan assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block]Schedule of fair values of the company's plan assets by asset category Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]Schedule of summary of the changes in the fair value of level 3 assets Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]Schedule of income (loss) before income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]Schedule of components of the provision for income taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]Schedule of reconciliations of the Federal statutory rate to the Company's effective tax rate Schedule of Deferred Tax Assets and Liabilities [Table Text Block]Schedule of the tax effects of significant temporary differences that comprise deferred tax assets and liabilities Tabular disclosure of schedule of deferred taxes are included consolidated balance sheets.Schedule of Deferred Taxes are Included Consolidated Balance Sheets [Table Text Block]Schedule of deferred taxes included in the line items of the consolidated balance sheets Summary of Valuation Allowance [Table Text Block]Schedule of the valuation allowance for deferred tax assets Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]Schedule of the reconciliation of the beginning and ending amount of unrecognized tax benefits Schedule of Derivative Instruments [Table Text Block]Schedule of significant outstanding derivatives employed to manage market risk and designated as cash flow hedges Derivative Instruments, Gain (Loss) [Table Text Block]Schedule of effects of derivatives Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]Schedule of fair value of assets and liabilities measured on a recurring basis Schedule of Segment Reporting Information, by Segment [Table Text Block]Schedule of information regarding reportable segments Reconciliation of Assets from Segment to Consolidated [Table Text Block]Schedule of identifiable assets Long-lived Assets by Geographic Areas [Table Text Block]Schedule of geographic information regarding property, plant and equipment, net Tabular disclosure of basis spread on variable rates on debt instruments.Schedule of Long-Term Debt Instruments, Basis Spread on Variable Rate [Table Text Block]Schedule of the basis spread on variable rates Tabular disclosure of financial covenants on debt instruments.Schedule of Long-Term Debt Instruments, Covenants [Table Text Block]Schedule of financial covenants Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Accounts Receivable [Member]Accounts Receivable Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member]Customer Concentration Risk Customer [Axis] Customer [Domain] Ten Largest Customers [Member]Ten Largest Customers [Member]Ten Largest Customers Concentration Risk [Line Items]Concentration risk Concentration Risk, PercentageConcentration risk (as a percent) Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Building and Building Improvements [Member]Building and Building Improvements Machinery and Equipment [Member]Machinery and Equipment Software and Software Development Costs [Member]Software and Software Development Costs Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member]Minimum Maximum [Member]Maximum Property, Plant and Equipment [Line Items]Property, Plant and Equipment Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]Property, Plant and Equipment, Depreciation Method Property, Plant and Equipment, Useful LifeEstimated useful lives Derivative [Table] Derivative Instrument [Axis] Derivative Contract [Domain] Interest Rate Contract [Member] Interest Rate Swap [Member]Interest Rate Swap Hedging Relationship [Axis] Hedging Relationship [Domain] Cash Flow Hedging [Member]Cash Flow Hedging Derivative [Line Items] Notional Disclosures [Abstract]Derivatives Derivative, Notional AmountDerivative, notional amount Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]Net Income (Loss) per Share and Weighted Average Shares Net Income (Loss) Available to Common Stockholders, BasicNet income - basic Net Income (Loss) Available to Common Stockholders, DilutedNet income - diluted Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment ArrangementsDilutive effect of restricted stock units (in shares) Accounting Standards Update and Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Accounting Standards Update 2023-07 [Member]Accounting Standards Update 2023-07 Accounting Standards Update 2023-09 [Member]Accounting Standards Update 2023-09 New Accounting Pronouncements or Change in Accounting Principle [Line Items]New Accounting Standards Change in Accounting Principle, Accounting Standards Update, Adopted [true false]Change in Accounting Principle, Accounting Standards Update, Adopted Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Domain] Zoetis Inc. Medicated Feed Additive Product Portfolio [Member]Zoetis Inc Medicated Feed Additive Product Portfolio [Member]Zoetis Inc Medicated Feed Additive Product Portfolio Asset Acquisition [Line Items]Proposed Acquisition Asset Acquisition, Price of Acquisition, ExpectedAsset acquisition, price of acquisition, expected Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]Business Segments Number of Reportable SegmentsNumber of reportable segments Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Domain] Animal Health [Member]Animal Health [Member]Animal Health Medicated Feed Additives and Others [Member]Medicated Feed Additives and Others [Member]MFAs and other Nutritional Specialties [Member]Nutritional Specialties [Member]Nutritional Specialties Vaccines [Member]Vaccines [Member]Vaccines Represents segment manufactures and markets trace minerals for the cattle, swine, poultry and pet food markets.Mineral Nutrition [Member]Mineral Nutrition Performance Products [Member]Performance Products [Member]Performance Products Disaggregation of Revenue [Line Items]Net sales Geographical [Axis] Geographical [Domain] UNITED STATESUnited States Latin America and Canada [Member]Latin America and Canada [Member]Latin America and Canada EMEA [Member]Europe, Middle East and Africa Asia Pacific [Member]Asia Pacific Payment Term, Low End of RangePayment Term, Low End of RangePayment term, minimum Payment Term, High End of RangePayment Term, High End of RangePayment term, maximum Average Customer Collection PeriodAverage Customer Collection PeriodAverage worldwide collection period for accounts receivable Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] 2021 Credit Facilities [Member]Credit Facilities [Member]2021 Credit Facilities Credit Agreement, 2022 Term Loan [Member]Credit Agreement, 2022 Term Loan [Member]2022 Term Loan Debt Instrument [Line Items]Debt Interest Income (Expense), Nonoperating [Abstract]Interest expense, net Interest Expense, Debt, Excluding AmortizationInterest expense, excluding amortization Interest Expense, OtherOther Interest Expense, NonoperatingInterest expense Interest and Other IncomeInterest income Capitalized Computer Software, AmortizationAmortization of capitalized software costs Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]Amortization of intangible assets Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months2025 Finite-Lived Intangible Assets, Amortization Expense, Year Two2026 Finite-Lived Intangible Assets, Amortization Expense, Year Three2027 Finite-Lived Intangible Assets, Amortization Expense, Year Four2028 Finite-Lived Intangible Assets, Amortization Expense, Year Five2029 Finite-Lived Intangible Assets, Amortization Expense, after Year FiveThereafter Depreciation, Depletion and Amortization [Abstract]Depreciation and amortization DepreciationDepreciation of property, plant and equipment Amortization of Intangible AssetsAmortization of intangible assets Research and Development Expense [Abstract]Research and development expense Research and Development ExpenseResearch and development expense Accounts Receivable, Net [Abstract]Accounts receivable, net Accounts Receivable, GrossTrade accounts receivable Allowance for Doubtful Accounts ReceivableReserve for credit lossesBalance at end of periodBalance at beginning of period Accounts Receivable, NetTrade accounts receivable, net Allowance for Doubtful Accounts Receivable [Roll Forward]Reserve for credit losses Provision for Doubtful AccountsProvision for estimated credit losses Represents the amount of effect of changes in exchanges rates.Allowance For Doubtful Accounts Receivable Effect Of Changes In Exchange RatesEffect of changes in exchange rates Accounts Receivable, Allowance for Credit Loss, WriteoffCredit losses realized Inventory, Net [Abstract]Inventories, net Inventory, Raw Materials, Net of ReservesRaw materials Inventory, Work in Process, Net of ReservesWork-in-process Inventory, Finished Goods, Net of ReservesFinished goods Land [Member]Land Construction in Progress [Member]Construction in Progress Property, Plant and Equipment, Net [Abstract]Property, plant and equipment, net Property, Plant and Equipment, GrossProperty, plant and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentAccumulated depreciation Capitalized Computer Software, Net [Abstract]Internal-use software costs, net of accumulated depreciation Capitalized Computer Software, Net, Beginning BalanceInternal-use software costs, net of accumulated depreciation Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Technology-Based Intangible Assets [Member]Technology-Based Intangible Assets Product Registrations, Marketing and Distribution Rights [Member]Product Registrations, Marketing and Distribution Rights [Member]Product Registrations, Marketing and Distribution Rights Customer Relationships [Member]Customer Relationships Trademarks and Trade Names and Other [Member]Trademarks and Trade Names and Other [Member]Trademarks and Trade Names and Other Weighted Average [Member]Weighted Average Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Net [Abstract]Intangibles, net Finite-Lived Intangible Asset, Useful LifeEstimated useful life of definite-lived intangible assets Finite-Lived Intangible Assets, GrossIntangibles Finite-Lived Intangible Assets, Accumulated AmortizationAccumulated amortization Goodwill.Goodwill Goodwill, Acquired During PeriodAcquisition Goodwill, Foreign Currency Translation Gain (Loss)Effect of changes in exchange rates Other Assets [Abstract]Other assets Operating Lease, Right-of-Use AssetROU operating lease assets Deferred Income Tax Assets, NetOther assetsDeferred income taxes Deposits AssetsDeposits Other InvestmentsInsurance investments Equity Method InvestmentsEquity method investments Derivative Asset, NoncurrentDerivative instruments Debt Issuance Costs, Noncurrent, NetDebt issuance costs Other Assets, Miscellaneous, NoncurrentOther Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]Operating Lease, Right-of-Use Asset, Statement of Financial Position Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]Derivative Asset, Noncurrent, Statement of Financial Position Accrued Liabilities and Other Liabilities [Abstract]Accrued expenses and other current liabilities Employee-related Liabilities, CurrentEmployee related Operating Lease, Liability, CurrentOperating lease liabilities, current portionCurrent operating lease liabilities Accrued Sales Commission, CurrentCommissions and rebates Accrued Professional Fees, CurrentProfessional fees Taxes Payable, CurrentIncome and other taxes Accrued Insurance, CurrentInsurance-related Accrued Insurance Premium Financing, CurrentAccrued Insurance Premium Financing, CurrentInsurance premium financing Other Liabilities, CurrentOther Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]Operating Lease, Liability, Current, Statement of Financial Position Insurance Premium Financing, Fixed Interest Rate PercentageInsurance Premium Financing, Fixed Interest Rate PercentageInsurance premium financing, fixed interest rate percentage (as a percent) Insurance Premium Financing, Monthly Payment AmountInsurance Premium Financing, Monthly Payment AmountInsurance premium financing, monthly payment amount Other Liabilities [Abstract]Other liabilities Operating Lease, Liability, NoncurrentOperating lease liabilities, non-current portionLong-term operating lease liabilities Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.Long Term And Deferred Income TaxesLong term and deferred income taxes Liability, Pension and Other Postretirement and Postemployment Benefits, NoncurrentSupplemental retirement benefits, deferred compensation and other Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit ObligationU.S. pension plan, net Liability, Defined Benefit Plan, NoncurrentInternational retirement plans Other Accrued Liabilities, NoncurrentOther long-term liabilities Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]Operating Lease, Liability, Noncurrent, Statement of Financial Position Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Accumulated Foreign Currency Adjustment Attributable to Parent [Member]Accumulated Foreign Currency Adjustment Attributable to Parent Accumulated Other Comprehensive Income, Long-term Intercompany Investments [Member]Accumulated Other Comprehensive Income, Long-term Intercompany Investments [Member]Accumulated Other Comprehensive Income, Long-term Intercompany Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]Accumulated Defined Benefit Plans Adjustment Attributable to Parent Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent [Abstract]Accumulated other comprehensive loss AOCI before Tax, Attributable to ParentAccumulated other comprehensive loss, before tax AOCI Tax, Attributable to ParentAccumulated other comprehensive loss, tax Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Line of Credit [Member]Line of Credit Loans Payable [Member]Loans Payable Revolving Credit Facility [Member]Revolving Credit Facility Letter of Credit [Member]Letter of Credit Secured Debt [Member]Secured Debt Term A Loan [Member]Term A Loan [Member]Term A Loan Revolver [Member]Revolver [Member]Revolver Incremental Term Loan, 2023, Due April 2026 [Member]Incremental Term Loan, 2023, Due April 2026 [Member]2023 Incremental Term Loan due April 2026 Variable Rate [Axis] Variable Rate [Domain] Secured Overnight Financing Rate (SOFR) [Member]Secured Overnight Financing Rate (SOFR) Base Rate [Member]Base Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member]Fed Funds Effective Rate Overnight Index Swap Rate Scenario [Axis] Scenario [Domain] Debt Instrument, Basis Spread on Variable Rate, Scenario One [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario One [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario One Debt Instrument, Basis Spread on Variable Rate, Scenario Two [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario Two [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario Two Debt Instrument, Basis Spread on Variable Rate, Scenario Three [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario Three [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario Three Debt Instrument, Basis Spread on Variable Rate, Scenario Four [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario Four [Member]Debt Instrument, Basis Spread on Variable Rate, Scenario Four Debt Instrument, Face AmountAggregate principal amount Debt Instrument, Periodic PaymentDebt instrument, periodic payment Debt Instrument, Frequency of Periodic PaymentDebt instrument, frequency of periodic payment Line of Credit Facility, Maximum Borrowing CapacityMaximum borrowing capacity Line of Credit Facility, Remaining Borrowing CapacityAggregate available credit facilities Long-term Line of CreditOutstanding borrowings Letters of Credit Outstanding, AmountLetters of credit outstanding Debt Instrument, Basis Spread on Variable RateBasis spread on variable rate (as a percent) Debt Instrument, TermDebt instrument, term Debt Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, MaximumDebt Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, MaximumMaximum First Lien Net Leverage Ratio Debt Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, Test

Period, MaximumDebt Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, Test Period, MaximumMaximum First Lien Net Leverage Ratio, Test Period Debt Instrument, Covenants, Interest Coverage Ratio, Trailing Four-quarter Basis, MinimumDebt Instrument, Covenants, Interest Coverage Ratio, Trailing Four-quarter Basis, MinimumMinimum interest coverage ratio Debt Instrument, Interest Rate, Stated Percentage [Abstract]Debt Debt Instrument, Interest Rate, Stated PercentageInterest rate (as a percent) Long-Term Debt, Weighted Average Interest Rate, over TimeLong-term debt, weighted average interest rate, over time Interest Rate Swap, July 2022 [Member]Interest Rate Swap, July 2022 [Member]Interest Rate Swap, July 2022 Derivative, Fixed Interest RateDerivative, fixed interest rate (as a percent) Long-Term Debt and Lease Obligation, Including Current Maturities [Abstract] Long-Term Debt, Unclassified [Abstract]Debt Maturities Long-term Debt, GrossLong-term debt, grossDebt payments, total Debt Issuance Costs, NetUnamortized debt issuance costs Long-Term DebtLong-term debt, current and non-current Long-Term Debt, by Current and Noncurrent [Abstract]Debt Maturities Long-Term Debt, Current MaturitiesLess: current maturities of long-term debt and other Long-Term Debt, Excluding Current MaturitiesLong-term debt Long-Term Debt, Gross, Maturity, Year OneLong-Term Debt, Gross, Maturity, Year OneDebt payments, 2025 Long-Term Debt, Gross, Maturity, Year TwoLong-Term Debt, Gross, Maturity, Year TwoDebt payments, 2026 Long-Term Debt, Gross, Maturity, Year ThreeLong-Term Debt, Gross, Maturity, Year ThreeDebt payments, 2027 Long-Term Debt, Gross, Maturity, Year FourLong-Term Debt, Gross, Maturity, Year FourDebt payments, 2028 Long-Term Debt, Maturity, Interest Payments, Year OneLong-Term Debt, Maturity, Interest Payments, Year OneInterest payments, 2025 Long-Term Debt, Maturity, Interest Payments, Year TwoLong-Term Debt, Maturity, Interest Payments, Year TwoInterest payments, 2026 Long-Term Debt, Maturity, Interest Payments, Year ThreeLong-Term Debt, Maturity, Interest Payments, Year ThreeInterest payments, 2027 Long-Term Debt, Maturity, Interest Payments, Year FourLong-Term Debt, Maturity, Interest Payments, Year FourInterest payments, 2028 Long-Term Debt, Maturity, Interest PaymentsLong-Term Debt, Maturity, Interest PaymentsInterest payments, total Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Operating Lease, Description [Abstract]Leases Lessee, Operating Lease, Remaining Lease TermRemaining term Lessee Disclosure [Abstract] Assets and Liabilities, Lessee [Abstract]Assets: Operating Lease, Liability [Abstract]Liabilities: Operating Lease, LiabilityLease liabilitiesTotal operating lease liabilities Lease, Cost [Abstract]Composition of net lease expense Operating Lease, CostOperating lease expense Variable Lease, CostVariable lease expense Short-term Lease, CostShort-term lease expense Lease, CostTotal lease expense Cash Flow, Operating Activities, Lessee [Abstract]Leases Operating Lease, PaymentsOperating cash flows used for ROU operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease LiabilityNon-cash changes to ROU operating assets and lease liabilities Operating Lease, Weighted Average Remaining Lease TermWeighted average remaining lease term - operating leases Operating Lease, Weighted Average Discount Rate, PercentWeighted average discount rate - operating leases (as a percent) Lessee, Operating Lease, Liability, Payment, Due [Abstract]Leases Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months2025 Lessee, Operating Lease, Liability, Payments, Due Year Two2026 Lessee, Operating Lease, Liability, Payments, Due Year Three2027 Lessee, Operating Lease, Liability, Payments, Due Year Four2028 Lessee, Operating Lease, Liability, Payments, Due Year Five2029 Lessee, Operating Lease, Liability, Payments, Due after Year Five2030 and thereafter Lessee, Operating Lease, Liability, Payments, DueTotal lease payments Operating Lease Liabilities, Gross Difference, Amount [Abstract]Leases Lessee, Operating Lease, Liability, Undiscounted Excess AmountLess: interest Schedule of Stock by Class [Table] Class of Stock [Line Items] Conversion of Stock, Shares ConvertedClass B common stock converted into Class A common shares Common Stock, Voting RightsCommon stock, voting rights Common Stock, Voting Rights, Votes Per ShareCommon Stock, Voting Rights, Votes Per ShareCommon stock, voting rights, votes per share Threshold defined as a percentage of minimum ownership of the total outstanding shares of Class A common stock and Class B common stock, taken as a single class.Minimum Common Stock Ownership Conversion ThresholdBFI ownership percentage at which the remaining Class B shares would convert to Class A Dividends, Common Stock [Abstract]Dividends Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]Stock Incentive Plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares AuthorizedShares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for GrantShares available for grant (in shares) Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Restricted Stock Units (RSUs) [Member]Restricted Stock Units (RSUs) Time-based Restricted Stock Units [Member]Time-based Restricted Stock Units [Member]Time-based Restricted Stock Units Performance-based Restricted Stock Units [Member]Performance-based Restricted Stock Units [Member]Performance-based Restricted Stock Units Award Date [Axis] Award Date [Domain] July 2023 [Member]July 2023 [Member]July 2023 Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member]Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche Two [Member]Share-Based Payment Arrangement, Tranche Two Share-based Compensation Arrangement by Share-based Payment Award [Line Items]Stock Incentive Plan Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in PeriodGranted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting PeriodVesting term Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, PercentageVesting percentage (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Vesting Percentage, MinimumShare-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Vesting Percentage, MinimumVesting, achievement of arithmetic average of closing stock price per share for each trading day, vesting percentage, minimum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, PeriodShare-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, PeriodVesting, achievement of arithmetic average of closing stock price per share for each trading day, period Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, MinimumShare-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, MinimumVesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, minimum (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, MaximumShare-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, MaximumVesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, maximum (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Change in Control, Shares of Stock Cease to Trade on Nationally Recognized Exchange, PercentageShare-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Change in Control, Shares of Stock Cease to Trade on Nationally Recognized Exchange, PercentageVesting, immediately vest in full, change in control, shares of stock cease to trade on nationally recognized exchange, percentage (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Qualifying Termination, PeriodShare-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Qualifying Termination, PeriodVesting, immediately vest in full, qualifying termination, period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueGrant date fair value (in dollars per share) Share-based Payment Arrangement, Disclosure [Abstract] Share-based Payment Arrangement, Additional Disclosure [Abstract]Stock Incentive Plan Share-based Payment Arrangement, ExpenseStock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]Stock Incentive Plan Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, AmountCost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionCost not yet recognized, period for recognition Schedule of Related Party Transactions, by Related Party [Table] Related Party, Type [Axis] Related Party, Type [Domain] Related Party [Member] Immediate Family Member of Management or Principal Owner [Member]Immediate Family Member of Management or Principal Owner Related Party Transaction [Axis] Related Party Transaction [Domain] Compensation and Benefit for Services [Member]Compensation and Benefit for Services [Member]Compensation and Benefit for Services Related Party Transaction [Line Items]Related Party Transactions Related Party Transaction, Amounts of TransactionAggregate compensation and benefits Defined Benefit Plan, Type [Extensible Enumeration]Defined Benefit Plan, Type Defined Benefit Plan, Sponsor Location [Extensible Enumeration]Defined Benefit Plan, Sponsor Location Defined Benefit Plan, Funding Status [Extensible Enumeration]Defined Benefit Plan, Funding Status Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items]Employee Benefit Plans Defined Benefit Plan, Settlement, Annuity Purchase Agreement, Benefit Obligation, Annuity Purchase PriceDefined Benefit Plan, Settlement, Annuity Purchase Agreement, Benefit Obligation, Annuity Purchase PriceAnnuity purchase price Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementSettlement expense Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]Change in projected benefit obligation Defined Benefit Plan, Benefit ObligationProjected benefit obligation at end of yearProjected benefit obligation at beginning of yearProjected benefit obligation Defined Benefit Plan, Interest CostInterest cost on benefit obligationInterest cost Defined Benefit Plan, Benefit Obligation, Benefits PaidBenefits paid Defined Benefit Plan, Actuarial Gain (Loss)Actuarial gain Partial settlement of pension planSettlement payments Defined Benefit Plan, Assumptions Used in Calculations [Abstract]Significant actuarial assumptions Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation Defined Benefit Plan, Projected Benefit Obligation, Discount RateDefined Benefit Plan, Projected Benefit Obligation, Discount RateDiscount rate used for the projected benefit obligation (as a percent) Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]Change in Fair Value Level 3 assetsChange in plan assets Defined Benefit Plan, Fair Value of Plan AssetsFair value of plan assets at end of yearFair value of plan assets at beginning of yearFair value of plan assets Defined Benefit Plan, Actual Return on Plan AssetsActual return on plan assets Defined Benefit Plan, Plan Assets, Benefits PaidBenefits paid Defined Benefit Plan, Plan Assets, Payment for SettlementSettlement payments Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]Funded status Defined Benefit Plan, Funded Status of PlanLiability funded status at end of year Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]Accumulated other comprehensive loss related to pension plan Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax, TotalBalance at end of periodBalance at beginning of period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Amortization of Net Actuarial Loss, before TaxOther Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Amortization of Net Actuarial Loss, before TaxAmortization of net actuarial loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Current Period Net Actuarial Gain (Loss), before TaxOther Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Current Period Net Actuarial Gain (Loss), before TaxCurrent period net actuarial loss Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Tax, Portion Attributable to Parent, TotalNet change Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]Net periodic pension expense Defined Benefit Plan, Expected Return on Plan AssetsExpected return on plan assets Defined Benefit Plan, Amortization of Actuarial (Gain) Loss, Immediate Recognition as Component in Net Periodic Benefit Cost (Credit), and Amortization of Prior Service CostsDefined Benefit Plan, Amortization of Actuarial (Gain) Loss, Immediate Recognition as Component in Net Periodic Benefit Cost (Credit), and Amortization of Prior Service CostsAmortization of net actuarial loss and prior service costs Defined Benefit Plan, Net Periodic Benefit Cost (Credit)Net periodic pension expense (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement Gain (Loss), Statement of Income or Comprehensive Income Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount RateDiscount rate for interest cost (as a percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on AssetsExpected rate of return on plan assets (as a percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount RateDiscount rate for year-end benefit obligation (as a percent) Represents minimum par value required for corporate bond to determine discount rate .Minimum Par Value Required For Corporate Bond To Determine Discount RateMinimum par value required for corporate bond to determine discount rate Defined Benefit Plan, Expected Future Benefit Payment [Abstract]Estimated future benefit payments Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months2025 Defined Benefit Plan, Expected Future Benefit Payments, Year Two2026 Defined Benefit Plan, Expected Future Benefit Payments, Year Three2027 Defined Benefit Plan, Expected Future Benefit Payments, Year Four2028 Defined Benefit Plan, Expected Future Benefit Payments, Year Five2029 Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter2030-2034 Defined Benefit Plan, Plan Assets, Allocation [Table] Defined Benefit Plan, Plan Assets, Category [Axis] Plan Asset Categories [Domain] Defined Benefit Plan, Debt Security [Member]Defined Benefit Plan, Debt Security Defined Benefit Plan, Equity Securities [Member]Defined Benefit Plan, Equity Securities Defined Benefit Plan, Global Asset Allocations and Risk Parity [Member]Defined Benefit Plan, Global Asset Allocations and Risk Parity [Member]Global Asset Allocations/Risk Parity Defined Benefit Plan, Plan Assets, Other [Member]Defined Benefit Plan, Plan Assets, Other [Member]Defined Benefit Plan, Plan Assets, Other Defined Benefit Plan, Plan Assets, Allocation [Line Items] Defined Benefit Plan, Plan Assets, Allocations [Abstract]Target asset allocations and weighted-average asset allocation of plan assets Defined Benefit Plan, Plan Assets, Target Allocation, PercentageTarget allocation (as a percent) Defined Benefit Plan, Plan Assets, Actual Allocation, PercentagePercentage of plan assets (as a percent) Defined Benefit Plan, Plan Assets, Category [Table] Defined Benefit Plan, Cash and Cash Equivalents [Member]Defined Benefit Plan, Cash and Cash Equivalents Defined Benefit Plan, Common Collective Trust [Member] Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities [Member]Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities [Member]Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities Defined Benefit Plan, Common Collective Trust, Fixed Income Securities [Member]Defined Benefit Plan, Common Collective Trust, Fixed Income Securities [Member]Defined Benefit Plan, Common Collective Trust, Fixed Income Securities Mutual Fund [Member]Mutual Fund Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1, 2 and 3 [Member] Fair Value, Inputs, Level 1 [Member]Level 1 Fair Value, Inputs, Level 2 [Member]Level 2 Fair Value, Inputs, Level 3 [Member]Level 3 Defined Benefit Plan, Plan Assets, Category [Line Items] Defined Benefit Plan, Information about Plan Assets [Abstract]Fair values of the plan assets by asset category Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Table] Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items] Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for SaleRedemptions Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for PurchasePurchases Defined Benefit Plan, Fair Value of Plan Assets, Period Increase (Decrease)Change in fair value Defined Benefit Plan, Cash and Cash Equivalents, Measurement Input, Price Per UnitDefined Benefit Plan, Cash and Cash Equivalents, Measurement Input, Price Per UnitCash and cash equivalents, measurement input, price per unit (in dollars per share) Defined Contribution Plan, Employer Matching Contribution, Percent of MatchEmployer matching contribution, percent of match (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross PayEmployer matching contribution, percent of employees' gross pay (as a percent) Defined Contribution Plan, Employer Discretionary Contribution, PercentDefined Contribution Plan, Employer Discretionary Contribution, PercentEmployer discretionary contribution (as a percent) Defined Contribution Plan, Cost RecognizedContribution expense Defined Contribution Plan, Sponsor Location [Extensible Enumeration]Defined Contribution Plan, Sponsor Location Employee-related Liabilities [Abstract]Other employee benefit plans Other Employee-related LiabilitiesOther employee-related liabilities Other Employee Benefit Plans Expense, International Retirement Plans, Supplemental Retirement Benefits and Long-term Incentive ArrangementsOther Employee Benefit Plans Expense, International Retirement Plans, Supplemental Retirement Benefits and Long-term Incentive ArrangementsOther employee benefit plans expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Income (Loss) from Continuing Operations before Income Taxes, DomesticDomestic Income (Loss) from Continuing Operations before Income Taxes, ForeignForeign Income Tax Expense (Benefit), Continuing Operations [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract]Current provision: Current Federal Tax Expense (Benefit)Federal Current State and Local Tax Expense (Benefit)State and local Current Foreign Tax Expense (Benefit)Foreign Current Income Tax Expense (Benefit)Total current provision Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]Deferred provision (benefit): Deferred Federal Income Tax Expense (Benefit)Federal Deferred State and Local Income Tax Expense (Benefit)State and local Deferred Foreign Income Tax Expense (Benefit)Foreign Deferred Foreign Income Tax Expense

(Benefit), Change in Valuation AllowanceDeferred Foreign Income Tax Expense (Benefit), Change in Valuation AllowanceChange in valuation allowance-foreign Deferred Income Tax Expense (Benefit)Total deferred benefit Effective Income Tax Rate Reconciliation, Percent [Abstract]Reconciliation of the federal statutory rate to the Company's effective tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, PercentU.S. federal statutory income tax rate (as a percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, PercentState and local taxes, net of federal benefit (as a percent) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, PercentHigher taxes on non-U.S. income (as a percent) Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits.Effective Income Tax Rate Reconciliation, Change In Unrecognized Tax Benefits, PercentChanges in uncertain tax positions (as a percent) Effective Income Tax Rate Reconciliation, GILTI, PercentGlobal Intangible Low-Taxed Income (as a percent) Effective Income Tax Rate Reconciliation, Tax Credit, PercentRecognition of federal and foreign tax credits (as a percent) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, PercentChange in valuation allowance (as a percent) Effective Income Tax Rate Reconciliation, FDII, PercentForeign derived intangible income (as a percent) Effective Income Tax Rate Reconciliation, Foreign Withholding and Related Taxes, Net, on Planned Repatriation, PercentEffective Income Tax Rate Reconciliation, Foreign Withholding and Related Taxes, Net, on Planned Repatriation, PercentNon-U.S. withholding and related taxes, net, on planned repatriation (as a percent) Effective Income Tax Rate Reconciliation, Impact of Foreign Tax Credit Regulations and Related Changes, PercentEffective Income Tax Rate Reconciliation, Impact of Foreign Tax Credit Regulations and Related Changes, PercentImpact of foreign tax credit regulations and related changes (as a percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Operating Expenses, PercentEffective Income Tax Rate Reconciliation, Nondeductible Expense, Operating Expenses, PercentNon-deductible operating expenses (as a percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Acquisition Costs, PercentEffective Income Tax Rate Reconciliation, Nondeductible Expense, Acquisition Costs, PercentNon-deductible acquisition costs (as a percent) Effective Income Tax Rate Reconciliation, Other Adjustments, PercentOther (as a percent) Effective Income Tax Rate Reconciliation, PercentEffective tax rate (as a percent) Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount [Abstract]Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Effective Income Tax Rate Reconciliation, GILTI, AmountProvision for income taxes, federal tax expense from the effects of GILTI Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets [Abstract] Deferred Tax Assets, Net [Abstract] Deferred Tax Assets, Net of Valuation Allowance [Abstract] Deferred Tax Assets, Gross [Abstract]Deferred tax assets: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee CompensationEmployee related accruals Deferred Tax Assets, InventoryInventory Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, ContingenciesEnvironmental remediation Deferred Tax Assets, Operating Loss Carryforwards, DomesticNet operating loss carry forwards-domestic Deferred Tax Assets, Operating Loss Carryforwards, ForeignNet operating loss carry forwards-foreign Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability asset.Deferred Tax Assets, Lease LiabilitiesOperating lease liabilities Deferred Tax Assets, Research and Development Cost CapitalizationDeferred Tax Assets, Research and Development Cost CapitalizationR&D cost capitalization Deferred Tax Assets, Unrealized Currency LossesUnrealized foreign exchange Deferred Tax Assets, Carried Foreign Interest ExpenseDeferred Tax Assets, Carried Foreign Interest ExpenseCarried foreign interest expense Deferred Tax Assets, OtherOther Deferred Tax Assets, GrossDeferred tax assets, gross Deferred Tax Assets, Valuation AllowanceValuation allowanceBalance at end of periodBalance at beginning of period Deferred Tax Assets, Net of Valuation AllowanceDeferred tax assets, net of valuation allowance Components of Deferred Tax Liabilities [Abstract] Deferred Tax Liabilities, Net [Abstract] Deferred Tax Liabilities, Gross [Abstract]Deferred tax liabilities: Deferred Tax Liabilities, Property, Plant and Equipment and Intangible AssetsDeferred Tax Liabilities, Property, Plant and Equipment and Intangible AssetsProperty, plant and equipment and intangible assets Deferred Tax Liabilities, Leasing ArrangementsOperating lease ROU assets Deferred Tax Liabilities, Unrealized Currency Transaction GainsUnrealized foreign exchange Deferred Tax Liabilities, Foreign withholding and Related Taxes, Net, on Planned RepatriationDeferred Tax Liabilities, Foreign withholding and Related Taxes, Net, on Planned RepatriationNon-U.S. withholding and related taxes, net, on planned repatriation Deferred Tax Liabilities, OtherOther Deferred Tax Liabilities, GrossTotal Deferred Tax Assets, NetNet deferred tax asset Deferred Income Tax Liabilities, NetOther liabilities Valuation Allowance [Abstract]Valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount(Benefit) provision for income taxes Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Domain] State and Local Jurisdiction [Member]State and Local Jurisdiction Foreign Tax Authority [Member]Foreign Tax Authority Operating Loss Carryforwards [Line Items]Income Taxes Operating Loss CarryforwardsNet operating loss carry forwards Operating Loss Carryforwards, Subject to ExpirationOperating Loss Carryforwards, Subject to ExpirationNet operating loss carry forwards, subject to expiration Operating Loss Carryforwards, Not Subject to ExpirationOperating Loss Carryforwards, Not Subject to ExpirationNet operating loss carry forwards, not subject to expiration Forecast [Member]Forecast Consolidated Entities [Axis] Consolidated Entities [Domain] Subsidiaries [Member] Foreign Subsidiaries [Member]Foreign Subsidiaries [Member]Foreign Subsidiaries Taxes Payable [Abstract]Taxes payable Foreign Earnings RepatriatedForeign earnings repatriated Accrued Tax Liability, Expected Repatriation of International EarningsAccrued Tax Liability, Expected Repatriation of International EarningsLiability related to the expected repatriation of international earnings Cash, Cash Equivalents, and Short-term Investments [Abstract]Cash and cash equivalents and short-term investments Cash, Cash Equivalents, and Short-term InvestmentsCash and cash equivalents and short-term investments Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]Reconciliations of the beginning and ending amounts of gross unrecognized tax benefits Unrecognized Tax BenefitsUnrecognized tax benefits-end of periodUnrecognized tax benefits-beginning of periodUnrecognized tax benefits Unrecognized Tax Benefits, Increase Resulting from Current Period Tax PositionsTax position changes-current period Unrecognized Tax Benefits, Period Increase (Decrease), TotalTax position changes-prior periods, including settlements with tax authorities Uncertain tax positions result of the lapse of the statute of limitationsLapse of statute of limitations Represents amount of increase (decrease) in unrecognized tax benefits resulting from foreign currency translation.Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency TranslationTranslation Income Tax Uncertainties [Abstract]Income Taxes Unrecognized Tax Benefits, Income Tax Penalties and Interest AccruedInterest and penalties Liability for Uncertainty in Income Taxes, NoncurrentTotal liabilities related to uncertain tax positions Income Tax Examination, Penalties and Interest Expense [Abstract]Interest and penalties expense Income Tax Examination, Penalties and Interest ExpenseRecognized interest and penalties expense (income) Environmental Expense and Liabilities [Abstract]Environmental Payments for Environmental LiabilitiesPayments for environmental liabilities Accrual for Environmental Loss Contingencies [Abstract]Environmental Accrual for Environmental Loss ContingenciesAccrual for environmental loss contingencies Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]Environmental Loss Contingency, Statement of Financial Position Employment Agreements, Certain Executive Management and Other Employees, Severance Benefits, Term, High End of RangeEmployment Agreements, Certain Executive Management and Other Employees, Severance Benefits, Term, High End of RangeSeverance benefits, term Unrecorded Unconditional Purchase Obligation, Fiscal Year Maturity [Abstract]Purchase Commitments Unrecorded Unconditional Purchase ObligationTotal purchase obligations Unrecorded Unconditional Purchase Obligation, to be Paid, Year One2023 Foreign Exchange Contract [Member] Foreign Exchange Option [Member]Foreign Exchange Option Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Other Assets [Member] Other Current Assets [Member]Other Current Assets Other Noncurrent Assets [Member]Other Noncurrent Assets Derivatives, Fair Value [Line Items] Derivative, Fair Value, Net [Abstract] Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]Other assets Derivative Asset, Subject to Master Netting Arrangement, before Offset of CollateralOther assets Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]Accrued expense and other current liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset of CollateralAccrued expense and other current liabilities Derivative, Fair Value, NetTotal Fair Value Position [Axis] Position [Domain] Long [Member]Long Short [Member]Short Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative, Gain (Loss) on Derivative, Net [Abstract]Derivatives Derivative, Gain (Loss) on Derivative, Net(Income) expense recorded in consolidated statements of operations Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]Derivative, Gain (Loss), Statement of Income or Comprehensive Income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent [Abstract]Derivatives This is the amount of gain (loss) on matured contracts, that we record to Inventory.Realized Gain (Loss) on Matured Contracts Recorded as InventoryRealized gains (losses) related to matured contracts recorded as a component of inventory Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Net Asset (Liability) [Abstract]Fair Value of Assets Derivative Assets (Liabilities), at Fair Value, NetForeign currency derivatives and interest rate swap Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]Changes in the fair value of the Level 3 assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, NetTransfers between levels, assets Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]Changes in the fair value of the Level 3 liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, NetTransfers between levels, liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)Changes in the fair value of the Level 3 liabilities Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Segment Reporting Information [Line Items] Segment Reporting Information, Profit (Loss) [Abstract] Segment Reporting Information, Income (Loss) before Income Taxes [Abstract] Segment Reporting Information, Operating Income (Loss) [Abstract]Adjusted EBITDAReconciliation of income before income taxes to Adjusted EBITDA Segment Reporting Information, Revenue for Reportable Segment [Abstract]Net sales Consolidation Items [Axis] Consolidation Items [Domain] Operating Segments [Member]Operating Segments Adjusted earnings before interest taxes depreciation and amortization.Adjusted Earnings Before Interest Taxes Depreciation And AmortizationAdjusted EBITDA - Total segmentsAdjusted EBITDA Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]Corporate Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Corporate Cost consists of the cost of employees, marketing expenses, other corporate indirect costs.Corporate CostsCorporate costs Acquisition-related Cost of Goods SoldAcquisition-related Cost of Goods SoldAcquisition-related costs of goods sold Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.Acquisition Related Transaction CostsAcquisition-related transaction costs Restructuring ChargesPhibro Forward income growth initiatives implementation costs Gain (Loss) Related to Litigation SettlementInsurance proceeds Environmental Remediation Expense, after RecoveryEnvironmental remediation costs Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]Restructuring Charges, Statement of Income or Comprehensive Income Environmental Remediation Expense, after Recovery, Statement of Income or Comprehensive Income [Extensible Enumeration]Environmental Remediation Expense, after Recovery, Statement of Income or Comprehensive Income Reconciliation of Assets from Segment to Consolidated [Table] Segment Reporting, Asset Reconciling Item [Line Items] ISRAELIsrael BRAZILBrazil IRELANDIreland Other Countries [Member]Other Countries [Member]Other Segment Reporting Information, Additional Information [Abstract]Property, plant and equipment, net Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member]Subsequent Event 2024 Credit Agreement [Member]Credit Agreement, 2024 [Member]2024 Credit Agreement 2024 Credit Agreement, 2024 Credit Facilities [Member]Credit Agreement, 2024, 2024 Credit Facilities [Member] 2024 Credit Agreement, 2024 Credit Facilities, Revolving Credit Commitments and Term A-1 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Revolving Credit Commitments and Term 1 Loans [Member]Revolving Credit Commitments and Term A-1 Loans 2024 Credit Agreement, 2024 Credit Facilities, Term A-1 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Term 1 Loans [Member] 2024 Credit Agreement, 2024 Credit Facilities, Initial Term A-1 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Initial Term 1 Loans [Member]Initial Term A-1 Loans 2024 Credit Agreement, 2024 Credit Facilities, Delayed Draw Term A-1 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Delayed Draw Term 1 Loans [Member]Delayed Draw Term A-1 Loans 2024 Credit Agreement, 2024 Credit Facilities, Revolving Credit Commitments [Member]Credit Agreement, 2024, 2024 Credit Facilities, Revolving Credit Commitments [Member]Revolving Credit Commitments 2024 Credit Agreement, 2024 Credit Facilities, Term A-2 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Term 2 Loans [Member]Term A-2 Loans 2024 Credit Agreement, 2024 Credit Facilities, Initial Term A-2 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Initial Term 2 Loans [Member]Initial Term A-2 Loans 2024 Credit Agreement, 2024 Credit Facilities, Delayed Draw Term A-2 Loans [Member]Credit Agreement, 2024, 2024 Credit Facilities, Delayed Draw Term 2 Loans [Member]Delayed Draw Term A-2 Loans Subsequent Event [Line Items]Subsequent Event Debt Instrument, Covenants, Net Leverage Ratio, Prior to Closing Date, MaximumDebt Instrument, Covenants, Net Leverage Ratio, Prior to Closing Date, MaximumMaximum Net Leverage Ratio, prior to the Closing Date Debt Instrument, Covenants, Net Leverage Ratio, First Fiscal Quarter Ending after Closing Date through Eighteen-month Anniversary of Closing Date, MaximumDebt Instrument, Covenants, Net Leverage Ratio, First Fiscal Quarter Ending after Closing Date through Eighteen-month Anniversary of Closing Date, MaximumMaximum Net Leverage Ratio, first fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date Debt Instrument, Covenants, Net Leverage Ratio, Eighteen-month Anniversary of Closing Date to Thirty-month Anniversary of Closing Date, MaximumDebt Instrument, Covenants, Net Leverage Ratio, Eighteen-month Anniversary of Closing Date to Thirty-month Anniversary of Closing Date, MaximumMaximum Net Leverage Ratio, eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date Debt Instrument, Covenants, Net Leverage Ratio, Thirty-month Anniversary of Closing Date to Forty-two Month Anniversary of Closing Date, MaximumDebt Instrument, Covenants, Net Leverage Ratio, Thirty-month Anniversary of Closing Date to Forty-two Month Anniversary of Closing Date, MaximumMaximum Net Leverage Ratio, thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date Debt Instrument, Covenants, Net Leverage Ratio, after Forty-two Month Anniversary of Closing Date, MaximumDebt Instrument, Covenants, Net Leverage Ratio, after Forty-two Month Anniversary of Closing Date, MaximumMaximum Net Leverage Ratio, after the forty-two month anniversary of the Closing Date Debt Instrument, Covenants, Interest Coverage Ratio, Prior to Closing Date, MinimumDebt Instrument, Covenants, Interest Coverage Ratio, Prior to Closing Date, MinimumMinimum interest coverage ratio, prior to the Closing Date Debt Instrument, Covenants, Interest Coverage Ratio, First Fiscal Quarter Ending after Closing Date through Eighteen-month Anniversary of Closing Date, MinimumDebt Instrument, Covenants, Interest Coverage Ratio, First Fiscal Quarter Ending after Closing Date through Eighteen-month Anniversary of Closing Date, MinimumMinimum interest coverage ratio, first fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date Debt Instrument, Covenants, Interest Coverage Ratio, Eighteen-month Anniversary of Closing Date to Thirty-month Anniversary of Closing Date, MinimumDebt Instrument, Covenants, Interest Coverage Ratio, Eighteen-month Anniversary of Closing Date to Thirty-month Anniversary of Closing Date, MinimumMinimum interest coverage ratio, eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date Debt Instrument, Covenants, Interest Coverage Ratio, Thirty-month Anniversary of Closing Date to Forty-two Month Anniversary of Closing Date, MinimumDebt Instrument, Covenants, Interest Coverage Ratio, Thirty-month Anniversary of Closing Date to Forty-two Month Anniversary of Closing Date, MinimumMinimum interest coverage ratio, thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date Debt Instrument, Covenants, Interest Coverage Ratio, after Forty-two Month Anniversary of Closing Date, MinimumDebt Instrument, Covenants, Interest Coverage Ratio, after Forty-two Month Anniversary of Closing Date, MinimumMinimum interest coverage ratio, after the forty-two month anniversary of the Closing Date EX-101.PRE 22 pahc-20240630_pre.xml EX-101.PRE XML 24 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - USD ($)	**12 Months Ended**		
	Jun. 30, 2024	**Aug. 23, 2024**	**Dec. 31, 2023**
Document Information [Line Items]			
Document Type	10-K		
Document Annual Report	true		

Document Transition Report	false	
Document Period End Date	Jun. 30, 2024	
Entity File Number	001-36410	
Entity Registrant Name	Phibro Animal Health Corporation	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	13-1840497	
Entity Address, Address Line One	Glenpointe Centre East, 3rd Floor	
Entity Address, Address Line Two	300 Frank W. Burr Boulevard	
Entity Address, Address Line Three	Suite 21	
Entity Address, City or Town	Teaneck	
Entity Address, State or Province	NJ	
Entity Address, Postal Zip Code	07666-6712	
City Area Code	201	
Local Phone Number	329-7300	
Title of 12(b) Security	Class A Common Stock, $0.0001	
Trading Symbol	PAHC	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	
Entity Filer Category	Accelerated Filer	
Entity Small Business	false	
Entity Interactive Data Current	Yes	
Entity Emerging Growth Company	false	
ICFR Auditor Attestation Flag	true	
Document Financial Statement Error Correction [Flag]	false	
Entity Shell Company	false	
Current Fiscal Year End Date	--06-30	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	FY	
Entity Central Index Key	0001069899	
Amendment Flag	false	
Entity Public Float		$ 234,820,329
Entity Well-known Seasoned Issuer	No	
Entity Voluntary Filers	No	
Auditor Name	PricewaterhouseCoopers LLP	
Auditor Firm ID	238	
Auditor Location	Florham Park, New Jersey	
Common Class A [Member]		
Document Information [Line Items]		
Entity Listing, Par Value Per Share	$ 0.0001	
Entity Common Stock, Shares Outstanding	20,337,574	
Common Class B [Member]		
Document Information [Line Items]		
Entity Listing, Par Value Per Share	$ 0.0001	
Entity Common Stock, Shares Outstanding	20,166,034	

XML 25 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]			
Net sales	$ 1,017,679	$ 977,889	$ 942,261
Cost of goods sold	704,587	679,652	656,861
Gross profit	313,092	298,237	285,400
Selling, general and administrative expenses	259,777	226,390	206,414
Operating income	53,315	71,847	78,986
Interest expense, net	18,536	15,321	11,875
Foreign currency (gains) losses, net	23,863	2,455	(5,216)
Income before income taxes	10,916	54,071	72,327
Provision for income taxes	8,500	21,465	23,152
Net income	$ 2,416	$ 32,606	$ 49,175
Net income per share			
basic (in dollars per share)	$ 0.06	$ 0.81	$ 1.21
diluted (in dollars per share)	$ 0.06	$ 0.81	$ 1.21
Weighted average common shares outstanding			
basic (in shares)	40,504	40,504	40,504
diluted (in shares)	40,523	40,504	40,504

XML 26 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)			
Net Income (Loss)	$ 2,416	$ 32,606	$ 49,175
Change in fair value of derivative instruments	(11,485)	3,698	21,681
Foreign currency translation adjustment	(8,942)	3,972	(18,939)
Pension settlement recognition	10,674		
Unrecognized net pension gains (losses)	310	212	(4,235)
(Provision) benefit for income taxes	126	(979)	(4,327)
Other comprehensive income (loss)	(9,317)	6,903	(5,820)
Comprehensive income (loss)	$ (6,901)	$ 39,509	$ 43,355

XML 27 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
ASSETS		
Cash and cash equivalents	$ 70,613	$ 41,281
Short-term investments	44,000	40,000
Accounts receivable, net	169,452	163,479
Inventories, net	265,911	277,570
Other current assets	51,021	63,393
Total current assets	600,997	585,723
Property, plant and equipment, net	203,300	195,568
Intangibles, net	45,033	54,987
Goodwill	54,557	53,274
Other assets	78,297	81,845

Total assets	982,184	971,397
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current portion of long-term debt	29,795	22,295
Accounts payable	85,567	73,853
Accrued expenses and other current liabilities	88,786	79,852
Total current liabilities	204,148	176,000
Revolving credit facility	176,000	141,000
Long-term debt	282,289	311,541
Other liabilities	63,106	60,347
Total liabilities	725,543	688,888
Commitments and contingencies (Note 13)		
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at June 30, 2024, and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at June 30, 2024, and June 30, 2023	4	4
Paid-in capital	136,278	135,803
Retained earnings	243,886	260,912
Accumulated other comprehensive loss	(123,527)	(114,210)
Total stockholders' equity	256,641	282,509
Total liabilities and stockholders' equity	$ 982,184	$ 971,397

XML 28 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Preferred stock		
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	16,000,000	16,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Class A		
Common stock		
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	20,337,574	20,337,574
Common stock, shares outstanding (in shares)	20,337,574	20,337,574
Common Class B		
Common stock		
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	30,000,000	30,000,000
Common stock, shares issued (in shares)	20,166,034	20,166,034
Common stock, shares outstanding (in shares)	20,166,034	20,166,034

XML 29 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
OPERATING ACTIVITIES			
Net income	$ 2,416	$ 32,606	$ 49,175
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	36,178	34,012	32,705
Amortization of debt issuance costs	1,040	727	590
Deferred income taxes	(12,042)	(2,838)	(806)
Foreign currency (gains) losses, net	13,114	(10,398)	(4,808)
Acquisition-related items	521		316
Pension settlement cost	10,674		
Brazil employment taxes	4,202		
Stock-based compensation	475		
Gain on sale of investment			(1,203)
Other	(2,098)	334	319
Changes in operating assets and liabilities, net of business acquisition:			
Accounts receivable, net	(8,678)	5,335	(23,625)
Inventories, net	2,641	(11,222)	(46,999)
Other current assets	11,040	(7,419)	(1,804)
Other assets	3,922	750	(1,721)
Accounts payable	12,000	(22,830)	26,358
Accrued expenses and other liabilities	12,189	(5,747)	3,152
Net cash provided by operating activities	87,594	13,310	31,649
INVESTING ACTIVITIES			
Purchases of short-term investments	(65,523)	(40,000)	(64,100)
Maturities of short-term investments	61,523	17,000	90,100
Capital expenditures	(41,238)	(51,794)	(37,044)
Business acquisition, net of cash acquired	(3,282)		(13,511)
Sale of investment			1,353
Other, net	326	776	620
Net cash used by investing activities	(48,194)	(74,018)	(22,582)
FINANCING ACTIVITIES			
Revolving credit facility borrowings	276,000	264,000	297,000
Revolving credit facility repayments	(241,000)	(268,000)	(247,000)
Proceeds from long-term debt		62,000	
Payments of long-term debt	(22,295)	(15,315)	(9,375)
Debt issuance costs		(1,473)	
Payment of contingent consideration			(4,840)
Proceeds from insurance premium financing and other short-term debt	8,593	6,356	
Payments of insurance premium financing and other short-term debt	(8,624)	(1,139)	
Dividends paid	(19,442)	(19,442)	(19,442)
Net cash (used) provided by financing activities	(6,768)	26,987	16,343
Effect of exchange rate changes on cash	(3,300)	754	(1,374)
Net increase (decrease) in cash and cash equivalents	29,332	(32,967)	24,036
Cash and cash equivalents at beginning of period	41,281	74,248	50,212
Cash and cash equivalents at end of period	70,613	41,281	74,248
Supplemental cash flow information			
Interest paid, net	17,253	14,575	11,159
Income taxes paid, net	15,430	20,410	17,854
Non-cash investing and financing activities			
Property, plant and equipment	$ 2,367	$ 2,764	$ 2,953

XML 30 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN	Common	Paid-in	Retained Earnings (Accumulated	Accumulated Other Comprehensive Income

STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Stock	Capital	Deficit)	(Loss)	Total
Balance at Jun. 30, 2021	$ 4	$ 135,803	$ 218,015	$ (115,293)	$ 238,529
Balance (in shares) at Jun. 30, 2021	40,503,608				
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)			49,175	(5,820)	43,355
Dividends declared			(19,442)		(19,442)
Balance at Jun. 30, 2022	$ 4	135,803	247,748	(121,113)	262,442
Balance (in shares) at Jun. 30, 2022	40,503,608				
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)			32,606	6,903	39,509
Dividends declared			(19,442)		(19,442)
Balance at Jun. 30, 2023	$ 4	135,803	260,912	(114,210)	282,509
Balance (in shares) at Jun. 30, 2023	40,503,608				
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)			2,416	(9,317)	(6,901)
Dividends declared			(19,442)		(19,442)
Stock-based compensation expense		475			475
Balance at Jun. 30, 2024	$ 4	$ 136,278	$ 243,886	$ (123,527)	$ 256,641
Balance (in shares) at Jun. 30, 2024	40,503,608				

XML 31 R8.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals) - $ / shares	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Dividends declared			
Dividends declared (in dollars per share)	$ 0.48	$ 0.48	$ 0.48

XML 32 R9.htm IDEA: XBRL DOCUMENT

Description of Business	12 Months Ended Jun. 30, 2024
Description of Business	

Description of Business

1. Description of Business

Phibro Animal Health Corporation ("Phibro" or "PAHC") and its subsidiaries (together, the "Company") is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to "we," "our," "us," and similar expressions refer to Phibro and its subsidiaries.

XML 33 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards	12 Months Ended Jun. 30, 2024
Summary of Significant Accounting Policies and New Accounting Standards	

Summary of Significant Accounting Policies and New Accounting Standards

2. Summary of Significant Accounting Policies and New Accounting Standards

Principles of Consolidation and Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated from the consolidated financial statements. The decision whether to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.

We present our financial statements on the basis of our fiscal year ending June 30. All references to years in these consolidated financial statements refer to the fiscal year ending or ended on June 30 of that year.

Risks and Uncertainties

The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on or banning of the use of antibiotics in food-producing animals. The sale of antibiotics and antibacterials is a material portion of our business. Should product bans or restrictions, public perception, competition or other developments result in restrictions on the sale of such products, it could have a material adverse effect on our financial position, results of operations and cash flows.

An outbreak of disease carried by food animals, which could lead to the widespread death or precautionary destruction of food animals as well as reduced consumption and demand for animal protein, could adversely affect demand for our products. Such occurrences could have a material adverse effect on our financial condition, results of operations and cash flows.

The testing, manufacturing, and marketing of certain of our products are subject to extensive regulation by numerous government authorities in the United States and other countries.

We have significant assets in Israel, Brazil and other locations outside of the United States and a significant portion of our sales and earnings are attributable to operations conducted abroad. Our assets, results of operations and future prospects are subject to currency exchange fluctuations and restrictions, energy shortages, other economic developments, political or social instability in some countries, and uncertainty of, and governmental control over, commercial rights, which could result in a material adverse effect on our financial position, results of operations and cash flows.

We are subject to environmental laws and regulations governing the use, storage, handling, generation, treatment, emission, release, discharge and disposal of certain materials and wastes, the remediation of contaminated soil and groundwater, the manufacture, sale and use of regulated materials, including pesticides, and the health and safety of employees. As such, the nature of our current and former operations and those of our subsidiaries expose Phibro and our subsidiaries to the risk of claims with respect to such matters.

Our business could be impacted by economic sanctions, bans, boycotts, or broader military conflicts, including the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine. Other potential impacts include supply chain and logistics disruptions, macroeconomic impacts from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy, as well as heightened cybersecurity threats.

Pandemics and similar outbreaks could directly or indirectly impact our business, results of operations and financial condition. A pandemic or any other similar health crisis could have economic impacts on customers, suppliers and markets. A pandemic could affect our future revenues, expenses, reserves and allowances, manufacturing operations and employee-related costs.

Use of Estimates

The Company's consolidated financial statements have been prepared in accordance with GAAP. Preparation of these financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Actual results could differ from these estimates. Estimates are used when accounting for the valuation of intangible assets, depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax assets, sales discounts, rebates, allowances and incentives, contingencies, employee compensation and actuarial assumptions related to our pension plans. We regularly evaluate our estimates and assumptions using historical experience and other factors. Our estimates are based on complex judgments, probabilities and assumptions that we believe to be reasonable.

Revenue Recognition

We recognize revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to the customers. Certain of our businesses have terms where control of the underlying product transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery.

Revenue reflects the total consideration to which we expect to be entitled in exchange for delivery of products or services, net of variable consideration. Variable consideration includes customer programs and incentive offerings, including pricing arrangements, rebates and other volume-based incentives. We record reductions to revenue for estimated variable consideration at the time we record the sale. Our estimates for variable consideration reflect the amount by which we expect variable consideration to affect the revenue recognized. Such estimates are generally based on contractual terms and historical experience and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of variable compensation. Sales returns and product recalls have been insignificant and infrequent due to the nature of the products we sell.

Net sales include shipping and handling fees billed to customers. The associated costs are considered fulfillment activities and are included in cost of goods sold in the consolidated statements of operations when the related revenue is recognized. Net sales exclude value-added and other taxes based on sales.

Cash and Cash Equivalents

Cash equivalents include highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.

Short-term Investments

Short-term investments include highly liquid investments with maturities greater than three months and less than one year at the time of purchase. We classify these investments as held to maturity and we record the related interest income as earned. We determine the appropriate balance sheet classification at the time of purchase and at each balance sheet date. Investments held at financial institutions

may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.

Accounts Receivable and Reserve for Credit Losses

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. We grant credit terms in the normal course of business and generally do not require collateral or other security to support credit sales. Our ten largest customers represented, in aggregate, approximately 13% and 16% of accounts receivable at June 30, 2024 and 2023, respectively.

The reserve for credit losses is our best estimate of the credit losses in existing accounts receivable. We monitor the financial performance, historical and expected collection patterns, and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We also monitor domestic and international economic conditions for the potential future effect on our customers. Past due balances are reviewed individually for collectability. Account balances are charged against the reserve when we determine it is probable the receivable will not be recovered.

Inventories

Inventories are valued at the lower of cost or net realizable value. Cost is determined principally under weighted average and standard cost methods, which approximate first-in, first-out (FIFO) cost. Obsolete and unsalable inventories, if any, are reflected at estimated net realizable value. Inventory costs include materials, direct labor and manufacturing overhead.

Property, Plant and Equipment

Property, plant and equipment are stated at cost.

Depreciation is charged to results of operations using the straight-line method based upon the assets' estimated useful lives, ranging from two to thirty years for buildings and improvements, and three to ten years for machinery and equipment. We capitalize costs that extend the useful life or productive capacity of an asset. Repair and maintenance costs are expensed as incurred. In the case of disposals, the assets and related accumulated depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in the consolidated statements of operations.

Leases

We determine at the inception of an arrangement whether the arrangement contains a lease. If an arrangement contains a lease, we assess the lease term when the underlying asset is available for use ("lease commencement"). Individual lease terms reflect the non-cancellable period of the lease, reasonably certain renewal periods and consideration of termination options. We determine the lease classification as either operating or financing at lease commencement, which governs the pattern of expense recognition and presentation in our consolidated financial statements. Our current lease portfolio only includes operating leases.

We recognize a right-of-use ("ROU") asset and a corresponding lease liability at lease commencement for leases with terms exceeding twelve months. Short-term leases with terms of twelve months or less are not recognized on the consolidated balance sheet and lease payments are recognized on a straight-line basis over the term.

The values of the ROU assets and lease liabilities are calculated based on the present value of the fixed payment obligations over the lease term, using our incremental borrowing rate ("IBR"), determined at lease commencement. The IBR reflects the rate of interest we would expect to pay on a secured basis to borrow an amount equal to the lease payments under similar terms. The IBR incorporates the term and economic environment of the respective lease arrangements.

We have elected to account for lease and non-lease components together as a single lease component and include fixed payment obligations related to such non-lease components in the measurement of ROU assets and lease liabilities. Fixed lease payments are recognized on a straight-line basis over the lease term. Variable lease payments can include index-based lease payments, real estate taxes, maintenance costs, utilization charges and other non-lease services paid to lessors and are not determinable at lease commencement. Variable lease payments are not included in the measurement of ROU assets and lease liabilities and are recognized in the period incurred.

Capitalized Software Costs

We capitalize costs to obtain, develop and implement software for internal use. Amounts paid to third parties and costs of internal employees who are directly associated with the software project are also capitalized, depending on the stage of development.

We expense software costs that do not meet the capitalization criteria. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets and are amortized on a straight-line basis over three to seven years.

Debt Issuance Costs

Costs and original issue discounts or premiums related to issuance or modification of our debt are deferred on the consolidated balance sheet and amortized over the lives of the respective debt instruments. Amortization of debt issuance costs is included in interest expense in the consolidated statements of operations.

Business Combinations

Our consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition; goodwill is recorded for any excess of the purchase price over the fair values of the net assets acquired.

Significant judgment may be required to determine the fair values of certain tangible and intangible assets and in assigning their respective useful lives. Significant judgment also may be required to determine the fair values of contingent consideration, if any. We typically utilize third-party valuation specialists to assist us in determining fair values of significant tangible and intangible assets and contingent consideration. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect consideration of other marketplace participants and include the amount and timing of future cash flows, specifically the expected revenue growth rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets primarily are based on a number of factors including the competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Intangible assets associated with acquired in-process research and development activities ("IPR&D") are not amortized until a product is available for sale and regulatory approval is obtained.

Long-Lived Assets and Goodwill

We periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. We recognize an impairment loss when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss is the excess of the asset's carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations.

Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in a business combination. We assess goodwill for impairment annually during our fourth quarter, or more frequently if impairment indicators exist. Impairment exists when the carrying amount of goodwill exceeds its implied fair value. We may elect to assess our goodwill for impairment using a qualitative or a quantitative approach, to determine whether it is more likely than not that the fair value of goodwill is greater than its carrying value. During the three months ended June 30, 2024, we tested goodwill using the quantitative approach and determined goodwill was not impaired. We have not recorded any goodwill impairment charges in the periods included in the consolidated financial statements.

Foreign Currency Translation

We generally use local currency as the functional currency to measure the financial position and results of operations of each of our international subsidiaries. We translate assets and liabilities of these operations at the exchange rates in effect at the balance sheet date. We translate income statement accounts at the average rates of exchange prevailing during the period. Translation adjustments that arise from the use of differing exchange rates from period to period are included as a component of accumulated other comprehensive income (loss) in stockholders' equity. Certain of our Israeli operations have designated the U.S. dollar as their functional currency. Gains and losses arising from re-measurement of local currency accounts into U.S. dollars are included in determining net income.

Comprehensive Income

Comprehensive income consists of net income and the changes in: (i) the fair value of derivative instruments that qualify for hedge accounting; (ii) foreign currency translation adjustments; (iii) pension settlement recognition and unrecognized net pension gains (losses); and (iv) the related (provision) benefit for income taxes.

Derivative Financial Instruments

We record all derivative financial instruments on the consolidated balance sheets at fair value. Changes in the fair value of derivatives are recorded in results of operations or other comprehensive income (loss), depending on whether a derivative is designated and effective as part of a hedge transaction and, if so, the type of hedge transaction. Gains and losses on derivative instruments designated and effective as part of a hedge transaction are included in the results of operations in the periods in which operations are affected by the underlying hedged item.

From time to time, we use certain derivative instruments to mitigate the risk associated with certain economic factors, such as exchange rates and interest rates, which may potentially affect our future cash flows. As of June 30, 2024, we used (i) foreign currency option contracts to mitigate certain exposures related to changes in foreign currency exchange rates on forecasted inventory purchases, and (ii) an interest rate swap on $300,000 of notional principal to manage future cash flow exposure resulting from variable interest rates on that amount of debt. To qualify a derivative as a hedge, we document the nature and relationships between hedging instruments and hedged items, the prospective effectiveness of the hedging instrument as well as the ultimate effectiveness, the risk-management objectives, the strategies for undertaking the various hedge transactions and the methods of assessing hedge effectiveness. We do not engage in trading or other speculative uses of financial instruments.

Environmental Liabilities

Expenditures for ongoing compliance with environmental regulations are expensed or capitalized as appropriate. We capitalize expenditures made to extend the useful life or productive capacity of an asset, including expenditures that prevent future environmental contamination. Other expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. We record the expense and related liability in the period an environmental assessment indicates remedial efforts are probable and the costs can be reasonably estimated. Estimates of the liability are based upon currently available facts, existing technology and presently enacted laws and regulations taking into consideration the likely effects of inflation and other societal and economic factors. All available evidence is considered, including prior experience in remediation of contaminated sites, other companies' experiences and data released by the U.S. Environmental Protection Agency and other organizations. The estimated liabilities are not discounted. We record anticipated recoveries under existing insurance contracts if probable.

Income Taxes

The provision for income taxes includes U.S. federal, state, and foreign income taxes and foreign withholding taxes. Our annual effective income tax rate is determined based on our income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate and the tax effects of items treated differently for tax purposes than for financial reporting purposes. Tax law requires certain items be included in the tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as
depreciation expense. These temporary differences give rise to deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which we have already recorded the tax benefit in our income statement. Deferred tax liabilities generally represent the tax effect of items recorded as tax expense in our income statement for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our income statement, and the tax effect of assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.

The recognition and measurement of a tax position is based on management's best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual effective income tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, including research and development costs capitalized for income tax purposes and net operating loss carryforwards, is dependent upon generating sufficient future taxable income in the appropriate jurisdiction prior to the expiration of the amortization or carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.

We may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority in the jurisdictions where we operate. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.

Because there are a number of estimates and assumptions inherent in calculating the various components of our income tax provision, future events such as changes in tax legislation, the geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an effect on those estimates and our effective income tax rate.

Advertising

Advertising and marketing costs are expensed as incurred and are reflected in selling, general and administrative expenses.

Research and Development Expenditures

Research and development expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Most of our manufacturing facilities have scientists and technicians on staff involved in product development, quality assurance and providing technical services to customers. Research, development and technical service efforts are conducted at various facilities. Our animal health research and development activities relate to: companion animal product development, fermentation development and microbiological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional specialties development; and ethanol-related products.

Stock-Based Compensation

We recognize expense for stock-based compensation to employees, including grants of restricted stock units, over the requisite service period based on the grant date fair value of the awards. We determine the fair value of performance-based restricted stock units using the Monte Carlo simulation models. The models use historical and current market data to estimate the fair value. The models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards.

Net Income per Share and Weighted Average Shares

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.

Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common shares equivalents, resulting from
the assumed vesting of restricted stock units, unless the effect would be antidilutive. Common share equivalents were included in the calculation of diluted net income per share for the periods included in the consolidated financial statements, when applicable.

For the Year Ended June 30	2024	2023	2022
Net income	$ 2,416	$ 32,606	$ 49,175
Weighted average number of shares – basic	40,504	40,504	40,504
Dilutive effect of restricted stock units	19	—	—
Weighted average number of shares - diluted	40,523	40,504	40,504
Net income per share			
basic	$ 0.06	$ 0.81	$ 1.21
diluted	$ 0.06	$ 0.81	$ 1.21

New Accounting Standards

Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, requires the disclosure of significant segment expenses that are included in segment profit or loss and how the segment measures are used for decision-making. The ASU will be effective for Phibro’s fiscal year ending June 30, 2025, including retrospective disclosure for all prior periods presented, and interim periods subsequent to June 30, 2025. We are evaluating the impact to our segment disclosures.

ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU outlines specific categories to be provided in the rate reconciliation and requires additional information for those reconciling items that meet a quantitative threshold. The ASU requires disaggregated disclosure of federal, state and foreign income taxes paid, including disaggregation by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). The ASU also requires disaggregated disclosure of federal, state and foreign income (loss) from continuing operations before income taxes. The enhanced disclosures will be applied on a prospective basis and are required for Phibro’s fiscal year ending June 30, 2026. We are evaluating the impact of the additional income tax-related disclosures.

XML 34 R11.htm IDEA: XBRL DOCUMENT

Proposed Acquisition

12 Months Ended
Jun. 30, 2024

Proposed Acquisition

Proposed Acquisition

3. Proposed Acquisition

In April 2024, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc. (“Zoetis”) to acquire Zoetis’s medicated feed additive (MFA) product portfolio, certain water-soluble products and related assets (the “Proposed Acquisition”). The purchase price is $350,000, subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. Completion of the Proposed Acquisition is subject to satisfaction of customary closing conditions, including clearances by applicable regulatory authorities.

XML 35 R12.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information

12 Months Ended
Jun. 30, 2024

Statements of Operations-Additional Information

Disaggregated Revenue, Deferred Revenue and Customer Payment Terms

Disaggregated revenue and customer payment terms

We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The products help prevent, control and treat diseases and enhance nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products directly to integrated poultry, cattle and swine customers and through commercial animal feed manufacturers, distributors and veterinarians The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and
seasons. Our operations are primarily focused on regions where the majority of livestock production is consolidated in large commercial farms.

We have a diversified portfolio of products that are classified within our three reportable business segments — Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.

Animal Health

The Animal Health business develops, manufactures and markets products in three main categories:

- MFAs and other: MFAs and other products primarily consist of concentrated medicated products administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products. The MFAs and other category also includes antibacterials and other processing aids used in the ethanol fermentation industry.
- Nutritional specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.
- Vaccines: Vaccine products are primarily focused on preventing diseases in poultry, swine, beef and dairy cattle and aquaculture. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.

Mineral Nutrition

The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine, and beef and dairy cattle.

Performance Products

The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

The following tables present our revenues disaggregated by major product category and geographic region:

Net Sales by Product Type

For the Year Ended June 30	2024	2023	2022
Animal Health			
MFAs and other	$ 420,959	$ 387,349	$ 361,538
Nutritional specialties	164,671	172,504	157,196
Vaccines	120,852	99,998	88,321
Total Animal Health	$ 706,482	$ 659,851	$ 607,055
Mineral Nutrition	243,663	242,656	259,512
Performance Products	67,534	75,382	75,694
Total	$ 1,017,679	$ 977,889	$ 942,261

Net Sales by Region

For the Year Ended June 30	2024	2023	2022
United States	$ 584,763	$ 578,773	$ 561,803
Latin America and Canada	247,705	219,846	191,047
Europe, Middle East and Africa	121,977	117,815	122,480
Asia Pacific	63,234	61,455	66,931
Total	$ 1,017,679	$ 977,889	$ 942,261

Net sales by region are based on country of destination.

Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.

Additional Information

Additional Information

For the Year Ended June 30	2024	2023	2022
Interest expense, net			
2021 Credit Facilities	$ 20,646	$ 17,302	$ 11,918
2022 Term loan	862	589	—
Amortization of debt issuance costs	1,040	727	590
Other	462	58	183
Interest expense	23,010	18,676	12,691
Interest income	(4,474)	(3,355)	(816)
	$ 18,536	$ 15,321	$ 11,875

For the Year Ended June 30	2024	2023	2022
Depreciation and amortization			
Depreciation of property, plant and equipment	$ 26,517	$ 24,316	$ 23,781
Amortization of intangible assets	9,661	9,696	8,924
	$ 36,178	$ 34,012	$ 32,705

Depreciation of property, plant and equipment includes amortization of capitalized software costs of $1,436, $1,455 and $1,047 during 2024, 2023 and 2022, respectively.

Future amortization of intangible assets as of June 30, 2024 is expected to be:

For the Years Ending June 30	
2025	$ 7,918
2026	6,969
2027	6,591
2028	6,385
2029	6,385
Thereafter	10,785
Total	$ 45,033

For the Year Ended June 30	2024	2023	2022
Research and development expense	$ 29,194	$ 24,395	$ 20,832

XML 36 R13.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information

12 Months Ended

Jun. 30, 2024

Balance Sheets-Additional Information

Balance Sheets-Additional Information

5. Balance Sheets—Additional Information

As of June 30	2024	2023
Accounts receivable, net		
Trade accounts receivable	$ 170,913	$ 165,069
Reserve for credit losses	(1,461)	(1,590)
	$ 169,452	$ 163,479

As of June 30	2024	2023
Reserve for credit losses		
Balance at beginning of period	$ 1,590	$ 3,510
Provision for estimated credit losses	1,538	943
Effect of changes in exchange rates	(71)	(61)
Credit losses realized	(1,596)	(2,802)
Balance at end of period	$ 1,461	$ 1,590

As of June 30	2024	2023
Inventories, net		
Raw materials	$ 72,799	$ 84,328
Work-in-process	23,550	22,350
Finished goods	169,562	170,892
	$ 265,911	$ 277,570

As of June 30	2024	2023
Property, plant and equipment, net		
Land	$ 30,624	$ 27,813
Buildings and improvements	120,173	105,184
Machinery and equipment	273,965	291,454
Construction in progress	23,892	34,743
	448,654	459,194
Accumulated depreciation	(245,354)	(263,626)
	$ 203,300	$ 195,568

Certain of our facilities in Israel are on leased land. These leases expire in calendar years 2039, 2045 and 2062.

Property, plant and equipment, net includes internal-use software costs, net of accumulated amortization, of $3,123 and $3,426 at June 30, 2024 and 2023, respectively.

As of June 30	Weighted-Average Useful Life (Years)	2024	2023
Intangibles, net			
Cost			
Technology	12	$ 94,259	$ 95,576
Product registrations, marketing and distribution rights	9	18,117	18,557
Customer relationships	12	30,418	30,235
Trade names, trademarks and other	6	5,213	5,605
		148,007	149,973
Accumulated amortization			
Technology		(62,119)	(55,396)
Product registrations, marketing and distribution rights		(17,326)	(18,553)
Customer relationships		(19,001)	(16,884)
Trade names, trademarks and other		(4,528)	(4,153)
		(102,974)	(94,986)
		$ 45,033	$ 54,987

As of June 30	2024	2023
Goodwill		
Balance at beginning of period	$ 53,274	$ 53,226
Acquisition	1,397	—
Effect of changes in exchange rates	(114)	48
Balance at end of period	$ 54,557	$ 53,274

As of June 30	2024	2023
Other assets		
ROU operating lease assets	$ 37,604	$ 35,759
Deferred income taxes	19,371	8,711
Deposits	1,646	6,617
Insurance investments	6,305	6,067
Equity method investments	5,183	5,027
Derivative instruments	—	10,225
Debt issuance costs	911	1,408
Other	7,277	8,031
	$ 78,297	$ 81,845

As of June 30	2024	2023
Accrued expenses and other current liabilities		
Employee related	$ 37,612	$ 29,359
Current operating lease liabilities	7,460	6,053
Commissions and rebates	7,875	5,833
Professional fees	8,918	5,032
Income and other taxes	2,931	8,663
Insurance-related	1,265	1,284
Insurance premium financing	5,185	4,769
Other	17,540	18,859
	$ 88,786	$ 79,852

The insurance premium financing has a fixed interest rate of 6.95% and monthly payments of $648.

As of June 30	2024	2023
Other liabilities		
Long-term operating lease liabilities	$ 29,915	$ 29,077
Long-term and deferred income taxes	14,218	12,146
Supplemental retirement benefits, deferred compensation and other	6,678	6,552
U.S. pension plan	2,237	2,286
International retirement plans	3,212	4,210
Other long-term liabilities	6,846	6,076
	$ 63,106	$ 60,347

As of June 30	2024	2023
Accumulated other comprehensive loss		

Derivative instruments	$ 13,104	$ 24,589
Foreign currency translation adjustment	(124,004)	(115,062)
Unrecognized net pension losses	(13,012)	(23,996)
Provision for income taxes on derivative instruments	(3,304)	(6,207)
Benefit for income taxes on long-term intercompany investments	8,166	8,166
Provision for income taxes on net pension losses	(4,477)	(1,700)
	$ (123,527)	$ (114,210)

XML 37 R14.htm IDEA: XBRL DOCUMENT

Debt

12 Months Ended
Jun. 30, 2024

Debt

Debt

6. Debt

Subsequent Event – 2024 Credit Agreement

In July 2024, we entered into a Credit Agreement, (the "2024 Credit Agreement") with a group of lenders, to refinance all our outstanding debt, to pay fees and expenses of the transaction, to finance the purchase price of the Proposed Acquisition upon completion and for ongoing working capital requirements and general corporate purposes. See "Note 17 — Subsequent Event — 2024 Credit Agreement."

Term Loans and Revolving Credit Facilities

In April 2021, we entered into an amended and restated credit agreement (the "2021 Credit Agreement") under which we had a term A loan in an aggregate initial principal amount of $300,000 (the "2021 Term A Loan") and a revolving credit facility under which we could borrow up to $250,000, subject to the terms of the agreement (the "2021 Revolver"). In November 2022, we amended the 2021 Credit Facilities to increase the revolving commitments under the 2021 Revolver to an aggregate amount of $310,000 and to adopt the SOFR as the reference for the fluctuating rate of interest on the 2021 Credit Facilities, replacing the LIBOR reference rate. In June 2023, we obtained an additional incremental Term loan (the "2023 Incremental Term Loan") in the amount of $50,000 (the 2021 Revolver, the 2021 Term A Loan, and the 2023 Incremental Term Loan are collectively referred to as the "2021 Credit Facilities").

Borrowings under the 2021 Credit Facilities bear interest at rates based on the ratio of the Company and its subsidiaries' net consolidated first lien indebtedness to the Company and its subsidiaries' consolidated EBITDA (the "First Lien Net Leverage Ratio"). The interest rate per annum applicable to the 2021 Revolver and the 2021 Term A Loan is based on a fluctuating rate of interest plus an applicable rate equal to 1.50%, 1.75%, 2.00% or 2.25% in the case of adjusted SOFR rate loans and 0.50%, 0.75%, 1.00% or 1.25% in the case of base rate loans. The interest rate per annum applicable to the 2023 Incremental Term Loan is based on a fluctuating rate of interest plus an applicable rate equal to 2.00%, 2.25%, 2.50% or 2.75% in the case of adjusted SOFR rate loans and 1.00%, 1.25%, 1.50% or 1.75% in the case of base rate loans. The applicable rates are based on the First Lien Net Leverage Ratio (as defined in the 2021 Credit Agreement, as amended).

Pursuant to the terms of the 2021 Credit Agreement, the 2021 Credit Facilities are subject to various covenants that, among other things and subject to the permitted exceptions described therein, restrict us and our subsidiaries with respect to: (i) incurring additional debt; (ii) making certain restricted payments or making optional redemptions of other indebtedness; (iii) making investments or acquiring assets; (iv) disposing of assets (other than in the ordinary course of business); (v) creating any liens on our assets; (vi) entering into transactions with affiliates; (vii) entering into merger or consolidation transactions; and (viii) creating guarantee obligations; provided, however, that we are permitted to pay distributions to stockholders out of available cash subject to certain annual limitations and so long as no default or event of default under the 2021 Credit Facilities shall have occurred and be continuing at the time such distribution is declared. Indebtedness under the 2021 Credit Facilities is collateralized by a first priority lien on substantially all assets of Phibro and certain of our domestic subsidiaries. The 2021 Credit Facilities mature in April 2026.

The 2021 Credit Agreement requires, among other things, compliance with financial covenants that permit: (i) a maximum First Lien Net Leverage Ratio of 4.00:1.00 (or, specifically with respect to the Test Periods ended June 30, 2024, a maximum of 4.25:1.00); and (ii) a minimum interest coverage ratio of 3.00:1.00, each calculated on a trailing four-quarter basis. The 2021 Credit Agreement contains an acceleration clause should an event of default (as defined in the 2021 Credit Agreement) occur. As of June 30, 2024, we were in compliance with the financial covenants.

As of June 30, 2024, we had $176,000 in borrowings drawn under the 2021 Revolver and had outstanding letters of credit of $2,294, leaving $131,706 available for further borrowings and letters of credit under the 2021 Revolver, subject to restrictions in our 2021 Credit Facilities. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year.

Other Long-Term Debt

In September 2022, we entered into a credit agreement (the "2022 Term Loan") in the amount of $12,000, collateralized by certain facilities. The 2022 Term Loan matures in September 2027. The interest rate per annum applicable to the 2022 Term Loan is based on a fluctuating rate of interest, at the Company's election from time to time, equal to either (i) one-month adjusted SOFR plus 2.00%; or (ii) a base rate determined by reference to the greater of (a) the Prime Rate and (b) the Federal Funds Effective Rate plus 0.50%. The 2022 Term Loan is repayable in monthly installments of $35, with the balance payable at maturity.

Interest Rates

Interest rates as of the balance sheet dates and the weighted-average rates for the years presented were:

	June 30		Years Ended June 30		
	2024	2023	2024	2023	2022
2021 Revolver	6.00 %	6.09 %	6.14 %	5.42 %	2.08 %
2021 Term A Loan	2.36 %	2.36 %	2.36 %	2.37 %	2.99 %
2023 Incremental Term Loan	7.68 %	7.44 %	7.64 %	7.40 %	— %
2022 Term Loan	7.43 %	7.25 %	7.41 %	6.43 %	— %

Interest rates as of the balance sheet dates are based on rates in effect as of those dates, including SOFR fluctuating rates of interest, applicable rates and the interest rate swap agreement.

We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating SOFR portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025. We have designated the interest rate swap as a highly effective cash flow hedge. For additional details, see "Note 14 — Derivatives."

Debt Maturities

As of June 30	2024	2023
2021 Term A Loan due April 2026	$ 256,875	$ 273,750
2023 Incremental Term Loan due April 2026	45,000	50,000
2022 Term Loan due September 2027	11,265	11,685
	313,140	335,435
Unamortized debt issuance costs	(1,056)	(1,599)
	312,084	333,836
Less: current maturities of long-term debt and other	(29,795)	(22,295)
Long-term debt	$ 282,289	$ 311,541

Interest rates in the table are based on rates in effect as of the balance sheet dates, including fluctuating rates of interest, applicable rates and the interest rate swap agreement.

Aggregate Maturities of Long-Term Debt and Revolver

For the Years Ending June 30	Annual Maturities	Interest Payments
2025	$ 29,795	$ 19,785
2026	272,920	26,598
2027	420	755
2028	10,005	184
Total	$ 313,140	$ 47,322

For purposes of estimating future interest payments until maturity, we assume long-term debt decreases in accordance with the scheduled amortization and the 2021 Revolver continues unchanged at the June 30, 2024. We assume the March 2020 interest rate swap agreement remains in place through its June 2025 maturity and future interest rates and applicable rates are the same as the rates at June 30, 2024.

XML 38 R15.htm IDEA: XBRL DOCUMENT

Leases

12 Months Ended
Jun. 30, 2024

Leases

Leases

7. Leases

Our lease portfolio consists of real estate, vehicles and equipment ROU assets, classified as operating leases. The remaining non-cancelable lease terms, inclusive of renewal options reasonably certain of exercise, range from one to 23 years.

The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:

As of June 30	2024	2023	Balance Sheet Classification
Assets:			
Operating lease ROU assets	$ 37,604	$ 35,759	Other Assets
Liabilities:			
Current portion	7,460	6,053	Accrued expenses and other current liabilities
Non-current portion	29,915	29,077	Other liabilities
Total operating lease liabilities	$ 37,375	$ 35,130	

The following table summarizes the composition of net lease expense:

For the Year Ended June 30	2024	2023	2022
Operating lease expense	$ 8,888	$ 8,363	$ 8,461
Variable lease expense	1,150	1,139	1,376
Short-term lease expense	1,397	1,522	1,214
Total lease expense	$ 11,435	$ 11,024	$ 11,051

The following tables include other supplemental information:

For the Year Ended June 30	2024	2023	2022
Operating cash flows used for ROU operating leases	$ 8,231	$ 7,798	$ 8,642
Non-cash changes to ROU operating assets and lease liabilities	$ 9,283	$ 5,114	$ 11,930

As of June 30	2024	2023
Weighted average remaining lease term (in years) - operating leases	9.6	10.6

Weighted average discount rate - operating leases	4.73 %	3.89 %

At June 30, 2024 maturities of future lease liabilities were:

For the Years Ending June 30	
2025	$ 8,800
2026	7,085
2027	5,212
2028	3,920
2029	3,048
2030 and thereafter	17,200
Total lease payments	45,265
Less: interest	7,890
Total operating lease liabilities	$ 37,375

There were no significant future payment obligations related to executed lease agreements for which the related lease had not yet commenced as of June 30, 2024. Our lease agreements do not contain any material restrictive covenants or residual value guarantee provisions.

XML 39 R16.htm IDEA: XBRL DOCUMENT

Common Stock, Preferred Stock and Dividends

12 Months Ended
Jun. 30, 2024

Common Stock, Preferred Stock and Dividends

Common Stock, Preferred Stock and Dividends

8. Common Stock, Preferred Stock and Dividends

Preferred stock and common stock at June 30, 2024 and 2023 were:

As of June 30	2024	2023		2024	2023
	Authorized Shares		Par value	Issued and outstanding shares	
Preferred stock	16,000,000	16,000,000	$ 0.0001	—	—
Common stock – Class A	300,000,000	300,000,000	$ 0.0001	20,337,574	20,337,574
Common stock – Class B	30,000,000	30,000,000	$ 0.0001	20,166,034	20,166,034

Holders of our Class B common stock converted zero shares of Class B common stock to Class A common stock in 2024 and 2023.

Common Stock

General

Except as otherwise provided by our amended and restated certificate of incorporation or applicable law, the holders of our Class A common stock and Class B common stock shall vote together as a single class. There are no cumulative voting rights.

Holders of our Class A common stock and Class B common stock are entitled to receive dividends when and if declared by our Board of Directors out of funds legally available therefore, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock.

Upon our dissolution or liquidation or the sale of all or substantially all of our assets, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of our Class A common stock and Class B common stock will be entitled to receive our remaining assets available for distribution.

Class A Common Stock

Holders of our Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders.

Holders of our Class A common stock do not have preemptive, subscription or conversion rights. Our Class A common stock is not convertible and there are no redemption or sinking fund provisions applicable to our Class A common stock. Unless our Board of Directors determines otherwise, we will issue all of our capital stock in uncertificated form.

Class B Common Stock

Holders of our Class B common stock are entitled to 10 votes for each share held of record on all matters submitted to a vote of stockholders. BFI holds all of our outstanding Class B common stock.

Holders of our Class B common stock do not have preemptive or subscription rights. There are no redemption or sinking fund provisions applicable to our Class B common stock.

Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon any transfer, whether or not for value, except for certain transfers by and among BFI, its affiliates and certain Bendheim family members, as described in the amended and restated certificate of incorporation. Once transferred and converted into Class A common stock, the Class B common stock will not be reissued. In addition, all shares of Class B common stock will automatically convert to shares of Class A common stock when the outstanding shares of Class B common stock and Class A common stock held by BFI, its affiliates and certain Bendheim family members, together, is less than 15% of the total outstanding shares of Class A common stock and Class B common stock, taken as a single class.

Holders of our Class B common stock have the right to require us to register the sales of their shares under the Securities Act, under the terms of an agreement between us and the holders.

Preferred Stock

We do not have any preferred stock outstanding. Our Board of Directors has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the General Corporation Law of the State of Delaware.

Dividends

We declared and paid quarterly cash dividends totaling $19,442 for the years ended June 30, 2024, 2023 and 2022, to holders of our Class A common stock and Class B common stock.

XML 40 R17.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan

12 Months Ended
Jun. 30, 2024

Stock Incentive Plan

Stock Incentive Plan

9. Stock Incentive Plan

In March 2008, our Board of Directors and stockholders adopted the 2008 Incentive Plan (the "Incentive Plan"). The Incentive Plan provides directors, officers, employees and consultants to the Company with opportunities to purchase common stock pursuant to options that may be granted and receive grants of restricted stock and other stock-based awards granted, from time to time by the Board of Directors or a committee approved by the Board. The Incentive Plan provides for grants of stock options, stock awards and other incentives for up to 6,630,000 shares. There were 4,481,620 Class A shares available for grant pursuant to the Incentive Plan as of June 30, 2024.

Restricted Stock Units

Our Board of Directors has approved grants of 600,000 restricted stock units ("RSUs") to certain officers of the Company, pursuant to the Company's Incentive Plan and the RSU award agreements. Each RSU represents the right to receive a share of our common stock upon vesting. Certain RSUs are subject to time-based vesting, and certain RSUs are subject to performance-based vesting. The time-based RSUs vest in five equal annual amounts on each anniversary of the February 2024 grant date. The performance-based RSUs vest on the fourth anniversary of the July 2023 grant date and on the fifth anniversary of the February 2024 grant date, subject to continuation of employment on such dates, in increments of 10% (but no less than 20%) (with linear interpolation between increments) based upon the arithmetic average of the Company's closing stock price per share for each trading day in the 90-calendar day period ending on the vesting date (the "90-Day Average"). None of the RSUs will vest if the 90-Day Average is below $20, and 100% of the RSUs will vest if the 90-Day Average is $60 or above. In the event of a change in control of the Company, following which either (i) 100% of the shares of stock cease to be traded on a nationally recognized stock exchange and the Company is no longer listed on any such exchange or (ii) a Qualifying Termination occurs within 12 months, all unvested RSUs will immediately vest in full. All RSUs were unvested as of June 30, 2024.

We used Monte Carlo simulation models to determine the grant date fair values of the performance-based RSUs. Assumptions used by the models were based on information as of the grant date and included a risk-free rate of return, expected volatility and an expected dividend yield. The risk-free rate of return is based on U.S. treasury yields for bonds with similar maturities. Expected volatility is based on the historical volatility of the Company's common stock. The expected dividend yield considers estimated annual dividends and the grant date share price of the underlying common stock.

The fair value of the time-based RSUs is equal to the closing market price of the underlying common stock on the grant date, less the present value of expected dividends over the vesting period.

The weighted-average grant date fair value of the RSUs granted in 2024 was $5.44 per share. We recognize stock-based compensation expense for the RSUs on a straight-line basis over the vesting periods. Stock-based compensation expense related to RSUs was $475, $0 and $0 for the years ended June 30, 2024, 2023 and 2022, respectively. At June 30, 2024, there was $2,788 of unrecognized compensation expense related to the RSUs, which will be recognized over a weighted-average period of 4.1 years.

Stock Options

There was no stock-based compensation expense related to employee stock options in the periods included in the consolidated financial statements, and there was no stock option activity during 2024.

XML 41 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions

12 Months Ended
Jun. 30, 2024

Related Party Transactions

Related Party Transactions

10. Related Party Transactions

Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to the Company as employees or consultants and received aggregate compensation and benefits of $1,590, $1,924 and $2,203 during 2024, 2023 and 2022, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

XML 42 R19.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans

12 Months Ended
Jun. 30, 2024

Employee Benefit Plans

Employee Benefit Plans

11. Employee Benefit Plans

Domestic Pension Plan

We maintain a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to December 31, 2013, who meet certain requirements of age, length of service and hours worked per year. We amended the plan to eliminate credit for future service and compensation increases, effective September 2016. Plan benefits are based upon years of service and average compensation, as defined. The measurement dates for the plan were as of June 30, 2024 and 2023.

In July 2023, we entered into an annuity purchase agreement to irrevocably transfer a portion of the pension benefit obligation to a third-party insurance company. The annuity purchase price was $26,381 and was approximately equal to the benefit obligation transferred. The annuity purchase was funded from pension assets. We recognized a partial settlement of the pension plan, resulting from the recognition of net pension losses previously included in Accumulated other comprehensive loss. We recorded $10,674 of expense in selling, general and administrative expenses in our consolidated statement of operations during the year ended June 30, 2024.

Changes in the projected benefit obligation were:

For the Year Ended June 30	2024	2023
Change in projected benefit obligation		
Projected benefit obligation at beginning of year	$ 60,673	$ 63,079
Interest cost	1,775	2,608
Benefits paid	(954)	(2,865)
Actuarial gain	(1,852)	(2,149)
Settlement payment	(26,381)	—
Projected benefit obligation at end of year	$ 33,261	$ 60,673

The discount rate used for the projected benefit obligation at June 30, 2024 and 2023, was 5.4% and 5.0%, respectively.

The projected benefit obligation for the year ended June 30, 2024 decreased due to the agreement to irrevocably transfer a portion of the pension benefit obligation to a third-party insurance company, as well as actuarial gains at the annual remeasurement period due to a higher discount rate, partially offset by losses derived from other actuarial assumptions. The discount rate used each period is determined with reference to current long-term bond market rates. The projected benefit obligation also increases each year by the interest cost due to the passage of time and decreases each year by the benefits paid to plan participants.

Changes in the plan assets and funded status of the plan were:

For the Year Ended June 30	2024	2023
Change in plan assets		
Fair value of plan assets at beginning of year	$ 58,387	$ 61,286
Actual return on plan assets	(28)	(34)
Benefits paid	(954)	(2,865)
Settlement payment	(26,381)	—
Fair value of plan assets at end of year	$ 31,024	$ 58,387
Liability funded status at end of year	$ (2,237)	$ (2,286)

The actual return on plan assets for the year ended June 30, 2024 was lower than expected due to a reduction in the market value of fixed income securities. Benefits paid decreased compared with the prior year as the pension settlement reduced the number of participants receiving benefits. Our investment strategy is to hold a significant portion of our plan assets in fixed income securities with maturities and amounts approximately matching projected future benefit payments.

The funded status is included in other liabilities in the consolidated balance sheets at June 30, 2024 and 2023, respectively. We seek to maintain an asset balance that meets the long-term funding requirements identified by actuarial projections while also satisfying ERISA fiduciary responsibilities. We do not expect to contribute to the domestic pension plan during 2025.

Accumulated other comprehensive loss related to the plan was:

For the Year Ended June 30	2024	2023
Accumulated other comprehensive loss related to pension plan		
Balance at beginning of period	$ (23,996)	$ (24,208)
Amortization of net actuarial loss	370	721
Current period net actuarial loss	(60)	(509)
Settlement expense recognized	10,674	—
Net change	10,984	212
Balance at end of period	$ (13,012)	$ (23,996)

Net periodic pension expense was:

For the Year Ended June 30	2024	2023	2022
Interest cost on benefit obligation	$ 1,775	$ 2,608	$ 1,675
Expected return on plan assets	(1,884)	(2,624)	(3,413)
Amortization of net actuarial loss and prior service costs	370	721	480
Settlement expense	10,674	—	—
Net periodic pension expense (income)	$ 10,935	$ 705	$ (1,258)

Significant actuarial assumptions used for the net periodic pension expense for the plan were:

For the Year Ended June 30	2024	2023	2022
Discount rate for interest cost	5.0 %	4.3 %	2.2 %
Expected rate of return on plan assets	5.8 %	4.4 %	4.4 %
Discount rate for benefit obligation	5.1 %	4.6 %	2.9 %

The plan used the Aon AA Bond Universe as a benchmark for its discount rate as of June 30, 2024, 2023 and 2022. The discount rate is determined by matching the plan's timing and amount of expected cash outflows to a bond yield curve constructed from a population of AA-rated corporate bond issues that are generally non-callable and have at least $250 million par value outstanding. From this, the discount rate that results in the same present value is calculated.

Estimated future benefit payments, based on the benefit obligation as of June 30, 2024 are:

For the Years Ending June 30	
2025	$ 1,388
2026	1,600
2027	1,809
2028	1,955
2029	2,113
2030 – 2034	11,486

The plan's target asset allocation for 2025 and the weighted-average asset allocation of plan assets as of June 30, 2024 and 2023 are:

	Target Allocation	Percentage of Plan Assets	
For the Year Ended June 30	2025	2024	2023
Debt securities	65% - 85%	79%	75%
Equity securities	10% - 30%	18%	12%
Global asset allocation/risk parity (1)	0% - 15%	2%	3%
Other	0% - 10%	1%	10%

(1) The global asset allocation/risk parity category consists of a variety of asset classes including, but not limited to, global bonds, global equities, real estate and commodities.

The expected long-term rate of return for the plan's total assets is generally based on the plan's asset mix. In determining the rate to use, we consider the expected long-term real returns on asset categories, expectations for inflation, estimates of the effect of active management and actual historical returns.

The investment policy and strategy is to earn a long-term investment return sufficient to meet the obligations of the plan, while assuming a moderate amount of risk in order to maximize investment return. In order to achieve this goal, assets are invested in a diversified portfolio consisting of debt securities, equity securities and other investments in a manner consistent with ERISA's fiduciary requirements.

The fair values of the plan assets by asset category were:

	Fair Value Measurements Using			
As of June 30, 2024	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	$ 277	—	—	$ 277
Common-collective funds				
Global large cap equities	—	5,077	524	5,601
Fixed income securities	—	24,650	—	24,650
Mutual funds				
Global asset allocations/risk parity	496	—	—	496
	$ 773	$ 29,727	$ 524	$ 31,024

	Fair Value Measurements Using			
As of June 30, 2023	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	$ 6,063	$ —	$ —	$ 6,063
Common-collective funds				
Global large cap equities	—	5,552	1,519	7,071
Fixed income securities	—	43,794	—	43,794
Mutual funds				
Global asset allocations/risk parity	1,426	—	—	1,426
Other	—	—	33	33
	$ 7,489	$ 49,346	$ 1,552	$ 58,387

The table below provides a summary of the changes in the fair value of Level 3 assets:

Change in Fair Value Level 3 assets	2024	2023
Balance at beginning of period	$ 1,552	$ 1,962
Redemptions	(1,316)	(603)
Purchases	200	—
Change in fair value	88	193
Balance at end of period	$ 524	$ 1,552

The following outlines the valuation methodologies used to estimate the fair value of plan assets:

- Cash and cash equivalents are valued at $1 per unit;
- Common-collective funds are determined based on current market values of the underlying assets of the fund;

- Mutual funds are valued using quoted market prices in active markets; and
- For Level 3 managed assets, business appraisers use a combination of valuations and appraisal methodologies, as well as a number of assumptions to create a price that brokers evaluate. For Level 3 non-managed assets, pricing is provided by various sources, such as issuer or investment manager.

Other employee benefit plans

We provide a 401(k) retirement savings plan, under which United States employees may make pre-tax and post-tax contributions. The Company contributes: (i) a matching contribution equal to 100% of the first 6.0% of an employee's contribution; and (ii) an additional discretionary contribution of up to 4.5% of compensation, depending on the employee's age and years of service, provided that such contributions comply with ERISA non-discrimination requirements. Employee and Company contributions are subject to certain ERISA limitations. Employees are immediately vested in Company contributions. Our contribution expense was $5,395, $6,214 and $6,341 in 2024, 2023 and 2022, respectively.

Our consolidated balance sheets include other employee-related liabilities of $9,990 and $10,862 as of June 30, 2024 and 2023, respectively, including international retirement plans, supplemental retirement benefits and long-term incentive arrangements. Expense under these plans was $4,189, $4,067 and $3,788 in 2024, 2023 and 2022, respectively.

XML 43 R20.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended
Jun. 30, 2024

Income Taxes
Income Taxes

12. Income Taxes

The components of income before income taxes consisted of the following:

For the Year Ended June 30	2024	2023	2022
Domestic	$ (22,820)	$ 14,776	$ 27,695
Foreign	33,736	39,295	44,632
Income before income taxes	$ 10,916	$ 54,071	$ 72,327

Components of the provision for income taxes were:

For the Year Ended June 30	2024	2023	2022
Current provision:			
Federal	$ 3,037	$ 9,801	$ 4,874
State and local	1,718	1,810	1,468
Foreign	15,740	12,750	17,613
Total current provision	20,495	24,361	23,955
Deferred provision (benefit):			
Federal	(4,755)	(6,151)	(75)
State and local	(1,523)	(266)	251
Foreign	(4,468)	3,424	23
Change in foreign valuation allowances	(1,249)	97	(1,002)
Total deferred benefit	(11,995)	(2,896)	(803)
Provision for income taxes	$ 8,500	$ 21,465	$ 23,152

Reconciliations of the federal statutory rate to the Company's effective tax rate were:

For the Year Ended June 30	2024	2023	2022
U.S. federal statutory income tax rate	21.0 %	21.0 %	21.0 %
State and local taxes, net of federal benefit	(1.1)	2.0	2.0
Higher taxes on non-U.S. income	9.9	8.9	4.8
Changes in uncertain tax positions	30.7	5.1	4.4
Global Intangible Low-Taxed Income	18.3	3.3	0.3
Recognition of federal and foreign tax credits	(10.6)	(3.1)	(0.9)
Change in valuation allowance	(11.4)	0.2	(1.4)
Foreign derived intangible income	(3.8)	(3.7)	(2.1)
Non-U.S. withholding and related taxes, net, on planned repatriation	28.4	—	—
Impact of foreign tax credit regulations and related changes	(20.0)	1.9	—
Non-deductible operating expenses	11.3	0.9	0.8
Non-deductible acquisition costs	4.3	—	—
Other	0.9	3.2	3.1
Effective income tax rate	77.9 %	39.7 %	32.0 %

We record the Global Intangible Low-Taxed Income ("GILTI") aspects of comprehensive U.S. income tax legislation as a period expense. The provision for income taxes for the years ended June 30, 2024, 2023 and 2022, included $2,003, $1,775 and $207 of federal tax expense from the effects of GILTI, respectively.

The Company benefits from certain tax holidays in Israel; the impact of which are included within Higher taxes on non-U.S. income.

The tax effects of significant temporary differences that comprise deferred tax assets and liabilities were:

As of June 30	2024	2023
Deferred tax assets:		
Employee-related accruals	$ 6,620	$ 5,461
Inventory	1,521	2,864
Environmental remediation	767	1,733
Net operating loss carry forwards–domestic	777	839
Net operating loss carry forwards–foreign	3,813	4,389
Operating lease liabilities	6,788	6,521
R&D cost capitalization	7,227	4,283
Unrealized foreign exchange	1,470	—
Carried foreign interest expense	4,518	—
Other	7,224	(1,311)
	40,725	24,779
Valuation allowance	(1,288)	(2,598)
	39,437	22,181
Deferred tax liabilities:		
Property, plant and equipment and intangible assets	(5,282)	(6,286)
Operating lease ROU assets	(6,441)	(6,280)
Unrealized foreign exchange	—	(1,906)
Non-U.S. withholding and related taxes, net, on planned repatriation	(2,828)	—
Other	(6,182)	(712)
	(20,733)	(15,184)
Net deferred tax asset	$ 18,704	$ 6,997

Deferred taxes are included in the consolidated balance sheets as follows:

As of June 30	2024	2023
Other assets	$ 19,371	$ 8,711
Other liabilities	(667)	(1,714)
	$ 18,704	$ 6,997

The valuation allowance established against deferred tax assets was:

As of June 30	2024	2023	2022
Balance at beginning of period	$ 2,598	$ 2,618	$ 3,709
(Benefit) provision for income taxes	(1,310)	(20)	(1,091)
Balance at end of period	$ 1,288	$ 2,598	$ 2,618

The Company records valuation allowances against certain foreign and state deferred tax assets when, after considering all of the available evidence, it is more likely than not that these assets will not be realized.

The Company has $17,250 of state net operating loss carry forwards. $9,320 that will expire in 2024 through 2043, and $7,930 that do not expire, and $16,208 of foreign net operating loss carry forwards of which most are in jurisdictions that have no expiration.

If amounts are repatriated from certain of our foreign subsidiaries, we could be subject to additional non-U.S. income and withholding taxes. We expect to repatriate approximately $80,000 of non-U.S. earnings, which will be subject to applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes. As of June 30, 2024 we recorded a liability of $2,828 related to the planned repatriation of international earnings. We consider all other undistributed earnings of such foreign subsidiaries to be indefinitely reinvested. At June 30, 2024, our cash and cash equivalents and short-term investments included $111,890 held by our international subsidiaries. We do not provide
income taxes for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would reduce our effective income tax rate.

Reconciliations of the beginning and ending amounts of gross unrecognized tax benefits are as follows:

As of June 30	2024	2023	2022
Unrecognized tax benefits–beginning of period	$ 9,449	$ 7,832	$ 5,311
Tax position changes–current period	2,066	2,181	5,333
Tax position changes–prior periods, including settlements with tax authorities	615	193	(1,175)
Lapse of statute of limitations	(58)	(194)	(1,071)
Effect of changes in exchange rates	(211)	(563)	(566)
Unrecognized tax benefits–end of period	11,861	9,449	7,832
Interest and penalties–end of period	1,689	981	427

Total liabilities related to uncertain tax positions	$ 13,550	$ 10,430	$ 8,259

We recognize interest and penalties associated with uncertain tax positions as a component of the provision for income taxes. We recognized and recorded interest and penalties expense of $740, $589 and $74 for 2024, 2023 and 2022, respectively.

Income tax returns for the following periods are no longer subject to examination by the relevant tax authorities:

- U.S. federal and significant states, through June 30, 2019;
- Brazil, through December 31, 2018; and
- Israel, through June 30, 2020, for certain subsidiaries and through June 30, 2021, for certain subsidiaries.

XML 44 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

12 Months Ended
Jun. 30, 2024

Commitments and Contingencies

Commitments and Contingencies

13. Commitments and Contingencies

Environmental

Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, "Environmental Laws"). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination, and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the period during which such costs are likely to be incurred are difficult to predict.

While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We
devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.

The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based on our experience, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

The United States Environmental Protection Agency (the "EPA") oversees remediation of contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site ("Omega Chemical Site"), which is upgradient of the Santa Fe Springs, California facility of our subsidiary, Phibro-Tech, Inc. ("Phibro-Tech"). The EPA entered into a settlement agreement and court-approved consent decree (the "Consent Decree") with a group of companies, including Phibro-Tech and certain other subsidiaries of PAHC due to groundwater contamination from Phibro-Tech's Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site.

In February 2023, Phibro-Tech signed a definitive settlement agreement that provided for a "cash-out" settlement, with contribution protection, for Phibro-Tech and its affiliates releasing Phibro-Tech and its affiliates from liability for contamination of the groundwater plume affected by the Omega Chemical Site (with certain exceptions). The settlement agreement does not constitute an admission of liability on the part of Phibro-Tech or its affiliates. As part of the settlement, Phibro-Tech also resolved all claims for indemnification and contribution between Phibro-Tech and the successor to the prior owner of the Phibro-Tech site. The EPA, the Department of Justice and the district court have approved the definitive settlement agreement and the Consent Decree. The district court's order can be appealed within 60 days, which period will expire on September 10, 2024. As of June 30, 2024, Phibro-Tech and one of its affiliates have made settlement payments totaling $5,019, which represents all cash payments required by the definitive settlement agreement.

Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites to be approximately $4,282 and $8,505 at June 30, 2024 and 2023, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries are liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.

Claims and Litigation

PAHC and its subsidiaries are party to various claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

Employment and Severance Agreements

We have entered into employment agreements with certain executive management and other employees that specify severance benefits of up to 15 months of the employee's compensation.

Purchase Commitments

As of June 30, 2024, we have agreements to purchase goods and services totaling approximately $2,000 that are enforceable and legally binding and include amounts for future purchases. Payments for these obligations are expected to be approximately $2,000 in 2025.

XML 45 R22.htm IDEA: XBRL DOCUMENT

Derivatives

12 Months Ended
Jun. 30, 2024

Derivatives

Derivatives

14. Derivatives

We monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are recorded in accumulated other comprehensive income (loss).

We routinely assess whether the derivatives used to hedge transactions are effective. If we determine that a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.

We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see "Note 15— Fair Value Measurements."

We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating portion of our interest obligation on that amount of debt to a fixed interest rate of 0.61% through June 2025. We designated the interest rate swap as a highly effective cash flow hedge.

We are a party to foreign currency option contracts used to hedge cash flows related to monthly inventory purchases. The individual option contracts mature monthly through December 2024. The forecasted inventory purchases are probable of occurring and the individual option contracts were designated as highly effective cash flow hedges.

The consolidated balance sheet includes the net fair values of our outstanding foreign currency option contracts within the respective line items, based on the net financial position and maturity date of the individual contracts. The consolidated balance sheet includes the net fair values of our outstanding interest rate swap within the respective balance sheet line items, based on the expected timing of the cash flows. The consolidated balance sheet includes assets and liabilities for the fair values of outstanding derivatives that are designated and effective as cash flow hedges as follows:

As of June 30	2024	2023
Other current assets		
Foreign currency option contracts, net	$ 39	$ 333
Interest rate swap	13,151	14,031
Other assets		
Foreign currency option contracts, net	—	—
Interest rate swap	—	10,225
Accrued expense and other current liabilities		
Foreign currency option contracts, net	(41)	—
Interest rate swaps	—	—
Total Fair Value		
Foreign currency option contracts, net	(2)	333
Interest rate swap	13,151	24,256

Notional amounts of the derivatives as of the balance sheet date were:

As of June 30	2024
Interest rate swap	$ 300,000
Brazil Real-USD call options	R$ 36,000
Brazil Real-USD put options	R$ (36,000)
USD-Israel shekel call options	$ (3,043)
USD-Israel shekel put options	$ 3,043

The consolidated statements of operations and statements of other comprehensive income ("OCI") for the years ended June 30, 2024 and 2023 included the effects of derivatives as follows:

For the Year Ended June 30	2024	2023
Foreign currency option contracts, net		
(Income) expense recorded in consolidated statements of operations	$ (1,126)	$ 1,237
Consolidated statement of operations - total cost of goods sold	$ 704,587	$ 679,652
Consolidated statement of operations - total selling, general and administrative expenses	$ 259,777	$ 226,390
(Income) expense recorded in comprehensive income	$ 380	$ 270
Interest rate swap		
(Income) expense recorded in consolidated statements of operations	$ (14,503)	$ (9,870)
Consolidated statement of operations - total interest expense, net	$ 18,536	$ 15,321
(Income) expense recorded in comprehensive income	$ 11,105	$ (3,968)

We recognize gains and losses related to certain foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold. Inventory as of June 30, 2024 included realized net gains of $1,142 related to matured contracts. We anticipate the net gains included in inventory will be recognized in cost of goods sold within the next 12 months.

XML 46 R23.htm IDEA: XBRL DOCUMENT

Fair Value

12 Months Ended

Fair Value Measurements
Fair Value Measurements

15. Fair Value Measurements

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Financial assets and liabilities are measured at fair value using the three-level valuation hierarchy for disclosure of fair value measurements. The determination of the applicable level within the hierarchy of a particular asset or liability depends on the inputs used in the valuation as of the measurement date, notably the extent to which the inputs are market-based (observable) or internally derived (unobservable). Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs based on a company's own assumptions about market participant assumptions developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Significant observable inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly through corroboration with observable market data.

Level 3 — Unobservable inputs for which there is little or no market data available, and that are significant to the overall fair value measurement, are employed that require the reporting entity to develop its own assumptions.

In assessing the fair value of financial instruments at June 30, 2024 and 2023, we used a variety of methods and assumptions that were based on estimates of market conditions and risks existing at the time.

Short-Term Investments

Our short-term investments consist of cash deposits held at financial institutions. We consider the carrying amounts of these short-term investments to be representative of their fair value.

Current Assets and Liabilities

We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.

Debt

We record debt, including term loans and revolver balances, at amortized cost in our consolidated financial statements. We believe the carrying value of the debt is approximately equal to its fair value, due to the variable nature of the instruments and our evaluation of estimated market prices.

Derivatives

We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation rates.

Non-Financial Assets

Our non-financial assets, which primarily consist of goodwill, other intangible assets, property and equipment, and lease-related ROU assets, are not required to be measured at fair value on a recurring basis, and instead are reported at carrying value in the consolidated balance sheet. Assets and liabilities may be required to be measured at fair value on a non-recurring basis, either upon initial recognition or for subsequent accounting or reporting, including the initial recognition of net assets acquired in a business combination. These fair value measurements involve unobservable inputs that reflect estimates and assumptions that represent Level 3 inputs.

Fair Value of Assets (Liabilities)

As of	June 30, 2024			June 30, 2023		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Short-term investments	$ 44,000	$ —	$ —	$ 40,000	$ —	$ —
Foreign currency derivatives	$ —	$ (2)	$ —	$ —	$ 333	$ —
Interest rate swap	$ —	$ 13,151	$ —	$ —	$ 24,256	$ —

There were no transfers between levels during the periods presented. There were no changes in the fair value of the Level 3 liabilities.

For a detailed discussion on the fair value of our pension plan assets, see "Note 11 — Employee Benefit Plans."

XML 47 R24.htm IDEA: XBRL DOCUMENT

Business Segments
Business Segments

16. Business Segments

We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to a segment or segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the other segments because they are not used to evaluate the segments' operating results or financial position. Corporate costs include certain costs related to executive management, information technology, legal, finance, human resources and business development. The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.

We evaluate performance of our segments based on Adjusted EBITDA. We calculate Adjusted EBITDA as net income plus (a) interest expense, net, (b) provision for income taxes or less benefit for income taxes, (c) depreciation and amortization, (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (e) certain items that we consider to be unusual, non-operational or non-recurring.

For the Year Ended June 30	2024	2023	2022
Net sales			
Animal Health	$ 706,482	$ 659,851	$ 607,055
Mineral Nutrition	243,663	242,656	259,512
Performance Products	67,534	75,382	75,694
Total segments	$ 1,017,679	$ 977,889	$ 942,261
Depreciation and amortization			
Animal Health	$ 30,194	$ 27,714	$ 26,759
Mineral Nutrition	2,427	2,638	2,616
Performance Products	1,688	1,780	1,717
Total segments	$ 34,309	$ 32,132	$ 31,092
Adjusted EBITDA			
Animal Health	$ 145,606	$ 136,139	$ 124,106
Mineral Nutrition	16,449	17,417	24,038
Performance Products	7,662	9,346	8,706
Total segments	$ 169,717	$ 162,902	$ 156,850
Reconciliation of income before income taxes to Adjusted EBITDA			
Income before income taxes	$ 10,916	$ 54,071	$ 72,327
Interest expense, net	18,536	15,321	11,875
Depreciation and amortization – Total segments	34,309	32,132	31,092
Depreciation and amortization – Corporate	1,869	1,880	1,613
Corporate costs	58,480	50,149	45,767
Acquisition-related cost of goods sold	521	—	316
Acquisition-related transaction costs	6,405	—	279
Pension settlement cost	10,674	—	—
Brazil employment taxes	4,202	—	—
Stock-based compensation	475	—	—
Phibro Forward income growth initiatives implementation costs	366	—	—
Insurance proceeds	(899)	—	—
Environmental remediation costs	—	6,894	—
Gain on sale of investment	—	—	(1,203)
Foreign currency (gains) losses, net	23,863	2,455	(5,216)
Adjusted EBITDA – Total segments	$ 169,717	$ 162,902	$ 156,850

As of June 30	2024	2023
Identifiable assets		
Animal Health	$ 684,407	$ 698,522
Mineral Nutrition	67,088	75,814
Performance Products	50,862	49,678
Total segments	802,357	824,014
Corporate	179,827	147,383
Total	$ 982,184	$ 971,397

The Animal Health segment includes all goodwill of the Company. Corporate assets include cash and cash equivalents, short-term investments, debt issuance costs, income tax related assets and certain other assets.

The geographic location of property, plant and equipment, net was:

As of June 30	2024	2023
Property, plant and equipment, net		
United States	$ 87,526	$ 79,404
Israel	60,395	61,304
Brazil	30,348	30,359
Ireland	19,038	18,900
Other	5,993	5,601
	$ 203,300	$ 195,568

XML 48 R25.htm IDEA: XBRL DOCUMENT

Agreement	Jun. 30, 2024

Subsequent Event - 2024 Credit Agreement

Subsequent Event - 2024 Credit Agreement

17. Subsequent Event – 2024 Credit Agreement

In July 2024, we entered into the 2024 Credit Agreement with a group of lenders. Initial borrowings were used to refinance all our outstanding debt, to pay fees and expenses of the transaction, and for ongoing working capital requirements and general corporate purposes. Borrowings under the Delayed Draw Term A-1 and A-2 Loans will be used to finance the purchase price of the Proposed Acquisition upon completion of the acquisition (the "Closing Date").

Under the 2024 Credit Agreement, there are (i) Initial Term A-1 Loans in an initial aggregate principal amount of $162,000 (the "Initial Term A-1 Loans"), (ii) Delayed Draw Term A-1 Loans in an initial aggregate principal amount of $189,000 (the "Delayed Draw Term A-1 Loans" and, together with the Initial Term A-1 Loans, the "Term A-1 Loans") (iii) Initial Term A-2 Loans in an initial aggregate principal amount of $138,000 (the "Initial Term A-2 Loans"), (iv) Delayed Draw Term A-2 Loans in an initial aggregate principal amount of $161,000 (the "Delayed Draw Term A-2 Loans" and, together with the Initial Term A-2 Loans, the "Term A-2 Loans"), and (v) Revolving Credit Commitments in an initial aggregate principal amount of $310,000 (the "Revolving Credit Commitments" and, together with the Term A-1 Loans and Term A-2 Loans, the "2024 Credit Facilities"). The 2024 Credit Facilities mature in July 2029 in the case of the Term A-1 Loans and the Revolving Credit Commitments and in July 2031 in the case of the Term A-2 Loans.

Borrowings under the 2024 Credit Facilities bear interest at rates based on the ratio of the Company and its subsidiaries' net consolidated indebtedness to the Company and its subsidiaries' consolidated EBITDA (the "Net Leverage Ratio"). The interest rates per annum for loans under the 2024 Credit Facilities are based on a fluctuating rate of interest as selected by the Company plus an applicable rate as set forth in the table below:

	Revolving Credit and Term A-1 Loans		Term A-2 Loans	
Net Leverage Ratio	Base rate	SOFR	Base rate	SOFR
≥ 4.00:1.00	1.75 %	2.75 %	2.25 %	3.25 %
≥ 3.50:1.00 and < 4.00:1.00	1.50 %	2.50 %	2.00 %	3.00 %
≥ 2.25:1.00 and < 3.50:1.00	1.25 %	2.25 %	1.75 %	2.75 %
< 2.25:1.00	1.00 %	2.00 %	1.50 %	2.50 %

The Company may receive patronage from the lenders providing the Term A-2 Loans, to the extent eligible under such lender's patronage program, as determined by such lender in its sole discretion.

Pursuant to the terms of the 2024 Credit Agreement, the 2024 Credit Facilities are subject to various covenants that, among other things and subject to the permitted exceptions described therein, restrict us and our subsidiaries with respect to: (i) incurring additional debt; (ii) making certain restricted payments or making optional redemptions of other indebtedness; (iii) making investments or acquiring assets; (iv) disposing of assets (other than in the ordinary course of business); (v) creating any liens on our assets; (vi) entering into transactions with affiliates; (vii) entering into merger or consolidation transactions; and (viii) creating guarantee obligations; provided, however, that we are permitted to pay distributions to stockholders out of available cash subject to certain annual limitations and a quarterly maximum Net Leverage Ratio of 4.0x and so long as no default or event of default under the 2024 Credit Facilities shall have occurred and be continuing at the time such distribution is declared. Indebtedness under the 2024 Credit Facilities is collateralized
by a first priority lien on substantially all assets of Phibro and certain of our domestic subsidiaries. The 2024 Credit Agreement contains an acceleration clause should an event of default (as defined) occur.

The 2024 Credit Agreement requires, among other things, compliance with financial covenants that permit: (i) a maximum Net Leverage Ratio and (ii) a minimum interest coverage ratio, each calculated on a trailing four-quarter basis, as follows:

Period	maximum Net Leverage Ratio	minimum interest coverage ratio
Prior to the Closing Date	4.00:1.00	3.00:1.00
First fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date	4.75:1.00	2.50:1.00
Eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date	4.50:1.00	2.75:1.00
Thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date	4.25:1.00	3.00:1.00
After the forty-two month anniversary of the Closing Date	4.00:1.00	3.00:1.00

We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025. We have designated the interest rate swap as a highly effective cash flow hedge. For additional details, see "Note 14 — Derivatives."

XML 49 R26.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure			
Net Income (Loss)	$ 2,416	$ 32,606	$ 49,175

XML 50 R27.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Jun. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 51 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards (Policies)	12 Months Ended Jun. 30, 2024

Summary of Significant Accounting Policies and New Accounting Standards

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated from the consolidated financial statements. The decision whether to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.

We present our financial statements on the basis of our fiscal year ending June 30. All references to years in these consolidated financial statements refer to the fiscal year ending or ended on June 30 of that year.

Risks and Uncertainties

Risks and Uncertainties

The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on or banning of the use of antibiotics in food-producing animals. The sale of antibiotics and antibacterials is a material portion of our business. Should product bans or restrictions, public perception, competition or other developments result in restrictions on the sale of such products, it could have a material adverse effect on our financial position, results of operations and cash flows.

An outbreak of disease carried by food animals, which could lead to the widespread death or precautionary destruction of food animals as well as reduced consumption and demand for animal protein, could adversely affect demand for our products. Such occurrences could have a material adverse effect on our financial condition, results of operations and cash flows.

The testing, manufacturing, and marketing of certain of our products are subject to extensive regulation by numerous government authorities in the United States and other countries.

We have significant assets in Israel, Brazil and other locations outside of the United States and a significant portion of our sales and earnings are attributable to operations conducted abroad. Our assets, results of operations and future prospects are subject to currency exchange fluctuations and restrictions, energy shortages, other economic developments, political or social instability in some countries, and uncertainty of, and governmental control over, commercial rights, which could result in a material adverse effect on our financial position, results of operations and cash flows.

We are subject to environmental laws and regulations governing the use, storage, handling, generation, treatment, emission, release, discharge and disposal of certain materials and wastes, the remediation of contaminated soil and groundwater, the manufacture, sale and use of regulated materials, including pesticides, and the health and safety of employees. As such, the nature of our current and former operations and those of our subsidiaries expose Phibro and our subsidiaries to the risk of claims with respect to such matters.

Our business could be impacted by economic sanctions, bans, boycotts, or broader military conflicts, including the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine. Other potential impacts include supply chain and logistics disruptions, macroeconomic impacts from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy, as well as heightened cybersecurity threats.

Pandemics and similar outbreaks could directly or indirectly impact our business, results of operations and financial condition. A pandemic or any other similar health crisis could have economic impacts on customers, suppliers and markets. A pandemic could affect our future revenues, expenses, reserves and allowances, manufacturing operations and employee-related costs.

Use of Estimates

Use of Estimates

The Company's consolidated financial statements have been prepared in accordance with GAAP. Preparation of these financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Actual results could differ from these estimates. Estimates are used when accounting for the valuation of intangible assets, depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax assets, sales discounts, rebates, allowances and incentives, contingencies, employee compensation and actuarial assumptions related to our pension plans. We regularly evaluate our estimates and assumptions using historical experience and other factors. Our estimates are based on complex judgments, probabilities and assumptions that we believe to be reasonable.

Revenue Recognition

Revenue Recognition

We recognize revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to the customers. Certain of our businesses have terms where control of the underlying product transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery.

Revenue reflects the total consideration to which we expect to be entitled in exchange for delivery of products or services, net of variable consideration. Variable consideration includes customer programs and incentive offerings, including pricing arrangements, rebates and other volume-based incentives. We record reductions to revenue for estimated variable consideration at the time we record the sale. Our estimates for variable consideration reflect the amount by which we expect variable consideration to affect the revenue recognized. Such estimates are generally based on contractual terms and historical experience and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of variable compensation. Sales returns and product recalls have been insignificant and infrequent due to the nature of the products we sell.

Net sales include shipping and handling fees billed to customers. The associated costs are considered fulfillment activities and are included in cost of goods sold in the consolidated statements of operations when the related revenue is recognized. Net sales exclude value-added and other taxes based on sales.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash equivalents include highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.

Short-term Investments

Short-term Investments

Short-term investments include highly liquid investments with maturities greater than three months and less than one year at the time of purchase. We classify these investments as held to maturity and we record the related interest income as earned. We determine the appropriate balance sheet classification at the time of purchase and at each balance sheet date. Investments held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.

Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. We grant credit terms in the normal course of business and generally do not require collateral or other security to support credit sales. Our ten largest customers represented, in aggregate, approximately 13% and 16% of accounts receivable at June 30, 2024 and 2023, respectively.

Reserve for Credit Losses

The reserve for credit losses is our best estimate of the credit losses in existing accounts receivable. We monitor the financial performance, historical and expected collection patterns, and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We also monitor domestic and international economic conditions for the potential future effect on our customers. Past due balances are reviewed individually for collectability. Account balances are charged against the reserve when we determine it is probable the receivable will not be recovered.

Inventories

Inventories

Inventories are valued at the lower of cost or net realizable value. Cost is determined principally under weighted average and standard cost methods, which approximate first-in, first-out (FIFO) cost. Obsolete and unsalable inventories, if any, are reflected at estimated net realizable value. Inventory costs include materials, direct labor and manufacturing overhead.

Property, Plant and Equipment

Property, Plant and Equipment

Property, plant and equipment are stated at cost.

Depreciation is charged to results of operations using the straight-line method based upon the assets' estimated useful lives, ranging from two to thirty years for buildings and improvements, and three to ten years for machinery and equipment. We capitalize costs that extend the useful life or productive capacity of an asset. Repair and maintenance costs are expensed as incurred. In the case of disposals, the assets and related accumulated depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in the consolidated statements of operations.

Leases

Leases

We determine at the inception of an arrangement whether the arrangement contains a lease. If an arrangement contains a lease, we assess the lease term when the underlying asset is available for use ("lease commencement"). Individual lease terms reflect the non-cancellable period of the lease, reasonably certain renewal periods and consideration of termination options. We determine the lease classification as either operating or financing at lease commencement, which governs the pattern of expense recognition and presentation in our consolidated financial statements. Our current lease portfolio only includes operating leases.

We recognize a right-of-use ("ROU") asset and a corresponding lease liability at lease commencement for leases with terms exceeding twelve months. Short-term leases with terms of twelve months or less are not recognized on the consolidated balance sheet and lease payments are recognized on a straight-line basis over the term.

The values of the ROU assets and lease liabilities are calculated based on the present value of the fixed payment obligations over the lease term, using our incremental borrowing rate ("IBR"), determined at lease commencement. The IBR reflects the rate of interest we would expect to pay on a secured basis to borrow an amount equal to the lease payments under similar terms. The IBR incorporates the term and economic environment of the respective lease arrangements.

We have elected to account for lease and non-lease components together as a single lease component and include fixed payment obligations related to such non-lease components in the measurement of ROU assets and lease liabilities. Fixed lease payments are recognized on a straight-line basis over the lease term. Variable lease payments can include index-based lease payments, real estate taxes, maintenance costs, utilization charges and other non-lease services paid to lessors and are not determinable at lease commencement. Variable lease payments are not included in the measurement of ROU assets and lease liabilities and are recognized in the period incurred.

Capitalized Software Costs

Capitalized Software Costs

We capitalize costs to obtain, develop and implement software for internal use. Amounts paid to third parties and costs of internal employees who are directly associated with the software project are also capitalized, depending on the stage of development.

We expense software costs that do not meet the capitalization criteria. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets and are amortized on a straight-line basis over three to seven years.

Debt Issuance Costs

Debt Issuance Costs

Costs and original issue discounts or premiums related to issuance or modification of our debt are deferred on the consolidated balance sheet and amortized over the lives of the respective debt instruments. Amortization of debt issuance costs is included in interest expense in the consolidated statements of operations.

Business Combinations

Business Combinations

Our consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition; goodwill is recorded for any excess of the purchase price over the fair values of the net assets acquired.

Significant judgment may be required to determine the fair values of certain tangible and intangible assets and in assigning their respective useful lives. Significant judgment also may be required to determine the fair values of contingent consideration, if any. We typically utilize third-party valuation specialists to assist us in determining fair values of significant tangible and intangible assets and contingent consideration. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect consideration of other marketplace participants and include the amount and timing of future cash flows, specifically the expected revenue growth rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets primarily are based on a number of factors including the competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Intangible assets associated with acquired in-process research and development activities ("IPR&D") are not amortized until a product is available for sale and regulatory approval is obtained.

Long-Lived Assets and Goodwill

Long-Lived Assets and Goodwill

We periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. We recognize an impairment loss when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss is the excess of the asset's carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations.

Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in a business combination. We assess goodwill for impairment annually during our fourth quarter, or more frequently if impairment indicators exist. Impairment exists when the carrying amount of goodwill exceeds its implied fair value. We may elect to assess our goodwill for impairment using a qualitative or a quantitative approach, to determine whether it is more likely than not that the fair value of goodwill is greater than its carrying value. During the three months ended June 30, 2024, we tested goodwill using the quantitative approach and determined goodwill was not impaired. We have not recorded any goodwill impairment charges in the periods included in the consolidated financial statements.

Foreign Currency Translation

Foreign Currency Translation

We generally use local currency as the functional currency to measure the financial position and results of operations of each of our international subsidiaries. We translate assets and liabilities of these operations at the exchange rates in effect at the balance sheet date. We translate income statement accounts at the average rates of exchange prevailing during the period. Translation adjustments that arise from the use of differing exchange rates from period to period are included as a component of accumulated other comprehensive income (loss) in stockholders' equity. Certain of our Israeli operations have designated the U.S. dollar as their functional currency. Gains and losses arising from re-measurement of local currency accounts into U.S. dollars are included in determining net income.

Comprehensive Income

Comprehensive Income

Comprehensive income consists of net income and the changes in: (i) the fair value of derivative instruments that qualify for hedge accounting; (ii) foreign currency translation adjustments; (iii) pension settlement recognition and unrecognized net pension gains (losses); and (iv) the related (provision) benefit for income taxes.

Derivative Financial Instruments

Derivative Financial Instruments

We record all derivative financial instruments on the consolidated balance sheets at fair value. Changes in the fair value of derivatives are recorded in results of operations or other comprehensive income (loss), depending on whether a derivative is designated and effective as part of a hedge transaction and, if so, the type of hedge transaction. Gains and losses on derivative instruments designated and effective as part of a hedge transaction are included in the results of operations in the periods in which operations are affected by the underlying hedged item.

From time to time, we use certain derivative instruments to mitigate the risk associated with certain economic factors, such as exchange rates and interest rates, which may potentially affect our future cash flows. As of June 30, 2024, we used (i) foreign currency option contracts to mitigate certain exposures related to changes in foreign currency exchange rates on forecasted inventory purchases, and (ii) an interest rate swap on $300,000 of notional principal to manage future cash flow exposure resulting from variable interest rates on that amount of debt. To qualify a derivative as a hedge, we document the nature and relationships between hedging instruments and hedged items, the prospective effectiveness of the hedging instrument as well as the ultimate effectiveness, the risk-management objectives, the strategies for undertaking the various hedge transactions and the methods of assessing hedge effectiveness. We do not engage in trading or other speculative uses of financial instruments.

Environmental Liabilities

Environmental Liabilities

Expenditures for ongoing compliance with environmental regulations are expensed or capitalized as appropriate. We capitalize expenditures made to extend the useful life or productive capacity of an asset, including expenditures that prevent future environmental contamination. Other expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. We record the expense and related liability in the period an environmental assessment indicates remedial efforts are probable and the costs can be reasonably estimated. Estimates of the liability are based upon currently available facts, existing technology and presently enacted laws and regulations taking into consideration the likely effects of inflation and other societal and economic factors. All available evidence is considered, including prior experience in remediation of contaminated sites, other companies' experiences and data released by the U.S. Environmental Protection Agency and other organizations. The estimated liabilities are not discounted. We record anticipated recoveries under existing insurance contracts if probable.

Income Taxes

Income Taxes

The provision for income taxes includes U.S. federal, state, and foreign income taxes and foreign withholding taxes. Our annual effective income tax rate is determined based on our income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate and the tax effects of items treated differently for tax purposes than for financial reporting purposes. Tax law requires certain items be included in the tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as depreciation expense. These temporary differences give rise to deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which we have already recorded the tax benefit in our income statement. Deferred tax liabilities generally represent the tax effect of items recorded as tax expense in our income statement for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our income statement, and the tax effect of assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.

The recognition and measurement of a tax position is based on management's best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual effective income tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, including research and development costs capitalized for income tax purposes and net operating loss carryforwards, is dependent upon generating sufficient future taxable income in the appropriate jurisdiction prior to the

expiration of the amortization or carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.

We may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority in the jurisdictions where we operate. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.

Because there are a number of estimates and assumptions inherent in calculating the various components of our income tax provision, future events such as changes in tax legislation, the geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an effect on those estimates and our effective income tax rate.

Advertising

Advertising

Advertising and marketing costs are expensed as incurred and are reflected in selling, general and administrative expenses.

Research and Development Expenditures

Research and Development Expenditures

Research and development expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Most of our manufacturing facilities have scientists and technicians on staff involved in product development, quality assurance and providing technical services to customers. Research, development and technical service efforts are conducted at various facilities. Our animal health research and development activities relate to: companion animal product development, fermentation development and microbiological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional specialties development; and ethanol-related products.

Stock-Based Compensation

Stock-Based Compensation

We recognize expense for stock-based compensation to employees, including grants of restricted stock units, over the requisite service period based on the grant date fair value of the awards. We determine the fair value of performance-based restricted stock units using the Monte Carlo simulation models. The models use historical and current market data to estimate the fair value. The models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards.

Net Income per Share and Weighted Average Shares

Net Income per Share and Weighted Average Shares

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.

Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common shares equivalents, resulting from
the assumed vesting of restricted stock units, unless the effect would be antidilutive. Common share equivalents were included in the calculation of diluted net income per share for the periods included in the consolidated financial statements, when applicable.

For the Year Ended June 30	2024	2023	2022
Net income	$ 2,416	$ 32,606	$ 49,175
Weighted average number of shares – basic	40,504	40,504	40,504
Dilutive effect of restricted stock units	19	—	—
Weighted average number of shares - diluted	40,523	40,504	40,504
Net income per share			
basic	$ 0.06	$ 0.81	$ 1.21
diluted	$ 0.06	$ 0.81	$ 1.21

New Accounting Standards

New Accounting Standards

Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,* requires the disclosure of significant segment expenses that are included in segment profit or loss and how the segment measures are used for decision-making. The ASU will be effective for Phibro’s fiscal year ending June 30, 2025, including retrospective disclosure for all prior periods presented, and interim periods subsequent to June 30, 2025. We are evaluating the impact to our segment disclosures.

ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures,* enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU outlines specific categories to be provided in the rate reconciliation and requires additional information for those reconciling items that meet a quantitative threshold. The ASU requires disaggregated disclosure of federal, state and foreign income taxes paid, including disaggregation by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). The ASU also requires disaggregated disclosure of federal, state and foreign income (loss) from continuing operations before income taxes. The enhanced disclosures will be applied on a prospective basis and are required for Phibro’s fiscal year ending June 30, 2026. We are evaluating the impact of the additional income tax-related disclosures.

XML 52 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards (Tables)

12 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies and New Accounting Standards

Schedule of net income per share and weighted average shares

For the Year Ended June 30	2024	2023	2022
Net income	$ 2,416	$32,606	$49,175
Weighted average number of shares – basic	40,504	40,504	40,504
Dilutive effect of restricted stock units	19	—	—
Weighted average number of shares - diluted	40,523	40,504	40,504
Net income per share			
basic	$ 0.06	$ 0.81	$ 1.21
diluted	$ 0.06	$ 0.81	$ 1.21

XML 53 R30.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information (Tables)

12 Months Ended

Jun. 30, 2024

Statements of Operations-Additional Information

Schedule of revenues disaggregated by major product category and geographic region

Net Sales by Product Type

For the Year Ended June 30	2024	2023	2022
Animal Health			
MFAs and other	$ 420,959	$387,349	$361,538
Nutritional specialties	164,671	172,504	157,196
Vaccines	120,852	99,998	88,321
Total Animal Health	$ 706,482	$659,851	$607,055
Mineral Nutrition	243,663	242,656	259,512
Performance Products	67,534	75,382	75,694
Total	$1,017,679	$977,889	$942,261

Net Sales by Region

For the Year Ended June 30	2024	2023	2022
United States	$ 584,763	$578,773	$561,803
Latin America and Canada	247,705	219,846	191,047
Europe, Middle East and Africa	121,977	117,815	122,480
Asia Pacific	63,234	61,455	66,931
Total	$1,017,679	$977,889	$942,261

Schedule of interest expense, net

For the Year Ended June 30	2024	2023	2022
Interest expense, net			
2021 Credit Facilities	$20,646	$17,302	$11,918
2022 Term loan	862	589	—
Amortization of debt issuance costs	1,040	727	590
Other	462	58	183
Interest expense	23,010	18,676	12,691
Interest income	(4,474)	(3,355)	(816)
	$18,536	$15,321	$11,875

Schedule of depreciation and amortization

For the Year Ended June 30	2024	2023	2022
Depreciation and amortization			
Depreciation of property, plant and equipment	$26,517	$24,316	$23,781
Amortization of intangible assets	9,661	9,696	8,924
	$36,178	$34,012	$32,705

Schedule of amortization of intangible assets

For the Years Ending June 30	
2025	$ 7,918
2026	6,969
2027	6,591
2028	6,385
2029	6,385
Thereafter	10,785
Total	$ 45,033

Schedule of research and development expense

For the Year Ended June 30	2024	2023	2022
Research and development expense	$29,194	$24,395	$20,832

XML 54 R31.htm IDEA: XBRL DOCUMENT

Balance Sheets-

12 Months Ended

Additional Information (Tables)

Jun. 30, 2024

Balance Sheets-Additional Information

Schedule of accounts receivable, net

As of June 30	2024	2023
Accounts receivable, net		
Trade accounts receivable	$ 170,913	$ 165,069
Reserve for credit losses	(1,461)	(1,590)
	$ 169,452	$ 163,479

Schedule of reserve for credit losses

As of June 30	2024	2023
Reserve for credit losses		
Balance at beginning of period	$ 1,590	$ 3,510
Provision for estimated credit losses	1,538	943
Effect of changes in exchange rates	(71)	(61)
Credit losses realized	(1,596)	(2,802)
Balance at end of period	$ 1,461	$ 1,590

Schedule of inventories

As of June 30	2024	2023
Inventories, net		
Raw materials	$ 72,799	$ 84,328
Work-in-process	23,550	22,350
Finished goods	169,562	170,892
	$ 265,911	$ 277,570

Schedule of property, plant and equipment, net

As of June 30	2024	2023
Property, plant and equipment, net		
Land	$ 30,624	$ 27,813
Buildings and improvements	120,173	105,184
Machinery and equipment	273,965	291,454
Construction in progress	23,892	34,743
	448,654	459,194
Accumulated depreciation	(245,354)	(263,626)
	$ 203,300	$ 195,568

Schedule of intangibles, net

As of June 30	Weighted-Average Useful Life (Years)	2024	2023
Intangibles, net			
Cost			
Technology	12	$ 94,259	$ 95,576
Product registrations, marketing and distribution rights	9	18,117	18,557
Customer relationships	12	30,418	30,235
Trade names, trademarks and other	6	5,213	5,605
		148,007	149,973
Accumulated amortization			
Technology		(62,119)	(55,396)
Product registrations, marketing and distribution rights		(17,326)	(18,553)
Customer relationships		(19,001)	(16,884)
Trade names, trademarks and other		(4,528)	(4,153)
		(102,974)	(94,986)
		$ 45,033	$ 54,987

Schedule of goodwill

As of June 30	2024	2023
Goodwill		
Balance at beginning of period	$ 53,274	$ 53,226
Acquisition	1,397	—
Effect of changes in exchange rates	(114)	48
Balance at end of period	$ 54,557	$ 53,274

Schedule of other assets

As of June 30	2024	2023
Other assets		
ROU operating lease assets	$ 37,604	$ 35,759
Deferred income taxes	19,371	8,711
Deposits	1,646	6,617
Insurance investments	6,305	6,067
Equity method investments	5,183	5,027
Derivative instruments	—	10,225
Debt issuance costs	911	1,408
Other	7,277	8,031
	$ 78,297	$ 81,845

Schedule of accrued expenses and other current liabilities

As of June 30	2024	2023
Accrued expenses and other current liabilities		
Employee related	$ 37,612	$ 29,359
Current operating lease liabilities	7,460	6,053
Commissions and rebates	7,875	5,833
Professional fees	8,918	5,032
Income and other taxes	2,931	8,663
Insurance-related	1,265	1,284
Insurance premium financing	5,185	4,769
Other	17,540	18,859
	$ 88,786	$ 79,852

The insurance premium financing has a fixed interest rate of 6.95% and monthly payments of $648.

Schedule of other liabilities

As of June 30	2024	2023
Other liabilities		
Long-term operating lease liabilities	$ 29,915	$ 29,077
Long-term and deferred income taxes	14,218	12,146
Supplemental retirement benefits, deferred compensation and other	6,678	6,552
U.S. pension plan	2,237	2,286
International retirement plans	3,212	4,210
Other long-term liabilities	6,846	6,076
	$ 63,106	$ 60,347

Schedule of accumulated other comprehensive loss

As of June 30	2024	2023
Accumulated other comprehensive loss		
Derivative instruments	$ 13,104	$ 24,589
Foreign currency translation adjustment	(124,004)	(115,062)
Unrecognized net pension losses	(13,012)	(23,996)
Provision for income taxes on derivative instruments	(3,304)	(6,207)
Benefit for income taxes on long-term intercompany investments	8,166	8,166
Provision for income taxes on net pension losses	(4,477)	(1,700)
	$ (123,527)	$ (114,210)

XML 55 R32.htm IDEA: XBRL DOCUMENT

Debt (Tables)

12 Months Ended
Jun. 30, 2024

Debt

Schedule of long term debt

	June 30		Years Ended June 30		
	2024	2023	2024	2023	2022
2021 Revolver	6.00 %	6.09 %	6.14 %	5.42 %	2.08 %
2021 Term A Loan	2.36 %	2.36 %	2.36 %	2.37 %	2.99 %
2023 Incremental Term Loan	7.68 %	7.44 %	7.64 %	7.40 %	— %
2022 Term Loan	7.43 %	7.25 %	7.41 %	6.43 %	— %

As of June 30	2024	2023
2021 Term A Loan due April 2026	$256,875	$273,750
2023 Incremental Term Loan due April 2026	45,000	50,000
2022 Term Loan due September 2027	11,265	11,685
	313,140	335,435
Unamortized debt issuance costs	(1,056)	(1,599)

	312,084	333,836
Less: current maturities of long-term debt and other	(29,795)	(22,295)
Long-term debt	$282,289	$311,541

Schedule of aggregate maturities of long term debt

For the Years Ending June 30	Annual Maturities	Interest Payments
2025	$ 29,795	$ 19,785
2026	272,920	26,598
2027	420	755
2028	10,005	184
Total	$ 313,140	$ 47,322

XML 56 R33.htm IDEA: XBRL DOCUMENT

Leases (Tables)

12 Months Ended
Jun. 30, 2024

Leases

Summary of operating lease information

The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:

As of June 30	2024	2023	Balance Sheet Classification
Assets:			
Operating lease ROU assets	$ 37,604	$ 35,759	Other Assets
Liabilities:			
Current portion	7,460	6,053	Accrued expenses and other current liabilities
Non-current portion	29,915	29,077	Other liabilities
Total operating lease liabilities	$ 37,375	$ 35,130	

The following table summarizes the composition of net lease expense:

For the Year Ended June 30	2024	2023	2022
Operating lease expense	$ 8,888	$ 8,363	$ 8,461
Variable lease expense	1,150	1,139	1,376
Short-term lease expense	1,397	1,522	1,214
Total lease expense	$ 11,435	$ 11,024	$ 11,051

The following tables include other supplemental information:

For the Year Ended June 30	2024	2023	2022
Operating cash flows used for ROU operating leases	$ 8,231	$ 7,798	$ 8,642
Non-cash changes to ROU operating assets and lease liabilities	$ 9,283	$ 5,114	$ 11,930

As of June 30	2024	2023
Weighted average remaining lease term (in years) - operating leases	9.6	10.6
Weighted average discount rate - operating leases	4.73 %	3.89 %

Summary of maturities of future lease liabilities

For the Years Ending June 30	
2025	$ 8,800
2026	7,085
2027	5,212
2028	3,920
2029	3,048
2030 and thereafter	17,200
Total lease payments	45,265
Less: interest	7,890
Total operating lease liabilities	$ 37,375

XML 57 R34.htm IDEA: XBRL DOCUMENT

Common Stock, Preferred Stock and Dividends (Tables)

12 Months Ended
Jun. 30, 2024

Common Stock, Preferred Stock and Dividends

Schedule of preferred shares and common shares

As of June 30	2024 Authorized Shares	2023 Authorized Shares	Par value	2024 Issued and outstanding shares	2023 Issued and outstanding shares
Preferred stock	16,000,000	16,000,000	$0.0001	—	—
Common stock – Class A	300,000,000	300,000,000	$0.0001	20,337,574	20,337,574
Common stock – Class B	30,000,000	30,000,000	$0.0001	20,166,034	20,166,034

XML 58 R35.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans (Tables)

12 Months Ended
Jun. 30, 2024

Employee Benefit Plans

Schedule of changes in projected benefit obligation, plan assets and the funded status

For the Year Ended June 30	2024	2023
Change in projected benefit obligation		
Projected benefit obligation at beginning of year	$ 60,673	$ 63,079
Interest cost	1,775	2,608
Benefits paid	(954)	(2,865)
Actuarial gain	(1,852)	(2,149)
Settlement payment	(26,381)	—
Projected benefit obligation at end of year	$ 33,261	$ 60,673

For the Year Ended June 30	2024	2023
Change in plan assets		
Fair value of plan assets at beginning of year	$ 58,387	$ 61,286
Actual return on plan assets	(28)	(34)
Benefits paid	(954)	(2,865)
Settlement payment	(26,381)	—
Fair value of plan assets at end of year	$ 31,024	$ 58,387
Liability funded status at end of year	$ (2,237)	$ (2,286)

Schedule of accumulated other comprehensive (income) loss related to the pension plan

For the Year Ended June 30	2024	2023
Accumulated other comprehensive loss related to pension plan		
Balance at beginning of period	$ (23,996)	$ (24,208)
Amortization of net actuarial loss	370	721
Current period net actuarial loss	(60)	(509)
Settlement expense recognized	10,674	—
Net change	10,984	212
Balance at end of period	$ (13,012)	$ (23,996)

Schedule of net periodic pension expense

For the Year Ended June 30	2024	2023	2022
Interest cost on benefit obligation	$ 1,775	$ 2,608	$ 1,675
Expected return on plan assets	(1,884)	(2,624)	(3,413)
Amortization of net actuarial loss and prior service costs	370	721	480
Settlement expense	10,674	—	—
Net periodic pension expense (income)	$ 10,935	$ 705	$ (1,258)

Schedule of significant actuarial assumptions

For the Year Ended June 30	2024	2023	2022
Discount rate for interest cost	5.0 %	4.3 %	2.2 %
Expected rate of return on plan assets	5.8 %	4.4 %	4.4 %
Discount rate for benefit obligation	5.1 %	4.6 %	2.9 %

Schedule of estimated future benefit payments, including benefits attributable to future service

For the Years Ending June 30	
2025	$ 1,388
2026	1,600
2027	1,809
2028	1,955
2029	2,113
2030 – 2034	11,486

Schedule of weighted-average asset allocation of plan assets

For the Year Ended June 30	Target Allocation 2025	Percentage of Plan Assets 2024	Percentage of Plan Assets 2023

Debt securities	65% - 85%	79%	75%
Equity securities	10% - 30%	18%	12%
Global asset allocation/risk parity (1)	0% - 15%	2%	3%
Other	0% - 10%	1%	10%

(1) The global asset allocation/risk parity category consists of a variety of asset classes including, but not limited to, global bonds, global equities, real estate and commodities.

Schedule of fair values of the company's plan assets by asset category

	Fair Value Measurements Using			
As of June 30, 2024	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	$ 277	—	—	$ 277
Common-collective funds				
Global large cap equities	—	5,077	524	5,601
Fixed income securities	—	24,650	—	24,650
Mutual funds				
Global asset allocations/risk parity	496	—	—	496
	$ 773	$ 29,727	$ 524	$ 31,024

	Fair Value Measurements Using			
As of June 30, 2023	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	$ 6,063	$ —	$ —	$ 6,063
Common-collective funds				
Global large cap equities	—	5,552	1,519	7,071
Fixed income securities	—	43,794	—	43,794
Mutual funds				
Global asset allocations/risk parity	1,426	—	—	1,426
Other	—	—	33	33
	$ 7,489	$ 49,346	$ 1,552	$ 58,387

Schedule of summary of the changes in the fair value of level 3 assets

Change in Fair Value Level 3 assets	2024	2023
Balance at beginning of period	$ 1,552	$ 1,962
Redemptions	(1,316)	(603)
Purchases	200	—
Change in fair value	88	193
Balance at end of period	$ 524	$ 1,552

XML 59 R36.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended Jun. 30, 2024

Income Taxes

Schedule of income (loss) before income taxes

For the Year Ended June 30	2024	2023	2022
Domestic	$ (22,820)	$ 14,776	$ 27,695
Foreign	33,736	39,295	44,632
Income before income taxes	$ 10,916	$ 54,071	$ 72,327

Components of the provision for income taxes were:

Schedule of components of the provision for income taxes

For the Year Ended June 30	2024	2023	2022
Current provision:			
Federal	$ 3,037	$ 9,801	$ 4,874
State and local	1,718	1,810	1,468
Foreign	15,740	12,750	17,613
Total current provision	20,495	24,361	23,955
Deferred provision (benefit):			
Federal	(4,755)	(6,151)	(75)
State and local	(1,523)	(266)	251
Foreign	(4,468)	3,424	23
Change in foreign valuation allowances	(1,249)	97	(1,002)
Total deferred benefit	(11,995)	(2,896)	(803)
Provision for income taxes	$ 8,500	$ 21,465	$ 23,152

Schedule of reconciliations of the Federal statutory rate to the Company's effective tax rate

For the Year Ended June 30	2024	2023	2022
U.S. federal statutory income tax rate	21.0 %	21.0 %	21.0 %
State and local taxes, net of federal benefit	(1.1)	2.0	2.0
Higher taxes on non-U.S. income	9.9	8.9	4.8
Changes in uncertain tax positions	30.7	5.1	4.4
Global Intangible Low-Taxed Income	18.3	3.3	0.3
Recognition of federal and foreign tax credits	(10.6)	(3.1)	(0.9)
Change in valuation allowance	(11.4)	0.2	(1.4)
Foreign derived intangible income	(3.8)	(3.7)	(2.1)
Non-U.S. withholding and related taxes, net, on planned repatriation	28.4	—	—
Impact of foreign tax credit regulations and related changes	(20.0)	1.9	—
Non-deductible operating expenses	11.3	0.9	0.8
Non-deductible acquisition costs	4.3	—	—
Other	0.9	3.2	3.1
Effective income tax rate	77.9 %	39.7 %	32.0 %

Schedule of the tax effects of significant temporary differences that comprise deferred tax assets and liabilities

As of June 30	2024	2023
Deferred tax assets:		
Employee-related accruals	$ 6,620	$ 5,461
Inventory	1,521	2,864
Environmental remediation	767	1,733
Net operating loss carry forwards–domestic	777	839
Net operating loss carry forwards–foreign	3,813	4,389
Operating lease liabilities	6,788	6,521
R&D cost capitalization	7,227	4,283
Unrealized foreign exchange	1,470	—
Carried foreign interest expense	4,518	—
Other	7,224	(1,311)
	40,725	24,779
Valuation allowance	(1,288)	(2,598)
	39,437	22,181
Deferred tax liabilities:		
Property, plant and equipment and intangible assets	(5,282)	(6,286)
Operating lease ROU assets	(6,441)	(6,280)
Unrealized foreign exchange	—	(1,906)
Non-U.S. withholding and related taxes, net, on planned repatriation	(2,828)	—
Other	(6,182)	(712)
	(20,733)	(15,184)
Net deferred tax asset	$ 18,704	$ 6,997

Schedule of deferred taxes included in the line items of the consolidated balance sheets

As of June 30	2024	2023
Other assets	$ 19,371	$ 8,711
Other liabilities	(667)	(1,714)
	$ 18,704	$ 6,997

Schedule of the valuation allowance for deferred tax assets

As of June 30	2024	2023	2022
Balance at beginning of period	$ 2,598	$ 2,618	$ 3,709
(Benefit) provision for income taxes	(1,310)	(20)	(1,091)
Balance at end of period	$ 1,288	$ 2,598	$ 2,618

Schedule of the reconciliation of the beginning and ending amount of unrecognized tax benefits

As of June 30	2024	2023	2022
Unrecognized tax benefits–beginning of period	$ 9,449	$ 7,832	$ 5,311
Tax position changes–current period	2,066	2,181	5,333
Tax position changes–prior periods, including settlements with tax authorities	615	193	(1,175)
Lapse of statute of limitations	(58)	(194)	(1,071)
Effect of changes in exchange rates	(211)	(563)	(566)
Unrecognized tax benefits–end of period	11,861	9,449	7,832
Interest and penalties–end of period	1,689	981	427
Total liabilities related to uncertain tax positions	$ 13,550	$ 10,430	$ 8,259

XML 60 R37.htm IDEA: XBRL DOCUMENT

Derivatives (Tables)

12 Months Ended
Jun. 30, 2024

Derivatives

Schedule of significant outstanding derivatives employed to manage market risk and designated as cash flow hedges

As of June 30	2024	2023
Other current assets		
Foreign currency option contracts, net	$ 39	$ 333
Interest rate swap	13,151	14,031
Other assets		
Foreign currency option contracts, net	—	—
Interest rate swap	—	10,225
Accrued expense and other current liabilities		
Foreign currency option contracts, net	(41)	—
Interest rate swaps	—	—
Total Fair Value		
Foreign currency option contracts, net	(2)	333
Interest rate swap	13,151	24,256

Notional amounts of the derivatives as of the balance sheet date were:

As of June 30	2024
Interest rate swap	$ 300,000
Brazil Real-USD call options	R$ 36,000
Brazil Real-USD put options	R$ (36,000)
USD-Israel shekel call options	$ (3,043)
USD-Israel shekel put options	$ 3,043

Schedule of effects of derivatives

For the Year Ended June 30	2024	2023
Foreign currency option contracts, net		
(Income) expense recorded in consolidated statements of operations	$ (1,126)	$ 1,237
Consolidated statement of operations - total cost of goods sold	$ 704,587	$ 679,652
Consolidated statement of operations - total selling, general and administrative expenses	$ 259,777	$ 226,390
(Income) expense recorded in comprehensive income	$ 380	$ 270
Interest rate swap		
(Income) expense recorded in consolidated statements of operations	$ (14,503)	$ (9,870)
Consolidated statement of operations - total interest expense, net	$ 18,536	$ 15,321
(Income) expense recorded in comprehensive income	$ 11,105	$ (3,968)

XML 61 R38.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

12 Months Ended
Jun. 30, 2024

Fair Value Measurements

Schedule of fair value of assets and liabilities measured on a recurring basis

As of	June 30, 2024			June 30, 2023		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Short-term investments	$44,000	$ —	$ —	$40,000	$ —	$ —
Foreign currency derivatives	$ —	$ (2)	$ —	$ —	$ 333	$ —
Interest rate swap	$ —	$13,151	$ —	$ —	$24,256	$ —

XML 62 R39.htm IDEA: XBRL DOCUMENT

Business Segments (Tables)

12 Months Ended
Jun. 30, 2024

Business Segments

Schedule of information regarding reportable segments

For the Year Ended June 30	2024	2023	2022
Net sales			
Animal Health	$ 706,482	$659,851	$607,055
Mineral Nutrition	243,663	242,656	259,512
Performance Products	67,534	75,382	75,694
Total segments	$1,017,679	$977,889	$942,261
Depreciation and amortization			
Animal Health	$ 30,194	$ 27,714	$ 26,759
Mineral Nutrition	2,427	2,638	2,616
Performance Products	1,688	1,780	1,717
Total segments	$ 34,309	$ 32,132	$ 31,092
Adjusted EBITDA			
Animal Health	$ 145,606	$136,139	$124,106
Mineral Nutrition	16,449	17,417	24,038
Performance Products	7,662	9,346	8,706
Total segments	$ 169,717	$162,902	$156,850
Reconciliation of income before income taxes to Adjusted EBITDA			
Income before income taxes	$ 10,916	$ 54,071	$ 72,327
Interest expense, net	18,536	15,321	11,875
Depreciation and amortization – Total segments	34,309	32,132	31,092
Depreciation and amortization – Corporate	1,869	1,880	1,613
Corporate costs	58,480	50,149	45,767
Acquisition-related cost of goods sold	521	—	316
Acquisition-related transaction costs	6,405	—	279
Pension settlement cost	10,674	—	—
Brazil employment taxes	4,202	—	—
Stock-based compensation	475	—	—
Phibro Forward income growth initiatives implementation costs	366	—	—
Insurance proceeds	(899)	—	—
Environmental remediation costs	—	6,894	—
Gain on sale of investment	—	—	(1,203)
Foreign currency (gains) losses, net	23,863	2,455	(5,216)
Adjusted EBITDA – Total segments	$ 169,717	$162,902	$156,850

Schedule of identifiable assets

As of June 30	2024	2023
Identifiable assets		
Animal Health	$ 684,407	$ 698,522
Mineral Nutrition	67,088	75,814
Performance Products	50,862	49,678
Total segments	802,357	824,014
Corporate	179,827	147,383
Total	$ 982,184	$ 971,397

Schedule of geographic information regarding property, plant and equipment, net

As of June 30	2024	2023
Property, plant and equipment, net		
United States	$ 87,526	$ 79,404
Israel	60,395	61,304
Brazil	30,348	30,359
Ireland	19,038	18,900
Other	5,993	5,601
	$ 203,300	$ 195,568

XML 63 R40.htm IDEA: XBRL DOCUMENT

Subsequent Event - 2024 Credit Agreement (Tables)

12 Months Ended
Jun. 30, 2024

Subsequent Event - 2024 Credit Agreement

Schedule of the basis spread on variable rates

	Revolving Credit and Term A-1 Loans		Term A-2 Loans	
Net Leverage Ratio	**Base rate**	**SOFR**	**Base rate**	**SOFR**
≥ 4.00:1.00	1.75 %	2.75 %	2.25 %	3.25 %
≥ 3.50:1.00 and < 4.00:1.00	1.50 %	2.50 %	2.00 %	3.00 %
≥ 2.25:1.00 and < 3.50:1.00	1.25 %	2.25 %	1.75 %	2.75 %
< 2.25:1.00	1.00 %	2.00 %	1.50 %	2.50 %

Schedule of financial covenants

Period	maximum Net Leverage Ratio	minimum interest coverage ratio

Prior to the Closing Date	4.00:1.00	3.00:1.00
First fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date	4.75:1.00	2.50:1.00
Eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date	4.50:1.00	2.75:1.00
Thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date	4.25:1.00	3.00:1.00
After the forty-two month anniversary of the Closing Date	4.00:1.00	3.00:1.00

XML 64 R41.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards - Accounts Receivable and Allowance for Doubtful Accounts (Details)

	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Accounts Receivable | Customer Concentration Risk | Ten Largest Customers		
Concentration risk		
Concentration risk (as a percent)	13.00%	16.00%

XML 65 R42.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards - Property, Plant and Equipment and Capitalized Software (Details)

	Jun. 30, 2024
Building and Building Improvements	
Property, Plant and Equipment	
Property, Plant and Equipment, Depreciation Method	us-gaap:StraightLineDepreciationMethodMember
Building and Building Improvements | Minimum	
Property, Plant and Equipment	
Estimated useful lives	2 years
Building and Building Improvements | Maximum	
Property, Plant and Equipment	
Estimated useful lives	30 years
Machinery and Equipment	
Property, Plant and Equipment	
Property, Plant and Equipment, Depreciation Method	us-gaap:StraightLineDepreciationMethodMember
Machinery and Equipment | Minimum	
Property, Plant and Equipment	
Estimated useful lives	3 years
Machinery and Equipment | Maximum	
Property, Plant and Equipment	
Estimated useful lives	10 years
Software and Software Development Costs	
Property, Plant and Equipment	
Property, Plant and Equipment, Depreciation Method	us-gaap:StraightLineDepreciationMethodMember
Software and Software Development Costs | Minimum	
Property, Plant and Equipment	
Estimated useful lives	3 years
Software and Software Development Costs | Maximum	
Property, Plant and Equipment	
Estimated useful lives	7 years

XML 66 R43.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards - Derivative Financial Instruments (Details) $ in Thousands

	Jun. 30, 2024 USD ($)
Interest Rate Swap | Cash Flow Hedging	
Derivatives	
Derivative, notional amount	$ 300,000

XML 67 R44.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards - Net Income Per Share and Weighted Average Shares (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Net Income (Loss) per Share and Weighted Average Shares			
Net Income (Loss)	$ 2,416	$ 32,606	$ 49,175
Net income - basic	2,416	32,606	49,175
Net income - diluted	$ 2,416	$ 32,606	$ 49,175
Weighted average number of shares			
Weighted average number of shares - basic (in shares)	40,504	40,504	40,504
Dilutive effect of restricted stock units (in shares)	19		
Weighted average number of shares - diluted (in shares)	40,523	40,504	40,504
Net income per share			
basic (in dollars per share)	$ 0.06	$ 0.81	$ 1.21
diluted (in dollars per share)	$ 0.06	$ 0.81	$ 1.21

XML 68 R45.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards - New Accounting Standards (Details)

	Jun. 30, 2024
Accounting Standards Update 2023-07	
New Accounting Standards	
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2023-09	

New Accounting Standards

Change in Accounting Principle, Accounting Standards Update, Adopted	false

XML 69 R46.htm IDEA: XBRL DOCUMENT

Proposed Acquisition (Details) $ in Thousands	1 Months Ended Apr. 30, 2024 USD ($)
Zoetis Inc Medicated Feed Additive Product Portfolio	
Proposed Acquisition	
Asset acquisition, price of acquisition, expected	$ 350,000

XML 70 R47.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Segments (Details) - segment	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Business Segments			
Number of reportable segments	3	3	3

XML 71 R48.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Net Sales by Product Type (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Net sales			
Net sales	$ 1,017,679	$ 977,889	$ 942,261
Animal Health			
Net sales			
Net sales	706,482	659,851	607,055
MFAs and other			
Net sales			
Net sales	420,959	387,349	361,538
Nutritional Specialties			
Net sales			
Net sales	164,671	172,504	157,196
Vaccines			
Net sales			
Net sales	120,852	99,998	88,321
Mineral Nutrition			
Net sales			
Net sales	243,663	242,656	259,512
Performance Products			
Net sales			
Net sales	$ 67,534	$ 75,382	$ 75,694

XML 72 R49.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Net Sales by Region (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Net sales			
Net sales	$ 1,017,679	$ 977,889	$ 942,261
United States			
Net sales			
Net sales	584,763	578,773	561,803
Latin America and Canada			
Net sales			
Net sales	247,705	219,846	191,047
Europe, Middle East and Africa			
Net sales			
Net sales	121,977	117,815	122,480
Asia Pacific			
Net sales			
Net sales	$ 63,234	$ 61,455	$ 66,931

XML 73 R50.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - General Information (Details)	12 Months Ended
	Jun. 30, 2024
Statements of Operations-Additional Information	
Payment term, minimum	30 days
Payment term, maximum	120 days
Average worldwide collection period for accounts receivable	60 days

XML 74 R51.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Interest Expense, Net (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Interest expense, net			
Amortization of debt issuance costs	$ 1,040	$ 727	$ 590
Other	462	58	183
Interest expense	23,010	18,676	12,691
Interest income	(4,474)	(3,355)	(816)
Interest expense, net	18,536	15,321	11,875
2021 Credit Facilities			
Interest expense, net			
Interest expense, excluding amortization	20,646	17,302	$ 11,918
2022 Term Loan			
Interest expense, net			
Interest expense, excluding amortization	$ 862	$ 589	

XML 75 R52.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Capitalized Software (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Statements of Operations-Additional Information			
Amortization of capitalized software costs	$ 1,436	$ 1,455	$ 1,047

XML 76 R53.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Amortization of intangible assets		
2025	$ 7,918	
2026	6,969	
2027	6,591	
2028	6,385	
2029	6,385	
Thereafter	10,785	
Total	$ 45,033	$ 54,987

XML 77 R54.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Depreciation and Amortization (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Depreciation and amortization			
Depreciation of property, plant and equipment	$ 26,517	$ 24,316	$ 23,781
Amortization of intangible assets	9,661	9,696	8,924
Depreciation and amortization	$ 36,178	$ 34,012	$ 32,705

XML 78 R55.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information - Research and Development Expense (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Research and development expense			
Research and development expense	$ 29,194	$ 24,395	$ 20,832

XML 79 R56.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Accounts receivable, net			
Trade accounts receivable	$ 170,913	$ 165,069	
Reserve for credit losses	(1,461)	(1,590)	$ (3,510)
Trade accounts receivable, net	$ 169,452	$ 163,479	

XML 80 R57.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Reserve for Credit Losses (Details) - USD ($) $ in Thousands	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Reserve for credit losses		
Balance at beginning of period	$ 1,590	$ 3,510
Provision for estimated credit losses	1,538	943
Effect of changes in exchange rates	(71)	(61)
Credit losses realized	(1,596)	(2,802)
Balance at end of period	$ 1,461	$ 1,590

XML 81 R58.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Inventories, net		
Raw materials	$ 72,799	$ 84,328
Work-in-process	23,550	22,350
Finished goods	169,562	170,892
Inventory, net	$ 265,911	$ 277,570

XML 82 R59.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Property, plant and equipment, net		
Property, plant and equipment, gross	$ 448,654	$ 459,194
Accumulated depreciation	(245,354)	(263,626)
Property, plant and equipment, net	203,300	195,568
Land		
Property, plant and equipment, net		
Property, plant and equipment, gross	30,624	27,813
Building and Building Improvements		
Property, plant and equipment, net		
Property, plant and equipment, gross	120,173	105,184
Machinery and Equipment		
Property, plant and equipment, net		
Property, plant and equipment, gross	273,965	291,454
Construction in Progress		
Property, plant and equipment, net		
Property, plant and equipment, gross	$ 23,892	$ 34,743

XML 83 R60.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information -

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Internal-use software costs, net of accumulated depreciation		
Internal-use software costs, net of accumulated depreciation	$ 3,123	$ 3,426

XML 84 R61.htm IDEA: XBRL DOCUMENT

Balance Sheets- Additional Information - Intangibles, Net - Weighted-Average Useful Life (Details) - Weighted Average	Jun. 30, 2024
Technology-Based Intangible Assets	
Intangibles, net	
Estimated useful life of definite-lived intangible assets	12 years
Product Registrations, Marketing and Distribution Rights	
Intangibles, net	
Estimated useful life of definite-lived intangible assets	9 years
Customer Relationships	
Intangibles, net	
Estimated useful life of definite-lived intangible assets	12 years
Trademarks and Trade Names and Other	
Intangibles, net	
Estimated useful life of definite-lived intangible assets	6 years

XML 85 R62.htm IDEA: XBRL DOCUMENT

Balance Sheets- Additional Information - Intangibles, Net - Total (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Intangibles, net		
Intangibles	$ 148,007	$ 149,973
Accumulated amortization	(102,974)	(94,986)
Total	45,033	54,987
Technology-Based Intangible Assets		
Intangibles, net		
Intangibles	94,259	95,576
Accumulated amortization	(62,119)	(55,396)
Product Registrations, Marketing and Distribution Rights		
Intangibles, net		
Intangibles	18,117	18,557
Accumulated amortization	(17,326)	(18,553)
Customer Relationships		
Intangibles, net		
Intangibles	30,418	30,235
Accumulated amortization	(19,001)	(16,884)
Trademarks and Trade Names and Other		
Intangibles, net		
Intangibles	5,213	5,605
Accumulated amortization	$ (4,528)	$ (4,153)

XML 86 R63.htm IDEA: XBRL DOCUMENT

Balance Sheets- Additional Information - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Goodwill		
Balance at beginning of period	$ 53,274	$ 53,226
Acquisition	1,397	
Effect of changes in exchange rates	(114)	48
Balance at end of period	$ 54,557	$ 53,274

XML 87 R64.htm IDEA: XBRL DOCUMENT

Balance Sheets- Additional Information - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Other assets		
ROU operating lease assets	$ 37,604	$ 35,759
Deferred income taxes	19,371	8,711
Deposits	1,646	6,617
Insurance investments	6,305	6,067
Equity method investments	5,183	5,027
Derivative instruments		10,225
Debt issuance costs	911	1,408
Other	7,277	8,031
Other assets, total	$ 78,297	$ 81,845
Operating Lease, Right-of-Use Asset, Statement of Financial Position	Other assets, total	Other assets, total
Derivative Asset, Noncurrent, Statement of Financial Position	Other assets, total	Other assets, total

XML 88 R65.htm IDEA: XBRL DOCUMENT

Balance Sheets- Additional Information - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Accrued expenses and other current liabilities		
Employee related	$ 37,612	$ 29,359
Current operating lease liabilities	7,460	6,053
Commissions and rebates	7,875	5,833
Professional fees	8,918	5,032
Income and other taxes	2,931	8,663
Insurance-related	1,265	1,284
Insurance premium financing	5,185	4,769

Other	17,540	18,859
Accrued expenses and other current liabilities, total	$ 88,786	$ 79,852
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities, total	Accrued expenses and other current liabilities, total

XML 89 R66.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Insurance Premium Financing (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Balance Sheets-Additional Information	
Insurance premium financing, fixed interest rate percentage (as a percent)	6.95%
Insurance premium financing, monthly payment amount	$ 648

XML 90 R67.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Other liabilities		
Long-term operating lease liabilities	$ 29,915	$ 29,077
Long term and deferred income taxes	14,218	12,146
Supplemental retirement benefits, deferred compensation and other	6,678	6,552
U.S. pension plan, net	2,237	2,286
International retirement plans	3,212	4,210
Other long-term liabilities	6,846	6,076
Other liabilities, total	$ 63,106	$ 60,347
Operating Lease, Liability, Noncurrent, Statement of Financial Position	Other liabilities, total	Other liabilities, total

XML 91 R68.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Accumulated other comprehensive loss		
Accumulated other comprehensive loss	$ (123,527)	$ (114,210)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent		
Accumulated other comprehensive loss		
Accumulated other comprehensive loss, before tax	13,104	24,589
Accumulated other comprehensive loss, tax	(3,304)	(6,207)
Accumulated Foreign Currency Adjustment Attributable to Parent		
Accumulated other comprehensive loss		
Accumulated other comprehensive loss, before tax	(124,004)	(115,062)
Accumulated Other Comprehensive Income, Long-term Intercompany		
Accumulated other comprehensive loss		
Accumulated other comprehensive loss, tax	8,166	8,166
Accumulated Defined Benefit Plans Adjustment Attributable to Parent		
Accumulated other comprehensive loss		
Accumulated other comprehensive loss, before tax	13,012	23,996
Accumulated other comprehensive loss, tax	$ (4,477)	$ (1,700)

XML 92 R69.htm IDEA: XBRL DOCUMENT

Debt - General Information (Details) $ in Thousands	12 Months Ended Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Nov. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Apr. 30, 2021 USD ($)
Line of Credit | 2021 Credit Facilities					
Debt					
Maximum First Lien Net Leverage Ratio	4.00				
Maximum First Lien Net Leverage Ratio, Test Period	4.25				
Minimum interest coverage ratio	3.00				
Line of Credit | 2021 Credit Facilities | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario One					
Debt					
Basis spread on variable rate (as a percent)	1.50%				
Line of Credit | 2021 Credit Facilities | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Two					
Debt					
Basis spread on variable rate (as a percent)	1.75%				
Line of Credit | 2021 Credit Facilities | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Three					
Debt					
Basis spread on variable rate (as a percent)	2.00%				
Line of Credit | 2021 Credit Facilities | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Four					
Debt					
Basis spread on variable rate (as a percent)	2.25%				
Line of Credit | 2021 Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One					
Debt					
Basis spread on variable rate (as a percent)	0.50%				
Line of Credit | 2021 Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two					
Debt					
Basis spread on variable rate (as a percent)	0.75%				
Line of Credit | 2021 Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three					
Debt					
Basis spread on variable rate (as a percent)	1.00%				
Line of Credit | 2021 Credit Facilities | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four					
Debt					
Basis spread on variable rate (as a percent)	1.25%				
Loans Payable | Term A Loan					
Debt					
Aggregate principal amount					$ 300,000
Loans Payable | 2023 Incremental Term Loan due April 2026					
Debt					
Aggregate principal amount		$ 50,000			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario One					

Debt				
Basis spread on variable rate (as a percent)	2.00%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Two				
Debt				
Basis spread on variable rate (as a percent)	2.25%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Three				
Debt				
Basis spread on variable rate (as a percent)	2.50%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Four				
Debt				
Basis spread on variable rate (as a percent)	2.75%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One				
Debt				
Basis spread on variable rate (as a percent)	1.00%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two				
Debt				
Basis spread on variable rate (as a percent)	1.25%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three				
Debt				
Basis spread on variable rate (as a percent)	1.50%			
Loans Payable | 2023 Incremental Term Loan due April 2026 | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four				
Debt				
Basis spread on variable rate (as a percent)	1.75%			
Revolving Credit Facility | Revolver				
Debt				
Maximum borrowing capacity		$ 310,000		$ 250,000
Aggregate available credit facilities	$ 131,706			
Outstanding borrowings	176,000			
Letter of Credit				
Debt				
Letters of credit outstanding	$ 2,294			
Letter of Credit | Maximum				
Debt				
Debt instrument, term	1 year			
Secured Debt | 2022 Term Loan				
Debt				
Aggregate principal amount			$ 12,000	
Debt instrument, periodic payment	$ 35			
Debt instrument, frequency of periodic payment	monthly			
Secured Debt | 2022 Term Loan | Secured Overnight Financing Rate (SOFR)				
Debt				
Basis spread on variable rate (as a percent)	2.00%			
Secured Debt | 2022 Term Loan | Fed Funds Effective Rate Overnight Index Swap Rate				
Debt				
Basis spread on variable rate (as a percent)	0.50%			

XML 93 R70.htm IDEA: XBRL DOCUMENT

Debt - Interest Rates - Stated Rates (Details)	**Jun. 30, 2024**	**Jun. 30, 2023**
Revolving Credit Facility | Revolver		
Debt		
Interest rate (as a percent)	6.00%	6.09%
Loans Payable | Term A Loan		
Debt		
Interest rate (as a percent)	2.36%	2.36%
Loans Payable | 2023 Incremental Term Loan due April 2026		
Debt		
Interest rate (as a percent)	7.68%	7.44%
Secured Debt | 2022 Term Loan		
Debt		
Interest rate (as a percent)	7.43%	7.25%

XML 94 R71.htm IDEA: XBRL DOCUMENT

Debt - Interest Rates - Weighted Average Rates (Details)	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Revolving Credit Facility | Revolver			
Debt			
Long-term debt, weighted average interest rate, over time	6.14%	5.42%	2.08%
Loans Payable | Term A Loan			
Debt			
Long-term debt, weighted average interest rate, over time	2.36%	2.37%	2.99%
Loans Payable | 2023 Incremental Term Loan due April 2026			
Debt			
Long-term debt, weighted average interest rate, over time	7.64%	7.40%	
Secured Debt | 2022 Term Loan			
Debt			
Long-term debt, weighted average interest rate, over time	7.41%	6.43%	

XML 95 R72.htm IDEA: XBRL DOCUMENT

Debt - Derivatives (Details) - Cash Flow Hedging - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jul. 31, 2022**
Interest Rate Swap		
Derivatives		
Derivative, notional amount	$ 300,000	
Interest Rate Swap, July 2022		
Derivatives		
Derivative, notional amount		$ 300,000
Derivative, fixed interest rate (as a percent)		0.61%

XML 96 R73.htm IDEA: XBRL DOCUMENT

Debt - Reconciliation (Details) - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jun. 30, 2023**

Debt Maturities		
Long-term debt, gross	$ 313,140	$ 335,435
Unamortized debt issuance costs	(1,056)	(1,599)
Long-term debt, current and non-current	312,084	333,836
Loans Payable | Term A Loan		
Debt Maturities		
Long-term debt, gross	256,875	273,750
Loans Payable | 2023 Incremental Term Loan due April 2026		
Debt Maturities		
Long-term debt, gross	45,000	50,000
Secured Debt | 2022 Term Loan		
Debt Maturities		
Long-term debt, gross	$ 11,265	$ 11,685

XML 97 R74.htm IDEA: XBRL DOCUMENT

Debt - Classification (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Debt Maturities		
Long-term debt, current and non-current	$ 312,084	$ 333,836
Less: current maturities of long-term debt and other	(29,795)	(22,295)
Long-term debt	$ 282,289	$ 311,541

XML 98 R75.htm IDEA: XBRL DOCUMENT

Debt - Aggregate Maturities of Long-Term Debt and Revolver (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Debt		
Debt payments, 2025	$ 29,795	
Debt payments, 2026	272,920	
Debt payments, 2027	420	
Debt payments, 2028	10,005	
Debt payments, total	313,140	$ 335,435
Interest payments, 2025	19,785	
Interest payments, 2026	26,598	
Interest payments, 2027	755	
Interest payments, 2028	184	
Interest payments, total	$ 47,322	

XML 99 R76.htm IDEA: XBRL DOCUMENT

Leases - General Information (Details)	Jun. 30, 2024
Minimum	
Leases	
Remaining term	1 year
Maximum	
Leases	
Remaining term	23 years

XML 100 R77.htm IDEA: XBRL DOCUMENT

Leases - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Assets:		
ROU operating lease assets	$ 37,604	$ 35,759
Operating Lease, Right-of-Use Asset, Statement of Financial Position	Other assets	Other assets
Liabilities:		
Operating lease liabilities, current portion	$ 7,460	$ 6,053
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Operating lease liabilities, non-current portion	$ 29,915	$ 29,077
Operating Lease, Liability, Noncurrent, Statement of Financial Position	Other liabilities	Other liabilities
Total operating lease liabilities	$ 37,375	$ 35,130

XML 101 R78.htm IDEA: XBRL DOCUMENT

Leases - Composition of Net Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Composition of net lease expense			
Operating lease expense	$ 8,888	$ 8,363	$ 8,461
Variable lease expense	1,150	1,139	1,376
Short-term lease expense	1,397	1,522	1,214
Total lease expense	$ 11,435	$ 11,024	$ 11,051

XML 102 R79.htm IDEA: XBRL DOCUMENT

Leases - Other Supplemental Information (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Leases			
Operating cash flows used for ROU operating leases	$ 8,231	$ 7,798	$ 8,642
Non-cash changes to ROU operating assets and lease liabilities	$ 9,283	$ 5,114	$ 11,930
Weighted average remaining lease term - operating leases	9 years 7 months 6 days	10 years 7 months 6 days	
Weighted average discount rate - operating leases (as a percent)	4.73%	3.89%	

XML 103 R80.htm IDEA: XBRL DOCUMENT

Leases - Maturities of Future Lease Liabilities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Leases	
2025	$ 8,800
2026	7,085
2027	5,212
2028	3,920
2029	3,048
2030 and thereafter	17,200
Total lease payments	$ 45,265

XML 104 R81.htm IDEA: XBRL DOCUMENT

Leases - Gross Difference (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Leases		

Total lease payments	$ 45,265	
Less: interest	7,890	
Lease liabilities	$ 37,375	$ 35,130

XML 105 R82.htm IDEA: XBRL DOCUMENT

Common Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock - Tabular Disclosure (Details) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Preferred stock		
Preferred stock, shares authorized (in shares)	16,000,000	16,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Class A		
Common stock		
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	20,337,574	20,337,574
Common stock, shares outstanding (in shares)	20,337,574	20,337,574
Common Class B		
Common stock		
Common stock, shares authorized (in shares)	30,000,000	30,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	20,166,034	20,166,034
Common stock, shares outstanding (in shares)	20,166,034	20,166,034

XML 106 R83.htm IDEA: XBRL DOCUMENT

Common Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock - Additional Information (Details) - shares	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Common Stock, Preferred Stock and Dividends		
Class B common stock converted into Class A common shares	0	0

XML 107 R84.htm IDEA: XBRL DOCUMENT

Common Stock, Preferred Stock and Dividends - Common Stock (Details)	12 Months Ended
	Jun. 30, 2024
	Vote
Common stock	
BFI ownership percentage at which the remaining Class B shares would convert to Class A	15.00%
Common Class A	
Common stock	
Common stock, voting rights	Holders of our Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders.
Common stock, voting rights, votes per share	1
Common Class B	
Common stock	
Common stock, voting rights	Holders of our Class B common stock are entitled to 10 votes for each share held of record on all matters submitted to a vote of stockholders.
Common stock, voting rights, votes per share	10

XML 108 R85.htm IDEA: XBRL DOCUMENT

Common Stock, Preferred Stock and Dividends - Dividends (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Dividends			
Dividends declared and paid	$ 19,442	$ 19,442	$ 19,442

XML 109 R86.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - General Information (Details) - shares	Jun. 30, 2024	Mar. 31, 2008
Stock Incentive Plan		
Shares authorized (in shares)		6,630,000
Shares available for grant (in shares)	4,481,620	

XML 110 R87.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Restricted Stock Units (Details) - $ / shares	1 Months Ended			12 Months Ended
	Jul. 05, 2023	Feb. 29, 2024	Jul. 31, 2023	Jun. 30, 2024
Restricted Stock Units (RSUs)				
Stock Incentive Plan				
Grant date fair value (in dollars per share)				$ 5.44
Restricted Stock Units (RSUs) | July 2023				
Stock Incentive Plan				
Granted (in shares)	600,000			
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, period				90 days
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, minimum (in dollars per share)				$ 20
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, maximum (in dollars per share)				$ 60
Vesting, immediately vest in full, change in control, shares of stock cease to trade on nationally recognized exchange, percentage (as a percent)				100.00%
Vesting, immediately vest in full, qualifying termination, period				12 months
Time-based Restricted Stock Units | July 2023				
Stock Incentive Plan				
Vesting term		5 years		
Performance-based Restricted Stock Units | July 2023				
Stock Incentive Plan				
Vesting percentage (as a percent)				10.00%
Vesting, achievement of arithmetic average of closing stock price per share for each trading day, vesting percentage, minimum (as a percent)				20.00%
Performance-based Restricted Stock Units | July 2023 | Share-Based Payment Arrangement, Tranche One				
Stock Incentive Plan				
Vesting term			4 years	
Performance-based Restricted Stock Units | July 2023 | Share-Based Payment Arrangement, Tranche Two				

Stock Incentive Plan	
Vesting term	5 years

XML 111 R88.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Restricted Stock Units (RSUs)			
Stock Incentive Plan			
Stock-based compensation expense	$ 475	$ 0	$ 0
Employee Stock Option			
Stock Incentive Plan			
Stock-based compensation expense	$ 0	$ 0	$ 0

XML 112 R89.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Cost Not yet Recognized (Details) - Restricted Stock Units (RSUs) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($)
Stock Incentive Plan	
Cost not yet recognized, amount	$ 2,788
Cost not yet recognized, period for recognition	4 years 1 month 6 days

XML 113 R90.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Immediate Family Member of Management or Principal Owner | Compensation and Benefit for Services			
Related Party Transactions			
Aggregate compensation and benefits	$ 1,590	$ 1,924	$ 2,203

XML 114 R91.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - General Information (Details)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Employee Benefit Plans			
Defined Benefit Plan, Type	us-gaap:PensionPlansDefinedBenefitMember	us-gaap:PensionPlansDefinedBenefitMember	us-gaap:PensionPlansDefinedBenefitMember
Defined Benefit Plan, Sponsor Location	United States	United States	United States
Defined Benefit Plan, Funding Status	us-gaap:FundedPlanMember	us-gaap:FundedPlanMember	us-gaap:FundedPlanMember

XML 115 R92.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Annuity Purchase Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended	
	Jul. 31, 2023	Jun. 30, 2024	Jun. 30, 2022
Employee Benefit Plans			
Annuity purchase price	$ 26,381		
Settlement expense		$ 10,674	$ 0

XML 116 R93.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Change in Projected Benefit Obligation - Tabular Disclosure (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Change in projected benefit obligation			
Projected benefit obligation at beginning of year	$ 60,673	$ 63,079	
Interest cost	1,775	2,608	$ 1,675
Benefits paid	(954)	(2,865)	
Actuarial gain	(1,852)	(2,149)	
Settlement payments	(26,381)		
Projected benefit obligation at end of year	$ 33,261	$ 60,673	$ 63,079

XML 117 R94.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Change in Projected Benefit Obligation - Additional Information (Details)		
	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation		
Discount rate used for the projected benefit obligation (as a percent)	5.40%	5.00%

XML 118 R95.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Change in Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Change in plan assets		
Fair value of plan assets at beginning of year	$ 58,387	$ 61,286
Actual return on plan assets	(28)	(34)
Benefits paid	(954)	(2,865)
Settlement payments	(26,381)	
Fair value of plan assets at end of year	$ 31,024	$ 58,387

XML 119 R96.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Funded Status (Details) - USD ($) $ in Thousands			
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Funded status			
Projected benefit obligation	$ 33,261	$ 60,673	$ 63,079
Fair value of plan assets	31,024	58,387	$ 61,286
Liability funded status at end of year	$ (2,237)	$ (2,286)	

XML 120 R97.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Accumulated other comprehensive loss related to pension plan			
Balance at beginning of period		$ (23,996)	$ (24,208)

Amortization of net actuarial loss	370	721	
Current period net actuarial loss	(60)	(509)	
Unrecognized net pension gains (losses)	310	212	$ (4,235)
Pension settlement recognition	10,674		
Net change	10,984	212	
Balance at end of period	$ (13,012)	$ (23,996)	$ (24,208)

XML 121 R98.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Net Periodic Pension Expense (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Net periodic pension expense			
Interest cost on benefit obligation	$ 1,775	$ 2,608	$ 1,675
Expected return on plan assets	(1,884)	(2,624)	(3,413)
Amortization of net actuarial loss and prior service costs	370	721	480
Settlement expense	10,674		0
Net periodic pension expense (income)	$ 10,935	$ 705	$ (1,258)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement Gain (Loss), Statement of Income or Comprehensive Income	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses

XML 122 R99.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Actuarial Assumptions - Tabular Disclosure (Details)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Significant actuarial assumptions			
Discount rate for interest cost (as a percent)	5.00%	4.30%	2.20%
Expected rate of return on plan assets (as a percent)	5.80%	4.40%	4.40%
Discount rate for year-end benefit obligation (as a percent)	5.10%	4.60%	2.90%

XML 123 R100.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Actuarial Assumptions - Additional Information (Details) $ in Millions	12 Months Ended
	Jun. 30, 2024 USD ($)
Employee Benefit Plans	
Minimum par value required for corporate bond to determine discount rate	$ 250

XML 124 R101.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Estimated Future Benefit Payments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Estimated future benefit payments	
2025	$ 1,388
2026	1,600
2027	1,809
2028	1,955
2029	2,113
2030-2034	$ 11,486

XML 125 R102.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Asset Allocation (Details)	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plan, Debt Security		
Target asset allocations and weighted-average asset allocation of plan assets		
Percentage of plan assets (as a percent)	79.00%	75.00%
Defined Benefit Plan, Debt Security | Minimum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	65.00%	
Defined Benefit Plan, Debt Security | Maximum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	85.00%	
Defined Benefit Plan, Equity Securities		
Target asset allocations and weighted-average asset allocation of plan assets		
Percentage of plan assets (as a percent)	18.00%	12.00%
Defined Benefit Plan, Equity Securities | Minimum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	10.00%	
Defined Benefit Plan, Equity Securities | Maximum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	30.00%	
Global Asset Allocations/Risk Parity		
Target asset allocations and weighted-average asset allocation of plan assets		
Percentage of plan assets (as a percent)	2.00%	3.00%
Global Asset Allocations/Risk Parity | Minimum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	0.00%	
Global Asset Allocations/Risk Parity | Maximum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	15.00%	
Defined Benefit Plan, Plan Assets, Other		
Target asset allocations and weighted-average asset allocation of plan assets		
Percentage of plan assets (as a percent)	1.00%	10.00%
Defined Benefit Plan, Plan Assets, Other | Minimum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	0.00%	
Defined Benefit Plan, Plan Assets, Other | Maximum		
Target asset allocations and weighted-average asset allocation of plan assets		
Target allocation (as a percent)	10.00%	

XML 126 R103.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Fair Values of

Plan Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Fair values of the plan assets by asset category			
Fair value of plan assets	$ 31,024	$ 58,387	$ 61,286
Level 1			
Fair values of the plan assets by asset category			
Fair value of plan assets	773	7,489	
Level 2			
Fair values of the plan assets by asset category			
Fair value of plan assets	29,727	49,346	
Level 3			
Fair values of the plan assets by asset category			
Fair value of plan assets	524	1,552	$ 1,962
Defined Benefit Plan, Cash and Cash Equivalents			
Fair values of the plan assets by asset category			
Fair value of plan assets	277	6,063	
Defined Benefit Plan, Cash and Cash Equivalents | Level 1			
Fair values of the plan assets by asset category			
Fair value of plan assets	277	6,063	
Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities			
Fair values of the plan assets by asset category			
Fair value of plan assets	5,601	7,071	
Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities | Level 2			
Fair values of the plan assets by asset category			
Fair value of plan assets	5,077	5,552	
Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities | Level 3			
Fair values of the plan assets by asset category			
Fair value of plan assets	524	1,519	
Defined Benefit Plan, Common Collective Trust, Fixed Income Securities			
Fair values of the plan assets by asset category			
Fair value of plan assets	24,650	43,794	
Defined Benefit Plan, Common Collective Trust, Fixed Income Securities | Level 2			
Fair values of the plan assets by asset category			
Fair value of plan assets	24,650	43,794	
Mutual Fund			
Fair values of the plan assets by asset category			
Fair value of plan assets	496	1,426	
Mutual Fund | Level 1			
Fair values of the plan assets by asset category			
Fair value of plan assets	$ 496	1,426	
Defined Benefit Plan, Plan Assets, Other			
Fair values of the plan assets by asset category			
Fair value of plan assets		33	
Defined Benefit Plan, Plan Assets, Other | Level 3			
Fair values of the plan assets by asset category			
Fair value of plan assets		$ 33	

XML 127 R104.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Change in Fair Value of Level 3 Assets (Details) - USD ($) $ in Thousands	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Change in Fair Value Level 3 assets		
Fair value of plan assets at beginning of year	$ 58,387	$ 61,286
Fair value of plan assets at end of year	31,024	58,387
Level 3		
Change in Fair Value Level 3 assets		
Fair value of plan assets at beginning of year	1,552	1,962
Redemptions	(1,316)	(603)
Purchases	200	
Change in fair value	88	193
Fair value of plan assets at end of year	$ 524	$ 1,552

XML 128 R105.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Fair Value Assumptions (Details)	Jun. 30, 2024 $ / shares
Employee Benefit Plans	
Cash and cash equivalents, measurement input, price per unit (in dollars per share)	$ 1

XML 129 R106.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - 401(k) Retirement Savings Plan (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Employee Benefit Plans			
Employer matching contribution, percent of match (as a percent)	100.00%		
Employer matching contribution, percent of employees' gross pay (as a percent)	6.00%		
Employer discretionary contribution (as a percent)	4.50%		
Contribution expense	$ 5,395	$ 6,214	$ 6,341
Defined Contribution Plan, Sponsor Location	United States	United States	United States

XML 130 R107.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans - Other Employee Benefit Plans (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other employee benefit plans			
Other employee-related liabilities	$ 9,990	$ 10,862	
Other employee benefit plans expense	$ 4,189	$ 4,067	$ 3,788

XML 131 R108.htm IDEA: XBRL DOCUMENT

Income Taxes - Income (Loss) before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]			
Domestic	$ (22,820)	$ 14,776	$ 27,695

Foreign	33,736	39,295	44,632
Income before income taxes	$ 10,916	$ 54,071	$ 72,327

XML 132 R109.htm IDEA: XBRL DOCUMENT

Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Current provision:			
Federal	$ 3,037	$ 9,801	$ 4,874
State and local	1,718	1,810	1,468
Foreign	15,740	12,750	17,613
Total current provision	20,495	24,361	23,955
Deferred provision (benefit):			
Federal	(4,755)	(6,151)	(75)
State and local	(1,523)	(266)	251
Foreign	(4,468)	3,424	23
Change in valuation allowance-foreign	(1,249)	97	(1,002)
Total deferred benefit	(11,995)	(2,896)	(803)
Provision for income taxes	$ 8,500	$ 21,465	$ 23,152

XML 133 R110.htm IDEA: XBRL DOCUMENT

Income Taxes - Reconciliation of Federal Statutory Rate to Effective Tax Rate (Details)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Reconciliation of the federal statutory rate to the Company's effective tax rate			
U.S. federal statutory income tax rate (as a percent)	21.00%	21.00%	21.00%
State and local taxes, net of federal benefit (as a percent)	(1.10%)	2.00%	2.00%
Higher taxes on non-U.S. income (as a percent)	9.90%	8.90%	4.80%
Changes in uncertain tax positions (as a percent)	30.70%	5.10%	4.40%
Global Intangible Low-Taxed Income (as a percent)	18.30%	3.30%	0.30%
Recognition of federal and foreign tax credits (as a percent)	(10.60%)	(3.10%)	(0.90%)
Change in valuation allowance (as a percent)	(11.40%)	0.20%	(1.40%)
Foreign derived intangible income (as a percent)	(3.80%)	(3.70%)	(2.10%)
Non-U.S. withholding and related taxes, net, on planned repatriation (as a percent)	28.40%		
Impact of foreign tax credit regulations and related changes (as a percent)	(20.00%)	1.90%	
Non-deductible operating expenses (as a percent)	11.30%	0.90%	0.80%
Non-deductible acquisition costs (as a percent)	4.30%		
Other (as a percent)	0.90%	3.20%	3.10%
Effective tax rate (as a percent)	77.90%	39.70%	32.00%

XML 134 R111.htm IDEA: XBRL DOCUMENT

Income Taxes - Global Intangible Low-Taxed Income (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount			
Provision for income taxes, federal tax expense from the effects of GILTI	$ 2,003	$ 1,775	$ 207

XML 135 R112.htm IDEA: XBRL DOCUMENT

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands				
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Deferred tax assets:				
Employee related accruals	$ 6,620	$ 5,461		
Inventory	1,521	2,864		
Environmental remediation	767	1,733		
Net operating loss carry forwards-domestic	777	839		
Net operating loss carry forwards-foreign	3,813	4,389		
Operating lease liabilities	6,788	6,521		
R&D cost capitalization	7,227	4,283		
Unrealized foreign exchange	1,470			
Carried foreign interest expense	4,518			
Other	7,224	(1,311)		
Deferred tax assets, gross	40,725	24,779		
Valuation allowance	(1,288)	(2,598)	$ (2,618)	$ (3,709)
Deferred tax assets, net of valuation allowance	39,437	22,181		
Deferred tax liabilities:				
Property, plant and equipment and intangible assets	(5,282)	(6,286)		
Operating lease ROU assets	(6,441)	(6,280)		
Unrealized foreign exchange		(1,906)		
Non-U.S. withholding and related taxes, net, on planned repatriation	(2,828)			
Other	(6,182)	(712)		
Total	(20,733)	(15,184)		
Net deferred tax asset	$ 18,704	$ 6,997		

XML 136 R113.htm IDEA: XBRL DOCUMENT

Income Taxes - Deferred Taxes Included in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	Jun. 30, 2023
Income Taxes		
Other assets	$ 19,371	$ 8,711
Other liabilities	(667)	(1,714)
Net deferred tax asset	$ 18,704	$ 6,997

XML 137 R114.htm IDEA: XBRL DOCUMENT

Income Taxes - Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Valuation allowance			
Balance at beginning of period	$ 2,598	$ 2,618	$ 3,709
(Benefit) provision for income taxes	(1,310)	(20)	(1,091)
Balance at end of period	$ 1,288	$ 2,598	$ 2,618

XML 138 R115.htm IDEA: XBRL DOCUMENT

Income Taxes - Net Operating Loss Carry	Jun. 30, 2024

Forwards (Details) $ in Thousands	USD ($)
State and Local Jurisdiction	
Income Taxes	
Net operating loss carry forwards	$ 17,250
Net operating loss carry forwards, subject to expiration	9,320
Net operating loss carry forwards, not subject to expiration	7,930
Foreign Tax Authority	
Income Taxes	
Net operating loss carry forwards	$ 16,208

XML 139 R116.htm IDEA: XBRL DOCUMENT

Income Taxes - Repatriation (Details) - USD ($) $ in Thousands	12 Months Ended	
	Jun. 30, 2025	Jun. 30, 2024
Taxes payable		
Liability related to the expected repatriation of international earnings		$ 2,828
Foreign Subsidiaries		
Cash and cash equivalents and short-term investments		
Cash and cash equivalents and short-term investments		$ 111,890
Forecast		
Taxes payable		
Foreign earnings repatriated	$ 80,000	

XML 140 R117.htm IDEA: XBRL DOCUMENT

Income Taxes - Gross Unrecognized Tax Benefits Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Reconciliations of the beginning and ending amounts of gross unrecognized tax benefits			
Unrecognized tax benefits-beginning of period	$ 9,449	$ 7,832	$ 5,311
Tax position changes-current period	2,066	2,181	5,333
Tax position changes-prior periods, including settlements with tax authorities	615	193	(1,175)
Lapse of statute of limitations	(58)	(194)	(1,071)
Translation	(211)	(563)	(566)
Unrecognized tax benefits-end of period	$ 11,861	$ 9,449	$ 7,832

XML 141 R118.htm IDEA: XBRL DOCUMENT

Income Taxes - Liabilities Related To Uncertain Tax Positions (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Taxes				
Unrecognized tax benefits	$ 11,861	$ 9,449	$ 7,832	$ 5,311
Interest and penalties	1,689	981	427	
Total liabilities related to uncertain tax positions	$ 13,550	$ 10,430	$ 8,259	

XML 142 R119.htm IDEA: XBRL DOCUMENT

Income Taxes - Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Interest and penalties expense			
Recognized interest and penalties expense (income)	$ 740	$ 589	$ 74

XML 143 R120.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Environmental (Details) - USD ($) $ in Thousands	17 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Environmental		
Payments for environmental liabilities	$ 5,019	
Environmental		
Accrual for environmental loss contingencies	$ 4,282	$ 8,505
Environmental Loss Contingency, Statement of Financial Position	Other liabilities, Accrued expenses and other current liabilities	Other liabilities, Accrued expenses and other current liabilities

XML 144 R121.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Employment and Severance Agreements (Details)	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies	
Severance benefits, term	15 months

XML 145 R122.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Purchase Commitments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Purchase Commitments	
Total purchase obligations	$ 2,000
2023	$ 2,000

XML 146 R123.htm IDEA: XBRL DOCUMENT

Derivatives - General Information (Details) - Cash Flow Hedging - USD ($) $ in Thousands	Jun. 30, 2024	Jul. 31, 2022
Interest Rate Swap		
Derivatives		
Derivative, notional amount	$ 300,000	
Interest Rate Swap, July 2022		
Derivatives		
Derivative, notional amount		$ 300,000
Derivative, fixed interest rate (as a percent)		0.61%

XML 147 R124.htm IDEA: XBRL DOCUMENT

Derivatives - Balance Sheet Location (Details) - Cash Flow Hedging - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023

Foreign Exchange Option		
Accrued expense and other current liabilities		
Accrued expense and other current liabilities	$ (41)	
Total Fair Value	(2)	$ 333
Foreign Exchange Option | Other Current Assets		
Other assets		
Other assets	39	333
Interest Rate Swap		
Accrued expense and other current liabilities		
Total Fair Value	13,151	24,256
Interest Rate Swap | Other Current Assets		
Other assets		
Other assets	$ 13,151	14,031
Interest Rate Swap | Other Noncurrent Assets		
Other assets		
Other assets		$ 10,225

XML 148 R125.htm IDEA: XBRL DOCUMENT

Derivatives - Notional Amounts (Details) - Jun. 30, 2024 - Cash Flow Hedging R$ in Thousands, $ in Thousands	**USD ($)**	**BRL (R$)**
Foreign Exchange Option | Long		
Derivatives		
Derivative, notional amount	$ 3,043	R$ 36,000
Foreign Exchange Option | Short		
Derivatives		
Derivative, notional amount	3,043	R$ 36,000
Interest Rate Swap		
Derivatives		
Derivative, notional amount	$ 300,000	

XML 149 R126.htm IDEA: XBRL DOCUMENT

Derivatives - Effects of Derivatives (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Derivatives			
Consolidated statement of operations - total cost of goods sold	$ 704,587	$ 679,652	$ 656,861
Consolidated statement of operations - total selling, general and administrative expenses	259,777	226,390	206,414
Interest expense, net	18,536	15,321	11,875
Derivatives			
(Income) expense recorded in comprehensive income	11,485	(3,698)	$ (21,681)
Foreign Exchange Option			
Derivatives			
(Income) expense recorded in comprehensive income	380	270	
Foreign Exchange Option | Cash Flow Hedging			
Derivatives			
(Income) expense recorded in consolidated statements of operations	$ (1,126)	$ 1,237	
Derivative, Gain (Loss), Statement of Income or Comprehensive Income	Consolidated statement of operations - total cost of goods sold	Consolidated statement of operations - total cost of goods sold	
Interest Rate Swap			
Derivatives			
(Income) expense recorded in comprehensive income	$ 11,105	$ (3,968)	
Interest Rate Swap | Cash Flow Hedging			
Derivatives			
(Income) expense recorded in consolidated statements of operations	$ (14,503)	$ (9,870)	
Derivative, Gain (Loss), Statement of Income or Comprehensive Income	Interest expense, net	Interest expense, net	

XML 150 R127.htm IDEA: XBRL DOCUMENT

Derivatives - Additional Information (Details) $ in Thousands	**Jun. 30, 2024 USD ($)**
Foreign Exchange Option | Cash Flow Hedging	
Derivatives	
Realized gains (losses) related to matured contracts recorded as a component of inventory	$ (1,142)

XML 151 R128.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Value of Assets (Details) - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jun. 30, 2023**
Fair Value of Assets		
Short-term investments	$ 44,000	$ 40,000
Level 1		
Fair Value of Assets		
Short-term investments	44,000	40,000
Level 2 | Foreign Exchange Option		
Fair Value of Assets		
Foreign currency derivatives and interest rate swap	(2)	333
Level 2 | Interest Rate Swap		
Fair Value of Assets		
Foreign currency derivatives and interest rate swap	$ 13,151	$ 24,256

XML 152 R129.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets Measured on Recurring Basis, Unobservable Inputs (Details) - USD ($) $ in Thousands	**12 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**
Changes in the fair value of the Level 3 assets		
Transfers between levels, assets	$ 0	$ 0

XML 153 R130.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details) - USD ($) $ in Thousands	**12 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**

Changes in the fair value of the Level 3 liabilities		
Transfers between levels, liabilities	$ 0	$ 0
Changes in the fair value of the Level 3 liabilities	$ 0	$ 0

XML 154 R131.htm IDEA: XBRL DOCUMENT

Business Segments - General Information (Details) - segment	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Business Segments			
Number of reportable segments	3	3	3

XML 155 R132.htm IDEA: XBRL DOCUMENT

Business Segments - Net Sales (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Net sales			
Net sales	$ 1,017,679	$ 977,889	$ 942,261
Animal Health			
Net sales			
Net sales	706,482	659,851	607,055
Mineral Nutrition			
Net sales			
Net sales	243,663	242,656	259,512
Performance Products			
Net sales			
Net sales	$ 67,534	$ 75,382	$ 75,694

XML 156 R133.htm IDEA: XBRL DOCUMENT

Business Segments - Depreciation and Amortization (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Depreciation and amortization			
Depreciation and amortization	$ 36,178	$ 34,012	$ 32,705
Operating Segments			
Depreciation and amortization			
Depreciation and amortization	34,309	32,132	31,092
Operating Segments | Animal Health			
Depreciation and amortization			
Depreciation and amortization	30,194	27,714	26,759
Operating Segments | Mineral Nutrition			
Depreciation and amortization			
Depreciation and amortization	2,427	2,638	2,616
Operating Segments | Performance Products			
Depreciation and amortization			
Depreciation and amortization	$ 1,688	$ 1,780	$ 1,717

XML 157 R134.htm IDEA: XBRL DOCUMENT

Business Segments - Adjusted EBITDA (Details) - Operating Segments - USD ($) $ in Thousands	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Adjusted EBITDA			
Adjusted EBITDA	$ 169,717	$ 162,902	$ 156,850
Animal Health			
Adjusted EBITDA			
Adjusted EBITDA	145,606	136,139	124,106
Mineral Nutrition			
Adjusted EBITDA			
Adjusted EBITDA	16,449	17,417	24,038
Performance Products			
Adjusted EBITDA			
Adjusted EBITDA	$ 7,662	$ 9,346	$ 8,706

XML 158 R135.htm IDEA: XBRL DOCUMENT

Business Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Reconciliation of income before income taxes to Adjusted EBITDA			
Income before income taxes	$ 10,916	$ 54,071	$ 72,327
Interest expense, net	18,536	15,321	11,875
Depreciation and amortization	36,178	34,012	32,705
Corporate costs	58,480	50,149	45,767
Acquisition-related costs of goods sold	521		316
Acquisition-related transaction costs	6,405		279
Pension settlement cost	10,674		
Brazil employment taxes	4,202		
Stock-based compensation	475		
Phibro Forward income growth initiatives implementation costs	366		
Insurance proceeds	(899)		
Environmental remediation costs		6,894	
Gain on sale of investment			(1,203)
Foreign currency (gains) losses, net	$ 23,863	$ 2,455	$ (5,216)
Restructuring Charges, Statement of Income or Comprehensive Income	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses
Environmental Remediation Expense, after Recovery, Statement of Income or Comprehensive Income	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses	Consolidated statement of operations - total selling, general and administrative expenses
Operating Segments			
Reconciliation of income before income taxes to Adjusted EBITDA			
Depreciation and amortization	$ 34,309	$ 32,132	$ 31,092
Foreign currency (gains) losses, net	23,863	2,455	(5,216)
Adjusted EBITDA - Total segments	169,717	162,902	156,850
Operating Segments | Animal Health			
Reconciliation of income before income taxes to Adjusted EBITDA			

Depreciation and amortization	30,194	27,714	26,759
Adjusted EBITDA - Total segments	145,606	136,139	124,106
Operating Segments | Mineral Nutrition			
Reconciliation of income before income taxes to Adjusted EBITDA			
Depreciation and amortization	2,427	2,638	2,616
Adjusted EBITDA - Total segments	16,449	17,417	24,038
Operating Segments | Performance Products			
Reconciliation of income before income taxes to Adjusted EBITDA			
Depreciation and amortization	1,688	1,780	1,717
Adjusted EBITDA - Total segments	7,662	9,346	8,706
Corporate			
Reconciliation of income before income taxes to Adjusted EBITDA			
Depreciation and amortization	$ 1,869	$ 1,880	$ 1,613

XML 159 R136.htm IDEA: XBRL DOCUMENT

Business Segments - Identifiable Assets (Details) - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jun. 30, 2023**
Assets		
Assets	$ 982,184	$ 971,397
Operating Segments		
Assets		
Assets	802,357	824,014
Operating Segments | Animal Health		
Assets		
Assets	684,407	698,522
Operating Segments | Mineral Nutrition		
Assets		
Assets	67,088	75,814
Operating Segments | Performance Products		
Assets		
Assets	50,862	49,678
Corporate		
Assets		
Assets	$ 179,827	$ 147,383

XML 160 R137.htm IDEA: XBRL DOCUMENT

Business Segments - Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jun. 30, 2023**
Property, plant and equipment, net		
Property, plant and equipment, net	$ 203,300	$ 195,568
United States		
Property, plant and equipment, net		
Property, plant and equipment, net	87,526	79,404
Israel		
Property, plant and equipment, net		
Property, plant and equipment, net	60,395	61,304
Brazil		
Property, plant and equipment, net		
Property, plant and equipment, net	30,348	30,359
Ireland		
Property, plant and equipment, net		
Property, plant and equipment, net	19,038	18,900
Other		
Property, plant and equipment, net		
Property, plant and equipment, net	$ 5,993	$ 5,601

XML 161 R138.htm IDEA: XBRL DOCUMENT

Subsequent Event - 2024 Credit Agreement - General Information (Details) - Subsequent Event - Secured Debt $ in Thousands	**Jul. 31, 2024 USD ($)**
Initial Term A-1 Loans	
Subsequent Event	
Aggregate principal amount	$ 162,000
Delayed Draw Term A-1 Loans	
Subsequent Event	
Aggregate principal amount	189,000
Revolving Credit Commitments	
Subsequent Event	
Aggregate principal amount	310,000
Initial Term A-2 Loans	
Subsequent Event	
Aggregate principal amount	138,000
Delayed Draw Term A-2 Loans	
Subsequent Event	
Aggregate principal amount	$ 161,000

XML 162 R139.htm IDEA: XBRL DOCUMENT

Subsequent Event - 2024 Credit Agreement - Interest Rates (Details) - Subsequent Event - Secured Debt	**1 Months Ended**
	Jul. 31, 2024
Revolving Credit Commitments and Term A-1 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One	
Subsequent Event	
Basis spread on variable rate (as a percent)	1.75%
Revolving Credit Commitments and Term A-1 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two	
Subsequent Event	
Basis spread on variable rate (as a percent)	1.50%
Revolving Credit Commitments and Term A-1 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three	
Subsequent Event	
Basis spread on variable rate (as a percent)	1.25%
Revolving Credit Commitments and Term A-1 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four	

Subsequent Event	
Basis spread on variable rate (as a percent)	1.00%
Revolving Credit Commitments and Term A-1 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario One	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.75%
Revolving Credit Commitments and Term A-1 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Two	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.50%
Revolving Credit Commitments and Term A-1 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Three	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.25%
Revolving Credit Commitments and Term A-1 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Four	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.00%
Term A-2 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario One	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.25%
Term A-2 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Two	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.00%
Term A-2 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Three	
Subsequent Event	
Basis spread on variable rate (as a percent)	1.75%
Term A-2 Loans | Base Rate | Debt Instrument, Basis Spread on Variable Rate, Scenario Four	
Subsequent Event	
Basis spread on variable rate (as a percent)	1.50%
Term A-2 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario One	
Subsequent Event	
Basis spread on variable rate (as a percent)	3.25%
Term A-2 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Two	
Subsequent Event	
Basis spread on variable rate (as a percent)	3.00%
Term A-2 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Three	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.75%
Term A-2 Loans | Secured Overnight Financing Rate (SOFR) | Debt Instrument, Basis Spread on Variable Rate, Scenario Four	
Subsequent Event	
Basis spread on variable rate (as a percent)	2.50%

XML 163 R140.htm IDEA: XBRL DOCUMENT

Subsequent Event - 2024 Credit Agreement - Financial Covenants (Details) - Subsequent Event - Secured Debt - 2024 Credit Agreement	**Jul. 31, 2024**
Subsequent Event	
Maximum Net Leverage Ratio, prior to the Closing Date	4.00
Maximum Net Leverage Ratio, first fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date	4.75
Maximum Net Leverage Ratio, eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date	4.50
Maximum Net Leverage Ratio, thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date	4.25
Maximum Net Leverage Ratio, after the forty-two month anniversary of the Closing Date	4.00
Minimum interest coverage ratio, prior to the Closing Date	3.00
Minimum interest coverage ratio, first fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date	2.50
Minimum interest coverage ratio, eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date	2.75
Minimum interest coverage ratio, thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date	3.00
Minimum interest coverage ratio, after the forty-two month anniversary of the Closing Date	3.00

XML 164 R141.htm IDEA: XBRL DOCUMENT

Subsequent Event - 2024 Credit Agreement - Derivatives (Details) - Cash Flow Hedging - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jul. 31, 2022**
Interest Rate Swap		
Derivatives		
Derivative, notional amount	$ 300,000	
Interest Rate Swap, July 2022		
Derivatives		
Derivative, notional amount		$ 300,000
Derivative, fixed interest rate (as a percent)		0.61%

EXCEL 165 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ($R%'%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+
(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !,A1Q9C$O@A>\ K @ $0
&1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R'%+*2;-I:.G#@8K:.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/ MGT"U#E+[B,_1!XQD,3T,KNV2U&'#SD1! B1]1]=2.2;ZL7GTT2D:G_$$0>D/ M=4(0G*_
(2FC2,$$+.),9$UMM-01%?EXQ1L]X\-G;#/.:, 6'7:4H"HK8,TT M,5R&MH8[8((11I>^"VAF8J[^BHTCK^2E70)N&&WR:^+[>-AQQK!Q;+@ZT*L#X++I9!\]3ZY_O"["SMO[-'^
M8^.;8%/#K[MHO@!02P,$% @ 3(4<69E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+
MUES@6QHO(];JM-O=5H1I:*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;.7\VMX^9<_I.ATR@6XP&U@@?\YO1^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!:I)]J/3%0@R#3LZG5C.=GSVQ.V?C.K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?
*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=]$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E
L&08:7)"82]3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!& 'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+
([W1]072N0/]J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!]':-*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?
EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ.C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/.053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(]P# 4A
M%W+C[^^3:G>.U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5.V[&KXF M8$O#>FZ=+2?_VU[4/:07/4;SHYG@'K,' MYA.L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?
-2K6J5D*Q$_ M2P=\'Y(&8XQ:]#1?CQ1BK::QK<;:.,0QY@%CS#*%F.-^'19H:.]6+K#F-"F]! MU4#E/]O4#6CV#30.9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !,A1Q9A@@+0;4("&/0 &
'AL+W=O3.*KCB.?B*0DXE("BW^O)"1I M*I7$<_QG(]K9W5,&[G_>]H^KEQQ+SQ57GO(-B\HS+E#_0U6>R M>:$SJ1?1M*C^HM7ZVC._@Z*RX#3;!(LGR))_1^_;4#L!?A!38"W"? ^!+AU M ?
XFP&\;$&P"@HK.^E4J#B/.\?4EHRO$Y-5"37ZH8%:1XO637/[N.\[$MXF(_MX]US<3@:UHHWTS5K: MJY%V/?25YGQ1"-V8Q+I_3SSG[F&][>*#BES(_1:YS@CS'"PP/%,+APW)^_MBCR_-GP$AX](),
[N5N$^\#;^#KU?Z?F'T._S_GDGKD(33K+BWR;D:\G +"D; MB4_%$D?DJB-:@8*P5]*Y_OO?W+[S#Q.NFV(C2V(:RF"',H#4%RU33L8WQ::)3$-VOD.VCGXJIM.=IRD!-V7V1-A)ERPAN.X7:\?
MN(Z)%!C:EI0E,8W4O8[411-2#V2>%%S41X[N<68L7+#.=)$\,2K:OB03;=]G M@E.^0"%EHEI7G:X)(JC8%](E,0VBZZ@.SVF"<9)'ZI5/T(R+BHHH$R#*G+-W
M\3\VLCV@/KHUX8.#VO*SI:8#W$N1W28 '_$;FL2BN4N>DVB=K=77WP.2KM]U MSP,GN!@8Z8'!K>E94M/I>8J>UX3>,(Z%>G&R_8"J1/?/W%SF8,G?4Y(O:9*+ M AR*WX,1=(L+?H)\%]-
Q2JGI%PEAS=90+:GI4)5U<.%T&H;ZN*)&J+"D[SAH M+%K9%_3]%-V4C*$;6J;D%:/8B-.J>;'EIN-4]L&%#0",<\&(N93"HK,R$074 MUZY"FCKTD>FF0E.UP8;]P1R-1H*8+FD,.[8"([UUT!Z)/-
=*RZBYLJ>E#LLI>>+ !>$RX M<++T&;G>KT^_H1F)2B9*F0D9K&1^TC#%HB,>BO*:92+CGG$:O9R@7YQ31YA@ M9!P$MNH];*GI=)7W\&"C\,APG.1S-'O/GFAJA H+3(>?0R,EJQ[#EII.27D.
M#S8$VT*';M^B!<[GI':DX(#0_7 V&O[3R,NJ?;"EIO-2]L%K9!]"D>7+X;OU M"&=5S$0.4A9&<+#B#V*"N&HUM2.X1(\Y1*\1BY!CMPQ%(ID;4Z9N9V#=891
M1(2$$(C78D9R5AV"+36=G'((7B.',.MPF@IO68BO"W,I@W5JA]3AN-;TCF$, M/&4,O$;&8))S44B]>7$YJHZWU=7(#5:LJYU6?8$M-9V:\@5>(U]PFQ$VETW9 M[T*A&N?-EC@W5U-
8L+ZP674$MM1T;.H1>'!"/PG'#VA8Q@D7SG/(.1%NJAK; M'*=X;J0&Z]5-$<)AK:$=PR%XRB%X<'*_F_@:)SG.HT38AD*F%!<>U7N9P M##_@*S_@P^G\-F4:)X4TJ3\(9N"TZP&Y;M?
I=WVC284C6V.[AD'PE4'PX;Q^_MK\(J;F-QTIB%'!"KFZ*&PUH3.X9%\/<6)\$)_4=BFRG^>F:PW/B'D9C=%4C' ML_>^L@=^(WM0S4@)8),\)F_H#V)NRV L.:;A]"_.+RZ,U*Q:_UMJ.C5E#7PX
MI1^*0A:O"UI-PG% H+[=M^H);*GIF)0G\!MY@FGYE";1G.3$1A\ J[1>'VC5 M'VS4SBHUN1[Y]=KS@W/\3U1S%]->%3R[S=*_K^+%*+[DM-5CF8$%S07#GM2 M%*5Y!/>
YKUI%C6$@UHS.4;R[ZODWV^T%ND;3H7N,5+[0*7V 9R+;RG)Z:>:96DW M!R1$O\ 6.$-3S%Y.T#U9H2^BC!E3D!"6:LWN&/E]H/+[$[)-[-#V\FBGU^) MG+8S>FY8J6T7:55M9$M-IZAR_N
(,Q("JUL2K*J-;*GI//=V)31R!'=)(2=7 M3F2U1-]P6A+IIM!L@9EYL\):M;^7**VG.W=9TH:551]@2TUGI7Q T&B*0)_F MK1 5Z,^2%QSG54=A M2TUGI1Q%T&B#P__5YMGT!^%&36_SW'[?\?
^GS:/])'I[&U?EO%VU ;A D=R2 ML-[#NCN[VV0\K+;6]M3EZQW*7[&<]BM02IY%]',Z$(TS6V_Z71]PNJRVP3Y1 MSFE6?5P0'!,F+Q#?/U/*MP?R!KNMU]?_!5!+ P04 " !,A1Q9#Y\"X'D-
DU#\?.2)7P_,8CQ\N A M7JU5_L"?(\CM9X8OH$BM@RWB7K@^S]8!>3D^18\D<5_M*^TV$"+K50\K8*A M!6F *L*L-X:8%Y$O!M#'%J.KN[G=_]=1U,K07(6*P9Q3Z)^+)ZD$S)E_=<4ND]GZ
M9/E"R3V]A$95A MPK3CLPQUBM!\J=Q-"2:>ZXW&YNZP&EW=R/-\OR4+-#*;4I?4LB,"IR9P!@EF M7"K$EVC%>221Y$FD0RES> ?O]K#M^%Z+I"L#6M>A+1*-S'']/A*W)G$'27X7
M7JT7P9*QV#VWFK12P\:C5NUI71D4^M%FJ@D?F.C;&>P:L9Q$&&.>Q5<;8Z M12N6,1$F"-8^%$:P1L?YW,RW,\2>87^6^B'G=5OEP&!J]Y-&1EUKA%N,&AEV M;6+K&?V:T1]DO-

NPG"1;P0*?+T$Z#K_S9L>RB-/"Z*H\XMOMGM*H_)'OZB%& M-<1H$.(Z4PR6$_72&Z M9 &O TXF V<@!,L6/]')"KR=_(P2F%!,]|)5:8_&A^6[5HM-)[.=5E\&&M47 MAY*>;b('5H2\TE'%-O?
$P,ZR:L0A%3[KYT^5[*C$>$3:W:61P=SWVOVED7G4 MHEX/$VV8Z"#3O>"[N##) /4Z$^VTPG;-#*8F+0'J3$C9"'; M+C;2_N6@"G;.AE"W5[HJB[K8;2-T9?:(]$ZCQ@H0>]!0-0@(5KC2U&IA!BW%
M>ZW4AV8+/BK;<0D;+T*&S0C\V(H7Z 2,?\23)!2RJ>1G;2G+=/Y!5^*S=H?/ MM"J?X,._SM3MQI SVN-02&-1R+!'B>))DJUCT'D3W38@ZU6N(W9@!Q,.!$&]P M&GPO?A4#8[B#?
7[%$,R(%);JZD<>WRJIP-7_]y,'21'[YX<'YDM*^ALQX5M M:!,9]DW-Y*A+1\N7;=C8P?;[?'R)EGP]NP8I3%/9-@'4Z#(9BNX8'7TX[! MT,JZ,*_)2ACSX-PC96)5G!])&,7;3)5G!?
73^HSJHCB9;3V_S,^NBO.4)DUY M\'43BA48+)2P):3$9QXL-J(\2RIO%-\4IRM/7"F>%I=K%D9,Y +X?LFY>KG) M7U"?Z$W_!U!+ P04 " !,A1Q9%LN4:N8# #T# &
'AL+W=ON\$)W(*=LYVD>Y_^QD#9! CJ2GT3L)GY>W[C>!@&1RZ^RYA2A5ZSE.FA M$2NUNS5-N8Y1N1N0-WU$&3S9<9$3!4&Q-N1.41+E3EIJV97EF1A)FC ;YW%*.
M!GROTH31I4!RGV5$_+BG*3\,#6R\33PFVUCI"7,TV)$M75'UO%L*&)F52I1D ME,F$,R3H9FCZ117CC_K@>S:&A8.B*:TK72$@0N!SJF M:;J5((Y_2U&C6E,[GMZ_J7 .X0'FA4@ZYNG?2:3BH1$8**
(;LD_5(S]^H250 M7^NM>2KS7W0L;2T#K?=2\;QTA@BRA!57\EHFXL0!>Q<<[-+!KCNX%OR)N"G1N/%?+7X M.IO/&P?)QO^F(JNOBY6JVO40\^K M";KZ=
(T^H82AIYCO)6&1')@*&M=4?YKH,X+X(P+X0 +;1 V]:?;3G\2+')!XF=Y=>M\NVJ8_F M4%MG;,TS"JGC4K:FKI#HYQ*ZDAY&MHN]@7DX34G3R+$]]V8U:5JY(?;[E=49 M1+^"Z'=*C&//"ME2?Q
U)!#J0=$\1WT !%,F!Z,H*SZ02>ZC8J060%OK^25@] MC-V@7V-LFCE>&-00FT8V]@+;SL7SFU8<86=7%=+P0^))KE& M+Y313:(0!)P6/.*L,@K3;VM87/[[7HY:MKT0C^L4;48N8[MMU-
AZV=3875R M+51.!0(&^" $>]OR E04V?12D2TUSR-VL% C:C'S0LNI@;6)l0;/ND!VTB[A M[DK[BTRX4>Y[$*VN,S7-G+!OU7>KOM(,9%=N\K9:P'7NFBC:] MFJU:][N\8:W-W^N6/F\S?
\H4WP,/1&SUR4O!B2M&Q]B$D6+70P4W^5-YPM7 MT,+FMS%\EE"A#»#YAG/U-M +5!\ZN \4$L#!!0 ($R%'%[E@E)<$P8 M ,D7 8 »>&PO=R(W:%?H:%?H:YOOA\@3(0]>]>N4N("^! M' *^X0H179HFG[LDP+Q!(Q+**PO* BQDDRU-'C&"G20l\$T+PK898"\T!KWD MW)0>C06OA>2*0,\#@+, HZ(3]=]
QFO)OZ\I2O4"7/0B_"2S(CX&4V9;)FY MBN,%).0>#0$CB[XO1)=CU%4)2<0OCZQYX1@HE"=*GU7CONDJ;4#DB/ID+)8'E MSX]B>\K)>GC3R9JY'VJQ.+QJ_JW!%["/&%.QM3_[3G"[1M= SAD@6-?/-
#U M-?(-U&MN2P?.8"QIDR=)!X(7I+W[);D0A 35W)%A9@E4WPYO:ZZ& MCY,K.!K>#N_&$S"[GDP>9^!LBAD)A4N$-\<^_PR^@(_ !-R5IWG/%+)[)6+. MLZY&:.5?6CJZ^QV$#V/ <6-
![JE2/ZZ?;>KHIH7-R*R>W$CU[A]Y4OB^$,>(M>9/GSV4J\4"S7$ -L$L>X3GI&W($<<)6O!A\^H#:\&L9W8G$-%8[9[6KU+=9 MST&$&5AA/R;@S N!0WT?,PXBPM*Q^[GL;]1=M),N5'58#6
#0HAZYJK(N3=, M(VCF!,W#"-*W$.!8N)1Y_^0%19*>+;6?ZG<*ON3-33Y; #4"-816CM!Z%X+' M>;S??NN-]VW?51&:X79NN/TNPW(VX *'CA,,T^@IM9%AX
<'#MRM2+H\2&L+1ZU0K5*0IK!70X1;WRE2D7:5G0 MMCNM3G,:H$:D[G\SXZ/*2;:<_P'5+).O U$C4H?83.6H>B[7ZMNHU&:EP*'C M_E1J.NYFWD?-HVHA_:9$U(C4_6^6!:AR,CZ^
MSG5K0]2(3"',PAY5_4'P [.E%W+@DX5,A8V.?"%9NN=.&X)&R:,UB0JY"4X, M78(=PE2 O+Z@5+PVU$XX_^=C\!]02P,$% @ 3(4<6>;Z_]8,"@ ,30 M !@ !X;"]W;W)K\EU4?!1[GLF_;$2^BTKY-7^<
M%?N<1^NJT2Z=$+\I=+GHKG\PF> M_/SA: *X+=4/L\79/GKD*U[^N; +Y;?9TA\1DK*@Q#?U9?K]?G$47?$4OZ7RD4D_WOB2YZFRI.\C[\;IY/C-57# M[N>?WC]7XJ68AZC@2Y'^E:S+[?DDF*
UWT2'M/PJGG_CC2!7^8M%6E3_HN?& MUIF@^%"48MP2[+Z_^A'$XA. ^P--"!- Z(W8 ,-:-. GMJ -0U8%9E: M2A6',"JCQ5DNGE&NK*4W];$*9M5:RD\RU>^K,I=_362[49.A^*PV%E*V+
MLUDJI[T%YFL7-]2[KZY&'ZV&"OHBLW!:H*EOS== !3-[\40'YJ>"26#W^?L@^ M(N]\0.0A#+BAY>G-*= \/+TYL:BAQ_Z@E3\ZX. V[NKKQ?WUS:_H8GE__>WZ
M_OIJ!46Y]L)@+RI9?"KV4<_4(3&=!:,Y*P7/7:,.M'K-Y7]S(1)EDL=AO*&9U6[=JJ_+ATX(P[)W-GKJO.(TH\1S.*C2MV!S![M&] M=_?N\>Y=:,\]?K^K)
[O,JF6!2B&S:BRR.$DYRHZRU._]6QP56[3/Q5,B)Q%Z M>$&R$.11F62/=29-RH07ZG @N&.,G#&=A2,YZX7>,X;>LPZ-MR ,'^_E6&G M!0K'/O#BOP]}D;RQ-\UY&J6]PT]^@V'!,8<)P9H>^P7?FF:
2U(\T)^X@U'8 MJQJN0>&"EV7*50ZOYABH&0-SS//U7K1?\,VJ1_+6#P]IPT.LX;G,HW^2%/= M/A4O570&)V_CJ1L>)N%*CX[U>F^.SDC>^M%IF0],H6BQ*D7\?:J4Y:G9R
M35<.%IF&52\\'?!HHC,JT8WEK1^=ENFF'>I^E;D1],D52122E2S)GGB-26!\ MK,I>"CBC>@L:;WIAH@/!^5&;&6CQ6VYY3D8#!"9; &:5;@HA(SP? MN/66N[!G9=[E-
LH>>:,%6'E1V$E450,K#BL#2)!*TPMF]*JH\\' HI)=*&K2E M!F1=+;(6^X^%,V%8WGKQ[VE0_P*'L;Q.*B%AL1>GCO%#RD?I YLLMPT\ S8 M!?/YT*1HZ1#\;\:"SPT E>]J2D/:
(K]#E#V);1T1^QT=YPM^^A%3150!H!UQ'"TMS@#,ID0N.PPIIAWQJ#N YZ0E,6(G,2DE7C.X#\49O ZRXJJBS9V%A1H@ADF M..GKD-DVSJ>LS2?7T(F%'LD@%Y+4H1.TK=G+H YBHTV2KPW;E.YH
9IA0;/6B: MR84&&\@.I.4AP]PE_KFV]7JA"U",BH)C>HM',M;/X0M.!$[,T=\G@;J=$O M<:+8BKRP,{).0E]J(?3OK2U0> M\FJ8OU&@&N17E84":?;89]0)YI-G>&U;7L0NSLLHSV21FE=0I;)U+JP'0&4(-A
MHN_P+"$%_OZO \A.^HL:*A"MNA"L.AR"0#MD7:K;%;]E=/2QJ9 (90$A@%_MU'H/,YI $"-1%P^5VI9]B\U5B>M\NQ.WIS:QO06$FB7SAU8Y.$6H^@\(MMA2 ***?;0!&OJ\?:0!&'AF8LI0E*&HGJ&-
=/A1U3:{[]_6:3 %>8@$VBC)D MYS,'Z[N>D!TA,C! 'K0%*TJL9?GS]9<+BT&ZS(%-HZ(@5#(63H!8!$T*-%8\M6]!6VRD7,^;1 MFUSL4"JRQQH!U
$4]&W4$TEJ(I5GKL+"L2[:CU'+9]3.9W=-7ZM"=T*$3(Z2 M*8O,]5U?R Z[=L1H]_+F#@>@##.?ZII'NF@_M-"WA43OA-1U>\9S(5-FK3XBR0JY1\\'-?KO7-X=]5 *DT.Y7P(;R1PN-U Z M_?
R19,4AK\;3O*==PQ6GP8L'46>$'3'+,@,8ZKO)=H5_+\1:FF3VED3S3-3[96 M&W8)N&AB 9*]#2>$3C1+GS=KB^EQ4IFWZ\[@O,[1<[O>_M;G:ZV.C0#MN0\ MW1)7P8
9\>:!OG,'F&&/LH5%#FOICIGI[VJSX7&5(OF/N#H60C(SRD+2'!&)-MK H$*_$MBFE!AT!9KZKK_(A7YCZ XM\UGDT[:1GTW(>%1R]6 /ZTWMU\E4O M\>5LK3YPN=1_DJO@-19D)KF1.:7&P 4
CY*Y9_0FX(XY=."!" 9B(+ CX')(M$XI*], ?DRQ3 U?V]I[GB8 GJ0ES#)-/Z\!S'Q&F+[R \Q*OL86[9AO7=RN#OM]_5A+E-8Z-ZGT MD63UD^<=#^,)&);U1O85C>>L'M 5^]MIII:S&O"BK C6X]\-
.QL(^<8W! 9@Q M5W\]}3,,'8'#B182VS,3S7GYKSPEEZNCN/+E M]JGD3K:EF%5"7, M_;^.L]LTWU&K;$K'Q/+^R0U=S8EYUUW]78\?RQ>B>E M0-
7Y;_U2PO'7XWLO%]7;'MKOE_A36+^]TKJI7Z;Y$N6R_!4HY1OITOGHXO*.MZ_=3ZB^EV%=O;#R(LA2[ZN.61W*AJ SDWS=\"E#^_] LEKO*<_!0 ^R !@ !X;"]W;W)KGL=-.7RI8B9D \H%LY[Y]
M!2;8@,#VG>Y S./N3]+ ^Q4H+&6Q(\I8N,*;@/0KC="@M*%U>RG+]+W"$T@NR MQ#&[\T^2"%%VFKS*Z3+!:)Xf1:&L*HHI1RB(I=$@O_:0C 9D1<,@Q@\)2%=1
MA)OUS@DFZ$$I8\+C\'K@F87Y-%@5B[O%_GY4/"SN,23Z,@\B*M5*RT(A'$^ZC_KM\K\ YG]Z5# W^L_(GS:%& M*N.5X-A7:WS?)Z?H=_M<[V\/FQTG88+I[-S\ 4$L#!!0 ($R%"%ED"0];RB(M_+=M 9
>&PO=V]R:W H965T1Q 8DK! @,$ 2!%__>M?'W. W)7D.*_R M1=ME@9GNGKZ/V6\/ ?#>,YT;BP^[MO/?W=F.X_Z;^ =]M76[TB_[O>DHFW4_M[,J1?ATV]_U^<&7 +^W.:^U>7EU_>WY5 =^?
[,_FS5\/WW_;3V#;=>S44?MKM MRN'XU+7]X;L[#^[8!Z^;S7,$!_>__W9?;MP;.[[=OQKHM_MAE;K9NN M:,;$0@?$O7?-.V!(OIC_;ZB\8=\)E57KWK& ?-?6X_>[.UW>*V]W+]1U?]X>_M.
<7G"ZQ7]:WG?XN#//O5U9VBFOS8[_1E@F#7=/)_^4'!D+SP]>4-+US!"U<, MMVS$4#XOQ_+[;X?^4 QXFE;##XP]OTW -1T.Y MKW3CI[+QU0T;/[@]_MYWX]87W2UJ_,%[A.6
94K0^7IU:TK_L_4+8N'EXOB MZO+]T2WK/0RD>_M/KX%K4WK?Z?1.O6C<^C=:4L?B>_BE=#TU7-QJ7G;*EG?>?IM;H4X;<7-MGY;^X;]>8?
=NE&]^WKJB"L^ZNE@W74GKE&WAZ1%'"FCTQ;:\=L7*N:X@T/?E M0,\U4"E5/]3TM",I';?\NX*UC\!L7.>&LFV/^-[M1WEWI'W?=@U^>X-]?"W MSW_X^NK]\O%?GSQYQ3\^>'R/
,>5VJEV_(IN(7ALF]?0RR/T28;%GU;^]9MR M(+(MBY?=Z(;]W^W+[DA*K 7(0LUQ*#M?LH9,L71M0\I&Z#'T.][ZHU1:,C%K M5S6LL@+],1Z\-
Q=BGK]*N!3W\B#OJ*GCJX<,*T;,)!Z<:1>EL43VIU,!P'$5"3T\)C70_6?PD[\,M[$ MQF?VZODG>IM@TWT!V;@M1WYN6;QN_'LYP,<$Q3"2^1TA(3B!QOO)R?.$?C^" M&+0!67"P$IEN3RNOZ-
#=@,^)/@W!!B[&4F0M2"!/=UF3AC R$P")=N>D$ M$CKH+9UP2_L23!N<;P?2 =AQ:)1?P2PPREW'1!.$"5C\F,)_(\C"L,YL3UX! M9?EW(Q.C5Q)G*M7V_6#<"H9939[4G;<5WVS[J:T+V6L$=!Y0IH
OBOVT(!56 M$DJ22/09XL"XNF(;OO!JF?9J=TU^4UOJ[U*A5-PF5-A3+#P4[6UW6FG9J25 M 1 +=X) 61-B58B14S+3$+VO6\$,ME79&.O4BH4]DJ_+=;DV!'>3[# N"+V
M>]!'#T;C1P;20<1O1SX#H_R"U$_#@ IL+;F3)@[@#G$P"?N2M"H1@WZMR@G[_MPE#4P'ZJC/SILJEZ("4]5;0SO':[8,=]FMI?\@#O(6]#6ZAL\'"AEH+'"% M-LD;H)$1%Z;+4.BK:AI4&?PV4A.$]6?
1&EQ+)@.Z<4';=-.;V'0:.^%<\2 ,;T MO1M5*$RVE%,.^H*L6)!5HKW[,,+7)L@'MYE;T<5T:MVTC;S(2S^4KET43X?RUZ9-5FC[2LE _4[M89)^NF69K3T340B(/$8:%!#2%".!-
Y]&LM5RPHP(3O.A4A%>Y1D:.MZ6?Q$ MZPC(MQW5>]+#@.7I _=Z=(;7RRY%H7FW+;.D.VH*5!IF2)7%W @]@<"T]$'RE4 MHD^$-(X@(`>D2%(l0=]%K]L,>
(LXEC?.X^Q9ETU+:PJ4=OW.Q?/1KAF"I8$ MSIA\%@=]=^#86598O!F\^(#89R;345O!!Y4.L=2 M&D]8@/91] Q @>50^AS*TQ^X#>03DIAF?@L*E>5Z^5SC8D/QU]0&+R%M1Y $[M%#^?
GU@^1=75<=N%^I#LF4)O5%"RK+M>/S)T5<W%?TD-PG MGLV*;$[@;M5]H27OT(5)"$ +Q(5?CP>.J7$QOO\57BQYX\HD9A(`>Z=.6 MS_@@A0Q\=HW_$?UJ4&Z/XMW)7
M"F'LR]=PD4IQYMX/Q"..<&#YCLZ;0.]#+,"G_9X,%/%=(U;M[3>-9]>%&"'8 M]HK5KJR&/]!KJ2?GA10.WEE/H&C2\012,]9SG+\-*F[2F&_,'> V=_}';> M+<*2+HXH,@4#;UX^
BG7(IH@.=OU/R$]0-:G/.QD1S1A%@9L M.?."7O#ACRNH%>)\0#%N(;$$*_H39);=>L\A39M.01OQ7BDIEBD&HFH["> 'MWX1FF9-WJ^X_M>HDA5>02C8ZSBJ_C905/XJ8O,F0+P5H?
^!,&C'1P^GY9G$H AO'WSUV/]ND3=BYB4">WHB*%.)OFX(-MP+3T)-1([-30WID5[YW06F[#G3PYL3Z24.4YJ*$H>K 3=A%X)S\Q+:1JQN M(Q2>4UV-DU .AJ3MF?OI$.$0M('3C$??B!Q-
%&%)#8VU MB?9*5H'|#9GV\CT]X1QV/G@+%ML4"94LJQ _=K1, ""!7F93;!NX)>S'@5W('H+?HV,,D>S-X+GL\%<< MXT-9$ JM^U#\,M4;\PX'4M_&D^=Y^P"1{\5RS1{Q"AB4GO0SG=&R>"U,3/]7
M/3G;3!QK&DG]+>@6X5*+@^5@F!][BGTWJD'(K]&4#6GYG4B,^)E0NBS;G'M2 MG2?>'KWKUQ14/HZY-,@F2-\@%O/Q/4YO06+4MV+O5:(',%CP+X).71;AG#) M=+Y3521@$AZ#FZ_(N+1'2?
\)UK:_R48X&[M]N)4DM^.X!VG>LLVMRY6.TG4 M<(SG.[AURI$'$Z)7!SY)M+$JXK ?'#.8^%(KS9ZUHFECB-(/81-@'.)O!AD M-QHV%9WCQ,\U-02G>VX+/$YIG/S:GS$B%,?
#.5N]JNT.&/T"WS:$E&Q/D: M *FRN0I^(B_DH% L>R&R$>5 :=P[U(S4$'H(R4W4;[J&W^C-%(W9!&.H0% M+3,S%U(L>< -">FZ2[F6# I=U?E(WO$Q09X;)6$%EL]:<1:XM8H8ZT1LB@C!!
MPHN@X\T:B2/[^A0V>V.0 MX_K:IQG<.#D]-5U20X1]YF_MA;T@W0?-'73]2# 4>0Z!]Q7#KCHXXID[>Z+/[A3!,&1YZ4P%Y2DG6(/HLU MA5T%Z6A-@";[*5X4Z6L$]
<'98NH;\'1FMHUO2NI&F3(S\U5/3<K6DM*E]P&N M:$/RQ4)Q(B>GRS.5EA2ZL)D;06*[Q&==%Q#GD],4%<1=E7:L(,#)*MAR8 M&OQR*Z23$?+C(?[A[+=Z&V&AC]PR0=&URT%!<30;4/?
2<2=&41 @X[^)20 MA0!K(`_DWHD26:+R)%1VT\#Z3\/% (0U7S/K8.//=X4..W*(VN'9B?H.R8] MW+S@.,(..I.+W+(CT#;P$SBRY>AW=50LI^!2L"KX!"*1K)$\VH,/*%X#X+#.Z_WBVQ
M(=NM9P1+,.Q8_]NP5_3R4=5*7')+W!CL95QOI"*]^]0(NDC'K6;VOP!MV;(PC M>0#T2"7;B152Y=3! M)JFP+57[P"/[M:Y/B(HX(V1N GU44G9:OR0* HU@(3WU@(T1P('CX)X;L MP9=_8A?
W'+5&*_5)!P, .3S\\7%BFBYRX5]B@68$B.0X%MY3C@!,.M!:!F! MS9Z$<]<(BYP!B$^ !+D9-69,LK1N8--,+(?0).!"E9\O46NO-GC-SG28< M!9H#T7DK1Q8RMBQOR*Z23$Q-+)3[DQ_=!)\:1_5-
GC280A%XC*RAX ME"VM:VSID@YT;M^2?6($AD2WBRL&/%RC>R4_]4-!9W7[Q\\=,]?I6D=T5NC!LU14[>'_N7K!X5/Q)=%'^151Q"V"2X1J__/()& M!:,Z8F8]D\R[)!))>:PXI5?/LVF$]-
:AMO2*V7PD,%ZUYF7"U>$8,?EV'[YU MX5L.B\=2H1;$GZAJ3Q880F-SD)<&I+LI7GX(3^V3SNK&M6+'V\,^BFI(PDL ML,)K>HNBN0XY>,L/1!SXN1B[2^:JE$KD1;<^^2(_V[4]O8T.5 O>?
@VFOS@#/G^_0MG&SZ> @\[,{BMU@$95T> M&35S5U.\,:9>>527>7'$-0OCEP#GZFR@AZI2E\2$&[X1R ,9* M3/Q<4M7(I/0)8N&4Q O.+8A9(P*%\&4@<>!2AOA1;' S59*2MU$W>HRZ69H.
MBYT83BT=LD;JRIK7+SYK)/4.0*F&+'EW[H,F&?/'I)0! MGP*\Q9D.U-; 81W+,?L0Q.NHHFJ18QVFL6,)+*L*VW0, FA_HA)GJ@0HS] M+<8X)P WH65KI FCWW 2 9Z$[J26DG;_J?DRS[9H27A<;>?
CT>\.XS]JV0 M'0C?JK^%=.*=G1A+3#">'AZ,'C>U1#N1_:U6]A\K*U6&?4HW!D }<. 6:9 MPY0 QP?6$'TVL6><0ITX27IP?ZO7+5&;%(}> MZX>W29SXEL_=:BQ>>C_Q*G+R\B^+-
GW!@W2&/.&KOQ.5I\=/L,(:T!.H)9S1OI[P%(K9A4NW]/*VE\B'C"8-4 PF? MG4.P0L8 GY.D719/+3ORK ^MU)'TXG9[2]R1<*38$'=^XH3*W7.OZP<'5 G M/K=1H0U9D]
[ZXE0C6$KL(E0:*DJX^ET5J4/ML!O-1 /0XL\OC4$:V?#2O MLM8F#'AM/D 9LGFH)[EXL.E6^BB"P3*'?YD +UBYE=-Y'&0KEL23N=,^6]W" M@E@2O[%"CGR3Y[*$1&W D+(=J;CUU
I7W@";)$4^%T"KE8]YF&)!-*NI\,B7 MPHK:,B?*]0+*]9@T'P!.8K=&53G0(1Z?V.0;%%P.R6%(;S&?0*B;0!8G*^.D MM'0>0\4DQ946K5@A=>=++7+.J>NW0YY>4T9&AC;TG"Y*?494O2K[=R-D1988Y
M2=DWL[RV!>>]6>79H=W0X!&P1+)]65:J=DY8P3>`I7K'=\]15=J;I9.VC@6S6S-N3-H^60!UBXYRKTJZ?MJ&\[S P 'K&F_!)OQ4N; QK=*QIK-D.%9DL MF7G(F[5&F?:9AK+BEC2B3U-K!PS#>!.ED?
F)HJ,MKJ(+UCKG<,(1H@M"5Y2I MB'G5.HY8!-UREK^@0@GI!FY1)E+H)E!)YE"[5V:.E&$* M%)CC&L6YYHK&>] J M6+7<$!TR lQW5UI;9Z0 #95"$S084;(>6>V64VM!R^G1$^V2>S9J.9JT6T 5
M\)EW9_YB,(1-AT$5MDP(G,NAVNK<0O %TZIN"'I?O?YSN=L ?4Y3'>]^1PC1-M!=:,2!+@%3O)BH9=8FXB1V>1LZS7[7.ILPK]B*;N'[F)ZTE4M7U<_O.?'N5 M*DE^L\\U:_^RSC))RLZIO&
[(CEST86=1!6;]+)N8&@.5+*348U$@M@)GPH8L M?,6!V+8TAWD8F,&N1(4" CN99\RE2,+M%/G*>-344#Z14L9OP]!E&@(=3C$ MH\)VB]E[UC:OK3CA[:YS0\ZV(=&Y>'Y:)=1
<%74R2J.49.41ZI457V3.E#? MWZ43 5%SARQWI%M60"_9:'*2V0.Y&>G=:Z)S$ 'CY/8,$1UXR]U(7CHVN.YX M"BH"6T8##=U !VP#0(<3P4FRW%&M4*Q3BH*?*^//%3&*!U56.#T1-LB6/9P8
MID"7VSM%@\O}>?%*4"-AP'],TA]WV/:U:CV"$X SP0&7(0\"5R7E-E1U24&Y5[,8BAR O@E!2,Z6P:;#$ *)-\@=' M;!643]A.E#PEDL80]>E(L£$:)OWCCTMDG;HU*"!\Y -+8[>LR82GG3/!(I]'
M:,\9TK0'1>9HL\HZ"QG&YUQL,TZ*7V>14@L<4LGAO0.ZV9 C8W>I>TEH58N! M*X6;$9](6LOO9?FP//8_D9OS1907.G#QS(,+?D:[],[OO4N;_*`,537QD&T
M4N1K/OR9BB)*12">]J6\UIZ/]+_ 39MV67>PDFYBD!$)/ M?$]",)IF2,=,T-L@VDJ_/]>5DVVIX52@;&R)T!6L.CV8)QRV)!4%)PK\4T0=2KR$,'0>'=BH,3+'PO-T)*.:LF9HOX@/V5),\[)QS2\)~M,.ZW+
MV$SFGF#>ZKBG8GX7)NT>SP:.?25^2RXO^1QJR#CIA]$67>TS#4UZ8$P[!<_M[HMDX0BOM\LWRZ&\\V@K(84SBFSD>:7(B\/(G'@9D8I_"_^N N9KGG.1_:MH1&K]>FVIZG--+\ DR!D6/*
(2B3.2R'.LW.4X_!4(^>X0H@\H@OZ37&WN7=& MP1&!FVO1.TF"4#B#=>U.^D.VKMZX9(SC;.U'"]{5135\ZS&C]/S-IA LC5J M>GQ>P)VZ)$_Y0L])B9P&=9Q]"-A^+SW4'.W9_3
MC6&8\X%.YX5!{N.&B])SJD/D(X8?DZ@X\S DXW\N.YGC<,S(G M3YZ1,!X>.,N(OQF:F:AIGN@,Z4[,GH8RJ8)'C,T[R^SFK+.#=X<;[W9D UF1 MHCL3R1GZGTT]M*KE56\2N3YV43*T:**<)I
FD=#%GR,8\,#+8!;)A63)' ^676& M7[(]=`5HJ#H&OUS[_5A7SL.B<(?RCU6^./#R\0%Y27?;T(>D]B#T"0FS;Y(MDY[0)8"OK!6,1&CWSTDO>]{D]|;R&3S[\)3%S<^"+D289-FO-LZ-'[()8Y M/-
*Q)$5*UVU*360.I5VUH_VX1 P>U9T>1ZNB8.C^74!Z2T!Y1#*K,7D0F+5%*P1>\:,7L]*T2S?2H3O:KM>H M3],QX4(,OL>HW)>5YGAC+BAF2+.5F9GWG&.K9$A6?I0
MB,]*]F:],.*27(T@_,YE#1^:*N8@YV.9:/R_@CR;?TN^=3\3+U4E?5MXZP-=) MI4@++Z8Q-2LXOF:A!4?V@V8N0W=L\-BX]{IFCG3D\1BS(NF,K77VQ7ZQD.F>
M]KUI3>X,B^N

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
SO({HIPL>/.;$!!7>>W2Y^.+RT4=^?6Y,'],F M-ZCK.5@/_G(6X@=7YS'!YQ_'Y")P[WP-P$O'<^[C!*N/?/SO_O^/RV> MG]X?BVMEQEV7RZ\?)+\^6%X].'"6)[UTVU_(B>TV9[^VB.M8/,$+YZ\>1I& M"77RV*TXR6Z^#CK[[<[\G,EQ]?7GO& 2XFF/'M?]X\QA&OO?D\7HJ[*&@/?7LOB{HLM^]>C' , /L& 9 >&PO=V]R:W-
H9665TM5+'[S8D_WJ*D0//VIMW#*IO&^NT]3\"FOAQM2@84M)MA:>IW;7 MNL:B*'*HUFF>9;.36J5[9Q\.6-7"VJ]5&@8W%EQ;U\(^W*"F_3*9)/W"}[6K M?%A(5XM&[/ >_=_QO(L'5@*5;-
QB@Q8+)?)>G)],PO^T>$?A7MW.(:0R9;H M:YA\+))9)%@2A1ND#@^?#?=[Q%K0,1R_AVX$R&D %X/.[9W\?<.9>M<'A+^E]5 M<&]97"508"E:[3_1_@,>\KD,?)*TBU_8=[XY1Y2M\U0?
P#ROE>G^XL>A#D>.MJ^P7@/P R*/N+E!4^59XL5J8VH,.WLP6!C'5B&9QRH1-N?>6K8IQ?K6QU)## M-M,R6ZN<<']5:!DZ9@SV5!Y:,CB7_!1G
M&?]JS1BFV0CR+)^=X9L.>4XCW_0\^Q89]=9P@VY=HV0N$SX"CBTWS%9O7@€V M>9W-SVB<#1IGY]A_6^_YEND83A'!BV=7>3;=PT<#Z$8J'2L[@CT"&H^6O97Q M! (VK945'W00IH!
[H1'6.XO(.]'#A:N,P.N79?/.;S-$PF;_D,^PK^(_0*\?Q MY!@N#IAN;? +\8)$B_!HF;R9.ZBQ4%)X5E4B?T11]'!\%>+N_?HE-):*5GIH MR/[2M*(12+2>>Q#L&61?.=+MEI4?'%W.O:*.C.
(YY*4GN9RH6*]R#) 9L>FS-MY=!)!$[L^?0R&V49GU'7;K]PEPCI#)$\84O;RB* XX&W#ZY)&P(07^NW @:.M\2"'8G:1PE4@/$A-3IG=&&ZI;C3&7:2R8SBUPZSI2(D37,]2R!]6]-1=MU
M2#)%1++H1AY6Z>*]J F%%D>A@^P"B.31O1%!F<==R 8D91.LKLHQ%-SYU\.C MAE2CW<6VZSA@:WS7FX:5H;.ONX;VZ_X]"W?"[I1QH+%D:#9^.]6_P-02P,$% @ 3(4<67H*Q*3+ M"P *R(!D
!X,"]W.W&KSULS5IKC]NV$OTK.MQ#8H&D#U6K)EV=ED@!V2M7BX[ZLW+.S75T?GIR?NWRG]M) S$%5>+.,O M=BJK/KMN3M8)0M>M" /D^ET<;Z7NCJI?,ICU_;RJ6GJ4E?JV@K7I/?2WCY7
MI3D^_XO/NH&W>KNK:>#\NE!:M4[5?]RN+9X.N^5*\'JO*]=-):S:/#N[B\M3VD^3_A5JZ,+/@NR9&W.!WKXQGAV-B6%5*GRFB1(_+E1+U19DB"H\4;JRK+]_5LE9P"YW*V9
9Q(MZ8JMXY\;HJ5#$6< YM>Y633N7GR8,2 M?VBJB9A-(Y%,D_D#\F;]"V8L; ,/NUM)-P15D1BK=2&%O52VUN1R[HN,2S_:&2.F9T"A=FZB7B_4\,6 M.U4>\$2&U1'VK&J+?*7)-?
BP%H5V"@3A>$A5.UGE2E1.;1E%HC9>@MY#XHUJ M5<68+.L=KSF"G+Y=*V(@!(>> N\I[9H$%_ $RD-QK6&&@+MBMO:2]=U6IK.1:] M"[RQ+(6]T4?
&ZUSOK&FV.W(GQC(M^-^TW2A5AC*R+R%PHL&YJTRZ_48BKKJ35-HLG+LXK'RNBJP'7S. D5OP1\%*(S[<4FSKDQ6I81J1'7LK1$C:8&N+4>;:@K79 MP&.HMT8PX?.M!;T-!47+.>CK%<2,(P*U
Q(1/9_<,$2Z;B/1 ,(*2I4H5D[< MH$R1M&[1 >Y3MO+": ,LGXB?&RM,SQJLT\""JL1BV!BZ$;(V]K6*/*:?]'=!*>N;E=.,W,HZYW$&]@#&"@%2EQ7(-O*P:[! X!YNW
MGBB__FJ9Q,F%N/+A^H[#%8DW+31_Z[%)GKI6EMF3TN&ZU6B$7LE\UPF$ZH@Q M$"Q C(*G,.Y6()P\ 3VN"P1R%K6)_62\,6-M/-*KW#*.&U&,"SC&C5#F;;=-N MAI)%;1$?Y9[WM4B6UV(-
Z^O_%/#*@'ARYWF0_" XH=$(?.C8PY:?$[N>RO[M1;) :F.N(MKNFE ...M57+@(*.?&,12J87I"A_MC"\>3\2[@<\H1]KS'?0>$\O 6OI7]*QUJOX3/D-$ U G9U3HE\TVM=.X,W*%?P M
\$+26*VJH+8;HE'6BZ1-EBT\9V8SV;/TQ>\0V[R7!>?WZ&;.)[X!%4BC;^4> M^RT*N:?$I>G$>Z[65+7AZIP]^S6AG]1RL)=/[F.O M?P27W&AK*O9V&76^]E4 ?J;$+84!R@&OD3=_8;*S9"Z49:C
/NAO;YUO9%SY4PK)4.)h\;?A<.MGP5J8L4)73)CL.Y2_GF2]+"(ZU-0P5O[FNG4=N4XB^?F]N9-7%SD>F6S'] M'89JU0&F!E!>5N9&,..K!3 !-1C+*%2B0\')#"AF+=K]X'HTQK$B7'TR MVE<(+K+(8
7S?: SO85,AS06X1,9# M^5IO;IEQ@"Z"1^)N (\&O6%_RL%K;8>>@\MY=D$-I*]F\O=@BERY50;@<@/[;.N2HK8@,,.^X MN\+2UA7B_>U!<:,WG5W\;WJ?&\O^_('[U\\W",(']DZS;3^%K@"'AUGXD-SI
M"__J_G<:@FIXD9@GTVB5KH*1V3*+9O/1R*.TMGR4S6]GQDOYM$BBX?G(+(G2 MZ?Q$F3C.HGBUZ$O3\ .+*+..D?'UZMHM5]>)^N8QF22S>&V#M8%WYY)++{(IHO MDV!DD.9O/Z0Y'IEDT3=-
[6+5W_7P6+19!*.9)M$@7)RHED)W&R?VVY$U:9'#C MX(XLC6:!@L'P8C5OK1MTC:.IG,&|86!6618MEZ,1Z)!^ +*X>!P+?VYIT?6+$H"9,&D>7HJ8K&(5K/X.T26ZY 5 MW&/0W3(WD3E:
[HE06TL_$F&,FM<_N_DRY%!Z=' = M3E]##W0 0R_INNL%@F=W#X)'2]@JO;^1'DCT1A:.LT=C2V+HR[HNJ/LKO$Q M41M ;P06)%_C]_O8K_\POA!.?=?
K]XO_%\GG7^.G+ZQZ"8$R\^:'N@T$HD*.M]?-WZ8,M8O&"VK=:0 8KE'I4DA]A0K0(6 KICO(^ #>MB# **EUY9ND@7]9&G M 5DN3DM5&C!$^>)>OU//4PO_IH\L;@ORP9V#!=3<7/
MHY9E'NB1#KU!O)R=>'IPT@P4-PWF@NT&E\0HZ:MX6 TV 3?UK[^91_-L GAX MGD6S-.V>E .'B\8D:'M$NZ6SD^)3;EI'CE]DI3?^__GT ^G<@_U(AW]$>]A(7Z 5M*!>32+PT@ #]DR/H$H
MG12KK2;^E$0H,]?MTCU>3L3KQI^&/^L^R5NV(/%?=*$YHO3DKS!0U]?JR?\$0X> MEO2]AHWVP8_ %+58TE 5#*1@ 0\WM@:.+9)@VU#P_%+58TE 5#*1@ 0\WM@:.+9)@VU#P_%+58TE 5#*1@ 0\WM@:.+9)@VU#P_%

G5MK9}B.QFB"M=":B!4JP.1$+ZNO5Y)/ZW03H.QDOV)2D>`ONO_MGL4T&C0[_9!$D6K;.E6(>BT3),%>$6JF!+_:5"(=$GLMD+>V\)?T[*.5IR(_MZ/62G9$,"!EP5=F5JAE;=7!H ^7&NADT.3OG*?(5(I<_LKSHI0WTPZ 37-[T-M=21OT-LWBAIXB8?OU\Q3\M<3ZH[C-LK,/$5F(FI=ZO,OA)???%VI9A?3`'U-M$V# #RZN_5(3MP&>]5<5GP`P-XBMNZIQY."H59-<$GZ!0R)-@ "M-OK),C> M-%"W 90**99&=788[`4->@HLF/EHA7_ #"ALT_3Q2826)@LK&IFXN_6[7"."5G1X27D)H)-M%7'B:"(*6\),?
<;2$:I'=..1.1PI$5#%LLG+1>@`(AB:U4K2"5*\,!K5N%^,0(KB> M*`3)A+D4)?@FGX=]B!AI"UQWCY2'U=AYPAR*.+#.N_%QYIQ MH3I*:(=$[=9>.@PPY)BV"'32M*5,2"U'FK'Q7EAT%CDDB36?]L\60\ AQ17]_M4M-"OQ_^)'"'3#,HJ MSOV7"8;=-
0,_6"*5/18/&3>:.B).[*7G)65L_"1!TXKO?DIMU&0$YFL54<:)MP3?Z$>F/EHRC0T,O5H1?#DA43H,7<>9^&.6/=1N\558KU!),.G=4AI.]:X(A M(P."L\P<R:34LR?*L^IMP%,4.D3IU?P5:U 6(VP#KD%)P,>6^U2A4H;4E^ M$D<)GH)'D)&
[LA0(9]89BGJK>]UUQ1LPTH22PQ`V!=&Z/1M`-)8e\87Y6 MPL\@MZ CG4/>H&JE+555?"K&R:Y4[GQ@MZ>83=.1D3;:<]Q>NNLE?18K6'M.1&30#8-VF3ETJC_^.(#!N=XFX%=-[R.4QM>K4_ HQ-MGNP.*H&O+TWP3UP&O);&6G28]F "!%/IM,%+!*/#2BYX,Y,:`JTF
MGB3ZU%$-C@".2(S=N=<8RK5$#>.++\:0@_"O I4DTIPZK,O 7V. 81#'+`VA)3A)245#&%\\(5L M@:1-PP% R#ZT*E>7G')`NZK!?_IH=6`!0%A+U21YTHK=WI;>C\A6454GNIF<<<,V1;ZL¥)MTI.AZ M/#!; 5OQH!) <7=!KTUC0W5L931(?>IBU@A#*0
^W%]ZS)TOY5ZGK 0@=@.G,T42Q(@#*>>1HAT'4-YP7?IL.[$%A*B3 M'C4*U*$F,/:<CH[CIT,X&;&2>N5<6O+1>K0P8U43:?FSM1! E&:@&[C'.O M4.FV5HX.,T0',0C'UQ\N/K@W@$)*'<%0P50:81U:U-3J/HN@Y$I"
MN.OYJ:-`1\CHN\R$C=4J+4E%J8K(TDH,'U9s1800[%IB.54IT6IU-FO?9I MS(X?L\:FI+L:32Y5B5E.`:^-1D=&Q8I<4&'%S MG>G1IBFE#2V:.-&\GIJ855^3JLE<5*1N(@&uC\B(s>B?VCRN)R6 MA(PQG,WB7F&D3:R\9.C>4H.R.B_.GX>6)@,H.I&
K<1-6VIZ-HM]:CI$ M9 KO54<4=_W-'(-C>-2`1N<24K</B(.]0]'<62]=2.LIT^(:.'UVM\L|-`M5/3C2Y\&Y(WX=$*D_D+E[=!=\%%VF0=D@Y3X4-`.!_#]233Z$,)X>] M[.N%.0=%"[.3\?+%193;T9N\!FX4.T24BI9I1WBVBNVS:K<[!YUX%GN18Y M55:W-
*&:-3,$D/VIBZ:S^N`-W.MC&:.TA<6*8*:!DC5/%$'_.55TO!#'= RE7!I(^-'3!U.+HBCG(OS.S9_-6J) M&BL.IQN9P+OR"C^7Y<QXR'^P%\RMP'%;2/05#E&K0E@0#FRW2@1\94H6@!9H M..F8<^M$P9SARG^2LF@-
L60/W$<@^EZ5T3]T4K%*`Q!105T0.0D4N=]N!9#67 M:M!4M7#0.%76%$4F!H&P5B^5_/&W%]H4!3J.)-MY>R=,ANRU+YMUF>]V<M&E*L,%HC5E 2G>08B6$HU- +#1*3K%KDVP"O(A.=%45*PT<#E]E=0 +.A)1;T@)<.*%]9"""6EO+UBM*.4'4.Q
(%5G]!0<5^M;1%^.0W2 8 M&FD!.%)=8.V*.S!FPPRB"U6O'F?=8-T(C#\N]$H4$.X#!?<3G0-K%.Q)<5O"/+]G53D43+!49)>L@<'X MZC>2^A%B!"`GK8>T.KF$=3'8'+:+ *H1^&HIU9E=\KQI%$RB#GWF1Q',5Q M6:#8KW6I8&\"BK.&-'@C ,("AC\
^EOO[%)S"GFMC< @:#6C?IB>EW+}.2?5 M8]U"G.#*0LR=3\^%?!0!50D7Q.,t\@^@c@C18KACL%0+WB@.@5@C'!G!-$2.*6@4#^OC%04@"50_8+]5S(`M!UCH#D3Q<)QNC%04@"50_8+]5S(`M!UCH#D3Q<)QNC%04@"50_8+]5S(`M!UCH#D3Q<)QN

K45WY.1)K\0N/_$(KOYMR2TI.V,.)USXU/D$!!TA!,=!*%"B]K M$5UY.1)K\1H<>0WL_.W<9HR68B;F.!>=KB#S#,L9U<1OH*&)HUC!I\? . @4 M?-::NN)S)-;"%QWQ159\7\7*2JRAF$!6+D%.JPJDF+%G(%94.\SF57\N9KN* M9ZF)9Z3SC%6>>DP2#!67YK6!*QN
5YLZHR$4PT.%&<) I!0Y VB$ZM M974EZ$BL17!X)#BT$KQ[CXOUIRE(:<5%7UQG8IC,_GUUA!SJ3S1"ZB.M!X4H M48=(:UE="3H2:Q&$?K/B]ZT,'TKA* 4UL9HY/+Z /*4K7"Z)<>'NZU-(&*O+ M&OLUNZX?G:K-7*FU>9\X+&CE/1%#9G8".RLY$=?
A@KJP^Y49.M0[Y0"JS[[] MPIVANU2;N5)K0V\L%+3:@O$WOB+,2!:9QH10):M'J6$ U7'57D1G9&_A=&!C M=:#=ZQALYP58,C'K&SD&>@_U8S100>IA*(QC=8JWE]89Y%M8'MAX'F@W/3]P MOL'[;; \ISMNE<)AF&@3M>&,(1@HCV:3DV-*[4VW<;6P.C\':&3 M5:-
Q6PBZ]!\3IVI3IVHS5VKM5FG<$;3;HULFS1%_O@#K')>\WB@EOS;96MKW M^DQ,]6)9E3WFY/!,&-M+-T'] 4J0VN\-81%*(K7?.W5+KM3:A!N_!+L9IKMO M#S:0NA?J1V&H[B@9PU#BJR"=FB97:FV0C6V"=M_4=P6],%K*;K*^T[#]60\++1C*7;USJ*?("B)E1 MCB
ED5^O,6>O[_DAW8WUQ5BA+AKLU77>SG=JQURIM5NFL6/(;L=>=09(]UQ] ML8!2QV%36 R5J*F]B,[(WL),H9/W478S]9URG!N1&6P2\K4-YHDI#@H_J^[C MV^OH3.TM_!1J_!2R^RFY>SK7EL5&C/I+(9C$OFI*#6'1X;> MR8MJ^3N$OS%;9F4E9O>%D/$Z8#!#?
M+RCE+R?R=?CQ!Q;C_P!02P,$% @ 3(4<64I-W!AO @ 6P8 !H !X M;"]W;W)KS: M7*0)KQ4E#.8"R;HLL?AS!Y1O)X[O[!<>R+I09L%-DPJO80'JJ9H+';D=2TY* M8))PA@2L)LXG?SP=FGR;\)/ 5A[,D7&RY/S9!/?YQ/&,(*"0*<.];"!*5!J MB+2,WRVGTQUI@(?S/?
MGZUU[66()4TY_D5P5$^?&03FL<$W5]]^@=:/%9AQ M*NT7;=MO ((6$)P+"%M :(TVRJRM&58X M303?(F&R-9N9V-I8M'9#F+G%A1)ZEVB<2N]9QDM CW@'$EVC&:Q ",C;!;U+ MZUR'A*$I9Y)3DF.EXSM,,%K,T.7%%;HPH,>"UQ*S M7":NTFK-F6[6*KMKE
6O*/M:LP$*O0\H\(*H!SX]'QX>PUU=HZY005>HP/*% M9Q2JSTR#COK1YBV.984SF#CZL4D0&W#2]^_\D?>QS]I_(CLR&G9&P[?8TQ^J M (&PE/IB^XPVZ*%%FQZQ2?W;,/83=W/HX&763>S_2SI2%G7*HC.448*7A!)% M^N^AH8@/#KX>C>(3=3U)?NQ'_?
&G;SAF_*^ZYZ;[]^/PKNFAGT:AR]+>!-[MT8G(EUFCV]OX1-[\/1-V_V&Q9HPB2BL-,P;Q!HOFE;6!(I7MALLN=*]Q4X+ MW?U!F 2]O^)<[0/38+K_2?H74$L#!!0 ($R%'%D_$5VTS (#4(: M >&PO=V]R:W-H965T,8AH) IPX#U M9P&W0*DATF[\;3F=[D@#W!ROV7];
[5K+%$NXY?0/R54Q=BX=E,,,UU0]\N4O M:/4,#%_&J;2_:-G8#CT'9;54O&S!VH.2L.:+5VT<-@!^O <0M(!@&Q#M 80M M(#P6$+6 R$:FD6+CD&*%DY'@2R2,M68S QM,B];R"3-I?U)"[Q*-4\D=RW@) MZ!FO0*)S]
(HC6U";JB^$9AE@$Y34)A0>:;W7YY2='IRADX08>BYX+7$+)1?0A>U 4O.L2>3#"U%Q(S M5($@/.^+8\,WL'RF4"Z28'!U.7(7F_'I,8K]+:-TUR@<>E>=T0<]@T[/X*"> MTPDPF!%UABK!%\167%WP]1.T;U>9M]NGJF$=;OAR[H>^MR6KQRK8LDG[F+PK
MOU]6W,F*CTT3L/QP@N*=L/K!Y7:"=HUVLYCV&&UFL5'B;A34$L3<-B:),EXS MU92D;K7K?3>VY&^M3W1/;%K8.TW34.^QT%=3(@HS3>E=#+5+HFE2S43QRI;M M*5>Z"=AAH?LZ"&.@]V>&ULM95M;YLP$,>_ MRHE54R=UA9 'DHX@]4'36NVA:MKMM0.7X-
78S#8A_?:S#479FD35NKX!/]W_ M?F??V7$MY+W*$36L"\;5U,NU+D]\7Z4Y%D0=BQ*YF5D(61!MNG+IJU(BR9Q1 MP?PP"$9^02CWDMB-7)BZEWVCLYF]CU;L%WBK7::(.-9"[$O>U<9E,O ML$#
(,-56@9C?"L^1,2MD,'ZUFE[GTAINMA_5/[K832QSHO!7/!4%PBU9HX+W M\-6DP;<2)=&4+^&S4 K.B90/8+:@)C)3<'B!FE"FWL$!4 ZWN:@4X9F*?6UP MK*B?MJ[/&M?A#M=7%3^&?G $81 .X&YV 8<'[_Z4\4TT74AA%U+H= <[=&>: M: 3#9/A3PN"JDE1EU&7!-
LJ]:K8H3E1)4IQZ)NL5RA5ZR=LWO5'P80]KOV/M M._7^,[9_&UO_%=@&'=M@[S[:7!!=+C";"ZG+A46;"]N &\FAD[07PBKI1>$P MB/W5%I)A1S)\&H8H[V,IH#-#<5MJL%H7,AJ7[8YGROS#^FW+B#'+^H',:O MP#;IV";_OQPF3\MA%
;COX[2W[B_[5/XA<@EY0H8+HQ=?3-VDA0-HUI2(C']ME-;AL+QPZVTY9_/]M)0PMI1K7T0^/7.?>> MF^N;.UYQ\203 (76*65RXB1*9>>N*Z,$4BS/> 9,[\RY2+'24[%P928 QQ:4 M4C?PO+Z;8L*<<&S7;D4XYKFBA,&M0#)/4RQ>+H'RU<3QG,8CH! I0X'U8PE3H-
0P:3^>2U*GLFF V^,-^W*IR58>Y 25CSQN@S$%L#0[P$$ M)2!X"^CN 71*0,<*+3RSLJZPPN%8\!42YK1F,P,;&XO6:@@SK_%>";U+-$Z% MURSB*: 'O :)3M$=9%@)@FV(CZ] 84+EB=YXO+]"QT^RL!?LL><'Z(8SE4CTC<40[Q*XVOE*0,!1%]0 MX
6]&H>F'X=W&]SI5 'M6+[.'KXBDAE^P3,*=?$IX-UZN+FUYS+#$4P=/?M_[6J>M);(=I=U*;,>)/?Q%\(Q0HE[F=:9808P41RH!!.M,7U(] M%]O9Q.8(L""$;:H3:)&RX<&J2#K63)3UI9A, R&8W=9([Y7B>\U MBMXWYO44RP3I.X\B,X#GG"PQ
M!::D790)%^I4O]U4O^0E2)6:K;J]-L,2$MD.P$95 $9-&9 6P%IM')H0 ;O M4MWW_>'(JT_V825U^,]DURI5G?N-R$/=;XEL1^2H$CGZO\(]:E-I2V0[2GWO M]:/O?:AZ;4KP:Z5^^TDNO^G>N[P:>OI7I54AJMGJH:K&PO=V]R:W-H965TJPK*E9.*65SY;HB*Z'&XI(U0-
6='>,UENJ2%ZYH..# MXM:84"==FKT;GBY9*RM"X88CT=8UYO^NH6+[E>,[3QNWI"BEWG#398,+N -Y MW]QP=>4.+#FI@0K"*.P6SGO_*O-0N,-X&\">W&P1MK)EK'O^N)COG(\+0@J MR*1FP.KO :ZAJC21DO%/S^D,C]2!A^LG]@_&N_*RQ0*N6?6-Y+)<.7,'Y;##
M;25OV?XOZ/W$FB]CE3"_:-]C/0=EK9"L[H.5@IK0[A_]GDX"/"3$P%!'Q", M Z(3 6$?$#XW(.H#(I.9SHK)PP9+G"XYVR.NT8I-+TPR3;2R3Z@N^YWDZBY1 M<3+]2#-6 _J*T&@"_0G9T*@>\HA8P4E_T&N;Z$U4-@1*="MVJ<9J0@V57NU M
8E))5ZKT/N[#7KU\C5ZB0A%7TO6"DQSL72E4JF?Y6:]HG6G*#BAR _0%T9E M*=![FD-^3. J>X/'X,GC.CC+^*FEERCTWJ# "R*+H.OGAX>6\,WSPX,S;L*A M8J'A"T_P'9= (+9#L@2TA8)02FB!5-H1T-PL:]92:3"%J6Q[6%FI*KOM*VNK M4ZA*-#B#E;,:C@#^ $[ZQPL_\=
[:PH_]&0_^@<>WI_M*H47/TN@\MT)RRWI;6CCPV][LH/Z2**%DOWX3!=4]!L'@;'H,T4%(>^/X". M[,6#O?BL/7W<&R:(.=]9B6D!XB)K.0V9]B_$4X)GT^?&?BC]^S: HJ3 M<3FLH,0N?C&(7_S/!J*Z]OG6L9@<>-^?)V-G4]2TP6RFH*,&TSES#P:+&GAA
M!C2!,OU5Z;Z_P^XP [XSH\]H?ZUFPVZ4^TG3#99?,%==4Z *=HK2NYPI2;P; MUKH+R1HSOFR95,.0699JO@6N >K^CC'Y=*$?,$S,Z0]02P,$% @ 3(4< M66U%..;4 @ *0D !H !X;"]W;W)KS,-M#MU^\Z23,>*6)3 MOX#MG'-\[[G.=?
H,J1[U$L"0IYP+/7"6QA37KJNS)>147\H"!#Z92Y53@U.U M<'6A@,Y*4L[=P/,Z;DZ9<))^N39625^N#&<"QHKH59Y3]>L&N-P,'-]Y7KAC MBZ6Q"V[2+^@"[L%,BK'"F=NHS%@.0C,IB(+YP/GH7X]BBR\!WQEL]-:8V$RF M4C[:R>ULX'@V(."0&:M \6\-0^#<"F$8/VM-
I]G2$K?'S^J?RMPQERG5,)3\ M!YN9Y<#I.60&<[KBYDYN/D.=3QE@)KDN?\FFQGH.R5;:R+PF8P0Y$]4_?:I] MV"+XT0N$H"8$]Q+"FA">2HAJ0G0J(:X)9>INE7MI7$H-3?I*;HBR:%2S@]+] MDHU^,6'/R;U1^)0ASR2W(I,YD ?Z!)J\)U\9G3+.#,/9'7!J8$8>))F(#)3!
M4V>!9"PULU76Y#P%7.7Z JF3^Y2J(;JJ(M@AMA"3T^G!RWTT>ET?Y?N8F6:\@1->8)2+SRA M/&U65NRHG6U[S+4N: 8#!YN(!K4&)WG[QN]X']J,?4VQ]#7%1J\DME."L"E! M>$P]F0@%F5P(]AO?!8/"?PH"YLRTUJ.2BDLIVZ+7B>_W.G@2UMM&'Z*NHNAJ
M%Y0>@KJ],-@%C0Y!<>C_W6XGX:A).#J:*TP@#8:@N\OP?N(WD,#T%7O3U#TD-,%'3W4CT:]'^>@;BQ)#YJR8,TE!.^U1Q5W1R-)*NF M.=K343PWQS;#XL/C$<:QM^=8"\J+PCU4>HCJ!?&>^:.C:?VK:>[6-6,_(KY1
MM6!X"W"8H[QWV<7=5'4Q5Q,CB_+FF4J#]U@Y7.*W#"@+P.=S*XT.RDNI9EP"&K"LN]-@KC:FO?%_G M)514G\H:!*[,I:JHP:E:^+I60 L'JK@?!L&Y7U$FO#1QL:E*$]D8S@1,%=%- M55'U>P)R-L$'MBB-#;@ITE-%S #\UA/%<[\GJ5@%0C-I" *YF/O>G25 MQ3;?)?Q@L-
);8V([>9+RV4[NBK$7V T!A]Q8!HJO)=P YY8(M_&KX_3ZDA:X M/=ZPW[K>L9FP!1B=[P"$'2!\#=A5(>H T:& N ,XJ?VV%:=#1@U- M$R571-EL9+,#)Z9#8_M,V&.?&86K#'$FO1.YK(!\IVO0Y"-Y%#DH@U^+C9"I MU,R>CB;'&6"4ZQ.;,\O(\=$).2(VK92-
IJ+0B6]P.Y;4S[O2D[9TN*/T*"3W M4IA2DR^B@.(E@8]]],V$FV8FX5[&;XTX)5'P@81!&]LZ.9P>#0 SPZ'AWNZ MB?JCB1Q?M/-H#"C0AJ"\!*\YY8;A(<$:QQJ&]&[YXF$^:R!7NJ8YC#UT" UJ M"5[Z_MWH//@\I-5;DF5O1/9"Q[C7,=['GCY +A>"_8$"/]A]DI)CYF[#R9"V
M;8TS5\-ZZ3*]B(/$7VY+]G_.V>6GESG9$$^?TO;G;UWG"M3"V:(FN6R$:2]# M'^V=]]H9SJOX!!VY-=!_-*V=WU.U8'BO.VT\.]W=M+0CA"A#>U+XI=[GKOGSO%E MM)'J3N< AMP77.BQEQNS.O-
]G>904'TB5R!P9R%500U.U=+7*P4TVH94XU3"3_R3*3C[U3CV2PH"4W M-W+S"6H]D>5+)=?N23:U;>"1M-1&%C48(RB8J-[TOL[##B".GP&$-2!*:!? M_I.:!69DW5)#4U&2FZ(LM;(9@ F&,JZ/<.=V=DD.#X[(6&"?,]EJ1&O
M1[[!]"RWGI817%01A,]$T!N2:W2:_250;9/X*.<1E.XU701=C)^*<4)Z0?' M) S"04M DY?#^QWA])L4]QU?_QF^O12VY.>"#]KA]C,^TRN:PMC#[U2#6H.7 MO'W3BX,/;=I>B6Q/Z:!1.NAB3Z;TH3I)>+L0V#LYG-$YX\S@J6I+0<4;.5Y[
M\:R3*.B]'_GK76F=SO]26M1(B_ZMB-%K%O&5R/:4QHW2N+.(YVFJ2JQ82PVE MUB3=O2#:A_*>4@/ W_*.53H],HB!JCO<'"3>##SL#WKZJO-MC'V^SAF,P, M-6!WB5R0*R8H2D##]=3,=I0V+=T.OYD9 1N,?9WVD,YM)@:W/#'"\^0%D#W%](:;83ZZ#YG4E^ U!+
P04 M " !,A1Q9JJ@1-"$" #:! &@ 'AL+W=O&ULG53;BMLP$/T5X4)I81M?VR+U<65)O'N MWU>2'6*V3STQ=9A:370TH,$#Y,H6H2",AGDJ?=M=9ZJ W(F8:N).0A!]-[F061$P0<"G0,U/Z.L '.'9&5\6?@#,:2#GB^/K%_];W;7O;4P$;Q
MWZS$)@L^!Z2$BAXX/JKN&PS]S!U?H;CQ7]+UN;*!\GY,%6; RYER64_Q*$MI>QH>34T#JYROCC("=D&MV0 M)$IF5_BFXP9-/=_T?S;H4L,]W>PRG9NQI6EI 5E@A\B /D*0OW\7+Z(O5\3. M1K&S:^SYZ_'L04+%T-P0!"TNZ;S.%,^)\ =S255X=M\$Z-I/E2&%.DCLK][H
M'0=WU=_7U_1^ZA^HKIDTA$-EH='D=AX0W4]2;Z!J_>W=*[2SX)>-?7Q NP0; MKY3"D^$*C,]9_A=02P,$% @ 3(4<6<3(A404 @ I 0 !H !X;"]W M;W)KQR_<)OSATYF1-G).=4B\N^%ZD0>@$@8#<.@:&KP.L00A'A#+^#)S! M6-(!3]='J]_>.WK9,0-
K)7[SPE9I\"D@!>Q9*^RCZK[!X.?6\>5*&/\D79]J MC\EY:ZRJ!S JJ+GLW^QUN(<30!2= 40#(/*Z^T)>Y0.S+$NTZHAVVAHM!6-MB+/NSC#.R5[2EW/$D^SN(%8FH;ED ;8\0;T 8+L_;OY7?CY M@L;%J"%QB3U[4I8)TAR5JIW@)7.M.JFTY[KU7&
[2#AG.79C0PX2">%007U2 ME[Z8JA7_3RUZTG1N?G\R77)IB( ]PL+9/>)U/Q-]8%7C^W"G+':U7U;X&P'M M$O!\KY0]!JZUQQ]3]A=02P,$% @ 3(4<6>#ZGM&P @ R D !H !X M;"]W;W)KV"THXTX< MV;$;&4=BHW/&X482M2D**I\N(1?
5S/&=YX%;MLZT&7#CJ*1K6(*^*V\D]MS6 M)64%<,4$)Q)6,^>3?S&?FOEVP@\&E=H$T-R+\2#Z5RG,\ZI@KG(?J)49S-GZI 45G23ZUM174'# M,S)^BOZ,(D^78"F+%=G^'Q.548^X\J3*TC7C*]Q[&ZY(*Y;^7!OMS%G+2)"=K$ M!-9O^(+?-=
<@06ER2S60947++J2#'F8'7JB2)C!S<(LID%MPXO?O_+'WL0NP M)[,]W+#%#:U[^'H=='&&?7+V9+;'.6PYAP>7]0_G.>'"%#B6.RW$ANLN[MIL M9,W,'^(V#CWSB=SM+M'!=_XCT:@E&AU9J.<$-\-3QT:HF0[:';N6/9GMD8]; M\O'_U.RX3\Z>S/8X)RWGI,^:/6AV+/?
DM0VP1S1MB:9O)EJQ1TCQ[&BJ6)HJ M/J6*4%*"3(#KLR[(@_['0M9FOK=#Z0WP&N3_1>GNG+/FCO.-2CP$%4'>T*.W1>R\T'N2VF>%5"Z29@,]70NCGCCG-V\M;_!M02P,$% M @ 3(4<65<6+^R1 P @A$!H !X;"]W;W)K5;O'9Q=N@C5C,]M).FD_M?
C:A)#3$65;V)6#P/=QS[\$Y9K@4\H?* #2ZRQE7(R_3NCCU?95DD!-U) K@ MYLY4R)QH,Y0S7Q422%H&Y

=B[OW!-9YFV%_SQL" SN ']M;B29N37*"G-@2LJ.)(P'7EG^'2"!S:@ MG/&-PE)MG"-+Y5:('W;P+AUY@I(]JI"; 3@>$= 6 6$?QL050%1272564GK@F@R'DJQ1-+.-FCV MI*Q-&6W84&[;>*.EN4M-G!Y?@*0+8DNIT"MT3ACA":";4D$?1$+*6C^_$TH M4R_E
E1&;HTW4=O(9U1/C/7OMYZ;LM2U">O:A"5>O //Z,2H@*,W M=TE&^ S0Y*6HXV7$\B^BJ>J(F,//.N*9 +\,;/GN!^\+J-94=@#CB8&T'@O^[_E?X'16C*[1F M-3;,$7[T$EE!;,H.1[CW<*5OF1;&8:_?KD^\]BC8;5*V%7K ,NG&/KA9_\.X
MX+5SP6[KLF\%P9U:DZ[0FF37Y@2[WLMONHU65\;9XXR#".U2YMA;8[2T< MJOPD>+)?F$[X@WO5$5JS&&LW@_N/$V:G;J4KM";9M5_!3I>PGVRGCJ5":\@\ M",/>_WZ&QMD^W7B(Y%FZZH0@ZF)"XX&!D"N-ORK@19%N6>^%=KLP,O3#$@*
MTDXP]Z="Z/N!W8;7GUW&?P!02P,$% @ 3(4<62_CZRW5 @ ?PL !H M !X;"]W;W)K)ZA/3= ME,;,"0/[[Z 5^I)&9X)T"NTI2*GY>8\'SH=)S-@TF\C)1YX(9!1I9PBDS%G(' Q="XZYZ,.,0%VQ[<8<[DU!H/RP/FCF=S,APXQ&6&"
M,V4DJ/Y;XPB3Q"CI/'Z4HD[U3A.X/=ZH7UEX#?-)8YX\CV>JVCHG#HPQP5= M)6K"\VLL@7I&;\83:7\A+_<2!V8KJ7A:!NL,TI@5__2I+,160,??$^"5 =Z_ M!OAE@&]!B\PLUI@J&@:"YR#,;JUF!K8V-EK3Q,P%T]'U$9P97V 5SC?!FS M)4P.(&;P->(K2=E<'D-]'KA*9VS>Z\
[*["Z+[+P]V=U/QW!X<+0C<-0<>#FY MAENGNDM%NT%QA\>)I%E"T1OF36@+_@EK/E+J9&/7,O MSV5&9SAT],63*-;HA&_?=/KD_2[.EL1JZ'Z%[EMU_^_FV,7IM\G9DEB-LUMQ M=AN/^)GS&-CF"E![!79Q%V(]*V8^D^O0)UT_<-?;/,6FSCZ#ZJOB]PDA#=GW
MJNQ[_VG0:<3%3H)&P9>>7$MB-?9^Q=Y_C4/[;7*V)%;C'%2<@S8=6H@-FATZ M>+5#3ZOL3QNSOV$*=4T43*A"F.8TVY5TH\9+#ZLEL1KN685[]AI3GK7)V9)8 MC;-#GIL'TJ8M2[7ZEY-8C]6&PO=V]R:W-H965TK,-M!8Z9IAQ8)DW3XS%FT)E41/I.,,V(\?
*P^/ISAQO:/&-Q81P\)*E.9L8,>>K:]-D\YADF%W1%;BL5B:;%40')5*66HBR_+,#">Y,1V7[^Z+Z9BN>9KDY+X ;)UEN/CW MAJ1T,S&@L7WQD"QC+E^8T_$*+\DCX5]7]X5X,AN4*,E(SA*:@X(L)L9'>!TB M)!5*B;\2LF$[]T"Z\D3I-_EP%TT,2\Z(I&3.)006EV#PQ @-
$9('7*7^@F\^D=LB5>'..LO(7;&I9 MRP#S->,TJY7%#+(DKZ[XI29B1\%S7E% M0(Z5,&N%>R> GQ-P:D5G)*9RI62 MAQ!S/!T7=_,**2W0Y$U)9JDMW$]RN>Z/O!"CB=#CTY 4R3.6W#-P"6X7"[$> M#- %V!TX"PG'2_O3 J8D HR+BTA17(:S2)0%EIE&ACFG'*=@3EDY
MM*0T8D#H12JB*X-N:5 FT>>I;SENX(_-YUT*]\4\?^2YJ"L6*L1<+_!@(J9Q MVVW<=O6Y+7*NT%]>@"7)Q6 *Q/X%.!*Y)6&*",.D!?Q76'JR*NFXN^X@-R1 M[_<)48@ASQY9/4(48I;G0$=-B-<0X@T2\/?,P<&VO MYXM"RK41[+FBD(*!
[ZH]\1M/_%/2@*\S#>@$"S6!=4@+&M*"P>4_N\OG-"/G MV^47!J$1[&W[M2P2]X)5M/VK<' VZ*0H?4=;DX/9E'N-\2< ?*[G55M:*$NM"YS.W4C_/Y[K+:QNWWLH/>)F"F$D-__C@S/]E@V M4,L&.F8K@O_#+,8?!+M%?A,HJ7X\"IY&$1_=YSI1 MUH769;%(=#+46
MPEK10EUH7>;:6A@.%\-O[%!5R7Z05W*[(=; M#(2_-YLY!2T:*97E@ MQ41,K7->'50T;YM#L8_E45#O_0V\#JNCK1:F.FG[@@N1+!E(R4) 6E>^"*2B M.KRJ'CA=E<&UL MM5113]PP#/XK5HTYM+XV(HV[)+V#:3]^3EJJ MF\2QI[VTMF-__NS8R39D'FR-
Z."Q4=K.H]JY]C2.;5%C(^P1M:CY9$6F$8Y5 M4\6V-2C*$-2H.$V2D[@14D=Y%FPW)L^H$.=9*RIG4U.SV?>/SA\E[BQ6S+X2NZ) M'KQR7?8B@Q)7HE+NES14.]1Q[O(*4#5_8#+Y)!$5G'35#,#-HI.[_XG'HPU9 MFNX(2(>-
/#N$P66"^%$GAG:@/'>C.:%4&J(9G)2^TM9.L.GDN-P![(#5\JZFS0I].21NV 5CP[:Y;(/+U4:$_E.%#Q3\DZ/YQ, M9FD6K[%*XY+CMXS@.DWL5<U;\0HW/8?X'4$L#!!0 ($R%'%FO-O0&$, /,, : >&PO M=V]R:W-H965TRS26\;B\3.;*VR#C@69&4)K;G.'T[Q81:X:B8
MN^7AB.4R(11N.1)YFF+^? $)6XTMU]I,W)%%+/6$'8XRO(IR/OLEJN17:/, M2 I4$$81A_G8.G?/)JZG$XJ(!P(KT;A'6LHC8T]Z<#T;6XYF! E$4D-@=5G" M!))$(RD>?RM0JWZF3FS>;]"O"O%*S",6,&')'S*3\=@:6F@&MJEC'0E$N)$NK9,4@);2\XG6U$8T$-
]B2X%4)WKX)?I7@%T)+ M9H6L2RQQ..)LA;B.5FCZIMB;(ENI(527<2JY6B4J3X97F'#T@),@L0D$4(-_Y@CS'"SK2)_NG^^UT6VU&O2->O2->@>>_OR.U[BY1 M)4K0C:+?OC.1X0C&EGJ]!/ E6.'G3V[?^=HET1!82[!?"_9WH8?3F"%Y+(&G MJI!+$+)P0)?
D$J=7X.C_AV48!([CC.QE4TM'E-.,:I$,:I+!3I(_80D)1U1VYTWJ$D.]G"> MA_XA=6ZH4X&B;^LHQG0!Z%>FCZ(NOCLA/UHB0V M]<-:_="()X[LZ=;K#<\[S7.ZA>=NN(\6SA1:6WRCEW&-F+6",27: M$%I;]$N[XNYL#DP9MGI*\]AV?;?GOC)M1Y@7>+W^*]_:C8Y4?
P[<8+X@5* $ MYBK/.1DH %YVV.5 LJQH4A^95"UO<1NKKQ+@.D"MSQF3FX'N>^OOG/_4$L# M!!0 ($R%'%FR.74+A (/D% : >&PO=V]R:W-H965TSCWO-[=_C2E=(O5"$:>*V%I$E0&=.XI" MK2;!*%@'[OFB,BX09FG#%OB
YJFYTW87#BP%KU$25Q(TEI/@8G0^&[M\G_#, M<44;:W!.YDJ]N,U-,0DB)P@%YL8Q,/M:X@R%<$16QJ^>,QB.=,#-]9K]RGNW M7N:,<*;$3UZ8:A)\":# DK7"W*O5-?9^3AU?K@3Y)ZSZW"B O"6CZAYL%=1< M=F_VVM=A S ZVP&(>T#\'C#> 4AZ0.*-
=LJ\K4MF6)9JM0+MLBV;6_C:>+1U MPZ7KXH/1]BNW.)-=.;[AF8D6X189M1IMBPS!)[@@0KOHHP78FM]CWFK-Y0*F MC#@=PY-4+YD!]^L8G*!Y,ID*H32=67INZ)*'_F!2Q20 /-=V5;! M[H#Q]@/<,#BGAN4X">QM=SW#(/OX8706?=WF_C^1O:G%>*C%>!][]JB9I!
(U MP1S-"E&"<.;M[[;?,=XZAG=X%IF41HN-QWMR^ADAANWJ$:]\,.%(%>M--V/ M-42'^77AK^V[^-3.M6X,_;7IAN(MTPLNR1HJ+65T\MGJT=V@Z39&-?ZNSI6Q M-]\O*SN;4;L$^[U4RJPW[H!AVF=_%!+ P4 " !,A1Q96?'@EYH" ## M!@ &@
'AL+W=O&ULK57O;YLP$/U73JR: M6JDK!))NZ@A2DZY:IT:J^FN?#1S!JK&9;4+WW\\VA*95DNY@#OP3[?._YW5UX MQ*V03ZI$U/<,:ZF7JEU?>;[*BNQ(NI$U,C-22%D1;39RJ6O:HDD=Z"*^6$0 MG/H5H=Q+8A>[D4DL<HQQL)JJDJ(O_.D(EVZHV\=>"6+DMM
WX2UV2)=Z@? MZAMI=O[DM,*N:*"@\1BZIV/SN83F^\2'BFV.F,-MI)4B">[NLU^ZVDTM*5$X%^PWS74Y];YYD&-!&J9O M1?L3^WJ^#QN T>D.0-@#PK> \0Y MU ,B5VBGS)5U031)8BE:D#;;L-F%ZXU#FVHHMU.\T]*<4H/3R26A$AX):Q 6
M2%0CT8Q(*_@^UY2DE%%-4:V/&Z.'N @X/CN *(?[4C2*\%S%OC;RK0@_ZZ7..JGA#JFC$!:" MZU+!#YYC_IK -W4/Q8?KXF?A7L?9?#3^!*#B&, C'6P3-_Q\>[9$3#;.('%^T M@V]>$KXTW39MTB5"84>S1K.MC=TMX^VW6%LX4S7)<.J9 M]]X.#KWD\Z?
1:?![6PL^B.Q50\9#0\;[V)-[2;@J4"I(4;>(')CM@/G/O=.! MCG;B:*V/K9(@]E>;9>W+>*5U,FB=[-7Z4<.;O"M]7T8GW=_P@PKETMFD@DPT M7'=OQQ =G/C<&=";^,PX=&>H+S2=O2^(7%*NS$ *0QF9W4:+VKE. M*K3Q,+KVQ%PS?K>0?4$L#!!0 ($R%'%F78'T 50(
M 'X& : >&PO=V]R:W-H965T>@+^!R?[SL7 MFX]9)^2#*@$T>JP95W-<:MU;"5%9"355(]$ -SM;(6NJC2D+HAH)-'>@FI$P M"":DIA7'R)K&-MX%_*R@4P=K9#O9"/%@C=M\C@-;$##(MM&6@YK6#)3!FB4P9OWM./*2TP,/UGOVSZ]WTLJ$*EH+]JG)=SO$'C'+8TI;I
M>]%]A;Z?*\N7":;<$W4^=A)@E+5*B[H'FPKJBOLW?>SG< 83TX PAX0/@?$ M)P!1#X@N!<0]P(V:^%;<'%*J:3*3HD/21ALVNW##=&C3?L7ML:^U-+N5P>ED MT2KC40JMH3"GJ15ZC[X !TD9NN7^6MGS>9."IA53;\V^\J$SHDT!EH9D?;*%
M3Q:>2#8.T9W@NE3H$\\A?TI 3.5#^>&^_$5XEO%;RTD.:FPN& '0M63'>,5EJK+]ZXX<((S ZI*%WH>U,&,;OEJP6I8% M)1L.1%U5F/^W)B4[+AW?>1CX5NQSJ0?*]V1+Y(_#AJN>V[%D146H*!@% MG.R6SI5_F?B!!IB(GP4YBI,VT%)N&?NE.W]G2\?
3*R(E2:6FP.KKCER3LM1, M:AW_MJ1.-Z<&GK8?V\RXI686RS(-2O_*3*9+YV9 S*RPW4IO['C9](*BC1? MRDIA/L&QB461]):2%:U8+6"JJ#--[YOC3@!^.@9 &P!< @(GP$$+2!X*2!L M :%QH%B?$BPQ*L%9T? =;1BTPUCID$K^075^[Z57#TM%$ZNUK50(T* +=FK
M[90"? 1?U7';XI((\"XA$A>E>*]&?VP3\.[M>_ 6%!1\SUDM,,W$PI5J%9K+ M3=L9U\V,\)D9?0AN&)6Y)]H1K(^@:N6WVF #QK6<)+Q2TTO0.!] -"#XTJ')/A-V^3++%$UK-NWEDW/S]= MYC8MLTF66"+K6>9[CQ>3#\9SQ M3ZYY_J2*#>&F2* I
1O.LCJ5XX(F:5Y[#*RR);;8^A;"1POA^=G38FWY9I,M ML<76]^WQ/NM/WOU^XUOPY#Z%XB@(A_GS-$Q%#7^8DM$P-\'V>.>U$L5X7M3 M=PJ0LIK*INSH1KO:]LI4=(/QM:YY31WV2-,4S#>8[PLJ0$EVBM*[B-6:>%.# M-AW)#J8JNV52U7BFF:NZG7 =H)
[O&),/'3U!]T_ZG]02P,$% @ 3(4< M66Y18^2V P 7!0 !H !X;"]W;W)KD>D((G4"*S>'L@U*0I-4OOXKX4ZW7?JQ./K M1_K[NGA5S$T6Y)H5_^:IS!;.U $IV>"JD%_8_@-I"YIH7L(*4;^"?1OK.2"I MA&1EFZQV4.:T><<_6B&.$E2AY@34)J!A0G BP6\3_. =BHAZA M),?-P=
47)6,R_QGL_Z)A+GA7BC(N]N8_#ZU1OP"N04?,U8)52XF+M2[4SS MW:3=Q:K9!3JQ"XC #:,R$^!OFI*T#W!525U=Z+&N%1%6E?JSH!?"]MP!Y*#!L MZ/KYZ;XA/7Y^.AJIQN]].R:]Y_@G>DQ/!1R=BDKO!!6:<_BVY%#NF',)K.W8=C?0Q1
M@0=1/RHV1*'(FW11O8HF7463T8H^[PA7NZ?;SK^F,D89YSX--F&Q)5A/N[#3 M+K1KJM"FC#9AL2583\:HDS&R:ZH&%_7LXGNS@:D,40CZ0U,9HJ W0V933;N* MIF>:"OP"5S0O<0$^$%S(S%36*//MK>>B\X6A'^@(M_:=. M"5 TM)TA*O2G0]>9HF!XPG2'-
AB.]\%&TZT)K\<(-"%@S5E:)>9FC3>L+M R?_,&"X73X7\T4%4V] MH>],43 :^,X]&KN4A&_K\94 ";NH;"85W6HW(KNJ!T.#]94>G=7CG .FF;O= M8+[-J0 %V2BD=Q&I+?%FE-7<2+:KASOW3$I6UI<9P2GA.D!]OF%,/M[H+^@& MBLO?4$L#!!0 ($R%'%DR)?-C<,
%D0 : >&PO=V]R:W-H965T M8R#,;R@HDY)!M;;YC&"5:5.0V=)S +E!&K.5*Y)< MQ]\::C775,+V\0/]DTY>)G.+.+Z@^:\L$>G"FEH@P1M4YN([W5_B.J&)XL4T MY_H3[.M8QP)QR04M:K%<09&1ZAO=UT:T:T:&]PC #6 M@7^,\(O%K@'2KP:X&O MG:E2T3Y$2*#EG-
$]8"I:TM2!-E.K9?H94??]6C!Y-L,ZL5R57,YP#]Q5MY. MP<%]<)]\EA?&^?BX^OPC.@>[;#C,D,K)M"VZN(W#R^BUX#3(" M?]J2TY(@D?&X+N4!U&3NN%[.J%@.?68P+P14E(N7@(TEPT@78,K,F/?B0W@J. M$K^4Y!1XSCL
'>@/+.CB<+DW((\.E\.1;+SF9GF:YSW#Z]V8(8,K@#\,4"^1 M,[Y#,5Y8\BW!,;O#UO+-*S=P/@R98Q(6&8)UC/;X_PQ^B'&58")!JB7Y=W2 M#6:A&\[MN[8E0V%PYL!N6#00-@FF$Z<)ZZ0Q:=*8C*=!L@+EX!*C7*1#28S*
M7WKW3<(B0[".;4%C6W!LV00FC3,)BPS!.L:%C7'AL653 <+V@^Y/ B?HEXWJQ7-@-AT'=;M$X:TR:-Z6@:5W+,9-U\+07+U&YC*)%1Q$N?).PR!"L M8]VLL6YV;.G,3!IG$A89@G6,=W1O>)!][WI,-5Q@$L%](3Z-FGA_TZ^AIU#1\\AMD MMWJN K.M[ETYB&E)1-6?-+--?
WRNN\+>_$KUS;J7>\143?<58MN,<)#CC40Z MIZ%<$JOZV&H@Z$YW=K=4R#Y1'Z:R]\=,!&PO=V]R:W-H965T?W?-5^=L M+_.LI-<I16UMO!I*]D*QH&RL/BJQL_I//;2">T@"U#=!3&^"V M 7YJ []MX-
>1::C4<8B))*MSSAX!KZP56O6A#F;=6M'/RFK<;R57OV;JG5Q= M[87Z1@AP2S=J.*4 9^"&)JQ,LCPC]="P>_"N3%A^P1U5$XT>GCZ0SU0 R*FP?KN-P8N?7H*?0%:"#UNV%Z1,Q?E<*M\K M#^9)Z^=5XR<:\1,B\)Z5DL8G,\?
3H,SM%KX7@C[5O'0*D08A4>K'IW%D<[B*W0D54&2@'Y62XF@ MKT!)I8E) Q.>,HD66=BL%I@I#,Q6,$H7)B9!$,[QHFD(&%"&N=7 M..AW$?F1IW$P6'G07VHM0A14RIQ6 J.F;%S_O6%6\(+0
MUSC;.YQ*VA5:/SPGX@M:PW/%R9]9#FBQR]F7.CJC*TF+U'L]E7;0HV/M;W)T M'*'UHX.ZZ"!K=&XE2SZ>5:J^RAE%M3Z-)O,6JA>>4']?[/U-CHXCM'YT.L$' MK3)G=;W-[C@#JOIY)#P]*)&-PI%;]:1R#JE**@$R-;OJ5X_84T[;7W]!U!=X
MNU.30_@]E!SLI!S\FI83>Y6,$PIVG"64CA0F_B N9]%RJ0?&VM7DP#A"ZP>F M$X70K@K?E@\99V4]:7)5WAZR(4\L%.)2(0;34UH+859_]*'6"$]H5 MYW^(JFFKQ8WDM*FXU.LFJZ 9 V0%FQP@EV@Q'.K7,X@\/++\=P(6VA6L2DXT
MVZA9L^>@IP)0<5HL="GM8Z"$LMX9N*TJW*LXW2Z39.& =KM8!QNJWTT,-A M"\5(W=[IFI5*+V=IK23%:5=L1WG]CE9;.))5+ZZ@N6J_>04VM%0_YDU9E!9J M=5"NU\O#H>XSO=/K'\B7^,?PI3]5NBH VLN ?CZ]._/XWL#CWO-/IQ?
(E_#%_Z&Y9=-87LU=2OC0\JVQQV:TU#;P>9NM X18M= MH?4#V-5;"#[W+BER67&MG:+%KM#ZT>[J-V2OWR;OR+5XIRLU]K&G2VV3&8)8 MWY,SF4%OBI*(F0OB?2SG#/P MH5C5.TV!5:/Z!=!82"9\^G3LLDIVBQ*[1^M+MJ"MFKJ>GY=+BE
MCSVHE]%K@QD*0ZA7VR:S(%R,[!&CKHY"7SDB^):4,]RKA_XB\/3M*I,=#B#6 MSSY,=LB'WE@^[90_L@M*8\IYGS5Z\9>]Y-GHX+G'A4@7RDJP&358"UX]?8:#4FD)9#G:/8!0,%GN3U3"A&*Q4$:*]>?.36[P%Y9OZ-K0 "=N7LKG6>OSV
M>./ZLKYGK'U_!=_$S;WI#J:YQOV>\$U6"I#3>P7IO0Z52[RY&=T\2+:K[PK? M,2E947_<4I)27AFHW^\9DX>'JH/C_?357U!+ P04 " !,A1Q960GI]GH# M !1$0 &@ 'AL+W=O&ULK5A=;YLP%/TK M%JNF5H*I336UD7[I%
[;H]N^$FL0J8V:;H/WXV9"2D!#41+P$V]QS MN,<^Q-<-EEP\RP6P 0]JJ]G,JAM5 [N]!!U:5U 0N4YSR#5=V<)%3IK]C,A- MHP*4Q+;K.#T[H2RU1H-B;")& YZKF*4P$4CF24+%WRN(^7)H8>MMX)[-%\H, MV*-!1N?P .HQFPC=LRN6B"602L93)& VM"[QQ1@3 R@B?
C%8RHTV,E*>.'\V MG=MH:#DF(XAAJ@P%U9<7$&,<&R:=QY\5J54]TP WVV_L7POQ6LP3E3#F\6\6 MJ<76(A:*8$;S6-WSY0VL! 6&;\IC6?RB91D;!A::YE+Q9 76&20L+:_T=341 M&P#L[P&X*X#[7H"W GB%T#*S0M8U570T$'R)A(G6;*91S$V!UFI8:I;Q00E]
MEVF<&EWE4H](B1Y@KE='2?09W4:ZP6:,/L6 +J4$/7IZ#8]R6)[I^X\/U^CT MY R=():BGPN>2YI@K9U^5SW;W//M;GIXCS_F$7,?U&^#C]\.] M.MS6LU!-A5M-A5OP>7OX2J5-,DJ=E,OB$LQ%X_K,)J:?E56GYK M6C\R$%2Q=%ZYL"G%5HY#5Z$CLIK UA?
1*X;K/QL+/>9YW#K7>G M@X3VWO=<"6;*FL9-M)7XT,7IBJT^#1OE!C[2@BM@5S([8J0+7)<2N'4;;Y/I MAHL= C9LF%#6!B0??]_>%T X/8*H-&&$Q#%@2"= IH('N73/;FW\;:\9F^<=\W'ACLJYBR5*(:9!CKGYG0NRO-[V5$*X[M3USI W717 "-0)@ ?7_&N7KKF%-
U]15E]!]02P,$% @ 3(4<668I4J1K M P 01(!H !X;"]W;W)KF6:8C*'F(I+ED*BKDP9CZE42SXS1FPAHS"!$4=B$<>4OPPA8JN^08S7$W?A;"[U M"7/02^D,QB#OTQ%7*[-@"<(8$A&R!'&8]HW/Y.J:>!J05?P)824VCI&V\L#8 MHU[EG -4:29E(ZGG-0H/E,#-X]?
V;]FYI69!RK@FD5_ MPT#.^X9GH "F=!').[;Z!KDA5_--6"2R5[3*:[&!)@LA69R#E8(X3-;O]#EO MQ : .'L 5@ZPW@JP'RY0*-(H(1), ?7E:A*DNN$ _5;C. M;T#2,!(?5/G]^ :=GWU 9RA,T.\Y6P@%$#U3*GGZ0\Q)+F6XEF+MD?)]D5PB M&U\@"UM.#?SZ[7"
["C=54XK.6$5GK(S/WL-7=B$MN@!E%Q*0=1;7G$X]I_Y. M7HF43]!OJ"^= +X$8_#^'>G@3W6&6R*KV+<+^W83^Y'VUYQNQJE_098#"]LV MQCUSN6ELMXSXKMOQBK**9*>0[#1*OD]""0$:2RJA-G^-\$,WIR6RBE.W<.J> M()MNF_9;(JO8[Q3V.R?
(YIJSNQ$ZK^M:G:UH[E9U?0<[]G);8JC[+H84XI\AG MJ[-,6VS5%I33#&F<%HYM@;L3/.)C>R>?-66>OS&25D67,PAI'D)^R3GP6EV- MN(.WIB6VJLMR<"'=4Z2SU;&F+;9J"\K!AC0.#L>VP-NYQW%]W]X.9TU5!Y.M M;)H;]_?ZXN%9&EVR__I&1Q=C@'&@#7!>KZ
ME#'YNM!/$8JG1H/_4$L#!!0 ($R%'%F$5>59_0(%8, : >&PO=V]R:W-H965TIH4[[2&V^,U^K?<>>/,E"BX$NPOG>G%T.DY: 9SDC%]*U8_H'2H M8_$BP53^BU;E6<]!4::T2$ICPR"AO'B2IS(06P:^O\/ +PW\G'?QHISEF&@2 M#J18(6E/&S0[R%W-K0TYRJTJ$RW-
+C5V.IQD4P6/&7"-OB[M[QGR/;^-KB3, MJ$:C6 (DQ?IWX")0]>\^!AL4$_'H EEZI/9KX&:0)09(#2&J48GB')TMQ"9 M(GRF!JXV]"T)-RJI7A94_1U4?V;L'+7PYX+@_62,3D\^_0_C&N^K$/A5"/P< MM[T#]YI338U?=R 3-#K#Z)<@O)9?(XZ]/Q0P!D:>
[>H5HT<;F$IV)+R>)V-KD224&W34:V>C6A[QJM?<>T? MK&?_"/RPMTGTWCLJ6H)M2]K"WDY)\5:]P6_)MO[NZ]D,M&^\-E4!^P;'S:F_+NTVZ=J(MF_0-C4"=P[7]1BE 6]J M VY,[6_5-:@HOBEKNY6EV@[[M]$QI0KQ&!N#+WSKD&011-;3+1(\\9Q*K1I
M0_/APC3^(.T!LS\70]\GMA>M_DJ$_P!02P,$% @ 3(4<68A>44(3!0 M'B@ !H !X;"]W;W)KHM$).*X^(VM M)Y[N>'_K=SISO&/\FUA3*L&/+,W%)%A+N;D,0[%8TXR(,[:AN3KSQ'A&I-KE MJU!L."7+1'E!>\36A
M.W&P#70H<\:^Z9U/RTD0:8]H2A=2FR#J:TMO:)IJ2\J/[[71H+FG'GBXO;=^ M5P:O@ID306]8^D>RE.M)XCK0,:;'L+EHKR$^SJ:Z, + HA M658/5AYD25Y]DQ_U1!P,4';:!\!Z "S]KFY4>GE+))F..=L!KJ]6UO1&&6HY M6CF7Y#HK,\G5V42-D]-9,1?T>T%S"3YL]>=[".
(P0VGRT2"JQ6G-*N.?\HE MY51(\$@D%>#DEDJ2I.)4G6JQ,J.+0MD MW0NQZ%4KNH;AHO:K>O*+=CA5@P^ MLURN!?B0+^GRG^-#%6(3)]S'>0VM!G\MTC. XG=E=!9[J)DW5-K#'?8>Z9:E MVR1?[6?JAF59(O54"4#R)?A">0:NWL?@-T9R ?
X"UTH[Y=2I;3TI:CZ%Y(4> M\4Z?3 28E3\LH,3ZE?"$S--JP#LP6]!<'6'@/J=MDVGU5?^P+\6&+.@D4#<0 ME&]I,/WYIW@8_6*9"=S,!"ZMHQ/?P)JI:FI%,[7;_=1RG8L3 MHM(%-I2K&9:G;;Y7UN.H-*\?Q70>;N .O1ST7AU<93Z62L@M$5I];9GAN+(4"QR
MUE!MXC]V\0"TL5<9U>:?Z0AV""F&QC-XC%*Z8P5O#=3J;=\\&;#'R%U*/H ; M&^+&5F"Z2ZDR?_$O)77HR(VMI/V]3K:%XGW6\IS73^#NR0G^4+;*.5U,KN_ M>SSU4#'90^F;00/_>.@N,A]0C@V58RM4W44V:GU>P:["*38\CNU /DJ==116 M]E#Z)M$4"?
&%N\Y\H!L:=$,K=YUU5IM_IK,.F4$#;&@']G'*K*O^L@?3-XNF MAH#066C0!]BA 3NTO[(["PVU"ZU3:8;GT,[SHU1:5WEFCZ5O%DV1 0?N0O,! M=VC@#NVO]LY"&[:59[!#90;HT [T6D3P?^E(V7WIFP)3(L!S=Y7X0#,T:(;V M%WAGE5R\
[G&$#)&1GA(!]H10:MR/YZ[BJ4VOS+ M'B?HH %NQZDGE735-W9O^B;!(!]Y=[F1#S(B0T;DM]&-7MGI1@:(R Y$/U+I M*E#LSO1-@\$LV#WMFR,#:>S>S,9>_CT^ M^/O8;S,;MS:S48>&#$VQG:9OHJ&NXL?N:]\4&7YC]VXU]D%=;*B+_7:K\2N[MU=C
%MMA^Q9"ZBJ-[*[V39+!.W;O1F,?W!T8[@[\=J,'+^Q&AP=+MC+*5^7" M- $6K,AEM7JK.=HL?KNJEGR9RZN5H\T^,R?V.OD&S)'#Z-U!+ P04 " !,A1Q9[LSA M1@H# >;# &@ 'AL+W=O&ULQ9=M3]LP
M$,>_BI5)TR8!>>@CK(T$96B;QH2HMKUVTTMCX=C!=EKX]CL[:>@@[5A!XDWJ MISO__H[ONQEQA0GOJ^3#'*JCV0! F=2J7)]L*L6OBX4 MT+DSRKD?!4'?SRD37CQR8U8F M&WM#C\PAI24WUW+U!6I!/>LOD5R()UG5:P./)*4V,J^-D2!GHOJE=_5!;!B$
MW2T&46W@#L*O-G*4Y]30>*3DBBB[&KW9AI/JK!&."?M6ID;A+$,[$T_+F8;; M$H0AGY?V>4BB(.J2B8(Y,^1TH0#R:OR""2H21CF92%Q*A='DPSD8RKC^B/,M MKJ:0E.B(G,-LJ^>1;U'"I?&3FOFL8HZV,'\K^1'IA ?.W]_F/LIOSB!JSB!R M_CK//(,VHLI#M]V##9T37=
$QA[&A@:U!"]^_R[L!Y]V\'4:OLXN[_$EO6-Y MF9,?&*3?80D*PX5<4[S5!Z103"IB)#$9D F7FHD%P9L ;2*J;09N&QNNRQB/ M;]E"UFW(NGN3I4QI@T^=X(VY+:DRH B(N06DJ>T\1L8!)#7KOB7J.XM[?B_T->OS23,67N]Y?9:Y.Y M166_4=G?6^4NWC9]^.7
Y68ER=X2^VT2HRT:!XW&P=X:'^[G*] /GAMUPX9\ MN)N<"4?.!%("!EDB:WRU1U(8/L'KM.,=-WC'+\-[\\QP_/0^1=M")@P>OJ3! MRW2_37ZHJ1^IW98'PXW"(7R9W#=(%#7R,RYS^% .@Y+Q1Y$ 2/2VR#G@V(BRU/8<9VQGF% K#$S;'0\#5LB4
M4+CC2!19AOG+%:2LG%FN]=9P3S:)U UV&.1X TN0#_D=5S6[<8E)!E001A&' M]=>4VGEF.#@A2B*1VP.JQA3FDJ39283S5 MGE;S22ULE]_=8%.%R Q2<69:I]CD:!KM1S0#<0;0C>J[6&Y0*_H*["W;:*#W_Q'HE%#-#IRH9XCM1E>.C9"Q730[MBY
M[,ELAWSO+&PO_Q.??8OB%NAY5>RI,(@ MN50%T::KYE%5*DJR"D@%CWJ=3A(5A(EP/!3+XKK053"32Z%'8;\)!>[V-1N% MW>1C&#BYB_]K*?75N\#=3SZYE*TNQ.'+F#4 M24&#!\)'X81P-E4,6#DI&%^[<\",\FE"K0I"Y.N"Y']T<%=UX.*J74*)J2R MN5T&]WM:#]\#-
CTPR#AO#/9"%Q@/2Z(U5>+:=.Q@&WP"!77[;ET:AW-%UMU> M/VP)F:23*7*J&K2=.--:#SD-<[BLT7<RC #46A:FD3$REX)8#QM&W3"R M,\KY+3Q./_,=[56^M6\=V#71-(VANNED7 ?TM]6<]K9L_"+=H&0/4G]9FND(
MVX<"I3>*YFQE^ZN\,8"I=W%U4I9_9FSN2BHF_RS$XZ'9,,+%E*Q1Y,-2F5F M E2%P0-5FLVV([\5*>_H2F_*:97CGGMOT/._7>.:B;JW8%E&Q9/#C)'79&K^XMC1-^,SFI,E MUW<-. K;]G>:L661-J-N8"]J46W[&TROFS1'59.+B8RN:#:INVH^M:IG&<)-B*3B9>!Q-
LW9($?OQJF#=@8'D@T]^M-;[;>(4)K#8A_W8"1IO[=QO( ]L%K'8@OS\/U)2?$\>PJY@W[G& MD33%$*A%?XTF";(Z"7S\^X,])7&!IQ!', 'C DCNU[<.]] M%&W>4U'[;[CQ'U!+ P04 " !,A1Q9EXJ[', 3 @ "P %]R96QS M+RYR96QSG9*Y;L,P#$!_Q=;">=">, ?0(8(@@S9?
$6!/D!5J(/V!(%BD6=OZ_;I7&0 M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-# ML%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ($R%'%FJE/2J< D
.Q< / M >&PO=V]R:V)O;VLN>&ULQ9Q;<7S]2-]@2AJ_.RTZ_Q*&Y+03::^NV/_W,U8]EGO]@ M_Z9)IB];3T6Q_7AQH>,GD7+]9[X5F;EGG:N4%^:FVESHK1)I9^$*-+DHAT$ MT47*9=;Z_&G_6G-UX=[("Q$7,L_17OANQ0_]=O]]B9[EEHN92*+E\M6]?]$
MM%@J,YG*7V)UV0I:3#_E/[_F2O[*LX(GBUCE27+9"NL[O@M5R/C=Y86%?.!+ M75TI^/*>&Y#+5A28%UQ+I8OJ$=7K<\/X+,R#ZUMED5_+I!!JP@OQ1>7E5F8;M^S+F4UPX'Z-JA_W?NA$_JO^G&?/U6L9BDDL=E*K*B;DYU2V6\51< MMO8/83Q;L6E6F$9BLZQ^*?
-8^TG-6\]6]:HV:H"IX,@6P#R'9CD..[;W,'L@,@.[\1\FIT M,[H=3]GBZW3ZL' NP"PVQ@@.YMS![('O-?=6CQ5<',@*047.07T>W#F0? M0/8;A'QL.Y # #F@A9P('2NYM==9OF97I9:9T-J!&P*X(2WQDTX'\5Q7HP[@;P $7P@!;3B'J;:[$R8/^4YMT/Y0+M0JR7A7UC^QAM
M6_%N*U3]F//1:B7])D1^"8D%<\43GL6"55G%'B[/>%(+V\5$A@F)%3,1R)\E MO3()B6UR([@6;D<-D35":FWD:6I"R*+(XQ]_L+D2:Z&4Z1+5!>:Z+43>"(G% M4>/,S$\MLTDKFYN?G7C1--N?*)*H/BF>:5^F_]R4C5X3$LIBF MVR1_$8)=B4RL95$UGT>'9!$2V\)\JWDJV
/_U^L6;:2&-K$:;+>011U_[2AD M,;9@9C@DLECZD,@1;6)'3(22S]SV!P\)CC>(?7#-I6+?>5(*]LW$N5+5#G/Q MD ?:Q![8ITEL(3;OP) 4VL126)1++?XI[:!W^FS_/6?MH-UE8Q.+37]U,9$M MVL2VF/,7]JS97*CJZ=;\$ZGC)+??M N)7-$F=L4LTW(EE(W$*]-GV4B9D+QY
M_T-$SF@3.P-FR-X8HXW$T286!\;LN)C((&WJ\09*EKW6[""I=(BE I-E'Q-I MI4.NE67!SAZX>5?]P85"8ND0BZ7.FH]BP:DKZKDKE#[[7RG22X=8+\<3P*.M MB?32(=:+FPD>A4-:Z1!KQ$9 3>\]Y"% M>L06PIAN>.\A"_6(+80QW?#>0Q;J48^"(*87WI&%>L06PIAN>
(^0A:)&)]7< M\!XA"T7$%L*8;GB/D(6B!M?S_? >(0M%U.LX$-,-[Q&R4$1L(8SISB9R)1 M@Q9Z#%T+17#O6(,6>@Q="T7(0E&#%GH,70M%R$(1^0:RI9W=^B(RDQLE[O[: M:A3L8B(+1<06VF'.LD(HH0MV;SBTN5 E>"MW8;2/+-0GMM IS/\)N7DJW*71
M/K)0_W.]B/,LEHE\^TV^PT0*ZO^&+64&;C1(;P\"^\:)4)B*):F3D8B(%]8D5M%O>.Q6/7$RD MH#ZQ@EXQ1UJ+W=:@&\FK@QS^QJ ^W,!,K*!7S'&>;O/=W*;YMF_-^YG[7$RD MH#ZQ@EXQ[XHGH=BBW&Z3:M!>?_\N)E)0GUA!KYA^U[DNS2W!;AS, 5+0@%A!
M;UU(Y5JSB5ROC8ML)E(%)1<3*6A ?6X&KIB[R>8 66A ?7(&8KK)Y@!9:-#H M_@,WV1P@"PVH3]! 3'?*8X L-""VT+%=QHZ37$QDH4$#FZ&KC$D72L9NZCY M%AJ0+PH=Q:PNGU]Y 0D>I"%?%#]*.ZV)+#0@MM#I7>:'X[4ALM"0
MV$(G=AKM.Y&+B2PT)+;02%D(6&C1S1J5JS*+E[D&X(#W826PAB>CT]#/#1SJ8\--6%3+US M;0$\YQDT9B([Q< \4'C2,VC*1?7F4P\4GO4,&K51UP.%!T&#IGQD6_2@,\$S MHD%31NH&X=F/#QXH/"4:-.6D>H;) X5'1@-B*WD[W>VZ077S["'7^@-;"@\4 MGAP-B+UT
%I-*&;[?35S[X!W ^1!K_Q%.G[Y8/DD)+E% 7:/@ -2FRKL]=-F&W?B="9J)NGS!NUZ_Y85Z6S+T0*&9 MJ L8'/;Z:H[^KTR9,+7)Y"\/%)J)NIK! :BSNL7L%)0'"LU$7=3@ /2O+!:J MX#*KXM/<_XU",U'7-X"U!-BY"PIK'H2-%CWP\U%8]R"D+GR 03L>**Z.0[Z7
MX6VCQ9&U;0\4FHFZ,((/ZFUA,O$^]D"AF:@+)?B@M_EN:]4HM96EM)?APTH) M(76I!!]TNEZ+N$Z:ZSL\4&@FZG()/NAA!:?4 X5FHJZ9<.J0ZVX&P@.%9J*N MFG :M)K3\4"AF:CK)IP&K;3O@L+""2%YY81W!X>]:.J!0C-1UTXX!FJSYP5/ M[%X[#Q2:B;J>PC'0B=B:?
+3*GCU0:";J"@O'0$>KOTMM%T.G5QXH-!-UC85C MH,XLA <*S41=9>$9$8Z&QE5[_7IM=[$Q"PX$)(77'A&*@[MFOR_<_V-P#A6:B M+K^_JP9X^2BLOQ!2%V# H-[4."S#$#9;A\'=UQ3"0@PA?24&!!IYH-!,=2V& MB^KA^O.GE5B;W_[JUKR)-M=CGL1SQ>R?
71+>LX/:=9DD8W/M+KO)^6I?K'M? M:/SS?U!+ P04 " !,A1Q9:E%G3LP# "D4@ &@ 'AL+U]R96QS+W=O M'P_-R_W!4GMX?3TWY]N3S=3G_&[O+\ M_9EGWWX?Y_\Y\7!![^W]?SE<_WB:G]=_'#S]/)R^+_?SO.[.ONU/=_-ZL9M^ M/;X]O4RO#_;IY>3=V=7-Q>YT=6.
[:>M!40;%[04?6. +VCZAT!>B?5.P'T3JIW NB=5.\$ MT#NY#TL >B?5.P'T3JIW NB=5.\$T#NIW@F@8$]IT@G@Y9]&:!W M4;T+0.^B>A> WD7U+@"]B^H^R["NGY4 O8OJ70]70]Z%N:7;6[_+.I!C?R8#['O_'_O?RS5:'+X=@6AK;3\?P@AK2P+#'7#VV@
MK@"]J^I= 7I7U;"&]ZJ=P/HP^'3^I'_(T@ZF[ZS\N-+X= ^Z+@-&N V:J>Z"?S5A>V;&K\@:"+_9?R; D?DL97]Q%'<%A^5NP/T[JIW!^C=5>\.T+NKWAV@ M=U>=U>].T#OKNKGIW@-Y=]]1X O;N[V&_>H@7^H]IBB]C)]>JO]C-2
Z#U4[P'0>ZC> Z#W4+#W4+T'0.^A>@^ WL/%.@"]+?ADS3$2'Z4-,1(GI4TQ$B^EC3$2-Z7-,1(_I M@TQ$D>F33$*3:2[*-$*5:2[+-$*7:=%G]03179IA#;37)QIA#K37)YIA#[3 M7*!IA$+37*)IA$;37*1IA$K37*9IA$[37*AIA%+37*IIA%;37*QIA%K3DO^J M%
(+H+M@T0K%I+MDT0K-I+MHT0K5I+MLT0K=I+MPT0KEI+MTT0KMI+MXT0KUI M+M^T#^TWE_7WX[R\+?I[[09\I-[KR^_.;Z_>OGW2?\VO'(]O9^Q7/X!4$L# M!!0 ($R%'%G\)L\UW (-U. 3 6T-O;G1E;G1?5'EP97-=+GAM;,VW;S6Z;0!2&X5N5E6V5U;04;M-
VV6?0&J!G'R/R)F:3.W7=P?J16J=7(ME?INC PSYQP8Z=E]U]\>)^M6Q[X;W";;>S]]2!*WW=N^=O$XV2$\V8US7_OP M=[Y+IGI[J.]LHI4RR78]_7! MSG/;V-5M/?LO=1]6)<]V%+[*;9UHW;6^O[M+GXJ>G6^LP]?V#[]RL7]3V7.-0PK;^=Q3Z&0G7U[_A5? M.X;2%[^?
74Z[L1Q8ED<3)9 MG% 6)Y7%B65A&UL4$L! A0#% @ 3(4< M68Q+X(7O *P(!$ (!KP &1O8U!R;W!S+V%P<"YX;6Q02P$ A0#% @ 3(4<69E&PO=V]R:W-H965T&UL4$L! A0#% @ 3(4<60^? G'^! W1, !@1 (!>%P M @ >&PO=V]R:W-
H965T&UL4$L! A0#% @ M3(4<6> W?9R" P !1$!@ (!DB 'AL+W=O&ULUL4$L! A0#% @ 3(4<6<[,0ZV(@ L08 M !@ (!S0 'AL+W=O&UL4$L! A0#% @ 3(4< M67H*Q*3+"P *R(!D ("!FV
'AL+W=O&UL4$L! A0#% @ 3(4<648T,3UD!0 -P\ M !D ("!PH('AL+W=O&UL4$L! A0#% @ 3(4<6&PO=V]R:W-H965T&UL4$L! A0# M% @ 3(4<6;MS M%]4N" #AD !D ("!H] 'AL+W=O&UL4$L! A0#% @ 3(4<61#"'B@ !D ("!9 'AL+W=O&UL4$L! A0#% @ 3(4<6:MC.&NQ!0 _D9 !D ("!M=DX
('AL+W=O&UL4$L! A0#% @ 3(4<61#"V^8 @ !D ("!V0 'AL+W=O&UL4$L! A0#% @ 3(4<6;,0ZV(@ L08 !D ("!!V@('AL+W=O&UL4$L! A0#% @ M3(4<6<=0F30H!@ UQ0 !D ("!!B$0 'AL+W=O&UL4$L! A0#% @
3(4<69?HQ<>,! XPT !D ("!2B0! 'AL+W=ODK 0!X M;"]W;W)K&UL4$L! A0#% @ 3(4<63S\CUO@ M" =1\ !D ("!" 30! 'AL+W=O&UL4$L! A0#% @ M3(4<6?@URY&] @ (@@ !D ("!(O8! 'AL+W=O&UL4$L! A0#% @
3(4<60#T.>?(P Z14 !D ("!8%$! M 'AL+W=O!0 &0 @(%?50$ >&PO=V]R:W-H965TA7 0!X;"]W;W)K&UL4$L! A0#% @ M3(4<61BK0?M* @ 6P< !D ("! UP! 'AL+W=O&UL4$L! A0#% @ 3(4<60)(# "'$P &0 @(%@ M: $ >&PO=V]R:W-H965T&UL4$L! A0#% @
3(4<69#/S!?2 P L! !D M ("!$F\! 'AL+W=O&UL4$L! A0#% @ 3(4<61_@2>KD @ @@@ !D ("!SG@! 'AL M+W=OP$ >&PO=V]R:W-H965T&UL4$L! A0#% @ 3(4< M6=443ZO] @ @ @ !D ("!(!=8$! 'AL+W=O&UL4$L!
A0#% @ 3(4<61/=BG-2 @ E04 M !D ("!5XL! 'AL+W=O&UL4$L! A0#% @ 3(4<6>!&PO=V]R:W-H965T M&UL4$L! A0# M% @ 3(4<69""X_10 @ ,@4 !D ("!I9D! 'AL+W=O&UL4$L! A0#% @ 3(4<61IX MU4)8#_Z !D
("!%JH! 'AL+W=O&UL4$L! A0#% @ 3(4<63I#822I @ N0D !D M ("!R;T! 'AL+W=O&UL4$L! A0#% @ 3(4<68]9]%@! P /@P !D ("! MZL8! 'AL+W=O&UL4$L! A0#% @ 3(4<6;V074W: @ ^ @ !D
("!T<\! 'AL+W=O&UL4$L! A0#% @ 3(4<609AT)&PO=V]R M:W-H965TKG 0!X;"]W;W)K&UL M4$L! A0#% @ 3(4<61S,XN18 M @ >08 !D ("!_M@! 'AL+W=O&UL4$L! A0#% @ 3(4<61.;Z]M8 P MG@L !D ("!T/X! 'AL+W=O&UL4$L! A0#% @ 3(4<61.Y#N.I @ O@< !D M
3(4<6;6.Y'30!0 C2P !D ("!9.H! 'AL+W=O&UL4$L! A0#% @ M3(4<6?@URY&] @ (@@ !D ("!(O8! 'AL+W=O&UL4$L! A0#% @ 3(4<67L4P\#J @ GP@ !D ("!)Q," 'AL M+W=O&PO=V]R:W-H965T&PO=V]R:W-
H965T&PO=V]R:W-H965T M&PO=V]R:W-H965T#@ &@ @(%H-@(>&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T
M&PO=V]R:W-H965T&PO M=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T MT; " #("0 &@ M @(&U90(>&PO=V]R:W-H965T&PO M=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T M&PO=V]R:W-
H965T@(>&PO M=V]R:W-H965T?0(>&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T M&PO=V]R:W-H965T&PO M=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T M&PO=V]R:W-H965T* &@ @($:H (>&PO
M=V]R:W-H965T# &@ @(%EI0(>&PO=V]R:W-H965T&PO>O @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !,A1Q9 M:E%G3LP# "D4@ &@ @ &$N0(>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !,A1Q9 M_";/-=P_@ !Q-@ $P @ &(O0(6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 M 1 +T3 %4 %X"P("D ,@
5'EP97-=+GAM;%!+!08 !0 ! "5P (! end XML 166 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 167 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData

p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px;
overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font:
normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent;
color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display:
block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc {
background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px
solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap;
} .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none;
} .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 169 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1
html3185181false1050false7 falsefalseR1.htm995200090 - Document - Document and Entity InformationSheethttp://www.pahc.com/role/DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm995200100 -
Statement - CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://www.pahc.com/role/StatementConsolidatedStatementsOfOperationsCONSOLIDATED STATEMENTS OF OPERATIONSStatements2 falsefalseR3.htm995200200 - Statement -
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)Sheethttp://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLossCONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)Statements3
falsefalseR4.htm995200300 - Statement - CONSOLIDATED BALANCE SHEETSSheethttp://www.pahc.com/role/StatementConsolidatedBalanceSheetsCONSOLIDATED BALANCE SHEETSStatements4 falsefalseR5.htm995200305 - Statement -
CONSOLIDATED BALANCE SHEETS (Parentheticals)Sheethttp://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticalsCONSOLIDATED BALANCE SHEETS (Parentheticals)Statements5 falsefalseR6.htm995200400 - Statement -
CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlowsCONSOLIDATED STATEMENTS OF CASH FLOWSStatements6 falsefalseR7.htm995200500 - Statement - CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITYSheethttp://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITYStatements7
falsefalseR8.htm995200505 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Parentheticals)Sheethttp://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParentheticalsCONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals)Statements8
falsefalseR9.htm995210101 - Disclosure - Description of BusinessSheethttp://www.pahc.com/role/DisclosureDescriptionOfBusinessDescription of BusinessNotes9 falsefalseR10.htm995210201 - Disclosure - Summary of Significant Accounting Policies and
New Accounting StandardsSheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsSummary of Significant Accounting Policies and New Accounting StandardsNotes10 falsefalseR11.htm995210301
- Disclosure - Proposed AcquisitionSheethttp://www.pahc.com/role/DisclosureProposedAcquisitionProposed AcquisitionNotes11 falsefalseR12.htm995210401 - Disclosure - Statements of Operations-Additional
InformationSheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationStatements of Operations-Additional InformationNotes12 falsefalseR13.htm995210501 - Disclosure - Balance Sheets-Additional
InformationSheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationBalance Sheets-Additional InformationNotes13 falsefalseR14.htm995210601 - Disclosure - DebtSheethttp://www.pahc.com/role/DisclosureDebtDebtNotes14
falsefalseR15.htm995210701 - Disclosure - LeasesSheethttp://www.pahc.com/role/DisclosureLeasesLeasesNotes15 falsefalseR16.htm995210801 - Disclosure - Common Stock, Preferred Stock and
DividendsSheethttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommon Stock, Preferred Stock and DividendsNotes16 falsefalseR17.htm995210901 - Disclosure - Stock Incentive
PlanSheethttp://www.pahc.com/role/DisclosureStockIncentivePlanStock Incentive PlanNotes17 falsefalseR18.htm995211001 - Disclosure - Related Party TransactionsSheethttp://www.pahc.com/role/DisclosureRelatedPartyTransactionsRelated Party
TransactionsNotes18 falsefalseR19.htm995211101 - Disclosure - Employee Benefit PlansSheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansEmployee Benefit PlansNotes19 falsefalseR20.htm995211201 - Disclosure - Income
TaxesSheethttp://www.pahc.com/role/DisclosureIncomeTaxesIncome TaxesNotes20 falsefalseR21.htm995211301 - Disclosure - Commitments and ContingenciesSheethttp://www.pahc.com/role/DisclosureCommitmentsAndContingenciesCommitments and
ContingenciesNotes21 falsefalseR22.htm995211401 - Disclosure - DerivativesSheethttp://www.pahc.com/role/DisclosureDerivativesDerivativesNotes22 falsefalseR23.htm995211501 - Disclosure - Fair Value
MeasurementsSheethttp://www.pahc.com/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes23 falsefalseR24.htm995211601 - Disclosure - Business SegmentsSheethttp://www.pahc.com/role/DisclosureBusinessSegmentsBusiness
SegmentsNotes24 falsefalseR25.htm995211701 - Disclosure - Subsequent Event - 2024 Credit AgreementSheethttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementSubsequent Event - 2024 Credit AgreementNotes25
falsefalseR26.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes26 falsefalseR27.htm995445 - Disclosure - Insider Trading
ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes27 falsefalseR28.htm99920202 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards
(Policies)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPoliciesSummary of Significant Accounting Policies and New Accounting Standards
(Policies)Policieshttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandards28 falsefalseR29.htm99930203 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards
(Tables)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTablesSummary of Significant Accounting Policies and New Accounting Standards
(Tables)Tableshttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandards29 falsefalseR30.htm99930403 - Disclosure - Statements of Operations-Additional Information
(Tables)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTablesStatements of Operations-Additional Information (Tables)Tableshttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformation30
falsefalseR31.htm99930503 - Disclosure - Balance Sheets-Additional Information (Tables)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTablesBalance Sheets-Additional Information
(Tables)Tableshttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformation31 falsefalseR32.htm99930603 - Disclosure - Debt (Tables)Sheethttp://www.pahc.com/role/DisclosureDebtTablesDebt
(Tables)Tableshttp://www.pahc.com/role/DisclosureDebt32 falsefalseR33.htm99930703 - Disclosure - Leases (Tables)Sheethttp://www.pahc.com/role/DisclosureLeasesTablesLeases (Tables)Tableshttp://www.pahc.com/role/DisclosureLeases33
falsefalseR34.htm99930803 - Disclosure - Common Stock, Preferred Stock and Dividends (Tables)Sheethttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsTablesCommon Stock, Preferred Stock and Dividends
(Tables)Tableshttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividends34 falsefalseR35.htm99931103 - Disclosure - Employee Benefit Plans (Tables)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansTablesEmployee
Benefit Plans (Tables)Tableshttp://www.pahc.com/role/DisclosureEmployeeBenefitPlans35 falsefalseR36.htm99931203 - Disclosure - Income Taxes (Tables)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesTablesIncome Taxes
(Tables)Tableshttp://www.pahc.com/role/DisclosureIncomeTaxes36 falsefalseR37.htm99931403 - Disclosure - Derivatives (Tables)Sheethttp://www.pahc.com/role/DisclosureDerivativesTablesDerivatives
(Tables)Tableshttp://www.pahc.com/role/DisclosureDerivatives37 falsefalseR38.htm99931503 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.pahc.com/role/DisclosureFairValueMeasurementsTablesFair Value Measurements
(Tables)Tableshttp://www.pahc.com/role/DisclosureFairValueMeasurements38 falsefalseR39.htm99931603 - Disclosure - Business Segments (Tables)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsTablesBusiness Segments
(Tables)Tableshttp://www.pahc.com/role/DisclosureBusinessSegments39 falsefalseR40.htm99931703 - Disclosure - Subsequent Event - 2024 Credit Agreement
(Tables)Sheethttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementTablesSubsequent Event - 2024 Credit Agreement (Tables)Tableshttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreement40
falsefalseR41.htm99940201 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Accounts Receivable and Allowance for Doubtful Accounts
(Details)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsSummary of Significant Accounting Policies and New Accounting
Standards - Accounts Receivable and Allowance for Doubtful Accounts (Details)Details41 falsefalseR42.htm99940202 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Property, Plant and Equipment and
Capitalized Software (Details)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetailsSummary of Significant Accounting Policies and
New Accounting Standards - Property, Plant and Equipment and Capitalized Software (Details)Details42 falsefalseR43.htm99940203 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Derivative Financial
Instruments (Details)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetailsSummary of Significant Accounting Policies and New Accounting Standards -
Derivative Financial Instruments (Details)Details43 falsefalseR44.htm99940204 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Net Income Per Share and Weighted Average Shares
(Details)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetailsSummary of Significant Accounting Policies and New Accounting Standards -
Net Income Per Share and Weighted Average Shares (Details)Details44 falsefalseR45.htm99940205 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - New Accounting Standards
(Details)Sheethttp://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetailsSummary of Significant Accounting Policies and New Accounting Standards - New Accounting
Standards (Details)Details45 falsefalseR46.htm99940301 - Disclosure - Proposed Acquisition (Details)Sheethttp://www.pahc.com/role/DisclosureProposedAcquisitionDetailsProposed Acquisition
(Details)Detailshttp://www.pahc.com/role/DisclosureProposedAcquisition46 falsefalseR47.htm99940401 - Disclosure - Statements of Operations-Additional Information - Segments
(Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationSegmentsDetailsStatements of Operations-Additional Information - Segments
(Details)Detailshttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTables47 falsefalseR48.htm99940402 - Disclosure - Statements of Operations-Additional Information - Net Sales by Product Type
(Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetailsStatements of Operations-Additional Information - Net Sales by Product Type (Details)Details48 falsefalseR49.htm99940403 -
Disclosure - Statements of Operations-Additional Information - Net Sales by Region (Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetailsStatements of Operations-Additional
Information - Net Sales by Region (Details)Details49 falsefalseR50.htm99940404 - Disclosure - Statements of Operations-Additional Information - General Information
(Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationGeneralInformationDetailsStatements of Operations-Additional Information - General Information (Details)Details50 falsefalseR51.htm99940405 -
Disclosure - Statements of Operations-Additional Information - Interest Expense, Net (Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetailsStatements of Operations-Additional
Information - Interest Expense, Net (Details)Details51 falsefalseR52.htm99940406 - Disclosure - Statements of Operations-Additional Information - Capitalized Software
(Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationCapitalizedSoftwareDetailsStatements of Operations-Additional Information - Capitalized Software (Details)Details52 falsefalseR53.htm99940407 -
Disclosure - Statements of Operations-Additional Information - Amortization of Intangible Assets (Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetailsStatements of
Operations-Additional Information - Amortization of Intangible Assets (Details)Details53 falsefalseR54.htm99940408 - Disclosure - Statements of Operations-Additional Information - Depreciation and Amortization
(Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationDepreciationAndAmortizationDetailsStatements of Operations-Additional Information - Depreciation and Amortization (Details)Details54
falsefalseR55.htm99940409 - Disclosure - Statements of Operations-Additional Information - Research and Development Expense
(Details)Sheethttp://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationResearchAndDevelopmentExpenseDetailsStatements of Operations-Additional Information - Research and Development Expense (Details)Details55
falsefalseR56.htm99940501 - Disclosure - Balance Sheets-Additional Information - Accounts Receivable, Net (Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccountsReceivableNetDetailsBalance Sheets-Additional
Information - Accounts Receivable, Net (Details)Details56 falsefalseR57.htm99940502 - Disclosure - Balance Sheets-Additional Information - Reserve for Credit Losses
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationReserveForCreditLossesDetailsBalance Sheets-Additional Information - Reserve for Credit Losses (Details)Details57 falsefalseR58.htm99940503 - Disclosure - Balance
Sheets-Additional Information - Inventories (Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInventoriesDetailsBalance Sheets-Additional Information - Inventories (Details)Details58 falsefalseR59.htm99940504 -
Disclosure - Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Tabular Disclosure
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetailsBalance Sheets-Additional Information - Property, Plant and Equipment, Net - Tabular Disclosure
(Details)Details59 falsefalseR60.htm99940505 - Disclosure - Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Additional Information
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetAdditionalInformationDetailsBalance Sheets-Additional Information - Property, Plant and Equipment, Net - Additional Information
(Details)Details60 falsefalseR61.htm99940506 - Disclosure - Balance Sheets-Additional Information - Intangibles, Net - Weighted-Average Useful Life
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetailsBalance Sheets-Additional Information - Intangibles, Net - Weighted-Average Useful Life (Details)Details61
falsefalseR62.htm99940507 - Disclosure - Balance Sheets-Additional Information - Intangibles, Net - Total (Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetailsBalance Sheets-Additional
Information - Intangibles, Net - Total (Details)Details62 falsefalseR63.htm99940508 - Disclosure - Balance Sheets-Additional Information - Goodwill
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationGoodwillDetailsBalance Sheets-Additional Information - Goodwill (Details)Details63 falsefalseR64.htm99940509 - Disclosure - Balance Sheets-Additional Information -
Other Assets (Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetailsBalance Sheets-Additional Information - Other Assets (Details)Details64 falsefalseR65.htm99940510 - Disclosure - Balance Sheets-
Additional Information - Accrued Expenses and Other Current Liabilities (Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetailsBalance Sheets-Additional Information -
Accrued Expenses and Other Current Liabilities (Details)Details65 falsefalseR66.htm99940511 - Disclosure - Balance Sheets-Additional Information - Insurance Premium Financing
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInsurancePremiumFinancingDetailsBalance Sheets-Additional Information - Insurance Premium Financing (Details)Details66 falsefalseR67.htm99940512 - Disclosure
- Balance Sheets-Additional Information - Other Liabilities (Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetailsBalance Sheets-Additional Information - Other Liabilities (Details)Details67
falsefalseR68.htm99940513 - Disclosure - Balance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss)
(Details)Sheethttp://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetailsBalance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss) (Details)Details68
falsefalseR69.htm99940601 - Disclosure - Debt - General Information (Details)Sheethttp://www.pahc.com/role/DisclosureDebtGeneralInformationDetailsDebt - General Information (Details)Details69 falsefalseR70.htm99940602 - Disclosure - Debt -
Interest Rates - Stated Rates (Details)Sheethttp://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetailsDebt - Interest Rates - Stated Rates (Details)Details70 falsefalseR71.htm99940603 - Disclosure - Debt - Interest Rates - Weighted
Average Rates (Details)Sheethttp://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetailsDebt - Interest Rates - Weighted Average Rates (Details)Details71 falsefalseR72.htm99940604 - Disclosure - Debt - Derivatives
(Details)Sheethttp://www.pahc.com/role/DisclosureDebtDerivativesDetailsDebt - Derivatives (Details)Details72 falsefalseR73.htm99940605 - Disclosure - Debt - Reconciliation
(Details)Sheethttp://www.pahc.com/role/DisclosureDebtReconciliationDetailsDebt - Reconciliation (Details)Details73 falsefalseR74.htm99940606 - Disclosure - Debt - Classification
(Details)Sheethttp://www.pahc.com/role/DisclosureDebtClassificationDetailsDebt - Classification (Details)Details74 falsefalseR75.htm99940607 - Disclosure - Debt - Aggregate Maturities of Long-Term Debt and Revolver
(Details)Sheethttp://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetailsDebt - Aggregate Maturities of Long-Term Debt and Revolver (Details)Details75 falsefalseR76.htm99940701 - Disclosure - Leases - General
Information (Details)Sheethttp://www.pahc.com/role/DisclosureLeasesGeneralInformationDetailsLeases - General Information (Details)Details76 falsefalseR77.htm99940702 - Disclosure - Leases - Assets and Liabilities
(Details)Sheethttp://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetailsLeases - Assets and Liabilities (Details)Details77 falsefalseR78.htm99940703 - Disclosure - Leases - Composition of Net Lease Cost
(Details)Sheethttp://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetailsLeases - Composition of Net Lease Cost (Details)Details78 falsefalseR79.htm99940704 - Disclosure - Leases - Other Supplemental Information
(Details)Sheethttp://www.pahc.com/role/DisclosureLeasesOtherSupplementalInformationDetailsLeases - Other Supplemental Information (Details)Details79 falsefalseR80.htm99940705 - Disclosure - Leases - Maturities of Future Lease Liabilities
(Details)Sheethttp://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetailsLeases - Maturities of Future Lease Liabilities (Details)Details80 falsefalseR81.htm99940706 - Disclosure - Leases - Gross Difference
(Details)Sheethttp://www.pahc.com/role/DisclosureLeasesGrossDifferenceDetailsLeases - Gross Difference (Details)Details81 falsefalseR82.htm99940801 - Disclosure - Common Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock -
Tabular Disclosure (Details)Sheethttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetailsCommon Stock, Preferred Stock and Dividends - Preferred Stock and Common
Stock - Tabular Disclosure (Details)Details82 falsefalseR83.htm99940802 - Disclosure - Common Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock - Additional Information
(Details)Sheethttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockAdditionalInformationDetailsCommon Stock, Preferred Stock and Dividends - Preferred Stock and Common Stock - Additional
Information (Details)Details83 falsefalseR84.htm99940803 - Disclosure - Common Stock, Preferred Stock and Dividends - Common Stock
(Details)Sheethttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetailsCommon Stock, Preferred Stock and Dividends - Common Stock (Details)Details84 falsefalseR85.htm99940804 - Disclosure - Common
Stock, Preferred Stock and Dividends - Dividends (Details)Sheethttp://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsDividendsDetailsCommon Stock, Preferred Stock and Dividends - Dividends (Details)Details85
falsefalseR86.htm99940901 - Disclosure - Stock Incentive Plan - General Information (Details)Sheethttp://www.pahc.com/role/DisclosureStockIncentivePlanGeneralInformationDetailsStock Incentive Plan - General Information (Details)Details86
falsefalseR87.htm99940902 - Disclosure - Stock Incentive Plan - Restricted Stock Units (Details)Sheethttp://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetailsStock Incentive Plan - Restricted Stock Units (Details)Details87
falsefalseR88.htm99940903 - Disclosure - Stock Incentive Plan - Stock-Based Compensation Expense (Details)Sheethttp://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetailsStock Incentive Plan - Stock-Based
Compensation Expense (Details)Details88 falsefalseR89.htm99940904 - Disclosure - Stock Incentive Plan - Cost Not yet Recognized (Details)Sheethttp://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetailsStock Incentive Plan -
Cost Not yet Recognized (Details)Details89 falsefalseR90.htm99941001 - Disclosure - Related Party Transactions (Details)Sheethttp://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetailsRelated Party Transactions
(Details)Detailshttp://www.pahc.com/role/DisclosureRelatedPartyTransactions90 falsefalseR91.htm99941101 - Disclosure - Employee Benefit Plans - General Information
(Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansGeneralInformationDetailsEmployee Benefit Plans - General Information (Details)Details91 falsefalseR92.htm99941102 - Disclosure - Employee Benefit Plans - Annuity Purchase
Agreement (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansAnnuityPurchaseAgreementDetailsEmployee Benefit Plans - Annuity Purchase Agreement (Details)Details92 falsefalseR93.htm99941103 - Disclosure - Employee Benefit
Plans - Change in Projected Benefit Obligation - Tabular Disclosure (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetailsEmployee Benefit Plans - Change in Projected
Benefit Obligation - Tabular Disclosure (Details)Details93 falsefalseR94.htm99941104 - Disclosure - Employee Benefit Plans - Change in Projected Benefit Obligation - Additional Information
(Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationAdditionalInformationDetailsEmployee Benefit Plans - Change in Projected Benefit Obligation - Additional Information (Details)Details94
falsefalseR95.htm99941105 - Disclosure - Employee Benefit Plans - Change in Plan Assets (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInPlanAssetsDetailsEmployee Benefit Plans - Change in Plan Assets
(Details)Details95 falsefalseR96.htm99941106 - Disclosure - Employee Benefit Plans - Funded Status (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansFundedStatusDetailsEmployee Benefit Plans - Funded Status (Details)Details96
falsefalseR97.htm99941107 - Disclosure - Employee Benefit Plans - Accumulated Other Comprehensive Income (Loss) (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetailsEmployee
Benefit Plans - Accumulated Other Comprehensive Income (Loss) (Details)Details97 falsefalseR98.htm99941108 - Disclosure - Employee Benefit Plans - Net Periodic Pension Expense
(Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetailsEmployee Benefit Plans - Net Periodic Pension Expense (Details)Details98 falsefalseR99.htm99941109 - Disclosure - Employee Benefit Plans -
Actuarial Assumptions - Tabular Disclosure (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsTabularDisclosureDetailsEmployee Benefit Plans - Actuarial Assumptions - Tabular Disclosure (Details)Details99
falsefalseR100.htm99941110 - Disclosure - Employee Benefit Plans - Actuarial Assumptions - Additional Information (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsAdditionalInformationDetailsEmployee
Benefit Plans - Actuarial Assumptions - Additional Information (Details)Details100 falsefalseR101.htm99941111 - Disclosure - Employee Benefit Plans - Estimated Future Benefit Payments
(Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetailsEmployee Benefit Plans - Estimated Future Benefit Payments (Details)Details101 falsefalseR102.htm99941112 - Disclosure - Employee
Benefit Plans - Asset Allocation (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetailsEmployee Benefit Plans - Asset Allocation (Details)Details102 falsefalseR103.htm99941113 - Disclosure - Employee Benefit
Plans - Fair Values of Plan Assets (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetailsEmployee Benefit Plans - Fair Values of Plan Assets (Details)Details103 falsefalseR104.htm99941114 - Disclosure -
Employee Benefit Plans - Change in Fair Value of Level 3 Assets (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetailsEmployee Benefit Plans - Change in Fair Value of Level 3 Assets
(Details)Details104 falsefalseR105.htm99941115 - Disclosure - Employee Benefit Plans - Fair Value Assumptions (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValueAssumptionsDetailsEmployee Benefit Plans - Fair Value
Assumptions (Details)Details105 falsefalseR106.htm99941116 - Disclosure - Employee Benefit Plans - 401(k) Retirement Savings Plan (Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetailsEmployee
Benefit Plans - 401(k) Retirement Savings Plan (Details)Details106 falsefalseR107.htm99941117 - Disclosure - Employee Benefit Plans - Other Employee Benefit Plans
(Details)Sheethttp://www.pahc.com/role/DisclosureEmployeeBenefitPlansOtherEmployeeBenefitPlansDetailsEmployee Benefit Plans - Other Employee Benefit Plans (Details)Details107 falsefalseR108.htm99941201 - Disclosure - Income Taxes - Income
(Loss) before Income Taxes (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetailsIncome Taxes - Income (Loss) before Income Taxes (Details)Details108 falsefalseR109.htm99941202 - Disclosure - Income
Taxes - Components of Provision for Income Taxes (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetailsIncome Taxes - Components of Provision for Income Taxes (Details)Details109
falsefalseR110.htm99941203 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Rate to Effective Tax Rate
(Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetailsIncome Taxes - Reconciliation of Federal Statutory Rate to Effective Tax Rate (Details)Details110
falsefalseR111.htm99941204 - Disclosure - Income Taxes - Global Intangible Low-Taxed Income (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesGlobalIntangibleLowTaxedIncomeDetailsIncome Taxes - Global Intangible Low-Taxed Income
(Details)Details111 falsefalseR112.htm99941205 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailsIncome Taxes - Deferred Tax Assets
and Liabilities (Details)Details112 falsefalseR113.htm99941206 - Disclosure - Income Taxes - Deferred Taxes Included in Consolidated Balance Sheets
(Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxesIncludedInConsolidatedBalanceSheetsDetailsIncome Taxes - Deferred Taxes Included in Consolidated Balance Sheets (Details)Details113 falsefalseR114.htm99941207 -
Disclosure - Income Taxes - Valuation Allowance (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesValuationAllowanceDetailsIncome Taxes - Valuation Allowance (Details)Details114 falsefalseR115.htm99941208 - Disclosure - Income Taxes -
Net Operating Loss Carry Forwards (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetailsIncome Taxes - Net Operating Loss Carry Forwards (Details)Details115 falsefalseR116.htm99941209 - Disclosure -
Income Taxes - Repatriation (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetailsIncome Taxes - Repatriation (Details)Details116 falsefalseR117.htm99941210 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits
Reconciliation (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetailsIncome Taxes - Gross Unrecognized Tax Benefits Reconciliation (Details)Details117 falsefalseR118.htm99941211 -
Disclosure - Income Taxes - Liabilities Related To Uncertain Tax Positions (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesLiabilitiesRelatedToUncertainTaxPositionsDetailsIncome Taxes - Liabilities Related To Uncertain Tax Positions
(Details)Details118 falsefalseR119.htm99941212 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)Sheethttp://www.pahc.com/role/DisclosureIncomeTaxesUncertainTaxPositionsDetailsIncome Taxes - Uncertain Tax Positions
(Details)Details119 falsefalseR120.htm99941301 - Disclosure - Commitments and Contingencies - Environmental (Details)Sheethttp://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetailsCommitments and Contingencies -
Environmental (Details)Details120 falsefalseR121.htm99941302 - Disclosure - Commitments and Contingencies - Employment and Severance Agreements
(Details)Sheethttp://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEmploymentAndSeveranceAgreementsDetailsCommitments and Contingencies - Employment and Severance Agreements (Details)Details121 falsefalseR122.htm99941303 -
Disclosure - Commitments and Contingencies - Purchase Commitments (Details)Sheethttp://www.pahc.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetailsCommitments and Contingencies - Purchase Commitments
(Details)Details122 falsefalseR123.htm99941401 - Disclosure - Derivatives - General Information (Details)Sheethttp://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetailsDerivatives - General Information (Details)Details123
falsefalseR124.htm99941402 - Disclosure - Derivatives - Balance Sheet Location (Details)Sheethttp://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetailsDerivatives - Balance Sheet Location (Details)Details124
falsefalseR125.htm99941403 - Disclosure - Derivatives - Notional Amounts (Details)Sheethttp://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetailsDerivatives - Notional Amounts (Details)Details125 falsefalseR126.htm99941404 - Disclosure
- Derivatives - Effects of Derivatives (Details)Sheethttp://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetailsDerivatives - Effects of Derivatives (Details)Details126 falsefalseR127.htm99941405 - Disclosure - Derivatives - Additional

Information (Details)Sheethttp://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetailsDerivatives - Additional Information (Details)Details127 falsefalseR128.htm99941501 - Disclosure - Fair Value Measurements - Fair Value of Assets (Details)Sheethttp://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetailsFair Value Measurements - Fair Value of Assets (Details)Details128 falsefalseR129.htm99941502 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis, Unobservable Inputs (Details)Sheethttp://www.pahc.com/role/DisclosureFairValueMeasurementsAssetsMeasuredOnRecurringBasisUnobservableInputsDetailsFair Value Measurements - Assets Measured on Recurring Basis, Unobservable Inputs (Details)Details129 falsefalseR130.htm99941503 - Disclosure - Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details)Sheethttp://www.pahc.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredOnRecurringBasisUnobservableInputsDetailsFair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details)Details130 falsefalseR131.htm99941601 - Disclosure - Business Segments - General Information (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsGeneralInformationDetailsBusiness Segments - General Information (Details)Details131 falsefalseR132.htm99941602 - Disclosure - Business Segments - Net Sales (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetailsBusiness Segments - Net Sales (Details)Details132 falsefalseR133.htm99941603 - Disclosure - Business Segments - Depreciation and Amortization (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetailsBusiness Segments - Depreciation and Amortization (Details)Details133 falsefalseR134.htm99941604 - Disclosure - Business Segments - Adjusted EBITDA (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetailsBusiness Segments - Adjusted EBITDA (Details)Details134 falsefalseR135.htm99941605 - Disclosure - Business Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetailsBusiness Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA (Details)Details135 falsefalseR136.htm99941606 - Disclosure - Business Segments - Identifiable Assets (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetailsBusiness Segments - Identifiable Assets (Details)Details136 falsefalseR137.htm99941607 - Disclosure - Business Segments - Property, Plant and Equipment, Net (Details)Sheethttp://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetailsBusiness Segments - Property, Plant and Equipment, Net (Details)Details137 falsefalseR138.htm99941701 - Disclosure - Subsequent Event - 2024 Credit Agreement - General Information (Details)Sheethttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetailsSubsequent Event - 2024 Credit Agreement - General Information (Details)Details138 falsefalseR139.htm99941702 - Disclosure - Subsequent Event - 2024 Credit Agreement - Interest Rates (Details)Sheethttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetailsSubsequent Event - 2024 Credit Agreement - Interest Rates (Details)Details139 falsefalseR140.htm99941703 - Disclosure - Subsequent Event - 2024 Credit Agreement - Financial Covenants (Details)Sheethttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetailsSubsequent Event - 2024 Credit Agreement - Financial Covenants (Details)Details140 falsefalseR141.htm99941704 - Disclosure - Subsequent Event - 2024 Credit Agreement - Derivatives (Details)Sheethttp://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetailsSubsequent Event - 2024 Credit Agreement - Derivatives (Details)Details141 falsefalseAll ReportsBookAll Reports pahc-20240630.xsdpahc-20240630_cal.xmlpahc-20240630_def.xmlpahc-20240630_lab.xmlpahc-20240630_pre.xmlpahc-20240630x10k.htm pahc-20240630x10k009.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 172 MetaLinks.json IDEA: XBRL DOCUMENT { "version":"2.2", "instance": { "pahc-20240630x10k.htm": { "nsprefix": "pahc", "nsuri":"http://www.pahc.com/20240630", "dts": { "schema": { "local": ["pahc-20240630.xsd"], "remote":["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["pahc-20240630_cal.xml"] }, "definitionLink": { "local": ["pahc-20240630_def.xml"] }, "labelLink": { "local": ["pahc-20240630_lab.xml"] }, "presentationLink": { "local": ["pahc-20240630_pre.xml"] }, "inline": { "local": ["pahc-20240630x10k.htm"] } }, "keyStandard": 438, "keyCustom": 80, "axisStandard": 32, "axisCustom": 0, "memberStandard": 62, "memberCustom": 40, "hidden": { "total": 64, "http://fasb.org/us-gaap/2024": 61, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 318, "entityCount": 1, "segmentCount": 105, "elementCount": 970, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1190, "http://xbrl.sec.gov/dei/2024": 43, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.pahc.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations", "longName": "995200100 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R4": { "role": "http://www.pahc.com/role/StatementConsolidatedBalanceSheets", "longName": "995200300 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals", "longName": "995200305 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_UE0n3PUYt0eZyDIE6n0Obg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "995200500 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KZRVnyyixkayOWaOxn7V5Q", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KZRVnyyixkayOWaOxn7V5Q", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2j-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParentheticals", "longName": "995200505 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals)", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "Unit_Divide_USD_shares_UE0n3PUYt0eZyDIE6n0Obg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pahc.com/role/DisclosureDescriptionOfBusiness", "longName": "995210101 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandards", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards", "shortName": "Summary of Significant Accounting Policies and New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pahc.com/role/DisclosureProposedAcquisition", "longName": "995210301 - Disclosure - Proposed Acquisition", "shortName": "Proposed Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformation", "longName": "995210401 - Disclosure - Statements of Operations-Additional Information", "shortName": "Statements of Operations-Additional Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformation", "longName": "995210501 - Disclosure - Balance Sheets-Additional Information", "shortName": "Balance Sheets-Additional Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.pahc.com/role/DisclosureDebt", "longName": "995210601 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.pahc.com/role/DisclosureLeases", "longName": "995210701 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividends", "longName": "995210801 - Disclosure - Common Stock, Preferred Stock and Dividends", "shortName": "Common Stock, Preferred Stock and Dividends", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pahc.com/role/DisclosureStockIncentivePlan", "longName": "995210901 - Disclosure - Stock Incentive Plan", "shortName": "Stock Incentive Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.pahc.com/role/DisclosureRelatedPartyTransactions", "longName": "995211001 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlans", "longName": "995211101 - Disclosure - Employee Benefit Plans", "shortName": "Employee Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxes", "longName": "995211201 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.pahc.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211301 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.pahc.com/role/DisclosureDerivatives", "longName": "995211401 - Disclosure - Derivatives", "shortName": "Derivatives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.pahc.com/role/DisclosureFairValueMeasurements", "longName": "995211501 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.pahc.com/role/DisclosureBusinessSegments", "longName": "995211601 - Disclosure - Business Segments", "shortName": "Business Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }], "R31": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables", "longName": "99930503 - Disclosure - Balance Sheets-Additional Information (Tables)", "shortName": "Balance Sheets-Additional Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.pahc.com/role/DisclosureDebtTables", "longName": "99930603 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.pahc.com/role/DisclosureLeasesTables", "longName": "99930703 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsTables", "longName": "99930803 - Disclosure - Common Stock, Preferred Stock and Dividends (Tables)", "shortName": "Common Stock, Preferred Stock and Dividends (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables", "longName": "99931103 - Disclosure - Employee Benefit Plans (Tables)", "shortName": "Employee Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxesTables", "longName": "99931203 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.pahc.com/role/DisclosureDerivativesTables", "longName": "99931403 - Disclosure - Derivatives (Tables)", "shortName": "Derivatives (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.pahc.com/role/DisclosureFairValueMeasurementsTables", "longName": "99931503 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.pahc.com/role/DisclosureBusinessSegmentsTables", "longName": "99931603 - Disclosure - Business Segments (Tables)", "shortName": "Business Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementTables", "longName": "99931703 - Disclosure - Subsequent Event - 2024 Credit Agreement (Tables)", "shortName": "Subsequent Event - 2024 Credit Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:ScheduleOfLongTermDebtInstrumentsBasisSpreadOnVariableRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:ScheduleOfLongTermDebtInstrumentsBasisSpreadOnVariableRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Accounts Receivable and Allowance for Doubtful Accounts (Details)", "shortName": "Summary of Significant Accounting Policies and New Accounting Standards - Accounts Receivable and Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_MajorCustomersAxis_pahc_TenLargestCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_U4E-H1i6JkupLn6e5ZDB-w", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_MajorCustomersAxis_pahc_TenLargestCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_U4E-H1i6JkupLn6e5ZDB-w", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Property, Plant and Equipment and Capitalized Software (Details)", "shortName": "Summary of Significant Accounting Policies and New Accounting Standards - Property, Plant and Equipment and Capitalized Software (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_6_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_wcyw3dXFskSUXm44vGbDqA", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_wcyw3dXFskSUXm44vGbDqA", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingStandardsDerivativeFinancialInstrumentsDetails", "longName": "99940203 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Derivative Financial Instruments (Details)", "shortName": "Summary of Significant Accounting Policies and New Accounting Standards - Derivative Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_d_ZkZNugxUG4shr8NhdvEQ", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails", "longName": "99940204 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - Net Income Per Share and Weighted Average Shares (Details)", "shortName": "Summary of Significant Accounting Policies and New Accounting Standards - Net Income Per Share and Weighted Average Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R45": { "role": "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails", "longName": "99940205 - Disclosure - Summary of Significant Accounting Policies and New Accounting Standards - New Accounting Standards (Details)", "shortName": "Summary of Significant Accounting Policies and New Accounting Standards - New Accounting Standards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202307Member_jBg16I2380SUA6Q2soSaSw", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202307Member_jBg16I2380SUA6Q2soSaSw", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.pahc.com/role/DisclosureProposedAcquisitionDetails", "longName": "99940301 - Disclosure - Proposed Acquisition (Details)", "shortName": "Proposed Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_4_1_2024_to_2024_us-gaap_AssetAcquisitionAxis_pahc_ZoetisIncMedicatedFeedAdditivesProductPortfolioMember_59XatRpP70lhdPHUiK8JbA", "name": "us-gaap:AssetAcquisitionPriceOfAcquisitionExpected", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_to_2024_us-gaap_AssetAcquisitionAxis_pahc_ZoetisIncMedicatedFeedAdditivesProductPortfolioMember_59XatRpP70lhdPHUiK8JbA", "name": "us-gaap:AssetAcquisitionPriceOfAcquisitionExpected", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationSegmentsDetails", "longName": "99940401 - Disclosure - Statements of Operations-Additional Information - Segments (Details)", "shortName": "Statements of Operations-Additional Information - Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_yStHKpOx0ihu7V5A4OW4g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails", "longName": "99940402 - Disclosure - Statements of Operations-Additional Information - Net Sales by Product Type (Details)", "shortName": "Statements of Operations-Additional Information - Net Sales by Product Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_ProductOrServiceAxis_pahc_AnimalHealthMember_QCMPfhQnL0yC2BJGF3Iq_A", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R49": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails", "longName": "99940403 - Disclosure - Statements of Operations-Additional Information - Net Sales by Region (Details)", "shortName": "Statements of Operations-Additional Information - Net Sales by Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_StatementGeographicalAxis_country_US_0tMdy69HY02fDmt-6uFsyQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R50": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationGeneralInformationDetails", "longName": "99940404 - Disclosure - Statements of Operations-Additional Information - General Information (Details)", "shortName": "Statements of Operations-Additional Information - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:PaymentTermLowEndOfRange", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:PaymentTermLowEndOfRange", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails", "longName": "99940405 - Disclosure - Statements of Operations-Additional Information - Interest Expense, Net (Details)", "shortName": "Statements of Operations-Additional Information - Interest Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:InterestExpenseOther", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfInterestExpenseNetTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R52": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationCapitalizedSoftwareDetails", "longName": "99940406 - Disclosure - Statements of Operations-Additional Information - Capitalized Software (Details)", "shortName": "Statements of Operations-Additional Information - Capitalized Software (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CapitalizedComputerSoftwareAmortization1", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CapitalizedComputerSoftwareAmortization1", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails", "longName": "99940407 - Disclosure - Statements of Operations-Additional Information - Amortization of Intangible Assets (Details)", "shortName": "Statements of Operations-Additional Information - Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationDepreciationAndAmortizationDetails", "longName": "99940408 - Disclosure - Statements of Operations-Additional Information - Depreciation and Amortization (Details)", "shortName": "Statements of Operations-Additional Information - Depreciation and Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfDepreciationAndAmortizationTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfDepreciationAndAmortizationTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationResearchAndDevelopmentExpenseDetails", "longName": "99940409 - Disclosure - Statements of Operations-Additional Information - Research and Development Expense (Details)", "shortName": "Statements of Operations-Additional Information - Research and Development Expense (Details)", "isDefault":

"R59": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "longName": "99940504 - Disclosure - Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Tabular Disclosure (Details)", "shortName": "Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetAdditionalInformationDetails", "longName": "99940505 - Disclosure - Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Additional Information (Details)", "shortName": "Balance Sheets-Additional Information - Property, Plant and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:CapitalizedComputerSoftwareNet", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:CapitalizedComputerSoftwareNet", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails", "longName": "99940506 - Disclosure - Balance Sheets-Additional Information - Intangibles, Net - Weighted-Average Useful Life (Details)", "shortName": "Balance Sheets-Additional Information - Intangibles, Net - Weighted-Average Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_6_30_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_VEDOGkV0XUqjm_8BGKTueQ", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_VEDOGkV0XUqjm_8BGKTueQ", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails", "longName": "99940507 - Disclosure - Balance Sheets-Additional Information - Intangibles, Net - Total (Details)", "shortName": "Balance Sheets-Additional Information - Intangibles, Net - Total (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationGoodwillDetails", "longName": "99940508 - Disclosure - Balance Sheets-Additional Information - Goodwill (Details)", "shortName": "Balance Sheets-Additional Information - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_6_30_2023_N73EKU9IEGsnuFaP2zrw", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_3BJAvmHzU-69whaCkgoVg", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R64": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails", "longName": "99940509 - Disclosure - Balance Sheets-Additional Information - Other Assets (Details)", "shortName": "Balance Sheets-Additional Information - Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DepositsAssets", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R65": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "99940510 - Disclosure - Balance Sheets-Additional Information - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Balance Sheets-Additional Information - Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "pahc:AccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "pahc:AccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInsurancePremiumFinancingDetails", "longName": "99940511 - Disclosure - Balance Sheets-Additional Information - Insurance Premium Financing (Details)", "shortName": "Balance Sheets-Additional Information - Insurance Premium Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:InsurancePremiumFinancingFixedInterestRatePercentage", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p", "pahc:AccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:InsurancePremiumFinancingFixedInterestRatePercentage", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p", "pahc:AccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails", "longName": "99940512 - Disclosure - Balance Sheets-Additional Information - Other Liabilities (Details)", "shortName": "Balance Sheets-Additional Information - Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:LongTermDeferredIncomeTaxes", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table": "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R68": { "role": "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "99940513 - Disclosure - Balance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Balance Sheets-Additional Information - Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_yBTDYQurkSWcvot091FIA", "name": "us-gaap:AociBeforeTaxAttributableToParent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "p", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R69": { "role": "http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "longName": "99940601 - Disclosure - Debt - General Information (Details)", "shortName": "Debt - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_pahc_CreditFacilitiesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_9Jwkm8hgT06UpGyRgx4WmA", "name": "pahc:DebtInstrumentCovenantsFirstLienNetLeverageRatioTrailingFourQuarterBasisMaximum", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_pahc_CreditFacilitiesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_9Jwkm8hgT06UpGyRgx4WmA", "name": "pahc:DebtInstrumentCovenantsFirstLienNetLeverageRatioTrailingFourQuarterBasisMaximum", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p": "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRateDetails", "longName": "99940602 - Disclosure - Debt - Interest Rates - Stated Rate (Details)", "shortName": "Debt - Interest Rates - Stated Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_pahc_RevolverMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_ziEpRD59IEuhIjlKLioBg", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p": "td", "tr", "table": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_pahc_RevolverMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_ziEpRD59IEuhIjlKLioBg", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p", "td", "tr", "table": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "longName": "99940603 - Disclosure - Debt - Interest Rates - Weighted Average Rates (Details)", "shortName": "Debt - Interest Rates - Weighted Average Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_DebtInstrumentAxis_pahc_RevolverMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_wBd5fKEqkkqoB80v7tEdBA", "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p", "td", "tr", "table": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_DebtInstrumentAxis_pahc_RevolverMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_wBd5fKEqkkqoB80v7tEdBA", "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p": "td", "tr", "table": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "longName": "99940604 - Disclosure - Debt - Derivatives (Details)", "shortName": "Debt - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_d_ZkZNugxUG4shr8NhdvEQ", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": null }, "R73": { "role": "http://www.pahc.com/role/DisclosureDebtReconciliationDetails", "longName": "99940605 - Disclosure - Debt - Reconciliation (Details)", "shortName": "Debt - Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R74": { "role": "http://www.pahc.com/role/DisclosureDebtClassificationDetails", "longName": "99940606 - Disclosure - Debt - Classification (Details)", "shortName": "Debt - Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true } }, "R75": { "role": "http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails", "longName": "99940607 - Disclosure - Debt - Aggregate Maturities of Long-Term Debt and Revolver (Details)", "shortName": "Debt - Aggregate Maturities of Long-Term Debt and Revolver (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:LongTermDebtGrossMaturityYearOne", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:LongTermDebtGrossMaturityYearOne", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails", "longName": "99940701 - Disclosure - Leases - General Information (Details)", "shortName": "Leases - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_6_30_2024_srt_RangeAxis_srt_MaximumMember_u7TnU-G3-UmTRvOM3xnoxQ", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_RangeAxis_srt_MaximumMember_u7TnU-G3-UmTRvOM3xnoxQ", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails", "longName": "99940702 - Disclosure - Leases - Assets and Liabilities (Details)", "shortName": "Leases - Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails", "longName": "99940703 - Disclosure - Leases - Composition of Net Lease Cost (Details)", "shortName": "Leases - Composition of Net Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.pahc.com/role/DisclosureLeasesOtherSupplementalInformationDetails", "longName": "99940704 - Disclosure - Leases - Other Supplemental Information (Details)", "shortName": "Leases - Other Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails", "longName": "99940705 - Disclosure - Leases - Maturities of Future Lease Liabilities (Details)", "shortName": "Leases - Maturities of Future Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.pahc.com/role/DisclosureLeasesGrossDifferenceDetails", "longName": "99940706 - Disclosure - Leases - Gross Difference (Details)", "shortName": "Leases - Gross Difference (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr", "table": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R82": { "role": "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommon

gaap_RestrictedStockUnitsRSUMember_rq7CyId7d0yVZ2eFUzVTRQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_rq7CyId7d0yVZ2eFUzVTRQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "longName": "99940904 - Disclosure - Stock Incentive Plan - Cost Not yet Recognized (Details)", "shortName": "Stock Incentive Plan - Cost Not yet Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_xP4Rrz-ND0eR0RkgEGfxsQ", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_xP4Rrz-ND0eR0RkgEGfxsQ", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941101 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_RelatedPartyTransactionAxis_pahc_CompensationAndBenefitForServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_jxhRGr75oEWkmO8LBUziDQ", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_RelatedPartyTransactionAxis_pahc_CompensationAndBenefitForServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_jxhRGr75oEWkmO8LBUziDQ", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansGeneralInformationDetails", "longName": "99941101 - Disclosure - Employee Benefit Plans - General Information (Details)", "shortName": "Employee Benefit Plans - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": null, "uniqueAnchor": null }, "R92": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAnnuityPurchaseAgreementDetails", "longName": "99941102 - Disclosure - Employee Benefit Plans - Annuity Purchase Agreement (Details)", "shortName": "Employee Benefit Plans - Annuity Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_7_31_2023_qqeTtbjXgkKxqhE4XnXXow", "name": "pahc:DefinedBenefitPlanSettlementAnnuityPurchaseAgreementBenefitObligationAnnuityPurchasePrice", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_7_31_2023_qqeTtbjXgkKxqhE4XnXXow", "name": "pahc:DefinedBenefitPlanSettlementAnnuityPurchaseAgreementBenefitObligationAnnuityPurchasePrice", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails", "longName": "99941103 - Disclosure - Employee Benefit Plans - Change in Projected Benefit Obligation - Tabular Disclosure (Details)", "shortName": "Employee Benefit Plans - Change in Projected Benefit Obligation - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "As_Of_6_30_2023_N73EKU9HEGsunuFaP2zrw", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R94": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationAdditionalInformationDetails", "longName": "99941104 - Disclosure - Employee Benefit Plans - Change in Projected Benefit Obligation - Additional Information (Details)", "shortName": "Employee Benefit Plans - Change in Projected Benefit Obligation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:DefinedBenefitPlanProjectedBenefitObligationDiscountRate", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:DefinedBenefitPlanProjectedBenefitObligationDiscountRate", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInPlanAssetsDetails", "longName": "99941105 - Disclosure - Employee Benefit Plans - Change in Plan Assets (Details)", "shortName": "Employee Benefit Plans - Change in Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "As_Of_6_30_2023_N73EKU9HEGsunuFaP2zrw", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R96": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFundedStatusDetails", "longName": "99941106 - Disclosure - Employee Benefit Plans - Funded Status (Details)", "shortName": "Employee Benefit Plans - Funded Status (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R97": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "99941107 - Disclosure - Employee Benefit Plans - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Employee Benefit Plans - Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "As_Of_6_30_2023_N73EKU9HEGsunuFaP2zrw", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodAmortizationOfNetActuarialLossBeforeTax", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R98": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails", "longName": "99941108 - Disclosure - Employee Benefit Plans - Net Periodic Pension Expense (Details)", "shortName": "Employee Benefit Plans - Net Periodic Pension Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedBenefitPlanInterestCost", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNetBenefitCostTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R99": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsTabularDisclosureDetails", "longName": "99941109 - Disclosure - Employee Benefit Plans - Actuarial Assumptions - Tabular Disclosure (Details)", "shortName": "Employee Benefit Plans - Actuarial Assumptions - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsAdditionalInformationDetails", "longName": "99941110 - Disclosure - Employee Benefit Plans - Actuarial Assumptions - Additional Information (Details)", "shortName": "Employee Benefit Plans - Actuarial Assumptions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:MinimumParValueRequiredForCorporateBondToDetermineDiscountRate", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "pahc:MinimumParValueRequiredForCorporateBondToDetermineDiscountRate", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "longName": "99941111 - Disclosure - Employee Benefit Plans - Estimated Future Benefit Payments (Details)", "shortName": "Employee Benefit Plans - Estimated Future Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails", "longName": "99941112 - Disclosure - Employee Benefit Plans - Asset Allocation (Details)", "shortName": "Employee Benefit Plans - Asset Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanDebtSecurityMember_cPJ26AIIdUaRUWO3F88OGg", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanDebtSecurityMember_cPJ26AIIdUaRUWO3F88OGg", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValueOfPlanAssets", "longName": "99941113 - Disclosure - Employee Benefit Plans - Fair Values of Plan Assets (Details)", "shortName": "Employee Benefit Plans - Fair Values of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_DPmI-QitmEiwAlO8v8i_GQ", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R104": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails", "longName": "99941114 - Disclosure - Employee Benefit Plans - Change in Fair Value of Level 3 Assets (Details)", "shortName": "Employee Benefit Plans - Change in Fair Value of Level 3 Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "As_Of_6_30_2023_N73EKU9HEGsunuFaP2zrw", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1PeVKvGMmUanD4z2_UhzcQ", "name": "us-gaap:DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R105": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValueAssumptionsDetails", "longName": "99941115 - Disclosure - Employee Benefit Plans - Fair Value Assumptions (Details)", "shortName": "Employee Benefit Plans - Fair Value Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:DefinedBenefitPlanCashAndCashEquivalentsMeasurementInputPricePerUnit", "unitRef": "Unit_Divide_USD_shares_UE0n3PUYt0eZyDIE6n0Obg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:DefinedBenefitPlanCashAndCashEquivalentsMeasurementInputPricePerUnit", "unitRef": "Unit_Divide_USD_shares_UE0n3PUYt0eZyDIE6n0Obg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetails", "longName": "99941116 - Disclosure - Employee Benefit Plans - 401(k) Retirement Savings Plan (Details)", "shortName": "Employee Benefit Plans - 401(k) Retirement Savings Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansOtherEmployeeBenefitPlansDetails", "longName": "99941117 - Disclosure - Employee Benefit Plans - Other Employee Benefit Plans (Details)", "shortName": "Employee Benefit Plans - Other Employee Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetails", "longName": "99941201 - Disclosure - Income Taxes - Income (Loss) before Income Taxes (Details)", "shortName": "Income Taxes - Income (Loss) before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails", "longName": "99941202 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)", "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAajh8GhhDA", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_pvdPTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.pahc.com/role/DisclosureIncom

"-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R116": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails",
"longName": "99941209 - Disclosure - Income Taxes - Repatriation (Details)", "shortName": "Income Taxes - Repatriation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116",
"firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "pahc:AccruedTaxLiabilityExpectedRepatriationOfInternationalEarnings", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag",
"name": "pahc:AccruedTaxLiabilityExpectedRepatriationOfInternationalEarnings", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"],
"reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails", "longName": "99941210 - Disclosure -
Income Taxes - Gross Unrecognized Tax Benefits Reconciliation (Details)", "shortName": "Income Taxes - Gross Unrecognized Tax Benefits Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "117", "firstAnchor": { "contextRef": "As_Of_6_30_2023_N73EKU9IlEGsunuFaP2zrw", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true },
"uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-
sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-
20240630x10k.htm", "unique": true } }, "R118": { "role": "http://www.pahc.com/role/DisclosureIncomeTaxesLiabilitiesRelatedToUncertainTaxPositionsDetails", "longName": "99941211 - Disclosure - Income Taxes - Liabilities Related To Uncertain Tax
Positions (Details)", "shortName": "Income Taxes - Liabilities Related To Uncertain Tax Positions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef":
"As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef":
"As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R119": { "role":
"http://www.pahc.com/role/DisclosureIncomeTaxesUncertainTaxPositionsDetails", "longName": "99941212 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)", "shortName": "Income Taxes - Uncertain Tax Positions (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-
gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1,
"baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } },
"R120": { "role": "http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetails", "longName": "99941301 - Disclosure - Commitments and Contingencies - Environmental (Details)", "shortName": "Commitments and
Contingencies - Environmental (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "Duration_2_1_2023_To_6_30_2024_HhyePryy8EWstIPI0KQoUw",
"name": "us-gaap:PaymentsForEnvironmentalLiabilities", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1,
"baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_2_1_2023_To_6_30_2024_HhyePryy8EWstIPI0KQoUw", "name": "us-gaap:PaymentsForEnvironmentalLiabilities", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } },
"R121": { "role": "http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEmploymentAndSeveranceAgreementsDetails", "longName": "99941302 - Disclosure - Commitments and Contingencies - Employment and Severance Agreements
(Details)", "shortName": "Commitments and Contingencies - Employment and Severance Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef":
"Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "pahc:EmploymentAgreementsCertainExecutiveManagementAndOtherEmployeesSeveranceBenefitsTermHighEndOfRange", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "pahc:EmploymentAgreementsCertainExecutiveManagementAndOtherEmployeesSeveranceBenefitsTermHighEndOfRange", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R122": { "role":
"http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "longName": "99941303 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)", "shortName": "Commitments and
Contingencies - Purchase Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-
gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"],
"reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
"unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique":
true } }, "R123": { "role": "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "longName": "99941401 - Disclosure - Derivatives - General Information (Details)", "shortName": "Derivatives - General Information (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_d_ZkZNugxUG4shr8NhdvEQ", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R124": { "role":
"http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "longName": "99941402 - Disclosure - Derivatives - Balance Sheet Location (Details)", "shortName": "Derivatives - Balance Sheet Location (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_iQPbpyA44U2X98zNMXWUOw", "name": "us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-
gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-
gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_iQPbpyA44U2X98zNMXWUOw", "name": "us-
gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-
gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R125": {
"role": "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "longName": "99941403 - Disclosure - Derivatives - Notional Amounts (Details)", "shortName": "Derivatives - Notional Amounts (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_PositionAxis_us-gaap_LongMember_m4kdhMUrpU2K9BPfWeYF3A", "name": "us-gaap:DerivativeNotionalAmount", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-
gaap_CashFlowHedgingMember_us-gaap_PositionAxis_us-gaap_LongMember_m4kdhMUrpU2K9BPfWeYF3A", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R126": { "role":
"http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails", "longName": "99941404 - Disclosure - Derivatives - Effects of Derivatives (Details)", "shortName": "Derivatives - Effects of Derivatives (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": {
"contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_kp3qhCRHT0aexJV4XB0sYg", "name": "us-
gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-
gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R127": { "role":
"http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "longName": "99941405 - Disclosure - Derivatives - Additional Information (Details)", "shortName": "Derivatives - Additional Information (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_iQPbpyA44U2X98zNMXWUOw", "name": "pahc:RealizedGainLossOnMaturedContractsRecordedAsInventory", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-
gaap_CashFlowHedgingMember_iQPbpyA44U2X98zNMXWUOw", "name": "pahc:RealizedGainLossOnMaturedContractsRecordedAsInventory", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R128": { "role":
"http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails", "longName": "99941501 - Disclosure - Fair Value Measurements - Fair Value of Assets (Details)", "shortName": "Fair Value Measurements - Fair Value of Assets
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:ShortTermInvestments", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": {
"contextRef": "As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_DPmI-QitmEiwAlO8v8i_GQ", "name": "us-gaap:ShortTermInvestments", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef":
"pahc-20240630x10k.htm", "unique": true } }, "R129": { "role": "http://www.pahc.com/role/DisclosureFairValueMeasurementsAssetsMeasuredOnRecurringBasisUnobservableInputsDetails", "longName": "99941502 - Disclosure - Fair Value Measurements -
Assets Measured on Recurring Basis, Unobservable Inputs (Details)", "shortName": "Fair Value Measurements - Assets Measured on Recurring Basis, Unobservable Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "p", "ix:continuation", "div", "div",
"body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R130": { "role": "http://www.pahc.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredOnRecurringBasisUnobservableInputsDetails",
"longName": "99941503 - Disclosure - Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details)", "shortName": "Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Inputs (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "p", "ix:continuation", "div", "div", "body",
"html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R131": { "role": "http://www.pahc.com/role/DisclosureBusinessSegmentsGeneralInformationDetails", "longName": "99941601 - Disclosure - Business
Segments - General Information (Details)", "shortName": "Business Segments - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef":
"Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_yStHlKpQx0ihu7V5A4QW4g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-
gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R132": { "role":
"http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "longName": "99941602 - Disclosure - Business Segments - Net Sales (Details)", "shortName": "Business Segments - Net Sales (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true },
"uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_pahc_AnimalHealthMember_Ew8E80yvkkCqaidS8dpqHg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div",
"div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R133": { "role": "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "longName": "99941603 - Disclosure -
Business Segments - Depreciation and Amortization (Details)", "shortName": "Business Segments - Depreciation and Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133",
"firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R134": { "role":
"http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "longName": "99941604 - Disclosure - Business Segments - Adjusted EBITDA (Details)", "shortName": "Business Segments - Adjusted EBITDA (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_9ldCoDpH4Uy1L7zvXAr-5Q",
"name": "pahc:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R135": { "role":
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "longName": "99941605 - Disclosure - Business Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA
(Details)", "shortName": "Business Segments - Reconciliation of Income before Income Taxes to Adjusted EBITDA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": {
"contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": {
"contextRef": "Duration_7_1_2023_To_6_30_2024_32o5R5r1n0KmAaJh8GhhDA", "name": "pahc:CorporateCosts", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr",
"table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R136": { "role":
"http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "longName": "99941606 - Disclosure - Business Segments - Identifiable Assets (Details)", "shortName": "Business Segments - Identifiable Assets (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag", "name": "us-gaap:Assets", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": {
"contextRef": "As_Of_6_30_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_7jEejPnKGE6lD6HnVVuWfQ", "name": "us-gaap:Assets", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true
} }, "R137": { "role": "http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails", "longName": "99941607 - Disclosure - Business Segments - Property, Plant and Equipment, Net (Details)", "shortName": "Business
Segments - Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "As_Of_6_30_2024_alzDFn2oxEu-d4WnjHHkag",
"name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef":
"pahc-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_StatementGeographicalAxis_country_US_4jg6n1l4yUGz7_puH-dU0g", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef":
"Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "div", "div", "body", "html"],
"reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "unique": true } }, "R138": { "role": "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "longName": "99941701 - Disclosure - Subsequent
Event - 2024 Credit Agreement - General Information (Details)", "shortName": "Subsequent Event - 2024 Credit Agreement - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "138", "firstAnchor": { "contextRef": "As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_pahc_CreditAgreement20242024CreditFacilitiesInitialTerm1LoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-
gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cxxiSx_dtUapa1yfG2DlLg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_7_31_2024_us-
gaap_DebtInstrumentAxis_pahc_CreditAgreement20242024CreditFacilitiesInitialTerm1LoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-
gaap_SubsequentEventMember_cxxiSx_dtUapa1yfG2DlLg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-
gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R139": { "role":
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails", "longName": "99941702 - Disclosure - Subsequent Event - 2024 Credit Agreement - Interest Rates (Details)", "shortName": "Subsequent Event - 2024
Credit Agreement - Interest Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef":
"Duration_7_1_2024_To_7_31_2024_srt_StatementScenarioAxis_pahc_DebtInstrumentBasisSpreadOnVariableRateScenarioOneMember_us-
gaap_DebtInstrumentAxis_pahc_CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-
gaap_SubsequentEventMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_mzDq1bux4U2RXsAM0pyw-w", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil":
"false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfLongTermDebtInstrumentsBasisSpreadOnVariableRateTableTextBlock", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1,
"baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_srt_StatementScenarioAxis_pahc_DebtInstrumentBasisSpreadOnVariableRateScenarioOneMember_us-
gaap_DebtInstrumentAxis_pahc_CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsAndTerm1LoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-
gaap_SubsequentEventMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_mzDq1bux4U2RXsAM0pyw-w", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil":
"false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfLongTermDebtInstrumentsBasisSpreadOnVariableRateTableTextBlock", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1,
"baseRef": "pahc-20240630x10k.htm", "first": true, "unique": true } }, "R140": { "role": "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "longName": "99941703 - Disclosure - Subsequent Event -
2024 Credit Agreement - Financial Covenants (Details)", "shortName": "Subsequent Event - 2024 Credit Agreement - Financial Covenants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"140", "firstAnchor": { "contextRef": "As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_pahc_CreditAgreement2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-
gaap_SubsequentEventMember_FNinNXhd6EKPk9b4DodfRQ", "name": "pahc:DebtInstrumentCovenantsNetLeverageRatioPriorToClosingDateMaximum", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfLongTermDebtInstrumentsCovenantsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_pahc_CreditAgreement2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-
gaap_SubsequentEventMember_FNinNXhd6EKPk9b4DodfRQ", "name": "pahc:DebtInstrumentCovenantsNetLeverageRatioPriorToClosingDateMaximum", "unitRef": "Unit_Standard_pure_5Z4y3QYFtkCgDrnBF99OjQ", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": ["p", "td", "tr", "table", "pahc:ScheduleOfLongTermDebtInstrumentsCovenantsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-20240630x10k.htm", "first": true, "unique":
true } }, "R141": { "role": "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "longName": "99941704 - Disclosure - Subsequent Event - 2024 Credit Agreement - Derivatives (Details)", "shortName":
"Subsequent Event - 2024 Credit Agreement - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-
gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_d_ZkZNugxUG4shr8NhdvEQ", "name": "us-gaap:DerivativeNotionalAmount",
"unitRef": "Unit_Standard_USD_pvdDTsfnSEGaAqZPI2J-sA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "pahc-
20240630x10k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AOCIAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentAbstract", "presentation":
["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Abstract]", "terseLabel": "Accumulated other
comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of
Significant Accounting Policies and New Accounting Standards" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202307Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccountingStandardsUpdate202307Member", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label":
"Accounting Standards Update 2023-07 [Member]", "terseLabel": "Accounting Standards Update 2023-07", "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." } }
}, "auth_ref": ["r347", "r348"] }, "us-gaap_AccountingStandardsUpdate202309Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202309Member", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2023-09 [Member]", "terseLabel":

"Accounting Standards Update 2023-09", "documentation": "Accounting Standards Update 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures." } }, "auth_ref": ["r686", "r687", "r688"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r99", "r1127"] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of reserve for credit losses", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r1303"] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGross", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccountsReceivableNetDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Gross", "verboseLabel": "Trade accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r232", "r349", "r350", "r1496"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r1047"] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccountsReceivableNetDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net", "totalLabel": "Trade accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r977", "r1046", "r1148", "r1495", "r1496"] }, "us-gaap_AccountsReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccountsReceivableNetDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net [Abstract]", "verboseLabel": "Accounts receivable, net" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1297"] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetails"], "lang": { "en-us": { "role": { "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Accrual for environmental loss contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": ["r438", "r1093", "r1249", "r1250", "r1332", "r1335"] }, "us-gaap_AccrualForEnvironmentalLossContingenciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingenciesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetails"], "lang": { "en-us": { "role": { "label": "Accrual for Environmental Loss Contingencies [Abstract]", "terseLabel": "Environmental" } } }, "auth_ref": [] }, "pahc_AccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Liabilities, Current [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedInsuranceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedInsuranceCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Insurance, Current", "terseLabel": "Insurance-related", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r102"] }, "pahc_AccruedInsurancePremiumFinancingCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AccruedInsurancePremiumFinancingCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued Insurance Premium Financing, Current", "label": "Accrued Insurance Premium Financing, Current", "terseLabel": "Insurance premium financing" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "pahc_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities and Other Liabilities, Current", "label": "Accrued Liabilities and Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities, total" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "verboseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r102"] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Sales Commission, Current", "verboseLabel": "Commissions and rebates", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r102", "r1070"] }, "pahc_AccruedTaxLiabilityExpectedRepatriationOfInternationalEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AccruedTaxLiabilityExpectedRepatriationOfInternationalEarnings", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued Tax Liability, Expected Repatriation of International Earnings", "label": "Accrued Tax Liability, Expected Repatriation of International Earnings", "terseLabel": "Liability related to the expected repatriation of international earnings" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": ["r3", "r4", "r13", "r26", "r126", "r267", "r1268", "r1269"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r55", "r222", "r881"] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r241", "r249", "r250", "r717", "r1075", "r1267"] }, "pahc_AccumulatedOtherComprehensiveIncomeLongTermIntercompanyInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AccumulatedOtherComprehensiveIncomeLongTermIntercompanyInvestmentsMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "documentation": "Accumulated Other Comprehensive Income, Long-term Intercompany Investments [Member]", "label": "Accumulated Other Comprehensive Income, Long-term Intercompany Investments [Member]", "terseLabel": "Accumulated Other Comprehensive Income, Long-term Intercompany" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r240", "r249", "r273", "r774", "r775", "r776", "r777", "r778"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated other comprehensive income", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r25", "r26", "r127", "r233", "r875", "r919", "r923"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r248", "r249", "r773", "r774", "r775", "r776", "r777", "r778"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r13", "r26", "r728", "r731", "r809", "r914", "r915", "r1267", "r1268", "r1269", "r1283", "r1284", "r1285", "r1287"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the parent." } } }, "auth_ref": ["r2", "r13", "r26", "r124", "r125", "r249", "r250", "r774", "r775", "r776", "r777", "r778", "r1267"] }, "pahc_AcquisitionRelatedCostOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AcquisitionRelatedCostOfGoodsSold", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "documentation": "Acquisition-related Cost of Goods Sold", "label": "Acquisition-related Cost of Goods Sold", "terseLabel": "Acquisition-related costs of goods sold" } } }, "auth_ref": [] }, "pahc_AcquisitionRelatedItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AcquisitionRelatedItems", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents amount of business acquisition related items.", "label": "Acquisition Related Items", "verboseLabel": "Acquisition-related items" } } }, "auth_ref": [] }, "pahc_AcquisitionRelatedTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AcquisitionRelatedTransactionCosts", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Acquisition Related Transaction Costs", "verboseLabel": "Acquisition-related transaction costs" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r1196"] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformation"], "lang": { "en-us": { "role": { "label": "Additional Financial Information Disclosure [Text Block]", "verboseLabel": "Additional Information", "documentation": "The entire disclosure of supplemental information, including descriptions and explanations of the income statement and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r115"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r943", "r1283", "r1284", "r1285", "r1287", "r1454", "r1530"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r1209"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth_ref": ["r1209"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r1209"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r1209"] }, "pahc_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "documentation": "Adjusted earnings before interest taxes depreciation and amortization.", "label": "Adjusted Earnings Before Interest Taxes Depreciation And Amortization", "totalLabel": "Adjusted EBITDA - Total segments", "verboseLabel": "Adjusted EBITDA" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label": "Adjustments for New Accounting Pronouncements [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r209", "r210", "r211", "r212", "r213", "r214", "r276", "r277", "r278", "r279", "r289", "r347", "r348", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r416", "r417", "r426", "r684", "r685", "r686", "r687", "r688", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r763", "r764", "r782", "r783", "r784", "r804", "r805", "r806", "r807", "r808", "r809", "r831", "r832", "r833", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital APIC for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r69", "r70", "r601"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Advertising Costs, Policy [Policy Text Block]", "terseLabel": "Advertising", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r191"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r1243"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1167", "r1178", "r1188", "r1221"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r1170", "r1181", "r1191", "r1224"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r1244"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r1209"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r1216"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r1171", "r1182", "r1192", "r1216", "r1225", "r1229", "r1237"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r1235"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r634", "r643"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationReserveForCreditLossesDetails"], "lang": { "en-us": { "role": { "label": "Allowance for Doubtful Accounts Receivable", "negatedLabel": "Reserve for credit losses", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r234", "r351", "r368", "r371", "r374", "r1496"] }, "pahc_AllowanceForDoubtfulAccountsReceivableEffectOfChangesInExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AllowanceForDoubtfulAccountsReceivableEffectOfChangesInExchangeRates", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationReserveForCreditLossesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of effect of changes in exchanges rates.", "label": "Allowance For Doubtful Accounts Receivable Effect Of Changes In Exchange Rates", "verboseLabel": "Effect of changes in exchange rates" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationReserveForCreditLossesDetails"], "lang": { "en-us": { "role": { "label": "Allowance for Doubtful Accounts Receivable [Roll Forward]", "verboseLabel": "Reserve for credit losses", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationReserveForCreditLossesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "

gaap_AociTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociTaxAttributableToParent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "AOCI Tax, Attributable to Parent", "negatedLabel": "Accumulated other comprehensive loss, tax", "documentation": "Amount of tax expense (benefit) allocated to accumulated other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "auth_ref": ["r1532", "r1533", "r1534", "r1535"] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Proposed Acquisition" } } }, "auth_ref": [ ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r1446"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r1446"] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "terseLabel": "Proposed Acquisition", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r1446"] }, "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionPriceOfAcquisitionExpected", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Price of Acquisition, Expected", "terseLabel": "Asset acquisition, price of acquisition, expected", "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition." } } }, "auth_ref": ["r1446"] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": ["r1446"] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisition"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "Proposed Acquisition", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": ["r1446"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r169", "r183", "r226", "r264", "r309", "r317", "r335", "r339", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r713", "r718", "r766", "r871", "r982", "r1084", "r1085", "r1127", "r1157", "r1339", "r1340", "r1484"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "ASSETS" } } }, "auth_ref": [ ] }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "presentation": ["http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [ ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r217", "r238", "r264", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r713", "r718", "r766", "r1127", "r1339", "r1340", "r1484"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r1161", "r1162", "r1174"] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r1161", "r1162", "r1174"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r1161", "r1162", "r1174"] }, "pahc_AverageCustomerCollectionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "AverageCustomerCollectionPeriod", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Average Customer Collection Period", "label": "Average Customer Collection Period", "verboseLabel": "Average worldwide collection period for accounts receivable" } } }, "auth_ref": [ ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432"] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432"] }, "ecd_AwardExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExercisePrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r1232"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grnt Date" } } }, "auth_ref": ["r1233"] }, "ecd_AwardFmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardFmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r1228"] }, "ecd_AwardFmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardFmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r1228"] }, "ecd_AwardFmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardFmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r1228"] }, "ecd_AwardFmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardFmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r1228"] }, "ecd_AwardFmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardFmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r1228"] }, "ecd_AwardFmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardFmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r1228"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r605", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r630", "r631", "r632", "r633"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r1231"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1230"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r1229"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r1229"] }, "country_BR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "BR", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "BRAZIL", "terseLabel": "Brazil" } } }, "auth_ref": [ ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } }, "auth_ref": ["r425", "r1498", "r1499"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r80", "r83", "r425", "r1498", "r1499"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheets Additional Information" } } }, "auth_ref": [ ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Base Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [ ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Principles of Consolidation and Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandards"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies and New Accounting Standards", "documentation": "The entire disclosure for the presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r142"] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Building Improvements", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r161", "r162", "r163", "r164"] }, "us-gaap_CapitalExpenditureIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpenditureIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property, plant and equipment", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r35", "r36", "r37"] }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareAmortization1", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Amortization", "verboseLabel": "Amortization of capitalized software costs", "documentation": "Amount of expense for amortization of capitalized computer software costs." } } }, "auth_ref": ["r1062"] }, "us-gaap_CapitalizedComputerSoftwareNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Net, Beginning Balance", "terseLabel": "Internal-use software costs, net of accumulated depreciation", "documentation": "The carrying value of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } } }, "auth_ref": ["r1061"] }, "us-gaap_CapitalizedComputerSoftwareNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Net [Abstract]", "terseLabel": "Internal-use software costs, net of accumulated depreciation" } } }, "auth_ref": [ ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r32", "r220", "r1068"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r33"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash and cash equivalents and short-term investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r1266"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]", "terseLabel": "Cash and cash equivalents and short-term investments" } } }, "auth_ref": [ ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r32", "r139", "r261"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r9", "r139"] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": ["r78"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://www.pahc.com/role/DisclosureLeasesOtherSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Leases" } } }, "auth_ref": [ ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": ["r203", "r204", "r214", "r275", "r347", "r354", "r355", "r356", "r361", "r362", "r416", "r426", "r686", "r695", "r696", "r704", "r705", "r707", "r723", "r724", "r736", "r737", "r763", "r764", "r783", "r804", "r805", "r831", "r832", "r912", "r913"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r1207"] }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "verboseLabel": "Schedule of changes in projected benefit obligation, plan assets and the funded status" } } }, "auth_ref": ["r18"] }, "ecd_ChngInFrVlAsOfVstngDtOfPrYrEqtyAwrdsUnvstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrVlAsOfVstngDtOfPrYrEqtyAwrdsUnvstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r1204"] }, "ecd_ChngInFrVlOfOutsdngAndUnvstdEqtyAwrds

"Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r108", "r174", "r874", "r968" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r148", "r433", "r435", "r1048", "r1325", "r1334"] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails", "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails",
"http://www.pahc.com/role/DocumentDocumentAndEntityInformation", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Class A", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r1530"] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails",
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/DocumentDocumentAndEntityInformation",
"http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Common Class B", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": ["r1530"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r154"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r1145", "r1146", "r1147", "r1149", "r1150", "r1151", "r1154", "r1283", "r1284", "r1287", "r1454", "r1520", "r1530"] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails",
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails",
"http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r113"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r113", "r969"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals",
"http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "verboseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r113"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r134", "r969", "r984", "r1149", "r1519"] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Value Outstanding", "verboseLabel": "Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at June 30, 2024; and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at June 30, 2024; and June 30, 2023" } } }, "auth_ref": ["r113", "r969"] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Voting Rights", "verboseLabel": "Common stock, voting rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r62"] }, "pahc_CommonStockVotingRightsVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CommonStockVotingRightsVotesPerShare", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Votes Per Share", "label": "Common Stock, Voting Rights, Votes Per Share", "terseLabel": "Common stock, voting rights, votes per share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r1213"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r1212"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r1214"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r1211"] }, "pahc_CompensationAndBenefitForServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CompensationAndBenefitForServicesMember", "presentation": [
"http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Compensation and Benefit for Services [Member]", "label": "Compensation and Benefit for Services [Member]", "terseLabel": "Compensation and Benefit for Services" } } }, "auth_ref": [] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
"http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (loss)", "terseLabel": "Comprehensive income (loss)", "documentation": "Comprehensive income is the amount of revenue, expense, gain and loss that are recognized during the period that are excluded from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r27", "r244", "r246", "r254", "r867", "r887", "r888"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributable", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "verboseLabel": "Comprehensive Income", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r42", "r43", "r92", "r93", "r346", "r1047"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r42", "r43", "r92", "r93", "r346", "r925", "r1047"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r42", "r43", "r92", "r93", "r346", "r1047", "r1259"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Risks and Uncertainties", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r98", "r194"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration risk", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r1047"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk (as a percent)", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r42", "r43", "r92", "r93", "r346"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r42", "r43", "r92", "r93", "r346"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as to percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r42", "r43", "r92", "r93", "r346", "r1047"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r270", "r713", "r714", "r718", "r719", "r818", "r1053", "r1338", "r1341", "r1342"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r270", "r713", "r714", "r718", "r719", "r818", "r1053", "r1338", "r1341", "r1342"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r181", "r270", "r309", "r319", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r443", "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r1084", "r1085", "r1339", "r1340"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r181", "r270", "r309", "r319", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r443", "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r1084", "r1085", "r1339", "r1340"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "verboseLabel": "Class B common stock converted into Class A common shares", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r35", "r36", "r37"] }, "pahc_CorporateCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CorporateCosts", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "documentation": "Corporate Cost consists of the cost of employees, marketing expenses, other corporate indirect costs.", "label": "Corporate Costs", "terseLabel": "Corporate costs" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "terseLabel": "Corporate", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r129", "r339", "r340", "r1293"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureDerivativeEffectsOfHedgesOnIncomeDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold", "verboseLabel": "Consolidated statement of operations - total cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r130", "r131", "r829"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "pahc_CreditAgreement2022TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement2022TermLoanMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails",
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"], "lang": { "en-us": { "role": { "documentation": "Credit Agreement, 2022 Term Loan [Member]", "label": "Credit Agreement, 2022 Term Loan [Member]", "terseLabel": "2022 Term Loan" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesDelayedDrawTerm1LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesDelayedDrawTerm1LoansMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Delayed Draw Term A-1 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Delayed Draw Term 1 Loans [Member]", "terseLabel": "Delayed Draw Term A-1 Loans" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesDelayedDrawTerm2LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesDelayedDrawTerm2LoansMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Delayed Draw Term A-2 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Delayed Draw Term 2 Loans [Member]", "terseLabel": "Delayed Draw Term A-2 Loans" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesInitialTerm1LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesInitialTerm1LoansMember", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Initial Term A-1 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Initial Term 1 Loans [Member]", "terseLabel": "Initial Term A-1 Loans" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesInitialTerm2LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesInitialTerm2LoansMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Initial Term A-2 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Initial Term 2 Loans [Member]", "terseLabel": "Initial Term A-2 Loans" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesMember", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities [Member]", "label": "Credit Agreement, 2024 [Member]", "terseLabel": "2024 Credit Agreement" } } }, "auth_ref": [] }, "pahc_CreditAgreement2024RevolvingCreditCommitmentsAndTerm1LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement2024RevolvingCreditCommitmentsAndTerm1LoansMember", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Revolving Credit Commitments and Term A-1 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Revolving Credit Commitments and Term 1 Loans [Member]", "terseLabel": "Revolving Credit Commitments and Term A-1 Loans" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesRevolvingCreditCommitmentsMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Revolving Credit Commitments [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Revolving Credit Commitments [Member]", "terseLabel": "Revolving Credit Commitments" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesTerm1LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesTerm1LoansMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Term A-1 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Term 1 Loans [Member]" } } }, "auth_ref": [] }, "pahc_CreditAgreement20242024CreditFacilitiesTerm2LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement20242024CreditFacilitiesTerm2LoansMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "2024 Credit Agreement, 2024 Credit Facilities, Term A-2 Loans [Member]", "label": "Credit Agreement, 2024, 2024 Credit Facilities, Term 2 Loans [Member]", "terseLabel": "Term A-2 Loans" } } }, "auth_ref": [] }, "pahc_CreditAgreement2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "CreditAgreement2024Member", "presentation": ["http://www.pahc.com/role/Disclos

gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Foreign", "documentation": "Amount of current foreign
income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r1260", "r1280"] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense
(Benefit)", "totalLabel": "Total current provision", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": ["r683", "r1280"] }, "us-
gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Current provision:" } }
}, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "verboseLabel": "State and local", "documentation": "Amount of
current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } }
}, "auth_ref": ["r1260", "r1280", "r1445"] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]",
"terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues,
segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r143", "r346"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CustomerRelationshipsMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails",
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships",
"documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r71", "r1315", "r1316", "r1317", "r1318", "r1319", "r1321", "r1323", "r1324"] }, "us-
gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]",
"verboseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture,
debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided,
restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [
"r149", "r262", "r420", "r421", "r422", "r423", "r424", "r441", "r442", "r454", "r460", "r461", "r462", "r463", "r464", "r465", "r470", "r477", "r478", "r480", "r780"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails",
"http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails",
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Debt
Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r22", "r101", "r102", "r170", "r173", "r270", "r455", "r456", "r457", "r458", "r459", "r461",
"r466", "r467", "r468", "r469", "r471", "r472", "r473", "r474", "r475", "r476", "r1094", "r1095", "r1096", "r1097", "r1098", "r1125", "r1278", "r1326", "r1327", "r1328", "r1474", "r1476"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread on variable rate (as a percent)",
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "pahc_DebtInstrumentBasisSpreadOnVariableRateScenarioFourMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentBasisSpreadOnVariableRateScenarioFourMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Basis Spread on Variable Rate, Scenario Four [Member]", "label": "Debt Instrument,
Basis Spread on Variable Rate, Scenario Four [Member]", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate, Scenario Four" } } }, "auth_ref": [] }, "pahc_DebtInstrumentBasisSpreadOnVariableRateScenarioOneMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentBasisSpreadOnVariableRateScenarioOneMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Basis Spread on Variable Rate, Scenario One [Member]", "label": "Debt Instrument,
Basis Spread on Variable Rate, Scenario One [Member]", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate, Scenario One" } } }, "auth_ref": [] }, "pahc_DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentBasisSpreadOnVariableRateScenarioThreeMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Basis Spread on Variable Rate, Scenario Three [Member]", "label": "Debt Instrument,
Basis Spread on Variable Rate, Scenario Three [Member]", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate, Scenario Three" } } }, "auth_ref": [] }, "pahc_DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentBasisSpreadOnVariableRateScenarioTwoMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Basis Spread on Variable Rate, Scenario Two [Member]", "label": "Debt Instrument,
Basis Spread on Variable Rate, Scenario Two [Member]", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate, Scenario Two" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails",
"http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross", "totalLabel": "Debt payments, total", "documentation": "Amount, before unamortized
(discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r22", "r173",
"r481"] }, "pahc_DebtInstrumentCovenantsFirstLienNetLeverageRatioTrailingFourQuarterBasisMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsFirstLienNetLeverageRatioTrailingFourQuarterBasisMaximum", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument,
Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, Maximum", "label": "Debt Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, Maximum", "terseLabel": "Maximum First Lien Net Leverage Ratio" } } },
"auth_ref": [] }, "pahc_DebtInstrumentCovenantsFirstLienNetLeverageRatioTrailingFourQuarterBasisTestPeriodMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsFirstLienNetLeverageRatioTrailingFourQuarterBasisTestPeriodMaximum", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Debt
Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, Test Period, Maximum", "label": "Debt Instrument, Covenants, First Lien Net Leverage Ratio, Trailing Four-quarter Basis, Test Period, Maximum", "terseLabel": "Maximum
First Lien Net Leverage Ratio, Test Period" } } }, "auth_ref": [] }, "pahc_DebtInstrumentCovenantsInterestCoverageRatioAfterFortyTwoMonthAnniversaryOfClosingDateMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630",
"localname": "DebtInstrumentCovenantsInterestCoverageRatioAfterFortyTwoMonthAnniversaryOfClosingDateMinimum", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": {
"en-us": { "role": { "documentation": "Debt Instrument, Covenants, Interest Coverage Ratio, after Forty-two Month Anniversary of Closing Date, Minimum", "label": "Debt Instrument, Covenants, Interest Coverage Ratio, after Forty-two Month Anniversary
of Closing Date, Minimum", "terseLabel": "Minimum interest coverage ratio, after the forty-two month anniversary of the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsInterestCoverageRatioEighteenMonthAnniversaryOfClosingDateToThirtyMonthAnniversaryOfClosingDateMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsInterestCoverageRatioEighteenMonthAnniversaryOfClosingDateToThirtyMonthAnniversaryOfClosingDateMinimum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Interest Coverage Ratio, Eighteen-month Anniversary of Closing Date
to Thirty-month Anniversary of Closing Date, Minimum", "label": "Debt Instrument, Covenants, Interest Coverage Ratio, Eighteen-month Anniversary of Closing Date to Thirty-month Anniversary of Closing Date, Minimum", "terseLabel": "Minimum
interest coverage ratio, eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsInterestCoverageRatioFirstFiscalQuarterEndingAfterClosingDateThroughEighteenMonthAnniversaryOfClosingDateMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsInterestCoverageRatioFirstFiscalQuarterEndingAfterClosingDateThroughEighteenMonthAnniversaryOfClosingDateMinimum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Interest Coverage Ratio, First Fiscal Quarter Ending after Closing Date
through Eighteen-month Anniversary of Closing Date, Minimum", "label": "Debt Instrument, Covenants, Interest Coverage Ratio, First Fiscal Quarter Ending after Closing Date through Eighteen-month Anniversary of Closing Date, Minimum",
"terseLabel": "Minimum interest coverage ratio, first fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsInterestCoverageRatioPriorToClosingDateMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentCovenantsInterestCoverageRatioPriorToClosingDateMinimum",
"presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Interest Coverage Ratio, Prior to Closing Date,
Minimum", "label": "Debt Instrument, Covenants, Interest Coverage Ratio, Prior to Closing Date, Minimum", "terseLabel": "Minimum interest coverage ratio, prior to the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsInterestCoverageRatioThirtyMonthAnniversaryOfClosingDateToFortyTwoMonthAnniversaryOfClosingDateMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsInterestCoverageRatioThirtyMonthAnniversaryOfClosingDateToFortyTwoMonthAnniversaryOfClosingDateMinimum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Interest Coverage Ratio, Thirty-month Anniversary of Closing Date to
Forty-two Month Anniversary of Closing Date, Minimum", "label": "Debt Instrument, Covenants, Interest Coverage Ratio, Thirty-month Anniversary of Closing Date to Forty-two Month Anniversary of Closing Date, Minimum", "terseLabel": "Minimum
interest coverage ratio, thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date" } } }, "auth_ref": [] }, "pahc_DebtInstrumentCovenantsInterestCoverageRatioTrailingFourQuarterBasisMinimum": { "xbrltype":
"pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentCovenantsInterestCoverageRatioTrailingFourQuarterBasisMinimum", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"],
"lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Interest Coverage Ratio, Trailing Four-quarter Basis, Minimum", "label": "Debt Instrument, Covenants, Interest Coverage Ratio, Trailing Four-quarter Basis, Minimum",
"terseLabel": "Minimum interest coverage ratio" } } }, "auth_ref": [] }, "pahc_DebtInstrumentCovenantsNetLeverageRatioAfterFortyTwoMonthAnniversaryOfClosingDateMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630",
"localname": "DebtInstrumentCovenantsNetLeverageRatioAfterFortyTwoMonthAnniversaryOfClosingDateMaximum", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": {
"en-us": { "role": { "documentation": "Debt Instrument, Covenants, Net Leverage Ratio, after Forty-two Month Anniversary of Closing Date, Maximum", "label": "Debt Instrument, Covenants, Net Leverage Ratio, after Forty-two Month Anniversary of
Closing Date, Maximum", "terseLabel": "Maximum Net Leverage Ratio, after the forty-two month anniversary of the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsNetLeverageRatioEighteenMonthAnniversaryOfClosingDateToThirtyMonthAnniversaryOfClosingDateMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsNetLeverageRatioEighteenMonthAnniversaryOfClosingDateToThirtyMonthAnniversaryOfClosingDateMaximum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Net Leverage Ratio, Eighteen-month Anniversary of Closing Date to
Thirty-month Anniversary of Closing Date, Maximum", "label": "Debt Instrument, Covenants, Net Leverage Ratio, Eighteen-month Anniversary of Closing Date to Thirty-month Anniversary of Closing Date, Maximum", "terseLabel": "Maximum Net Leverage
Ratio, eighteen-month anniversary of the Closing Date to the thirty-month anniversary of the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsNetLeverageRatioFirstFiscalQuarterEndingAfterClosingDateThroughEighteenMonthAnniversaryOfClosingDateMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsNetLeverageRatioFirstFiscalQuarterEndingAfterClosingDateThroughEighteenMonthAnniversaryOfClosingDateMaximum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Net Leverage Ratio, First Fiscal Quarter Ending after Closing Date
through Eighteen-month Anniversary of Closing Date, Maximum", "label": "Debt Instrument, Covenants, Net Leverage Ratio, First Fiscal Quarter Ending after Closing Date through Eighteen-month Anniversary of Closing Date, Maximum", "terseLabel":
"Maximum Net Leverage Ratio, first fiscal quarter ending after the Closing Date through the eighteen-month anniversary of the Closing Date" } } }, "auth_ref": [] }, "pahc_DebtInstrumentCovenantsNetLeverageRatioPriorToClosingDateMaximum": {
"xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DebtInstrumentCovenantsNetLeverageRatioPriorToClosingDateMaximum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Net Leverage Ratio, Prior to Closing Date, Maximum", "label": "Debt
Instrument, Covenants, Net Leverage Ratio, Prior to Closing Date, Maximum", "terseLabel": "Maximum Net Leverage Ratio, prior to the Closing Date" } } }, "auth_ref": [] },
"pahc_DebtInstrumentCovenantsNetLeverageRatioThirtyMonthAnniversaryOfClosingDateToFortyTwoMonthAnniversaryOfClosingDateMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"DebtInstrumentCovenantsNetLeverageRatioThirtyMonthAnniversaryOfClosingDateToFortyTwoMonthAnniversaryOfClosingDateMaximum", "presentation": [
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Net Leverage Ratio, Thirty-month Anniversary of Closing Date to
Forty-two Month Anniversary of Closing Date, Maximum", "label": "Debt Instrument, Covenants, Net Leverage Ratio, Thirty-month Anniversary of Closing Date to Forty-two Month Anniversary of Closing Date, Maximum", "terseLabel": "Maximum Net
Leverage Ratio, thirty-month anniversary of Closing Date to the forty-two month anniversary of the Closing Date" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails"
], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r455", "r780", "r781", "r1095", "r1096",
"r1125"] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": [
"http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument, frequency of periodic payment", "documentation":
"Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": ["r22", "r97"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage",
"verboseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r104", "r456"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentageAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentageAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails"], "lang": { "en-us": {
"role": { "label": "Debt Instrument, Interest Rate, Stated Percentage [Abstract]", "terseLabel": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentLineItems", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails",
"http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails",
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r270", "r455", "r456", "r457", "r458", "r459", "r461", "r466", "r467",
"r468", "r469", "r471", "r472", "r473", "r474", "r475", "r476", "r479", "r1094", "r1095", "r1096", "r1097", "r1098", "r1125", "r1278", "r1474", "r1476"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails",
"http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails",
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails",
"http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r22", "r270",
"r455", "r456", "r457", "r458", "r459", "r461", "r466", "r467", "r468", "r469", "r471", "r472", "r473", "r474", "r475", "r476", "r1094", "r1095", "r1096", "r1097", "r1098", "r1125", "r1278", "r1326", "r1327", "r1328", "r1474", "r1476"] }, "us-
gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt instrument, periodic payment", "documentation": "Amount of the required periodic
payments including both interest and principal payments." } } }, "auth_ref": ["r22", "r97"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails",
"http://www.pahc.com/role/DisclosureDebtReconciliationDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt
Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r22", "r62", "r65", "r96", "r152", "r153", "r270", "r455", "r456", "r457", "r458", "r459", "r461", "r466", "r467",
"r468", "r469", "r471", "r472", "r473", "r474", "r475", "r476", "r479", "r1094", "r1095", "r1096", "r1097", "r1098", "r1125", "r1278", "r1474", "r1476"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term",
"documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-
gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredChargesPolicyTextBlock", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "verboseLabel": "Debt Issuance Costs",
"documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": ["r225"] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": {
"label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred
national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1280", "r1444", "r1445"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance
costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1344", "r1473", "r1474", "r1476"] }, "us-
gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Debt issuance costs", "documentation": "Amount, after
accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1473", "r1474", "r1476"] }, "us-
gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "Foreign", "documentation": "Amount of deferred
foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r1280", "r1444"] }, "pahc_DeferredForeignIncomeTaxExpenseBenefitChangeInValuationAllowance": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.pahc.com/20240630", "localname": "DeferredForeignIncomeTaxExpenseBenefitChangeInValuationAllowance", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "documentation": "Deferred Foreign Income Tax Expense (Benefit), Change in Valuation Allowance", "label": "Deferred
Foreign Income Tax Expense (Benefit), Change in Valuation Allowance", "terseLabel": "Change in valuation allowance-foreign" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails",
"http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxesIncludedInConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Other assets", "verboseLabel": "Deferred income
taxes", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r651", "r652"] }, "us-
gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred benefit", "documentation": "Amount of
deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r9", "r202", "r1280"] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-
us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Deferred provision (benefit):" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax
Liabilities, Gross", "negatedTotalLabel": "Total", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": ["r109", "r110", "r171", "r674"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxesIncludedInConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "negatedLabel": "Other liabilities", "documentation": "Amount,
after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r651", "r652", "r872"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred Income
Taxes and Tax Credits", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r141"] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State and local", "documentation":

"Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1280", "r1444", "r1445"] }, "pahc_DeferredTaxAssetsCarriedForeignInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DeferredTaxAssetsCarriedForeignInterestExpense", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Carried Foreign Interest Expense", "label": "Deferred Tax Assets, Carried Foreign Interest Expense", "terseLabel": "Carried foreign interest expense" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred tax assets, gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": ["r675"] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Inventory", "verboseLabel": "Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": ["r1442"] }, "pahc_DeferredTaxAssetsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DeferredTaxAssetsLeaseLiabilities", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability asset.", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxesIncludedInConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": ["r1439"] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net of valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": ["r1439"] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "verboseLabel": "Net operating loss carry forwards-domestic", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": ["r1442"] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "verboseLabel": "Net operating loss carry forwards-foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": ["r1442"] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "verboseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": ["r1442"] }, "pahc_DeferredTaxAssetsResearchAndDevelopmentCostCapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DeferredTaxAssetsResearchAndDevelopmentCostCapitalization", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Research and Development Cost Capitalization", "label": "Deferred Tax Assets, Research and Development Cost Capitalization", "terseLabel": "R&D cost capitalization" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "terseLabel": "Employee related accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation." } } }, "auth_ref": ["r1442"] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Environmental remediation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities." } } }, "auth_ref": ["r1442"] }, "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Unrealized Currency Losses", "terseLabel": "Unrealized foreign exchange", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions." } } }, "auth_ref": ["r1442"] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.pahc.com/role/DisclosureIncomeTaxesValuationAllowanceDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r676"] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "pahc_DeferredTaxLiabilitiesForeignWithholdingAndRelatedTaxesNetOnPlannedRepatriation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DeferredTaxLiabilitiesForeignWithholdingAndRelatedTaxesNetOnPlannedRepatriation", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Foreign withholding and Related Taxes, Net, on Planned Repatriation", "label": "Deferred Tax Liabilities, Foreign withholding and Related Taxes, Net, on Planned Repatriation", "negatedLabel": "Non-U.S. withholding and related taxes, net, on planned repatriation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Operating lease ROU assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": ["r1442"] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": ["r1442"] }, "pahc_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Property, Plant and Equipment and Intangible Assets", "label": "Deferred Tax Liabilities, Property, Plant and Equipment and Intangible Assets", "negatedLabel": "Property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Unrealized Currency Transaction Gains", "negatedLabel": "Unrealized foreign exchange", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions." } } }, "auth_ref": ["r1442"] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": ["r3", "r4", "r26", "r126", "r1387"] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]", "terseLabel": "Accumulated other comprehensive loss related to pension plan" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Actual Return on Plan Assets", "verboseLabel": "Actual return on plan assets", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": ["r536", "r1109"] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Actuarial Gain (Loss)", "verboseLabel": "Actuarial gain", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": ["r529"] }, "pahc_DefinedBenefitPlanAmortizationOfActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCreditAndAmortizationOfPriorServiceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanAmortizationOfActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCreditAndAmortizationOfPriorServiceCosts", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Amortization of Actuarial (Gain) Loss, Immediate Recognition as Component in Net Periodic Benefit Cost (Credit), and Amortization of Prior Service Costs", "label": "Defined Benefit Plan, Amortization of Actuarial (Gain) Loss, Immediate Recognition as Component in Net Periodic Benefit Cost (Credit), and Amortization of Prior Service Costs", "verboseLabel": "Amortization of net actuarial loss and prior service costs" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsTargetAllocationsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Allocations [Abstract]", "terseLabel": "Target asset allocations and weighted-average asset allocation of plan assets" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "verboseLabel": "Discount rate for year-end benefit obligation (as a percent)", "documentation": "Weighted-average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": ["r568"] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "verboseLabel": "Discount rate for interest cost (as a percent)", "documentation": "Weighted-average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": ["r570"] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets", "verboseLabel": "Expected rate of return on plan assets (as a percent)", "documentation": "Weighted average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": ["r570", "r592"] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansActuarialAssumptionsTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used in Calculations [Abstract]", "terseLabel": "Significant actuarial assumptions" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFundedStatusDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Projected benefit obligation at end of year", "periodStartLabel": "Projected benefit obligation at beginning of year", "terseLabel": "Projected benefit obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": ["r524"] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": ["r531", "r595"] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": ["r545", "r546", "r548", "r549", "r550", "r551", "r552", "r553", "r573", "r1107", "r1108", "r1109"] }, "pahc_DefinedBenefitPlanCashAndCashEquivalentsMeasurementInputPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMeasurementInputPricePerUnit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValueAssumptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Cash and Cash Equivalents, Measurement Input, Price Per Unit", "label": "Defined Benefit Plan, Cash and Cash Equivalents, Measurement Input, Price Per Unit", "terseLabel": "Cash and cash equivalents, measurement input, price per unit (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Defined Benefit Plan, Cash and Cash Equivalents", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": ["r1107"] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "verboseLabel": "Change in projected benefit obligation", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in fair value of plan assets", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "pahc_DefinedBenefitPlanCommonCollectiveTrustFixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanCommonCollectiveTrustFixedIncomeSecuritiesMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Common Collective Trust, Fixed Income Securities [Member]", "label": "Defined Benefit Plan, Common Collective Trust, Fixed Income Securities [Member]", "terseLabel": "Defined Benefit Plan, Common Collective Trust, Fixed Income Securities" } } }, "auth_ref": [] }, "pahc_DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanCommonCollectiveTrustGlobalLargeCapEquitiesMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities [Member]", "label": "Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities [Member]", "terseLabel": "Defined Benefit Plan, Common Collective Trust, Global Large Cap Equities" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCommonCollectiveTrustMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Common Collective Trust [Member]", "documentation": "Regulated trust, responsible for collective investment and reinvestment of asset from employee benefit plan maintained by more than one employer or controlled group." } } }, "auth_ref": ["r1369"] }, "us-gaap_DefinedBenefitPlanDebtSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDebtSecurityMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Debt Security [Member]", "terseLabel": "Defined Benefit Plan, Debt Security", "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution, in which defined benefit plan asset is invested." } } }, "auth_ref": ["r1369"] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Equity Securities [Member]", "terseLabel": "Defined Benefit Plan, Equity Securities", "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": ["r1107", "r1109"] }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]", "terseLabel": "Estimated future benefit payments" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter", "verboseLabel": "2030-2034", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": ["r555"] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months", "verboseLabel": "2025", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": ["r555"] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payments, Year Five", "verboseLabel": "2029", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": ["r555"] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payments, Year Four", "verboseLabel": "2028",

overfunded (underfunded) status." }], "auth_ref": ["r520", "r544", "r1109"] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFundedStatusDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]", "terseLabel": "Funded status" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanFundingStatusExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundingStatusExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Funding Status [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Funding Status", "documentation": "Indicates status of funding for defined benefit plan designed to provide retirement benefits." } } }, "auth_ref": ["r1258", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405"] }, "pahc_DefinedBenefitPlanGlobalAssetAllocationsAndRiskParityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanGlobalAssetAllocationsAndRiskParityMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Global Asset Allocations and Risk Parity [Member]", "label": "Defined Benefit Plan, Global Asset Allocations and Risk Parity [Member]", "terseLabel": "Global Asset Allocations/Risk Parity" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInformationAboutPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInformationAboutPlanAssetsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Information about Plan Assets [Abstract]", "terseLabel": "Fair values of the plan assets by asset category" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost on benefit obligation", "verboseLabel": "Interest cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": ["r523", "r527", "r559", "r585", "r1109", "r1110"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic pension expense (income)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": ["r557", "r583", "r1109", "r1110"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Net periodic pension expense" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes expected return (loss) on plan asset component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": ["r557", "r583"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes interest cost component of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": ["r557", "r583"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement Gain (Loss), Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes settlement gain (loss) component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": ["r557", "r583"] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "U.S. pension plan, net", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": ["r580", "r1109"] }, "us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsAllocationLineItems", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Allocation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r545", "r1109"] }, "us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsAllocationTable", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Allocation [Table]", "documentation": "Disclosure of information about investment allocation of defined benefit plan assets. Includes, but is not limited to, investment allocation percentage or range of percentages." } } }, "auth_ref": ["r545", "r1109"] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedLabel": "Benefits paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": ["r540", "r1406"] }, "us-gaap_DefinedBenefitPlanPlanAssetsCategoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsCategoryLineItems", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r546", "r548", "r553", "r1109"] }, "us-gaap_DefinedBenefitPlanPlanAssetsCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsCategoryTable", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Table]", "documentation": "Disclosure of information about defined benefit plan asset investment. Includes, but is not limited to, fair value of category of plan asset and its level within fair value hierarchy." } } }, "auth_ref": ["r546", "r548", "r553", "r1109"] }, "us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsLevel3ReconciliationDecreaseForSale", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale", "negatedLabel": "Redemptions", "documentation": "Amount, measured using unobservable input, of decrease in plan asset of defined benefit plan from sale." } } }, "auth_ref": ["r1258"] }, "us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsLevel3ReconciliationIncreaseForPurchase", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase", "verboseLabel": "Purchases", "documentation": "Amount, measured using unobservable input, of increase in plan asset of defined benefit plan from purchase." } } }, "auth_ref": ["r1258"] }, "us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsLevel3ReconciliationLineItems", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r549", "r550", "r551", "r552", "r1109"] }, "us-gaap_DefinedBenefitPlanPlanAssetsLevel3ReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsLevel3ReconciliationTable", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Table]", "documentation": "Disclosure of information about defined benefit plan assets measured using unobservable inputs." } } }, "auth_ref": ["r549", "r550", "r551", "r552", "r1109"] }, "pahc_DefinedBenefitPlanPlanAssetsOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanPlanAssetsOtherMember", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Other [Member]", "label": "Defined Benefit Plan, Plan Assets, Other [Member]", "terseLabel": "Defined Benefit Plan, Plan Assets, Other" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "verboseLabel": "Target allocation (as a percent)", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": ["r545", "r1109"] }, "pahc_DefinedBenefitPlanProjectedBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanProjectedBenefitObligationDiscountRate", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Projected Benefit Obligation, Discount Rate", "label": "Defined Benefit Plan, Projected Benefit Obligation, Discount Rate", "terseLabel": "Discount rate used for the projected benefit obligation (as a percent)" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAnnuityPurchaseAgreementDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansNetPeriodicPensionExpenseDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedLabel": "Settlement expense", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement." } } }, "auth_ref": ["r522", "r564", "r590"] }, "pahc_DefinedBenefitPlanSettlementAnnuityPurchaseAgreementBenefitObligationAnnuityPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedBenefitPlanSettlementAnnuityPurchaseAgreementBenefitObligationAnnuityPurchasePrice", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAnnuityPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Settlement, Annuity Purchase Agreement, Benefit Obligation, Annuity Purchase Price", "label": "Defined Benefit Plan, Settlement, Annuity Purchase Agreement, Benefit Obligation, Annuity Purchase Price", "terseLabel": "Annuity purchase price" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Partial settlement of pension plan", "negatedLabel": "Settlement payments", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": ["r526"] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedLabel": "Settlement payments", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": ["r543"] }, "us-gaap_DefinedBenefitPlanSponsorLocationExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSponsorLocationExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Sponsor Location [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Sponsor Location", "documentation": "Indicates location of employer sponsoring defined benefit plan designed to provide retirement benefits." } } }, "auth_ref": ["r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r568", "r570", "r571", "r573", "r576", "r579", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592"] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "terseLabel": "Percentage of plan assets (as a percent)", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": ["r1368"] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInProjectedBenefitObligationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost Recognized", "verboseLabel": "Contribution expense", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": ["r596"] }, "pahc_DefinedContributionPlanEmployerDiscretionaryContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionPercent", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetails"], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Discretionary Contribution, Percent", "label": "Defined Contribution Plan, Employer Discretionary Contribution, Percent", "terseLabel": "Employer discretionary contribution (as a percent)" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of employees' gross pay (as a percent)", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution, percent of match (as a percent)", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanSponsorLocationExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanSponsorLocationExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlans401KRetirementSavingsPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Sponsor Location [Extensible Enumeration]", "terseLabel": "Defined Contribution Plan, Sponsor Location", "documentation": "Indicates location of employer sponsoring defined contribution plan designed to provide retirement benefits." } } }, "auth_ref": [] }, "us-gaap_DepositsAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssets", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Deposits Assets", "verboseLabel": "Deposits", "documentation": "Carrying value of payments made to third parties for security purposes that are expected to be returned or applied towards payment in the future." } } }, "auth_ref": ["r1264"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationDepreciationAndAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation of property, plant and equipment", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r9", "r54"] }, "us-gaap_DepreciationAndAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortizationAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationDepreciationAndAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization [Abstract]", "verboseLabel": "Depreciation and amortization" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationDepreciationAndAmortizationDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r9", "r309", "r322", "r339", "r1084", "r1085"] }, "us-gaap_DerivativeAssetFairValueNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetFairValueNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]", "terseLabel": "Other assets" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Noncurrent, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as noncurrent." } } }, "auth_ref": ["r720"] }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Foreign currency derivatives and interest rate swap", "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments." } } }, "auth_ref": ["r10", "r1457", "r1458", "r1459"] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative instruments", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r239"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails", "http://www.pahc.com/role/DisclosureGeneralInformationDetails", "http://www.pahc.com/role/DisclosureInformationAboutSecuritiesDetails", "http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r958", "r960", "r974", "r975", "r976", "r978", "r979", "r980", "r981", "r983", "r984", "r985", "r986", "r1002", "r1003", "r1004", "r1005", "r1008", "r1009", "r1010", "r1011", "r1032", "r1033", "r1034", "r1035", "r1145", "r1147", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467"] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral", "terseLabel": "Other assets", "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": ["r16", "r19", "r21", "r89"] }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral", "negatedLabel": "Accrued expense and other current liabilities", "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": ["r16", "r19", "r21", "r89"] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-g

{"statements of operations", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r1452"] }, "us-gaap_DerivativeGainLossOnDerivativeNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Gain (Loss) on Derivative, Net [Abstract]", "terseLabel": "Derivatives" } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": ["r1452"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r81", "r84", "r85", "r1672", "r950", "r960", "r974", "r975", "r976", "r978", "r979", "r980", "r981", "r983", "r984", "r985", "r986", "r1002", "r1003", "r1004", "r1005", "r1008", "r1009", "r1010", "r1011", "r1032", "r1033", "r1034", "r1035", "r1074", "r1145", "r1147", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467"] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivatives" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureDerivatives"], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivatives", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": ["r166", "r722", "r734"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": ["r15", "r81", "r84"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r15", "r81", "r84", "r85", "r90", "r91", "r721"] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r721"] }, "us-gaap_DerivativeLiabilityFairValueNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]", "terseLabel": "Accrued expense and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r734"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1450", "r1451"] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r15", "r75", "r76", "r77", "r79", "r82", "r84", "r86", "r88", "r91", "r734"] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "verboseLabel": "Derivative Financial Instruments", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": ["r15", "r75", "r76", "r79", "r87", "r269", "r288"] }, "pahc_DescriptionOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "DescriptionOfBusinessAbstract", "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Net sales", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r517", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r517", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "verboseLabel": "Schedule of revenues disaggregated by major product category and geographic region", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1345"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlan"], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "Stock Incentive Plan", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r599", "r604", "r635", "r636", "r638", "r1112"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockAbstract", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock [Abstract]", "terseLabel": "Dividends" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsDividendsDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared", "terseLabel": "Dividends declared and paid", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": ["r154"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r1161", "r1162", "r1174"] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r1161", "r1162", "r1174", "r1217"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r1195"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supported SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvdsPdOrOthrEarngsNotInEqtyAwrdsNotOthrwsRfltdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsPdOrOthrEarngsNotInEqtyAwrdsNotOthrwsRfltdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r1206"] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"], "lang": { "en-us": { "role": { "label": "EMEA [Member]", "terseLabel": "Europe, Middle East and Africa", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": ["r1532", "r1533", "r1534", "r1535"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r252", "r280", "r281", "r282", "r283", "r284", "r285", "r290", "r293", "r304", "r305", "r306", "r308", "r702", "r711", "r745", "r746", "r868", "r889", "r1077"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "diluted (in dollars per share)", "verboseLabel": "diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r252", "r280", "r281", "r282", "r283", "r284", "r285", "r293", "r304", "r305", "r306", "r308", "r702", "r711", "r745", "r746", "r868", "r889", "r1077"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Net income per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net Income per Share and Weighted Average Shares", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r39", "r40", "r307"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r772"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate (as a percent)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r655", "r1115"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Reconciliation of the federal statutory rate to the Company's effective tax rate" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "U.S. federal statutory income tax rate (as a percent)", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r266", "r655", "r689", "r1115"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance (as a percent)", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": ["r661", "r1115", "r1281", "r1434"] }, "pahc_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefitsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefitsPercent", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits.", "label": "Effective Income Tax Rate Reconciliation, Change In Unrecognized Tax Benefits, Percent", "verboseLabel": "Changes in uncertain tax positions (as a percent)" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, FDII, Percent", "negatedLabel": "Foreign derived intangible income (as a percent)", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign derived intangible income (FDII)." } } }, "auth_ref": ["r1115", "r1434", "r1436"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Higher taxes on non-U.S. income (as a percent)", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": ["r656", "r659", "r1115", "r1281", "r1434"] }, "pahc_EffectiveIncomeTaxRateReconciliationForeignWithholdingAndRelatedTaxesNetOnPlannedRepatriationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationForeignWithholdingAndRelatedTaxesNetOnPlannedRepatriationPercent", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Foreign Withholding and Related Taxes, Net, on Planned Repatriation, Percent", "label": "Effective Income Tax Rate Reconciliation, Foreign Withholding and Related Taxes, Net, on Planned Repatriation, Percent", "terseLabel": "Non-U.S. withholding and related taxes, net, on planned repatriation (as a percent)" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGlobalIntangibleLowTaxedIncomeDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount", "terseLabel": "Provision for income taxes, federal tax expense from the effects of GILTI", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": ["r1115", "r1434", "r1436"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent", "terseLabel": "Global Intangible Low-Taxed Income (as a percent)", "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": ["r1115", "r1434", "r1436"] }, "pahc_EffectiveIncomeTaxRateReconciliationImpactOfForeignTaxCreditRegulationsAndRelatedChangesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationImpactOfForeignTaxCreditRegulationsAndRelatedChangesPercent", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Impact of Foreign Tax Credit Regulations and Related Changes, Percent", "label": "Effective Income Tax Rate Reconciliation, Impact of Foreign Tax Credit Regulations and Related Changes, Percent", "terseLabel": "Impact of foreign tax credit regulations and related changes (as a percent)" } } }, "auth_ref": [] }, "pahc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCostsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCostsPercent", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Acquisition Costs, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Acquisition Costs, Percent", "terse

"State and local taxes, net of federal benefit (as a percent)", "documentation": "Percentage of the difference between reported income tax expense (benefit) and computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } }, "auth_ref": ["r658", "r1115", "r1281", "r1434"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryRateToEffectiveTaxRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "negatedLabel": "Recognition of federal and foreign tax credits (as a percent)", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": ["r660", "r662", "r1281", "r1434"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "verboseLabel": "Employee related", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r102"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansOtherEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities [Abstract]", "terseLabel": "Other employee benefit plans" } } }, "auth_ref": [ ] }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Stock Incentive Plan" } } }, "auth_ref": [ ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]", "terseLabel": "Stock Incentive Plan" } } }, "auth_ref": [ ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Cost not yet recognized, period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r637"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Cost not yet recognized, amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r1433"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ ] }, "pahc_EmploymentAgreementsCertainExecutiveManagementAndOtherEmployeesSeveranceBenefitsTermHighEndOfRange": { "xbrltype": "durationItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "EmploymentAgreementsCertainExecutiveManagementAndOtherEmployeesSeveranceBenefitsTermHighEndOfRange", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEmploymentAndSeveranceAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Employment Agreements, Certain Executive Management and Other Employees, Severance Benefits, Term, High End of Range", "label": "Employment Agreements, Certain Executive Management and Other Employees, Severance Benefits, Term, High End of Range", "terseLabel": "Severance benefits, term" } } }, "auth_ref": [ ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [ ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [ ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [ ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the city or town" } } }, "auth_ref": [ ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [ ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [ ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r1159"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [ ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r1159"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [ ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r1159"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [ ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1246"] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: 0.01" } } }, "auth_ref": [ ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [ ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r1159"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r1159"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r1159"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r1159"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [ ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r1247"] }, "us-gaap_EnvironmentalCostsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalCostsPolicy", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Environmental Costs, Policy [Policy Text Block]", "verboseLabel": "Environmental Liabilities", "documentation": "Disclosure of accounting policy for obligations that resulted from improper or other-than normal operation of a long-lived asset in the past. This accounting policy may address (1) whether the related remediation costs are expensed or capitalized, (2) whether the obligation is measured on a discounted basis, (3) the event, situation, or set of circumstances that generally triggers recognition of loss contingencies arising from the entity's environmental remediation-related obligations, and (4) the timing of recognition of any recoveries." } } }, "auth_ref": ["r427", "r428", "r440", "r1092", "r1251"] }, "us-gaap_EnvironmentalExpenseAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalExpenseAndLiabilitiesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetails"], "lang": { "en-us": { "role": { "label": "Environmental Expense and Liabilities [Abstract]", "terseLabel": "Environmental" } } }, "auth_ref": [ ] }, "us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetails"], "lang": { "en-us": { "role": { "label": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Environmental Loss Contingency, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes accrual for environmental loss contingency." } } }, "auth_ref": ["r440", "r1093"] }, "us-gaap_EnvironmentalRemediationExpenseAfterRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationExpenseAfterRecovery", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Environmental Remediation Expense, after Recovery", "terseLabel": "Environmental remediation costs", "documentation": "Amount, after recovery, of expense for known and estimated future costs arising from requirement to perform environmental remediation." } } }, "auth_ref": ["r1357"] }, "us-gaap_EnvironmentalRemediationExpenseAfterRecoveryStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationExpenseAfterRecoveryStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Environmental Remediation Expense, after Recovery, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Environmental Remediation Expense, after Recovery, Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes environmental remediation expense after credit for recovery." } } }, "auth_ref": ["r1331"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r1200"] }, "ecd_EqtyAwrdsAdjsExclgValRptrdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRptrdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r1242"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r1242"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r1242"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Common Stock, Preferred Stock and Dividends" } } }, "auth_ref": [ ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r14", "r211", "r248", "r249", "r250", "r271", "r272", "r273", "r277", "r284", "r286", "r288", "r310", "r358", "r364", "r417", "r499", "r684", "r685", "r698", "r699", "r700", "r703", "r710", "r711", "r726", "r728", "r729", "r730", "r731", "r733", "r744", "r773", "r774", "r775", "r776", "r777", "r778", "r783", "r786", "r809", "r886", "r914", "r915", "r916", "r943", "r1015"] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "terseLabel": "Equity method investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r309", "r327", "r339", "r352", "r1262", "r1301"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r1210"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r1167", "r1178", "r1188", "r1221"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r1165", "r1175", "r1185", "r1218"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } } }, "auth_ref": ["r1216"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r748", "r749", "r757", "r1119"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r748", "r749", "r757", "r1119"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredOnRecurringBasisUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Changes in the fair value of the Level 3 liabilities" } } }, "auth_ref": [ ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails", "http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r468", "r548", "r549", "r550", "r551", "r552", "r553", "r747", "r749", "r750", "r751", "r752", "r756", "r757", "r758", "r822", "r823", "r824", "r1095", "r1096", "r1107", "r1108", "r1109", "r1119", "r1121"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [ ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of similar groups of items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election, and (d) information to enable users to understand the difference between aggregate fair value and the aggregate contractual principal amount of loans and long-term debt instruments (as defined) that are not recorded at fair value." } } }, "auth_ref": ["r75", "r76", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r

"lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]", "terseLabel": "Changes in the fair value of the Level 3 assets" } } }, "auth_ref": [] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [
"http://www.pahc.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredOnRecurringBasisUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis,
Liability, Period Increase (Decrease)", "terseLabel": "Changes in the fair value of the Level 3 liabilities", "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the
entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r1460", "r1467"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredOnRecurringBasisUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis,
Liability, Transfers, Net", "terseLabel": "Transfers between levels, liabilities", "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": ["r1464", "r1467"] },
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansChangeInFairValueOfLevel3AssetsDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails",
"http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques
to measure fair value." } } }, "auth_ref": ["r468", "r548", "r549", "r550", "r551", "r552", "r553", "r747", "r749", "r750", "r751", "r752", "r756", "r757", "r758", "r822", "r823", "r824", "r1095", "r1096", "r1107", "r1108", "r1109", "r1119", "r1121"] }, "us-
gaap_FairValueNetAssetLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetAssetLiabilityAbstract", "presentation": [
"http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability) [Abstract]", "terseLabel": "Fair Value of Assets" } } }, "auth_ref": [] }, "us-
gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Fair Values
Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } },
"auth_ref": ["r80", "r82", "r90"] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [
"http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate",
"documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref":
["r1453"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful life of definite-
lived intangible assets", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization",
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r224", "r391", "r409", "r1091"] }, "us-
gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation":
["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "verboseLabel":
"Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1322", "r1536"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
"verboseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim
and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r411", "r1063", "r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "verboseLabel": "2029",
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when
interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r411", "r1063", "r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "verboseLabel": "2028",
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods
when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r411", "r1063", "r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "verboseLabel": "2027",
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when
interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r411", "r1063", "r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "verboseLabel": "2026",
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods
when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r411", "r1063", "r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails",
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by
major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r402", "r404", "r405", "r406", "r408", "r409", "r412", "r413", "r830", "r834", "r1063"] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [
"http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity
[Abstract]", "terseLabel": "Amortization of intangible assets" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross",
"crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Intangibles",
"documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r391", "r409", "r834", "r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails",
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r402", "r409", "r412", "r413", "r414", "r830", "r1063",
"r1091"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails", "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": {
"role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can
be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r402", "r404", "r405", "r406", "r408", "r409", "r412", "r413", "r1063"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationAmortizationOfIntangibleAssetsDetails",
"http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "verboseLabel": "Intangibles, net", "documentation": "Amount after amortization of assets,
excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r830", "r1321"] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails",
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangibles, net" } } },
"auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [
"http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority", "documentation": "Designated foreign jurisdiction
entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": ["r655", "r656"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails",
"http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Foreign currency (gains) losses, net", "documentation": "Amount,
before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r768", "r769", "r770", "r771", "r1012"] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Foreign
Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Foreign currency (gains) losses, net", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r141", "r990", "r1155",
"r1469", "r1470", "r1529"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Foreign
Currency Transactions and Translations Policy [Policy Text Block]", "verboseLabel": "Foreign Currency Translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's
functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the
financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r767"] }, "us-gaap_ForeignEarningsRepatriated": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignEarningsRepatriated", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Foreign Earnings Repatriated", "terseLabel": "Foreign earnings repatriated",
"documentation": "Amount of foreign earnings repatriated from subsidiaries outside the country of domicile." } } }, "auth_ref": [] }, "pahc_ForeignEmploymentTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630",
"localname": "ForeignEmploymentTaxes", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails",
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Foreign Employment Taxes", "label": "Foreign Employment Taxes", "terseLabel": "Brazil employment taxes" } } }, "auth_ref": [] },
"us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [
"http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails",
"http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": {
"en-us": { "role": { "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": ["r1074", "r1107", "r1118", "r1119"] }, "us-
gaap_ForeignExchangeOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeOptionMember", "presentation": [
"http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails",
"http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails"], "lang": {
"en-us": { "role": { "label": "Foreign Exchange Option [Member]", "terseLabel": "Foreign Exchange Option", "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an
exchange, during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [] }, "pahc_ForeignSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname":
"ForeignSubsidiariesMember", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "documentation": "Foreign Subsidiaries [Member]", "label": "Foreign Subsidiaries [Member]",
"terseLabel": "Foreign Subsidiaries" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel":
"Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r1171", "r1182", "r1192", "r1225"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement,
Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r1171", "r1182", "r1192", "r1225"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home
Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r1171", "r1182", "r1192", "r1225"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r1171", "r1182", "r1192", "r1225"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } },
"auth_ref": ["r1171", "r1182", "r1192", "r1225"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year
that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [
"r1205"] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Gain (Loss) Related to Litigation Settlement", "negatedLabel": "Insurance proceeds",
"documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": ["r1084", "r1335"] }, "us-
gaap_GainOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainOnSaleOfInvestments", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain on Sale
of Investments", "negatedLabel": "Gain on sale of investment", "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying
value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale." } } }, "auth_ref": ["r1270", "r1271", "r1276", "r1493"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationGoodwillDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"],
"lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset
representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r223", "r392", "r866", "r1085",
"r1090", "r1120", "r1127", "r1305", "r1312"] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Acquired During Period", "verboseLabel": "Acquisition", "documentation": "Amount of increase in asset
representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": ["r395", "r1090"] }, "us-
gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Effect of changes in exchange rates",
"documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not
individually identified and separately recognized." } } }, "auth_ref": ["r399"] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill.", "verboseLabel": "Goodwill", "documentation": "A roll forward is a reconciliation of a concept from the beginning
of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses
directly attributable to the revenue generation activity." } } }, "auth_ref": ["r128", "r132", "r182", "r264", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r766", "r1079", "r1084", "r1290", "r1292", "r1294", "r1295", "r1296",
"r1339"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails",
"http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails", "http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails",
"http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails",
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Domain]", "documentation": "Nature or
intent of a hedge." } } }, "auth_ref": ["r15"] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": [
"http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "auth_ref": [] }, "country_IL": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/country/2024", "localname": "IL", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "ISRAEL", "terseLabel": "Israel" } } }, "auth_ref":
[] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": {
"en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r1161", "r1162", "r1174"] }, "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Immediate Family Member of
Management or Principal Owner [Member]", "terseLabel": "Immediate Family Member of Management or Principal Owner", "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom
they might be controlled or influenced, because of the family relationship." } } }, "auth_ref": ["r1481", "r1482"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [
"http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text
Block]", "verboseLabel": "Long-Lived Assets and Goodwill", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit",
"presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "verboseLabel": "Domestic",
"documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": ["r265", "r654"] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
"http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "terseLabel": "Income
before income taxes", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and
income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r129", "r178", "r182", "r869", "r883", "r1079", "r1084", "r1290", "r1292", "r1294", "r1295", "r1296"] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit",
"presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "verboseLabel": "Foreign",
"documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." }
} }, "auth_ref": ["r265", "r654"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype":

"stringItemType":"nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeStatementAbstract","lang":{"en-us":{"role":{"label":"Income Statement [Abstract]"}}},"auth_ref":[]},"us-gaap_IncomeStatementRelatedDisclosuresAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeStatementRelatedDisclosuresAbstract","lang":{"en-us":{"role":{"label":"Statements of Operations-Additional Information"}}},"auth_ref":[]},"us-gaap_IncomeTaxAuthorityAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxAuthorityAxis","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Authority [Axis]","documentation":"Information by income tax jurisdiction."}}},"auth_ref":["r260","r655","r656","r667","r680","r1115","r1441"]},"us-gaap_IncomeTaxAuthorityDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxAuthorityDomain","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Authority [Domain]","documentation":"Income tax jurisdiction."}}},"auth_ref":["r260","r655","r656","r667","r680","r1115","r1441"]},"us-gaap_IncomeTaxDisclosureAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxDisclosureAbstract","lang":{"en-us":{"role":{"label":"Income Taxes"}}},"auth_ref":[]},"us-gaap_IncomeTaxDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxDisclosureTextBlock","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxes"],"lang":{"en-us":{"role":{"label":"Income Tax Disclosure [Text Block]","verboseLabel":"Income Taxes","documentation":"The entire disclosure for income tax."}}},"auth_ref":["r266","r647","r655","r663","r664","r665","r671","r678","r690","r692","r693","r694","r937","r1115"]},"us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxExaminationPenaltiesAndInterestExpense","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesUncertainTaxPositionsDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Examination, Penalties and Interest Expense","verboseLabel":"Recognized interest and penalties expense (income)","documentation":"The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."}}},"auth_ref":["r1437"]},"us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpenseAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxExaminationPenaltiesAndInterestExpenseAbstract","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesUncertainTaxPositionsDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Examination, Penalties and Interest Expense [Abstract]","terseLabel":"Interest and penalties expense"}}},"auth_ref":[]},"us-gaap_IncomeTaxExpenseBenefit":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxExpenseBenefit","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails","http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"],"lang":{"en-us":{"role":{"label":"Income Tax Expense (Benefit)","totalLabel":"Provision for income taxes","verboseLabel":"Income tax expense (benefit)","documentation":"Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."}}},"auth_ref":["r188","r205","r287","r288","r309","r325","r339","r653","r655","r691","r891","r1115"]},"us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxExpenseBenefitContinuingOperationsAbstract","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Expense (Benefit), Continuing Operations [Abstract]"}}},"auth_ref":[]},"us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesGlobalIntangibleLowTaxedIncomeDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"}}},"auth_ref":[]},"us-gaap_IncomeTaxPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxPolicyTextBlock","presentation":["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"],"lang":{"en-us":{"role":{"label":"Income Tax, Policy [Policy Text Block]","verboseLabel":"Income Taxes","documentation":"Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."}}},"auth_ref":["r247","r649","r650","r671","r672","r677","r682","r931"]},"us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxReconciliationOtherReconcilingItemsAbstract","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesGlobalIntangibleLowTaxedIncomeDetails"],"lang":{"en-us":{"role":{"label":"Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount [Abstract]","terseLabel":"Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount"}}},"auth_ref":[]},"us-gaap_IncomeTaxUncertainties Abstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxUncertainties Abstract","presentation":["http://www.pahc.com/role/DisclosureIncomeTaxesLiabilitiesRelatedToUncertainTaxPositionsDetails"],"lang":{"en-us":{"role":{"label":"Income Tax Uncertainties [Abstract]","terseLabel":"Income Taxes"}}},"auth_ref":[]},"us-gaap_IncomeTaxesPaidNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxesPaidNet","crdr":"credit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Income Taxes Paid, Net","verboseLabel":"Income taxes paid, net","documentation":"Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."}}},"auth_ref":["r34","r260","r679","r680"]},"us-gaap_IncreaseDecreaseInAccountsPayable":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccountsPayable","crdr":"debit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Accounts Payable","verboseLabel":"Accounts payable","documentation":"The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."}}},"auth_ref":["r8"]},"us-gaap_IncreaseDecreaseInAccountsReceivable":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccountsReceivable","crdr":"credit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Accounts Receivable","negatedLabel":"Accounts receivable, net","documentation":"The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."}}},"auth_ref":["r8"]},"us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities","crdr":"debit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities","verboseLabel":"Accrued expenses and other liabilities","documentation":"Amount of increase (decrease) in accrued expenses, and obligations classified as other."}}},"auth_ref":["r275"]},"us-gaap_IncreaseDecreaseInInventories":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInInventories","crdr":"credit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Inventories","negatedLabel":"Inventories, net","documentation":"The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."}}},"auth_ref":["r8"]},"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOperatingCapitalAbstract","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Operating Capital [Abstract]","verboseLabel":"Changes in operating assets and liabilities, net of business acquisition:"}}},"auth_ref":[]},"us-gaap_IncreaseDecreaseInOtherNoncurrentAssets":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOtherNoncurrentAssets","crdr":"credit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Other Noncurrent Assets","negatedLabel":"Other assets","documentation":"Amount of increase (decrease) in noncurrent assets classified as other."}}},"auth_ref":["r1275"]},"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets","crdr":"credit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Prepaid Expense and Other Assets","negatedLabel":"Other current assets","documentation":"Amount of increase (decrease) in prepaid expenses, and assets classified as other."}}},"auth_ref":["r8"]},"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInStockholdersEquityRollForward","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"],"lang":{"en-us":{"role":{"label":"Increase (Decrease) in Stockholders' Equity [Roll Forward]","terseLabel":"Increase (Decrease) in Stockholders' Equity","documentation":"A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."}}},"auth_ref":[]},"us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements","presentation":["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails"],"lang":{"en-us":{"role":{"label":"Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements","terseLabel":"Dilutive effect of restricted stock units (in shares)","documentation":"Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."}}},"auth_ref":["r294","r295","r296","r306","r603"]},"pahc_IncrementalTermLoan2023DueApril2026Member":{"xbrltype":"domainItemType","nsuri":"http://www.pahc.com/20240630","localname":"IncrementalTermLoan2023DueApril2026Member","presentation":["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails","http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails","http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails","http://www.pahc.com/role/DisclosureDebtReconciliationDetails"],"lang":{"en-us":{"role":{"documentation":"Incremental Term Loan, 2023, Due April 2026 [Member]","label":"Incremental Term Loan, 2023, Due April 2026 [Member]","terseLabel":"2023 Incremental Term Loan due April 2026"}}},"auth_ref":[]},"ecd_IndividualAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"IndividualAxis","presentation":["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure","http://xbrl.sec.gov/ecd/role/ErrCompDisclosure","http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"],"lang":{"en-us":{"role":{"label":"Individual [Axis]","terseLabel":"Individual:"}}},"auth_ref":["r1171","r1182","r1192","r1216","r1225","r1229","r1237"]},"ecd_InsiderTradingArrLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingArrLineItems","lang":{"en-us":{"role":{"label":"Insider Trading Arrangements [Line Items]","terseLabel":"Insider Trading Arrangements:"}}},"auth_ref":["r1235"]},"ecd_InsiderTradingPoliciesProcLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingPoliciesProcLineItems","lang":{"en-us":{"role":{"label":"Insider Trading Policies and Procedures [Line Items]","terseLabel":"Insider Trading Policies and Procedures:"}}},"auth_ref":["r1163","r1241"]},"ecd_InsiderTrdPoliciesProcAdoptedFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTrdPoliciesProcAdoptedFlag","presentation":["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"],"lang":{"en-us":{"role":{"label":"Insider Trading Policies and Procedures Adopted [Flag]","terseLabel":"Insider Trading Policies and Procedures Adopted"}}},"auth_ref":["r1163","r1241"]},"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTrdPoliciesProcNotAdoptedTextBlock","presentation":["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"],"lang":{"en-us":{"role":{"label":"Insider Trading Policies and Procedures Not Adopted [Text Block]","terseLabel":"Insider Trading Policies and Procedures Not Adopted"}}},"auth_ref":["r1163","r1241"]},"pahc_InsurancePremiumFinancingFixedInterestRatePercentage":{"xbrltype":"percentItemType","nsuri":"http://www.pahc.com/20240630","localname":"InsurancePremiumFinancingFixedInterestRatePercentage","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInsurancePremiumFinancingDetails"],"lang":{"en-us":{"role":{"documentation":"Insurance Premium Financing, Fixed Interest Rate Percentage.","label":"Insurance Premium Financing, Fixed Interest Rate Percentage","terseLabel":"Insurance premium financing, fixed interest rate percentage (as a percent)"}}},"auth_ref":[]},"pahc_InsurancePremiumFinancingMonthlyPaymentAmount":{"xbrltype":"monetaryItemType","nsuri":"http://www.pahc.com/20240630","localname":"InsurancePremiumFinancingMonthlyPaymentAmount","crdr":"credit","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInsurancePremiumFinancingDetails"],"lang":{"en-us":{"role":{"documentation":"Insurance Premium Financing, Monthly Payment Amount.","label":"Insurance Premium Financing, Monthly Payment Amount","terseLabel":"Insurance premium financing, monthly payment amount"}}},"auth_ref":[]},"us-gaap_InterestAndOtherIncome":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestAndOtherIncome","crdr":"credit","presentation":["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"],"lang":{"en-us":{"role":{"label":"Interest and Other Income","negatedLabel":"Interest income","documentation":"The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."}}},"auth_ref":[]},"us-gaap_InterestExpenseDebtExcludingAmortization":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestExpenseDebtExcludingAmortization","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"],"lang":{"en-us":{"role":{"label":"Interest Expense, Debt, Excluding Amortization","terseLabel":"Interest expense, excluding amortization","documentation":"Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."}}},"auth_ref":["r135","r475","r1097","r1098"]},"us-gaap_InterestExpenseNonoperating":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestExpenseNonoperating","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"],"lang":{"en-us":{"role":{"label":"Interest Expense, Nonoperating","totalLabel":"Interest expense","documentation":"Amount of interest expense classified as nonoperating."}}},"auth_ref":["r321","r1272"]},"us-gaap_InterestExpenseOther":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestExpenseOther","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"],"lang":{"en-us":{"role":{"label":"Interest Expense, Other","verboseLabel":"Other","documentation":"Amount of interest expense classified as other."}}},"auth_ref":[]},"us-gaap_InterestIncomeExpenseNonoperatingAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestIncomeExpenseNonoperatingAbstract","presentation":["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails"],"lang":{"en-us":{"role":{"label":"Interest Income (Expense), Nonoperating [Abstract]","terseLabel":"Interest expense, net"}}},"auth_ref":[]},"us-gaap_InterestIncomeExpenseNonoperatingNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestIncomeExpenseNonoperatingNet","crdr":"credit","presentation":["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails","http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails","http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationInterestExpenseNetDetails","http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"],"lang":{"en-us":{"role":{"label":"Interest Income (Expense), Nonoperating, Net","negatedLabel":"Interest expense, net","documentation":"Amount of interest income (expense) classified as nonoperating."}}},"auth_ref":["r1092"]},"us-gaap_InterestPaidExcludingCapitalizedInterestOperatingActivities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestPaidExcludingCapitalizedInterestOperatingActivities","crdr":"credit","presentation":["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"label":"Interest Paid, Excluding Capitalized Interest, Operating Activities","verboseLabel":"Interest paid, net","documentation":"Amount of cash paid for interest (excluding capitalized interest) classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."}}},"auth_ref":["r255","r258","r259"]},"us-gaap_InterestRateContractMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestRateContractMember","presentation":["http://www.pahc.com/role/DisclosureDebtDerivativesDetails","http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails","http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails","http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails","http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails","http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails","http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails","http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"],"lang":{"en-us":{"role":{"label":"Interest Rate Contract [Member]","documentation":"Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate."}}},"auth_ref":["r1065","r1074","r1107","r1119"]},"pahc_InterestRateSwapJuly2022Member":{"xbrltype":"domainItemType","nsuri":"http://www.pahc.com/20240630","localname":"InterestRateSwapJuly2022Member","presentation":["http://www.pahc.com/role/DisclosureDebtDerivativesDetails","http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails","http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails"],"lang":{"en-us":{"role":{"documentation":"Interest Rate Swap, July 2022 [Member].","label":"Interest Rate Swap, July 2022 [Member]","terseLabel":"Interest Rate Swap, July 2022"}}},"auth_ref":[]},"us-gaap_InterestRateSwapMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestRateSwapMember","presentation":["http://www.pahc.com/role/DisclosureDebtDerivativesDetails","http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails","http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails","http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails","http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails","http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails","http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails","http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"],"lang":{"en-us":{"role":{"label":"Interest Rate Swap [Member]","terseLabel":"Interest Rate Swap","documentation":"Forward-based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."}}},"auth_ref":["r1065","r1152","r1153"]},"us-gaap_InternalUseSoftwarePolicy":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InternalUseSoftwarePolicy","presentation":["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"],"lang":{"en-us":{"role":{"label":"Internal Use Software, Policy [Policy Text Block]","verboseLabel":"Capitalized Software Costs","documentation":"Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally."}}},"auth_ref":["r415"]},"us-gaap_InventoryFinishedGoodsNetOfReserves":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryFinishedGoodsNetOfReserves","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInventoriesDetails"],"lang":{"en-us":{"role":{"label":"Inventory, Finished Goods, Net of Reserves","verboseLabel":"Finished goods","documentation":"Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."}}},"auth_ref":["r146","r1071"]},"us-gaap_InventoryNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryNet","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInventoriesDetails","http://www.pahc.com/role/StatementConsolidatedBalanceSheets"],"lang":{"en-us":{"role":{"label":"Inventory, Net","terseLabel":"Inventories, net","totalLabel":"Inventory, net","documentation":"Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."}}},"auth_ref":["r236","r1069","r1127"]},"us-gaap_InventoryNetAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryNetAbstract","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInventoriesDetails"],"lang":{"en-us":{"role":{"label":"Inventory, Net [Abstract]","terseLabel":"Inventories, net"}}},"auth_ref":[]},"us-gaap_InventoryPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryPolicyTextBlock","presentation":["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"],"lang":{"en-us":{"role":{"label":"Inventory, Policy [Policy Text Block]","verboseLabel":"Inventories","documentation":"Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."}}},"auth_ref":["r189","r219","r235","r388","r389","r390","r828","r1076"]},"us-gaap_InventoryRawMaterialsNetOfReserves":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryRawMaterialsNetOfReserves","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInventoriesDetails"],"lang":{"en-us":{"role":{"label":"Inventory, Raw Materials, Net of Reserves","verboseLabel":"Raw materials","documentation":"Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."}}},"auth_ref":["r146","r1073"]},"us-gaap_InventoryWorkInProcessNetOfReserves":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryWorkInProcessNetOfReserves","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationInventoriesDetails"],"lang":{"en-us":{"role":{"label":"Inventory, Work in Process, Net of Reserves","verboseLabel":"Work-in-process","documentation":"Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."}}},"auth_ref":["r146","r1072"]},"us-gaap_InvestmentPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentPolicyTextBlock","presentation":["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"],"lang":{"en-us":{"role":{"label":"Investment, Policy [Policy Text Block]","terseLabel":"Short-term Investments","documentation":"Disclosure of accounting policy for investment in financial asset."}}},"auth_ref":["r890","r927","r928","r929","r930","r1025","r1026"]},"pahc_July2023Member":{"xbrltype":"domainItemType","nsuri":"http://www.pahc.com/20240630","localname":"July2023Member","presentation":["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"],"lang":{"en-us":{"role":{"documentation":"July 2023 [Member].","label":"July 2023 [Member]","terseLabel":"July 2023"}}},"auth_ref":[]},"us-gaap_LandMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LandMember","presentation":["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails"],"lang":{"en-us":{"role":{"label":"Land [Member]","terseLabel":"Land","documentation":"Part of earth's surface not covered by water."}}},"auth_ref":["r1346"]},"pahc_LatinAmericaAndCanadaMember":{"xbrltype":"domainItemType","nsuri":"http://www.pahc.com/20240630","localname":"LatinAmericaAndCanadaMember","presentation":["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"],"lang":{"en-us":{"role":{"documentation":"Latin America and Canada [Member].","label":"Latin America and Canada [Member]","terseLabel":"Latin America and Canada"}}},"auth_ref":[]},"us-gaap_LeaseCost":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCost","crdr":"debit","presentation":["http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails"],"lang":{"en-us":{"role":{"label":"Lease, Cost","totalLabel":"Total lease expense","documentation":"Amount of lease cost recognized by lessee for lease contract."}}},"auth_ref":["r792","r1126"]},"us-gaap_LeaseCostAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCostAbstract","presentation":["http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails"],"lang":{"en-us":{"role":{"label":"Lease, Cost [Abstract]","terseLabel":"Composition of net lease expense"}}},"auth_ref":[]},"us-gaap_LeaseCostTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCostTableTextBlock","presentation":["http://www.pahc.com/role/DisclosureLeasesTables"],"lang":{"en-us":{"role":{"label":"Lease, Cost [Table Text Block]","terseLabel":"Summary of operating lease information","documentation":"Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."}}},"auth_ref":["r1479"]},"us-gaap_LeasesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeasesAbstract","lang":{"en-us":{"role":{"label":"Leases [Abstract]","terseLabel":"Leases"}}},"auth_ref":[]},"us-gaap_LesseeDisclosureAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeDisclosureAbstract","presentation":["http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails","http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails","http://www.pahc.com/role/DisclosureLeasesGrossDifferenceDetails","http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails","http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesOtherSupplementalInformationDetails"],"lang":{"en-us":{"role":{"label":"Lessee Disclosure [Abstract]"}}},"auth_ref":[]},"us-gaap_LesseeLeaseDescriptionLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeLeaseDescriptionLineItems","presentation":["http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails"],"lang":{"en-us":{"role":{"label":"Lessee, Lease, Description [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":["r791","r802"]},"us-gaap_LesseeLeaseDescriptionTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeLeaseDescriptionTable","presentation":["http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails"],"lang":{"en-us":{"role":{"label":"Lessee, Lease, Description [Table]","documentation":"Disclosure of information about lessee's leases."}}},"auth_ref":["r791","r802"]},"us-gaap_LesseeOperatingLeaseDescriptionAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseDescriptionAbstract","presentation":["http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails"],"lang":{"en-us":{"role":{"label":"Lessee, Operating Lease, Description [Abstract]","terseLabel":"Leases"}}},"auth_ref":[]},"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityMaturityTableTextBlock","presentation":["http://www.pahc.com/role/DisclosureLeasesTables"],"lang":{"en-us":{"role":{"label":"Lessee, Operating Lease, Liability, Maturity [Table Text Block]","terseLabel":"Summary of maturities of future lease liabilities","documentation":"Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."}}},"auth_ref":["r1480"]},"us-gaap_LesseeOperatingLeaseLiabilityPa

annual periods when interim periods are reported from current statement of financial position date (rolling approach)." }] }, "auth_ref": ["r800"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "verboseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r800"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r800"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r800"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r800"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesGrossDifferenceDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r800"] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r802", "r1477"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r785"] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorLeasesPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": ["r198", "r199", "r200", "r803"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [ ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [ ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r22", "r101", "r102", "r103", "r106", "r107", "r108", "r111", "r264", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r714", "r718", "r719", "r766", "r967", "r1078", "r1157", "r1339", "r1484", "r1485"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r119", "r175", "r877", "r1127", "r1279", "r1302", "r1468"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [ ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r103", "r104", "r105", "r264", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r714", "r718", "r719", "r766", "r1127", "r1339", "r1484", "r1485"] }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesLiabilitiesRelatedToUncertainTaxPositionsDetails"], "lang": { "en-us": { "role": { "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "totalLabel": "Total liabilities related to uncertain tax positions", "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent." } } }, "auth_ref": ["r107"] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-term Line of Credit", "terseLabel": "Outstanding borrowings", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r22", "r173", "r1494"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r100", "r105"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Aggregate available credit facilities", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r100", "r105", "r442"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "terseLabel": "Line of Credit", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [ ] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Loans Payable, Current", "terseLabel": "Current portion of long-term debt", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r102"] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Loans Payable [Member]", "terseLabel": "Loans Payable", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ ] }, "del_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://sbrl.sec.gov/del/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [ ] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsTables"], "lang": { "en-us": { "role": { "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "verboseLabel": "Schedule of geographic information regarding property, plant and equipment, net" "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": ["r144"] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongMember", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails"], "lang": { "en-us": { "role": { "label": "Long [Member]", "terseLabel": "Long", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [ ] }, "pahc_LongTermAndDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermAndDeferredIncomeTaxes", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Long Term And Deferred Income Taxes", "verboseLabel": "Long term and deferred income taxes" } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtClassificationDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Long-term debt, current and non-current", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r22", "r173", "r467", "r482", "r1095", "r1096", "r1125", "r1494"] }, "us-gaap_LongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Unclassified [Abstract]", "terseLabel": "Debt Maturities" } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDebtReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt and Lease Obligation, Including Current Maturities [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByCurrentAndNoncurrentAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDebtClassificationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, by Current and Noncurrent [Abstract]", "terseLabel": "Debt Maturities" } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtClassificationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Less: current maturities of long-term debt and other", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r227"] }, "pahc_LongTermDebtGrossMaturityYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtGrossMaturityYearFour", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Gross, Maturity, Year Four", "label": "Long-Term Debt, Gross, Maturity, Year Four", "terseLabel": "Debt payments, 2028" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtGrossMaturityYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtGrossMaturityYearOne", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Gross, Maturity, Year One", "label": "Long-Term Debt, Gross, Maturity, Year One", "terseLabel": "Debt payments, 2025" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtGrossMaturityYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtGrossMaturityYearThree", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Gross, Maturity, Year Three", "label": "Long-Term Debt, Gross, Maturity, Year Three", "terseLabel": "Debt payments, 2027" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtGrossMaturityYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtGrossMaturityYearTwo", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Gross, Maturity, Year Two", "label": "Long-Term Debt, Gross, Maturity, Year Two", "terseLabel": "Debt payments, 2026" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtMaturityInterestPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtMaturityInterestPayments", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, Interest Payments", "label": "Long-Term Debt, Maturity, Interest Payments", "totalLabel": "Interest payments, total" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtMaturityInterestPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtMaturityInterestPaymentsYearFour", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, Interest Payments, Year Four", "label": "Long-Term Debt, Maturity, Interest Payments, Year Four", "terseLabel": "Interest payments, 2028" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtMaturityInterestPaymentsYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtMaturityInterestPaymentsYearOne", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, Interest Payments, Year One", "label": "Long-Term Debt, Maturity, Interest Payments, Year One", "terseLabel": "Interest payments, 2025" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtMaturityInterestPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtMaturityInterestPaymentsYearThree", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, Interest Payments, Year Three", "label": "Long-Term Debt, Maturity, Interest Payments, Year Three", "terseLabel": "Interest payments, 2027" } } }, "auth_ref": [ ] }, "pahc_LongTermDebtMaturityInterestPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "LongTermDebtMaturityInterestPaymentsYearTwo", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtAggregateMaturitiesOfLongTermDebtAndRevolverDetails"], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, Interest Payments, Year Two", "label": "Long-Term Debt, Maturity, Interest Payments, Year Two", "terseLabel": "Interest payments, 2026" } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDebtClassificationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r228"] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": ["http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Long-term debt, weighted average interest rate, over time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [ ] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-term Line of Credit, Noncurrent", "verboseLabel": "Revolving credit facility", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r22", "r56", "r57"] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLoansPayable", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Loans Payable, Noncurrent", "terseLabel": "Long-term debt", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r22"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r22", "r1326", "r1327", "r1328"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r22", "r58", "r1326", "r1327", "r1328"] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r346", "r1102", "r1137", "r1142", "r1345", "r1497", "r1500", "r1501", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails", "http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r436", "r437", "r439", "r440", "r597", "r644", "r752", "r827", "r910", "r911", "r924", "r959", "r960", "r1023", "r1027", "r1029", "r1030", "r1036", "r1059", "r1060", "r1089", "r1099", "r1111", "r1121", "r1122", "r1123", "r1124", "r1138", "r1343", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure" } } }, "auth_ref": ["r1208"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r1208"] }, "pahc_MedicatedFeedAdditivesAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "MedicatedFeedAdditivesAndOthersMember", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "documentation": "Medicated Feed Additives and Others [Member]", "label": "Medicated Feed Additives and Others [Member]", "terseLabel": "MFAs and other" } } }, "auth_ref": [ ] }, "pahc_MineralNutritionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "MineralNutritionMember", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents segment manufactures and markets trace minerals for the cattle, swine, poultry and pet food markets.", "label": "Mineral Nutrition [Member]", "terseLabel": "Mineral Nutrition" } } }, "auth_ref": [ ] }, "pahc_MinimumCommonStockOwnershipConversionThreshold": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "MinimumCommonStockOwnershipConversionThreshold", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold defined as a percentage of minimum ownership of the total outstanding shares of Class A common stock and Class B common stock, taken as a single class.", "label": "Minimum Common Stock Ownership Conversion Threshold", "verboseLabel": "BFI ownership percentage at which the rema

funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": ["r1369"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": ["r346", "r1102", "r1137", "r1142", "r1345", "r1497", "r1500", "r1501", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1209"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.pahc.com/role/DisclosureDescriptionOfBusiness"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "verboseLabel": "Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r190", "r206"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r257"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "auth_ref": [ ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r257"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "auth_ref": [ ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r139", "r140", "r141"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "auth_ref": [ ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r133", "r141", "r179", "r216", "r242", "r245", "r250", "r264", "r276", "r280", "r281", "r282", "r283", "r284", "r287", "r288", "r302", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r702", "r711", "r746", "r766", "r885", "r991", "r1013", "r1014", "r1155", "r1339"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r254", "r280", "r281", "r282", "r283", "r290", "r291", "r303", "r306", "r711"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": ["r254", "r292", "r298", "r299", "r300", "r301", "r303", "r306"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNetIncomePerShareAndWeightedAverageSharesDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Net Income (Loss) per Share and Weighted Average Shares" } } }, "auth_ref": [ ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Standards", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r209", "r210", "r211", "r212", "r213", "r214", "r274", "r276", "r277", "r278", "r279", "r282", "r289", "r308", "r347", "r348", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r416", "r417", "r426", "r684", "r685", "r686", "r687", "r688", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r763", "r764", "r782", "r783", "r784", "r804", "r805", "r806", "r807", "r808", "r809", "r831", "r832", "r833", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r926"] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": ["r38", "r209", "r210", "r211", "r212", "r213", "r214", "r274", "r276", "r277", "r278", "r279", "r282", "r289", "r308", "r347", "r348", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r416", "r417", "r426", "r684", "r685", "r686", "r687", "r688", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r763", "r764", "r782", "r783", "r784", "r804", "r805", "r806", "r807", "r808", "r809", "r831", "r832", "r833", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r926"] }, "us-gaap_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "New Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1208"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r1171", "r1182", "r1192", "r1216", "r1225"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r1199"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1198"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1216"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1236"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1236"] }, "us-gaap_NotionalAmountOfDerivativesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotionalAmountOfDerivativesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureDebtDerivativesDetails", "http://www.pahc.com/role/DisclosureDerivativesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Notional Disclosures [Abstract]", "terseLabel": "Derivatives" } } }, "auth_ref": [ ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsGeneralInformationDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r1080", "r1088", "r1291"] }, "pahc_NutritionalSpecialtiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "NutritionalSpecialtiesMember", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "documentation": "Nutritional Specialties [Member]", "label": "Nutritional Specialties [Member]", "terseLabel": "Nutritional Specialties" } } }, "auth_ref": [ ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r182", "r1079", "r1290", "r1292", "r1294", "r1295", "r1296"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r793", "r1126"] }, "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract", "presentation": ["http://www.pahc.com/role/DisclosureLeasesGrossDifferenceDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Gross Difference Amount [Abstract]", "terseLabel": "Leases" } } }, "auth_ref": [ ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.pahc.com/role/DisclosureLeasesMaturitiesOfFutureLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Leases" } } }, "auth_ref": [ ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails", "http://www.pahc.com/role/DisclosureLeasesGrossDifferenceDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Lease liabilities", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r788"] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "presentation": ["http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [ ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion", "verboseLabel": "Current operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r788"] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": ["r789"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails", "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current portion", "verboseLabel": "Long-term operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r788"] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails", "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": ["r789"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesOtherSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows used for ROU operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r790", "r796"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails", "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "ROU operating lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r787"] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails", "http://www.pahc.com/role/DisclosureLeasesAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": ["r789"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.pahc.com/role/DisclosureLeasesOtherSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases (as a percent)", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r799", "r1126"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.pahc.com/role/DisclosureLeasesOtherSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases", "documentation": "Weighted average remaining lease term for operating lease, in PnYnMnDTnHnMnS format for example, P1Y5M13D represents reported fact of one year five months, and thirteen days." } } }, "auth_ref": ["r798", "r1126"] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating loss carry forwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r681"] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Income Taxes", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r681"] }, "pahc_OperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Not Subject to Expiration", "label": "Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Net operating loss carry forwards, not subject to expiration" } } }, "auth_ref": [ ] }, "pahc_OperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "OperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Subject to Expiration", "label": "Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carry forwards, subject to expiration" } } }, "auth_ref": [ ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": ["r681"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r340", "r1084", "r1085"] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Noncurrent", "verboseLabel": "Other long-term liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r107"] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]", "verboseLabel": "Other assets" } } }, "auth_ref": [ ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r237", "r1127"] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetLocationTable"], "lang": { "en-us": { "role": { "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": ["r80", "r90"] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous, Noncurrent", "verboseLabel": "Other", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [ ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other

"negatedLabel": "(Income) expense recorded in comprehensive income", "verboseLabel": "Change in fair value of derivative instruments", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r240"] },
"pahc_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodAmortizationOfNetActuarialLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodAmortizationOfNetActuarialLossBeforeTax", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Amortization of Net Actuarial Loss, before Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Amortization of Net Actuarial Loss, before Tax", "terseLabel": "Amortization of net actuarial loss" } } }, "auth_ref": [] }, "pahc_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodCurrentPeriodNetActuarialGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodCurrentPeriodNetActuarialGainLossBeforeTax", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Current Period Net Actuarial Gain (Loss), before Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Current Period Net Actuarial Gain (Loss), before Tax", "terseLabel": "Current period net actuarial loss" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax", "terseLabel": "Pension settlement recognition", "documentation": "Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan." } } }, "auth_ref": ["r5", "r127", "r156"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r7", "r13", "r165", "r243", "r246", "r284"] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Unrecognized net pension gains (losses)", "totalLabel": "Unrecognized net pension gains (losses)", "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": ["r126", "r127", "r156"] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "(Provision) benefit for income taxes", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r7", "r13", "r165"] }, "pahc_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "OtherCountriesMember", "presentation": [
"http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [
"http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": ["r80", "r90"] }, "pahc_OtherEmployeeBenefitPlansExpenseInternationalRetirementPlansSupplementalRetirementBenefitsAndLongTermIncentiveArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "OtherEmployeeBenefitPlansExpenseInternationalRetirementPlansSupplementalRetirementBenefitsAndLongTermIncentiveArrangements", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansOtherEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Other Employee Benefit Plans Expense, International Retirement Plans, Supplemental Retirement Benefits and Long-term Incentive Arrangements", "label": "Other Employee Benefit Plans Expense, International Retirement Plans, Supplemental Retirement Benefits and Long-term Incentive Arrangements", "terseLabel": "Other employee benefit plans expense" } } }, "auth_ref": [] }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansOtherEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Other Employee-related Liabilities", "terseLabel": "Other employee-related liabilities", "documentation": "Amount of obligations incurred for employer-related costs classified as other." } } }, "auth_ref": ["r172"] }, "us-gaap_OtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestments", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Investments", "terseLabel": "Insurance investments", "documentation": "Amount of investments classified as other." } } }, "auth_ref": ["r878", "r1263"] }, "us-gaap_OtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities [Abstract]", "verboseLabel": "Other liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "verboseLabel": "Other", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r102", "r1127"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Other liabilities, total", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r107"] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other Noncash Income (Expense)", "negatedLabel": "Other", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r141"] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesBalanceSheetLocationDetails"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of other liabilities", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r1208"] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1169", "r1180", "r1190", "r1223"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r1172", "r1183", "r1193", "r1226"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1172", "r1183", "r1193", "r1226"] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [
"http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1197"] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": ["r6"] }, "pahc_PaymentTermHighEndOfRange": { "xbrltype": "durationItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "PaymentTermHighEndOfRange", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Payment Term, High End of Range", "label": "Payment Term, High End of Range", "terseLabel": "Payment term, maximum" } } }, "auth_ref": [] }, "pahc_PaymentTermLowEndOfRange": { "xbrltype": "durationItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "PaymentTermLowEndOfRange", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationGeneralInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Payment Term, Low End of Range", "label": "Payment Term, Low End of Range", "terseLabel": "Payment term, minimum" } } }, "auth_ref": [] }, "us-gaap_PaymentsForEnvironmentalLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForEnvironmentalLiabilities", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesEnvironmentalDetails"], "lang": { "en-us": { "role": { "label": "Payments for Environmental Liabilities", "terseLabel": "Payments for environmental liabilities", "documentation": "Cash outflows made during the period for environmental remediation activities." } } }, "auth_ref": ["r1274"] },
"pahc_PaymentsForInsurancePremiumFinancingAndOtherShortTermDebtFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "PaymentsForInsurancePremiumFinancingAndOtherShortTermDebtFinancingActivities", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Payments for Insurance Premium Financing and Other Short-term Debt, Financing Activities", "label": "Payments for Insurance Premium Financing and Other Short-term Debt, Financing Activities", "negatedLabel": "Payments of insurance premium financing and other short-term debt" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": ["r1256", "r1273"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r31"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r137"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Business acquisition, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r29"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r187", "r1447", "r1448", "r1449"] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchases of short-term investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r136"] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r1207"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r1207"] }, "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent", "terseLabel": "Supplemental retirement benefits, deferred compensation and other", "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent." } } }, "auth_ref": ["r66", "r67", "r107", "r155"] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlans"], "lang": { "en-us": { "role": { "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "verboseLabel": "Employee Benefit Plans", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": ["r519", "r545", "r547", "r553", "r572", "r574", "r575", "r576", "r577", "r578", "r593", "r594", "r596", "r1109"] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "International retirement plans", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": ["r107", "r520", "r521", "r544", "r1109"] }, "us-gaap_PensionExpenseReversalOfExpenseNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionExpenseReversalOfExpenseNoncash", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails",
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Pension Expense (Reversal of Expense), Noncash", "terseLabel": "Pension settlement cost", "documentation": "Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits." } } }, "auth_ref": ["r9"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r1199"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r1216"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r1209"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r1198"] },
"pahc_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": [
"http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units [Member]", "label": "Performance-based Restricted Stock Units [Member]", "terseLabel": "Performance-based Restricted Stock Units" } } }, "auth_ref": [] }, "pahc_PerformanceProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "PerformanceProductsMember", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails",
"http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "documentation": "Performance Products [Member]", "label": "Performance Products [Member]", "terseLabel": "Performance Products" } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails",
"http://www.pahc.com/role/DisclosureEmployeeBenefitPlansFairValuesOfPlanAssetsDetails"], "lang": { "en-us": { "role": { "label": "Plan Asset Categories [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": ["r545", "r546", "r548", "r549", "r550", "r551", "r552", "r553", "r573", "r1107", "r1108", "r1109"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r1200"] },
"ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r1245"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r1199"] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionAxis", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails"], "lang": { "en-us": { "role": { "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionDomain", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails"], "lang": { "en-us": { "role": { "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] },
"us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred stock" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r112", "r484"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r112", "r969"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r112", "r484"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r112", "r969", "r988", "r1530", "r1531"] }, "pahc_ProceedsFromInsurancePremiumFinancingAndOtherShortTermDebtFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ProceedsFromInsurancePremiumFinancingAndOtherShortTermDebtFinancingActivities", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Proceeds from Insurance Premium Financing and Other Short-term Debt, Financing Activities", "label": "Proceeds from Insurance Premium Financing and Other Short-term Debt, Financing Activities", "terseLabel": "Proceeds from insurance premium financing and other short-term debt" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Other Long-Term Debt", "terseLabel": "Proceeds from long-term debt", "documentation": "Amount of cash inflow from issuance of long-term debt classified as other." } } }, "auth_ref": ["r30"] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [
"http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Revolving credit facility borrowings", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r30"] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments", "verboseLabel": "Maturities of short-term investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r28", "r136"] }, "us-gaap_ProceedsFromSaleOfInvestmentProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfInvestmentProjects", "crdr": "debit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Investment Projects", "terseLabel": "Sale of investment", "documentation": "The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it." } } }, "auth_ref": ["r28"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r342",

"r829", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r1066", "r1100", "r1136", "r1138", "r1139", "r1143", "r1144", "r1336", "r1337", "r1345", "r1497", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527"] }, "pahc_ProductRegistrationsMarketingAndDistributionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ProductRegistrationsMarketingAndDistributionRightsMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails", "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "documentation": "Product Registrations, Marketing and Distribution Rights [Member]", "label": "Product Registrations, Marketing and Distribution Rights [Member]", "terseLabel": "Product Registrations, Marketing and Distribution Rights" } } }, "auth_ref": [ ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r342", "r829", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r1066", "r1100", "r1136", "r1138", "r1139", "r1143", "r1144", "r1336", "r1337", "r1345", "r1497", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r216", "r242", "r245", "r256", "r264", "r276", "r284", "r287", "r288", "r353", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r702", "r711", "r712", "r715", "r716", "r746", "r766", "r869", "r884", "r942", "r991", "r1013", "r1014", "r1116", "r1117", "r1156", "r1269", "r1339"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r11", "r801"] }, "us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]", "terseLabel": "Property, Plant and Equipment, Depreciation Method", "documentation": "Indicates method of allocating cost over useful life in systematic and rational manner for property, plant, and equipment." } } }, "auth_ref": ["r418"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Property, plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r147", "r221", "r882"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r801"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r11", "r801", "r870", "r882", "r1127"] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "verboseLabel": "Property, plant and equipment, net" } } }, "auth_ref": [ ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property, Plant and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r11", "r195", "r201", "r880"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment, net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r11"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTabularDisclosureDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r147", "r801"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [ ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationReserveForCreditLossesDetails"], "lang": { "en-us": { "role": { "label": "Provision for Doubtful Accounts", "verboseLabel": "Provision for estimated credit losses", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r253", "r372"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1197"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r1197"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails", "http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails", "http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r436", "r437", "r439", "r440", "r545", "r597", "r630", "r631", "r632", "r644", "r752", "r825", "r826", "r827", "r910", "r911", "r924", "r959", "r960", "r1023", "r1027", "r1029", "r1030", "r1036", "r1059", "r1060", "r1089", "r1099", "r1111", "r1121", "r1122", "r1123", "r1124", "r1138", "r1147", "r1329", "r1343", "r1458", "r1487", "r1488", "r1489", "r1490", "r1491"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails", "http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureEmployeeBenefitPlansAssetAllocationDetails", "http://www.pahc.com/role/DisclosureLeasesGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r436", "r437", "r439", "r440", "r545", "r597", "r630", "r631", "r632", "r644", "r752", "r825", "r826", "r827", "r910", "r911", "r924", "r959", "r960", "r1023", "r1027", "r1029", "r1030", "r1036", "r1059", "r1060", "r1089", "r1099", "r1111", "r1121", "r1122", "r1123", "r1124", "r1138", "r1147", "r1329", "r1343", "r1458", "r1487", "r1488", "r1489", "r1490", "r1491"] }, "pahc_RealizedGainLossOnMaturedContractsRecordedAsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "RealizedGainLossOnMaturedContractsRecordedAsInventory", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This is the amount of gain (loss) on matured contracts, that we record to Inventory.", "label": "Realized Gain (Loss) on Matured Contracts Recorded as Inventory", "verboseLabel": "Realized gains (losses) related to matured contracts recorded as a component of inventory" } } }, "auth_ref": [ ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidated": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidated", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails"], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": ["r52", "r53"] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsTables"], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Schedule of identifiable assets", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": ["r52", "r53"] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r51", "r53"] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliations of the beginning and ending amounts of gross unrecognized tax benefits", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r1164", "r1175", "r1185", "r1218"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r349", "r573", "r813", "r814", "r873", "r879", "r962", "r963", "r964", "r965", "r966", "r987", "r989", "r1022"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r267", "r268", "r813", "r814", "r815", "r816", "r873", "r879", "r962", "r963", "r964", "r965", "r966", "r987", "r989", "r1022"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Amounts of Transaction", "verboseLabel": "Aggregate compensation and benefits", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r95"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r813", "r814", "r1483"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [ ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r349", "r995", "r996", "r999"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth_ref": [ ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r349", "r573", "r813", "r814", "r873", "r879", "r962", "r963", "r964", "r965", "r966", "r987", "r989", "r1022", "r1483"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": ["r810", "r811", "r812", "r814", "r817", "r938", "r939", "r940", "r997", "r998", "r999", "r1019", "r1021"] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Revolving credit facility repayments", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r138"] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Payments of long-term debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": ["r138"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationResearchAndDevelopmentExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r646", "r1063", "r1084", "r1492"] }, "us-gaap_ResearchAndDevelopmentExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseAbstract", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationResearchAndDevelopmentExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Abstract]", "terseLabel": "Research and development expense" } } }, "auth_ref": [ ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Research and Development Expenditures", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r645"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r1165", "r1176", "r1186", "r1219"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r1166", "r1177", "r1187", "r1220"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r1173", "r1184", "r1194", "r1227"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Phibro Forward income growth initiatives implementation costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r9", "r430", "r431", "r1333"] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": ["r1252", "r1253"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "verboseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r116", "r154", "r876", "r918", "r923", "r936", "r970", "r1127"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r211", "r271", "r272", "r273", "r277", "r284", "r286", "r288", "r358", "r364", "r417", "r684", "r685", "r698", "r699", "r700", "r703", "r710", "r711", "r726", "r729", "r730", "r733", "r744", "r783", "r786", "r914", "r916", "r943", "r1530"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r180", "r181", "r309", "r318", "r319", "r333", "r339", "r342", "r344", "r346", "r516", "r517", "r829"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r207", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r1064"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformation"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Disaggregated Revenue, Deferred Revenue and Customer Payment Terms", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r207", "r500", "r501", "r502", "r503", "r504", "r505

"http://sbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://sbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1236"] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReparationDetails"], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": ["r598", "r1286"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureIncomeTaxesReparationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r289", "r598", "r1254", "r1286"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivable, net", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r114", "r120"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of accumulated other comprehensive loss", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss). " } } }, "auth_ref": ["r26", "r1451", "r1472"] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "verboseLabel": "Schedule of weighted-average asset allocation of plan assets", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": ["r158"] }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Schedule of accumulated other comprehensive (income) loss related to the pension plan", "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost. " } } }, "auth_ref": ["r156"] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used [Table Text Block]", "verboseLabel": "Schedule of significant actuarial assumptions", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": ["r567"] }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "verboseLabel": "Schedule of fair values of the company's plan assets by asset category", "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements." } } }, "auth_ref": ["r157"] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "verboseLabel": "Schedule of components of the provision for income taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1443"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of long term debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r22", "r62", "r65", "r96", "r152", "r153", "r1095", "r1097", "r1282", "r1474"] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "verboseLabel": "Schedule of the tax effects of significant temporary differences that comprise deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax assets or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r1439"] }, "pahc_ScheduleOfDeferredTaxesAreIncludedConsolidatedBalanceSheetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ScheduleOfDeferredTaxesAreIncludedConsolidatedBalanceSheetsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of schedule of deferred taxes are included consolidated balance sheets.", "label": "Schedule of Deferred Taxes are Included Consolidated Balance Sheets [Table Text Block]", "verboseLabel": "Schedule of deferred taxes included in the line items of the consolidated balance sheets" } } }, "auth_ref": [] }, "pahc_ScheduleOfDepreciationAndAmortizationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ScheduleOfDepreciationAndAmortizationTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of depreciation and amortization.", "label": "Schedule of Depreciation and Amortization [Table Text Block]", "terseLabel": "Schedule of depreciation and amortization" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesTables"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of effects of derivatives", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r81", "r84", "r721"] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments [Table Text Block]", "verboseLabel": "Schedule of significant outstanding derivatives employed to manage market risk and designated as cash flow hedges", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r15", "r75", "r76", "r77", "r79", "r82", "r84", "r86", "r88"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net income per share and weighted average shares", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1289"] }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]", "verboseLabel": "Schedule of summary of the changes in the fair value of level 3 assets", "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period." } } }, "auth_ref": ["r1371"] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Schedule of reconciliations of the Federal statutory rate to the Company's effective tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r657", "r1115", "r1434"] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Expected Benefit Payments [Table Text Block]", "verboseLabel": "Schedule of estimated future benefit payments, including benefits attributable to future service", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": ["r159"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value of assets and liabilities measured on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1455", "r1456"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTextBlock"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r102", "r109", "r412", "r413", "r414", "r830", "r1063", "r1091"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangibles, net", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r1091", "r1320"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r1090", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314"] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "verboseLabel": "Schedule of income (loss) before income taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": ["r1280"] }, "pahc_ScheduleOfInterestExpenseNetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ScheduleOfInterestExpenseNetTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense, net.", "label": "Schedule of Interest Expense, Net [Table Text Block]", "terseLabel": "Schedule of interest expense, net" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r24", "r121", "r122", "r123"] }, "pahc_ScheduleOfLongTermDebtInstrumentsBasisSpreadOnVariableRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ScheduleOfLongTermDebtInstrumentsBasisSpreadOnVariableRateTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of basis spread on variable rates on debt instruments.", "label": "Schedule of Long-Term Debt Instruments, Basis Spread on Variable Rate [Table Text Block]", "terseLabel": "Schedule of the basis spread on variable rates" } } }, "auth_ref": [] }, "pahc_ScheduleOfLongTermDebtInstrumentsCovenantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ScheduleOfLongTermDebtInstrumentsCovenantsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial covenants on debt instruments.", "label": "Schedule of Long-Term Debt Instruments, Covenants [Table Text Block]", "terseLabel": "Schedule of financial covenants" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "verboseLabel": "Schedule of aggregate maturities of long term debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r12"] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureEmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Net Benefit Costs [Table Text Block]", "verboseLabel": "Schedule of net periodic pension expense", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": ["r160"] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Schedule of other assets", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": ["r1264"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationPropertyPlantAndEquipmentNetTableDisclosureDetails", "http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r11", "r801"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.pahc.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r94", "r95", "r995", "r996", "r999"] }, "pahc_ScheduleOfResearchAndDevelopmentExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ScheduleOfResearchAndDevelopmentExpenseTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of research and development expense.", "label": "Schedule of Research and Development Expense [Table Text Block]", "terseLabel": "Schedule of research and development expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r48", "r49", "r50"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Schedule of information regarding reportable segments", "documentation": "Tabular disclosure of total assets for each reportable segment. An entity discloses certain information on each reportable segment if the measure is included in the measure of profit or loss used by the chief operating decision maker or that are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r48", "r49", "r50"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostsNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r600", "r602", "r605", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r630", "r631", "r632", "r633"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails", "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r60", "r61", "r62", "r63", "r64", "r65", "r150", "r152", "r153", "r154", "r229", "r230", "r231", "r311", "r484", "r485", "r486", "r488", "r491", "r496", "r498", "r932", "r933", "r934", "r935", "r1099", "r1248", "r1277"] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table Text Block]", "verboseLabel": "Schedule of preferred shares and common shares", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": ["r23", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r112", "r113", "r152", "r153", "r154"] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "verboseLabel": "Schedule of the reconciliation of the beginning and ending amount of unrecognized tax benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": ["r668", "r1114"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of amortization of intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r1091", "r1322"] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesStatedRatesDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails", "http://www.pahc.com/role/DisclosureDebtReconciliationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "terseLabel": "Secured Debt", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR)", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r1453"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://sbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r1150"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://sbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r1160"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r180", "r181", "r182", "r183", "r309", "r314", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r346", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r414", "r420", "r432", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r1081", "r1084", "r1085", "r1090", "r1141", "r1497", "r1500", "r1501", "r1

defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsGeneralInformationDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]", "terseLabel": "Business Segments" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegments"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Business Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r183", "r309", "r313", "r314", "r315", "r316", "r317", "r329", "r331", "r332", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r346", "r1080", "r1082", "r1083", "r1084", "r1086", "r1087", "r1088"] }, "us-gaap_SegmentReportingInformationAdditionalInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationAdditionalInformationAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Additional Information [Abstract]", "terseLabel": "Property, plant and equipment, net" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationIncomeLossBeforeIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationIncomeLossBeforeIncomeTaxesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]", "terseLabel": "Adjusted EBITDA", "verboseLabel": "Reconciliation of income before income taxes to Adjusted EBITDA" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationProfitLossAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationRevenueAbstract", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]", "terseLabel": "Net sales" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesEffectsOfDerivativesDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Consolidated statement of operations - total selling, general and administrative expenses", "verboseLabel": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r134"] }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r8"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting term", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r1112"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r620"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r620"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock Incentive Plan", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r600", "r602", "r605", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r630", "r631", "r632", "r633"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r113"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanGeneralInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r68"] }, "pahc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayPeriod", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Period", "terseLabel": "Vesting, achievement of arithmetic average of closing stock price per share for each trading day, period" } } }, "auth_ref": [] }, "pahc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayPricePerShareMaximum": { "xbrltype": "perShareItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayPricePerShareMaximum", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, Maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, Maximum", "terseLabel": "Vesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, maximum (in dollars per share)" } } }, "auth_ref": [] }, "pahc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayPricePerShareMinimum": { "xbrltype": "perShareItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayPricePerShareMinimum", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, Minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Share Price, Minimum", "terseLabel": "Vesting, achievement of arithmetic average of closing stock price per share for each trading day, share price, minimum (in dollars per share)" } } }, "auth_ref": [] }, "pahc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayVestingPercentageMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingAchievementOfArithmeticAverageOfClosingStockPricePerShareForEachTradingDayVestingPercentageMinimum", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Vesting Percentage, Minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Achievement of Arithmetic Average of Closing Stock Price Per Share for Each Trading Day, Vesting Percentage, Minimum", "terseLabel": "Vesting, achievement of arithmetic average of closing stock price per share for each trading day, vesting percentage, minimum (as a percent)" } } }, "auth_ref": [] }, "pahc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingImmediatelyVestInFullChangeInControlSharesOfStockCeaseToTradeOnNationallyRecognizedExchangePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingImmediatelyVestInFullChangeInControlSharesOfStockCeaseToTradeOnNationallyRecognizedExchangePercentage", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Change in Control, Shares of Stock Cease to Trade on Nationally Recognized Exchange, Percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Change in Control, Shares of Stock Cease to Trade on Nationally Recognized Exchange, Percentage", "terseLabel": "Vesting, immediately vest in full, change in control, shares of stock cease to trade on nationally recognized exchange, percentage (as a percent)" } } }, "auth_ref": [] }, "pahc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingImmediatelyVestInFullQualifyingTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingImmediatelyVestInFullQualifyingTerminationPeriod", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Qualifying Termination, Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting, Immediately Vest in Full, Qualifying Termination, Period", "terseLabel": "Vesting, immediately vest in full, qualifying termination, period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanCostNotYetRecognizedDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails", "http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r605", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r630", "r631", "r632", "r633"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche One", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "verboseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r599", "r608", "r627", "r628", "r629", "r630", "r633", "r639", "r640", "r641", "r642"] }, "us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage (as a percent)", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r407"] }, "us-gaap_ShortMemberExplicitDomainItemType": { "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortMember", "presentation": ["http://www.pahc.com/role/DisclosureDerivativesNotionalAmountsDetails"], "lang": { "en-us": { "role": { "label": "Short [Member]", "terseLabel": "Short", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureFairValueMeasurementsFairValueOfAssetsDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r176", "r177", "r1265"] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease expense", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r794", "r1126"] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPropertyPlantAndEquipmentAndCapitalizedSoftwareDetails"], "lang": { "en-us": { "role": { "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and Software Development Costs", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryForwardsDetails"], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and local jurisdiction", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": ["r655"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsAdjustedEbitdaDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsDepreciationAndAmortizationDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsIdentifiableAssetsDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsNetSalesDetails", "http://www.pahc.com/role/DisclosureBusinessSegmentsReconciliationOfIncomeBeforeIncomeTaxesToAdjustedEbitdaDetails"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r180", "r181", "r182", "r183", "r215", "r309", "r314", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r346", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r414", "r419", "r429", "r432", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r1081", "r1084", "r1085", "r1090", "r1141", "r1497", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsCommonStockDetails", "http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividendsPreferredStockAndCommonStockTabularDisclosureDetails", "http://www.pahc.com/role/DocumentDocumentAndEntityInformation", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r208", "r229", "r230", "r231", "r264", "r293", "r297", "r304", "r306", "r311", "r312", "r353", "r443", "r446", "r447", "r448", "r452", "r453", "r484", "r485", "r488", "r491", "r498", "r766", "r932", "r933", "r934", "r935", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r969", "r992", "r1015", "r1038", "r1039", "r1040", "r1041", "r1042", "r1248", "r1277", "r1288"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpenseDetails", "http://www.pahc.com/role/StatementConsolidatedOtherComprehensiveIncomeLossDetails", "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r113", "r117", "r118", "r211", "r248", "r249", "r250", "r271", "r272", "r273", "r277", "r284", "r286", "r288", "r310", "r358", "r364", "r417", "r499", "r684", "r685", "r698", "r699", "r700", "r702", "r710", "r711", "r726", "r728", "r729", "r730", "r731", "r733", "r744", "r773", "r774", "r775", "r776", "r777", "r778", "r783", "r786", "r809", "r886", "r914", "r915", "r916", "r943", "r1015"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r344", "r345", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r955", "r956", "r957", "r1024", "r1028", "r1031", "r1037", "r1045", "r1049", "r1050", "r1051", "r1052", "r1054", "r1055", "r1056", "r1057", "r1058", "r1067", "r1101", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1140", "r1147", "r1345", "r1497", "r1500", "r1501", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesReconciliationDetails", "http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails", "http://www.pahc.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r271", "r272", "r273", "r310", "r786", "r820", "r927", "r954", "r961", "r962", "r963", "r964", "r965", "r966", "r969", "r972", "r973", "r974", "r975", "r976", "r978", "r979", "r980", "r981", "r983", "r984", "r985", "r986", "r987", "r989", "r993", "r994", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1015", "r1148"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholders

"http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r271", "r272", "r273", "r310", "r349", "r786", "r829", "r927", "r954", "r961", "r962", "r963", "r964", "r965", "r966", "r969", "r972", "r973", "r974", "r975", "r976", "r978", "r979", "r980", "r981", "r983", "r984", "r985", "r986", "r987", "r989", "r993", "r994", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1015", "r1148"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r1168", "r1179", "r1189", "r1222"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockTransactionsParentheticalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockTransactionsParentheticalDisclosuresAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParentheticals"], "lang": { "en-us": { "role": { "label": "Stock Transactions, Parenthetical Disclosures [Abstract]", "terseLabel": "Dividends declared" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r113", "r147", "r148", "r149", "r971", "r980", "r1016", "r1017", "r1127", "r1157", "r1279", "r1302", "r1468", "r1530"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r72", "r73", "r74", "r211", "r212", "r249", "r271", "r272", "r273", "r277", "r284", "r286", "r358", "r364", "r417", "r499", "r684", "r685", "r698", "r699", "r700", "r703", "r710", "r711", "r726", "r728", "r729", "r730", "r731", "r733", "r744", "r773", "r774", "r778", "r784", "r800", "r915", "r916", "r941", "r971", "r988", "r1016", "r1017", "r1043", "r1156", "r1279", "r1302", "r1468", "r1530"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureCommonStockPreferredStockAndDividends"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock, Preferred Stock and Dividends", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r151", "r263", "r483", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r499", "r735", "r1018", "r1020", "r1044"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r779", "r820"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r779", "r820"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementDerivativesDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r779", "r820"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r779", "r820"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementFinancialCovenantsDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r779", "r820"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Event - 2024 Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreement"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event - 2024 Credit Agreement", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r819", "r821"] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SubsidiariesMember", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]" } } }, "auth_ref": ["r1392", "r1481", "r1482", "r1483"] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Summary of Valuation Allowance [Table Text Block]", "verboseLabel": "Schedule of the valuation allowance for deferred tax assets", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": ["r1440"] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformation"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "Balance Sheets Additional Information", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r1261"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.pahc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental cash flow information" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1215"] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "verboseLabel": "Income and other taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r101", "r102"] }, "us-gaap_TaxesPayableCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrentAndNoncurrentAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesRepatriationDetails"], "lang": { "en-us": { "role": { "label": "Taxes Payable [Abstract]", "terseLabel": "Taxes payable" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails", "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": ["r20", "r1315", "r1316", "r1317", "r1318", "r1319", "r1321", "r1323", "r1324"] }, "pahc_TenLargestCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "TenLargestCustomersMember", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"], "lang": { "en-us": { "role": { "documentation": "Ten Largest Customers [Member]", "label": "Ten Largest Customers [Member]", "terseLabel": "Ten Largest Customers" } } }, "auth_ref": [] }, "pahc_TermALoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "TermALoanMember", "presentation": ["http://www.pahc.com/role/DisclosureDebtInterestRatesScheduledRepaymentsDetails", "http://www.pahc.com/role/DisclosureDebtInterestRatesWeightedAverageRatesDetails"], "lang": { "en-us": { "role": { "documentation": "Term A Loan [Member]", "label": "Term A Loan [Member]", "terseLabel": "Term A Loan" } } }, "auth_ref": [] }, "pahc_TimeBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "TimeBasedRestrictedStockUnitsMember", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Time-based Restricted Stock Units [Member]", "label": "Time-based Restricted Stock Units [Member]", "terseLabel": "Time-based Restricted Stock Units" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1207"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1214"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r184", "r185", "r186", "r1298", "r1299", "r1300"] }, "pahc_TrademarksAndTradeNamesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "TrademarksAndTradeNamesAndOtherMember", "presentation": ["http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetTotalDetails", "http://www.pahc.com/role/DisclosureBalanceSheetsAdditionalInformationIntangiblesNetWeightedAverageUsefulLifeDetails"], "lang": { "en-us": { "role": { "documentation": "Trademarks and Trade Names and Other [Member]", "label": "Trademarks and Trade Names and Other [Member]", "terseLabel": "Trademarks and Trade Names and Other" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r1235"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1237"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.pahc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1238"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1239"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1239"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1237"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1237"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available", "terseLabel": "Aggregate available" } } }, "auth_ref": ["r1240"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1238"] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsNewAccountingStandardsDetails"], "lang": { "en-us": { "role": { "label": "Type of Adoption [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r209", "r210", "r211", "r212", "r213", "r214", "r276", "r277", "r278", "r279", "r289", "r347", "r348", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r416", "r417", "r426", "r684", "r685", "r686", "r687", "r688", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r763", "r764", "r782", "r783", "r784", "r804", "r805", "r806", "r807", "r808", "r809", "r831", "r832", "r833", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.pahc.com/role/DisclosureBusinessSegmentsPropertyPlantAndEquipmentNetDetails", "http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByRegionDetails"], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r1234"] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails", "http://www.pahc.com/role/DisclosureIncomeTaxesLiabilitiesRelatedToUncertainTaxPositionsDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits end of period", "periodStartLabel": "Unrecognized tax benefits beginning of period", "verboseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r648", "r668", "r1114"] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesLiabilitiesRelatedToUncertainTaxPositionsDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Interest and penalties", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": ["r666", "r1114"] }, "pahc_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromForeignCurrencyTranslation", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents amount of increase (decrease) in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation", "verboseLabel": "Translation" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "verboseLabel": "Tax position changes current period", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": ["r669", "r1114"] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Period Increase (Decrease), Total", "verboseLabel": "Tax position changes prior periods, including settlements with tax authorities" } } }, "auth_ref": ["r670"] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Uncertain tax positions result of the lapse of the statute of limitations", "negatedLabel": "Lapse of statute of limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": ["r670"] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationAbstract", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Unrecorded Unconditional Purchase Obligation, Fiscal Year Maturity [Abstract]", "terseLabel": "Purchase Commitments" } } }, "auth_ref": [] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One", "terseLabel": "2023", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": ["r434", "r1478"] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Unrecorded Unconditional Purchase Obligation", "totalLabel": "Total purchase obligations", "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts." } } }, "auth_ref": ["r434", "r1478"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.pahc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndNewAccountingStandardsPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r45", "r46", "r47", "r192", "r193", "r196", "r197"] }, "pahc_VaccinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "VaccinesMember", "presentation": ["http://www.pahc.com/role/DisclosureStatementsOfOperationsAdditionalInformationNetSalesByProductTypeDetails"], "lang": { "en-us": { "role": { "documentation": "Vaccines [Member]", "label": "Vaccines [Member]", "terseLabel": "Vaccines" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceAbstract", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesValuationAllowanceDetails"], "lang": { "en-us": { "role": { "label": "Valuation Allowance [Abstract]", "terseLabel": "Valuation allowance" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": ["http://www.pahc.com/role/DisclosureIncomeTaxesValuationAllowanceDetails"], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "(Benefit) provision for income taxes", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": ["r673"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.pahc.com/role/DisclosureLeasesCompositionOfNetLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r795", "r1126"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.pahc.com/role/DisclosureDebtGeneralInformationDetails", "http://www.pahc.com/role/DisclosureSubsequentEvent2024CreditAgreementInterestRatesDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.pahc.com/role/DisclosureStockIncentivePlanRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r1407", "r1408", "r1409", "r1410",

period." } } }, "auth_ref": ["r290", "r306"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding
and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r1201"] }, "pahc_ZoetisIncMedicatedFeedAdditiveProductPortfolioMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.pahc.com/20240630", "localname": "ZoetisIncMedicatedFeedAdditiveProductPortfolioMember", "presentation": ["http://www.pahc.com/role/DisclosureProposedAcquisitionDetails"], "lang": { "en-us": { "role": {
"documentation": "Zoetis Inc. Medicated Feed Additive Product Portfolio [Member]", "label": "Zoetis Inc Medicated Feed Additive Product Portfolio [Member]", "terseLabel": "Zoetis Inc Medicated Feed Additive Product Portfolio" } } }, "auth_ref": [] } } }
}, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic":
"10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
"Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r7": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic":
"230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10",
"Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic":
"10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r17": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r18": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)(b)(c)", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "20", "Topic": "210", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "SubTopic": "20", "Topic": "210",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-9" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r26": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r27": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r28": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" },
"r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45",
"Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230",
"SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r39": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" },
"r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-
50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50",
"Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10",
"Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic":
"10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r52": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" },
"r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-31" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45",
"Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10",
"Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470",
"SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r65": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r66": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r67": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55",
"Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810",
"SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r78": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
}, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-
50-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50",
"Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10",
"Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r89": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" },
"r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-
55-182" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10",
"Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic":
"10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942",
"SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r125": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" },
"r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "
(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-
10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(b)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-14" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "SubTopic": "10", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480209/205-20-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagra

"Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-599-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-20-599-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479140/326-30-35-13A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fas

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/410-30/tableOfContent" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "

"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.O3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.O5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r698": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic":
"323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r702": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r707": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805",
"SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r712": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" },
"r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r718": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r724": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r729": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "
(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r734": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r739": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r744": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r750": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r755": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r761": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r766": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent"
}, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r776": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r783": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "
(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher":
"FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r790": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r796": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r802": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph":
"(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r807": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r814": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r824": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912",
"SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r830": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" },
"r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476988/932-323-50-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479119/940-320-50-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(b)(2))", "Publisher": "FASB", "URI": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-12" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-19" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-2" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-2" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-3" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-3" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-3" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-5" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-5" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-5" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-5" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-6" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-6" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "599

"Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-1" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "2", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-2" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-3" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-5" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-5C" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-599-6" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310", }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "f", "Paragraph": "a" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "A" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "B" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "C" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "D" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "E" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "ii" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "1", "Subparagraph": "iii" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "f", "Paragraph": "2" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "v" }, "r1209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "ii" }, "r1218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "iii" }, "r1219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "iv" }, "r1220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "3", "Subparagraph": "ii", "Sentence": "A" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "3", "Subparagraph": "ii", "Sentence": "C" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "3", "Subparagraph": "ii", "Sentence": "D" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "3", "Subparagraph": "ii", "Sentence": "E" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "3", "Subparagraph": "ii", "Sentence": "F" }, "r1235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1265": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1270": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1274": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1278": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1281": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1285": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1290": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1295": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1300": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" },
"r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1306": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1310": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1314": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1318": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1322": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1328": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-12" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-12" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1333": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" },
"r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1335": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" },
"r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1339": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1342": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1346": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1350": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1354": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1358": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1362": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1366": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1370": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1374": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1378": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1382": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1386": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1390": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1394": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification

"https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1531": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1534": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 173 0001558370-24-012517-xbrl.zip IDEA: XBRL DOCUMENT
begin 644 0001558370-24-012517-xbrl.zip M4$L#!!0 ($R%'%FE7.-$_B(*&Q 0 1 <&%H8RTR,#(T,#8S,"YX M77GVZ0("GQ O"B76H.JI(=BP"Z 7P-H %T-W[XT]O:,5X(\ZGG?CZY M.#T_8AK>39UEY]/PF Q^/[D3S_^UQ]^^._!X._7DP?#]JQP3=S L!@Q V(;
MKS18&3-OLS%=XY$P1AW'N&;47A+#N#@__>[T_/3"& Q^Y"2N31^*>*[!:5V> M7HB$FYB:YWXROC^[A/^=7[XSOOMT?7I_-QX?A3Y'J%F"RK+^.;;GWQK1=:F M$9AL28(GK(-A\.CM[?7T]W9@KZ]3RUIS&^8M$/6\D(W M8&5UCA+WN[JPDW*Z0L).
M%4!,2B1"I.QD=\D2QT9H3^>,<\A9W&VI#;!AI54!U)V\8-46M$GU/4#T[72 M/O'MHAZ!O!=G?W]\F/*1)S+C().-NECBW'!]623.E^<@T<++[$$UV=&]Z'I!Y^12-B;O3G667S':6O9]QX(?S MTLR8&!7X\0^&P903]N,,A-3 /[Y,[HL' M#N_M6^I;CN>'C$P!9-MD]M"U;T(_\-
;#-^K?>FN3NK$,^2<&A>;5*R)J)NIF MDP5U*6\%3'VPV Z,E"#\$#0-(&I$5 TD:T1T#4'XA[-],L%04MT[%"IWZYM%]EQ>*/ JO&"$*'!5S;N(&9S'.HC>,M M^>B/%^.-F.ST:TQG<$_CZ.GV=08 MWQGCY]%D.+N'#!H]5?1NO#6T?
X7+U@NY!YUZ31X\7Q7*LM)27"_KX'HS?GR> MC'X>/4WO?QD9]T_P>V1\\S">3O^H@:X"^MIT<&6=K@@)JB#=S2<%[ZH:O.OA MP_#I9F1,?QZ-9GHHJ@]%TU_=.=ZK\N!+\DL1>U=KN VG/QMW#^._:>P*U)AP MO3;9=KR8TJ4+VJYENL'0XOL\ZBZ? 2>+$A^4BR?
RFGX76H?_1()HFGPF;+HR M&8&?Y?3L*(J&M["R%32 M2&MCB&H:4"L#*H-2ZH*E*"V1E1= ^IK\)KQ,J+*1ESG*,DWOHFKK9>%0OV[M0 ,;VC:OB.G<@YK/UOSKO1L0Z)-@]+:!E9T #&72V 5-F8B].W]?H,3'?%'*
M4LZ#E+61X0TE!'LCYO\M%RXM+YW(RW#ML8#^A_\]7D!7F^X2#T&&O@_Z1'O9 M4:.OEZ/OVLM1MBI8)JV,$=5&RU0W,G7+SW9HA+]K9_N]O4 I$)=+T_?MI2E; M#[ZP[8B7EJ1R2=K9L11/&I%.X4^(1>B+"2.T?!UK24TF*^_/+_9E)>9H1"PK
MYIN8KY$RUDM7>^&X=U^@&SQ&2Q7M1C3D@G#55! RW#3VK;!_9AY,S<'VV<&] MDVN/_AW2#4[,*QFYAQ:RE)RC:6C$1>Y_.1V6ZKR(^KSK<%KQ%>;I$[1E#(P MXHIE.6A9:S?/"/40M]XS+S"=%O--*2VYW.147_5Y)^&:2 FRUH+12C#&P8JP MROU1(QIR0?
C85! X-[W)Z4@U92&QXZ,(/*WCG7O##5R"!VK.J0.E6N@FM3E(M!>'&5]F(F:6;%W$)<(W6)T_:JFJD*I;,@\FQ/)< M"\9@U6E;>489SA_RY_E(#/[9I:=QDN!TXYB^SZ_7)#@59Y3C]*$$IUUZ&B<) M3L/EDG&KUT&!"7CSGA; *%)N0D6."
(!_WKC^657"XJEY%CFE*,$RPQQ'*%X2,/3#&2@ M(95"FIU/[\) ?%<=HNK%Y2#G-*,$Y-U9..(3PZP'O-, M&/5L:CUCAWIN?+!<0SBD-.3BD+/^*14'U,<$-R-F)P[#-?H5Z$?C9&:^$3\= ML-=DX>TDEK[_,[\N\!4\\BCF9]&<\J.>#;42U'PWXT9F?,_,>Z$X
M7NX\5@OR&D3DT.=VT7O0I\Q0-4_8&2 "6@(:2,#N,3!LJHA-F.EPU2KPV'8" M*^O,&X$&;06PGD(9_"(7BG9TY7*2VZ'OR\39NXZ(:&$D5#.1H!)Z1U)+ M1U^U]"A)SRV!G14C-ORH<=I6GX!<'G*;^3UY$(PXQ/I KB/0^7KOA+ 9NW=+ M?
1QK24$MBG*QR.TI*\0"/@C>!G6-+/>]RU$M*6J2DAE<$\+W:#/O"W0C@\YS M(<=S?)*J("*U24EEXT*F96:GAIBG,?.,A"N?2A*^6B8J9 *TMC4-N+L&QI?P MN/LA<=$O\3EDUHH?T"=92J2A&1&9'%SE58D,%;Y&[+!"\]Z8VTY_5Q2RC M+R9J6'YV'G_P)+?I2J5D +_+
[RDRE/<-7PQ!7@-:90\5^M0EOC\E2R[]^]I^ M-)/F3@!FWM#^5^C#1#J:T\ VRZRANJ4N$Y "&QE1 T-4H7!'$:\71>SVZ&6H[P\Q8$#Q;_HN0$S;;#-&)S%LJ&2LQ)G#,QP_I';U8IPA9D_ MN8,&)Y@U=M- *<<[>3;1MGA% @K-48Y^LE=*"N 5'ZF*L5",;W;)ZW&G'AQE
M98*Z SNQ:>!9OZX\QR;,1P>F8*L:+J6"@A3F][4"J/P\?/H-#7NGR!A?/.7 MG\+T!$9#Q-= MI7$U9 8%!=H=*P\'D^=2YU'<9)H;&I@._0_, M;MXB>#5+G51_GTK(93FW]^E.EBN]7*.-0B_;H14@L_9!IBK)RD2@X(2X?G@IM#SC53#F6R.NA,%[4DM.QY(S(0EXJ\EIPX"J9
YB$O.7TQ()@QS\UE#6@W)M8:V%:558. M;FY5+P,W%Q);PZP"<\;LH@+0@EQRZ'*A^F+HLI8>&AZINZ;J.BC++@/LN_Q* MF#IMZK6PMFV=%]VS/K/8G)7_&KKV+7VA-G'Q?F$O)5-*-0[GX1C)Q.7[O+A$ M9 U.]ULCX1I]X*=Q297XB4X^/4M!A^,\B-1E,K61J0(R(A?
PH'?5'); M/L$ESL'Y:)QKX>?XT>'LPRUDW C M&<"H-T]>\ _"X],M7;SJ5X:^JK <\?Q;2,6(\\ \P,;8DL!(&6F@*X".W5V> M319L9\R$,6+QX^P2:&?9)6!>G.?U.^%PPVD:6:(:N+KQ/EP7[2Z%U\IPR0B_ MJJ@3X$-"0@;P17YE+H_H$?%*O6P2;AKYFLB/_("N<1A%
(:Q$DKFML@=]3D@J M!7F7NU(I2#B*\%M)AIBI%H:ZTP Z/:.=::7358V2("6L U0",PGZ!NJMBEZ!42@YE@9U"%LJ8.&I!VG*A-J E MSP_+$*TL)H>TX(&5+*0E1IP:TG)(DSW((S'Q-S_OR6Q,*C%>J-X3DW#-.7?8R[5H==:H[FO8U7YPO*HVE4OI>K7%".:MX+ MI@#5+
.]LM9'MNJ%=$6,54C(T4B#O"2,M5"T M$@KY"6DC&G(QR!MYJHN!/D$]5!!(Y6B?S>A5BD44(+(R#FBM)$Z3*C*&;MO M,;I!KN.%4-CS)^I%F2187IQ?%%U1)I3P(%70TL!T'9RKX_A;O08.IX'@K M]ZZ5P_2Q2 W(^]!J/)3]8U4=8Z78U'.)U0@I>[[."XPUWEF4(U-
P.%#YG**&JLJBN<)J60Y%M?.'[G@UNV,E M^V(Y&.J&Q!H8J363S%1)#D?!CCUGB*2!:'!37/]>6 Y6"T,AC6'GSV7%&;I^ M $N0K;8)N#SDDU;?B&SZ#KASL9FAY6[70A,3K1:9JT,^+O5-5 4M,*TNNTJ$ MHS8!F2!T\""!KS%!5@QSLKE9/"^+_#^47I10X-
:>2E6#%LF109,66A]W>^2 MB[+BGM])D_5]@2EM'&I=]WZ[R[-B<.H4E6'7,HJU!KC6]4 QGA4Y)?!=7.3A M*PF&I9%2N3(H!BB?089+P7Y@)[*11D/E;+L*]C/($-#$M]&@U'OO+H8EJJL M,H *U.JR&!@:+.4S[)*]4'$N&41*<0\T."W.MWB#"J- M0M+V6=E]2M78O^O
&AM+)*-<>[IU(0[J'O)=T)2+2,%K%W5%1'O,'TQ:;LP- M#4P'WQ69>HO@U2Q]1*T;HG)YR455J2\O&?Z&J(6F&X$9@+]83)KA8="&.[: MXZ%-9&\G=4M>+D2Y ,#UA4C4)#J:2NNBWUOJY$8%NY>]D#N/16KA@^?[Y?'S
M6I*3"_4H=I[$X[1.02TGNZ0%5*1&L-.2M(+]W(1_F>69D3<-U'(7' M73:6 2E%J5#D'YQ2%8JMQS-Q+N6DZD]];C8$78--QL'*XMJC\IKE)0AGI! MU*#D<7%.W\@RT)/^;_7.>!U]X[#,9!+T?5Z1[?R]<:UV'$8"TS]:2%:.B%QB M;:B5V.,L3U"DM 5O?SU3!W^I8A M;-
K_1:R V"B>.[0I3 #AA:RK+%)[?<-&U"7"XKZVY?IFX=)19(\:54@8UR; M+*%DM4%T<5*E6LZ,6C$WE)K'$SO=ODJ?:"XG(I4%]_,E:^63'0:-=#^]WYQ5\F)*"1D?34 M?*'NTL>4&I!+:(.S+[Y]8]&RL^(&4:*A,:_'O[\SJ$HH0;^4AIR M_',O+Y7B'UV2E+DJ:?
15?)5^'036@; M"7$-I>+@99[O?W$9L;REB_:O\#6>!?T)?'0MZM JA;X5+2GT>45^?U C3R/+ M%)/$1.X;NWRU5*A)Q1<800PZRH5?SU[TR$'9&JY:3(YU[B9Z#^N$/((RD.O&S$3=+DZH[4P=G9G'7X]+)PA8]#MUZ9/86;W MYFBVCNZ7]^XF+)683FG+9*?
"K_77L@+@5$+0S0!I)Z&+PBWQK9JAA17;0D MU96D!VK.0>$*8+ >1IQ:,9#+E'((@(&1J8D6K$.&$% VC%$O*!,$E;BY_[_M M8? _<],G$[(PWOB7 /)\/O$I+-#D)/ZV8F3Q^02!'J!3__F'J_-_0E-/W]:. MR(+D=\3B;M@H$)*ZC=J5JQZVR3'G==L$18ASD.;\VW-
%ST%MG%%*VH@*N 3ZW3IO9P1RT9J[\H9%V;'/SA&S;C: MA-;A*K+C'_6XYB6$NGZ &Y!BUH5%\-= E!O@I\'%Y>"J9H_'Y-[S7W:@S%\4 M0,;O&S?\8S0T7++$QWK4F#N,[93"&GS$IE]\:%\/Q0[(U"%HS=\.V!G..RA, MEP. \4IUP!64Y+]]Y8HL3'_.287^ !ODJPR
;*&E:6[BL><$?D*FWG@H)-BJ M$OBE81U\%M3B+_)'O.%7BQF(!\UFVSJS4+:(^-&F!K#K(*Y5KPK9,LFO%I7 M:=P/YXV7 "A;R)U$?FQ M'5IX>K?7G(H\/6S1([&IA2/_CA [LNU[X<\M< N0?.L4_>PI8E\F3R7TD-H;KPUQIR*#&Y$]1K^%)3_4K0S(,'T\
]Z9S7;D*7JW1G$6]/ MFI>7"%#+Q:RA-,'.D*[#=29>Q_@5]HK^BFY@:(#NY .%V0HFV57F5*-V*4G; MH=H8TJ$3(:DC#;=X790X%'-'T;Y?KT'F0.PGD=$G7VM\5&! MSJ$![A,)(L626C%5G(;C<.6[B])X\0P9A9(3S];BJ*5W]>K](=6^2#^;D?G& MA, :">W$<)L>VWC
B%Q[KCWS;@EH#VOH:+QIQSD/Y[,]$6].Y8@FQ6B"IR^I M0>TD%]74?EEX4Y<863]'(UCT7J<4>SIYE-0;6LPP$-HMB?Z=$#]T<'6X8]X: MQ(?0I7L3'W5S;4<]USG5(Y+#C)(6F-AV)SN?]O-5 M7HG'>J4Z6FGR\4S)#YZ[Y&
<7&"D[@BYCNR]:*LWU^T#:1))G=$VN021M&*>@ M#V*@$*XF?8&E>4^C5,O:2^4Q+F\@K:_1&K!#5 MS4?3-9?V$U\-H5+A4O,S;-%'D',Q05TTTRN_!;-6-P\'$16Q[,8* M9;+ZQF-![!QCQ3WO5WN2U^6:DSJ6&2>CC&;FB-)(_?!WZ@<>::\%W=:&V($[M+M&39/TF%*?
2B2EZV<1=X@G&CO*"IAU25O1(^B2>//"1/FI3LW#]JLC3PT4L?[*7AJ?C2TBN?W0KN13J@=;R_=T20RR12=O%IU4B6Q MH^BC"&8^#E!IB(P\45N?4/_79Y@'@JU"Y]2@TM]>X;8"\:43-BI60WFH0T:X MI17;[F029ZO[/=.<4MM3V4/IL_N#P?17W,#)7^'\&(ZJ-
EG?"NYA^0SHQ:! MIN%Y1/78:D"NH*>F*Y.1WV3]K=PD%H6^BO5U;FGAFI'57AJSC&?)/O21)HF= M#W2/.-A+ KBOU,ECF6WD;ES_<5#G2^Z98:_"5Z9<$G:M:U2 MR)YM/(5.7A+VNTKCC)DV69OL5P2._WA"PW^QS<[;Q:GE[^$,'MW WIE6XE6^
M;QQ7DJ&';9F0%\]Y*8!G/Z&'=1>69'A-.7TU-W\.G2TZ1^7:(LO8P[;=DCFL M0Y WQ(\WW@MQ83CZ=Y3YP0,E:!OP0"(SV0F2A@$$PN8N[[R0_34T&328QQ)X M--_P2GQG0>R89\VH]JJ_GDU^8(J+[(/W M6GBL6IZE?X>AF;J6'A-7Y.E?@U)KR,J7BTLO1AJ6[^FU2'S-
DSEE+;_IR=\. M*1;KRSF;["@66A6N0VY=$-\'K3>,K #.Q(8GU9]A%H(/&]/=HD6Z'X7+ROO. M=4:RATNJJ#E.YCP.)+?:I\'V'S NQFYVBI!G/18AJ6S)[-53;33/^G4T>L6(M,M9QYJ^BX:B0J+8[RGN,S1:M$+I9O-K[U8-<6NIKZXKRH2\M]=5U1<6$H%#N
M:^N.BFE"7NQKZHR:G7 \C4_W!*(-\2X MOX*&PEYH9[N'K*>9:5NAPH=4*-T M3WLB]B$15E)X%A9M[PO\EQ7R]E#9Y[;WT]C>B4!($3&T6Z(:QMSR$TV/33^-SYYSMW,_+;TLI;U\YX M].;23RZ-W1RTSU#)X#4\W&%^ 8]>'5/'-S97N3E[/Z&'$S._K^6>$SM!,]*;
M[.MMFB76)H=H"?@+@((>RM:* H;X>;P8@NJY6I. 6G&0E/'BQO%\R,;OBX75 M B=XY[&1::WP;A72;\UM3#"V_X#"^9N.8ZAL+\U6^M-QN7 Z_:M:#^]9>M-' M_"O/TN?165#+7MI(];+'*:!%]P^$)S[]Z%CB,\6[BQI.=P OYX MP;OM!KV59QXW5!J[3[%!F[.=))[?
(L)*NF)UB/!O5-_#+ZT]@1J47XW&'RW,-TP8MIC]Q>,9P+\N%T5R G\],8N*3#A;DJB MA^I\S<;,7KVV_9$A\17T!]Z:M.Z1+)'C[Q/66C"V(][*/8A3B-^1 ''-KW,2:1M@50#M*YWYAQCI= M@4@+ X4T%5U'X]!:^];/'9'M36?*UAF82BU";!]#KW7:G=W2[4U_2H3S?ST2 M4
QP5_CP01QP]1E:N_ MTUH3*@O_26;EU2";CYYKDUP1&# MF%@BDO A(N15WCV\>]*]O'AKVLQ,C$8>+JV[#BRE?+3]=[_>F!A-/)Z=($]D M%38AR_CY1QY^(7XL*PHYWJP_6W$ZVOZ-6_LW&JPP^':D,HC7 5!M?2+!F =W M<'?GOV:=W)Y=+WNZ. Y7X\9*
(WRUH'PLRU/>^/.=@H'HNQYK; 6UQ?\K^O0K ME^MARTMLQ?9-Q'@@^9D77QG?@C KFYW5(-4KZ[(Z[MT%;6KE+EY![QCZ.!]R M;GEX1WW+=&+[PI'+9\8%_)EIY&P%U5ZN1AC9A!"7'V(/79?B.Q0P%R8F"ZWD M[Z"5.49TE%HX\V8KRH+M83
Y0!6.$0F%]O$SV&"+M[\'0>(53A&)/AD<-B> M;L#B&'JR<#VKT=96ZV8#/D?;IQW.F.WZ_ #U.%I,#]);M$+GH#4Z6IPZ7.7: MA87JOAZ]PD1Q?QR%E4/G0IZ H0YI?"OMVG@U=H%NEXVWWS7)]W"7WKJAW7?= M\?<6(G_92K#R%(ZW-
^[QK<'(Q[E=IY02.MZ^N26.N27V+3-?V_=/);&OIH_: MS=B5Q(ZWCS)#HUW_E!(ZWKYIWRE'T1MIP)!L^)A47_1+;;H58I"T);G?7ST) M3")M8*)D-^^C4A(][9/R2(R^7_ X0ORZ\)!1OF$(6>1$#378?3#XB02)H2P6 MN"8+C^%]A'MF=$F8,"4X=['['YX0RA\6', MK\T?
_P]02P,$% @ 3(4<67(E02N,) V3(" !4 !P86AC+3(P,C0P M-C,P7V-A;"YX;6SM75MOXSBR?C_^0\ZV9==8-.=2W?2:>S,PKGU!$AB(W9/ M[WD:*!9MC 0,Z46-B9_W+@>[/#+P?__/6__^L?_W-X^*_+IWO#(E/_M!3F>,:7(])!EO&%O84S(ZZOI&
^(4FS;QB7%UAP9QO'1A_,/1Q^.C#A>>]?OWX\>WM[C$/L>-ZIC-%!P:4_^H&'^_)U/0"]J2]OS]3.V[@]&/2%[<$^^TP+G;(M/AT>GQR>'G]X=ZV#D$2!]@]B,.Q#$9SCBXN+C\%?XZ*YDA4MPU]Q2?F$0;_^ MEV&$C*;$1D]H9@3=?O56K^B7 Q>_O
JLT>#;@J+9+P>OYF)ZR,1U='9ZQ'#_M9>R!T)DV71")3:VF XD']WA;/B*,.![]\!@W7Q_NLO0OQIK\,"4O']D?/THU M]W$K *[(RRM%"^2X>(GN8&"]H'OB-H.&VW9[T"Y-FPE_O$#(4P>QT+X .P\^8'7NN$9C@*0Z)=:PTO6WS1J3K MAAF3,=S% @L'O?
N$I@@O31"5ZL"IV]?6H=\Y2Y ;H5C1MJKUL'68(TI +[W5 MR&:VW[%N_N/C5Z:QP/R)^>S;)ETWUQ(CU&CH0"-B>\5FO@GQ3+LUS>#WM'78 M0V^!:(WY0:V'+DP=]9$5S=;,Z0G(NO(I!4V\Q^8SMJ%6:]9 OO]N-*%]3G"[MZ4(G_!

_+T9 MR4@TW@JX;Y291CR;P1H M(G!BTG]2PB?9='O OOLA+LXL%9=8L;76T(;!"C317M LWX:&&YD(6K:@:WP M"%T]P6":D!LPA5,/!A'485_J8J_9:WOLN$9@\RFRX)?&_!:%YK<",!ACM@\S MPYW#/=QI$+%,[. MHO!=["#7':-YP+)-4QGJ5VY.G)"!]:?
O@H[=/&//,M4V*!KN.\4:DTYC[D0_M)D2Y0%4J1.'D]&-4XJ/+#BM9UX?80R\'E7R-6]L(>H 6IZ8]98XA:^OX0Q"S M\9?-UE/4IHK?P^]1)XRFIH(7TE#0NX>8@YY\Q1[KZ.+B,XMM.3HR#HVD&?CY M:O@X'M[?70\F-]?&> +_/-P\3L;&\-88CFZ>!I,[*!!$=\1P;#+-
=&@S'2:T MF'D!XV:F^QQPSWON;REY"8V6#W9K+:"]0DU,*.25=W(OW$88&U 31 VGS M^.AW_<6>OSC[/3+V=&GLXOS_G9Q=GQ\?G&TQ-:?. 9OD+(RVF.!IT:F-R M!JA*I1QU2KIC"=1#])>#XP/#=P$E>0UW7P^,MR!^(?A+![H8P67$<\9.24F- M9-
^56/.*)!7Z(6X)>%%4CWA2O6P&[&.43 [?4,.V[MB 5S6 M"W:PZ]%@U1CMPG)$+%990W&KF_<:D'55@=@S"7D1AWT2A\1, B^8NR*HKJJA M^+MW[Y095ZE$W>C0+7 +SYTPZF>ZFE#3<6$"!-J^F=A9'X#PW0:)%C*,.3\" MQGS^J5%U^1$A#
<13V0V$:^&#Z.GF]]N'L=WO]\8=X_P^XWQU_OA>/RW#G85"\"#\(WOU=W7AS88H*D[5P8UOG/X&[+F*/8M!C-P5I[0-!-_FC@&VM:&^L@I:;//81$?_!8I0W *S!R,-1,:LY7M$/%3V;MC\PX: M\%M8<=K);=8HW))=EB9.],N(N!Y%'J:!H\T"-'\W;3]K&12L>3,=_]3V[;)6
MTXV!,FZL\0>ELM WPHZ_.V9X91E9R91(L8N=^;5/63:!("RYCMJW2$U68,<@ ML"_Q*V^1T-D$\[-$#*97"LH.05+?Y4U(9X%BG;9YVV^382Z0AOZ)V6;^A= M#NX'CU@;)G-PLCA'Y818FG:06"Y=V52NH(YA?E=O!-UH;H:B5)<6 41%,I8-17\ M> '6G%U-
9AE2PG4E;ZN\J&A/Q"H,3=.E'ZSW L M_$]TDEN7W3DIB:/0=%)+W8AGD?\>F?Y[06P@U67FW5N5;!A55^T6#T?Q4B4T M53=1F:05L0J5IKL,*;++?>)\08V$)RJ$4K&5P=)5>L1TW)&Y8BOH"O'E2^HM MOS(B"\0H"$]3.<;[(4*B+"ZU:_)JP\C$+
(^I^8H]TTZAXZUC*ROV2=J*:#4U MS$\LGZ6#K!N3.J"OZ33CUVB&I]RE4'7%/@E=$:VFEEPPEWS%773)5OJD#DU M%SYY["@QP_H-T;0@2B.W/TFE8AB,?S-N[X<_NHCA9N@V(DR?D.M1/ 4V1!&H MV0^IDN'M#Q S92]J7*/PWS !.!B'F_?IP@0GG:5U#].\ET3U;I.
(;O)#,+J# M-P! :RY7WUT6)Y$DVAJP'/AE9XSB#6AH7[K1LHUD%778IZFG&F;D*TDYLBZ0 MA?59AS1C-662%W(%6DV%F"T]E]U4=:: GB50Y(FUK,H^"%H:OZ:+CO3CP/"S MC:([^&E\'!40J;H/JJ#,AW:6)-QS5IC/PH= HE="@HQVQ4>JA47[+$MIW+NP MD1_BI-
*:NS'M3B@:;1D-5Y)[\[X-#:[(H]+U!X:GZHXDI_0^:(_,]$C8Y[H)._N.(\N.3UW3 M'L[6R8ZGP#/>NDZH\CZH0@U.1)KQ92L>8&2TPL<]F;8&TUJ1 UAY"LZE^O##9^^_ !+8-#MI7MGXK+IR%>Z9#\J[&1ZP$\GC'YD@S20=G'9%I MR:2H+PO#*BJ_#_*6
Q^+G+]+U]DS$)L;T/D[_QSQBU3=!TU0YD.L%!]^#;*) M*$XEP#_)*:VSGVI0Q8!8_OS-.FWD/Z+HU<16O(41F;KX@D!ARJQZC>VGQBAS M)E8E_MZA-JJ43)QA2+.D[A36WD]E$6=%K!T"^0.[UHZ-*V72KD?A78A]T0@1 M)L2ZP-\FU$@5.!?
2$IY57V*OVVR6A^=GQR>G^Z%(=7D4ZQE_A[(;/>-P+]QO MK1&R5-" AKJC;_2BY]F;;M#FJUNA>JU *+=L7T M ';+9PQ@I6NKRGI[H2=*3*@,LNK*W&RBN?1=[+!WQ\.["L$$'_Z%%Y4AT\1> M*H@L/RJ#NC28FC9##N!O?X+[)C+_*IF>?%%AZ1%K4XR4GS0-
@KUO5;0M/0 M@G6?^/I(LI6]4)0&6%)K=!>'64GTNNIZNJ !#55%V_6T*/LTO<*:'B;IY$5N M10:GRGH:ZE!-"9;/2^),T/0>T5.R9!O.9#2ALMX^:((:$\0?E>_.*-RYKL^> MGQK.PFQ)$;AK]"QB&DI]X-:U&&%IA-&6M-%-:*T3A;\!8 _ZYT>R#- V]5L MB ,<["2'5I#Z
/A$H]0)X7'52MPQK=7F/JA/\PP2?^>PFY7Q<,9&1FPRR^XR ME]38(]40AM_2ZI9S:R$S_SFN3QEQ(XI>L/^RQAR=>">'4 Q)M?5HOH,^Z\N6 MN%5Y6ZI1[5KO]K2C7 VVWW_=:IM9E=>MNI^R,&.D8[G5]?[**_5966IPH/+> M5D<:$.X9LCN#ZWW$H5-KQY*C-
BWTE.'TER,==*W[O=YM\;G;W'77V)W:!&PU M&C.IT-5P-L9S!_PE+VG%:X L]&Q,;3,#3Q$;VMOX]98H^.Q>L_2/MF@]O(M/1R='GXQ#8TTH2XL7TFJ0F9&B MUEB39<3T&D"> 12G_Y;0#"T!V49(MP&$&P&)09V8=B,B/OR3:_PUHO]O'63:
M2WC,$A0,ED!&^)I]RFA&&1BOL>U[W+@#A7:Z.>P2I/+2=/&T-M:@%0U-H;+4 M-TZN:K-!TT.+##01+=AI&?/%4R'T71+IQL3QZ+\\(\J\Q$"_0TMGT6:#H2 B>6+9*2K.@!I($''N:S[X568IT.(5I1 M#2AE+FM97'/]AONI22WQ13B>N6TO/Y66.KI>1!QWG8?
_SID1&O+YSO$0(/?B M-#C(DW;=/OU]SKGN"0',>U^3<+BFP4@1 35B.HR(D+\'3GN7?GA,4285Q2-Q M2'Q?B_]BMUC53@O-5MHHDBJ@%-3(#H%C'3(-R<@L:P_D4.IZ.V8#!]MUO7F/ M-D0$ M>9HF5F=-E1&2U:F'#K8:E.P>+]D!999=?-^\O-
(?'25_YA.5%D&R2'OW)F_(M7J('XG@+WDQ>K]'LL#K1(=]+M>CR-J,%)FCJZ\DA_5]DTLD;:41UHK;V4F/* ML&OJ*"H A)YY7H=B:_NK+%STFOJ@\A!OB<],>:@UMK?*P@4O'$^BO:Y V>9T M!,3K_SM?&\E\(:^DO] M-72:H"#H++.H[G+]W/:K6, M"##6%'0??E#
(%=Y(*"[;Q4#.4?*-\@,V.:4U'+JETMAXZ%X8DJ[&V+;)&QLX MMX1>$__9F_FV\!,F8I5W6L+J",73@'1NE%O,2B8XE-54YSJMN/@KY".55F0 M5[I()X?#$0%/YML#K$HH-NTPA>(3G,./F;D^*SK@Q87\W M*" M'.J$N'
9=&A$%*9[Z')V+F,F9]R45^DF]5HQ064+IO)*V2'R28=0+Q%);>11 MDP6HZ0P.2P+_A?$:62+[/ES@_*5S(\WW0&=:9<5.+=GB;4$VXTH7IKKE_\J_3-^ MA=V6I20ND:C;[F>_<$(/[\N'>T"KQVDFDWN;1Z@#4BLF%I MB(@OM<[B5-QM*2OBJTQLK7FUR0JA)Q1L
ME%7B$JZ7'1!G9\"59%#AH2I UW7?.;K\DK\R4"[V\40\DKH!7T_BC MB!?LB=T@&3]V7:"K7-JE=?HG;'FXFFY^1$!&E,Q0@,&T;U&5/2^OU%MIR^#5 M=.MD8KXC=V2N6!!ZN8P+2O9/L*(@-=U"B1B0/+0C-&HW2_=/JC) A>\P-[A$
MX#Z,5+TZJ*K:'V'61]WSMHGPRHG'J@S@RSRVY6Q5 WWLL.ZM$V.+J? L,'.\A*88J8P7[\@3WV=.:?B#T,&!49/MMX M'D7HW]RS>XO#&2L;'B#Q2_-/4+?3?P_4M%M>:;I#5#IV\QQKSE**MMT#Q6N/ M#YIN5(5'XKE%HF"H0$F]+!.^:!/6+.,[*V'4)?>>4+1 ?
+,B#!,@+Z\4+=@0 M6*+UVX0*2V/E/"(IDN(0@311\6NP?V5T_:WK/$\BS ONPH.OSM_YE6NEB[UL M,L67"*04Q']GGEH;F66[VE7U-#01BE+-['$KP=8TOH"!D9?ZWLE;0=+=WU%C M+V4]H2G,9C"Q15>O)2W]6?X)0=8]_)-MN%-+'6^A,,HX2ILMTLGB]-F[<\#9
M])FC>652N@]?+_-+@J[Y530<:452R"[Y).%H:C$+(XGEPJHWHXUW1'[B2+0R M@5>VZ;IXAJ>J)O",8P*S#>^2">PHB#5-0OGA:T')K*)=Z!"9OLG2_* 1Q:&I MK4N37[EC4%QXY\56 467=,Z,U,%\3M$G?9(=%V([QZ("HHNIB]\1'IFKHK0"
M$O6V2J;@U%Q172.MDQ90H>*IX.ULSBXC5F#ZKJB^5[+EX>UL7B\E5F2*KVQ@ MO^3+1=S9W%]&KH@;4%5_K^1,WS]H>:LCB'2.LET-'*M.D/_Y42[(/VR=;6N$ M.139MH4VH?S%P=YRX>\ZA? W=H]=#S>]0CZ*=];;=8YVY';&Q;$.:^CZ JZ MI\MVNCU6
MB_'RCCS6?^]\X)60F2^HX=#*@> /)BX"32WD]R;%+&RH2DZY M&2\(]9B#7"6F?,%=DY,@ EU><0IGBO2AYJWOQ=_KN?^Y\+9D5LJ>988=1O.2 M+LN!>P1+%,1Q-.(EW;7/>Q)4M'I7T2*"Y#V"A"=OR%ZB!^)X"UXR6M7FLB/C M!%QQ#<:VN.
*@AN:9(2F,ZXHQN+M7<56]E93RO!K.ME+02O8(U9N9[^5A,L! M3>\4RX KV&A6;6:OE83+ $VO[4IAP\LF+ EK9K]UA,< 36_ABF(;S#Q$&U*4 M3%M[JRW57-#E/F^X\@S"=:[Q;(8H$N/=BE>*#I>K61@]V>"5T&I2[' M9G'N^70*D5N?V>]Q9WJ^]
[E\7'>G,=]&%$GP?OPS+R''1EA3QW?L-A,I))F M0IBYAWO30J2J%NFEU!-#E:^F[:-T M"BIQ=2ZJW6OYBR/6V8RWE$P'+'SN7AW7PN].]IPR%I7FX$JS_!%YWQTS?!,: M6=],[+#J XI=\ JN?0K_'R&*B96D8^$Y3-U0HW9PQHEW+5>ZS3%70E[ZD>T@ MJF)D
M9'G_"7B_>>GXYT#H7!XZ>R^)H2%IY%PHM?Z%/R5+\+^"@OEC+LUHG[C9P(U M6Z"F&!1]+8D $Z^NQ8(EON4AA2A=24/S(RO!\B5*)5A-]PWS2-CH8IF0GY#G M4V?H**Q0^4WT7@\DH8OGN6K"_0;Z49C3S1V=WBK:2!/GG<13\#M M!"[$'+OVT82,D0?N3G
T<2QL-,6:2[/LR]&9#@O:9@UH#394AO=L*VE@ZOV5 M]4(B=/U3?Y)VG$*.CC<=YVB_+FAO_6NT??<<]]@MTZ7/O.;%+2C0%7$\[/BP M=HK.Z8B3Y]'-NT=-D"MV3+JZ Q4, XD#:/W2[.*&NQQXYBVA407<,/ MKH>GS?$H;C$["MDS!I^[-D8M2SQOP9IFGZ;K! 68M_
KGO/.--4;_*EUC7-/ MEXVG%+F)D\E."BE98K;U QCJ3:"Y9 T;$^BZ5W9G*^G7 %[J-H\""=%&6.0] ME0ZT@M(=6)%H?U0.0'DE;:T!%UYZ'"M@TW2"B)#<(J#.M"5ERZNEH7 5),85 MNQ1LO>7.@CH0RZ4#G%Y%Y12T.Y2TSK*N T'=7)JQWA7*4FY/+*&LI:18!\-5" K^EL
M'R/*S%IJ.B'21.\U0YD)NEN+<%Y3M!:EE7NO$PKPMYHW58S.JX7IS-&=P^*V M0U'8-GEC#S]Q3GUKM=D[I6B/*[HD84UMY&6? AS.HODRN"@ 6KEZ B,Y(3>S M&9IZ>,GJL"*VW^Y%((;VW\;Q*RM$TA*49"B\&Z-CQB).2PVN'7+C<%$W(2
MOC*2BG:&.=97O(&.CKZ*"ZI04NS0U D6P;DYI0<36I17P<,,@[)&536]IYJEQ):M M.M8B*&)G[[M#DT I*!BY@NX(T6D^87;#K?=(@,;!&4VS3HF@_H9M#Q?KE&HS M/5*>1EF@:=XI$6SP,8SXK>,'K1O94PVI8$!EDJF.LAO(&,]X/P,*A7'
M6NIE3U6L+HS:DWG*V#/*)_PG-(W&Z:]BAS:Z[L*O1Y3[J8=/LBK<\C[31P4?" M3DE*/9LH^@*5^ED*MA'+:O-GUBMMI,\11728/H?'X>OF[7M'SWW6:ZI$J-5(1$"@?XZZ(%'Z(OT6>"+M? M"?^&$G'BO]NG/\K_6=15:C5R2ZH$%\/!)2H>>[LBO+=.4OP6
CEY<#G5^B] M4I0CU32J1D"UGY"+Z!(Q7V\PG5+?M-W0'9XC<&FY85H-M-Q[E6F(]9I?84O@ MKI^.)Y=F92N9H2^F=2]RJ:BT%+O=4>1!9K&S4C *\^ (M)0EDTG^Z0I91QH M)W2FXO;+>JFV\89TV?46;J6^2+8&6N%7U%J1(IO-@#L+F,VNT1+9Y)7M=P7)
M#,U7[)EVE,5O2+JBC?5;ZK6XH&FH20XDBP=E2%"4^WNZ8J9+W-7DU>^+:C0# MO#*JI%7;P"8BG+J%%R;FBMQ@(8-0VD)?1-T4]';B-5KP^]C9B+!OQPKW1=(* M*%N*@&A>JL(AJ;)!E)K*N\8&M2#@EG*<-Y^WAN_$BU3)8M?BJ:$:QTK""+>> MP3Y&E")L1
DL'+T5"PQD:<=O_N/CP-F$GV'&,9TY"X8H?,2@H58U%KZP)/DS M-9-,T?_X((66+5Q9$"JE+,2O+*9$N'Z_*49^/]?.*1 Y1B"]]'-&OU2#57 MPB<(G00P!]^(V+[%6')%')?8V&(:?6G;;-$U7B!PMA0B&G,/PY=$-,*'F @# M.T.:#".BPP@)Z5^08T?YCG+C0#38,5\AJ_2?M-
R(R/-<8'5:CE#SM4:1@9.0 M[@;#^BIB 9CB>Q#;L]\ILF,'A'P'*TG!-K(+92,27LA0,-S'5<] I4/.H\Z- M"3&2]H,0]82 3@UV3.H*7+="]K!74<)= 2(S " &1;!"&>V/!P5<0*K<>UV+2%VEQ;S1$F1FZ/')T15Y> M<'B="BC/Q$R.?#I=F&ZZB/3T<)K/ M$,?"H:AB.H?/-
IX'_$\O@08OQ.?.$K5:[,RVB-,[=&XQ!?UW'+Q$U#6Y8>_U M&\X.KL\Z;!DTH"]YR],XCX2GL98-T#6B>&FRFY]NFA\LY29K4MKB?,H_JY;J M G[+;! 8<3\=;Q3$!-Z:F+*3;#25I2\S0U,>MP)NX>.WHEG#S^Z)?]1BB MS3[)I>]B![GN&,T#9W/S 8#0Q\\]83HA82H"9-
T\8\\RI6>JL_PM_I@4(Z:E M\!F :(.EZ$5MCQ@Q5<;-Y=WD>E!G8N.<.2:X3>J YYZ\[AJN>J(#@U?P6G!\ MKQ,4A'HE0>MU6]R--X@U?C]<'XO5H(;5?*.X%O,TG4%CFD.84> SP"+Q72>^ MKRE2-$OA(: MI&1RB^-.LR7Z*SA1L)4!-QU%BK/ LZ$S-FW$7-
,E*D\OQBG=7_&J -_JG=U4 M_KLX9R?HX'#VC1#+'1-[\SA&K%)_!5H#?TMIZH4%FPH7Y9K=ZEI[)UHA!E3> MR>W((_(01*DKPDP1Z\/9RM7<6IZ2XXUEJLQ3C&^:K8A/, MI. %MI*260CG71Z4MS&V)4!77K3MT-UBVP9)W-0]F*KPP&V,/,\.;I*4.%^5 M=?NK
O79H.M%W?'"I.C2=)D;4IDDL+AP_\4N@;LZ=WA'H_\)L%-_ZOD4>'(% M@.;)VMRH3N'=D:I$[@SG-B";XD+N =54 #)$P8 %0 '!A:&,M,C R M-# V,S!?9&5F+GAM;.U]6W,;;+F^T;L?^!Z'_9LQ+@MR^Z+.TZ?#8J2W)HC MBQI1W;
G7QRE*I"LZ6*!@RI*XOSZ!>I"U@6WNB+I1L1,6R030&9^2"1B/UY!%OMTXX^8((\8-@Z_Y'1?*&=+7T48^.$?/[/_/-'V)E3",/KY-?)_>;...X^W/[]Z]O+Q\ M]_+A.TQ6M/C9^W?_]\OMPEVCC?/6#Z/8"5WT9D+I?XZ2+V^QZ\2)>@K%7Y](MD%?
PX=VA+2$%^_0V)WO+OGK[_OSMA_??O4;>FY1%C?K?Y,+07[WX4*![_/V[M],<#*2O+D_S]IT^?WB6_Y0U2C43OH3^H,O_^&^328H)P0%Z0,M)TNS/\7Z+ M?GD3^9MMMP"I-OEL3M/SES=99NV\9LF<_?#AC*OJ?EYG=Y?].0^\]C/UX?Q,N M,=DD +V9L/I_>[@I,
<7J^L[%FW?LQW=Z];SK@^5%3$V:M3'#880#WV,6?N$$ M3">+-4)Q=.\0^O,:Q;[K!)$.^\WK'$Z4PY?1?#E;.^$*13?A(L;N'VL<>'1(MN?KGCBJVM5C:]?0[PH^RIZ0"[RGYVG %'2:1#@%P;2-2:7>/<4+W=! M3GB)8L?7@Q\ D["4?4_P%I%X?Q\X:5^F)K'-^O7,V?
JQ$_C_HJ:$E_$+[1@F M5-V615B*OD2$DVGL/Z-K/Z0VXCO!#1W?23*(&C%A38Y@J5$DROCJ4W#2LJI8 M)\#4]YNZU/HCG\VRK826U=,WTH7I9TY[<.(:1%//2UIEQG9P&.Y0O' "%%WL
M*7_>SHT?:8OM0.VK40C*>$"KMCCWT9XY%=R$,2(HBJ]>MRB,$.5P:"5(6NQ9 M#25GD\N+<,*C7#TZ3]O (ZLT&\1H@[8K;\<2DE-6S>LGD=,7:515%%N:72QZ;R\VU 3I6#,Z4J.S/!F M2]":=FSJ[-R5!TBZ-V7D/_K?>LGDOT%']&(;7!(E.M9%54-0#C^3#\0+47 M)
<.WE_S9FGUEA4,+41D5>I1&6O, 8AW7"^T%X-4Q *MT58[H@B;PN]F^H)J> M&;Y%3H2BGKJLLK*>F:>#VP:G0:5[2HP(87$G^HGZ#)?^L^^AD*W@*[\42O7C MT S(A@F%%8B&4P>OD=Y=?EHYG?*HWTB[//,E'^CH17PWSOCY+?3;!C^:53VX M8,DW27J&S?
=TLD^Z7;:4'.\1NJ C_=*/F>ZB:12AF,6@W?;S M1Y-Z1Q#IVO')[TZP0W0%S[Y(6&F'4(OJ1Q PSKK+(*^U9F,.(_X4N#>GG)!Y>F 8Z3#0-J^X[#KB+_!!%T0*M MDH;S/$:[L)ZJLH&9OT1;@MQTT&<["3:8Q/Z_VEM;F_H"%G'J_6,741_YZLF/ M/:
<7J015#BQ(.2PT7Z9S]P6B7;DXCS_B 23NVO; JKGQV%INZ2<;8MH/+ VJ M'5@@61ZL%]&T&NA]#\93A/ZYHXU&1A>ZJS?:K@6.F-5&DVV_$7*_6^'G=\CU MTH;OG[?I()[N8 B#?5D9K'#$$*\T88W\DFDJT)*ZJK.O6O-Z$'@LK[YR@&Z." M>H1<.L3-&XB\#1U"\ LB_!:K
MTE2W:P>$'.IC#;[-/E#!WO_T]OW[M^?)/O7_66U+0]^*_2W)KC.6RJ#@XLWT MU8\N\<;QZ2BZ='9!'#7:GJ-;F=)H='1XL(BE$STE6MQ%;U>.L\W,@K;'OF%5 M1D<#0V4XL;=A^,VJ[H'= MI*:W&[1Y:CM@\'DMU]N=T37EB;B[)_3VH(8>V>767F":&H@?^FEW"_(VF!\
M=>VV10D0H_.0=_C6CUD#Q^*30OE).IQ-OB0:CI)S-3FW 79+%2?9#DQ:CUOL MF^.PE7WQ-5V\3)^BF#CNH5\&SA,*?GG#)_KZOB*;F.S=^ (E.YQ23N[HPG1' MV.$9@5Q<6J%X0NJ2E$X'5"04S5+^ M%(:O+E"Q$5D! P)/79?LD%?G2M311?3B/B\KT;5C:*@?:
[(R:C<1\UWL,%)^ MX72:+"YT67*$*G93HOEZ+K"5&E5S:>KK!?;-UVGH;YS@5^0$\?I+":2,40%5 MS:PE=%V-6:0C+&UU5+NML,B,5<):;R8J /6+GT3B[G8Q2=@4 \NG_/HC#UPQ M[= BUL& ;*8O0SH\Z& ODN%BO1#RZW-*IYUMEB%EID9^C)INZ,36Y=ON1S-
"H_CF/= M@C% ;G8+[GN;Z/IHO4?77IET6I0 ZD,!M;UA#CYVHE]YC/ 6J]6 MF=2+ DH+\ *!@@(#&Y4."Q!L2(=/V6C[[^\J"KRE'YM$\GO*4DIC^I\^?3H[MF[R='&NF'_+*)[3V25K]A-6?A_H/+1B(Y!SN9 J<*)HOTP-8E#=15$=$+XP& M2DL8&
N*;$@#6'5"H8Q\TLY+20U=8Q43'7N^,$LK7E:*N2Z. GQNCU.&B:AF MSGEZY1@[OH;#9 >G1G_@E5'W"5$I])76)%V#2ZM4%HA=6\=1*%\K,&+N7[" M9[[85X1,]]]=(A(7C(5^.AH*_?!UEEX:X3^C]*C#/:+3M#=?3KU4=9R>HENL M9CY-"@(1G]MI] NV4D'W[M0"
(=R4M]&ZE[XPK("2>8H MC9+"L5NS+"1])#>DR68OC9+-]5$NVW5F:P89;LS?Z+.=ED#%.4]3D-%GP =V M1%DPS1U^XP[DI5_'Y):;':G*N:X>[9;I!K,;674F:+ 5CX=5-@QNR(I;^97 MC/,":O$J1$P/0U;Y_A(1?1-Y>UR+*)6/-3D9?R4B8KTX'DM9-MI)CN=9CC<#
M/_B1+(HE*R(T'U4AHZ+/<)@$6I7=1E9$0W1^HB,_XO]!0K=]<8AL@ZE*B:.G&H4!*&&G"EYR%A1K($:Z@6[M=K(&&.%FG(W>V=2BE$+-&B) ZW0*5T]2HDE7,^SRU3A2SEZ2$OIR]SMWZ4$A MZU&&9RZI -
)^9'@I_L7Y!R9I.A417I*&3\1=ZO+)1A+DSMF@^;+$@C"2+*3E MBB6E[K*>EZH5:S0^ZC*?QVV^WI=R:71:R&_A*#R#(9D2!-3"85%"#T16]B=! M\@E!6:Z1_+6272<'-2BX(4>C3P]"$8I3@Q;K1CO3-9,+W=)5EW=\!B]FGBQ M3WL_VY$@Z6 -:A
:7<,Z8.GIR!\;,Z7=LF$M,?0EJJ=KEVT',^[$\^B=NI&0 MQ8[>0C@8>WIJM[)I[.GAE5'OZ1&5.HESFD+IJE2][=U1*!E+>#"W9X?/="E> M7F5V].51=GAK3A:(//NN*&G)(^.N)42$XXK#]IQG#$3"19*05B88G[K+(DFA M6JS1_*C+)#Z_^4))RN?
HUGWHBI\17A%GNV8OX0I,7$C+-0 %/%B'JEPKA<1 M Q!1ZLGPB;7%[,^W46@;Z_PNF_#9[KHTHB9-9L]2:ZWO';8AM>25 M<;'5E<3B%.Z_ZJY&$8[XN\.2>Y[9S=E2_I@E4QH9#Q"PV))YYPZH99H_>8),0&11,?V1(2
M:XO7T]$LM9:Q#@_C'L$2,GTX=B5EUJQ[Y;RFA\!D;E611NQ.5:E,2B,=R2M4 M:HGZ&\-%]L325L=W7\IL%H=N#GN]&7!^A9B'_!1M^L<19/KAZRU:.4'2A7BK M7PY%#5P!S>"+55I3*1/5T[!-5>,BXN42[V1YI[9Y^L:1CC1^Y#CQU@5.Z7&*(I<2YW MH,8ZWWDNL
P\/.NC3R8564N9XX%D-'MZ/6-'=DR]0"*TW2J105'D9\SUNF+_MG4B@12QK<_S3X"4F2\>^89FMZ,7TBWWQ%XE1ZU<@M)%F51A6DK13U FUA.ZO M<[1" ZNX&KW[-!&CV+GX[$/L8,U[5)LN!*3/%#C2[CZU,DUE'[Q3Z?4B+D=0 M.I2\!W%9-WP2GDJ&O L4TC]B-
I5>)/>G)/MS9Y3Q%2;\:&Z+&H0&U[.0QY< MA1NE,\>EE_IUPA+=3\NW 0EKLV7 M'C"1EQ(?DE"7,]')V./MU*KC WN'/XZ7XTHS]PUJ$'?$9G5T/CRB#2%NS>/X MAT540I4Z93-AH'33PY^_^HA07:WWM^@9\384-RNLTVD5Q4TJIH!W5&=3?@2L M21UJ-
>G6TF,/UH,5=V#69%>62E63N@2(7P2>6+*5$Y" $ M52P>^>0-A.USR:C0.];CP\!"D<]X>8TH9MCL?0).P![U6]P1BF]9"XH+!03D M0HN1%0 BKOPN 6&!1B+W>'N &@&LR\OX]P8(F2]="'!EVFAWN0E=O$&/SNMT M%Z^3MT@DG85/++0;,3D(0:7=1$3>0-
C^NHA2[UB/C]&[AXCQ8N>0,6SNP.7" M1:%#?*PZ;%FDDQ^TK%*.)5'6[&]AM$6NO_01?XN)VG_&X8'K5X62NF-[%#E&4RENQFK/QHMQ^N MYDL.DQ%S9R/^3_+MI3TV(=Z;VG,C/5PEH[*/!SS)NZ4X4M;VBG;LY3@;IZ. M/E/.;G$47>Q_1=Z*2I?D#%EZ?NUOI:FW-
I5)LG!MJS.@2 XWTM%$2"]4A[3$ M$-=7-X(.:S(*XE9K'X=9JZ:\;-42O^C:P%H^C=SL]H6H/"&L) R!^>%@ :_1.20E%<$U8!H[< M&C%%09FFLO<=750!4@LQ2C@R%&<4B% /-DI8-W@2G?)Q0]E2GT,O$G(C9KA^[KS.J.'Y@@KA!-/M-O#3OI>>
M*:Z^3YJ$4%3KEG:524;:MM6=A"(5[P/W(86 >;"=X>8IL M+[#9<]G>/W91G&[XQ%G2#1G6(SW4WK<7< M[6K9_2+X"IDOW>,J9=IP1NTI MUDJXUPDEF3 >J7'AE%<(B,@U!>WW6@&IOK$>#P:R5W6FRR^QBIDUV@W88_?Q M_@N*U]B["9]1.B/>X=
M7)J6_H!D^]L,UR.TK58U0=>U<52)I:V: MN6/MR&;IGO$Z>^.GMW:$H-#EG2JI_LS/^%0(>KJMT\VJ35G//QU9S[_Y.@V" MC 71_1DRTH(*N).22R^+K&ZU7%35R4VF;VJV#-[^3WUA/QP)1ES"Q3"\:E" M8TX.Z6A;HE')TM]
(RU<@EK0X_J7V119+]]E763/K(K"+8O1>TN:1BJ=7 3$ M$>7N Y=86\P>G0FYMK$.#^.[%ERF2QZ&D-E*-_CW=Q7-W=*/R0^<[S/&ZG+E MLS=RO7>)4#>AYS_[WLX)HGD8[-^4P$"O,0H]Y%4$+91YTX\SP=A)+=?UC@9+ M/[ )K= <-\FF(LNX%I,U[X-;9^TF?)
[]\.$LX95]_6OCOO'[+L+JK,U\C=< M9I5T&;<2NK8]2:DG+&VV8^=)[/KMAB=KH>.(>&1=1L+;L:]LB9^<@/WES=FP M'>?^>5M(0FKWG7MG/WF.)O>(+#'9L#/MDT(U8W0GVMPC9MMB99U)0%3N2C6B MWCK2?3K0%C0SW;#T[GPY6[/KK6_"*4M)$=\)
[@F**$%RR-*Z)MW M7NUNLZ8EB;M[0F[\/:Z[BX%L<"G3 *+T,(A:HTM5-O.);X$FZ*N<1#HA'8>6; M-<8'0]O*2D_\;'"8\#:5;NWD$0X)17E&D>,@MJ<2 !P)0 %PH0O MA3$ SGL"X&(8 %I-:'2V1\G!%[U)K4 ^H/J=(&@X%=3$R!]J$T\;5:>/,N/% M/[LXC*F70OTK5NJ7-
Q%:L3^.OPM!W-'T/ W#G1.D2T*)OLMDH^O]0S]Z+TL!0O_'TS)*#.JDH^/PL2?[MKTD" HOT/--5F.R-D !1H1L=A>_[0:BAE(TL7NM1^@NQW'*^*3C*[X'[HI MOBX!)T_H)4?Q;1#)EO A7JODHVN^Q_[T'U5"@#Z9SR$L7-KQPQMG?6#"E04D'N<-
\#@W@4?'E;=$%I!X?&B QP<3 M>'1<;4MD@8/'C/XY)X_XI1H4EU*.CT7'%;A0$CA() ['G-P3_.R'KMCU$I&/ MCTG'U;A<'#C W.,H=H+_YV^E'C&?>'Q0.B[.9<(8A81UVBE!C@"$\L_CJ[WC MTKS,OE%%L[OG@OLU#L6AD#K)^
KON!ZOBV!4Z0OD[ECC[\^?"MD6#8[2ZR3C M*[WC,KLN H!1_M9/3DK<.^F3>O>(+-8.$0_T0OKQX>AE42V4QR@VC\3Q*%>+ M_>8)!QPL*K^/GXGKN'BN\ ]B\+EZ=9,-G() +)]L?,UW7";SQ0 P$*5'#+/M MLEL@5*0!H?]%Q M@N!B%U&^(W%OJ%"-
K_U>%L,5*0!H_R:,$;NIS']&ET[L9+U4DA?BDX^/1R_K M8)$X ("YVB#"7G;Y3/!+O&;[VYU0/#@)J,>'I9<4MD :HZC'+)%JG@) M(BTT_B[-7A+:03'I^+!T7+"+10$RN^1\7=-O M9-OZ:Y3C0]'3!O*:)("02+>5ZF%1HAT?C9ZVE7-D@3"C(';'-;MT KW^)Q+/
MYS6Z\7'H9>U>D\,H!E/*O)<8!]_-K?P^OLX[KL\K_ .P]_O=4^"[UP%VQ.&1 M$LWX.N]E\5V2 8#>_TX]Z?\,\4NX0ZV<']*-I)]L0*ZR0-*PLCM[6Z,;'HI<=Y#4YS,X!:.5!&D,XK_3J^OCLNHTO<0]#RM4\V M-YY8S_GOXY^9Z[@JKO /0=>WV?.88FT?*<;7=\?
E;DT"I<8'N&GF>-=$X?K] M"R=@5ZLMU@C%T;W#%N5K%/LNN[&PI$SIK3,?SKZ?O)T<&J!_S^9WB_GMS>7T M>IR3?RNW\[\[WD'3Z787WETT(B)["TWW6VCD -C[M9[H.7_;^&7O_C#D [/TS1B>)FO\AFAT*A&9NH%&SSIT*X-PZT[ZC)":6;E"G
M]I9DH_)]NM/02]Z#N?0CQNR._C1]BI)7!:5=JFV54#?]GA5TDW7 -4Y'6Z#L MSTFB D^V6[U123#S6@\F+[!L?!PH4YEG^[B-67P7Z@:6M J :73#@AM76CH MD";Q66TXEJ= M:X72V?6Y79UG2_5(6@>&"#PPS>#^.Q M*W7%9 6@#-
CP0K4)^.QJG;+E*6@>&8C@=O,/QLKV7CX,LK?E8EN4J]RC0.J MM2A],;!Q!XO'[LS-9XG'Q2/_YS7Z=WGZ\6DYL[^L-\]I^_SF\O MKQX6_VMR];??;A[_RZ8AU7RF +%##CA$\N?1%65.-AW)%\?\P%GA2YJ5%-!" M3$S*+*Z(CT D\[BDFQVDB;$R"915A-2@2A-
0B7WS&B]$*S3RD24Z*+KG&8T@ M(-'[U/\]/F[QW?NPEGSM:/G4"*@:(,F*66 @^%&.:Q>4 QE19Y[!TTZA3R MWX=5$8-9(2G0$/%O'H:IZ^XVNX YPXF+ST97@M9L:GQ&[*[J#9)W%_WR8%8\ MJJZC+Y)Y_.Q6B]/8:D'MAB G0IWS'S 07"-"7L)4@!BXUJ@3%=Z6#<6
M#UBHJ,XME2C8L:#'/;MPBBH^CHG_M(N9+3_B.QPRPZ7JI%RLDGM@4"3*]_15 M.12/LF6/*(\-_:@$F!F=:C)?T/=[-/J$\O=55^$.Q?/EH_J1D]< HI[VP^" M8CF!H7CI/_L>"KVH8'8S)UH+(!230_%X>\!/+"0P\ I/;3]BP2HX&4.>J"(\ M9I;4)I-#4 ^(*B+R8[1 Y-EW47K7P0-
R\2K%+G)D;Y+SG3S<3CDO_G;@G=:4(8WB/M+EF@^&QA*%Q4'C$H<,X>!0*($J,N6:C7[$$[(&O:G]2G(IB M <")^NETJ4YJ;,KSV*I28 >_NAF6P%+)-1!@$8D+8-%/1Z#HAZ]?G']@DO/& MVP$E(C(TN D/_:@&-Y$<9M3.K@6:+TO\
<$F:./=TO*9?.*O:F])Z1:"DFSJB6I+H,.(]P33.3C>WP>L M7.BQT.R6&2'].PNRLC,T"[R,7QR"6@01SX<+(N;,_V62L)^0'P1(/A5$F.0R M&(TA+MPU\G8!'>2%FI?NJMI:JR2L:&-3(,MG7S3$-3^+BP53 MK<.U2@+P:5M8KA:.L-;G%SL_8-M=*(?YGS>;+
<'/Z:DFZ2I=LZQIW[F%R1:! MU)32/)1?"=-/16R+\HF!5!: HH[UA(VJ6SFPID<,(T7? M:U >RB:@ED VD-1,&.>!'?L4!,T*O\%*!+1Q42H"&=0VMVO4?@7@1'#MHZ1+ MPY%?JI/-;B/49^5WTU.YP .H=TRMZ:"Z:]RE99_-SW-
JE1:YM;\Q"D[Z2X_L(V[0H%^B]!R%]SZ2_%M6!HEP;O1[= NBGC2T>I+1/QG MASV"?>V'3D@-.+@)(SIJ)J78Q #+)XC%,L&":/'B;+7A*1)#@49M;R)@ MBM*8!X4W@D2?J1YN<11=['%WHK._P\H2-SF:.UO&\Y/.I7!BBZVG+ET!#6/ M-X%,GXJ[;"T38DOBWE
MCG:G"N!Q*ZTX[$W>&4X^F&+6KGRZ-MO VF$K&.=9J^^N,9$PK]D =.P#E@1MU[,0'!1A8XV MS$\0+#HR7TZ]E FI>\PG!;2D:67.1?3X$IH'B3/&_[9E]]%3R@]G/^H<*%>5 MA3*_R^R1-EWH?Z M)5YYM9-
"O4879M,H0G&!&=F"2T!K8I*O<");+W%)82V+I""49G*N,.8G[BI? MTGR-B!C2RD9B7S(\AKYNX?]A%/O13>A^09[OL@OPKQ$=HY(+&I_9F.7MW)C= MK+S$@8_%-S&TJP?*FD5N;8=;&MH)":\SJ;Q;";U9KU4IB*PKG;:7696&^CTN
M6ZL=O[EZW2)7[%0VJ0"*#]D);YF AG,&A3<(Y]ML=W9TO!7W)EQBLDF^O4/Q MP@E0=+'/AI=D,U13O_$CY]Z& P\L0W#DXNV1C4F!CR0-$$\27B9/^TG&S82Q M8W;OJQ\YJQ5!]X3-^?(!/-P)]\(*RTRTJ&C3(%SDEUK+#B.R">#Y6SJ0)"? M3N++8^;
<5\8+2\YEW$3"V[PDM "\3)5!5;3/DV(H!W,.^ALG^!4Y0;P6NX\\ M*M/.H9:)"Q#G@1#Z93K?D;YD[V2^[(T"YK6O,)P#CK7%&/!$B,54)LVFZ;:5DBB/FXA\ Q584_ MU,4,[V'5%*O\F(_,1S_1F$@FQ#753GX]^O,ZO4+UZS5Z&8Y$!^C]/_"97 MJYI,CX==[*&5P"<8-7E
JS:)MH^RUR8@HM,#^6CW]+.%D[I_$992*Y$#AW/ M$7OI4G+3L[^V8M6BF/?4K[Y<3:4;*8L$$%9(6IKG,6]FP)Y&OG/ON.P0B/": M,P[-Z)K^V%+3 O[-&[9=@MHEJ%V"_@F7H/GM%VS/01BQEZ];+$+KA_H_:+T)S
M/B89(W])EJ5F;ZMZBH\W%LAOK.)0&CF#6^1#>A=(G1#8LE.L_/)IV[H@ ";3 M$E?L=27%O50B<@ +3[5MB?$HBC+44FE&$!U1KJD_%?CRM*:(TO3*4]=J#FLD MD2##JGA*I\UD2*<$YX^(;&ZQ(TG.:10"XQ0T4[Q4]FB#C]*!%U&;OOY$*H1X
MR#EM+SUW@FY"ZM2AW"7#(4X=*.ICRB]#:5 >9N>3(MU .F"7HU2<;";S<=FP MP23V_R6[4%]_.)2YK+$A\W!6BPL,YB)S\V5V_VZX2EX2$4 K+P*EDW:"4RXB M, @KMI=LT-/KE1FIZ:#O$#TP$PTV5$79]! KES =0QX"N+*$0/'+]\&F BN@ MJO*/CMKW
Z)6%0XH8$(9[U!KQS0I.CJ8/PP(IEQ4L_'A"R=@.R$7:X1B?EA8 M^*H#Y9ZNL7:!0X[5-8X8?W_VL1HQSEB:I#R)X\32UW?3H/;2<9AL07[_.](M;Z/8YW?+XX)]?A=81/O;?G[WE@Z,TITJ10(H88.6#WD613&O^6_QX6-!7,_ ^ M? S[X>-^W\L%_O#Q"=A9#?
=U4!E7%$W7-[=Y$6@1 1:PB47SCQ>]KW-"F!_MWO->W!6"+P_RC%8+20S^8!A.'7= MW687L!L*BD^TTK\#E.@]](I)'*%THAQ7;]6#[]*N^A/$\ L2*:0%B/Z";C* M;4> DXC^WH2Q$Z[8L\P1Y??OR%^MJ.^!9;R*&_. MU]N,L4G*V82Q!B3>>\U@0K?^,_*.
B07P$5Z$5]U!09ZNX2IB_T7YQ^8S (G MDKWET:@&J#%@77"+XT(CPA)/-AM/NEE-NS6!N:,)(=LOCCD#Q2G M\=5+]K7_M&,_/+#I4G;93^NZH/CE'?#LJ 'SW38_CU9\M5,1_925@.*]]!% MI7(.U3$?B>.A#;4==CE5\H$Q>;CT3]P+-0M""4YW[7*:XIHYCO[_7O$0W.!2
M^,V0@RH8!-LYJ!61#.I;>/"_]"L %Y%K(25=FK7>RKI=J%L@6Y3RMV/47AQR2P>DYG'G][7G@'3CS@66)@E/DQ)3DY2KR;\QOOZWT6"T MIO)DX>AF51CH]X?[L]FY@7C/^,,A.QLM"4$KRL *.K2ERX4U/W)7^)*&
MDP6T@(+&6O98>DJ$+Y)Y7.X=HCK#7R:!XO=*#:IT]*C$OGF-:W1U*1P-RD/! MBF=D@G. *I% X?>9JH -R]3)FCG1^CK +[\B;X4T.E7C6J!@V=A\!4#K20T* M[D?BA%$:8IYZ_]A%L?+Z$]W"4!:7?8$K%7:HB+R6#Q6NV!7UR:6$](NM$^YO MPF>4,BA)G?57-
Y359BNH>]8%J-Y]R;! W@4*Z1\Q.Z@<->_E6I5 2>WTU=NU MA :%M6R-58N"MULLWT))_+05NZEB>GF@::#J?W4SC-/_/!'G$J2^B2 "I MBYW0[*ZV!*6TP$+&4^SZ%VB)"7IT7GFH$.7@?.E^)7-QK6 <;/;P-M46+/Y'?8@S6?J^Y%23J=QLN:' ML_?59 VKF?Z355[*T-
B7,!O=?DS78W0EMF"**XAYY/"RI9HOH;)%\7\D%CE M2YH,1#RH;(K$N&!YPL"'-YY\OT/4/Y+>$<0BANH-RL2D!PI G;"Z-[9 ML^XL!X%#" 8$H265>T)= O, /*!G'#RSM\B*+ZKNI5@HRD#QLO5@40AC'J%; M%-
,>KC=2<4FAN,6:W80K@WD8%LBE#JK'!EH!APZ,!U">[+@"&$>@5-\VEV MA'W:'9@[:Y]V_],^[+HB*&&$$ISGK*C&9&DATUV@Y? LEG<\'>2\5T;J\?_N:N'_[BO/J;W4:HS\KO MIN=2Q77#%6[-J/1P#&_AHI .8U@P"@CH#(T(W[<>$01R&%)^QL-O8;1%KK_T
MD<=U[A6T0$8.J2D=]"\68ZA80]DJ])/D1XLM08XW#XL3=\[9/.0/V!WK@C 8 M*>WM$)9H+R<0%!]?<&\H%NHRO2 8%,6"G%!0I)7UUQM+M9E>.PR+9%%2(%A> MXYTDE]&A,M-GP09%LBBH^?5\F?E;Q3$O(;79TUP*(<09ZM,^FU66Y=IQT72# M=*3'V)RTW-
@9QR+P@ [ZE%F]!Y1[CS?O7?VDL>P%65,3W2=X:I)!!JS:X+^ MN4.ANY\OV\ G*VYZHNO>\23" 0/UMK"[\K")-0W87&!"\ O;XNILZ2_Q7@!L MLRI&!U@@_S (R#(1 <.L :(!B'[L%2)X M "0;T*.FA@?X/9AFF$T<%*F\8BB M;($\@I%P&AO?7-
I'@X;6A4G#2:Z)HRRQ+]2F3E%J9BKMJA_?.-K'GOJ7WOR5 M(CG?S ^)DO2\E_S9XF*1<\'%(GD3DZ1B^D7:3/;17C%BKQBQ5XS V'IOKQ@! ML;'^U*\8^19NN.AT\0C\&RY.ZA(8@3NOAP7,2V#LW1:F$;!W6\#PH>S=%O9N MBV_H;HL3N)*AP\T68UW)NMMY._3! MY:
[^CMCM(LB;'O)OK9)8M:>,14FLO+U)UJ!-9]ETEDUG@0K#V'06B*G)IK-L M.LNFLVPZRZ:S;#K+IK-L.LNFL[K&2VTZRZ:S;#K+IK-L.LNFLVPZZ\^4SF*K ME,=LE5*)>!>CX>RV[4?JY4EB=XUJ@=D1I:@WEM%\/N,2$?
_985<^M\E_.@/Z:I:5@1:EH(+1'G(E(D#80K+^9O1 M$9ME,Y7Y"GD14*MMM?7QL>()9AZKXFB;JB%L<11?[7Y&W8L_7H(=\0ZCM;]MZ!CH5 8M)-_*9= 1U#S>'-:DGH2$ M'K@;H6_%160E\IH';^9$Z^L OV1,2FK MDD,9!!N8)+]'5@4#"]BU_XJ\HC>LQ(Q3
DH7ZPP;1S;S =D'1(=PEGY+)N06 M,=GO!3'9UF6KN9UFZF_1-NIV&WLS9^K3? MWR(G0O.GP%^E:3@Z) 0[]@#/;$<(Y?^+$^](,H8HXIY^.G-,/7Q^<<,7+4%9^@Y62U% UZQH5&08:A'04S%T8UWX%$+_D MFD1)EP,O;17:S%ZF$NJS\KMICT=@



```
well as reduced consumption and demand for animal protein, could adversely affect demand for our products. Such occurrences could have a material adverse effect on our financial condition, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The testing, manufacturing, and marketing of certain
of our products are subject to extensive regulation by numerous government authorities in the United States and other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We have significant assets in Israel, Brazil and other locations outside of the United States and a significant portion of our sales and earnings are
attributable to operations conducted abroad. Our assets, results of operations and future prospects are subject to currency exchange fluctuations and restrictions, energy shortages, other economic developments, political or social instability in some countries, and uncertainty of, and governmental control over, commercial rights, which could result in a material adverse effect on our financial
position, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We are subject to environmental laws and regulations governing the use, storage, handling, generation, treatment, emission, release, discharge and disposal of certain materials and wastes, the remediation of contaminated soil and
groundwater, the manufacture, sale and use of regulated materials, including pesticides, and the health and safety of employees. As such, the nature of our current and former operations and those of our subsidiaries expose Phibro and our subsidiaries to the risk of claims with respect to such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
indent:18pt;margin:0pt 0pt 6pt 0pt;">Our business could be impacted by economic sanctions, bans, boycotts, or broader military conflicts, including the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine. Other potential impacts include supply chain and logistics disruptions, macroeconomic impacts from the exclusion of Russian financial institutions from the
global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy, as well as heightened cybersecurity threats. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pandemics and similar outbreaks could directly or indirectly impact our business, results of operations
and financial condition. A pandemic or any other similar health crisis could have economic impacts on customers, suppliers and markets. A pandemic could affect our future revenues, expenses, reserves and allowances, manufacturing operations and employee-related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Use of
Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company's consolidated financial statements have been prepared in accordance with GAAP. Preparation of these financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues,
expenses and related disclosures. Actual results could differ from these estimates. Estimates are used when accounting for the valuation of intangible assets, depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax assets, sales discounts, rebates, allowances and incentives,
contingencies, employee compensation and actuarial assumptions related to our pension plans. We regularly evaluate our estimates and assumptions using historical experience and other factors. Our estimates are based on complex judgments, probabilities and assumptions that we believe to be reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-
style:italic;margin:0pt 0pt 6pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We recognize revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to the customers. Certain of our
businesses have terms where control of the underlying product transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Revenue reflects the total consideration to which we expect to be entitled in exchange for delivery of
products or services, net of variable consideration. Variable consideration includes customer programs and incentive offerings, including pricing arrangements, rebates and other volume-based incentives. We record reductions to revenue for estimated variable consideration at the time we record the sale. Our estimates for variable consideration reflect the amount by which we expect variable
consideration to affect the revenue recognized. Such estimates are generally based on contractual terms and historical experience and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of variable compensation. Sales returns and product recalls have been insignificant and infrequent due to the
nature of the products we sell. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net sales include shipping and handling fees billed to customers. The associated costs are considered fulfillment activities and are included in cost of goods sold in the consolidated statements of operations when the related revenue is recognized.
Net sales exclude value-added and other taxes based on sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents include highly liquid investments with maturities of three
months or less when purchased. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Short-term Investments</p><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short-term investments include highly liquid investments with maturities greater than three months and less than one year at the time of purchase. We classify these investments as held to maturity and we record the related interest income as earned. We determine the appropriate balance sheet classification at the
time of purchase and at each balance sheet date. Investments held at financial institutions may at times exceed insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Trade accounts receivable are recorded at the invoiced amount
and do not bear interest. We grant credit terms in the normal course of business and generally do not require collateral or other security to support credit sales. Our ten largest customers represented, in aggregate, approximately 13% and 16% of accounts receivable at June 30, 2024 and 2023, respectively.</p>0.130.16<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
indent:18pt;margin:0pt 0pt 12pt 0pt;">The reserve for credit losses is our best estimate of the credit losses in existing accounts receivable. We monitor the financial performance, historical and expected collection patterns, and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We also monitor domestic and international economic
conditions for the potential future effect on our customers. Past due balances are reviewed individually for collectability. Account balances are charged against the reserve when we determine it is probable the receivable will not be recovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Inventories</p><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined principally under weighted average and standard cost methods, which approximate first-in, first-out (FIFO) cost. Obsolete and unsalable inventories, if any, are reflected at estimated net realizable value. Inventory
costs include materials, direct labor and manufacturing overhead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Property, Plant and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Property, plant and equipment are stated at cost.</p><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation is charged to results of operations using the <span style="-sec-ix-hidden:Hidden_fAmcI6st9E6OJfwNdoM5-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">straight-line</span></span> <span style="-sec-
ix-hidden:Hidden_NBh0ihnEUutTJ2AcqYoPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">method</span></span> based upon the assets' estimated useful lives, ranging from <span style="-sec-ix-hidden:Hidden_FKXobehSB0KqypMeC6NKfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-
style:normal;font-weight:normal;">two</span></span> to thirty years for buildings and improvements, and <span style="-sec-ix-hidden:Hidden_hbtCtsHLGUuiYgDN6F91zA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to ten years for machinery and equipment. We capitalize costs that extend the useful life
or productive capacity of an asset. Repair and maintenance costs are expensed as incurred. In the case of disposals, the assets and related accumulated depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in the consolidated statements of operations.</p>P30YP10Y<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-
style:italic;margin:0pt 0pt 6pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We determine at the inception of an arrangement whether the arrangement contains a lease. If an arrangement contains a lease, we assess the lease term when the underlying asset is available for use ("lease commencement"). Individual
lease terms reflect the non-cancellable period of the lease, reasonably certain renewal periods and consideration of termination options. We determine the lease classification as either operating or financing at lease commencement, which governs the pattern of expense recognition and presentation in our consolidated financial statements. Our current lease portfolio only includes operating leases.
</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We recognize a right-of-use ("ROU") asset and a corresponding lease liability at lease commencement for leases with terms exceeding twelve months. Short-term leases with terms of twelve months or less are not recognized on the consolidated balance sheet and lease payments are
recognized on a straight-line basis over the term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The values of the ROU assets and lease liabilities are calculated based on the present value of the fixed payment obligations over the lease term, using our incremental borrowing rate ("IBR"), determined at lease commencement. The
IBR reflects the rate of interest we would expect to pay on a secured basis to borrow an amount equal to the lease payments under similar terms. The IBR incorporates the term and economic environment of the respective lease arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have elected to account for lease
and non-lease components together as a single lease component and include fixed payment obligations related to such non-lease components in the measurement of ROU assets and lease liabilities. Fixed lease payments are recognized on a straight-line basis over the lease term. Variable lease payments can include index-based lease payments, real estate taxes, maintenance costs, utilization
charges and other non-lease services paid to lessors and are not determinable at lease commencement. Variable lease payments are not included in the measurement of ROU assets and lease liabilities and are recognized in the period incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Capitalized Software Costs</p><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We capitalize costs to obtain, develop and implement software for internal use. Amounts paid to third parties and costs of internal employees who are directly associated with the software project are also capitalized, depending on the stage of development.</p><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense software costs that do not meet the capitalization criteria. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets and are amortized on a <span style="-sec-ix-hidden:Hidden_DsY3fyTu_EGZZhEcRiMYBw;"><span style="font-family:'Times New
Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">straight-line basis</span></span> over <span style="-sec-ix-hidden:Hidden_B1BS3XzzFECDq_ax8Sv3PQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years.</p>P7Y<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Debt Issuance Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs and original issue discounts or premiums related to issuance or modification of our debt are deferred on the consolidated balance sheet and amortized over the lives of the
respective debt instruments. Amortization of debt issuance costs is included in interest expense in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Business Combinations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt
0pt;">Our consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition; goodwill is recorded for any excess of the purchase price over the fair values of the net assets acquired.</p><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant judgment may be required to determine the fair values of certain tangible and intangible assets and in assigning their respective useful lives. Significant judgment also may be required to determine the fair values of contingent consideration, if any. We typically utilize third-party valuation specialists to assist us in determining fair
values of significant tangible and intangible assets and contingent consideration. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, based on forecasts of the expected future cash flows attributable
to the respective assets. Significant estimates and assumptions inherent in the valuations reflect consideration of other marketplace participants and include the amount and timing of future cash flows, specifically the expected revenue growth rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and
assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets primarily are based on a number of factors including the competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their
estimated lives. Intangible assets associated with acquired in-process research and development activities ("IPR&amp;D") are not amortized until a product is available for sale and regulatory approval is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Long-Lived Assets and Goodwill</p><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset,
a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. We recognize an impairment loss when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of
the impairment loss is the excess of the asset's carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations.</p><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in a business combination. We assess goodwill for impairment annually during our fourth quarter, or more frequently if impairment indicators exist. Impairment exists when the carrying amount of goodwill
exceeds its implied fair value. We may elect to assess our goodwill for impairment using a qualitative or a quantitative approach, to determine whether it is more likely than not that the fair value of goodwill is greater than its carrying value. During the three months ended June 30, 2024, we tested goodwill using the quantitative approach and determined goodwill was not impaired. We have not
recorded any goodwill impairment charges in the periods included in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Foreign Currency Translation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt
0pt;">We generally use local currency as the functional currency to measure the financial position and results of operations of each of our international subsidiaries. We translate assets and liabilities of these operations at the exchange rates in effect at the balance sheet date. We translate income statement accounts at the average rates of exchange prevailing during the period. Translation
adjustments that arise from the use of differing exchange rates from period to period are included as a component of accumulated other comprehensive income (loss) in stockholders' equity. Certain of our Israeli operations have designated the U.S. dollar as their functional currency. Gains and losses arising from re-measurement of local currency accounts into U.S. dollars are included in
determining net income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Comprehensive Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income consists of net income and the changes in: (i) the fair value of derivative instruments that
qualify for hedge accounting; (ii) foreign currency translation adjustments; <span style="color:#231f20;">(iii) pension settlement recognition and unrecognized net pension gains (losses); and (iv) the related (provision) benefit for income taxes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Derivative Financial
Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We record all derivative financial instruments on the consolidated balance sheets at fair value. Changes in the fair value of derivatives are recorded in results of operations or other comprehensive income (loss), depending on whether a derivative is designated and
effective as part of a hedge transaction and, if so, the type of hedge transaction. Gains and losses on derivative instruments designated and effective as part of a hedge transaction are included in the results of operations in the periods in which operations are affected by the underlying hedged item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we use certain derivative instruments to mitigate the risk associated with certain economic factors, such as exchange rates and interest rates, which may potentially affect our future cash flows. As of June 30, 2024, we used (i) foreign currency option contracts to mitigate certain exposures related to changes in foreign currency exchange
rates on forecasted inventory purchases, and (ii) an interest rate swap on $300,000 of notional principal to manage future cash flow exposure resulting from variable interest rates on that amount of debt. To qualify a derivative as a hedge, we document the nature and relationships between hedging instruments and hedged items, the prospective effectiveness of the hedging instrument as well as the
ultimate effectiveness, the risk-management objectives, the strategies for undertaking the various hedge transactions and the methods of assessing hedge effectiveness. We do not engage in trading or other speculative uses of financial instruments.</p>300000000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Environmental
Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenditures for ongoing compliance with environmental regulations are expensed or capitalized as appropriate. We capitalize expenditures made to extend the useful life or productive capacity of an asset, including expenditures that prevent future environmental
contamination. Other expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. We record the expense and related liability in the period an environmental assessment indicates remedial efforts are probable and the costs can be reasonably estimated. Estimates of the liability are based upon currently
available facts, existing technology and presently enacted laws and regulations taking into consideration the likely effects of inflation and other societal and economic factors. All available evidence is considered, including prior experience in remediation of contaminated sites, other companies' experiences and data released by the U.S. Environmental Protection Agency and other organizations. The
estimated liabilities are not discounted. We record anticipated recoveries under existing insurance contracts if probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The provision for income taxes includes
U.S. federal, state, and foreign income taxes and foreign withholding taxes. Our annual effective income tax rate is determined based on our income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate and the tax effects of items treated differently for tax purposes than for financial reporting purposes. Tax law requires certain items be
included in the tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">depreciation expense. These
temporary differences give rise to deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which we have already recorded the tax benefit in our income statement. Deferred tax liabilities generally represent the tax effect of items recorded as tax expense in our income statement for which
payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our income statement, and the tax effect of assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
indent:18pt;margin:0pt 0pt 6pt 0pt;">The recognition and measurement of a tax position is based on management's best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual effective income tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain
deferred tax assets, including research and development costs capitalized for income tax purposes and net operating loss carryforwards, is dependent upon generating sufficient future taxable income in the appropriate jurisdiction prior to the expiration of the amortization or carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable
income is not likely to support the use of the deduction or credit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority in the jurisdictions where we operate. We evaluate our tax
positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because there
are a number of estimates and assumptions inherent in calculating the various components of our income tax provision, future events such as changes in tax legislation, the geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an effect on those estimates and our effective income tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Advertising</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advertising and marketing costs are expensed as incurred and are reflected in selling, general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-
style:italic;margin:0pt 0pt 6pt 0pt;">Research and Development Expenditures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Most of our
manufacturing facilities have scientists and technicians on staff involved in product development, quality assurance and providing technical services to customers. Research, development and technical service efforts are conducted at various facilities. Our animal health research and development activities relate to: companion animal product development, fermentation development and
microbiological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional specialties development; and ethanol-related products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognize expense for stock-based compensation to employees, including grants of restricted stock units, over the requisite service period based on the grant date fair value of the awards. We determine the fair value of performance-based restricted stock units using the Monte Carlo simulation models. The models use historical and current market data to
estimate the fair value. The models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Net Income per Share and Weighted Average Shares</p><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Diluted net income per share is calculated by dividing net
income by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common shares equivalents, resulting from </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">the assumed vesting of restricted stock units, unless the effect would be antidilutive. Common share equivalents were
included in the calculation of diluted net income per share for the periods included in the consolidated financial statements, when applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-
left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr>
<tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-
size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-
weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-
weight:bold;">For the Year Ended June 30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,416</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt
0.05pt 0pt;"> 32,606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-
bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,175</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span>
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of shares - basic </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt
0.05pt 0pt;"> 40,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt
0.05pt 0pt;"> 40,504</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dilutive effect of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of
shares - diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net income per share </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> basic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt
0.05pt 0pt;"> 0.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.21</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"><span style="white-space:pre-wrap;"> diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt
3pt 0.05pt 0pt;"> 0.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt
3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt
0.05pt 0pt;"> 1.21</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-
size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div>
</div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">
</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-
size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-
size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-
weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended June 30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2"
style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,175</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-
align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of shares - basic </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dilutive
effect of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-
align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of shares - diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,504</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net income per share </span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> basic</span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.21</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> diluted</span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.06</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.21</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-
size:1pt;text-indent:0pt;margin:0pt;"> </p>2416000241600032606000326060004917500049175000405040004050400040504000190004052300040504000405040000.060.811.210.060.811.21<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> requires the disclosure of significant segment expenses that are included in segment profit or loss and how the segment measures are
used for decision-making. The ASU will be effective for Phibro's fiscal year ending June 30, 2025, including retrospective disclosure for all prior periods presented, and interim periods subsequent to June 30, 2025. We are evaluating the impact to our segment disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ASU 2023-09, <i
```

Income Taxes (Topic 740): Improvements to Income Tax Disclosures, enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU outlines specific categories to be provided in the rate reconciliation and requires additional information for those reconciling items that meet a quantitative threshold. The ASU requires disaggregated disclosure of federal, state and foreign income taxes paid, including disaggregation by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). The ASU also requires disaggregated disclosure of federal, state and foreign income (loss) from continuing operations before income taxes. The enhanced disclosures will be applied on a prospective basis and are required for Phibro's fiscal year ending June 30, 2026. We are evaluating the impact of the additional income tax-related disclosures.

falsefalse

3. Proposed Acquisition

In April 2024, we entered into a Purchase and Sale Agreement (the "Purchase Agreement") with Zoetis Inc. ("Zoetis") to acquire Zoetis's medicated feed additive (MFA) product portfolio, certain water-soluble products and related assets (the "Proposed Acquisition"). The purchase price is $350,000, subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. Completion of the Proposed Acquisition is subject to satisfaction of customary closing conditions, including clearances by applicable regulatory authorities.

350000000

Disaggregated revenue and customer payment terms

We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The products help prevent, control and treat diseases and enhance nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products directly to integrated poultry, cattle and swine customers and through commercial animal feed manufacturers, distributors and veterinarians The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused on regions where the majority of livestock production is consolidated in large commercial farms.

We have a diversified portfolio of products that are classified within our three reportable business segments — Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.

Animal Health

The Animal Health business develops, manufactures and markets products in three main categories:

● MFAs and other: MFAs and other products primarily consist of concentrated medicated products administered through animal feeds, commonly referred to as Medicated Feed Additives ("MFAs"). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products. The MFAs and other category also includes antibacterials and other processing aids used in the ethanol fermentation industry.

● Nutritional specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.

● Vaccines: Vaccine products are primarily focused on preventing diseases in poultry, swine, beef and dairy cattle and aquaculture. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.

Mineral Nutrition

The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestock's diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine, and beef and dairy cattle.

Performance Products

The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

The following tables present our revenues disaggregated by major product category and geographic region:

Net Sales by Product Type

For the Year Ended June 30	2024	2023	2022
Animal Health			
MFAs and other	$ 420,959	$ 387,349	$ 361,538
Nutritional specialties	164,671	172,504	157,196
Vaccines	120,852	99,998	88,321
Total Animal Health	$ 706,482	$ 659,851	$ 607,055
Mineral Nutrition	243,663	242,656	259,512
Performance Products	67,534	75,382	75,694
Total	$ 1,017,679	$ 977,889	$ 942,261

Net Sales by Region

For the Year Ended June 30	2024	2023	2022
United States	$ 584,763	$ 578,773	$ 561,803
Latin America and Canada	247,705	219,846	191,047
Europe, Middle East and Africa	121,977	117,815	122,480
Asia Pacific	63,234	61,455	66,931
Total	$ 1,017,679	$ 977,889	$ 942,261

Net sales by region are based on country of destination.

Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.

333

Net Sales by Product Type

For the Year Ended June 30	2024	2023	2022
Animal Health			
MFAs and other	$ 420,959	$ 387,349	$ 361,538
Nutritional specialties	164,671	172,504	157,196
Vaccines	120,852	99,998	88,321
Total Animal Health	$ 706,482	$ 659,851	$ 607,055
Mineral Nutrition	243,663	242,656	259,512
Performance Products	67,534	75,382	75,694
Total	$ 1,017,679	$ 977,889	$ 942,261

Net Sales by Region

For the Year Ended June 30	2024	2023	2022
United States			

















%%

.MH?K=I*@[5.'8/»=BL|.7:Y&&(+0PONKP%'!*^G8MD#ZIUQIXVIH\^.A-.56X MFUY.7A.8F!=C*Z@]7V//0G]*R.5]<:R:?Z&.&22\FS.:JA)*6FF@#C*\IF.MKJ$V.!U\&PO=VIR.M:W-H965T.$RT)D.MY>SBS.ZIKRI.U%.G62G?
5Z3>%H6I'BJEKG;G,5,K0CYB=VMMJ\B?9QMQ)SI*.M_7G5OH-+1L]>29H4LZTR5J)*K\iE.=GK)'+//KO=MDH./:1.CRJU2OYO!37H^.M)-B0$._W-:'YGGAA+P4.+!=-.:?.3;BYXJZ#U9X$.9\$U/)*Y'.)4KI^.MGT4SDIJ5V.:ZG=IKI*%N!?$,O47EM?
\FN7>.O.2+*MM2&S.]%'O:.`]IF.H9.MXQUCEWR2XD.-V-IS:Q<5IO1*=/9^#\.MM:SNY>SBU32_%>'IK$W.6MU1\0U:EOQS0\GU\UK:.DW_HM.MI7?-.X?D$33&/AF&.)GA(@WYT!0E?T+UZ6A.ZQS0!A53?U!JXG+1V'E$<.M/M&A.<.G^AYU0H8F0DY='AZ(?
IG*C2IE]6MJC.+.$3:?N.XN1<.#>.>3M9R=.).MI.:[I.%'S PYB9O)2S\Z.K/E.N1E?)G*1!U%.G9.5I:O$CBSI4.<.MT3BFB8.M[=9JI.A.\:0DHDQEKA:TG]&@16=4.0>.O^.Z\%.+TT]'#BS6-?30$.MU\BN.=.0T)<OE=M.
Q>WWI<.=FG6#=@GNTMGWR.5<2*0HOW5$UC*5.9[CFOH.M.8W-(1H]?X<.)+4^9SI.XA)*U!#3$CU.6.5WD-)%SHU>.,6]^115.8MM+!O#$*%O%?.96KD>35EY'KA#.M1DEV_EVI>.G04=3L-:+5%NR.I._1%LG2HX6$GJNR.._3X/&IF2$FIP4&Q'M'/+
M.5%eZ.,+9_3Y1Z@^9=7Z^.A0I6HW@+1VLCI.PM:G1K(FTVH.,%F'HT.M%/56E(VJ\:.P?9OZBR&N._5#]C@.7>N:D&0FU(#W0PI2.*5VKTV%5C:I6D6 M++=R'*IVI'/.\+ZTG*.%04V$C'X3*!8.XI(=G@=/6O7I<.PL5$@&C& + M!H:%=X0$Y.@57M-A/)
+3)I"W5X#K3D04]$>BR&&'KU&>9N6=.M54$EM%5&P!_:8 M&#U'QB)Y(@MUK@5%,U\A51\=BDZM'*5]W'BZ2I-F\&?G@ 8<9V)!UIK-*E04L!6RK9'AM1^T81 B'!KDE]QNC#PW2,)!$5' 2!NA-56ENW M96 2IVU8& ZD(C=^.:'5TXX.ZN$A:*\(C6+R;I C!?
@\A(#108TC16;.> M#Z)SL7ES;8.4N-EDH)?LSWY5]!00/M*L>9!+OE<$M+LE$.VD \-//WI@&HI M=$9=P.3 %;@D0V0 UB%D@+L6F$88\-FA>]VY!D/&1![FP&4I6E[#8M-S:.GW M^H.PC.E0D)D+M!'M%;5^!U2AJI:0 T2=.LL8OLAA*5Z?!Q:60L.H1*IS4G:.M0H<$***
X83[E*8^X#[_R05VA.> 0I_IG+:?7CW^2B#@'K>B$(M*4A0 M7^(M8TFB577[.%M?.64CNT5)Q&[C7F6:.ZRY>],/UA%FQAF^3;U!9D-C.:K22#)-AW M-.#FU"K/4TL>*%YM":G;U=$D-\G)/YOD&KL.\7K0HQ>)X`M.Y:IS7W'B\.\%0/&O0*C<.ZI?QDIRTR^%"9C-IH
[^\3IF.IM97K>!K?7-MK;S+RM*@!2P\.M4BA1M@?MO'#`=L$P.9E?MC=!4S>4\CE.@99EB=A3G#IPOGBIOE.ZJBFQTT.O-/V4:QH;.E:6RV9=7T MF\^VIM0YWZ,..C.8AC5R.OKZI3.SWE/YZH&OZ M60+II>8^94Z=($ C4UYT(Z)9>T$3&AlP(<;BI Y&T
WSD#TZUP6]F+S%5!HM^ S'U<3+'8VP^4 Ms *E:?WLK?UPL!)7%Z8'Q/TO+O/F?N#NC8*39ZFY'HN.07&UIQ5=M:I.V5/XKA#8,,:#$%&7Y).4-Y&5%,Z!=D+0=I&65C81BO1(.M.DIVZWND9$?)'!=-!6^R+!)WSIWPIG@<;!2YL4L.1^Y*]>PD6CIW.NYV;.Z$
MDMLC00*%.W-M2NYP:A9=NS+ B\\4RBZCM-\MN5#!=!S6+LUTK-=,"@67AMAU M67)S?PI2.R91$FT7KL1BZ?Q"=SI>.\05<@_.NRNC0XZS8HA2A!6;$5.3"?1"?) M6GFZ0/!5P$;Y_HGW!*9UC=.^K&M7J=L+.^(?:W5$4AH3IEEO#U[.V)D&O/IE.W-95$'W=C/[
MQ#BV*Y(#),:(MV!N(9K<]DO2I^_VJ-9K5.OM0Y)*8Z(5:PE$XD5"R7F(N?* M$4PAZ[@IA%[@G#'I<$Y0K]> ^A(SYC)^A,'I5,#2:P$?:&(.> 2>R#ND(A;DG.[M)`.,/X^%KL=L%?%YQPP9#'1]4WIV>&*]9S @ ,BQ(_I.1/MP2#.6(,H.!>X MM>#L?
Y@Q=3$Q54V6WQ.!M4@QW U6)L3!4Z.DO^`TE'I4F.D@OE 6U&I$(Z(_MB=WP54.0I'&2)0 ,37DS3I-,K&7U>&M^R.WM.V&Y80I'B)<@$AHSEI&3/#=K MC"XP_0 0@&$_?<@$I_S(843\!+9:S3SH)=T7F&3W6N.GW_6CDORG@M#0G<Y(
MAA^N^'O0\VW!PWHQR_K-]\Y8E!?7NU\.\B2KM6NH MD>]@(NL0W#N\I.(#]*:>X:_3V'($M)?N8FA#M_3VY&I/$<^.(dZ|NHC#?CKJ M1_!@L?_V8OY_U;'8D00NUOX^.ZY9OP.$*X^D ^P1*VIC]XK!^30DDCAA_4YK)8E9.B!G.W&>P!SB)>IK M1]YMV%!H75B"?
$4+;T![<386&%1+WUXCK@B4[<08TC;B@+[V"OF) MYXA>.I9G)(`)&\7" Y>%.;A9;.VIEGC8 R3#.TGY(8M3EGR7-Q.,09HJKE.C M_K"SL.)T6]U\"681WBS80?E]H&KLFJ7F67!2O08>R*LWU4=N%@)MES!'5GHT MP0C]G=*.7%Z%=X&,.^WPI%^.E_BT .>)
<'^NM=M.O(#FL3C!!E[.`P04 M" !,A1Q9SB4FM*L' !R!P &0 'AL:+W=0I8_.YIO/W&=]YMI7]61>(IEY*:O3<$XR!+GQ?IP665) ("H5=.R:4] M1;&F6ONZ4DBS)IGD/@F"4[^D3'C)K/$!$(0F:\9P .<%NBY:]EX?R.5VIH7> MSO'(UH5Q#C^9572-
25O_[@=E+;!R5B)0C,I0&$>`2K!'BI'TXLN>X9;O3< MIV0EV;,SIK'V%SA"R#$U#H:88/?R+D#LC1^=9A>OZ5+W)-OT&\;[5;+BF[\ MEOPGRTPQ\)XJR#"G-3>(VHX,E9VIH,E-R"\%6S0#:.0VV98<$^ZG<(VR]%F MF>2&,@5F.<(<([TAUK=">N-
%PD)VN..KCF6_L+BI63SO$18M(#B"&L.ZE.(6S M+R+#[&\ W1+K.9(=QP491?0:BQ.(@@F0@.0C>%&O.6KPHK=I'1+. L7#0*Y@= M+G1%4YQ[MB(T]@UZR8=WX6EP.4($IFG6&*^C)TA9@5G.$F4/N^&\:RM:B6]/I M1U1DP!E=.T ML^S-P?IF#'[CWOL~
\@&5;2C=%[[*0RGPTJ$(=8H/;M<65@WI/<3P)@F#/ MX68AN1SU@,$]FN9'N. />;+2.0MADIM@&NR^E1@^R_$96410-K-\)]X^ M!T4-@M]2.A0DC^,A-'SC$B2>.B.GI0,A0@2E?;]$M6ZZO894UL*T+;'W]@ * M5=M' X2WK]$!56LF
'#,.6IPT.*ELM#U+!HLYY(12M?:R"!@#IVZI\ONM'TY9X&T7 M>+?>S8=]+5IQPR>72FZ0I.K.!S.[4IM.K0.FVLD&Y-0K^S6&=F=RL-4BT1K=B M_XY&IUY'>%T.>78P/A=M8XW6+=-%A>#Q.UT#M9F.5&KZM.9/I 8U"LU<I. M.7?C#2+^LJ2>
(Y)@'Y!SO&,#56VQ!&I,.U=IC1G80?5(fR00](GXFH$6:"% M^BI&DY]^H(Q<#^@8M H&0^B36TBZ,%'(),\@*]%.PPRU;ZOKH(P'I.1(6)C@.]2LA529AB-Z!TQ6 0%;,E==1 M;)4(?.R8HU3G81:R;@R8G33*B:.E4IF55);Y:3F46X=#OK@'I#*^P9 E M ?
HH#6BP(XJC).6$1A%B2-+H@C"\9X$%/.8_===#^.$H I=*\3:O.L1+(^?^ MC>^YZ9\^^X(:84F@2/P(A51/0'#49@.11.'7N2.FI^[(]&8T K0M\)U\KDCP?!0Z!1C2."H&|) M!7O?XN&$N-ZE(8-\)^B#2&65Y166Q'6I3F4TI?I W<1N9@)E!DCOULXIOU?
M=90F.^%N:$)!P9.06K1T.!1*CM>! M4(KC*#PAMRFJZ(O:(W8_XO:6V:=)%:54L%-RY5.BEGBCO.RCE'69-*.0ZW MA5*&ZD\.Q5!0'-!NGI 0$B00=?IEG>N:YI.^4*!@E@86WG%E(F6FD99%L8-Y^_MO:7>A>_ =A3.%YIWO2Y'-YI#.I&P%\'+#^C_;=MA:&%,(&XY&N\?6
(=8%!R(M'I.^EM\H_BT0D*A7A?RHT:?)V3H+>IZ>G8!^.V3Z^9EMRZU;2\O9_3TDB/IM MWXUGR_Q.2=M7:*#)YN7O EHW"!Y\:IFINB@40Y&U!IB1SS=OHBOYLQK?1: MU>5LI60I'0(>Q8GR?F3@5]?7W.EJUKG GK'4F3YD/)I>%*#SDOI8_PR/VOI
MQ>=*WC+U,%-`H.(9E/@A7\N@.',:%/IK92HT@=TMH'/ZG-42^\%W]]3G@~9 MIK17. @[%IR%V*I_&A!]A.3I.=!IX'87L4'%_'F2@2SI/Z!.?6\\'F_V! MP/^VZ_ 6UHY=GUIWW57?CVTI.2,@\4!5#'I_ M!D_-A10W6.GHP@2](-Q'TUB-AMIV.D4VY8%OG!D-XK@X.
TD32(H((WM\'= M34D,FV4I=-I>)1+&?1$,D8RW)V,DD6PBV4'RU5.>H#?4II50Y@&C5+<$AM^W6 M^V 5eED7U!EXC)2#'GP?4O.1;?WIAQ ?8+R#S7B%DK^7D<5P^G+&PO=VJR:W-H965T-S5STD MCT=.CTI-
AFBA2!%+LTLR'S=WX2AB3.LN!FH/4H.294NN%GNWH5FKY$GWIG(MPXBQUV!A05F4VLZ?E4E387$E<.;%D4?!=8JZ.LY-B-CUV&76G<<Y=.IW-MN%'HWZEI>V+(BH4]A)&A.9%B>.+:.<.I^_'/P.#K_X&:R5>]SZ_R9S.+F
M!&&.I.74,G)H#WF&>.R^2I5!SI'FC)!C];@?_-QI+EMN\$IE_XK59K@:H_$-M4UIF=IV.I[^5C6<8]]SX+OPK(0%$)?&[]V)@6%D%7+O]3K'5X?LXAJATB.MKI-V%%'Y9;/IUH=03.TI.2U\?O3>*$=)NRL9&5\?G9^.;=6GPI45]X/!C9
M%40!5L=.QD)186.PI9N!4SSWR:8IF[VFI+OSWR:8IF[VFI+OSWN!>.MJ\W2QP3WE9TI(A>1KV:?Y$\ M!V.Q?=4&.N09?TC6C$N9R-U.M0.8QEE.9=@=?-!+8(F]=.6G<]6C6G29DC!!.AAN!A@!=*E.M-(%KX78=
+=H=]GOV?].77+1K?PI5K*C(;2NV0XNsWA3.7=@B;=CO%>F^M0>;F[#0 I^1V>^HJ=5.FE.9)%=.LF^66#SZ6=8IYFD!L8#OB[6=(^AH.W M2<9=Hh?2#.]F@8IQDMP=I*K=.=@B:2D%^P3>.-7@1^ABA!"%.>)4O)=VM7KW<!L9U K
V"W#>N?84IZ3IITW?RXG1-A>0R%CR'6-&1X)>5.]> MPI_+SO5]HI)?2!5I%GYV0F77OX2T2&&LE^Q0VN-61*3]*6\&IW)E?+*^=4GT M-,/6LN#T325*A/3(CR57'.YH8R<_I]=YSLZFVF5!(C.X*.!F5\N-FB2!M=M.&+M:F&IPI>7.VZ5&:0?
< 1E5/U&9*YZO#6G^>KE$KZ+&'Z%)6>HD0W\X5 MO#3V>.Z?-F'1+/02/L5Z M9?.2MBYHPO4.\2.91*;35==U:\?.H6KG3_#I MP?2!ZYV@!9C2JZ,%(-?.I=HV5>W.G:Y6E!X/.S>A*0.T_>XJ99N.^\^ M>?_.5!+.P04 " !.A1O9Z3TFPZ(< @!P &0
!AL+W=0.9.FFV7MN)A7O)!/.\YW@\'NV4O(.;1 OWA9!F\RL+:,# MI*0:+!CII(:Ek>1^%$25*!#4VIDE0)!!A'T3 L&>=!.O*VN4Y&IK"'2YOK M.%5I./U!BB+MODSWV!6?+VQSA FHY^M<86V>S67-.M;E(P7* U?$C3FXV#2 MO9X-G+!W^.%O9PI[6X)BLE+!SDT_9:
(A<:0B@PM0Z!I6^.+.O3' 5$:OOK.H-W2 M!4Z.!`@?/'2BLF(S9TK\YG=C(.W 628LTK8A=HO(./3S!5PO@OI!K?*(`T M.E8533!E4'!9_)E!H\!0'=%XB!N N+' ?IS ;TFH:>)UEY6C?.LF2DU0ZT M%R8T. #:^.$ABPZ4IQ:75M.HISB;+^O1 Y:#D:\ESGC)!89*TJI*6RS7.E>.I
M1P.,9Q"5SN5&,6G)R'1FX-7>,&"!*?{M6PGT(1-!E<)DBD U!S>]6MF\$@ N M5S=H&!?FQ2BT1,BE%,9-\M,Z^?A,\MT8;I6T&P/O98;9,4)(2K1RQ'LYIO%% MQ.^5|$ O>@EQ%/=/)#3[#>A?1Z|>GT/%[#-XI3?_S)<\%:I6IDE5;S?R-.M6'!$1ZO?4,
(?IM=H:.MI3FEI<6O7/:Y-R5(#.HM!LG59IUAlZ4+D\$ M=]I2OUEHG%[9U0ZED&3#*?HH^2IA.!'=$=M'0%%XOB7HPO>AZ0HG.+9\ M2#?D6P.LOLVB3+*M'M(:N33L/6JW M1_8IM?^Z6S_U&`.'+94OEP8$Y@09=5Y38KBNQ_7$]M\WM)6R5-]^N*$G#+5S
**MH/5.<*>N?N W.1S'Y"U!+.P04 " !,A1O9 /0YY\@# #!%0 &0 'AL M+W=OWCN@5P@%P>ION@] M@"!/;9+H;?Z6N:0V9%8]H0;VU0]?^<*>%:I8G/@F#]IUQD MWFH1]FW4:B$+D%@,.HKH(DVY>KF#1!Z6'05>,5Z+W=ZX#G^UR/D.MF#^S#?*
MMOP;1(09%K(C"B(EIY]>GO'YLZ@G/&7@(,^^2.:L4^%,=/E:+#]=>Y@4?'0AN9/HTM&UIU3],/@:BQ& \.3%@1P-6 MKS*ED^<.-7"R4/1+G9%LUI'E^Z6U:(0'),N..:UXV.,.*.D$5@MI MCB.*Z3;5KE>BC%L9HS,^1'0U =ER3
M:/A1D9>P.%:"EYMU#68OHW.>X&L4^MV:\ S6]G&W'5_9\5/@"G<-Z2,H MQ*5)[=+D?U8,^9>L12;2(CWG#(J^83]F-?=IOJ45'8#LK*8[0P/)01MACV![M1%^:^(%SF-:Y#ZGGSVV!]$OC.9<S?VFW]3?#$"6 M!HU%!3TEOP-
H%'2FGYXO7'UCSDG@T,AX$"SID+P3QINW"/HFJN= MR#}(\90P??,EIBJWA6KAI%^9.W*(V1.?FV!QZ!"RE>6VXV\Z=?'U M*5!+ P04 "!.A1O9AY+0*5(" >!0 &0 'AL+W=OF5G815$3M11C:O.)& MV!/=HN^54IM&$(=F$]K6H"@\P^G#.(K.PT9(%;2)GUN;~
$=U5+!AVH#MFD:8 MWU=8ZWX1G ;/$W=R4Y$;"-.D%!O.D:[;M>$HG%@<*V:"R4BLP6"Z"RL.+]G+ MJPD .)/9V9PRND@>M'UVP^A9!Y 1AC3BY!L&?+5Y(?3LBE0%KY RF7SK@[OB9 M_<;?SK4\"(O?NOX!"ZH6P; < "BQ%5].=[FIQK.?,\>6ZMOX_.9@:.!9!WEG0S
M@EE!(I7P%4^C#SN_.X#B$= !'4// (FZ0)$FAC=4#QWTRB0[:D&W@<I!8C>A?Y MJNN,:.: APFM_70ER4M3^.-AM5DQ1B,/X++](1F_.1.UANQ23M-1<\(4 M3- O[KE?5,&^TMPDZ).6/#5e+5Z9XVQ>@'.]<'Y_B^.,1UUM#&\L/27CM?
MB2PH5XA!.H3V=N4ID=Y=U$BIH=G[>AS6'LAJ6Y_4#;#<.>`"Z%/$WLB#_=I MAAM02P.$% @ 3(4<63)E+4%9 @=@4 !D :X.'IW.W)K&UIM53:MLP#/I5PBN&%BAJQTFZ(7;.)*!5 @:.<.V$VU MZ%BH++[2G&I./IE.W'1H
NRP'$*1XGMI$U:!+/1D~$L*IE,M.HLK:9Q+$I M^]R9N; $E.L12=?.,E,O8]-I9#R-AFG27(9UTRF,.:'.Z'5C%HKA<*%)M/6 M-=. YRAI/8T&TCU\'.RON6,BH4I=\'C26FY@VF,S'.M/C%.|'X-GMG\)4\$3UIX9/H\0+0HF%)05,/59XA5)Z(B?C92M=+>T H,;NL)
@N2)OS#NHI==#R.H6F.I MWH*=@EJHLDVVSIL=+'I.*#=.M*@NTL45%X5R.):TQJTCW9I,.A\'#@@G3BC_M4AZL=K?*X6R^?-2000ZS)45]1H16G5ZC94*.;S@1H:+II:UABLI1MBZE!\;%.MEGI>T:<'Z=P1%6]KXJCOPM/G92>[WI3N\V4HX;.0%#>S2)-TI(U\W!Z
M!6%"7"!?3;NIL:O*?PIT+!4P^ M>I=1^I%"9N8A4$C=P(6=0KG(F:P:7R9,6]^!OIBN@2$5,?S66>?#<=>']-6;S MEQ;O6<46>AF&W?I%K;+=A/3>.K_N%%2#=>.6FQW32Z5,2*P=-:GX)+K:N!.MPU(3ANR\6O9=+9$Y;PY=%IOV\G)4=NJDM>]A+8[=
M<<^QSDY.MDK?PH.R4.MH0^"K=9.1Y$^P!B9&;@&!V5^KIF:*=Z^9E.RL1 M!]9$!=:GI6@8E:IRDI=5.@?=]=D4Z/>>.KU#^:%^R#.I7?R@I6H:JH:I^567X.A_Y-/1$4#.5*9^6.P(:I-Z7.=02?5D=!H=AS1#E$ZVV1+MNKR^@WYDRM0^Y=.>.>0&W?
M79W+.4=&M(PQK)T6'R.D1DFL#/DD2R@?$TI63+HV2F!2<9QI9R M0-+X4GB)#NPH:OGP1,#\GSX>]`5I%"MQ'#+.M^VI?P<^3H4959O0SS^HPEA?&ULK5E=.JLV%/TKA%8,+:;& M(06=V0:2;$4(0M1MJI5(8&4$GT2#IN_GU)R98LF59BEWF(1?E>

.MH?K=I*@[5.'8/»=BL|.7:Y&&(+0PONKP%'!*^G8MD#ZIUQIXVIH\^.A-.56X MFUY.7A.8F!=C*Z@]7V//0G]*R.5]<:R:?Z&.&22\FS.:JA)*6FF@#C*\IF.MKJ$V.!U\&PO=VIR.M:W-H965T.$RT)D.MY>SBS.ZIKRI.U%.G62G?
5Z3>%H6I'BJEKG;G,5,K0CYB=VMMJ\B?9QMQ)SI*.M_7G5OH-+1L]>29H4LZTR5J)*K\iE.=GK)'+//KO=MDH./:1.CRJU2OYO!37H^.M)-B0$._W-:'YGGAA+P4.+!=-.:?.3;BYXJZ#U9X$.9\$U/)*Y'.)4KI^.MGT4SDIJ5V.:ZG=IKI*%N!?$,O47EM?
\FN7>.O.2+*MM2&S.]%'O:.`]IF.H9.MXQUCEWR2XD.-V-IS:Q<5IO1*=/9^#\.MM:SNY>SBU32_%>'IK$W.6MU1\0U:EOQS0\GU\UK:.DW_HM.MI7?-.X?D$33&/AF&.)GA(@WYT!0E?T+UZ6A.ZQS0!A53?U!JXG+1V'E$<.M/M&A.<.G^AYU0H8F0DY='AZ(?
IG*C2IE]6MJC.+.$3:?N.XN1<.#>.>3M9R=.).MI.:[I.%'S PYB9O)2S\Z.K/E.N1E?)G*1!U%.G9.5I:O$CBSI4.<.MT3BFB8.M[=9JI.A.\:0DHDQEKA:TG]&@16=4.0>.O^.Z\%.+TT]'#BS6-?30$.MU\BN.=.0T)<OE=M.
Q>WWI<.=FG6#=@GNTMGWR.5<2*0HOW5$UC*5.9[CFOH.M.8W-(1H]?X<.)+4^9SI.XA)*U!#3$CU.6.5WD-)%SHU>.,6]^115.8MM+!O#$*%O%?.96KD>35EY'KA#.M1DEV_EVI>.G04=3L-:+5%NR.I._1%LG2HX6$GJNR.._3X/&IF2$FIP4&Q'M'/+
M.5%eZ.,+9_3Y1Z@^9=7Z^.A0I6HW@+1VLCI.PM:G1K(FTVH.,%F'HT.M%/56E(VJ\:.P?9OZBR&N._5#]C@.7>N:D&0FU(#W0PI2.*5VKTV%5C:I6D6 M++=R'*IVI'/.\+ZTG*.%04V$C'X3*!8.XI(=G@=/6O7I<.PL5$@&C& + M!H:%=X0$Y.@57M-A/)
+3)I"W5X#K3D04]$>BR&&'KU&>9N6=.M54$EM%5&P!_:8 M&#U'QB)Y(@MUK@5%,U\A51\=BDZM'*5]W'BZ2I-F\&?G@ 8<9V)!UIK-*E04L!6RK9'AM1^T81 B'!KDE]QNC#PW2,)!$5' 2!NA-56ENW M96 2IVU8& ZD(C=^.:'5TXX.ZN$A:*\(C6+R;I C!?
@\A(#108TC16;.> M#Z)SL7ES;8.4N-EDH)?LSWY5]!00/M*L>9!+OE<$M+LE$.VD \-//WI@&HI M=$9=P.3 %;@D0V0 UB%D@+L6F$88\-FA>]VY!D/&1![FP&4I6E[#8M-S:.GW M^H.PC.E0D)D+M!'M%;5^!U2AJI:0 T2=.LL8OLAA*5Z?!Q:60L.H1*IS4G:.M0H<$***
X83[E*8^X#[_R05VA.> 0I_IG+:?7CW^2B#@'K>B$(M*4A0 M7^(M8TFB577[.%M?.64CNT5)Q&[C7F6:.ZRY>],/UA%FQAF^3;U!9D-C.:K22#)-AW M-.#FU"K/4TL>*%YM":G;U=$D-\G)/YOD&KL.\7K0HQ>)X`M.Y:IS7W'B\.\%0/&O0*C<.ZI?QDIRTR^%"9C-IH
[^\3IF.IM97K>!K?7-MK;S+RM*@!2P\.M4BA1M@?MO'#`=L$P.9E?MC=!4S>4\CE.@99EB=A3G#IPOGBIOE.ZJBFQTT.O-/V4:QH;.E:6RV9=7T MF\^VIM0YWZ,..C.8AC5R.OKZI3.SWE/YZH&OZ M60+II>8^94Z=($ C4UYT(Z)9>T$3&AlP(<;BI Y&T
WSD#TZUP6]F+S%5!HM^ S'U<3+'8VP^4 Ms *E:?WLK?UPL!)7%Z8'Q/TO+O/F?N#NC8*39ZFY'HN.07&UIQ5=M:I.V5/XKA#8,,:#$%&7Y).4-Y&5%,Z!=D+0=I&65C81BO1(.M.DIVZWND9$?)'!=-!6^R+!)WSIWPIG@<;!2YL4L.1^Y*]>PD6CIW.NYV;.Z$
MDMLC00*%.W-M2NYP:A9=NS+ B\\4RBZCM-\MN5#!=!S6+LUTK-=,"@67AMAU M67)S?PI2.R91$FT7KL1BZ?Q"=SI>.\05<@_.NRNC0XZS8HA2A!6;$5.3"?1"?) M6GFZ0/!5P$;Y_HGW!*9UC=.^K&M7J=L+.^(?:W5$4AH3IEEO#U[.V)D&O/IE.W-95$'W=C/[
MQ#BV*Y(#),:(MV!N(9K<]DO2I^_VJ-9K5.OM0Y)*8Z(5:PE$XD5"R7F(N?* M$4PAZ[@IA%[@G#'I<$Y0K]> ^A(SYC)^A,'I5,#2:P$?:&(.> 2>R#ND(A;DG.[M)`.,/X^%KL=L%?%YQPP9#'1]4WIV>&*]9S @ ,BQ(_I.1/MP2#.6(,H.!>X MM>#L?
Y@Q=3$Q54V6WQ.!M4@QW U6)L3!4Z.DO^`TE'I4F.D@OE 6U&I$(Z(_MB=WP54.0I'&2)0 ,37DS3I-,K&7U>&M^R.WM.V&Y80I'B)<@$AHSEI&3/#=K MC"XP_0 0@&$_?<@$I_S(843\!+9:S3SH)=T7F&3W6N.GW_6CDORG@M#0G<Y(
MAA^N^'O0\VW!PWHQR_K-]\Y8E!?7NU\.\B2KM6NH MD>]@(NL0W#N\I.(#]*:>X:_3V'($M)?N8FA#M_3VY&I/$<^.(dZ|NHC#?CKJ M1_!@L?_V8OY_U;'8D00NUOX^.ZY9OP.$*X^D ^P1*VIC]XK!^30DDCAA_4YK)8E9.B!G.W&>P!SB)>IK M1]YMV%!H75B"?
$4+;T![<386&%1+WUXCK@B4[<08TC;B@+[V"OF) MYXA>.I9G)(`)&\7" Y>%.;A9;.VIEGC8 R3#.TGY(8M3EGR7-Q.,09HJKE.C M_K"SL.)T6]U\"681WBS80?E]H&KLFJ7F67!2O08>R*LWU4=N%@)MES!'5GHT MP0C]G=*.7%Z%=X&,.^WPI%^.E_BT .>)
<'^NM=M.O(#FL3C!!E[.`P04 M" !,A1Q9SB4FM*L' !R!P &0 'AL+W=0I8_.YIO/W&=]YMI7]61>(IEY*:O3<$XR!+GQ?IP665) ("H5=.R:4] M1;&F6ONZ4DBS)IGD/@F"4[^D3'C)K/$!$(0F:\9P .<%NBY:]EX?R.5VIH7> MSO'(UH5Q#C^9572-
25O_[@=E+;!R5B)0C,I0&$>`2K!'BI'TXLN>X9;O3< MIV0EV;,SIK'V%SA"R#$U#H:88/?R+D#LC1^=9A>OZ5+W)-OT&\;[5;+BF[\ MEOPGRTPQ\)XJR#"G-3>(VHX,E9VIH,E-R"\%6S0#:.0VV98<$^ZG<(VR]%F MF>2&,@5F.<(<([TAUK=">N-
%PD)VN..KCF6_L+BI63SO$18M(#B"&L.ZE.(6S M+R+#[&\ W1+K.9(=QP491?0:BQ.(@@F0@.0C>%&O.6KPHK=I'1+. L7#0*Y@= M+G1%4YQ[MB(T]@UZR8=WX6EP.4($IFG6&*^C)TA9@5G.$F4/N^&\:RM:B6]/I M1U1DP!E=.T ML^S-P?IF#'[CWOL~
\@&5;2C=%[[*0RGPTJ$(=8H/;M<65@WI/<3P)@F#/ MX68AN1SU@,$]FN9'N. />;+2.0MADIM@&NR^E1@^R_$96410-K-\)]X^ M!T4-@M]2.A0DC^,A-'SC$B2>.B.GI0,A0@2E?;]$M6ZZO894UL*T+;'W]@ * M5=M' X2WK]$!56LF
'#,.6IPT.*ELM#U+!HLYY(12M?:R"!@#IVZI\ONM'TY9X&T7 M>+?>S8=]+5IQPR>72FZ0I.K.!S.[4IM.K0.FVLD&Y-0K^S6&=F=RL-4BT1K=B M_XY&IUY'>%T.>78P/A=M8XW6+=-%A>#Q.UT#M9F.5&KZM.9/I 8U"LU<I. M.7?C#2+^LJ2>
(Y)@'Y!SO&,#56VQ!&I,.U=IC1G80?5(fR00](GXFH$6:"% M^BI&DY]^H(Q<#^@8M H&0^B36TBZ,%'(),\@*]%.PPRU;ZOKH(P'I.1(6)C@.]2LA529AB-Z!TQ6 0%;,E==1 M;)4(?.R8HU3G81:R;@R8G33*B:.E4IF55);Y:3F46X=#OK@'I#*^P9 E M ?
HH#6BP(XJC).6$1A%B2-+H@C"\9X$%/.8_===#^.$H I=*\3:O.L1+(^?^ MC>^YZ9\^^X(:84F@2/P(A51/0'#49@.11.'7N2.FI^[(]&8T K0M\)U\KDCP?!0Z!1C2."H&|) M!7O?XN&$N-ZE(8-\)^B#2&65Y166Q'6I3F4TI?I W<1N9@)E!DCOULXIOU?
M=90F.^%N:$)!P9.06K1T.!1*CM>! M4(KC*#PAMRFJZ(O:(W8_XO:6V:=)%:54L%-RY5.BEGBCO.RCE'69-*.0ZW MA5*&ZD\.Q5!0'-!NGI 0$B00=?IEG>N:YI.^4*!@E@86WG%E(F6FD99%L8-Y^_MO:7>A>_ =A3.%YIWO2Y'-YI#.I&P%\'+#^C_;=MA:&%,(&XY&N\?6
(=8%!R(M'I.^EM\H_BT0D*A7A?RHT:?)V3H+>IZ>G8!^.V3Z^9EMRZU;2\O9_3TDB/IM MWXUGR_Q.2=M7:*#)YN7O EHW"!Y\:IFINB@40Y&U!IB1SS=OHBOYLQK?1: MU>5LI60I'0(>Q8GR?F3@5]?7W.EJUKG GK'4F3YD/)I>%*#SDOI8_PR/VOI
MQ>=*WC+U,%-`H.(9E/@A7\N@.',:%/IK92HT@=TMH'/ZG-42^\%W]]3G@~9 MIK17. @[%IR%V*I_&A!]A.3I.=!IX'87L4'%_'F2@2SI/Z!.?6\\'F_V! MP/^VZ_ 6UHY=GUIWW57?CVTI.2,@\4!5#'I_ M!D_-A10W6.GHP@2](-Q'TUB-AMIV.D4VY8%OG!D-XK@X.
TD32(H((WM\'= M34D,FV4I=-I>)1+&?1$,D8RW)V,DD6PBV4'RU5.>H#?4II50Y@&C5+<$AM^W6 M^V 5eED7U!EXC)2#'GP?4O.1;?WIAQ ?8+R#S7B%DK^7D<5P^G+&PO=VJR:W-H965T-S5STD MCT=.CTI-
AFBA2!%+LTLR'S=WX2AB3.LN!FH/4H.294NN%GNWH5FKY$GWIG(MPXBQUV!A05F4VLZ?E4E387$E<.;%D4?!=8JZ.LY-B-CUV&76G<<Y=.IW-MN%'HWZEI>V+(BH4]A)&A.9%B>.+:.<.I^_'/P.#K_X&:R5>]SZ_R9S.+F
M!&&.I.74,G)H#WF&>.R^2I5!SI'FC)!C];@?_-QI+EMN\$IE_XK59K@:H_$-M4UIF=IV.I[^5C6<8]]SX+OPK(0%$)?&[]V)@6%D%7+O]3K'5X?LXAJATB.MKI-V%%'Y9;/IUH=03.TI.2U\?O3>*$=)NRL9&5\?G9^.;=6GPI45]X/!C9
M%40!5L=.QD)186.PI9N!4SSWR:8IF[VFI+OSWR:8IF[VFI+OSWN!>.MJ\W2QP3WE9TI(A>1KV:?Y$\ M!V.Q?=4&.N09?TC6C$N9R-U.M0.8QEE.9=@=?-!+8(F]=.6G<]6C6G29DC!!.AAN!A@!=*E.M-(%KX78=
+=H=]GOV?].77+1K?PI5K*C(;2NV0XNsWA3.7=@B;=CO%>F^M0>;F[#0 I^1V>^HJ=5.FE.9)%=.LF^66#SZ6=8IYFD!L8#OB[6=(^AH.W M2<9=Hh?2#.]F@8IQDMP=I*K=.=@B:2D%^P3>.-7@1^ABA!"%.>)4O)=VM7KW<!L9U K
V"W#>N?84IZ3IITW?RXG1-A>0R%CR'6-&1X)>5.]> MPI_+SO5]HI)?2!5I%GYV0F77OX2T2&&LE^Q0VN-61*3]*6\&IW)E?+*^=4GT M-,/6LN#T325*A/3(CR57'.YH8R<_I]=YSLZFVF5!(C.X*.!F5\N-FB2!M=M.&+M:F&IPI>7.VZ5&:0?
< 1E5/U&9*YZO#6G^>KE$KZ+&'Z%)6>HD0W\X5 MO#3V>.Z?-F'1+/02/L5Z M9?.2MBYHPO4.\2.91*;35==U:\?.H6KG3_#I MP?2!ZYV@!9C2JZ,%(-?.I=HV5>W.G:Y6E!X/.S>A*0.T_>XJ99N.^\^ M>?_.5!+.P04 " !.A1O9Z3TFPZ(< @!P &0
!AL+W=0.9.FFV7MN)A7O)!/.\YW@\'NV4O(.;1 OWA9!F\RL+:,# MI*0:+!CII(:Ek>1^%$25*!#4VIDE0)!!A'T3 L&>=!.O*VN4Y&IK"'2YOK M.%5I./U!BB+MODSWV!6?+VQSA FHY^M<86V>S67-.M;E(P7* U?$C3FXV#2 MO9X-G+!W^.%O9PI[6X)BLE+!SDT_9:
(A<:0B@PM0Z!I6^.+.O3' 5$:OOK.H-W2 M!4Z.!`@?/'2BLF(S9TK\YG=C(.W 628LTK8A=HO(./3S!5PO@OI!K?*(`T M.E8533!E4'!9_)E!H\!0'=%XB!N N+' ?IS ;TFH:>)UEY6C?.LF2DU0ZT M%R8T. #:^.$ABPZ4IQ:75M.HISB;+^O1 Y:#D:\ESGC)!89*TJI*6RS7.E>.I
**M1P.,9Q"5SN5&,6G)R'1FX-7>,&"!*?{M6PGT(1-!E<)DBD U!S>]6MF\$@ N M5S=H&!?FQ2BT1,BE%,9-

(I}¥#7O&8 MG&PI^\Y7A CPHRPJ/K560JRO;9NG*U)B?D77I)+?+!"DKI.9!-]FCS-2.XJT%E M82/"">P2YU4UF13WYFPVH1M1Y!69.\ W98G9\RTJZ'9J06M_XW/^N!+JACV; MK/$C61#Q=3UGLF6W+%E>DHKGM *.+*?6#;Q.$%* .N);3K;\X!JH5!XH_;X;
MGI*IY;@>D8*D0E%@^?%$IDA1**;9C_IWI%;I3 \\Q-Z5?ZB3E\D\8$!N;/%? MGHG5U(HLD)$EWA3B.lU^>)+N$?,67TH+7_\%Y%^M8(-UP0 M@W_D9%S@@G#P\ SFC&;;5(OSV[*WB9$X+S@[V34UT4*WKY\!IZ O)?5G3# M<97QB2UDG[63[?37QINF?^AS_R "I
[02*P[^JC*2]0ELF6R;,=IG?(M&& ? > M5%? = ?X R$&> HD-WKX>{&GCR>C@:R<9MQ\C*=P3?&HTN!H-G;0 U-.#U1OE MF]JQJ;6?&5PPIZ(-?O]-Q@X?^ID,4F6&"+K2>;UDGECI..2-5" .AJIWYM,, M.C ,PKGD/QV|<1P7AV$4#<(239B'4 #;L%X&?
IN;YK\3967LBX $ERE2Z+ M42BV Y^2:+#%$UI,M;&4+ ;+]^5P*1D)LD20V0IR<)6LO#R6FF@\<'D#IW BI"@ M5(H# C^.?#@H%V8s5[^KR^5]$?G&DW@ L,-!W+1 52L"-.E.8H_=^!-DB6&
MR!JZO:UN\>6U$IN4S"198HBL)QET.B E7%KM.C:%A!/>0$ O#E443YT:AZPV7 M%EU< 'TWTA<,/""$<#R+C6[ZI=8DS27]TQ^(J=1IG-G@E&VQ!1,7T74J8@N M+Z =UIN)MD24VQ]W3H_"T>]WPNZN4=S'@9>$,)A#6GB0N0[WK"&-'%^".(@ M1
UU%&..>\OO.$WE+7T2H]"5!!D6Y**K2l;YVNA_PM%8135&F5+.3+'U=>N. M+1PU@2_H%AQ/B^1<:.?8X+(t<=.(G#>R<)ARWFO>R5>22TRX_MVEQ&. R.9$E-L?7IZHPNC7Z@=HRI7*%MBBJVO6V=TX:@T$&W^&BR\\- M G=8.
[HX%/C!L'@T<7[L0Z2O'M193S1N/>>$U9MI54KVFW+:A,9ISH!(1MD2 M4VQ]"3O?B^#E!82,.EVC;(DIMKYNG=-%HX[P!=W0T0Y8$/KNP(C=:<)DU' K M(=&&:,$WI[[8# ^\).RQ/E?
@(^6;2C0;Q>W=INSBIMZQ'IR_A=+=)8/>85!F592DKG^1!18LI90l,0=%WONCI0(6A97ZX(S@A3 ?+D:5BWU ;M:$IZ9C\!4$L#!!0 ($R%"%D# 6.5%@. (<3 9 >&PO=VIR;W-H M965TNZI(-IA"XHQM.5575HO72*HN7IMBBS$J.E!5NKIGO6Z%"'"7FTWKLAL^G
M,'=+!0S-!V)758C_O, EV\)8GFWO>&[IW8L!:DP M^61=P\]YBS@>09C#:@C_B%X+X|:0$NY0>R,[GM-@=3? [[$ M9:F9U#R^MZ1.=T\/&X_LG^1Q2LOY[6@2U;^2P]IY3FJI P\0KM2WK+1;[@5 M%&F^G)6B_@7[-M9S0+X3DE4M6,V@(K3Y1S]:
(XX_2]@9X+< ?P@(GP$$+2!K M*2!L 6'M3".EIB%#$LVGG.T!UI&<33=J.VNTDD^H?O>EY.HJ43@V7'THDL5I' M*0!,@:^VF',)N+3)HBB(;)S2!*7-_M+)KI G\]3;C$150@/N?X!;OI>C|#$M$ M20%!7:],9N#IVP_@++2
4.+UA.%HC;N5+/5)W35=8?75_YH6%"ER^!P9XJG>X/2(FZ%8N M)(F'9 C?.@I#B9K&VAHANGR;G8HAS/'6P$)@-8&?:^(e\V.O+(EVR299;(.M>I<%67A&/N290TTH'Z:]DPAQ(.XF0R+!2\W?@-.TF2-!V$90;PF/=CV(7U M%$2=@FA4P1TE$A>@SEJCBE'X;Q?
>)EEB.QG6IS9%!^>=!%.RV8299;(>18E.MG6?)Z,(20).CS1VE81(\e\U0QA"5ID@S"].D-B#"%.Q.>=V@cF(IP?!H5Y0%"PI.MS9F.@!H'@4M$48%>.D-97K[%;)EELAZ#DXZ!R>G0\W$IF4VR3)+9W+H'>H MHS3rZ,%'FH/TP2+QHDCBD.3MQ'F2.(0Y.H//JT^(C
MN"9%,46)PA82L4VBQTMEDE#9^^-H_894M!.?6-[_F.FGD(KPD5H.0K1>F=)6LO#GU:3I2>M59'LF)-QI MY@<C G,=H*ZO6);/"7V#IN@M.AI02P,5% @ 3(4<6;A+0K1B @.@8 M !D !X;"IW;W)K&ULK95M;HP%,> BI5)TR:U M) 3(@:.1H-
U#)U$#1=M>F^@0 5OV0V0Z!;[S$S(J0:9)>T-LY^Y OSOGCEFM M]+,I "PY"'"[-/"BL++A:+("!#4#58+$-UNE!;6XU;00E!HH[IT$#^.,H2D)! MF0S2F3],Z72F\LN9A)4FIA*"ZN,2N*KGP3 X'3RQ76'-09<.2K]#.~COY4KC
M+NO4V_P@T%MSM;$9:)!ZMEM'O)Y$#D@X)!9If#Q-MI8<[X-P)(=:O5C/H0CK\.5) 9//"7/94 -WBQ)BN2WFP?N Y+'"E%;=/IOX" M:3X3IY4)M M36=.:U40I:U15"\^]IT8X)MVEK*W&MPS];-IVU {6V]BMN1.:"9IZ:IG;19X5-MMZ*DP:P&6#4!\% 8DTO#"'?
ZX3SU=T:.#)O:TN'6?$!.5N 39 M+S.*2$Z/I@=HT@%_.@6('[X!\F::/5.^8-(3#%EVCP3LLIFXF5+.QIO138;LSAB_+"'H@W8&^`ZK ME#UM7(#N;R+]#5!+ P04 " !,A1O9D,,.%\(# "P% &0 'AL+W=O MU06?R9PTXR@I1 46IQM:O4+B5DI6 IXI@S&G]2Y%;
(8X<<'C&P6TCW$U\6V6Y;I%"O21UOM+KI.5ZDG@("IZIZPVGX"WZ ^U-M/5\6(@$E>B#2"%OM#@EZ_>H->H9RB;VNV%81F8FI+%;^>U4Z;V.IJV-PSL6$7 M?694K@>5Z1S/(3@%%L1;EZ^!9WKF#B)^V!HJYSEOD.JYO"%CO-X9O'8E8+\2%*1)YAK&-
\/HF^5&;$@*,TM=!0+X$UCS7W .IH?:, M2:(0P9+1P$[D\UOY "T^6W)N,S_K?>UVOP9/$!4"[$E- 64,B& >[8B0 M?:L^S;'C.U/[Z5BDOE'D1],P^CL4#%9N:,%F M$E%;+(GH9B9RFK#1RB'KS7OE^Y'(&*QP' 5F)L6R620B;!=_5IP4,\?>.D 2O%#O&!BAB#. MI??BF&#)2&
G^F'GD|,XXSPL#4[G?D\:LY.?"TIP;#YEV#TP=/_KG+GH&_.2_*72#HR9OHZ(E8Z&=.GC(W.!P O>_CE@_^XII M&9'!*(@GW>,U&.2E(MA'I5P)?%65O$)EHUL]ZSIG'6W+!MNIY.R.W^ERO"H1 M#S!U:)?^9\%5.!2I&[2"=ZTCQXW5Y?'PS^% @ X 8 !D !X;"IW;W)K
M&ULK55=;YLP%/TK%)NF3EH+ 9\'4%*PI9U4K6I M6;=G%R(!)K&9?1.Z OK9AK"THE4?^@+^.%XGGO-(6FENM,5)+!F@L]HK$ MYMSW=5Y!3?6I;$"8G5*]F]*9JHVO&P6T<*":.^V$0S/R.,N&EB5N14FDBM\B9 M@"M%]+!.NI?H[\"[%3?QI@O7;%.A72#3I*$;6 />-
%?*S/R!I6 U",VD(K^ MN.>8G&>OC7_LY"*8>X%."#CD:!FH>>U@!9Q;(/&GY!3 M&XZTP,/OGOYKTVZTW%(-^E_I.P*KN??)(P64=,OQ6K.?H-IW4X $QFSP#"'A ^!<3/ *(>$+T6$/< 5VJ_P^+] MD%&D:,)D2Y2--FQV%(KIT$8^$[.M:U1FEQD+ MHF!V1#FY$-
WULGTZ(2O:,*2VQ@=N"E!H]-9I.'GL>*}5GVIF2"AL/A8U?8B\?M53('KH+;TJ; M'!QXO; ON=0%>]DH[GCM;I2R=0 $0\W6&MQH*FT\=!V4A0$\).09TV_^#; MK[%MG(=]DIY6R-9=4,9C0A$-I*(/3,Y.2
MZORTFZ!L6/<2C1^Y8.5^06!L@%FOY02IQ-IP//32_\!4$L#!!0 ($R%"M%69BRRUP ( )() 9 >&PO=VIR;W-H965TF5!1<%5CH4 M2UN6 G!6B0HNXX3V@4FS$]'U=R=2(=\I2AA<"\>07!4%%K^0@=/+-R!!8+Q/W M9)DK.V&GPQ(O80KJL.P3.K);EXP4P"3A#
E8C*5QX"*2F/PIX0>!C=P;(U/ M/,G$]QF(\LQ0$!AKHP#U!5GM+(IP>OIA_J6K7MR^D6;)M=5T'PE%2\;L28H"*NO^+GI MPY9@X+\A=H7"*AR)\ZU]I, MIC!.DAD)>82M-'L2A,I#S3V8 3;W1Z<M556G^P;GUO6I0]%'F.ZW?
()^<?>Z EMNY8VS.W,9M;^7EO^.TV@?QK.]Z: MT%5A,>EW6YK?!5*6> XC2[^/$!0:K/3CAT'H?.Z]IS^9O:K>:ZOW^MQ3W<2@ M]\!.%50]\ E8IUS$RB(?V>AN\U_I(<+!\%]P^!AUW@M2K;.@^3, D'![[4^$COH MP8-#X%%7>+ /'B2#'?!>ZR/!PQ8V 0>=X&'^^!>'.R
IUH?"IZUX-$A*0+ M/'H/>* UD>]Q*QIW@<.DH+?SA0+1A1_OX0^<:(^_IP\"BC) MWM?%#QS/VT?SPK\)(:K)KWMHQS6GE&Q9+PB2BL-ZYR+2!(^ =2\$FGU MB&PO=VIR;W-H965TOVI,:L HVM4W2IM?/-H0E*8GRT!>PS3F!
M>^[%@=S7C#^+#$"BUR*G8F1E4!;WMBV2# HLKED)5#U9,%%@!;9\;8N2 TX- MJB*@K,WR:0L 7(Q!'&&\!O FNQ-4,;R9RQ9SV\Y3T>6 MHP."'!*I%;"ZK> .\EP+[3!>&DVK?:4F,H\WZM^,=^5EC@7OAQA)'0\[6B&NT4M,#DTS#5O8)U66?2.Z>
M$L63T4QB"!.4B"V0#!+X%C70UR-TY3H$<[1/T_+UVG*O2#^KX24D\Q3=&X M8%R2O_7">0P2DUQ<+.33+$.G9O?H#\&^2F6L$@HNAK94<>NWVTD3XZ2.T3!0 MH^NA!T9EVM!?FD*Z*V KPZUK.^ZXAU5_%'1.^0[E\ASO* CH+O3Z?X/3Z= MIAUQXI?
T#0747P5D6ZTEW+!=UR^[*Y%25.8&0!70%\!5;I^9,,E^Z^M4O6180$'B>V0,6C3&!Q3WTVCV@PE5X2%/;< M%?,^>I :;X;[I+B#I3?'[@M:L=AKW78.^IP9ZD?>^1J MU66#%?OA?IN[.#Y@0"14HAX62=*[!*B9>=[QZ(EEI>L"<2=51S#!3/PG_4] M7S F-
O/!@O.W(H'4$L#!!0 ($R%"%EWW& !@P(-8& 9 >&PO M=VIR;W-H965TIMW9+.,555^Z^2@BN>9" M3X+!*E.8\#F.8!W=$S, -G<)9V+.4K :A MF1!$P7P27(S\3%%U2"#%9Z8TRLDD$2.=+$
ME,;OC<H/VF!F^,U^[?3<EH>J80+R7^QTE23X#0@=)2L@[0^N MU^&?XNJ04T.5L9(KHFPTLMF!^Z0#HWPF;.MG1N$N0Y5)9H8.P#8.3>2SG8"CC M^@"#V8VY=\(:N$"*CDJU&E!Z'!E.W"81%E^;4IQGO2',4DUI3^?)E2BA
MW"8(47.0/%%+(:.O.GYKO1%)HB\DCN)T(<'+M:.3 7C^=GC\BIJD.V/B^)<= M2%M-*3>. KXI0Q7WC.DPHI6.<|W0 88!^HD&M80@^_AA=)\6.K6>Y+EIT2Y M5&I6FZ6:"]3&UL MK55=.YLP%/TK%)NF5FK*=(1]*5);-*V3-E5)NSTI67*18Z6G.M8F7+0@!.*U!.;
<!QAG.:.,B2?TM04037BI*&#PO,I\Q^.+/:5^^F5)NM?TP M(ZM,F0]V-'GP"\N:@GHH'H6=VRV*2)@DG*$!RZEUXU'H8FO GX2V,C.&!DE M"\Z?S>0^G5I.20@H).HP8/U:PQU0:HAT&K\;3IO]0%VQUOY!Y5YK66!)=QQ
M^HND*IM:GRR4PA*75.WXYBLT>JH$$IYE!42;)M:Q4%)^Q?.&K#/(".Q2^^7Q MH0-P@P. KP%XIP+!\N"?"@@:0% Y4TN!?(BQPM%$\ T2)E]SF4E9H76\@DS M99\KH5>)QIGH%F/,$D!SPR`-VE`3#TP!?>LWF2F.@-TBR2\9$JB&21 UGA! MX1+|T-OR/
.%"947:NAI!J/SLPMTA@A#CQDO)6.!G:A*)VI^9R=-4K=L4M2! M!+Z5[KY5B7R"_H@=^=#O=[X/1+6\?;FMW6XNUF^OXO,/\+76B8YU#%?2? M+553T.ID6L"U+`"4TN?<0EB#5;T:8.[=#[WN?2>9/$ID>TXZ+<.^1?8HT>! M4] MXI6/?
1+65&%99K>.G)'SMC5&V'=-+$U53C8IZ!FXP=/=4IT6%8V=/=/#*FX$?NO^B=M2$ MK9KP,44>!C"GA*-@[#;T!07Y@>C 4H>5>Y.*VEW.]Z'Y!K]C1Z),(@!+.3>[< M6?3?!WEU!%BZH)+[G2+,T:9O]6!F$"!]J2+6=F+[>WOO1?U!+ P04 M" !,A1Q9U11/[T" " ^ &0
'AL+W=O%3B)MZ3!+L$!JV>*Q>C\<:N@U£@ M^5-.2Y)4Y6-GZ7 4.KBBZI%OQD =3]_HJ9Q^^XLVM:WGH6QE%2]H?TU9%%|.MXYC%\JZPZ(B-9%^6<1)(6U(+:Y6[@*T M%?K&I02)SFI!84+E!WVU:+!%YVA!1% 61#]#IVIW##$SAA MD_:0ZH5'1-
KI3*FIHO.KEQ54KUN*5/TU[+!*8P=7<=6UHG?O_CIU-7G/] M;?I?A-UIYJZ<IBP0@M8$I.B(GR^>H1(6X6E7Z)5>W^0'VB=^_TK>2NVB$=.M&H5]-]5H!?2H/9/HLX$?Q-I59E7!%(70[0_OME5;*#^>)PN$=\;35"IN!
MHP8X.@E\V7Z9C393'+,EKHP=0G'255!0I-WXD0')<#?X^VPR;RNVD'#>W@.M),YTG4;=#3 E7_;KO-(<'&ZNGT"IAIAA%0RIH!MRV$,WW!<@.6G#^KP*#V MHQU$=ABU3W,%Z:8N\P+$TO8XB1*^8IIZIYK5IHW>Y.ZQMS[H:7]A#R56I^
MP$)?GT04,BWI70XTDIGZ735IO+0M8\&5;D!VF.M/!!#&0# /;%?;B=F@^>B(M_P02P,5% @ 3(4<6=]G@7*/ @ Z 8 !D !X;"IW;W)K&ULK55=3]LP%/TK5H8FD"A)G"9I61H)BA!,FH3H&,/FN6TL M'#N5W1;^ >PDC4))*QIVDOC<GN-SKNWK9^OD]RH -
'HK&5Z:K0=L!-DXIL8 'Z]?]0IN=V:+#DM@2LJ.)*PG#E7_N4\ MLO%UP|*5&]5E/.OD18A?VIG/9XYG!0%L&8GX.F -CELC(^-MR.MV2%MAO MIAO:^_&RPM1.!?LF>;ZF#D3!^6P)&NF"\7V#EH_H>7+!%/(%VW:6.!!V5H M4:9@HZ"DO/F3MS8//8 _/@# +0!.%1"T@*
VYBBK;=T03=)$BBV2-MIPV4:= MFQIMW%!N=W&AI9FEI!?3:\((SP M+(.;?>4YM>DE#-WSYHS89(.;P-<"TE! MH=.;T0R=6;&GO8WZ/3D#]T@RM'O0IP5X;E*?&VTV17C !W3\7/.+ M%'CG""MX/ "??QT>?(2)B-=6G"?%ESS!0?X>G;/$0<I9*AA& \SV-MWI2]2
MPR#V; ScQQC3Q.)UAPI#9(2-KAU#3RLX:8L M:.(80]-IXfIZ%CY'3<8!GG1!'I2-,VVCHII>31$843ZJLA #.IK",+>NC@(M0V1/W4'4"?.&U86=NO"HNEO^[.EL5H).7SJPT_+^M$T€/">N4BV%:7O\!\IP|&G/4*\1@:8#>
M16P89%-7FXX655V:7H0VA:YN%N8I FD#$/$/Q2"+WKV6K7/6H/U!+ P04 M" !,A1O9EOA2XK$# !W$0 &0 'AL+W=O>G'-1#-=,MX5_$(M"\)B5)!F8&6LUTO3%.&:!%A0K4^2/VM0H_E/G;AI_HC^ MMA2OO-0C0>8L^4YCN9X9@0%BLL1%((C^S[3M2"W(U7!024?
Z";1UK&2 JA&H MG:P8I#2KCOA778B=!,@<2,#&I\MO$U"=@$]A%;-2U@V6.)QRM@5<1RLT?5+6 MILQ6:FBFI_%,,@(7EN:O"D-:4N3&=DGL<)T^C'UXKT4.8[(S%"K M4Q^^(4XXAGTK-=]@D<"ZA'G?PTAXG^2O.1.\<5ZANB:H?-IOO<0+/51.Z MV976$^9.X*0-
ZY!V&M+.(.FK"!2Y55)8K7H554B6C|CVB%Y.\P,+ <=%QTP MI8OSD&=[_53=AJK|/_4I8B_W@(QM(619>YP/P^#$=,Y@GI+?4/8&*?!0'/M(M4*68IU?,C@?4$^HU_P1+WAI3_DA@''?E!(S\XR9(//#MR&+_,>7'>'4;870-1O MR4E#>3)^(.]@=24R55A(
M%1@+K5N"G58'GL2V-6SG*6E;T$=[QNV+LUP8"E7P;;!@(,OV CCM;]$G_H-MMEV]7$?M^9"Z^IN.PN(3N'9P7[ER248":U@K9/@<.-RC]]IK.L7TI=OJ MS_;$3;#C'O-LVI7_%9ESC(A>5%MUE2_KX2L5(ZR0V"/7G&1D+K"F]|'^B= MPK2C]D9CH75+T'9'<+#[^'?
3^@?-OHV"B;WOV<,PY/C.?H=@[NR^I2>)CYBO M:"9 0I8JSIKP%@"O=OG50+:%W"C?,ZFVW>7IFN"8&ULK53O3ILP$/U7K Q-(+4D30]NC82E$UCTI,*CNVSFUP. M"\<.]I6|_WYG)T1%;B<^\"7QCWO/IYYI-V^U>,E +"G2BH"K>A.&-BNA
MXO9%;$MT"V$ZK_D6UH#W]3V3)Q M\3[@CX#6[HV94[+1^L%-;0-%$+F$0$*&CH'3;P=+D-(14I]/6.VG9< M++?^*.M%\#E@.12\D?BGV^_0Z[EP?)FQ5GJ9V\=& >SHUNF7'1Q.8&WAN/ M)C5"N5M*(.;+W-F9'I*T8AJ^L;=GIRQDZ84.QW1M+3'8>
M(FEQ&859G_=UEW=\);?C3IG231B<11/#\"?:XFA4F.^W"G^8ZU"V-MDNX&_,N"#P1-X\LAJ!.2IA6.U@_N=D*99F$@F#1^2?"FZX)=!/4M.^CC4;] M2C\IJ6^"<0&T7VB-+Q-7FD,G3O\!4$L#!!0 ($R%"%G55(-T^@(&@+ M 9 >&PO=VIR;W-
H965T226#AV9CL4_QW.3DB+U(@5)$ZTQMCWW'/G\|V- MEU+=ZAS D/N"'SWQE IHX8+[41 , M_8{8X4W'IMM<3<>R,IP)F"NBJZ*@ZF$&7"%G7N=@]KAD66fL!WZ+FD&5V"N MR[E"R6]!$E: T$P*HB"=>"?A\2SL6P5WX€>#15Y,$^Q*0LI,*YPG$R^PC(!#
M;"P$Q:\[. 7.+1+R^-.>]U-JIB^?D3_XIQ'9Q94PZGD-RPQ^<0[\D@"':VX MN93+KI X=&#O8LFU^R7+YFS@D;C21A:.,C(HF"C_Z7T3B#6%<+!%(6H4(L>[+M-N18GE%#IV.EET39TXAF%\Y5IXWDF+"WB@9^C^VX*#WR 5F2X_<.(AZ9W<@<(;)-<.THJ3IRP%\N$.
M#&5(.M> +\@SH7D,GOH5?!*D57WR(G6&(E-'#LQ?,YUB6-8>+A^]"@[[",OG\? M#H-/8S[+>.^@^]O8?PD_@+;)GH'? ;M/P&G1'IK W#9.%05G46>5|%,K4O MA EFH,?Q]26$K0)-MP:ZVU08D0>@2G>P/FA9'W1"595,IMB02\B8-LHE.\;W M!U6W8)C("!4),.
.;%&YE^#"UD;2G99>&/UAZ\?PU=DQW &_PY.?X=ME!]+I MT;/<=22/N!$.G75%Q1F!Z\S(V?E1D.=.",!.AE.7KU!8IVP"\,5ATF>+O+ M^\.6/]2&<*TUAMU=0M$$9R"],8P>G5& MA+OH9>&JF86=O>@_IT2WK>'VC/#*7YB8[@V+=SYC0A$.*4.'^(=9T58U%6!D
MZ4:IA318&MPROU$8E#V ^ZF4YE&PTUDI7$_ E!+ P04 "!,A1Q9*9L" MN1X$!,$P &0 'AL+W=OB'1;5V@82!T.&IMGCMJ:28=0<$OB#U9Y%?2 <_Y"%$'0WHIU/!IKIMMR>>H_<>HI>=P.MHS[$P"2HI
M?#.^N(UWZ,8+RQI-HI9"[:6O \&IXGDIR1P#IBO5[L-X3>%FO2628'.EG]-M1;PLH3JSC\!NOI05F,*B^/3]L XWO':,F#W*[B>,B*U(D<.)01D@ ^GZ-!$M MD-(6@PETW"CT>IP.<9$?S.9FID'--!ADIKUHA4UV-DE+IX=U5?
DNT'4IT)#5!"$)YE1U%PRS[4A54MR^&GCOM=5JZ@B=*ZLIMY .?6Y9PICA;\$AH7<'-L &IXVW+#,IB /> &L M7X.F.-+3E1A,PO P>YIGF5"@41BOX%KJ:XZ6SFGR#.I'QXW.R?&$KDPIM\ ML <+1R -5Y3AW8!C836W81F.(#1Y08.'#W.%CP26O>9LYD^
MW.'IXPT#5=F=9P07]A\D3%%3YX1]W&8 <-?[I5GVI;#:5X(3/W#]3C>&P.-^M8|===:CW3'(8VY*<@Q1O9)Y5%4H 5KZZ*I>"IO7;C545LN_HPQV6!F(0%]?M4"I>%^]%2OT";?D 4$L#!!0 ($R%"%G@7.74P@(,P" 9 > &PO M=VIR;W-H965TPXG!QIWM&;BV=9
"CT6E(F MQTZA5?ENC(MH.3RG#E? I)>B9VI%0F M^6=(0#YV)OI5+#;Q-N G@:7<&0H.'GLYG<96/'.X< 0IH. I:O%$'4(VCV M?GAX1$893FI?.$!ODWV<E+3<-'1+G55[+,"8P=?4LEB!4XR<?XSUA1W?XQV0<, W#H_IO M\EP?0I/>M,I[*=)
<07AM)DA@:]WW^.:H/H/W=$[1R=1]:I51A+$$O;+R1*>&QIK9+M_BH;>=.YFDB"!>?I[,Y,XO6DZ M;9.)F.:U K<1'$@^2=B$;U!$;(8&:>IOK$1[/[UVT?:%;,=%\[!D28@"SW?%-MY-PKE=I<^K[,2U\C>-<$WA.DG*BY]K/!0K'VY$007U]FN_.#"\'V^\Q95XVI.?N
M13;CC:HH(.<"R^.N!2AV32[^FWQ>[GQ0>.E;?\:.:[(DZ/G%S+.3%[U!4*.M6A.F*6=.D-7/^]BOZ9QN\#NB)2[+@+U=^T4.7<2SU0B!SN^O?-(^0.M+.I#(Z.6)DO8T!#:Z(&\D8K?G;FP'EK._%SE%IA^?B9I.Y:U"#!:FSF_M)-
AW6"%1Y@<.R',M585%58WUFM'0YEYC4LF!%,.51VC2O.<6^5]D&>?Q4%.M>G%%AF[#OR3X"=ZHD>F0)]W QQNB,%WD\W@<$7D#G[X!#X RI"]9:0 M9H6.<-4K#F2<0<.Y:D6"(R" -.%P"4[.;#"8.P?[W'-]2:G:].YH>?]%(+?&'R\WI.?S)%=K.)/8FI+ / M-
!Q35QIN'H$N"D*.;+86%=%.8B3L5BNR6[9"-+.PB;%^7IOI>!G641)-=ZIW MH);>=#{>D-61 A2Z'66(YH A9^)D!&52?9F11,P00>.0ZLT0/NK;.M%G%E@HK8E8PX"QPF3*]*$*AN^0>F?NF.!PSK0+3O2I!B>U?>)N6URZ'Q-K>W M>.H;.,%9WNB&POY€-
L;G>\\VOE.ES8;.=.XSA^.?L5C&K6[F^4K!-PHM$KS'1 MGF?;@>(:>R1\XDH?,UEI;\!B# &^QP'<.4R.*?.JLB^P=02P.5% @ M3(4<6;(1;*3 P Y0L !D !X;"IW;W)K&ULK MM9;;;MLX$(9)A= 610LXTR)!"Z#)0\X+:,.V6N^N.%NE6\BINA0[*/#+
M6LB<:AS*C:UV$FA6.?<|APGM'/*"BN95N\6,F^4G-6P$(25>8YE8\WP,5^ M9KG6K<4WMMEI\);ICNZ@27H!N%Q)'=1LE8#H5BHB 2UC/KVKV:NYYQ["S^ M9K!?1\ $!+(2X[<9W6 4SR5%$P"'!5)@3%OWN8 ^*KBJ?LF^L74LDI9*BIQQ M1H*<%?4 ?
6B$.'(QF<ZF#WSCX5;(U6976-+4TF4IQ))8N3S54E3 M>G,VK##+N-02OS+FT\D-Y;1(@2Q-'5OG67.RsLYN2OI36+$OB#?:2l+R,CL M!IQ "A2A14.^ZBU(,B^EAs*3SXRN&$=W-/KF%C1E7+U%UQ_+6_+FU5ORBK"" M?-^*4I&OFMH:\0Y&G3;H-
S6[=P;U4UE<$M%9$< OQCWN\Y>[^_=;12M5/Z9> =%%%@142F2-HKP)T7ZIWCC_OCF_J]4CN:PI5" E4@I\%*?O_E MALZ[ON3 4+!G4OBM%Y0].1[ON/B$0#KFE,.65^R=82@BF!ZRWWB1Z'K3>WI MXRRZ5M[$#R:MU3,\<8LW!0[;%#I.?!+W<[$A'1+#R?
[<\==#HB"A:A\X)<-8 A?T(G3)E6&6[]"2M4M9N/S)?=/<)=0S<5^Y>P.C/P3&FISMA'VQR25F=0IV'B=6)@0%I ?>9 MQ?&YEN,>G;ON(=_,0Y&1 M->6\>;]'D'Y&EQAV<55UV33I4.P?IPP*HZC.1F!;PM'I^OQG_A/T\MK'UTI%.7X"!4;A@V<:YKG-BYC"!E9'YOG_=:
I^IKV4HIO.15CUN\AX,T M!OA]+80^#,Q-K[W9)\ 4$L#!!0 ($R%"%F0@N/T4 (#(% 9 M>&PO=VIR;W-H965T)N;&K0=+(V5G&DT&Y85UO@90 I&;=.),HT5%SK*L["W MM'EF&I1"P|(RURC%)5X02*C0,W#Z,;$;I/$ M). GQQGU)3WP<+UGOPW>RLT-
'I(:SE"RZY+H"M/(;ORI+X.O%);O3I2_WO3NGR#4V M9"KM^.$H=BLTQ4)OV. &D OI3MD)$YHJTSCN"Y=%B.H'?BHE.S:-6DKZCY MTN@A&R=G+:$W2"?M8W;#!R>F?-#$9I%VFO:)I_>$#WN18_?8I]_MISN6K]=M_R.EI.I04K<1]# RRY2 MP!:@D6;)#:AC?
+]Q>LO96WN4A.)^=+!=Y,DRF"R^2@€Y>4Q=LC#B;]@\F_.U!& M8R576,U?:,B1<64:C<>DMD4N#H1.)Y= *8!/1L#?)E^'YW0CMF(0UH9+A!%+; M=B+!; $T=IN+!(,U86%9TJ8'U"?2^-@;W@1^'I_HC,?P%02P,5% @ 3(4< M61^D]R9A P :PH !D !X;"IW;W)K&ULK99M
<:IHX$;>_BL;MW+0S!#!A&W+@F89,!^GDIC+E M<'G1-V#9N^0??IVIT606GU?>!3#DL>)"SIR.?6E[^MB Q750UF#P"!M:AI?B/P4IO M?1,K92GE=INX*6=>8(F 0V%!"(_#S 'SFTDY/C1!??Z=UK'_>NGZ)\\2AF M237.)^^?E68S\\@>*6%%MIQ\DH.OT
E*;+O"%K^XJA_>?R3O"!/DWXW<,B!*/?4-$MKW^$5'<]?2!"=HOF[%_MD,3!@$!!-"%SJ_N'KJTI5$O??^B/CE1$R\^$:\55 9!%NQ2U(4;N$+8:+W5- M"YAYV&8:U _X^1_OPC3XTZ?O-P5!H3;NU<;GHN>W4JPO#*B*X}!0^,"%FG# M%GBM VW8I
EKQ\9#'DTF83+U' ,EN:R"+,NM7C'\>;N;1]\RD8<"\L^T+2DG\M55C(\"HBACVIB-FBVQO*.HG\\0.RPBL)1ZB9.>N+D+/%B6]<<HVC9$ $&!=B>O3V*(JS T2?T?A$PK,>,3N+>";P/@3MIMI>QBVNLSJR M(AHK"],#U&,CK*# C3KN4<=64;MYT_?
A*WTW/OZ@X[WR;#D=1D%V(]63GG/R M%LYGN@QNO9!3DY:OLT#H_#2H=5$(I.#(